<SEC-DOCUMENT>0001654954-23-015877.txt : 20231221
<SEC-HEADER>0001654954-23-015877.hdr.sgml : 20231221
<ACCEPTANCE-DATETIME>20231221161539
ACCESSION NUMBER:		0001654954-23-015877
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		86
CONFORMED PERIOD OF REPORT:	20230930
FILED AS OF DATE:		20231221
DATE AS OF CHANGE:		20231221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11889
		FILM NUMBER:		231505465

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>cvm_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:cvm="http://cvm.com/20230930"><head><title>cvm_10k.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html" /></head><body style="text-align:justify;font:10pt times new roman"><div style='display:none;text-align:justify;font:10pt times new roman;' id='XBRLDIV'><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2022-10-01to2023-09-30">0000725363</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2022-10-01to2023-09-30" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="From2022-10-01to2023-09-30">No</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="From2022-10-01to2023-09-30">--09-30</ix:nonNumeric><ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="From2022-10-01to2023-09-30">No</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="From2022-10-01to2023-09-30">FY</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="From2022-10-01to2023-09-30">2023</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFinStmtErrorCorrectionFlag" contextRef="From2022-10-01to2023-09-30" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-09-30" unitRef="USDPShares" decimals="INF">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-09-30" unitRef="Shares" decimals="0">600000000</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-09-30" unitRef="Shares" decimals="0">43448317</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-09-30" unitRef="Shares" decimals="0">47422304</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-09-30" unitRef="USDPShares" decimals="INF">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-09-30" unitRef="Shares" decimals="0">200000</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-09-30" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-09-30" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-09-30" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2022-09-30" unitRef="USD" decimals="0">250000</ix:nonFraction><ix:nonFraction name="cvm:ResearchAndDevelopmentCredit" contextRef="AsOf2022-09-30_cvm_IncomeTaxMember" unitRef="USD" decimals="0">1200000.0</ix:nonFraction><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="cvm:NumberOfOptionsExercised" contextRef="From2022-10-01to2023-09-30_cvm_ExercisableMember" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="From2021-10-01to2022-09-30_cvm_RestrictedStockAwardsMember" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-10-01to2023-09-30_cvm_RestrictedStockAwardsMember" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2021-10-01to2022-09-30_cvm_RestrictedStockAwardsMember" unitRef="Shares" decimals="0">0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type='simple' xlink:href='cvm-20230930.xsd'></link:schemaRef></ix:references><ix:resources><xbrli:context id="From2022-10-01to2023-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-11-20_us-gaap_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-11-01to2023-11-20_us-gaap_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_UnvestedRestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_UnvestedRestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_OptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_OptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_ErgomedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_cvm_ErgomedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-07-01to2023-07-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-04-30to2023-05-02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-30</xbrli:startDate><xbrli:endDate>2023-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-07-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-05-02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_SeriesMMAndNNAndUUWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesMMAndNNAndUUWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_OfficerAndDirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:OfficerAndDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_SeriesNAndXAndYWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNAndXAndYWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-01-01to2023-01-11_cvm_LandlordMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvm:LandlordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_us-gaap_OperatingExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_us-gaap_OperatingExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_us-gaap_OperatingExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_OperatingExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_us-gaap_LeaseAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_LeaseAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_us-gaap_LeaseAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_us-gaap_LeaseAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_ErgomedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_ErgomedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_LandlordMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvm:LandlordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_cvm_IncentiveStockBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:IncentiveStockBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_NonQualifiedStockOptionsPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_NonQualifiedStockOptionsPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_cvm_NonQualifiedStockOptionsPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_IncentiveStockBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:IncentiveStockBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_IncentiveStockOptionPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:IncentiveStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_NonQualifiedStockOptionsPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_StockCompensationPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:StockCompensationPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_IncentiveStockBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:IncentiveStockBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_StockBonusPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:StockBonusPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_NonVestedOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonVestedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_RestrictedStockAwardsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:RestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_RestrictedStockAwardsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:RestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_RestrictedStockAwardsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:RestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_cvm_RestrictedStockAwardsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:RestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_RestrictedStockAwardsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:RestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_ExercisableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_ExercisableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_ExercisableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_ExercisableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_cvm_ExercisableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_OutstandingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_OutstandingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_OutstandingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_cvm_OutstandingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_cvm_OutstandingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_IncomeTaxMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">cvm:IncomeTaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_IncomeTaxMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">cvm:IncomeTaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_cvm_IncomeTaxMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">cvm:IncomeTaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_srt_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_srt_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_srt_MaximumMember_cvm_RestrictedStocksMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_srt_MaximumMember_cvm_RestrictedStocksMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-02-01to2022-02-28_cvm_SeriesHHWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesHHWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-02-01to2022-02-28_cvm_SeriesAAWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesAAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-11-01to2021-11-30_cvm_SeriesZWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-12-01to2021-12-31_cvm_SeriesCCWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesCCWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember_cvm_TwoSeptemberTwoThousendTwentyFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:TwoSeptemberTwoThousendTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember_cvm_TwoSeptemberTwoThousendTwentyFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:TwoSeptemberTwoThousendTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2022-10-28_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_SeriesSSMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesSSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_SeriesHHMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesHHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_SeriesHHMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesHHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_SeriesCCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesCCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_SeriesCCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesCCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_SeriesBBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesBBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_SeriesBBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesBBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_SeriesAAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesAAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_SeriesAAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesAAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_SeriesZZMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_SeriesZZMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_SeriesZMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_SeriesZMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_SeriesWMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesWMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_SeriesWMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesWMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_ConsultantsOneMember_srt_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_cvm_ConsultantsOneMember_srt_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_cvm_ConsultantsMember_srt_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_cvm_SeriesTTMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesTTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_cvm_SeriesSSMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesSSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_cvm_SeriesNNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_cvm_SeriesMMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesMMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_cvm_SeriesYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_cvm_SeriesXMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_cvm_SeriesUUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesUUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_cvm_SeriesNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_ConsultantsMember_srt_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_SeriesNNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_SeriesMMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesMMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_SeriesYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_SeriesXMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_SeriesUUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesUUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_SeriesNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_ConsultantsMember_srt_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_SeriesNNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_SeriesMMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesMMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_SeriesYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_SeriesXMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_ConsultantsOneMember_srt_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_ConsultantsOneMember_srt_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_SeriesUUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesUUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_SeriesNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_ConsultantsMember_srt_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_SeriesTTMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesTTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_SeriesSSMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesSSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_SeriesNNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_SeriesMMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesMMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_SeriesYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_SeriesXMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_cvm_SeriesUUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesUUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_SeriesNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_us-gaap_PatentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt">FORM <ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:DocumentType">10-K</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong>&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Mark One)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric>&#160;&#160; ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">For the fiscal year ended <ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen">September 30, 2023</ix:nonNumeric>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">OR</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric>&#160;&#160; TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the transition period from _________ to __________.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Commission file number <ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityFileNumber">1-11889</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt"><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityRegistrantName">CEL-SCI CORPORATION</ix:nonNumeric></span></strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Exact name of registrant as specified in its charter)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen">Colorado</ix:nonNumeric></p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityTaxIdentificationNumber">84-0916344</ix:nonNumeric></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(State or other jurisdiction of incorporation or organization)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(I.R.S. Employer Identification No.)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityAddressAddressLine1">8229 Boone Blvd.</ix:nonNumeric>, <ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityAddressAddressLine2">Suite 802</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityAddressCityOrTown">Vienna</ix:nonNumeric>, <ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen">Virginia</ix:nonNumeric></p></td><td style="width:10%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityAddressPostalZipCode">22182</ix:nonNumeric></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Address of principal executive offices)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Zip Code)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Registrant's telephone number, including area code: (<ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:CityAreaCode">703</ix:nonNumeric>) <ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:LocalPhoneNumber">506-9460</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Title of each class</p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Trading Symbol </p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Name of each exchange on which registered</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:Security12bTitle">Common Stock</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:TradingSymbol">CVM</ix:nonNumeric> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen">NYSE</ix:nonNumeric> American</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Securities registered pursuant to Section 12(g) of the Act: None</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160; &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.&#160;&#160; &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160;&#160;No &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric>&#160;&#9746; No &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an &#8220;emerging growth company&#8221;. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:30%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Large accelerated filer </p></td><td style="width:20%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td><td style="width:30%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accelerated filer</p></td><td style="width:20%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9746;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Smaller reporting company</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td></tr><tr style="height:15px"><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Emerging Growth Company </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act): Yes&#160;<ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric>&#160;&#160; No &#9746;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The aggregate market value of the voting stock held by non-affiliates of the Registrant, based upon the closing sale price of the registrant&#8217;s common stock on March 31, 2023, as quoted on the NYSE American, was $<ix:nonFraction contextRef="AsOf2022-03-31" name="dei:EntityPublicFloat" format="ixt:numdotdecimal" scale="0" decimals="0" unitRef="USD">97,639,295</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 8, 2023, the Registrant had <ix:nonFraction contextRef="AsOf2023-12-08" name="dei:EntityCommonStockSharesOutstanding" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,980,804</ix:nonFraction> issued and outstanding shares of common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Documents Incorporated by Reference: None</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 0px;"></td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FORWARD-LOOKING STATEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">This report contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can generally identify these forward-looking statements by forward-looking words such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;future,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;plans,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;potential,&#8221; &#8220;continues&#8221; and similar words or expressions (as well as other words or expressions referencing future events, conditions or circumstances). These forward-looking statements involve risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements, including, but not limited to:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the progress and timing of, and the amount of expenses associated with, our research, development and commercialization activities for our product candidates, including Multikine;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our expectations regarding the timing, costs and outcome of any pending or future litigation matters, lawsuits or arbitration proceeding;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the success of our clinical studies for our product candidates;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to obtain U.S. and foreign regulatory approval for our product candidates and the ability of our product candidates to meet existing or future regulatory standards;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our expectations regarding federal, state and foreign regulatory requirements;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">he therapeutic benefits and effectiveness of our product candidates;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">he safety profile and related adverse events of our product candidates;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to manufacture sufficient amounts of Multikine or our other product candidates for use in our clinical studies or, if approved, for commercialization activities following such regulatory approvals;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our plans with respect to collaborations and licenses related to the development, manufacture or sale of our product candidates;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our expectations as to future financial performance, expense levels and liquidity sources;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to compete with other companies that are or may be developing or selling products that are competitive with our product candidates;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">anticipated trends and challenges in our potential markets;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to attract, retain and motivate key personnel;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to continue as a going concern; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our liquidity.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">All forward-looking statements are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained in this report speak only as of their respective dates. Except to the extent required by applicable laws and regulations, we undertake no obligation to update these forward-looking statements to reflect new information, events or circumstances or to reflect the occurrence of unanticipated events. In light of these risks and uncertainties, the forward-looking events and circumstances described in this report may not occur and actual results could differ materially from those anticipated or implied in such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PART I</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">ITEM 1. BUSINESS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">CEL-SCI&#8217;s PRODUCT CANDIDATES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body&#8217;s natural defense system. CEL-SCI is currently focused on the development of the following product candidates and technologies:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">1)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers; and</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology, or LEAPS, with several product candidates under development for the potential treatment of rheumatoid arthritis.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">None of CEL-SCI&#8217;s product candidates have been approved for sale, barter or exchange by the Food and Drug Administration (FDA) or any other regulatory agency for any use to treat disease in humans nor has the safety or efficacy of these products been established for any use. There can be no assurance that obtaining marketing approval from the FDA in the United States and by comparable agencies in most foreign countries will be granted.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">MULTIKINE AND THE PHASE III CLINICAL TRIAL RESULTS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><strong><span style="text-decoration:underline">Immunotherapy is a large, high growth market.</span></strong> Immunotherapies use the patient&#8217;s own immune system to fight disease. These &#8220;targeted therapies&#8221; are at the forefront of modern cancer research. A recent Bloomberg report from January 2023 asserted that:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; text-align:justify;">The global cancer immunotherapy market is expected to reach USD $196.45 billion by 2030, registering CAGR of 7.2% during the forecast period, according to a new report by Grand View Research, Inc. The rising adoption of the immunotherapy over other therapy options for cancer owing to its targeted action is anticipated to increase the adoption during the forecast period. Moreover, increasing regulatory approvals from authoritarian establishments for novel immunotherapy used for oncology is also expected to further fuel the market growth.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Source</span>: <span style="text-decoration:underline">https://www.bloomberg.com/press-releases/2023-01-18/cancer-immunotherapy-market-worth-196-45-billion-by-2030-grand-view-research-inc</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI hopes to participate in this growing market with its lead investigational therapy Multikine&#174; (Leukocyte Interleukin, Injection). Multikine has already been tested in about 750 human patients in multiple clinical trials, including a well-controlled, multicenter, global, 928 patient Phase III randomized controlled trial. Multikine is unique among approved cancer immunotherapies because it is <em><span style="text-decoration:underline">given first</span></em><span style="text-decoration:underline">, right after diagnosis and before surgery</span>. CEL-SCI believes that the Phase III clinical trial demonstrated that Multikine caused tumors to reduce in size and/or caused the disease to &#8220;downstage&#8221; within just a few weeks of treatment before surgery. Importantly, patients with these reductions and/or downstages had their <em><span style="text-decoration:underline">risk of death cut in half after five years</span></em> of follow up. CEL-SCI is discussing with regulators in Europe, the U.K., the U.S., and Canada to prepare for seeking marketing authorization and approval for immediate patient access to Multikine without waiting for the results of a confirmatory trial.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In 2023, the Multikine target patient population is estimated to include about 145,000 patients per year worldwide, with more than two-thirds of those outside the United States. Global growth rates of eligible cases are expected to rise 30% by 2030.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(<span style="text-decoration:underline">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10304137</span>)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><strong><span style="text-decoration:underline">What is Multikine and who is it for?</span></strong> Multikine is a biological medicinal immunotherapy comprising a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment <em><span style="text-decoration:underline">before</span></em> the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikine&#8217;s rationale for use is to incite a locoregional immune response against the tumor before the local immune system has been compromised by the standard of care and/or disease progression.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The Multikine target population is treatment-na&#239;ve adult patients with resectable locally advanced primary squamous cell carcinoma of the head and neck (SCCHN) in the oral cavity or soft palate and who present with no nodal involvement (N0) and no extracapsular spread (ECS) as determined by PET-CT/MRI. In addition, eligible patients must also have low tumor programmed death-ligand 1 (PD-L1) expression (defined as tumor proportion score (TPS)&lt;10)). PD-L1 is a protein receptor on the tumor surface that helps the tumor repel the immune system. CEL-SCI believes low PD-L1 patients would be more likely to respond to Multikine because their tumors have lower defenses against the patient&#8217;s immune system. CEL-SCI estimates that low PD-L1 patients represent about 70% of locally advanced primary SCCHN patients.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><strong><span style="text-decoration:underline">Multikine leads to longer survival with no safety issues.</span></strong> Clinical investigations of Multikine have demonstrated the following in the target population:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong><em><span style="text-decoration:underline">risk of death cut in half at five years</span></em></strong><strong><em> </em></strong>versus the control;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">28.6% absolute 5-year overall survival benefit versus control (p=0.0015);</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">0.349 hazard ratio vs control (95% CIs [0.18, 0.66], Wald p=0.0012);</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">&gt;35% rate of pre-surgery reductions and/or downstages (p&lt;0.01); and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">low PD-L1 tumor expression (vs high PD-L1 where Keytruda and Opdivo work best).</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">There were no demonstrable safety signals or toxicities observed in about 750 Multikine-treated subjects across multiple clinical trials. Adverse event (AE) and serious adverse event (SAE) incidences were not significantly different among treatment and control groups. There were no Multikine-related deaths and only two discontinuations. Multikine-related AEs before surgery were local and resolved after surgery. Although the literature reports that some of Multikine&#8217;s components may be toxic when administered systemically (e.g., TNF&#945;, IFN &#947;, IL-1&#946;), these toxicities did not emerge with Multikine, even at doses many times higher than those administered in the Phase III trial, primarily due to Multikine&#8217;s delivery by local injection and dosage.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI published its data as abstracts and posters at the annual conferences for the 2022 American Society of Clinical Oncology (ASCO), 2022 and 2023 European Society for Medical Oncology (ESMO), and the 2023 European Head and Neck Society&#8217;s (EHNS&#8217;s) annual European Conference On Head And Neck Oncology (ECHNO) and the 2023 European Society for Therapeutic Radiology and Oncology (ESTRO). These publications can be accessed at <span style="text-decoration:underline">http://www.cel-sci.com</span>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><strong><span style="text-decoration:underline">Multikine </span></strong><strong><span style="text-decoration:underline">works by inducing pre-surgical responses.</span></strong> CEL-SCI observed statistically significant pre-surgical responses after Multikine treatment, and therefore CEL-SCI believes in the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#10146;</p></td><td style="vertical-align:top;">Multikine causes pre-surgical responses;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#10146;</p></td><td style="vertical-align:top;">Pre-surgical responses lead to longer life;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#10146;</p></td><td style="vertical-align:top;">Therefore, selecting more patients predicted to have a pre-surgical response should lead to much better survival in the target population.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">A &#8220;pre-surgical response&#8221; is a significant change in disease before surgery. CEL-SCI saw two kinds of responses in the Phase III trial. First, there were &#8220;reductions&#8221; in the size of the tumor&#8212;a reduction of 30% or more qualified as a &#8220;pre-surgical reduction&#8221; or &#8220;PSR&#8221; for short. Second, there were disease &#8220;downstages,&#8221; (e.g., the disease improved from Stage IV to Stage III). CEL-SCI calls this a &#8220;pre-surgical downstaging&#8221; or &#8220;PSD&#8221; for short. CEL-SCI&#8217;s 2022 ESMO cancer conference presentation reported on PSR, and CEL-SCI&#8217;s new 2023 ESMO presentation reported on PSD.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Across the whole Phase III trial, PSRs were seen in 8.5% of Multikine patients compared to <em><span style="text-decoration:underline">none</span><strong> </strong></em>in the control group. PSDs were seen in 22% of Multikine patients as compared to 13% in the control group. Because Multikine was the only therapy given to these patients before surgery, it is CEL-SCI&#8217;s strong belief that Multikine had to be the cause of the higher rates of PSR and PSD.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">These data are presented visually below. The taller blue columns show PSR and PSD rates in all 529 Multikine-treated patients in the Phase III trial, and the gray columns show PSR and PSD rates for all 394 control patients. The p-values above the columns show comparisons between Multikine and the control groups. With Multikine, statistically speaking, CEL-SCI believes there is a better than a 95% chance that the increases in PSR/PSD in the Phase III study were caused by Multikine.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10kimg9.jpg" alt="cvm_10kimg9.jpg" /></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">It was not enough for us to show that Multikine likely leads to PSRs and PSDs as compared to a control group, CEL-SCI also had to test if PSRs and PSDs lead to improved survival. CEL-SCI&#8217;s Phase III trial demonstrated that PSR patients were 72% likely to be alive after five years, whereas control patients were only about 49% likely to be alive after five years. Patients with PSD saw similar improvement in CEL-SCI&#8217;s Phase III trial.&#160; Their five-year chance of survival was approximately 68%. Therefore, CEL-SCI&#8217;s Phase III trial demonstrated statistically that those patients who had PSR or PSD resulting from Multikine lived longer than those who were not treated with Multikine. It is important to note that these results are from the entire Phase III study population, not from a subgroup. The p-values of less than 0.005 means there was at least a 99.5% chance that these results are due to Multikine rather than random chance. The likelihood of living at least five years is shown in the graphic below for patients with PSR (blue), patients with PSD (orange) and patients who did not receive Multikine (gray). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10kimg10.jpg" alt="cvm_10kimg10.jpg" /></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><strong><span style="text-decoration:underline">CEL-SCI&#8217;s target population</span></strong><strong><span style="text-decoration:underline"> can be readily selected by doctors upon diagnoses using standard tests.</span></strong><strong>&#160; </strong>Having shown a potential causal link supported by strong statistics between Multikine and survival benefit, CEL-SCI believes that Multikine should be approved quickly. But recall that the Phase III study&#8217;s primary endpoint of 10% survival benefit was not met. How then can we say that Multikine actually benefits patients? The answer is that while Multikine has shown that it can help patients with PSR/PSD, there were not enough PSR/PSD in the Phase III study population to yield a 10% survival benefit for the whole population. In other words, the benefits from PSR/PSD were too diluted when averaged with the other patients in the study. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">None of this changes the fact that CEL-SCI observed statistical significance when analyzing Multikine&#8217;s ability to cause PSR/PSD and that these PSR/PSD statistically appear to lead to a higher chance of living five years or longer&#8212;CEL-SCI simply had to define a target population who would have a larger number of PSR/PSD. To do so, CEL-SCI analyzed Multikine&#8217;s biological mechanism of action, talked to regulators and physicians who knew best, and were guided by the Phase III data, including patient-specific data down at the cellular level. All this of course took time, but CEL-SCI believes it has succeeded and is ready to move forward.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">One of the first things we reported from the Phase III study was that Multikine was shown to work best in patients who were deemed &#8220;low risk&#8221; after surgery, about 40% of the study population. These patients saw a significant 14.1% absolute 5&#8209;year survival benefit vs the control group. It made sense biologically that these patients would benefit most from Multikine, because they tended to have immune systems that were not yet compromised by the disease. &#8220;High risk&#8221; patients, by contrast, typically had lymph nodes invaded by the tumor, and needed chemotherapy after surgery. Because their lymph nodes were compromised, this made it harder for their immune systems to work, and they needed surgery as soon as possible without waiting an extra three weeks to receive Multikine. CEL-SCI initially developed criteria for selecting &#8220;low-risk&#8221; patients at diagnosis&#8212;i.e., those having no lymph nodes invaded by the tumor (N0) or only one lymph node invaded by the tumor (N1) as well as no extracapsular spread as determined by PET scan. CEL-SCI published these criteria at the ASCO conference in 2022. However, after discussions with regulators and physicians, CEL-SCI saw that outcomes could be improved if the N1 patients were excluded, and only the N0 patients were included in the target population. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI also saw from the Phase III data that Multikine was more effective for patients with low PD-L1 tumor expression than for patients with high PD-L1 expression. This analysis was pre-specified in the statistical analysis plan. Targeting low PD-L1 differentiates Multikine from other immunotherapies. For example, checkpoint inhibitors like Keytruda and Opdivo appear to best serve patients having high PD-L1, because these drugs work by blocking PD-L1 receptors. While none of these drugs are currently approved as a first-line treatment before surgery, even if such approvals were to come in the future, the large majority of patients in this group having low PD-L1 would still be expected to need Multikine. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI&#8217;s target population is now directed to patients who present at diagnosis with N0 nodal involvement and no extracapsular spread and also with low PD-L1 tumor expression (defined as tumor proportions score (TPS) &lt; 10). These patients can be readily identified&#160;upon diagnosis&#160;with tests that physicians routinely use in cancer screening, a crucial achievement towards Multikine becoming available for use. For instance, a PET scan should be used to determine the N0 nodal status and no extracapsular spread, and a screening biopsy should be used to determine the low PD-L1 expression. Doctors already routinely screen head and neck cancer patients using PET scans and biopsy. Therefore, doctors can screen for Multikine patients without new tests or new costs.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10kimg11.jpg" alt="cvm_10kimg11.jpg" /></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><strong><span style="text-decoration:underline">Multikine cut the 5-year risk of death in half in the target population.</span></strong><strong> </strong>CEL-SCI&#8217;s results show that Multikine can cut the risk of death in half at five<strong> </strong>years versus the control group in the finalized target population. Survival increased from 45% in the control group to 73% in the Multikine group at five years. This means the risk of death fell to 27% in the Multikine group from 55% in the control, shown below.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><em>Risk of Death Fell To 27% From 55% In The Target Population at Five Years</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>&#160;</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10kimg17.jpg" alt="cvm_10kimg17.jpg" /></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Another way to see the survival benefit of Multikine in the target population is the Kaplan-Meier curve from our ESMO &#8217;23 poster, shown below. On the vertical axis is the probability of survival and the horizontal axis is time in months. The blue Multikine line is far above the green control line, meaning the chance of survival is much higher in the Multikine group at every point in time compared to the control. These results had a low p-value of 0.0015, which is very significant as a statistical matter. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10kimg18.jpg" alt="cvm_10kimg18.jpg" /></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI&#8217;s physician consultants tell it that the early separation of these two survival curves (e.g., at 12 months) adds validation to the potential positive effects of Multikine.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Another measure of survival benefit is called the &#8220;hazard ratio,&#8221; which compares the chances of dying between two different groups. Here, in the Multikine target population, the hazard ratio was 0.35, which means that deaths occurred in the Multikine group about one-third as frequently as in the control group. It is also important to note that the hazard ratio&#8217;s 95% confidence interval remained far below 1.0. In the case of Multikine, statistically speaking, there is a 95% chance that the hazard ratio would fall between 0.18 and 0.66 if Multikine were tested in the target population in another study. A hazard ratio of 0.66 as the &#8220;so called worst case scenario&#8221; is still below (better) than the hazard ratio required for most drug approvals. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">These positive survival outcomes&#8212;increased overall survival, reduced risk of death, widely separated Kaplan-Meier curves with early separation, low hazard ratio, low p-values, low confidence intervals&#8212;CEL-SCI believes were driven by high PSR/PSD rates in the target population, as shown in the graphic below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10kimg14.jpg" alt="cvm_10kimg14.jpg" /></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI relies on all of these data together to support its plan to request accelerated/conditional approval in the new target population without waiting until the completion of another clinical trial.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><strong><span style="text-decoration:underline">CEL-SCI&#8217;s regulatory strategy going forward is to seek immediate approval of Multikine wherever possible.</span></strong> CEL-SCI intends to seek approval for Multikine based on the data generated to date, using a conditional approval pathway with a follow-on confirmatory study since the survival benefit is high and statistics are strong. This view is based on advice from regulators and consultants, and CEL-SCI believes that the accelerated/conditional approval regulatory pathways are specifically designed for our situation. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">When the Phase III trial was designed, there was no evidentiary basis for excluding either of the low-risk or high-risk patient groups before surgery. Therefore, the study had to include a large percentage of high-risk patients with immune systems already compromised by disease. These subjects generally did not respond to Multikine. CEL-SCI has narrowed its target population as compared to the overall Phase III study population to focus on patients most likely to have PSR/PSD and to exclude the rest. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI acknowledges that efficacy in the target population has not been tested prospectively, but CEL-SCI believes that the data generated to date already presents a compelling patient need in the target population that justifies immediate access to Multikine. This is why the conditional approval pathways were created in the first place. CEL-SCI intends to base its request for regulatory approval, in part, on our view that patients should not have to wait many more years before gaining access to the benefits of Multikine PSRs/PSDs and increased survival, particularly given Multikine&#8217;s safety profile and data that mechanistically and empirically supports the target population definition.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The benefit-risk balance favoring immediate patient access to Multikine is described below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10kimg15.jpg" alt="cvm_10kimg15.jpg" /></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">An &#8220;unmet need&#8221; is a factor for approval considered by all major regulatory bodies worldwide. In the Multikine target population, there is also a tremendous unmet need for improved survival. The current standard of care provides only about a 50/50 chance of surviving five years, whereas Multikine could increase that survival rate to over 70% based on the Phase III data. Chemotherapy has improved outcomes for some head and neck patients, but chemotherapy is only indicated for high-risk patients, who are not likely to fall within the Multikine target population. Currently available immunotherapies are given after surgery or where surgery is not indicated, in contrast to Multikine, which is given before surgery to patients with resectable tumors. Available checkpoint inhibitors work best on tumors with high PD-L1 expression, whereas Multikine works best in tumors with low PD-L1 expression. Therefore, Multikine&#8217;s target population is underserved, and will continue to be underserved, by current therapies, but Multikine can meet the need for improved survival.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The major regulatory bodies with whom we are working, U.S. FDA, Health Canada, European Medicine Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) all have conditional approval pathways designed for situations where the target population has not been fully tested prospectively and there is strong data supporting clinical benefit for patients. The reason is that regulators understand that in many cases patients should not have to wait for additional data before being offered the chance to benefit from a new drug. Every situation is different and depends on the specific facts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI had meetings with the FDA and Health Canada earlier in 2023, but they have not yet seen the new data presented for the first time on October 22, 2023 at the ESMO conference, and CEL-SCI plans to provide it to them in Q1 2024. In Canada, CEL-SCI plans to ask for conditional approval under their Notice of Compliance with Conditions (NOC/C) pathway, as they had suggested in April 2023. This permits approval of drugs based on safety and &#8220;promising&#8221; efficacy data while a post-market confirmatory study is ongoing. The approval can be given <em><span style="text-decoration:underline">before</span></em> the post-market study. In the U.S., the FDA has an accelerated approval pathway that is similar, but a new law in December 2022 requires enrollment in the confirmatory study to be underway before approval will be given in the U.S. Therefore, CEL-SCI plans to start this confirmatory trial as soon as possible in the new year and will then seek accelerated approval using data from that study as well.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI&#8217;s first priority, however, is seeking approval in Europe and the UK, where CEL-SCI has submitted its final target population data.&#160; These are more than twice as many patients in the target population overseas than in North America. In Europe and the UK, CEL-SCI has submitted requests for Scientific Advice and are hopeful for meetings in H1 2024. Once a meeting date has been set, CEL-SCI will be able to discuss the data and gain advice on the path forward. It is possible that CEL-SCI may be advised at that time to proceed with formal application papers.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">CORPORATE HISTORY</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI was formed as a Colorado corporation in 1983. CEL-SCI&#8217;s principal office is located at 8229 Boone Boulevard, Suite 802, Vienna, VA 22182.&#160; CEL-SCI&#8217;s telephone number is 703-506-9460 and its website is <span style="text-decoration:underline">www.cel-sci.com</span>. CEL-SCI does not incorporate the information on its website into this report, and you should not consider it part of this report.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI makes its electronic filings with the Securities and Exchange Commission (SEC), including its annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to these reports.&#160; These filings are available on its website free of charge as soon as practicable after they are filed or furnished to the SEC.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">MORE ABOUT MULTIKINE</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; CEL-SCI&#8217;s lead investigational therapy, Multikine, is being developed as a potential therapeutic agent directed at using the immune system to produce an anti-tumor immune response. Data from CEL-SCI&#8217;s clinical trials suggest that Multikine may help the immune system &#8220;see&#8221; the tumor and then attack it, enabling the body&#8217;s own anti-tumor immune response to fight the tumor. Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to review by the FDA, in connection with CEL-SCI&#8217;s future anticipated regulatory submission for approval in the United States.&#160; Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency, and neither its safety nor its efficacy have been established.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Multikine is an immunotherapy product candidate comprised of a patented defined mixture of 14 human natural cytokines.&#160; If commercial approval is obtained, CEL-SCI intends to manufacture Multikine in a proprietary manner in CEL-SCI&#8217;s manufacturing facility near Baltimore, Maryland, USA. CEL-SCI spent many years and more than $200 million developing and validating the manufacturing process for Multikine. The pro-inflammatory cytokine mixture includes interleukins, interferons, chemokines and colony-stimulating factors, which contain elements of the body&#8217;s natural mix of defenses against cancer.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Multikine is designed to be used in a different way than cancer immunotherapy is generally being used.&#160; Generally, cancer immunotherapy is given to patients who have already failed other treatments such as surgery, radiation and/or chemotherapy and most of the time it is administered systemically.&#160; Multikine on the other hand is administered locally to treat tumors and their microenvironment before any other therapy has been administered because it is believed that this is the time when the immune system would be strongest and most amenable to activation against the tumor.&#160; For example, in the Phase III clinical trial, Multikine was injected locally around the tumor and near the adjacent draining lymph nodes for three weeks, five days a week as a first treatment before surgery, radiation and/or chemotherapy. The goal is to help the intact immune system recognize and kill the tumor micro metastases that usually cause recurrence of the cancer.&#160; In short, CEL-SCI believes that the local administration of Multikine before weakening of the immune system by surgery and radiation will result in better anti-tumor response than if Multikine were administered after surgery and radiation. In clinical studies of Multikine, administration of the investigational therapy to head and neck cancer patients has demonstrated the potential for lesser or no appreciable toxicity.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10kimg16.jpg" alt="cvm_10kimg16.jpg" /></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Source: Adapted from Timar et al., Journal of Clinical Oncology 23(15) May 20, 2005</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The first indication CEL-SCI is pursuing for its investigational drug product candidate Multikine is an indication for the neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck, or SCCHN (hereafter also referred to as advanced primary head and neck cancer).&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In October 2023, CEL-SCI presented a poster at the European Society for Medical Oncology (EMSO) annual Congress that reported three major new advancements supporting Multikine&#8217;s approvability:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">First, Multikine is most effective in patients having tumors with low PD-L1 expression, consisting of about 70% of the study population. (It should be noted that immune checkpoint inhibitors like Keytruda and Opdivo appear to work best in patients with tumors having high PD-L1 expression).</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Second, the Multikine target population can now be readily identified upon diagnosis, prior to surgery, using tests that physicians routinely use in cancer screenings.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Third, Multikine patients in the target population saw a significant increase in 5-year overall survival, from 45% for control patients who did not receive Multikine to 73% for Multikine-treated patients.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Link to poster:&#160; <span style="text-decoration:underline">https://cel-sci.com/wp-content/uploads/2023/10/ESMO-2023-Poster_893P_FINAL.pdf</span></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Previously, CEL-SCI published two abstracts and presented a poster related to its pivotal Phase III Multikine head and neck cancer clinical trial at the American Society of Clinical Oncology (ASCO) in June 2022. The abstract titles and corresponding links are as follows:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>&#8220;Leukocyte interleukin injection (LI) immunotherapy extends overall survival (OS) in treatment-naive low-risk (LR) locally advanced primary squamous cell carcinoma of the head and neck: The IT-MATTERS study.&#8221; </em></p></td></tr></tbody></table><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:10%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">o</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Link to abstract: <span style="text-decoration:underline">https://meetings.asco.org/abstracts-presentations/207201</span></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">o</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Link to poster: <span style="text-decoration:underline">https://cel-sci.com/wp-content/uploads/2022/06/CEL-SCI-ASCO-2022-Poster-6032-June-6-Head-and-Neck-Cancer-1.pdf</span></p></td></tr></tbody></table><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>&#8220;Novel algorithm for assigning risk/disease-directed treatment (DDT) choice in locally advanced primary squamous cell carcinoma of the head and neck (SCCHN): Using pretreatment data only.&#8221; </em></p></td></tr></tbody></table><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:10%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">o </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Link to abstract: <span style="text-decoration:underline">https://meetings.asco.org/abstracts-presentations/207202/</span></p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Since CEL-SCI launched its Phase III clinical trial for Multikine, CEL-SCI has incurred expenses of approximately $64.4 million as of September 30, 2023 on direct costs for the Phase III clinical trial. CEL-SCI estimates it will incur additional expenses of approximately $0.7 million for the remainder of the Phase III clinical trial and the filing of the application for marketing approval to the regulators.&#160; It should be noted that this estimate is based only on the information currently available from the CROs responsible for managing the Phase III clinical trial and does not include other related costs, e.g., preparations for the potential commercial manufacture of the drug.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Ultimately, the decision as to whether CEL-SCI&#8217;s drug product candidate is safe and effective can only be made by the FDA and/or by other regulatory authorities based upon an assessment of all of the data from an entire drug development program submitted as part of an application for marketing approval. As detailed in the Risk Factors section of this report, the completed Phase III clinical study for CEL-SCI&#8217;s investigational drug may not be able to be used as the pivotal study supporting a marketing application in the United States, and therefore a confirmatory study would need to be conducted to support a marketing application in the United States.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Development Agreements for Multikine</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In August 2008, CEL-SCI signed an agreement with Teva Pharmaceutical Industries Ltd., or Teva, that gives Teva the exclusive right and license to market, distribute and sell Multikine, if approved, in Israel and Turkey for treatment of head and neck cancer. The agreement terminates on a country-by-country basis 10 years after the product launch in each country or upon a material breach or upon bankruptcy of either party. The agreement will automatically extend for additional two-year terms unless either party gives notice of its intent not to extend the agreement. If CEL-SCI develops Multikine for other oncology indications and Teva indicates a desire to participate, the parties have agreed to negotiate in good faith with respect to Teva&#8217;s participation and contribution in future clinical trials.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Teva has agreed to use all reasonable efforts to obtain regulatory approval to market and sell Multikine in its territory at its own cost and expense. Pursuant to the agreement, it is CEL-SCI&#8217;s responsibility to supply Multikine and Teva&#8217;s responsibility to sell Multikine, if approved by regulatory authorities in the relevant countries. Net sales will be divided 50/50 between the two parties. Teva also initially agreed to fund certain activities relating to the conduct of a clinical trial in Israel as part of the global Phase III trial for Multikine. In July 2011, Serbia and Croatia were added to Teva&#8217;s territory, pursuant to a joinder agreement between CEL-SCI and PLIVA Hrvatska d.o.o., or PLIVA, an affiliate of Teva&#8217;s, subject to similar terms as described above. In January 2012, pursuant to an assignment and assumption agreement between CEL-SCI, Teva and GCP Clinical Studies Ltd., or GCP, Teva transferred all of its rights and obligations concerning the Phase III trial in Israel to GCP.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">In consideration for the rights granted by CEL-SCI to PLIVA under the joinder agreement, CEL-SCI will be paid by PLIVA (in U.S. dollars):</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">&#183; $100,000 upon EMA grant of Marketing Authorization for Multikine;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">&#183; $50,000 upon Croatia&#8217;s grant of reimbursement status for Multikine in Croatia; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">&#183; $50,000 upon Serbia&#8217;s grant of reimbursement status for Multikine in Serbia.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In November 2000, CEL-SCI signed an agreement with Orient Europharma Co., Ltd., or Orient Europharma, of Taiwan, which was amended in October 2008 and again in June 2010. Pursuant to this agreement, as amended, Orient Europharma has the exclusive marketing and distribution rights to Multikine, if approved by regulatory authorities, for head and neck cancer, naso-pharyngeal cancer and potentially cervical cancer indications in Taiwan, Singapore, Malaysia, Hong Kong, the Philippines, South Korea, Australia and New Zealand. CEL-SCI has granted Orient Europharma the first right of negotiation with respect to Thailand and China.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The agreement requires Orient Europharma to fund 10% of the cost of the clinical trials needed to obtain marketing approvals in these countries for head and neck cancer, naso-pharyngeal cancer and potentially cervical cancer.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">If Multikine is approved for sale, Orient Europharma will purchase Multikine from CEL-SCI for 35% of the gross selling price in each country. Orient Europharma is obligated to use the same diligent efforts to develop, register, market, sell and distribute Multikine in its territory as with its own products or other licensed products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The agreement will terminate on a country-by-country basis 15 years after the product approval for Multikine in each country, at which point the agreement will be automatically extended for successive two year periods, unless either party gives notice of its intent not to extend the agreement. The agreement may also be terminated upon the bankruptcy of either party or material misrepresentations that are not cured within 60 days. If the agreement ends before the 15-year term through no fault of either party, CEL-SCI will reimburse Orient Europharma for a prorated part of Orient Europhorma&#8217;s costs towards the clinical trials of Multikine. If Orient Europharma fails to make certain minimum purchases of Multikine during the term of the agreement, Orient Europhorma&#8217;s rights to the territory will become non-exclusive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI has a licensing agreement with Byron Biopharma LLC, or Byron, under which CEL-SCI granted Byron an exclusive license to market and distribute Multikine in the Republic of South Africa, if approved. This license will terminate 20 years after marketing approval in South Africa or after the bankruptcy or uncured material breach by either party. After the 20-year period has expired, the agreement will be automatically extended for successive two year periods, unless either party gives notice of its intent not to extend the agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Pursuant to the agreement, Byron will be responsible for registering Multikine in South Africa. If Multikine is approved for sale in South Africa, CEL-SCI will be responsible for manufacturing the product, while Byron will be responsible for sales in South Africa. Sales revenues will be divided equally between CEL-SCI and Byron.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">ABOUT LEAPS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI&#8217;s patented T-cell Modulation Process, referred to as LEAPS (Ligand Epitope Antigen Presentation System), uses &#8220;heteroconjugates&#8221; to direct the body to choose a specific immune response. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. LEAPS combines T-cell binding ligand peptides with small, disease associated, peptide antigens and may provide a new method to treat and prevent certain diseases.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The ability to generate a specific immune response is important because many diseases are often not combated effectively due to the body&#8217;s selection of the &#8220;inappropriate&#8221; immune response. The capability to specifically reprogram an immune response may offer a more effective approach than existing vaccines and drugs in attacking an underlying disease.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">LEAPS Candidates:&#160; CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000)</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">On September 19, 2017, CEL-SCI announced that it had been awarded a Phase 2 Small Business Innovation Research (SBIR) grant in the amount of $1.5 million from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), which is part of the U.S. National Institutes of Health (NIH).&#160; This grant provided funding to allow CEL-SCI to advance its first LEAPS product candidate, CEL-4000, towards an Investigational New Drug (IND) application for a Phase 1 safety study, by funding IND enabling studies and additional mechanism of action studies, among other preclinical development activities.&#160; Work on CEL-4000 was conducted at CEL-SCI&#8217;s research laboratory and Rush University Medical Center in Chicago, Illinois in the laboratories of Tibor Glant, MD, Ph.D., Jorge O. Galante Professor of Orthopedic Surgery and Katalin Mikecz, MD, Ph.D. Professor of Orthopedic Surgery &amp; Biochemistry.&#160; The SBIR grant was awarded based on published data described below by Dr. Glant's team in collaboration with CEL-SCI showing that the administration of a proprietary peptide using CEL-SCI's LEAPS technology prevented the development, and lessened the severity, including inflammation, of experimental proteoglycan induced arthritis (PGIA or GIA) when it was administered after the disease was induced in animals.&#160; This grant has been fully expended.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">As part of the follow-up to the grant funded work, CEL-SCI published a review comparing CEL-4000 and the new LEAPS peptide CEL-5000 to both the Janus kinase (JAK) inhibitors and disease modifying anti-rheumatic drugs (DMARDs) in use for RA and autoimmune arthritis.&#160; The article reviewed the mechanism of action and targets with pictorial graphics in the journal Biomedicines and can be found online at <span style="text-decoration:underline">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772713/</span>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In May 2019, CEL-SCI announced that a newly discovered LEAPS conjugate acts alone and can complement CEL-4000 therapeutically when administered in combination to an animal model of Rheumatoid Arthritis (RA).&#160; This new LEAPS conjugate appears to act on T cell pathways by a new mechanism that is different from the pathways used by the CEL-4000 vaccine. The data was presented at the American Association of Immunologists 103rd Annual Meeting (Immunology 2019) by Daniel Zimmerman, Ph.D., CEL-SCI&#8217;s Senior Vice President of Research, Cellular Immunology.&#160; The work was performed in conjunction with researchers at Rush University Medical Center, Chicago, Illinois and was funded by the SBIR Phase 2 Grant.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In July 2019, one of CEL-SCI&#8217;s collaborators from Rush, Dr. Adrienn Markovics presented new LEAPS data at i-Chem2019, International Conference on Immunity and Immunochemistry.&#160; Data presented was for a new second RA conjugate discovered which acts alone and can complement the existing CEL-4000 RA vaccine in an animal model of RA.&#160; The combination of the two RA conjugates provided not only broader epitope coverage, but also a greater therapeutic effect than either conjugate alone.&#160; The LEAPS work was performed in conjunction with researchers at CEL-SCI on CEL-4000 and the newly discovered LEAPS conjugate, CEL-5000.&#160; Both conjugates were evaluated alone and in combination in the model of proteoglycan [PG] induced arthritis (PGIA) called recombinant PG G1 domain-induced arthritis (GIA), an autoimmune mouse model of RA.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In February 2017 and November 2016, CEL-SCI announced preclinical data that demonstrate its investigational new drug candidate CEL-4000 has the potential to treat rheumatoid arthritis. This study was supported in part by the SBIR Phase I Grant and was conducted in collaboration with Drs. Katalin Mikecz and Tibor Glant, and their research team at Rush University Medical Center in Chicago, IL. This work was published in an article entitled &#8220;<em>An epitope-specific DerG-PG70 LEAPS vaccine modulates T cell responses and suppresses arthritis progression in two related murine models of rheumatoid arthritis</em>&#8221; and can be found online at <span style="text-decoration:underline">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568759/</span>. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Prior to the SBIR Phase 2 grant in 2014, CEL-SCI was awarded a Phase 1 SBIR grant in the amount of $225,000 from NIAMS.&#160; This grant funded the development of CEL-SCI&#8217;s LEAPS technology as a potential treatment for rheumatoid arthritis, an autoimmune disease of the joints.&#160; The work was conducted at Rush University Medical Center in Chicago, Illinois in the laboratories of Tibor Glant, MD, Ph.D., Katalin Mikecz, MD, Ph.D., and Allison Finnegan, Ph.D. Professor of Medicine.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">With the support of these SBIR grants, CEL-SCI is developing several new drug candidates, CEL-2000 and CEL-4000, as potential rheumatoid arthritis therapeutic treatments.&#160; The data from animal studies using the CEL-2000 treatment suggests that it could be used against rheumatoid arthritis with fewer administrations than those required by other anti-rheumatoid arthritis treatments currently on the market for arthritic conditions associated with the Th17 signature cytokine TNF-a. The preclinical data indicates these peptides could be used against rheumatoid arthritis where a Th1 signature cytokine (IFN-&#947;) is dominant. CEL-2000 and CEL-4000 each have the potential to become a personalized, disease-specific therapy, that acts at an earlier step in the disease process than current therapies, and which may be useful in patients not responding to existing rheumatoid arthritis therapies. CEL-SCI believes this represents a large unmet medical need in the rheumatoid arthritis market.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In March 2015, CEL-SCI and its collaborators published a review article on vaccine therapies for rheumatoid arthritis based in part on work supported by the SBIR Phase 1 grant.&#160; The article is entitled &#8220;Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic Ligand Epitope Antigen Presentation System vaccines for models of rheumatoid arthritis&#8221; and was published in Expert Review of Vaccines 1 - 18 and can be found online at <span style="text-decoration:underline">http://www.ncbi.nlm.nih.gov/pubmed/25787143</span>.&#160;&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Accordingly, even though the various LEAPS candidates have not yet been given to humans, they have been tested in vitro with human cells.&#160; They have induced similar cytokine responses that were seen in these animal models, which may indicate that the LEAPS technology might translate to humans.&#160; The LEAPS candidates have demonstrated protection against lethal herpes simplex virus (HSV1) and H1N1 influenza infection, as a prophylactic or therapeutic agent in animals.&#160; They have also shown some level of activity in animals in two autoimmune conditions, curtailing and sometimes preventing disease progression in arthritis and myocarditis animal models.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">None of the LEAPS investigational products have been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from the early-phase, preclinical-trials data involving these investigational products. Before obtaining marketing approval from the FDA in the United States, and by comparable agencies in most foreign countries, these product candidates must undergo rigorous preclinical and clinical testing which is costly and time consuming and subject to unanticipated delays.&#160; There can be no assurance that these approvals will be granted.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">INTELLECTUAL PROPERTY</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Patents and other proprietary rights are essential to CEL-SCI&#8217;s business. CEL-SCI files patent applications to protect its technologies, inventions and improvements that CEL-SCI considers important to the development of its business.&#160; CEL-SCI&#8217;S intellectual property portfolio covers its proprietary technologies, including Multikine and LEAPS, by multiple issued patents and pending patent applications in the United States and in key foreign markets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">On June 30, 2023, CEL-SCI filed a new patent application for Multikine based on novel findings from the Phase III study.&#160; This new application covers the use of Multikine for certain cancers, such as oral cavity and soft-palate tumors, that do not respond well to the use of checkpoint inhibitors in treatment.&#160; Multikine is protected by a U.S. patent, which is a composition-of-matter patent issued in May 2005 that, in its current format, expires in 2023.&#160; Additional composition-of-matter patents for Multikine have been issued in Japan (issued in November 2012 and currently set to expire in 2025) and three in Europe (issued in September 2015, May 2016 and October 2017, currently set to expire in 2025 and 2026).&#160; The most recent patent issued in October 2017, patent # EP 1 879 618 B1, titled &#8220;A Method for Modulating HLA Class II Tumor Cell Surface Expression With A Cytokine Mixture,&#8221; addresses Multikine&#8217;s mechanism of action to make tumors more visible to the immune system.&#160; This new patent is important because, along with the other Multikine issued patents, it addresses how Multikine enables the immune system to recognize and attack the tumor. One way tumor cells evade the immune system is by expressing human leukocyte antigens (HLA) on the tumor cell surface, thus appearing as &#8216;self&#8217; to the immune cells and therefore the tumor cells are not attacked.&#160; It is important to note that the tumors of the Multikine-treated best responders in CEL-SCI&#8217;s prior Phase II studies had no HLA Class II expressed on the cell surface following Multikine treatment as compared to controls. This points to Multikine&#8217;s ability to modulate HLA expression on the tumor cell surface, thereby allowing the immune system to recognize and attack the tumor.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In addition to the patents that offer certain protections for Multikine, the method of manufacture for Multikine, a complex biological product, is held by CEL-SCI as a trade secret. CEL-SCI considers this to be its best protection from competitors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">LEAPS is protected by patents in the United States issued between January 2019 and June 2021. The LEAPS patents, which expire between 2027 and 2032, include overlapping claims, with composition of both matter (new chemical entity), process and methods-of-use, to maximize and extend the coverage in their current format. One issued U.S. application is a joint application with Northeast Ohio Medical University (&#8220;Neoucom&#8221;) and CEL-SCI will share the ability to use the patent, unless CEL-SCI licenses the rights to the patent from Neoucom. In October 2017 and October 2020, patents were issued in Europe for LEAPS, which expire in 2029 and 2034, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI has five patent applications pending in the United States for LEAPS, which, if issued, would extend protection through 2040, subject to any potential patent term extensions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">As of December 8, 2023, there were no contested proceedings and/or third party claims with respect to CEL-SCI&#8217;s patents or patent applications.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">MANUFACTURING FACILITY</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Before starting the Phase III clinical trial, for reasons related to regulatory considerations, CEL-SCI built a dedicated manufacturing facility to produce its investigational biological product candidate Multikine. This facility produced multiple clinical lots for the Phase III clinical trial and has also passed quality systems review by a European Union Qualified Person on several occasions. CEL-SCI expanded the manufacturing facility so CEL-SCI will be able to meet the expected demand for Multikine, if approval to sell the drug is granted. This expansion was completed at the end of 2021, allowing CEL-SCI employees to return to work inside the manufacturing facility. In October 2023, CEL-SCI announced that the commissioning of the manufacturing facility was substantially complete, a significant milestone toward a planned Biologics License Application (BLA) with several regulatory agencies for approval of Multikine in the treatment of head and neck cancer.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s lease on the manufacturing facility expires on October 31, 2028. At that time CEL-SCI can either purchase the facility or extend its lease. See Item 2 of this report for more information concerning the terms of this lease.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">GOVERNMENT REGULATION</span></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">The FDA and other regulatory authorities at federal, state and local levels and in foreign countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing and post-approval monitoring and reporting of biologics such as those CEL-SCI is developing. CEL-SCI, along with third party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which it wishes to conduct studies or seek approval or licensure of its product candidates. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations requires the expenditure of substantial time and financial resources.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>U.S. Food and Drug Administration Regulation of Biological Products</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">In the United States, the FDA regulates biological products under the Federal Food, Drug, and Cosmetic Act, or FDCA, and the Public Health Service Act, or PHSA, and their implementing regulations. The process required by the FDA before biological product candidates may be marketed in the United States generally involves the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s Good Laboratory Practice, or GLP, regulations;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">submission to the FDA of an investigational new drug application, or IND, which must become effective before clinical trials may begin and must be updated annually;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">approval by an independent Institutional Review Board, or IRB, or ethics committee at each clinical site before the trial is initiated;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">performance of adequate and well-controlled human clinical trials in compliance with Good Clinical Practice, or GCP, regulations to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">preparation of and submission to the FDA of a Biologics License Application, or BLA, after completion of clinical trials;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">satisfactory completion of an FDA Advisory Committee review, if applicable;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with current Good Manufacturing Practice, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity and potency, and of selected clinical investigations to assess compliance with GCPs; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for use in the United States.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Prior to commencing the first clinical trial with a product candidate in the U.S., CEL-SCI must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for human studies. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to commence a clinical trial.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial commences at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board (DSMB) or independent data monitoring committee (IDMC), which provides recommendations for whether or not a study should move forward at designated check points based on access to certain data from the study and may suggest halting the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">For purposes of approval of a Biologics License Application, or BLA, human clinical trials are typically conducted in three or four sequential phases that may overlap.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Phase I &#8212; The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans and the side effects associated with increasing doses.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Phase II &#8212; The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase II clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase III clinical trials.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Phase III &#8212; The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Phase IV &#8212; In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. The FDA may also make these so-called Phase IV or post-marketing studies a condition to approval of the BLA.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Phase I, Phase II and Phase III testing may not be completed successfully within a specified period, if at all, and there can be no assurance that the data collected will support FDA approval or licensure of the product. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>BLA Submission and Review by the FDA</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of a use of the product, or from a number of alternative sources, including studies initiated by investigators.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">In most cases, the submission of a BLA is subject to a substantial application user fee. Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, for original BLAs, the FDA&#8217;s goal is to review the BLA within ten months after it accepts the application for filing, or, if the product relates to an unmet medical need in a serious or life-threatening indication and has received a priority review designation, six months after the FDA accepts the application for filing.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">After filing the marketing application, the FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve a biological product for marketing unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the data provided in the application, or the manufacturing process or manufacturing facilities for the product are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. The FDA also may refer applications for novel biologic candidates which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions on approval.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the biological product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete but the application is not ready for approval. A Complete Response Letter may request additional information or clarification, including new clinical studies. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the re-submitted BLA does not satisfy the criteria for approval.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">If a product receives regulatory approval, such approval is limited to the conditions of use (e.g., patient population, indication) described in the application. Further, depending on the specific risk(s) to be addressed, the FDA may require that contraindications, warnings or precautions be included in the product labeling, require that post-approval trials, including Phase IV clinical trials, be conducted to further assess a product&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a Risk Evaluation and Mitigation Strategy, or REMS, plan if it determines that a REMS is necessary to ensure that the benefits of the product outweigh its risks and to assure the safe use of the biological product, which can materially affect the potential market and profitability of the product. The REMS plan could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. The FDA may prevent or limit further marketing of a product based on the results of post- marketing trials or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Expedited Review and Approval</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">A sponsor may seek approval of its product candidate under programs designed to accelerate the FDA&#8217;s review and approval of new drugs and biological products that meet certain criteria. Specifically, new drugs and biological products are eligible for fast track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. For a fast track product, the FDA may consider sections of the BLA for review on a rolling basis before the complete application is submitted if relevant criteria are met. A fast track designated product candidate may also qualify for priority review.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Under the accelerated approval program, the FDA may approve a BLA on the basis of either a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Post-marketing studies or completion of ongoing studies after marketing approval are generally required to verify the biologic&#8217;s clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to the clinical benefit. In addition, the Food and Drug Administration Safety and Innovation Act, or FDASIA, which was enacted and signed into law in 2012, established the new Breakthrough Therapy designation. A sponsor may seek FDA designation of its product candidate as a breakthrough therapy if the product candidate is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Sponsors may request the FDA to designate a breakthrough therapy at the time of or any time after the submission of an IND, but ideally before an end-of-phase 2 meeting with the FDA. If the FDA designates a breakthrough therapy, it may take actions appropriate to expedite the development and review of the application, which may include holding meetings with the sponsor and the review team throughout the development of the therapy; providing timely advice to, and interactive communication with, the sponsor regarding the development of the drug to ensure that the development program to gather the nonclinical and clinical data necessary for approval is as efficient as practicable; involving senior managers and experienced review staff, as appropriate, in a collaborative, cross-disciplinary review; assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor; and considering alternative clinical trial designs when scientifically appropriate, which may result in smaller trials or more efficient trials that require less time to complete and may minimize the number of patients exposed to a potentially less efficacious treatment.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Fast Track designation, priority review and breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Post-Approval Requirements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">All therapeutic products manufactured or distributed pursuant to FDA approval or licensure are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements under the PDUFA for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications containing clinical data. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP requirements, which impose significant procedural and documentation requirements. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements on manufacturers. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. CEL-SCI cannot be certain that it, or CEL-SCI&#8217;s present or future suppliers, will be able to comply with the cGMP regulations and other FDA regulatory requirements. If CEL-SCI is not able to comply with these requirements, the FDA may, among other things, take enforcement action or seek sanctions against use, impose restrictions on a product or its manufacturer, require CEL-SCI to recall a product from distribution, or withdraw approval of the BLA.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">fines, warning letters or holds on post-approval clinical studies;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;</td></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">product seizure or detention, or refusal to permit the import or export of products;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">injunctions or the imposition of civil or criminal penalties; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">consent decrees, corporate integrity agreements, debarment, or exclusion from federal healthcare programs; or mandated modification of promotional materials and labeling and the issuance of corrective information.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">The FDA closely regulates the marketing, labeling, advertising and promotion of drugs and biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of unapproved, or &#8220;off-label,&#8221; uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Orphan Drug Designation</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs or biologics intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States and there is no reasonable expectation that the cost of developing and making the drug for this type of disease or condition will be recovered from sales in the United States.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market a drug for the same indication for a period of 7 years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity. Orphan drug exclusivity also could block the approval of one of CEL-SCI&#8217;s products for seven years if a competitor obtains approval of a product before CEL-SCI does, for the same indication CEL-SCI is seeking, or if CEL-SCI&#8217;s product candidate is determined to be contained within the scope of the competitor&#8217;s product for the same indication or disease. If one of CEL-SCI&#8217;s products designated as an orphan drug receives marketing approval for an indication broader than that which is designated, it may not be entitled to orphan drug exclusivity. Orphan drug status in the European Union has similar, but not identical, requirements and benefits.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Orphan drug designation must be requested before submitting a BLA to the FDA for review and approval. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Multikine has received Orphan Drug Status from the FDA.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Other U.S. Health Care Laws</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s sales, promotion, medical education and other activities following product approval will be subject to regulation by numerous regulatory and law enforcement authorities in the United States in addition to the FDA, including potentially the Federal Trade Commission, the Department of Justice, the Centers for Medicare and Medicaid Services, other divisions of the Department of Health and Human Services and state and local governments. CEL-SCI&#8217;s promotional and scientific/educational programs must comply with the anti-kickback provisions of the Social Security Act, the Foreign Corrupt Practices Act, the False Claims Act, the Physician Payments Sunshine Act, the Veterans Health Care Act and similar state laws.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Depending on the circumstances, failure to meet these applicable regulatory requirements can result in criminal prosecution, fines or other penalties, exclusion from government health care programs, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals, private &#8220;qui tam&#8221; actions brought by individual whistleblowers under the False Claims Act in the name of the government or refusal to allow CEL-SCI to enter into supply contracts, including government contracts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Coverage, Pricing and Reimbursement in the U.S.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Sales of pharmaceutical products depend significantly on the availability of third-party coverage and reimbursement. Third-party payors include government health administrative authorities, managed care providers, private health insurers and other organizations. These third-party payors are increasingly challenging the price and examining the cost-effectiveness of medical products and services. In addition, significant uncertainty exists as to the reimbursement status of newly approved healthcare products and new drug classes, including biological products such as CEL-SCI&#8217;s product candidates. CEL-SCI may need to conduct expensive clinical studies to demonstrate the comparative cost-effectiveness of its products. The product candidates that CEL-SCI develops may not be considered cost-effective. It is time consuming and expensive for CEL-SCI to seek reimbursement from third- party payors. Reimbursement may not be available or sufficient to allow CEL-SCI to sell its products on a competitive and profitable basis.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect CEL-SCI&#8217;s ability to sell its products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Foreign Regulation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">In addition to regulations in the United States, CEL-SCI will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its products to the extent CEL-SCI chooses to develop or sell any products outside of the United States. The approval process varies from country to country and the time may be longer or shorter than that required to obtain FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 1B. RISK FACTORS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">The risks described below could adversely affect the price of CEL-SCI&#8217;s common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Risk Factor Summary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI has incurred significant losses since its inception and anticipates that it will continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI will require substantial additional capital to remain in operation. A failure to obtain this necessary capital when needed could force CEL-SCI to delay, limit, reduce or terminate the product candidates&#8217; development or commercialization efforts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The costs of the product candidates&#8217; development and clinical trials are difficult to estimate and will be very high for many years, preventing CEL-SCI from making a profit for the foreseeable future, if ever.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI has not established a definite plan for the marketing of Multikine, if approved.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI depends heavily on the success of Multikine, for which Phase III results have been announced, while its other candidates are still in preclinical phases. CEL-SCI&#8217;s product candidates must undergo rigorous preclinical and clinical testing and regulatory approvals, which could be costly and time-consuming and subject CEL-SCI to unanticipated delays or prevent CEL-SCI from marketing any products. If CEL-SCI is unable to advance its product candidates in clinical development, obtain regulatory approval and ultimately commercialize its product candidates, or experience significant delays in doing so, CEL-SCI&#8217;s business will be materially harmed.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Even if CEL-SCI obtains regulatory approval for its investigational products, CEL-SCI will be subject to stringent, ongoing government regulation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI&#8217;s product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial utility of an approved prescribing label, or result in significant negative consequences following marketing approval, if any.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Biologics carry unique risks and uncertainties, which could have a negative impact on future results of CEL-SCI&#8217;s operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The current and future relationships with healthcare professionals, principal investigators, consultants, potential customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable healthcare laws and regulations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI&#8217;s commercial success depends, in part, upon attaining significant market acceptance of its product candidates, if approved, among physicians, patients, healthcare payors and major operators of cancer clinics.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI&#8217;s patents might not protect its technology from competitors, in which case CEL-SCI may not have any advantage over competitors in selling any products that CEL-SCI may develop.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Much of CEL-SCI&#8217;s intellectual property is protected as trade secrets or confidential know-how, not by patents.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">You may experience future dilution as a result of future equity offerings or other equity issuances by CEL-SCI.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The price of CEL-SCI&#8217;s common stock has been volatile and is likely to continue to be volatile, which could result in substantial losses for CEL-SCI&#8217;s shareholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Risks Related to CEL-SCI</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI has incurred significant losses since its inception and anticipates that it will continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has a history of net losses, expects to incur substantial losses and have negative operating cash flow for the foreseeable future, and may never achieve or maintain profitability. Since the date of its formation and through September 30, 2023, CEL-SCI incurred net losses of approximately $487 million. CEL-SCI has relied principally upon the proceeds from the public and private sales of its securities to finance its activities to date. To date, CEL-SCI has not commercialized any products or generated any revenue from the sale of products, and CEL-SCI does not expect to generate any product revenue for the foreseeable future. CEL-SCI does not know whether or when it will generate product revenue or become profitable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI is heavily dependent on the success of Multikine for which Phase III data has been announced and presented at ASCO 2022, ESMO 2022 ECHNO 2023, ESTRO 2023 AND ESMO 2023. CEL-SCI cannot be certain that Multikine will receive regulatory approval or be successfully commercialized even if CEL-SCI receives regulatory approval. Multikine is the only product candidate in late-stage clinical development and CEL-SCI&#8217;s business currently depends heavily on its successful development, regulatory approval and commercialization. CEL-SCI has no drug products for sale currently and may never be able to develop approved and marketable drug products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Even if CEL-SCI succeeds in developing and commercializing one or more of its product candidates, CEL-SCI expects to continue to incur significant operating and capital expenditures as CEL-SCI:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">continues to undertake preclinical development and clinical trials for product candidates;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">seeks regulatory approvals for product candidates; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">implements additional internal systems and infrastructure.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">To become and remain profitable, CEL-SCI must succeed in developing and commercializing product candidates which must generate significant revenue. This will require CEL-SCI to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of its product candidates, discovering or acquiring additional product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling any products for which CEL-SCI may obtain regulatory approval. CEL-SCI is only in the preliminary stages of most of these activities. CEL-SCI may never succeed in these activities and, even if CEL-SCI does, may never generate revenue that is significant enough to achieve profitability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Even if CEL-SCI does achieve profitability, it may not be able to sustain or increase profitability on a quarterly or annual basis. The failure to become and remain profitable could depress the value of CEL-SCI&#8217;s common stock and could impair its ability to raise capital, expand its business, maintain research and development efforts, diversify product offerings or even continue in operation. A decline in the value of CEL-SCI&#8217;s common stock could cause its stockholders to lose all or part of their investment.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI has identified conditions and events that raise substantial doubt about its ability to continue as a going concern for more than twelve months from the date of these financial statements.</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Primarily as a result of CEL-SCI&#8217;s losses incurred to date, CEL-SCI&#8217;s expected continued future losses, and the uncertainties associated with obtaining regulatory approval and ultimately commercializing its products, management has identified conditions and events that raise substantial doubt about CEL-SCI&#8217;s ability to continue as a going concern. CEL-SCI&#8217;s ability to continue as a going concern is contingent upon, among other factors, the sale of its securities or obtaining alternate financing.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI will require substantial additional capital to remain in operation. A failure to obtain this necessary capital when needed could force CEL-SCI to delay, limit, reduce or terminate the product candidates&#8217; development or commercialization efforts.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As of September 30, 2023, CEL-SCI had cash and cash equivalents of approximately $4.1 million. CEL-SCI believes that it will continue to expend substantial resources for the foreseeable future developing Multikine, LEAPS and any other product candidates or technologies that it may develop or acquire. These expenditures will include costs associated with research and development, obtaining regulatory approvals and having the products manufactured, as well as marketing and selling products approved for sale, if any. In addition, other unanticipated costs may arise. CEL-SCI cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of the product candidates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s future capital requirements depend on many factors, including:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the cost of completing Phase III clinical development of Multikine for the treatment of certain head and neck cancers;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the cost of a Phase IV confirmatory study;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the results of the applications to and meetings with the FDA, the EMA and other regulatory authorities and the consequential effect on operating costs;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the cost, timing and outcome of the efforts to obtain marketing approval for Multikine in the United States, Europe and in other jurisdictions, including the preparation and filing of regulatory submissions for Multikine with the FDA, the EMA and other regulatory authorities;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the scope, progress, results and costs of additional preclinical, clinical, or other studies for additional indications for Multikine, LEAPS and other product candidates and technologies that CEL-SCI may develop or acquire;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the timing of, and the costs involved in, obtaining regulatory approvals for LEAPS if clinical studies are successful;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the cost and timing of future commercialization activities for the products, if any of the product candidates are approved for marketing, including product manufacturing, marketing, sales and distribution costs;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the revenue, if any, received from commercial sales of the product candidates for which CEL-SCI receives marketing approval;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the cost of having the product candidates manufactured for clinical trials and in preparation for commercialization;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the costs involved in preparing, filing and prosecuting patent applications and maintaining, defending and enforcing its intellectual property rights, including litigation costs, and the outcome of such litigation; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the extent to which CEL-SCI acquires or in-licenses other products or technologies.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">27</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI will need to raise additional funds in order to continue its operations and additional funds may not be available when CEL-SCI needs them on terms that are acceptable to CEL-SCI, or at all. If adequate funds are not available to CEL-SCI on a timely basis, CEL-SCI may be required to delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for Multikine, LEAPS, or any other product candidates or technologies that CEL-SCI develops or acquires, or delay, limit, reduce or terminate its sales and marketing activities that may be necessary to commercialize its product candidates. Due to recurring losses from operations and future liquidity needs, there is substantial doubt about CEL-SCI&#8217;s ability to continue as a going concern without additional capital becoming available. The substantial doubt about CEL-SCI&#8217;s ability to continue as a going concern could have an adverse impact on CEL-SCI&#8217;s ability to execute its business plan, result in the reluctance on the part of certain suppliers to do business with CEL-SCI, or adversely affect CEL-SCI&#8217;s ability to raise additional debt or equity capital.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>The costs of the product candidates&#8217; development and clinical trials are difficult to estimate and will be very high for many years, preventing CEL-SCI from making a profit for the foreseeable future, if ever.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Clinical and other studies necessary to obtain approval of a new drug or biologic can be time consuming and costly, especially in the United States, but also in foreign countries. The estimates of the costs associated with future clinical trials and research may be substantially lower than what CEL-SCI actually experiences. It is impossible to predict what CEL-SCI will face in the development of a product candidate such as Multikine. The purpose of clinical trials is to provide both CEL-SCI and regulatory authorities with safety and efficacy data in humans. The difficult and often complex steps necessary to obtain regulatory approval, especially that of the FDA and the EMA, involve significant costs and may require several years to complete. CEL-SCI expects that it will need substantial additional financing over an extended period of time in order to fund the costs of future clinical trials, related research, and general and administrative expenses.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI&#8217;s LEAPS technology may not result in a viable drug candidate</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Using CEL-SCI&#8217;s LEAPS technology, CEL-SCI is developing a LEAPS immunotherapy for the potential treatment of Rheumatoid Arthritis. However, the development of this technology is in a preliminary stage and CEL-SCI is currently focused on getting Multikine approved for sale. There can be no assurance that the LEAPS technology will be successful in treating any disease. CEL-SCI&#8217;s primary focus at present is seeking the approval of Multikine for the treatment of head and neck cancer.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>An adverse determination in any future legal proceedings could have a material adverse effect on CEL-SCI.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI may be the target of claims asserting violations of securities fraud and derivative actions, or other litigation or arbitration proceedings in the future. Any future litigation could result in substantial costs and divert management&#8217;s attention and resources. These legal proceedings may result in large judgments or settlements against CEL-SCI, any of which could have a material adverse effect on its business, operating results, financial condition and liquidity.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">28</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Compliance with changing regulations concerning corporate governance and public disclosure may result in additional expenses.</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Changing laws, regulations and standards relating to corporate governance and public disclosure may create uncertainty regarding compliance matters. New or changed laws, regulations and standards are subject to varying interpretations in many cases. As a result, their application in practice may evolve over time. CEL-SCI is committed to maintaining high standards of corporate governance and public disclosure. Complying with evolving interpretations of new or changing legal requirements may cause CEL-SCI to incur higher costs as CEL-SCI revises current practices, policies and procedures, and may divert management time and attention from potential revenue-generating activities to compliance matters. If the efforts to comply with new or changed laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, CEL-SCI&#8217;s reputation may also be harmed. Further, CEL-SCI&#8217;s board members, chief executive officer, and other executive officers could face an increased risk of personal liability in connection with the performance of their duties. As a result, CEL-SCI may have difficulty attracting and retaining qualified board members and executive officers, which could harm its business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI has not established a definite plan for the marketing of Multikine, if approved.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has not established a definitive plan for marketing Multikine nor has CEL-SCI established a price structure for any of its product candidates, if approved. However, CEL-SCI intends, if it is in a position to do so, to sell Multikine itself in certain markets where it is approved, and or to enter into written marketing agreements with various third parties with established sales forces in such markets. The sales forces in turn would, CEL-SCI believes, focus on selling Multikine to targeted cancer centers, physicians and clinics involved in the treatment of head and neck cancer. CEL-SCI has already licensed future sales of Multikine, if approved, to three companies: Teva Pharmaceutical Industries Ltd. in Israel, Turkey, Serbia and Croatia; Orient Europharma in Taiwan, Singapore, Hong Kong, Malaysia, South Korea, the Philippines, Australia and New Zealand; and Byron BioPharma, LLC in South Africa. CEL-SCI believes that these companies will have the resources to market Multikine appropriately in their respective territories, if approved, but there is no guarantee that they will. There is no assurance that CEL-SCI will be able to find qualified third-party partners to market its products in other areas, on terms that are favorable to CEL-SCI, or at all.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI may encounter problems, delays and additional expenses in developing marketing plans with third parties. In addition, even if Multikine, if approved, is cost-effective and demonstrated to increase overall patient survival, CEL-SCI may experience other limitations involving the proposed sale of Multikine, such as uncertainty of third-party coverage and reimbursement. There is no assurance that CEL-SCI can successfully market Multikine, if approved, or any other product candidates it may develop.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI hopes to expand its clinical development capabilities in the future, and any difficulties hiring or retaining key personnel or managing this growth could disrupt its operations.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI is highly dependent on the principal members of its management and development staff. CEL-SCI expects to expand its clinical development and manufacturing capabilities, which will involve hiring additional employees. Future growth will require CEL-SCI to continue to implement and improve its managerial, operational and financial systems and continue to retain, recruit and train additional qualified personnel, which may impose a strain on its administrative and its operational infrastructure. The competition for qualified personnel in the biopharmaceutical field is intense. CEL-SCI is highly dependent on its ability to attract, retain and motivate highly qualified management and specialized personnel required for clinical development. Due to limited resources, CEL-SCI may not be able to effectively manage the expansion of its operations or recruit and train additional qualified personnel. If CEL-SCI is unable to retain key personnel or manage its future growth effectively, CEL-SCI may not be able to implement its business plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">29</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>If product liability or patient injury lawsuits are brought against CEL-SCI, CEL-SCI may incur substantial liabilities and may be required to limit clinical testing or future commercialization of Multikine or its other product candidates.</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI faces an inherent risk of product liability as a result of the clinical testing of Multikine and other product candidates and will face an even greater risk if CEL-SCI is able to commercialize any of its product candidates. For example, CEL-SCI may be sued if its Multikine or LEAPS product candidates, or any other future product candidates, allegedly cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing or, if approved, marketing, sale or during administration to patients. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Furthermore, Multikine is made, in part, from components of human blood. There are inherent risks associated with products that involve human blood such as possible contamination with viruses, including hepatitis or HIV. Any possible contamination could cause injuries to patients who receive contaminated Multikine, or could require CEL-SCI to destroy batches of Multikine, thereby subjecting CEL-SCI to possible financial losses, lawsuits and harm to its business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If CEL-SCI cannot successfully defend itself against product liability claims, CEL-SCI may incur substantial liabilities or be required to limit or cease the clinical testing or commercialization of its product candidates, if approved. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">decreased demand for Multikine or other product candidates, if approved and commercialized, or clinical holds or suspension of the IND while the candidates are still in clinical development;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">injury to CEL-SCI&#8217;s reputation;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">withdrawal of existing, or failure to enroll additional, clinical trial participants;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">costs to defend any related litigation;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">a diversion of management&#8217;s time and resources;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">substantial monetary awards to trial participants or patients;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">recalls of approved products, withdrawal of BLA approvals or new labeling, marketing or promotional restrictions;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">loss of revenue;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">inability to commercialize Multikine or other product candidates; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">a decline in the price of CEL-SCI&#8217;s common stock.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Although CEL-SCI has product liability insurance for Multikine in the amount of $10 million, the successful prosecution of a product liability case against CEL-SCI could have a materially adverse effect upon its business if the amount of any judgment exceeds the insurance coverage. Any claim that may be brought against CEL-SCI could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by CEL-SCI&#8217;s insurance or that is in excess of the limits of the insurance coverage. CEL-SCI&#8217;s insurance policies also have various exclusions, and CEL-SCI may be subject to a claim for which CEL-SCI has no coverage. CEL-SCI may have to pay any amounts awarded by a court or negotiated in a settlement that exceed the coverage limitations or that are not covered by its insurance, and CEL-SCI may not have, or be able to obtain, sufficient capital to pay such amounts. CEL-SCI completed enrollment in the Phase III clinical trial for Multikine in September 2016. Although no claims have been brought to date, participants in the clinical trials could bring civil actions against CEL-SCI for any unanticipated harmful effects allegedly arising from the use of Multikine or any other product candidate that CEL-SCI may attempt to develop.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">30</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI&#8217;s commercial success depends, in part, upon attaining significant market acceptance of its product candidates, if approved, among physicians, patients, healthcare payors and major operators of cancer clinics.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Even if CEL-SCI obtains regulatory approval for its product candidates, any resulting product may not gain market acceptance among physicians, healthcare payors, patients and the medical community, which are critical to commercial success. Market acceptance of any product candidate for which CEL-SCI receives approval depends on a number of factors, including:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the efficacy and safety of the products as demonstrated in clinical trials;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the timing of market introduction of such product as well as competitive products;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the clinical indications for which the biological product is approved;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the approval, availability, market acceptance and reimbursement for the companion diagnostic, if appropriate or necessary;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">acceptance by physicians, major operators of cancer clinics and patients of the biologic as a safe and effective treatment;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the potential and perceived advantages of such product candidate over alternative treatments, especially with respect to patient subsets that are targeted with such product;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the safety of such product seen in a broader patient group, including its use outside the approved indications;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the cost of treatment in relation to alternative treatments;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the availability of adequate reimbursement and pricing by third-party payors and government authorities;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">relative convenience and ease of administration;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the prevalence and severity of adverse side effects; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the effectiveness of sales and marketing efforts.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If CEL-SCI&#8217;s product candidates are approved but fail to achieve an adequate level of acceptance by physicians, healthcare payors and patients, CEL-SCI will not be able to generate significant revenues, and CEL-SCI may not become or remain profitable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Under CEL-SCI&#8217;s amended bylaws, stockholders that initiate certain proceedings may be obligated to reimburse CEL-SCI and its officers and directors for all fees, costs and expenses incurred in connection with such proceedings if the claim proves unsuccessful.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On February 18, 2015, CEL-SCI adopted new bylaws which include a fee-shifting provision in Article X for stockholder claims. Article X provides that in the event any stockholder initiates or asserts a claim against CEL-SCI, or any of its officers or directors, including any derivative claim or claim purportedly filed on CEL-SCI&#8217;s behalf, and the stockholder does not obtain a judgment on the merits that substantially achieves, in substance and amount, the full remedy sought, then the stockholder will be obligated to reimburse CEL-SCI and any of its officers or directors named in the action, for all fees, costs and expenses of every kind and description that CEL-SCI or its officers or directors may incur in connection with the claim. In adopting Article X, it is the intent that:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">31</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">all actions, including federal securities law claims, would be subject to Article X;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the phrase &#8220;a judgment on the merits&#8221; means the determination by a court of competent jurisdiction on the matters submitted to the court;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the phrase &#8220;substantially achieves, in both substance and amount&#8221; means the plaintiffs in the action would be awarded at least 90% of the relief sought;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">only persons who were stockholders at the time an action was brought would be subject to Article X; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">in addition to CEL-SCI, only the directors or officers named in the action would be allowed to recover.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The fee-shifting provision contained in Article X of the bylaws is not limited to specific types of actions, but is rather potentially applicable to the fullest extent permitted by law. Fee-shifting bylaws are relatively new and untested. The case law and potential legislative action on fee-shifting bylaws are evolving and there exists considerable uncertainty regarding the validity of, and potential judicial and legislative responses to, such bylaws. For example, it is unclear whether the ability to invoke the fee-shifting bylaw in connection with claims under the federal securities laws would be pre-empted by federal law. Similarly, it is unclear how courts might apply the standard that a claiming stockholder must obtain a judgment that substantially achieves, in substance and amount, the full remedy sought. The application of the fee-shifting bylaw in connection with such claims, if any, will depend in part on future developments of the law. CEL-SCI cannot assure its shareholders that CEL-SCI will or will not invoke the fee-shifting bylaw in any particular dispute. In addition, given the unsettled state of the law related to fee-shifting bylaws, such as CEL-SCI&#8217;s, CEL-SCI may incur significant additional costs associated with resolving disputes with respect to such bylaw, which could adversely affect CEL-SCI&#8217;s business and financial condition.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If a stockholder that brings any such claim, suit, action or proceeding is unable to obtain the required judgment, the attorneys&#8217; fees and other litigation expenses that might be shifted to a claiming stockholder are potentially significant. This fee-shifting bylaw may therefore dissuade or discourage stockholders and their attorneys from initiating lawsuits or claims against CEL-SCI or its directors and officers. In addition, it may impact the fees, contingency or otherwise, required by potential plaintiffs&#8217; attorneys to represent the stockholders or otherwise discourage plaintiffs&#8217; attorneys from representing the stockholders at all. As a result, this bylaw may limit the ability of stockholders to alter CEL-SCI&#8217;s management and direction, particularly through litigation or the threat of litigation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>The provision of the amended bylaws requiring exclusive venue in the U.S. District Court for Delaware for certain types of lawsuits may have the effect of discouraging lawsuits against CEL-SCI and its directors and officers.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Article X of CEL-SCI&#8217;s amended bylaws provides that stockholder claims brought against CEL-SCI, or its officers or directors, including any derivative claim or claim purportedly filed on its behalf, must be brought in the U.S. District Court for the district of Delaware and that with respect to any such claim, the laws of Delaware will apply.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The exclusive forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum the stockholder finds favorable for disputes with CEL-SCI or its directors or officers and may have the effect of discouraging lawsuits with respect to claims that may benefit CEL-SCI or its stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">32</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>A provision in our Bylaws regarding shareholder claims may not be enforceable.</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Article X of our bylaws provides that stockholder claims brought against us, or our officers or directors, including any derivative claim or claim purportedly filed on our behalf, must be brought in the U.S. District Court for the district of Delaware.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Although it is our intent that this provision applies to actions arising under the Securities Act of 1933 and the Securities Exchange Act of 1934 there is uncertainty as to whether a court would enforce this provision since Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations under the Securities Act.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In addition, since this provision in our bylaws applies to state law claims there is uncertainty as to whether any court would enforce this provision.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Risks Related to Clinical Development, Government Approvals and the Marketing of Biopharmaceutical Products</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI depends heavily on the success of Multikine, for which Phase III data has been presented, while its other candidates are still in preclinical phases. CEL-SCI&#8217;s product candidates must undergo rigorous preclinical and clinical testing and regulatory approvals, which could be costly and time-consuming and subject CEL-SCI to unanticipated delays or prevent CEL-SCI from marketing any products. If CEL-SCI is unable to advance its product candidates in clinical development, obtain regulatory approval and ultimately commercialize its product candidates, or experiences significant delays in doing so, CEL-SCI&#8217;s business will be materially harmed.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI currently has no products approved for sale and CEL-SCI cannot guarantee that it will ever have marketable products. CEL-SCI&#8217;s product candidates are subject to premarket approval from the FDA in the United States, the EMA in the European Union, and by comparable agencies in most foreign countries before they can be sold. Before obtaining marketing approval, these product candidates must undergo costly and time consuming preclinical and clinical testing which could subject CEL-SCI to unanticipated delays and may prevent CEL-SCI from marketing the product candidates in the future. There can be no assurance that such approvals will be granted on a timely basis, if at all.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of the product candidates may not be predictive of the results of later-stage clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. CEL-SCI&#8217;s current and future clinical trials may not be successful.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI is in the early development stages for the candidates designed using its LEAPS technology and has not yet initiated any clinical studies for any of those product candidates. Clinical trials can be delayed for a variety of reasons, including delays related to:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the availability of financial resources needed to commence and complete the planned trials;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">obtaining regulatory approval to commence a trial;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">obtaining Institutional Review Board, or IRB, approval at each clinical trial site;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">recruiting suitable patients to participate in a trial;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">having patients complete a trial or return for post-treatment follow-up;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">clinical trial sites deviating from trial protocol or dropping out of a trial;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">adding new clinical trial sites; or</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">manufacturing sufficient quantities of the product candidate for use in clinical trials.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">33</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the competence of the CRO running the study, size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials and clinicians' and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications CEL-SCI is investigating. Furthermore, CEL-SCI relies on CROs and clinical trial sites to ensure the proper and timely conduct of the clinical trials and while CEL-SCI has agreements governing their committed activities, CEL-SCI has limited influence over their actual performance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI could also encounter significant delays and/or need to terminate a development program for a product candidate if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of the product candidates while existing treatments have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by CEL-SCI, one or more of the IRBs for the institutions in which such trials are being conducted, by CEL-SCI upon a final recommendation by the Independent Data Monitoring Committee, or IDMC, with which CEL-SCI agrees for such trial, or by FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or the clinical protocols, as a result of inspection of the clinical trial operations or trial site(s) by FDA or other regulatory authorities, the imposition of a clinical hold or partial clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. The occurrence of any one or more of these events would have significant and severe material consequences for CEL-SCI and could impact CEL-SCI&#8217;s ability to continue as a going concern.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If CEL-SCI experiences termination of, or delays in the completion of, any clinical trial of its product candidates, the commercial prospects for the product candidates will be harmed, and the ability to generate product revenues will be delayed. In addition, any delays in completing the clinical trials will increase the costs, slow the product development and approval process and jeopardize the ability to commence product sales and generate revenues. Any of these occurrences may harm CEL-SCI&#8217;s business, prospects, financial condition and results of operations significantly. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to a delay or the denial of regulatory approval for the product candidates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI cannot be certain when or under what conditions it will undertake future clinical trials. Early trials for the other product candidates, or the plans for later trials, may not satisfy the requirements of regulatory authorities, such as the FDA. CEL-SCI may fail to find subjects willing to enroll in the trials. Accordingly, the clinical trials relating to the product candidates may not be completed on schedule, the FDA or foreign regulatory agencies may order CEL-SCI to stop or modify research, or these agencies may not ultimately approve any of the product candidates for commercial sale. Varying interpretations of the data obtained from pre-clinical and clinical testing could delay, limit or prevent regulatory approval of the product candidates. The data collected from the clinical trials may not be sufficient to support regulatory approval of the various product candidates, including Multikine. The failure to adequately demonstrate the safety and efficacy of any of the product candidates would delay or prevent regulatory approval of the product candidates in the United States, which could prevent CEL-SCI from achieving profitability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">34</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The development and testing of product candidates and the process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include, among other actions, refusal to approve pending applications, withdrawal of an approval, a clinical hold, termination of the Phase III study, warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, and payment of civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on CEL-SCI.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The requirements governing the conduct of clinical trials, manufacturing and marketing of the product candidates, including Multikine, outside the United States vary from country to country. Foreign approvals may take longer to obtain than FDA approvals and can require, among other things, additional testing and different trial designs. Foreign regulatory approval processes include all of the risks associated with the FDA approval process. Some of those agencies also must approve prices for products approved for marketing. Approval of a product by the FDA or the EMA does not ensure approval of the same product by the health authorities of other countries. In addition, changes in regulatory requirements for product approval in any country during the clinical trial process and regulatory agency review of each submitted new application may cause delays or rejections.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has only limited experience in filing and pursuing applications necessary to gain regulatory approvals. The lack of experience may impede its ability to obtain timely approvals from regulatory agencies, if at all. CEL-SCI will not be able to commercialize Multikine and other product candidates until CEL-SCI has obtained regulatory approval. In addition, regulatory authorities may also limit the types of patients to which CEL-SCI or its third-party partners may market Multikine (if approved) or the other product candidates. Any failure to obtain or any delay in obtaining required regulatory approvals may adversely affect CEL-SCI&#8217;s or its third-party partners&#8217; ability to successfully market the product candidates even if they are approved.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Even if CEL-SCI obtains regulatory approval for its investigational products, CEL-SCI will be subject to stringent, ongoing government regulation.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If CEL-SCI&#8217;s investigational products receive regulatory approval, either in the United States or internationally, those products will be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval and may contain requirements for potentially costly post-marketing testing, including Phase IV clinical trials, and surveillance of the safety and efficacy of the investigational products. CEL-SCI will continue to be subject to extensive regulatory requirements. These regulations are wide-ranging and govern, among other things:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">product design, development and manufacture;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">product application and use</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">adverse drug experience monitoring and reporting;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">product advertising and promotion;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">product manufacturing, including compliance with good manufacturing practices</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">record keeping requirements;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">registration and listing of products with the FDA, EMA and other state and national agencies;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">product storage and shipping;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">drug sampling and distribution requirements;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">electronic record and signature requirements; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">labeling changes or modifications.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">35</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI and any of its third-party manufacturers or suppliers must continually adhere to federal regulations setting forth human drug and biologic manufacturing requirements, known as current Good Manufacturing Practices, or cGMPs, and their foreign equivalents, which are enforced by the FDA, the EMA and other national regulatory bodies through their facilities inspection programs. If the facilities, or the facilities of the contract manufacturers or suppliers, cannot pass a pre-approval inspection by regulators or fail such inspections in the future, the FDA, EMA or other national regulators will not approve the marketing applications for the product candidates, or may withdraw any prior approval. In complying with cGMP and foreign regulatory requirements, CEL-SCI and any of its potential third-party manufacturers or suppliers will be obligated to expend time, money and effort in production, record-keeping and quality control to ensure that the product candidates meet applicable specifications and other requirements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If CEL-SCI does not comply with regulatory requirements at any stage, whether before or after marketing approval is obtained, CEL-SCI may be subject to, among other things, license suspension or revocation, criminal prosecution, seizure, injunction, fines, be forced to remove a product from the market or experience other adverse consequences, including restrictions or delays in obtaining regulatory marketing approval for such products or for other product candidates for which CEL-SCI seeks approval. This could materially harm CEL-SCI&#8217;s financial results, reputation and stock price. Additionally, CEL-SCI may not be able to obtain the labeling claims necessary or desirable for product promotion. If CEL-SCI or other parties identify adverse effects after any of the products are on the market, or if manufacturing problems occur, regulatory approval may be suspended or withdrawn. CEL-SCI may be required to reformulate products, conduct additional clinical trials, make changes in product labeling or indications of use, or submit additional marketing applications to support any changes. If CEL-SCI encounters any of the foregoing problems, its business and results of operations will be harmed and the market price of its common stock may decline.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The FDA and other governmental authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of CEL-SCI&#8217;s product candidates. If CEL-SCI is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if CEL-SCI is not able to maintain regulatory compliance, CEL-SCI may lose any marketing approval that it may have obtained, which would adversely affect its business, prospects and ability to achieve or sustain profitability. CEL-SCI cannot predict the extent of adverse government regulations which might arise from future legislative or administrative action. Without government approval, CEL-SCI will be unable to sell any of its product candidates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI&#8217;s product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial utility of an approved prescribing label, or result in significant negative consequences following marketing approval, if any.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Undesirable side effects caused by its product candidates could cause CEL-SCI or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Results of the clinical trials could reveal a high and unacceptable severity and/or prevalence of these or other side effects. In such an event, the trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order CEL-SCI to cease further development of, or deny approval of, the product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm CEL-SCI&#8217;s business, financial condition and prospects significantly.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Additionally, if one or more of the product candidates receives marketing approval, and CEL-SCI or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including but not limited to the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">36</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">regulatory authorities may withdraw approvals of such product or require product recalls;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">regulatory authorities may require additional warnings on the label or impose restrictions on product distribution or use;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">regulatory authorities may require CEL-SCI to conduct new post-marketing studies or clinical trials;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">CEL-SCI could receive warning or untitled letters from the FDA or comparable notices of violations from foreign regulatory authorities;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">CEL-SCI may be required to create a medication guide outlining the risks of such side effects for distribution to patients;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">CEL-SCI could be sued and held liable for harm caused to patients; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">CEL-SCI&#8217;s reputation may suffer.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Any of these events could prevent CEL-SCI from achieving or maintaining market acceptance of a particular product candidate, if approved, and could significantly harm its business, results of operations and prospects.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI relies on third parties to conduct its preclinical and clinical trials. If these third parties do not successfully carry out their contractual duties and meet regulatory requirements, or meet expected deadlines, CEL-SCI may not be able to obtain regulatory approval for or commercialize the product candidates and its business could be substantially harmed.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI does not have the ability to independently conduct large clinical trials. CEL-SCI has relied upon and plans to continue to rely upon third-party CROs to prepare for, conduct, monitor and manage data for its ongoing preclinical and clinical programs, including the global Phase III trial for Multikine. CEL-SCI relies on these parties for all aspects of the execution of its clinical trials and although CEL-SCI diligently oversees and carefully manages the CROs, CEL-SCI directly controls only certain aspects of their activities and relies upon them to provide timely, complete, and accurate reports on the conduct of the studies. Although such third parties provide support and represent CEL-SCI for regulatory purposes in the context of the clinical trials, ultimately CEL-SCI is responsible for ensuring that each of the studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards, and the reliance on the CROs does not relieve CEL-SCI of its regulatory responsibilities. CEL-SCI and the CROs acting on CEL-SCI&#8217;s behalf, as well as principal investigators and trial sites, are required to comply with Good Clinical Practice, or GCP, and other applicable requirements, which are implemented through regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area, or EEA, and comparable foreign regulatory authorities for all of the products in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators, and trial sites. If CEL-SCI or any of the CROs fail to comply with applicable GCPs or other applicable regulations, the clinical data generated in the clinical trials may be determined to be unreliable and CEL-SCI may therefore need to enroll additional subjects in the clinical trials, or the FDA, EMA or comparable foreign regulatory authorities may require CEL-SCI to perform an additional clinical trial or trials before approving the marketing applications. Moreover, if CEL-SCI or any of the CROs, principal investigators, or trial sites, fail to comply with applicable regulatory and GCP requirements, CEL-SCI, the CROs, principal investigators, or trial sites may be subject to enforcement actions, such as fines, warning letters, untitled letters, clinical holds, civil or criminal penalties, and/or injunctions. CEL-SCI cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of the clinical trials comply with cGCP regulations. In addition, the clinical trials must be conducted with product produced under cGMP regulations. The failure to comply with these regulations may require CEL-SCI to delay or repeat clinical trials, which would delay the regulatory approval process.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">37</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If any of the relationships with the third-party CROs terminate, CEL-SCI may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. In addition, the CROs are not CEL-SCI&#8217;s employees, and except for remedies available to CEL-SCI under the agreements with such CROs, CEL-SCI cannot control whether or not they devote sufficient time and resources to the on-going clinical, nonclinical and preclinical programs. If CROs do not successfully fulfill their regulatory obligations, carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to the clinical protocols, regulatory requirements or for other reasons, the clinical trials may be extended, delayed or terminated, and CEL-SCI may not be able to obtain regulatory approval for, or successfully commercialize, the product candidates. As a result, CEL-SCI&#8217;s results of operations and the commercial prospects for the product candidates would be harmed, the costs could increase and the ability to generate revenues could be delayed.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays may occur, which can materially impact CEL-SCI&#8217;s ability to meet the desired clinical development timelines. Though CEL-SCI diligently oversees and carefully manages its relationships with the CROs, there can be no assurance that CEL-SCI will not encounter similar challenges or delays in clinical development in the future or that these delays or challenges will not have a material adverse impact on CEL-SCI&#8217;s business, financial condition and prospects.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI has obtained orphan drug designation from the FDA for Multikine for neoadjuvant, or primary, therapy in patients with squamous cell carcinoma of the head and neck, but CEL-SCI may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug or biologic intended to treat a rare disease or condition, which is defined as one occurring in a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug or biologic will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Even though CEL-SCI has received orphan drug designation for Multikine for the treatment of squamous cell carcinoma of the head and neck, CEL-SCI may not be the first to obtain marketing approval of a product for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. CEL-SCI believes this to be unlikely since it does not know of any other company with a similar technology in Phase III studies. In addition, exclusive marketing rights in the United States may be limited if CEL-SCI seeks approval for an indication broader than the orphan-designated indication, or may be lost if the FDA later determines that the request for designation was materially defective or if CEL-SCI is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if CEL-SCI obtains orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different drugs with different active moieties can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve another drug with the same active moiety for the same condition if the FDA concludes that the later drug is safer, more effective, or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">38</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Biologics carry unique risks and uncertainties, which could have a negative impact on future results of CEL-SCI&#8217;s operations.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The successful discovery, development, manufacturing and sale of biological products like CEL-SCI&#8217;s candidates is a long, expensive and uncertain process. There are unique risks and uncertainties with biologics. For example, access to and supply of necessary biological materials, such as cell lines, may be limited and governmental regulations restrict access to and regulate the transport and use of such materials. In addition, the development, manufacturing and sale of biologics is subject to regulations that are often more complex and extensive than the regulations applicable to other pharmaceutical products. Manufacturing biologics, especially in large quantities, is often complex and may require the use of innovative technologies. Such manufacturing also requires facilities specifically designed and validated for this purpose and sophisticated quality assurance and quality control procedures. Biologics are also frequently costly to manufacture because production inputs are derived from living animal or plant material, and some biologics cannot be made synthetically. Failure to successfully discover, develop, manufacture and sell its biological product candidates would adversely impact CEL-SCI&#8217;s business and future results of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI may face substantial competition, which may result in others discovering, developing or commercializing competing products more quickly or more successfully than CEL-SCI.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The development and commercialization of new drug and biological products is highly competitive. CEL-SCI expects to face competition with respect to any product candidates that CEL-SCI may seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Many of the companies which CEL-SCI may compete with in the future have significantly greater financial resources and expertise in research and development, manufacturing, nonclinical studies, conducting clinical trials, obtaining marketing approvals and marketing approved products than CEL-SCI. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of CEL-SCI&#8217;s potential competitors. Smaller and early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties may compete with CEL-SCI in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, CEL-SCI&#8217;s programs.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI may be unable to successfully scale-up manufacturing of its lead product candidate Multikine in sufficient quality and quantity, which would delay or prevent CEL-SCI from commercializing this product, if approved for marketing by the FDA or other regulatory agencies.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In order to commercialize its product candidates, CEL-SCI will need to manufacture them in large quantities. At the present time, CEL-SCI is not manufacturing Multikine while the manufacturing plant for Multikine is being validated to produce commercial quantities of Multikine, if approved. CEL-SCI may be unable to successfully increase the manufacturing capacity for its lead product candidate Multikine due to issues that may arise during scale-up activities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">39</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Further, in order to release product and demonstrate stability of product candidates for future commercial use, CEL-SCI&#8217;s analytical methods must be validated in accordance with regulatory guidelines. CEL-SCI may not be able to successfully validate or maintain validation of its analytical methods during scale-up or demonstrate adequate purity, stability or comparability of its biological product candidates in a timely or cost-effective manner, or at all. Even if CEL-SCI believes its manufacturing processes meet all of the regulatory manufacturing requirements, the FDA will review those processes and the manufacturing facility as part of the review of the future BLA for Multikine when submitted. If CEL-SCI is unable to successfully scale up the manufacture of Multikine in sufficient quality and quantity, or if CEL-SCI encounters validation issues, the development, testing, and clinical trials of future product candidates, may be delayed or be infeasible, and regulatory approval or commercial launch of any resulting product, including Multikine, may be delayed or may not be successfully achieved.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>The current and future relationships with healthcare professionals, principal investigators, consultants, potential customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable healthcare laws and regulations.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Although CEL-SCI does not currently have any products on the market, if CEL-SCI begins commercializing its product candidates, CEL-SCI will be subject to additional healthcare statutory and regulatory requirements and oversight by federal and state governments as well as foreign governments in the jurisdictions in which CEL-SCI conducts its business. Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any drug candidates for which CEL-SCI obtains marketing approval. The current and future arrangements with healthcare professionals, principal investigators, consultants, potential customers and third-party payors may expose CEL-SCI to broadly applicable healthcare laws, including, without limitation:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation. In addition, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">federal civil and criminal false claims laws, including the federal False Claims Act, which impose criminal and civil penalties, including civil whistleblower actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a healthcare offense and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">40</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">HIPAA, which also imposes obligations on covered entities, including healthcare providers, health plans, and healthcare clearinghouses, as well as their respective business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the U.S. federal physicians payment transparency requirements, sometimes called the &#8220;Sunshine Act&#8221; and its implementing regulations, which requires certain manufacturers of drugs, devices, biologicals and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to physician payments and &#8220;other transfers of value&#8221; to physicians and teaching hospitals and, for transfers of value to other healthcare providers, as well as the ownership and investment interests held by physicians and their immediate family members;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">analogous state and foreign laws, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government which otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the U.S. federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under federal healthcare programs; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">state and foreign laws that govern the privacy and security of health information in certain circumstances, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Efforts to ensure that the future business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that the business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws. If CEL-SCI&#8217;s operations are found to be in violation of any of these laws or any other governmental regulations, CEL-SCI may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, fines, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of the operations, all of which could significantly harm CEL-SCI&#8217;s business. If any of the physicians or other healthcare providers or entities with whom CEL-SCI expects to do business, including current and future collaborators, are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also adversely affect CEL-SCI&#8217;s business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">41</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Failure to obtain or maintain adequate coverage and reimbursement for the product candidates, if approved, could limit the ability to market those products and decrease CEL-SCI&#8217;s ability to generate revenue.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Sales of CEL-SCI&#8217;s product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of the approved products will be paid by health maintenance, managed care, pharmacy benefit, and similar healthcare management organizations, or reimbursed by government authorities, private health insurers and other third-party payors. CEL-SCI anticipates that government authorities and other third-party payors will continue efforts to contain healthcare costs by limiting the coverage and reimbursement levels for new drugs and biologics. If coverage and reimbursement are not available, or are available only to limited levels, CEL-SCI may not be able to successfully commercialize its product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow CEL-SCI to establish or maintain pricing sufficient to realize a return on its investment. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for CEL-SCI&#8217;s product candidates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Moreover, in some countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, CEL-SCI may be required to conduct a clinical trial that compares the cost-effectiveness of its product candidate to other available therapies. If reimbursement of its products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, CEL-SCI&#8217;s business could be harmed, possibly materially.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Even if any product candidate receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If CEL-SCI&#8217;s product candidates do not achieve an adequate level of acceptance, CEL-SCI may not generate significant product revenues and CEL-SCI may not become profitable. The degree of market acceptance of its product candidates, including Multikine if approved for commercial sale, will depend on a number of factors, including:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the timing of CEL-SCI&#8217;s receipt of any marketing approvals;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the terms of any approvals and the countries in which approvals are obtained;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the efficacy and safety and potential advantages and disadvantages compared to alternative treatments, including future alternative treatments;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the prevalence and severity of any side effects associated with CEL-SCI&#8217;s product candidates;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the indications for which its products are approved and the scope of risk information required to be included in the product labeling;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">adverse publicity about CEL-SCI&#8217;s products or favorable publicity about competing products;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the approval of other products for the same indications as CEL-SCI&#8217;s products;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">CEL-SCI&#8217;s ability to offer its products for sale at competitive prices;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the convenience and ease of administration compared to alternative treatments;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">42</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the success of CEL-SCI&#8217;s physician education programs;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the strength of CEL-SCI&#8217;s marketing and distribution support; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the availability of third-party coverage and adequate reimbursement.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If any product candidate CEL-SCI commercializes fails to achieve market acceptance, it could have a material and adverse effect on CEL-SCI&#8217;s business, financial condition, results of operation and prospects.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI currently has no marketing and sales force. If CEL-SCI is unable to establish effective sales or marketing capabilities or enter into agreements with third parties to sell or market its product candidates, CEL-SCI may not be able to effectively sell or market its product candidates, if approved, or generate product revenues.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI currently has no sales and marketing infrastructure due to the fact that all of its product candidates are still in clinical development. To achieve commercial success for any approved product candidate for which CEL-SCI retains sales and marketing responsibilities, CEL-SCI must build its sales, marketing, managerial, and other non-technical capabilities or make arrangements with third parties to perform these services. For example, CEL-SCI has entered into agreements with certain foreign distributors to commercialize Multikine, if approved, within their respective territories. However, CEL-SCI may determine that there is a need to building its own sales force in the United States for the future marketing of Multikine, if approved, rather than seeking a U.S. co-marketing partner or relying on a contracted sales force. There are risks involved with either establishing its own sales and marketing capabilities or entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which CEL-SCI recruits a sales force and establishes marketing capabilities is delayed or does not occur for any reason, CEL-SCI would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and its investment would be lost if CEL-SCI cannot retain or reposition its sales and marketing personnel.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Factors that may inhibit CEL-SCI&#8217;s efforts to commercialize its product candidates on its own include:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">CEL-SCI&#8217;s inability to recruit, hire, retain and incentivize adequate numbers of effective sales and marketing personnel;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to use and administer CEL-SCI&#8217;s future products;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the lack of complementary products to be offered by sales personnel, which may put CEL-SCI at a competitive disadvantage relative to companies with more extensive product lines; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">unforeseen costs and expenses associated with establishing an independent sales and marketing organization.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If CEL-SCI does not establish sales and marketing capabilities successfully, either on its own or in collaboration with third parties, CEL-SCI will not be successful in commercializing Multikine, if approved, or any of its other product candidates that receive marketing approval or any such commercialization may experience delays or limitations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">43</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI&#8217;s business activities may be subject to the Foreign Corrupt Practices Act and similar anti-bribery and anti-corruption laws of other countries in which CEL-SCI operates or will operate in the future.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has conducted and has ongoing studies in international locations and may in the future initiate additional studies in countries other than the United States. Moreover, CEL-SCI has entered into agreements with foreign distributors to commercialize Multikine, if approved, in various territories outside of the United States. As a result, CEL-SCI&#8217;s business activities may be subject to the Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which CEL-SCI operates. The FCPA generally prohibits offering, promising, giving or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the healthcare providers who prescribe biopharmaceuticals are employed by their government, and the purchasers of biopharmaceuticals are government entities; therefore, CEL-SCI&#8217;s dealings with these prescribers and purchasers are subject to regulation under the FCPA. Recently the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of CEL-SCI&#8217;s employees, agents or contractors conducting business abroad will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against CEL-SCI, its officers or employees, the closing of CEL-SCI&#8217;s facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs and prohibitions on the conduct of CEL-SCI&#8217;s business. Any such violations could include prohibitions on CEL-SCI&#8217;s ability to offer its product candidates, if approved, in one or more countries and could materially damage its reputation, its brand, its future international marketing efforts, its ability to attract and retain employees and its business, prospects, operating results and financial condition.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Healthcare legislative reform measures may have a material adverse effect on CEL-SCI&#8217;s business and results of operations.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Existing regulatory policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of CEL-SCI&#8217;s product candidates. CEL-SCI cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If CEL-SCI is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if CEL-SCI is not able to maintain regulatory compliance, CEL-SCI may lose any marketing approval that it may have obtained and it may not achieve or sustain profitability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs that may result in more limited coverage or downward pressure on the price CEL-SCI may otherwise receive for its product candidates. For example, in March 2010, Congress passed the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Affordable Care Act, which expanded healthcare coverage through Medicaid expansion and the implementation of the individual mandate for health insurance coverage and which included changes to the coverage and reimbursement of drug products under federal healthcare programs. The ACA contains a number of provisions that affect coverage and reimbursement of drug and biological products and/or that could potentially reduce the demand for pharmaceutical products such as increasing drug rebates under state Medicaid programs for brand name prescription drugs and extending those rebates to Medicaid managed care and assessing a fee on manufacturers and importers of brand name prescription drugs reimbursed under certain government programs, including Medicare and Medicaid. Tax reform legislation was enacted at the end of 2017 that eliminates the tax penalty established under the ACA for individuals who do not maintain mandated health insurance coverage beginning in 2019. In a May 2018 report, the Congressional Budget Office estimated that, compared to 2018, the number of uninsured will increase by 3 million in 2019 and 6 million in 2028, in part due to the elimination of the individual mandate. The ACA has also been subject to judicial challenge. In December 2018, a federal district court, in a challenge brought by a number of state attorneys general, found the ACA unconstitutional in its entirety because, once Congress repealed the individual mandate provision, there was no longer a basis to rely on Congressional taxing authority to support enactment of the law. Pending appeals, which could take some time, the ACA is still operational in all respects. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">44</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s industry continues to face potential changes in the legal and regulatory landscape on the federal, state and international levels. Additional legislative actions to control U.S. healthcare or other costs have passed. The Budget Control Act, as amended, resulted in the imposition of 2% reductions in Medicare (but not Medicaid) payments to providers in 2013 and will remain in effect through 2027 unless additional Congressional action is taken. There has also been increasing and considerable public and government interest in the United States with respect to specialty drug pricing practices, including proposed federal and state legislation designed to bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, put in place limits and caps on pharmaceutical prices, request rebates for certain pharmaceutical products, and reform government program reimbursement methodologies for drugs. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what biopharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. In markets outside of the United States, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and control the prices of medicinal products for human use.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI expects that current or future healthcare reform measures may result in more rigorous coverage criteria and in additional downward pressure on the price that it receives for any approved product, including Multikine if it is approved for commercialization. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent CEL-SCI from being able to generate revenue, attain profitability or commercialize its product candidates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Legislative and regulatory proposals also have been made to expand post-approval requirements and restrict sales and promotional activities for biotechnology products. CEL-SCI cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations for biological products will be changed, or what the impact of such changes on the marketing approvals of its product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval and decision-making processes may significantly delay or prevent marketing approval, as well as subject CEL-SCI to more stringent product labeling and post-marketing testing and other requirements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Foreign governments often impose strict price controls, which may adversely affect CEL-SCI&#8217;s future profitability.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI intends to seek approval to market its lead investigational product, Multikine, in both the United States and foreign jurisdictions. If CEL-SCI obtains approval in one or more foreign jurisdictions, CEL-SCI will be subject to rules and regulations in those jurisdictions relating to Multikine. In some foreign countries, particularly in the European Union, prescription drug pricing is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug candidate. Coverage and reimbursement decisions in one foreign jurisdiction may impact decisions in other countries. To obtain reimbursement or pricing approval in some countries, CEL-SCI may be required to conduct clinical trials that demonstrate the product candidate is more effective than current treatments and that compare the cost-effectiveness of Multikine to other available therapies. If reimbursement of Multikine is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, CEL-SCI may be unable to achieve or sustain profitability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">45</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>If CEL-SCI fails to comply with environmental, health and safety laws and regulations, CEL-SCI could become subject to fines or penalties or incur costs that could harm its business.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI is subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes generated in its biologic manufacturing facility. CEL-SCI cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from its use of hazardous materials, including radioactive materials used in its research laboratory, CEL-SCI could be held liable for any resulting damages, and the amount of the liability could exceed its resources. CEL-SCI also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Risks Related to Intellectual Property</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI may not be able to achieve or maintain a competitive position, and other technological developments may result in its proprietary technologies becoming uneconomical or obsolete.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI is involved in a biomedical field that is undergoing rapid and significant technological change. The pace of change continues to accelerate. The successful development of product candidates from the compounds, compositions and processes, through research financed by CEL-SCI, or as a result of possible third-party licensing arrangements with pharmaceutical or other companies, is not assured. CEL-SCI may fail to apply for patents on important technologies or product candidates in a timely fashion, or at all.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Many companies are working on drugs designed to cure or treat cancer. Many of these companies have financial, research and development, and marketing resources which are much greater than CEL-SCI&#8217;s and are capable of providing significant long-term competition either by establishing in-house research groups or by forming collaborative ventures with other entities. In addition, smaller companies and non-profit institutions are active in research relating to cancer and infectious diseases. The future market share of Multikine or the other product candidates, if approved, will be reduced or eliminated if the competitors develop and obtain approval for products that are safer or more effective than CEL-SCI&#8217;S product candidates. Moreover, the patent positions of pharmaceutical companies are highly uncertain and involve complex legal and factual questions for which important legal principles are often evolving and remain unresolved. As a result, the validity and enforceability of patents cannot be predicted with certainty. In addition, CEL-SCI does not know whether:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">CEL-SCI was the first to make the inventions covered by each of its issued patents and pending patent applications;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">CEL-SCI was the first to file patent applications for these inventions;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">others will independently develop similar or alternative technologies or duplicate any of CEL-SCI&#8217;s technologies;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">any of the pending patent applications will result in issued patents;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">any of the patents will be valid or enforceable;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">46</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">any patents issued to CEL-SCI or its collaboration partners will provide CEL-SCI with any competitive advantages or will be challenged by third parties;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">CEL-SCI will be able to develop additional proprietary technologies that are patentable;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the U.S. government will exercise any of its statutory rights to CEL-SCI&#8217;s intellectual property that was developed with government funding; or</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">its business may infringe the patents or other proprietary rights of others.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI&#8217;s patents might not protect its technology from competitors, in which case CEL-SCI may not have any advantage over competitors in selling any products that CEL-SCI may develop.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s commercial success will depend in part on its ability to obtain additional patents and protect its existing patent position, as well as its ability to maintain adequate intellectual property protection for the technologies, product candidates, and any future products in the United States and other countries. If CEL-SCI does not adequately protect its technology, product candidates and future products, competitors may be able to use or practice them and erode or negate any competitive advantage CEL-SCI may have, which could harm CEL-SCI&#8217;s business and its ability to achieve profitability. The laws of some foreign countries do not protect the proprietary rights to the same extent or in the same manner as U.S. laws, and CEL-SCI may encounter significant problems in protecting and defending its proprietary rights in these countries. CEL-SCI will be able to protect its proprietary rights from unauthorized use by third parties only to the extent that its proprietary technologies, product candidates and any future products are covered by valid and enforceable patents or are effectively maintained as trade secrets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Certain aspects of CEL-SCI&#8217;s technologies are covered by U.S. and foreign patents. In addition, CEL-SCI has a number of new patent applications pending. There is no assurance that the applications which are pending or which may be filed in the future will result in the issuance of any patents. Furthermore, there is no assurance as to the breadth and degree of protection any issued patents might afford CEL-SCI. Disputes may arise between CEL-SCI and others as to the scope and validity of these or other patents. Any defense of the patents could prove costly and time consuming and there can be no assurance that CEL-SCI will be in a position, or will deem it advisable, to carry on such a defense. A suit for patent infringement could result in increasing costs, delaying or halting development, or even forcing CEL-SCI to abandon a product candidate. Other private and public concerns, including universities, may have filed applications for, may have been issued, or may obtain additional patents and other proprietary rights to technology potentially useful or necessary to CEL-SCI. CEL-SCI is not currently aware of any such patents, but the scope and validity of such patents, if any, and the cost and availability of such rights are impossible to predict.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Much of CEL-SCI&#8217;s intellectual property is protected as trade secrets or confidential know-how, not as a patent.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI considers proprietary trade secrets and/or confidential and unpatented know-how to be important to its business. Much of the intellectual property pertains to CEL-SCI&#8217;s manufacturing methodologies, certain aspects of which may not be suitable for patent filings and must be protected as trade secrets and/or confidential know-how. This type of information must be protected diligently by CEL-SCI to protect its disclosure to competitors, since legal protections after disclosure may be minimal or non-existent. Accordingly, much of the value of this intellectual property is dependent upon the ability of CEL-SCI to keep its trade secrets and know-how confidential.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">To protect this type of information against disclosure or appropriation by competitors, CEL-SCI&#8217;s policy is to require its employees, consultants, contractors and advisors to enter into confidentiality agreements with CEL-SCI. However, current or former employees, consultants, contractors and advisers may unintentionally or willfully disclose the confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Enforcing a claim that a third party obtained illegally, and is using, trade secrets and/or confidential know-how is expensive, time consuming and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">47</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In addition, in some cases a regulator considering the application for product candidate approval may require the disclosure of some or all of the proprietary information. In such a case, CEL-SCI must decide whether to disclose the information or forego approval in a particular country. If CEL-SCI is unable to market its product candidates in key countries, CEL-SCI&#8217;s opportunities and value may suffer.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Failure to obtain or maintain trade secrets and/or confidential know-how trade protection could adversely affect CEL-SCI&#8217;S competitive position. Moreover, competitors may independently develop substantially equivalent proprietary information and may even apply for patent protection in respect of the same. If successful in obtaining such patent protection, competitors could limit the use of such trade secrets and/or confidential know-how.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI may be subject to claims challenging the inventorship or ownership of its patents and other intellectual property.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in its patents or other intellectual property. CEL-SCI may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing the product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If CEL-SCI fails in defending any such claims, in addition to paying monetary damages, CEL-SCI may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on its business. Even if CEL-SCI is successful in defending against such claims, litigation could result in substantial costs and be a distraction to CEL-SCI&#8217;s management and employees.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Risks Related to CEL-SCI&#8217;s common stock</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Future equity offerings or other equity issuances may result in dilution to existing shareholders.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI expects that significant additional capital will be needed in the future to continue its planned operations. To raise additional capital, CEL-SCI may in the future offer additional shares of its common stock or other securities convertible into or exchangeable for its common stock. To the extent CEL-SCI raises additional capital by issuing equity securities, CEL-SCI&#8217;s stockholders may experience substantial dilution and new investors could gain rights superior to existing stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>The exercise of outstanding warrants and options will cause dilution.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">As of September 30, 2023, there were outstanding warrants which allow the holders to purchase 1,092,470 shares of common stock, with a weighted average exercise price of $3.16 per share, and outstanding options which allow the holders to purchase up to 14,757,558 shares of common stock, with a weighted average exercise price of $7.78 per share. The exercise of these outstanding warrants and options will cause dilution to holders of our common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">48</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Since CEL-SCI does not intend to pay dividends on its common stock, any potential return to investors will result only from any increases in the price of its common stock.</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">At the present time, CEL-SCI intends to use available funds to finance its operations. Accordingly, while payment of dividends rests within the discretion of its board of directors, no common stock dividends have been declared or paid by CEL-SCI and CEL-SCI has no intention of paying any common stock dividends in the foreseeable future. Additionally, any future debt financing arrangement may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on CEL-SCI&#8217;s common stock. Any return to CEL-SCI&#8217;s shareholders will therefore be limited to appreciation in the price of its common stock, which may never occur. If CEL-SCI&#8217;s stock price does not increase, CEL-SCI&#8217;S shareholders are unlikely to receive any return on their investments in CEL-SCI&#8217;s common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>The price of CEL-SCI&#8217;s common stock has been volatile and is likely to continue to be volatile, which could result in substantial losses for CEL-SCI&#8217;s shareholders.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s stock price has been, and is likely to continue to be, volatile. As a result of this volatility, CEL-SCI&#8217;s shareholders may not be able to sell their shares at or above the price they paid for their shares. The market price for CEL-SCI&#8217;s common stock may be influenced by many factors, including:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">actual or anticipated fluctuations in CEL-SCI&#8217;s financial condition and operating results;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">actual or anticipated changes in CEL-SCI&#8217;s growth rate relative to competitors;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">competition from existing products or new products or product candidates that may emerge;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">development of new technologies that may make CEL-SCI&#8217;s technology less attractive;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">changes in physician, hospital or healthcare provider practices that may make CEL-SCI&#8217;s product candidates less useful;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">announcements by CEL-SCI, its partners or competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the recruitment or departure of key personnel;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">failure to meet or exceed financial estimates and projections of the investment community;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">variations in its financial results or those of companies that are perceived to be similar to CEL-SCI;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">changes to coverage and reimbursement levels by commercial third-party payors and government payors, including Medicare, and any announcements relating to reimbursement levels;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">general economic, industry and market conditions; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the other factors described in this &#8220;Risk Factors&#8221; section.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>CEL-SCI has identified material weaknesses in its internal control over financial reporting. Failure to achieve and maintain effective internal controls over financial reporting could adversely affect CEL-SCI&#8217;s ability to report its results of operations and financial condition accurately and in a timely manner, which could have an adverse impact on CEL-SCI&#8217;s business.</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:45px">CEL-SCI&#8217;s management is responsible for establishing and maintaining adequate internal control over financial reporting designed to provide reasonable assurance regarding the reliability of financial reporting&#160;and the preparation of financial statements for external purposes in accordance with GAAP. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement in an entity&#8217;s annual or interim consolidated financial statements might not be prevented or detected on a timely basis.</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">As described in Item 9A of this Annual Report, management noted material weaknesses in its internal control over financial reporting as of September 30, 2023.&#160; CEL-SCI&#8217;s management concluded that material weaknesses existed relating to the logical access to information technology systems that support CEL-SCI&#8217;s financial reporting process and the operating effectiveness of certain management review controls. Although these control weaknesses did not result in any material misstatement of CEL-SCI&#8217;s financial statements for the periods presented, they could lead to a material misstatement of account balances or disclosures.&#160; As a result, CEL-SCI&#8217;s management concluded that its internal control over financial reporting was not effective as of September 30, 2023.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;&#160; &#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In order to remediate these material weaknesses, CEL-SCI will change certain control activities over financial reporting to include, but&#160;not limited to, the following: (i) evaluating and implementing enhanced process controls around access to information technology systems and (ii) enhancing the operating effectiveness of management&#8217;s review controls. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">If CEL-SCI is unable to remediate the material weaknesses timely and sufficiently or if CEL-SCI identifies future material weaknesses in its internal control over financial reporting or is unable to comply with the requirements of Section 404 in a timely manner or assert that its internal control over financial reporting is effective, CEL-SCI may experience a loss of investor confidence in the accuracy and completeness of its financial statements, incur material misstatements in its financial statements, incur difficulty accessing capital on favorable terms, or at all, be subject to fines, penalties or judgments, incur reputational harm, and the market price of its common stock may be adversely affected.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>&#160; Cybersecurity breaches could affect CEL-SCI&#8217;s operations.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Security breaches and other disruptions in our information technology systems could limit CEL-SCI&#8217;s capacity to effectively monitor and control its operations, compromise its suppliers&#8217; confidential information or otherwise adversely affect its operating results or business reputation. Any failure to effectively prevent, detect and/or recover from any such security breaches could result in legal claims or regulatory penalties under laws protecting the privacy of personal information, disrupt operations, and damage our reputation, which could adversely affect our business.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>ITEM 1B. <span style="text-decoration:underline">UNRESOLVED SEC COMMENTS </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">None</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">49</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 2. <span style="text-decoration:underline">PROPERTIES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI leases office space at 8229 Boone Blvd., Suite 802, Vienna, Virginia at a monthly rental of approximately $8,000. The lease on the office space expires on November 30, 2025. CEL-SCI believes this arrangement is adequate for the conduct of its present business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI has a 17,900 square foot laboratory located in Baltimore, Maryland. The laboratory is leased by CEL-SCI at a cost of approximately $22,000 per month. During the period ended September 30, 2021, the laboratory lease was extended ten years and expires on February 29, 2032.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In August 2007, CEL-SCI leased a building near Baltimore, Maryland (the San Tomas lease). The building, which consists of approximately 73,000 square feet, has been remodeled in accordance with CEL-SCI&#8217;s specifications so that it can be used by CEL-SCI to manufacture Multikine for CEL-SCI&#8217;s Phase III clinical trial and sales of the drug, if approved by the FDA. The lease expires on October 31, 2028 and required annual base rent payments of approximately $2.6 million during the twelve months ended September 30, 2023. The annual base rent escalates each year at 3% beginning on November 1st. CEL-SCI is also required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities, which were approximately $76,000 per month as of September 30, 2023. The lease allows CEL-SCI, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In August 2020, the Company entered into an amendment to the San Tomas lease agreement under which the landlord agreed to allow the Company to substantially upgrade the manufacturing facility in preparation for the potential commercial production of Multikine. The total cost of the upgrades was $11.1 million. The landlord agreed to finance the final $2.4 million of the costs incurred. The Company started repaying these costs on March 1, 2021 through increased lease payments which will continue over the remaining lease term. The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year on the $2.4 million financed.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 3. <span style="text-decoration:underline">LEGAL PROCEEDINGS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Not applicable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 4.</strong><strong> </strong><strong><span style="text-decoration:underline">MINE SAFETY DISCLOSURES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Not applicable.<strong> </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 5. <span style="text-decoration:underline">MARKET FOR CEL-SCI'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As of September 30, 2023, there were approximately 500 record holders of CEL-SCI&#8217;s common stock. CEL-SCI&#8217;s common stock is traded on the NYSE American under the symbol &#8220;CVM&#8221;.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Shown below are the range of high and low quotations for CEL-SCI&#8217;s common stock for the periods indicated as reported by the NYSE American.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Quarter Ending</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">High</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Low</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">12/31/2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12.82</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7.06</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3/31/2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7.73</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.80</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">6/30/2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.14</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.49</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">9/30/2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.42</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">12/31/2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.68</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.88</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3/31/2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.33</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.15</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">6/30/2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.94</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">9/30/2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.99</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.08</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">50</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Holders of common stock are entitled to receive dividends as may be declared by CEL-SCI&#8217;s Board of Directors out of legally available funds and, in the event of liquidation, to share pro rata in any distribution of CEL-SCI&#8217;s assets after payment of liabilities. CEL-SCI&#8217;s Board of Directors is not obligated to declare a dividend. CEL-SCI has not paid any dividends on its common stock and CEL-SCI does not have any current plans to pay any common stock dividends.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The provisions in CEL-SCI&#8217;s Articles of Incorporation relating to CEL-SCI&#8217;s preferred stock allow CEL-SCI&#8217;s directors to issue preferred stock with rights to multiple votes per share and dividend rights which would have priority over any dividends paid with respect to CEL-SCI&#8217;s common stock.&#160; The issuance of preferred stock with such rights may make more difficult the removal of management even if such removal would be considered beneficial to shareholders generally, and will have the effect of limiting shareholder participation in certain transactions such as mergers or tender offers if such transactions are not favored by incumbent management.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The market price of CEL-SCI&#8217;s common stock, as well as the securities of other biopharmaceutical and biotechnology companies, have historically been highly volatile, and the market has from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. Factors such as fluctuations in CEL-SCI&#8217;s operating results, announcements of technological innovations or new therapeutic products by CEL-SCI or its competitors, governmental regulation, developments in patent or other proprietary rights, public concern as to the safety of products which may be developed by CEL-SCI or other biotechnology and pharmaceutical companies, and general market conditions may have a significant effect on the market price of CEL-SCI&#8217;s common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 6. </strong><strong><span style="text-decoration:underline">SELECTED FINANCIAL DATA</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI is a smaller reporting company as defined by Rule 12b-2 of the Securities and Exchange Commission and is not required to provide the information required under this item.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 7. <span style="text-decoration:underline">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following discussion should be read in conjunction with the financial statements and the related notes thereto appearing elsewhere in this report.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Multikine (Leukocyte Interleukin, Injection) which, for simplicity, is referred to in this report as Multikine, is the trademark that the Company has registered for this investigational therapy, and this proprietary name is subject to FDA review under the Company&#8217;s future anticipated regulatory submission for approval. Multikine has not been licensed or approved by the FDA or any other regulatory agency. Neither has its safety or efficacy been established for any use.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI also owns and is developing a pre-clinical technology called LEAPS (Ligand Epitope Antigen Presentation System). CEL-SCI is using its LEAPS technology platform to investigate its lead peptide-based immunotherapy (CEL-4000) as a vaccine treatment for rheumatoid arthritis.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">All of CEL-SCI&#8217;s projects are under development. As a result, CEL-SCI cannot predict when it will be able to generate any revenue from the sale of any of its products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Since inception, CEL-SCI has financed its operations through the issuance of equity securities, convertible notes, loans and certain research grants. CEL-SCI will likely continue to generate net operating losses as it continues the development of Multikine and brings other drug candidates into clinical trials. Until such time as CEL-SCI becomes profitable, any or all of these financing vehicles or others may be utilized to assist CEL-SCI&#8217;s capital requirements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">51</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Results of Operations</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The Company incurred a net operating loss of approximately $31.5 million for the twelve months ended September 30, 2023. This net operating loss consists of significant non-cash expenses accounting for approximately 33% of the operating loss. The non-cash operating expenses include approximately $6.3 million in stock-based employee compensation and approximately $4.0 million in depreciation and amortization expense.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">During the year ended September 30, 2023, research and development expenses decreased by approximately $2.9 million, or 11%, compared to the year ended September 30, 2022. Major components of this decrease include an approximately $2.9 million decrease in employee stock compensation expense and a decrease of approximately $1.7 million in costs related to the Phase III clinical study. &#160;These decreases were offset by an increase of approximately $1.7 million of costs incurred to prepare for the potential commercial sale of Multikine. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">During the year ended September 30, 2023, general and administrative expenses decreased by approximately $1.7 million, or 16%, compared to the year ended September 30, 2022. This decrease is primarily due to a decrease in employee stock compensation expense of approximately $2.2 million offset by a $0.5 million increase in other net general and administrative expenses.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">During the years ended September 30, 2023 and 2022, CEL-SCI recorded a derivative gain of approximately $0.0 million and a gain of approximately $0.4 million, respectively. This variation was the result of no fair value adjustments made during the period since all of the derivative warrants expired during the year ended September 30, 2022. No derivative gains or losses were recorded during the year ended September 30, 2023. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Net interest expense decreased by approximately $0.4 million for the year ended September 30, 2023 compared to the year ended September 30, 2022. This decrease is primarily due to the Company earning approximately $0.3 million more in interest income and approximately $0.1 million less in interest expense from its finance leases during the year ended September 30, 2023 compared to the year ended September 30, 2022. &#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Research and Development Expenses</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; CEL-SCI&#8217;s research and development efforts involved Multikine and LEAPS. The table below shows the research and development expenses associated with each project during the reporting periods.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Year ended September 30, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Multikine</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,098,222</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,251,629</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;LEAPS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">373,274</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,103,717</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">22,471,496</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">25,355,346</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI&#8217;s Phase III clinical trial began in December 2010 after the completion and validation of CEL-SCI&#8217;s dedicated manufacturing facility.&#160; The Phase III clinical trial was fully enrolled in September 2016, reached its primary endpoint in April 2020 and achieved database lock in December 2020. The data was unblinded in June 2021, the primary endpoint results were announced in June 2021, additional data was presented at ASCO 2022, ESMO 2022, ECHNO 2023, ESTRO 2023 and ESMO 2023.&#160; As part of CEL-SCI&#8217;s global regulatory approval strategy, CEL-SCI concurrently plans to pursue filings for marketing authorization in the United States, Canada, United Kingdom and Europe.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">52</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">As explained in Item 1 of this report, clinical and other studies necessary to obtain regulatory approval of a new drug involve significant costs and require several years to complete. The extent of the Company&#8217;s clinical trials and research programs are primarily based upon the amount of capital available to the Company and the extent to which the Company has received regulatory approvals for clinical trials. The inability of the Company to conduct clinical trials or research, whether due to a lack of capital or regulatory approval, will prevent the Company from completing the studies and research required to obtain regulatory approval for any products which the Company is developing. Without regulatory approval, the Company will be unable to sell any of its products. Since all of the Company&#8217;s projects are under development, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Liquidity and Capital Resources&#160; </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI has had only limited revenues from operations since its inception in March 1983.&#160;&#160;CEL-SCI has relied primarily upon capital generated from the public and private offerings of its common stock and convertible notes.&#160;&#160;In addition, CEL-SCI has utilized short-term loans to meet its capital requirements.&#160;&#160;Capital raised by CEL-SCI has been used to acquire an exclusive worldwide license to use, and later purchase, certain patented and unpatented proprietary technology and know-how relating to the human immunological defense system and for clinical trials.&#160;&#160;Capital has also been used for patent applications, debt repayment, research and development, administrative costs, and for CEL-SCI&#8217;s laboratory and manufacturing facilities.&#160;&#160;CEL-SCI does not anticipate realizing significant revenues until it enters into licensing arrangements regarding its technology and know-how or until it receives regulatory approval to sell its products (which could take a number of years). As a result, CEL-SCI has been dependent primarily upon the proceeds from the sale of its securities to meet all of its liquidity and capital requirements and anticipates having to do so in the future.&#160; During fiscal year 2023 and 2022, CEL-SCI raised net proceeds of approximately $6.4 million and $0.1 million, respectively, through a combination of the sale of common stock and the exercise of warrants and options.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In August 2007, CEL-SCI leased a building near Baltimore, Maryland.&#160; The building, which consists of approximately 73,000 square feet, has been remodeled in accordance with CEL-SCI&#8217;s specifications so that it can be used by CEL-SCI to manufacture Multikine for CEL-SCI&#8217;s Phase III clinical trials and sales of the drug if approved by the FDA.&#160; The lease expires on October 31, 2028, and required annual base rent payments of approximately $2.6 million during the twelve months ended September 30, 2023.&#160; See Item 2 of this report for more information concerning the terms of this lease.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The following charts list the warrants that were exercised and the proceeds received during the years ended September 30, 2023 and 2022.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Fiscal Year 2023</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Proceeds</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,752</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,291</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">200,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">418,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">217,752</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">447,291</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">53</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Fiscal Year 2022</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Proceeds</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series CC</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,205</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">76,025</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">25,200</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,205</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">101,225</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">During the year ended September 30, 2023, the Company&#8217;s cash decreased by approximately $18.5 million. The significant component of this decrease included cash used to fund the Company&#8217;s regular operations of approximately $22.8 million, which includes the approximate $2.3 million deposit made to the Company&#8217;s landlord as a result of falling below certain cash requirements per the San Tomas lease. Other components of this decrease include approximately $0.4 million used to make leasehold improvements and acquire research and development equipment, and approximately $1.6 million in payments on the Company&#8217;s finance leases. These decreases were offset by approximately $5.8 million and $0.5 million of cash received from issuance of common stock and exercise of warrants, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">During the year ended September 30, 2022, the Company used approximately $19.6 million, or approximately $1.6 million per month, in cash, after considering the maturity and transfer to cash of the remaining $6.2 million in U.S. Treasury bills (T-bills). Significant components of this decrease include cash used to fund the Company&#8217;s regular operations of approximately $18.2 million, the purchase of property and equipment for approximately $0.6 million, approximately $0.2 million in share issuance costs and approximately $1.4 million in lease payments. These outflows are offset by approximately $0.8 million in lease incentives received from the landlord to partially offset costs of the manufacturing facility upgrade.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">During the year ended September 30, 2023, 217,752 warrants were exercised at a weighted average exercise price of $2.05 for total proceeds of approximately $0.45 million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Prepaid expenses decreased by approximately $0.2 million during the year ended September 30, 2023 as compared to September 30, 2022 primarily due to the timing of payments and recognition of related expenses.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Supplies are purchased for use in the Company&#8217;s manufacturing and R&amp;D efforts. During the year ended September 30, 2023, the supplies increased by approximately $0.2 million in support of the work to validate and prepare the manufacturing facility to produce Multikine for commercial purposes and before the Company&#8217;s Biologics License Application (BLA) can be submitted to the FDA.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Primarily as a result of CEL-SCI&#8217;s losses incurred to date, its expected continued future losses, and limited cash balances, CEL-SCI has included a disclosure in its financial statements expressing substantial doubt about its ability to continue as a going concern. CEL-SCI has included this disclosure on numerous occasions in the preceding years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Future Capital Requirements</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI&#8217;s material capital commitments include funding operating losses, funding its research and development program and making required lease payments. Additionally, the Company recently completed upgrading the manufacturing facility to prepare for the potential commercial production of Multikine. Total costs of this upgrade were approximately $11.1 million. The landlord of the property agreed to finance the final $2.4 million of costs and allow for the repayment through increased lease payments which began on March 1, 2021. As of September 30, 2022, the landlord had provided approximately all $2.4 million of the agreed funding. Because of the change in lease payments, the new financing arrangement was considered a lease modification.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">54</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">For information on employment contracts, see Item 11 of this report.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Further, CEL-SCI has contingent obligations with vendors for work that will be completed in relation to the Phase III trial. The timing of these obligations cannot be determined at this time. CEL-SCI estimates it will incur additional expenses of approximately $0.7 million for the filing of the clinical study report with the FDA. It should be noted that this estimate is based only on the information currently available from the CROs responsible for managing the Phase III clinical trial and does not include other related costs, e.g., the manufacturing of the drug.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI will need to raise additional funds, either through debt or equity financings or a partnering arrangement, to bring Multikine to market. The ability of CEL-SCI to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. However, it is possible that CEL-SCI will not be able to generate enough cash to continue operations at its current level.&#160;CEL-SCI&#8217;s management has engaged in fundraising for over 25 years and believes that the manner in which it is proceeding will produce the best possible outcome for the shareholders. There can be no assurances that CEL-SCI will be successful in raising additional funds.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Clinical and other studies necessary to obtain regulatory approval of a new drug involve significant costs and require several years to complete. The extent of CEL-SCI&#8217;s clinical trials and research programs are primarily based upon the amount of capital available to CEL-SCI and the extent to which CEL-SCI has received regulatory approvals for clinical trials. The inability of CEL-SCI to conduct clinical trials or research, whether due to a lack of capital or regulatory approval, will prevent CEL-SCI from completing the studies and research required to obtain regulatory approval for any products which CEL-SCI is developing. Without regulatory approval, CEL-SCI will be unable to sell any of its products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In the absence of revenues, CEL-SCI will be required to raise additional funds through the sale of securities, debt financings or other arrangements in order to continue with its research efforts. However, there can be no assurance that such financing will be available or be available on favorable terms. Ultimately, CEL-SCI must complete the development of its products, obtain appropriate regulatory approvals and obtain sufficient revenues to support its cost structure.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Since all of CEL-SCI&#8217;s projects are under development, CEL-SCI cannot predict with any certainty the funds required for future research and clinical trials, the timing of future research and development projects, or when it will be able to generate any revenue from the sale of any of its products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI's cash flow and earnings are subject to fluctuations due to changes in interest rates on its bank accounts, and, to an immaterial extent, foreign currency exchange rates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Critical Accounting Policies</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI's significant accounting policies are more fully described in Note 3 to the financial statements included as part of this report. However, certain accounting policies are particularly important to the portrayal of CEL-SCI&#8217;s financial position and results of operations and require the application of significant judgments by management. As a result, the financial statements are subject to an inherent degree of uncertainty. In applying those policies, management uses its judgment to determine the appropriate assumptions to be used in the determination of certain estimates. These estimates are based on CEL-SCI's historical experience, terms of existing contracts, observance of trends in the industry and information available from outside sources, as appropriate.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Management believes that the following critical accounting policies require the most significant judgments and estimates with respect to the preparation of CEL-SCI&#8217;s financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">55</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><em>Lease Accounting &#8211;</em>The measurement of the finance and operating lease right-of-use asset and lease liabilities requires the determination of an estimated lease term and an incremental borrowing rate, which involves complex judgment by management. The determination of the incremental borrowing rates for new and modified lease contracts is a critical accounting policy. Significant judgment is required by management to develop inputs and assumptions used to determine the incremental borrowing rate for lease contracts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><em>Share-based Compensation</em>&#8211; Share-based compensation cost to employees and nonemployees is measured at fair value as of the grant date in accordance with the provisions of ASC 718. The fair value of the stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The compensation cost is recognized as expense over the requisite service or vesting period. Performance-based options are valued using a Monte-Carlo simulation model, which requires inputs based on estimates, including the likelihood of the occurrence of performance and market conditions, volatility and expected option life.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160; &#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><em>Impairment of long-lived assets</em> &#8211; CEL-SCI&#8217;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#8217;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets in accordance with ASC 360-10-35-21 to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company&#160;&#160;tests&#160;&#160;for recoverability, then, if necessary, measures and records the impairment. The amount of the&#160;impairment loss would be the amount by which the carrying amount of the asset &#160;(group) exceeds its fair value.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 7A. <span style="text-decoration:underline">QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISKS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Not applicable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 8. </strong><strong><span style="text-decoration:underline">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">See the financial statements included with this report.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 9. <span style="text-decoration:underline">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Not applicable</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">56</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 9A. </strong><strong><span style="text-decoration:underline">CONTROLS AND PROCEDURES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;"><em>Evaluation of Disclosure Controls and Procedures</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Under the direction and with the participation of CEL-SCI&#8217;s management, including CEL-SCI&#8217;s Chief Executive Officer and Chief Financial Officer, CEL-SCI carried out an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures as of September 30, 2023. CEL-SCI maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its periodic reports with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and regulations, and that such information is accumulated and communicated to CEL-SCI&#8217;s management, including its principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. CEL-SCI&#8217;s disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching its desired disclosure control objectives.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI&#8217;s Chief Executive and Principal Financial Officer has concluded that, due to the material weaknesses described below, CEL-SCI&#8217;s disclosure controls and procedures were not effective as of September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Management&#8217;s Report on Internal Control over Financial Reporting</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI&#8217;s management is responsible for establishing and maintaining adequate internal control over financial reporting and for the assessment of the effectiveness of internal control over financial reporting. As defined by the Securities and Exchange Commission, internal control over financial reporting is a process designed by, or under the supervision of CEL-SCI&#8217;s&#160;principal executive officer and principal financial officer&#160;and implemented by CEL-SCI&#8217;s Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of CEL-SCI&#8217;s financial statements in accordance with U.S. generally accepted accounting principles.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Under the supervision and with the participation of management, including CEL-SCI&#8217;s Chief Executive and Principal Financial Officer, CEL-SCI evaluated the effectiveness of its internal control over financial reporting as of September 30, 2023 based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, or the COSO Framework. Management&#8217;s assessment included an evaluation of the design of CEL-SCI&#8217;s internal control over financial reporting and testing of the operational effectiveness of those controls.&#160;&#160; CEL-SCI's Chief Executive and Financial Officer concluded that as of such date, CEL-SCI's internal control over financial reporting was not&#160;effective.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Material Weaknesses in Internal Control Over Financial Reporting</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">A material weakness (as defined in Rule 12b-2 under the Exchange Act) is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of CEL-SCI&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As previously reported, the Company did not maintain effective information technology general controls related to logical access within certain information technology systems that support our financial reporting process. As a result of this material weakness, certain activity level controls that are dependent on information derived from these information technology systems were also deemed to be ineffective. This material weakness continues to exist as of September 30, 2023.</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In addition, CEL-SCI identified a material weakness related to the operating effectiveness of certain management review controls. As of September 30, 2023, CEL-SCI has remediated the vast majority of these; however, not enough time has passed to ensure the operating effectiveness.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Remediation of Material Weaknesses</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In order to remediate these material weaknesses, CEL-SCI will&#160; continue to (i) evaluate and implement enhanced process controls around the logical access to information technology systems and (ii) enhance the operating effectiveness of management review controls.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI is committed to maintaining a strong internal control environment and implementing measures designed to help ensure that control deficiencies contributing to the material weaknesses are remediated as soon as possible.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Notwithstanding the material weaknesses described above, CEL-SCI&#8217;s management has concluded that the consolidated financial statements included in this Annual Report on Form 10-K present fairly, in all material respects, our financial position, results of operations and cash flows in conformity with GAAP.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">57</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Changes in Internal Control over Financial Reporting</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI changed certain control activities over financial reporting in order to remediate certain material weaknesses that existed as of September 30, 2023.&#160; CEL-SCI implemented the following: (i) evaluating and implementing enhanced process controls around the logical access to information technology systems and (ii) enhancing the operating effectiveness of management review controls.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Other than as described above, there have been no other changes in CEL-SCI&#8217;s internal control over financial reporting occurred during the fiscal year ended September 30, 2023 that has materially affected, or is reasonably likely to materially affect, CEL-SCI&#8217;s internal control over financial reporting.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 9B. <span style="text-decoration:underline">OTHER INFORMATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">None.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 10. </strong><strong><span style="text-decoration:underline">DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Officers and Directors</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:22%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Age</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:44%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Position</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:22%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Geert R. Kersten, Esq.</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:7%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">65</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:44%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director, Chief Executive and Financial Officer and Treasurer</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:22%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Patricia B. Prichep</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:7%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">72</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:44%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Senior Vice President of Operations and Corporate Secretary</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:22%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Dr. Eyal Talor</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:7%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">67</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:44%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Scientific Officer</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:22%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Dr. Daniel H. Zimmerman</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:7%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">82</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:44%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Senior Vice President of Research, Cellular Immunology</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:22%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">John Cipriano</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:7%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">81</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:44%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Senior Vice President of Regulatory Affairs</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:22%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Dr. Peter R. Young</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:7%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">78</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:44%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:22%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Bruno Baillavoine</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:7%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">70</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:44%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:22%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Robert Watson</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:7%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">66</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:44%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:22%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Dr. Gail Naughton</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:7%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">68</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:44%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The directors of CEL-SCI serve in such capacity until the next annual meeting of CEL-SCI&#8217;s shareholders or until their successors have been duly elected and qualified. The officers of CEL-SCI serve at the discretion of CEL-SCI&#8217;s directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The principal occupations of CEL-SCI&#8217;s officers and directors, during the past several years, are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Geert Kersten has served in his current leadership role at CEL-SCI since 1995. Mr. Kersten has been with CEL-SCI since 1987. He has been involved in the pioneering field of cancer immunotherapy for over three decades and has successfully steered CEL-SCI through many challenging cycles in the biotechnology industry. Mr. Kersten also provides CEL-SCI with significant expertise in the fields of finance and law and has a unique vision of how CEL-SCI&#8217;s Multikine product could potentially change the way cancer is treated. Prior to joining CEL-SCI, Mr. Kersten worked at the law firm of Finley &amp; Kumble and worked at Source Capital, an investment banking firm located in McLean, VA. He is a native of Germany, graduated from high school in England, and completed his studies in the US. Mr. Kersten received his Undergraduate Degree in Accounting and an M.B.A. from George Washington University, and a law degree (J.D.) from American University in Washington, DC.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Patricia B. Prichep joined CEL-SCI in 1992 and has been CEL-SCI&#8217;s Senior Vice President of Operations since March 1994. Between December 1992 and March 1994, Ms. Prichep was CEL-SCI&#8217;s Director of Operations. Ms. Prichep became CEL-SCI&#8217;s Corporate Secretary in May 2000. She is responsible for all day-to-day operations of CEL-SCI, including human resources and is the liaison with CEL-SCI&#8217;s independent registered public accounting firm for financial reporting. From June 1990 to December 1992, Ms. Prichep was the Manager of Quality and Productivity for the NASD&#8217;s Management, Systems and Support Department and was responsible for the internal auditing and work flow analysis of operations. Between 1982 and 1990, Ms. Prichep was Vice President and Operations Manager for Source Capital, Ltd. She handled all operations and compliance for Source Capital and was licensed as a securities broker. Ms. Prichep received her B.A. from the University of Bridgeport in Connecticut.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">58</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Eyal Talor, Ph.D. joined CEL-SCI in October 1993. In October 2009, Dr. Talor was promoted to Chief Scientific Officer. Prior to this promotion, Dr. Talor was the Senior Vice President of Research and Manufacturing. He is a clinical immunologist with over 27 years of hands-on management of clinical research and drug development for immunotherapy application; pre-clinical to Phase III clinical trials, in the biopharmaceutical industry. His expertise includes biopharmaceutical R&amp;D and Biologics product development, GMP (Good Manufacturing Practices) manufacture, Quality Control testing, and the design and building of GMP manufacturing and testing facilities. He served as Director of Clinical Laboratories (certified by the State of Maryland) and has experience in the design of pre-clinical and clinical trials (Phase I &#8211; III) and GCP (Good Clinical Practices) requirements. He also has broad experience in the different aspects of biological assay development, analytical methods validation, raw material specifications, and QC (Quality Control) tests development under FDA/GMP, USP, and ICH guidelines. He has extensive experience in the preparation of documentation for IND and other regulatory submissions. His scientific area of expertise encompasses immune response assessment. He is the author of over 25 publications and has published a number of reviews on immune regulations in relation to clinical immunology. Before coming to CEL-SCI, he was Director of R&amp;D and Clinical Development at CBL, Inc., Principal Scientist &#8211; Project Director, and Clinical Laboratory Director at SRA Technologies, Inc. Prior to that he was a full-time faculty member at The Johns Hopkins University, Medical Institutions; School of Public Health. He has invented technologies which are covered by ten issued patents on Multikine&#8217;s composition of matter and method of use in cancer and two platform Peptide technologies, Antigen Directed Apoptosis of T-cells (&#8216;Adapt&#8217;) and LEAPS, for the treatment of autoimmune diseases, asthma, allergy, transplantation rejection and infectious diseases. He also is responsible for numerous product and process inventions as well as a number of pending US and PCT patent applications. He received his Ph.D. in Microbiology and Immunology from the University of Ottawa, Ottawa, Ontario, Canada, and had post-doctoral training in clinical and cellular immunology at The Johns Hopkins University, Baltimore, Maryland, USA. He holds an Associate teaching position at the Johns Hopkins University Medical Institutions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Daniel H. Zimmerman, Ph.D. was CEL-SCI&#8217;s Senior Vice President of Research, Cellular Immunology between 1996 and December 2008 and again since November 2009. He joined CEL-SCI in January 1996 as the Vice President of Research, Cellular Immunology. Dr. Zimmerman founded CELL-MED, Inc. and was its president from 1987-1995. From 1973-1987, Dr. Zimmerman served in various positions at Electronucleonics, Inc. His positions included: Scientist, Senior Scientist, Technical Director and Program Manager. Dr. Zimmerman held various teaching positions at Montgomery College between 1987 and 1995. Dr. Zimmerman has invented technologies which are covered by over a dozen US patents as well as many foreign equivalent patents. He is the author of over 50 scientific publications in the area of immunology and infectious diseases. He has been awarded numerous grants from National Institutes of Health, or NIH, and the Department of Defense, or DOD. From 1969-1973, Dr. Zimmerman was a Senior Staff Fellow at NIH. For the following 25 years, he continued on at NIH as a guest worker. Dr. Zimmerman received a Ph.D. in Biochemistry in 1969, and a Masters in Zoology in 1966 from the University of Florida as well as a B.S. in Biology from Emory and Henry College in 1963.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">John Cipriano was CEL-SCI&#8217;s Senior Vice President of Regulatory Affairs between March 2004 and December 2008 and again since October 2009. Mr. Cipriano brings to CEL-SCI over 30 years of experience with both biotech and pharmaceutical companies. In addition, he held positions at the United States Food and Drug Administration (FDA) as Deputy Director, Division of Biologics Investigational New Drugs, Office of Biologics Research and Review and was the Deputy Director, IND Branch, Division of Biologics Evaluation, Office of Biologics. Mr. Cipriano completed his B.S. in Pharmacy from the Massachusetts College of Pharmacy in Boston, Massachusetts and his M.S. in Pharmaceutical Chemistry from Purdue University in West Lafayette, Indiana.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">59</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Peter R. Young, Ph.D. has been a Director of CEL-SCI since August 2002. Dr. Young has been a senior executive within the pharmaceutical industry in the United States and Canada for most of his career, originally in organizations that are now part of Sanofi S.A. Over the last 20 years he has primarily held positions of Chief Executive Officer or Chief Financial Officer and has extensive experience with acquisitions and equity financing. Since November 2001, Dr. Young has been the President of Agnus Dei, LLC, which has acted as a partner in an organization managing immune system clinics which treat patients with diseases such as cancer, multiple sclerosis and hepatitis.&#160; Dr. Young was also the President and Chief Executive Officer of SRL Technology, Inc., a company involved in the development of pharmaceutical drug delivery systems.&#160; Between 1998 and 2001, Dr. Young was the Chief Financial Officer of Adams Laboratories, Inc., the developer of Mucinex&#174;. Dr. Young received his Ph.D. in Organic Chemistry from the University of Bristol, England after obtaining his Bachelor&#8217;s degree in Honors Chemistry, Mathematics and Economics. Subsequently, he qualified as a Fellow of the Chartered Institute of Management Accountants.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Bruno Baillavoine joined CEL-SCI&#8217;s board of directors in June 2015.&#160; Since 2017, Mr. Baillavoine has been the Director, Head of Pericles Group UK the subsidiary of the Paris-based leading French consulting firm Pericles Consulting Holdings SAS.&#160; Pericles is an expert in the fields of Banking, Finance, Asset Management and Insurance with over 500 institutional clients.&#160; Since November 2022, Mr. Baillavoine has been a director, initially&#160; non-executive, now executive of ESG.AI, a Canadian Company. Since July 2023, Mr. Baillavoine has been Executive Chair of Gratomic Inc., a Canadian Graphite mining company listed on the TSXV. He has also been an advisor to the Board of CSL Inc., now &#8220;Combat Sport Entertainmnet&#8221;, a US Mixed Martial Arts company from 2017 to 2022 and retains a financial interest in the Company.&#160; Between 2010-2016, Mr. Baillavoine was a partner of Globomass Holdings Limited, a London, England based developer of renewable energy projects. He became Executive Chairmans from 2012 to 2016. Globomass was acquired by CleanBay Inc. in 2016. Mr. Baillavoine remains a significant shareholder in CleanBay Inc.&#160;&#160; Between 1978 and 1982 he was the marketing manager of Ravenhead Ltd., a manufacturer of glass tableware, and part of United Distillers Group (later acquired by Grand Metropolitan). During this time Mr. Baillavoine became the UK Business Manager where he restored market share and profit for United Distillers. &#160;From 1982 to 1986 Mr. Baillavoine was Group Corporate Planning and Group Marketing Director for Prontaprint where he expanded the number of shops to 500 locations in four years. Mr. Baillavoine was with Grand Metropolitan Plc between 1986-1988 (now Diageo Plc), a FTSE 100 beverage, food, hotel and leisure company, as director in the Special Operations division.&#160; In this capacity, he developed plans for Grand Met&#8217;s trouble-shooting division for over 20,000 Grand Met retail outlets. From 1988-1991 he was the Managing Director of Nutri Systems (UK) Ltd., a subsidiary of the US based provider of professionally supervised weight loss programs.&#160; Between 1991 and 1995, Mr. Baillavoine was Director of BET Group plc, a multinational business support services group, and in 1992, was promoted to the Managing Director for the manufacturing businesses. The &#163;2.3 billion turnaround of BET during his tenure is one of the most successful turnarounds of a top 100 FTSE company.&#160; Since 1995, Mr. Baillavoine has held a number of CEO positions across a wide range of industries and geographical locations.&#160; Mr. Baillavoine has European and American educations (US high school and University of Wisconsin Eau Claire 1972-1976).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Robert Watson has been a director of CEL-SCI since December 2017. Mr. Watson was the President and CEO of Juvare, LLC (formerly Intermedix, Inc.) from July 2017 to July 2023.&#160; At present he is a Director of Juvare, LLC. &#160;Immediately prior to joining Intermedix, now Juvare, he was the President and Chief Growth Officer of NantHealth, Inc. (Nasdaq: NH) from January 2015 to May 2017. Prior to NantHealth, he was President and CEO of Streamline Health, Inc. (Nasdaq: STRM) from January 2011 to January 2015. Mr. Watson has over 40 years of experience in the healthcare information technology industry as a CEO, board member and advisor to multiple healthcare information technology companies. He has participated in over 75 acquisitions, raised nearly $750 million in capital, completed three public offerings and successfully sold five companies. Mr. Watson holds a MBA from the Wharton School of Business at the University of Pennsylvania and a BA degree from Syracuse University. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">60</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Gail K. Naughton, Ph.D. has been a Director of CEL-SCI since August 2022. Dr. Naughton has been a pioneer in the field of regenerative medicine for over 35 years. She was the founder of Advanced Tissue Sciences where she oversaw the design and development of the world&#8217;s first up-scaled manufacturing facility for cell-based products, established corporate development and marketing partnerships with companies including Smith &amp; Nephew, Ltd., Medtronic and Inamed Corporation, was pivotal in raising over $350M from the public market and corporate partnerships, and brought four human cell-based products from concept through FDA approval and market launch. Dr. Naughton founded Histogen Inc. in 2007 and holds more than 125 U.S. and foreign patents and has been extensively published in the field.&#160; Dr. Naughton served as Dean of the College of Business Administration at San Diego State University from 2002 until 2011, where she helped to make SDSU the first US campus to establish a Ph.D./MBA in life sciences. In 2000, Dr. Naughton received the 27th Annual National Inventor of the Year award by the Intellectual Property Owners Association in honor of her pioneering work in the field of tissue engineering and regenerative medicine.&#160; Dr. Naughton received her Ph.D. and M.S. from NYU Medical Center, and an MBA from UCLA. She currently sits on the Board of directors of Therapeutics MD and is the Chair of the Board of the La Jolla Institute for Immunology and is the Executive Chair for for-profit BiOHIP INC.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI believes its directors are qualified to serve as directors for the following reasons:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:18%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:42%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Reason</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:18%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Geert Kersten, Esq.</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:42%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Long standing relationship with CEL-SCI</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:18%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Dr. Peter Young</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:42%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Long standing relationship with CEL-SCI</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:18%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Bruno Baillavoine</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:42%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Long standing relationship with CEL-SCI</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:18%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Robert Watson</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:42%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Long standing relationship with CEL-SCI</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:18%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Dr. Gail Naughton</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:42%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Thirty-five years&#8217; experience in regenerative medicine</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">All of CEL-SCI&#8217;s officers devote substantially all of their time to CEL-SCI&#8217;s business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI&#8217;s Board of Directors does not have a &#8220;leadership structure&#8221;, as such, since each director is entitled to introduce resolutions to be considered by the Board and each director is entitled to one vote on any resolution considered by the Board. CEL-SCI&#8217;s Chief Executive Officer is not the Chairman of CEL-SCI&#8217;s Board of Directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI&#8217;s Board of Directors has the ultimate responsibility to evaluate and respond to risks facing CEL-SCI. CEL-SCI&#8217;s Board of Directors fulfills its obligations in this regard by meeting on a regular basis and communicating, when necessary, with CEL-SCI&#8217;s officers.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Dr. Peter R. Young, Bruno Baillavoine, Robert Watson, and Dr. Gail Naughton are independent directors as that term is defined in section 803 of the listing standards of the NYSE American.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI has adopted a Code of Ethics which is applicable to CEL-SCI&#8217;S principal executive, financial, and accounting officers and persons performing similar functions. The Code of Ethics is available on CEL-SCI&#8217;s website, located at <span style="text-decoration:underline">https://cel-sci.com/new-investor-information/</span><em>.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">If a violation of this code of ethics act is discovered or suspected, any person (anonymously, if desired) may send a detailed note, with relevant documents, to CEL-SCI&#8217;s Audit Committee, c/o Dr. Peter Young, 208 Hewitt Drive, Suite 103-143, Waco, TX 76712<strong>.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">61</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">For purposes of electing directors at its annual meeting, CEL-SCI has a Nominating and Governance Committee that is made up of CEL-SCI&#8217;s independent directors. The Nominating and Governance Committee selects the nominees to the Board of Directors which are subject to election by CEL-SCI&#8217;s shareholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI does not have any policy regarding the consideration of director candidates recommended by shareholders and under Colorado law, any shareholder can nominate a person for election as a director at the annual shareholders&#8217; meeting. However, CEL-SCI&#8217;s Board of Directors will consider candidates recommended by shareholders. To submit a candidate for the Board of Directors the shareholder should send the name, address and telephone number of the candidate, together with any relevant background or biographical information, to CEL-SCI&#8217;s Chief Executive Officer, at the address shown on the cover page of this report. The Board has not established any specific qualifications or skills a nominee must meet to serve as a director. Although the Board does not have any process for identifying and evaluating director nominees, the Board does not believe there would be any differences in the manner in which the Board evaluates nominees submitted by shareholders as opposed to nominees submitted by any other person.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI does not have a policy with regard to Board member&#8217;s attendance at annual meetings. All Board members attended the last annual shareholder&#8217;s meeting held on May 23, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Holders of CEL-SCI&#8217;s common stock can send written communications to CEL-SCI&#8217;s entire Board of Directors, or to one or more Board members, by addressing the communication to &#8220;the Board of Directors&#8221; or to one or more directors, specifying the director or directors by name, and sending the communication to CEL-SCI&#8217;s offices in Vienna, Virginia. Communications addressed to the Board of Directors as whole will be delivered to each Board member. Communications addressed to a specific director (or directors) will be delivered to the director (or directors) specified.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">A security holder communication not sent to the Board of Directors as a whole is not relayed to Board members which did not receive the communication.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 11. </strong><strong><span style="text-decoration:underline">EXECUTIVE COMPENSATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Components of Compensation &#8212; Executive Officers</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s executive officers are compensated through the following three components:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Base Salary</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Long-Term Incentives (&#8220;LTIs&#8221;) (stock options and/or grants of stock)</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Benefits</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">These components provide a balanced mix of base compensation and compensation that is contingent upon each executive officer&#8217;s individual performance. A goal of the compensation program is to provide executive officers with a reasonable level of security through base salary and benefits. CEL-SCI wants to ensure that the compensation programs are appropriately designed to encourage executive officer retention and motivation to create shareholder value. The Compensation Committee believes that CEL-SCI&#8217;s stockholders are best served when CEL-SCI can attract and retain talented executives by providing compensation packages that are competitive but fair.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">62</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Base Salaries</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Base salaries generally have been targeted to be competitive when compared to the salary levels of persons holding similar positions in other pharmaceutical companies and other publicly traded companies of comparable size. Each executive officer&#8217;s respective responsibilities, experience, expertise and individual performance are considered.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">A further consideration in establishing compensation for the senior employees is their long term history with CEL-SCI. Taken into consideration are factors that have helped CEL-SCI survive in times when it was financially weak, such as: willingness to accept salary cuts, willingness not to be paid at all for extended time periods, and in general an attitude that helped CEL-SCI survive during financially difficult times.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Long-Term Incentives</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Stock grants and option grants help to align the interests of CEL-SCI&#8217;s officers, directors and employees with those of its shareholders. Options and stock grants are made under CEL-SCI&#8217;s Stock Option, Incentive Stock Bonus, Stock Bonus and Stock Compensation Plans. Options are granted with exercise prices equal to the closing price of CEL-SCI&#8217;s common stock on the day immediately preceding the date of grant, with pro rata vesting at the end of each of the following three years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI believes that grants of equity-based compensation:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Enhance the link between the creation of shareholder value and long-term executive incentive compensation;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Provide focus, motivation and retention incentive; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Provide competitive levels of total compensation.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Benefits</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In addition to cash and equity compensation programs, executive officers participate in the health and welfare benefit programs available to other employees. In a few limited circumstances, CEL-SCI provides other benefits to certain executive officers, such as car allowances.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">All executive officers are eligible to participate in CEL-SCI&#8217;s 401(k) plan on the same basis as its other employees. CEL-SCI matches 100% of each employee&#8217;s contribution up to 6% of his or her salary.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table sets forth in summary form the compensation received by (i) the Chief Executive and Financial Officer of CEL-SCI and (ii) by each other executive officer of CEL-SCI who received in excess of $100,000 during the two fiscal years ended September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Name and Principal Position</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Fiscal Year</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Salary (1)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Bonus (2)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Stock Awards (3)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Option Awards (4)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">All Other Compensation</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(5)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Geert R. Kersten,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">637,157</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">19,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">305,977</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">65,631</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,027,965</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Executive and Financial Officer and Treasurer</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">616,355</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">17,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">748,458</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">55,631</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,437,844</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patricia B. Prichep,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">286,145</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">17,160</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">204,392</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,031</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">516,728</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Senior Vice President of Operations and Secretary</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">276,999</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">17,160</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">499,970</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,031</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">803,160</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Eyal Talor, Ph.D.,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">345,849</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,600</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">222,751</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6,031</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">584,231</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Scientific Officer</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">334,557</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,600</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">544,877</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6,031</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">895,065</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Daniel Zimmerman, Ph.D.,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">45,546</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">531</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">46,077</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Senior Vice President of Research, Cellular Immunology</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">256,825</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">15,769</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">239,506</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6,031</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">518,131</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">John Cipriano,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">246,940</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">79,554</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">31</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">326,525</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Senior Vice President of Regulatory Affairs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">239,074</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">194,599</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">31</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">433,704</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">63</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(1)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The dollar value of base salary (cash and non-cash) earned. The officers have agreed to take less than their actual salary for the year 2023. As of September 30, 2023, CEL-SCI owed back salaries to the following employees:</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160; Salary</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Geert Kersten</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">72,168</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patricia Prichep</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,146</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Eyal Talor, Ph.D.</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,291</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">John Cipriano</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,866</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(2)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The dollar value of bonus (cash and non-cash) earned.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(3)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">For all persons listed in the table, the shares issued as CEL-SCI's contribution on behalf of the named officer who participates in CEL-SCI's 401(k) retirement plan. The value of all stock awarded during the periods covered by the table is calculated according to ASC 718-10-30-3 which represented the grant date fair value.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(4)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The fair value of all stock options granted during the periods covered by the table are calculated on the grant date in accordance with ASC 718-10-30-3 which represented the grant date fair value.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(5)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">All other compensation received that CEL-SCI could not properly report in any other column of the table including the dollar value of any insurance premiums paid by, or on behalf of, CEL-SCI with respect to term life insurance for the benefit of the named executive officer and car allowances paid by CEL-SCI. Includes board of directors fees for Mr. Kersten.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Employee Pension, Profit Sharing or Other Retirement Plans</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">CEL-SCI has a defined contribution retirement plan, qualifying under Section 401(k) of the Internal Revenue Code and covering substantially all CEL-SCI&#8217;s employees.&#160;&#160;CEL-SCI&#8217;s contribution to the plan is made in shares of CEL-SCI's common stock. Each participant's contribution is matched by CEL-SCI with shares of common stock which have a value equal to 100% of the participant's contribution, not to exceed the lesser of $10,000 or 6% of the participant's total compensation.&#160;&#160;CEL-SCI's contribution of common stock is valued each quarter based upon the closing price of its common stock.&#160;&#160;The fiscal 2023 expenses for this plan were approximately $5,000. Other than the 401(k) Plan, CEL-SCI does not have a defined benefit, pension plan, profit sharing or other retirement plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Compensation of Directors During Year Ended September 30, 20</span></strong><strong><span style="text-decoration:underline">23</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Name</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Fees</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Stock Awards (1)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 10.35pt; text-align:center;">Option Awards (2)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Total</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Geert Kersten&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">305,977</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">355,977</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Peter R. Young&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">78,330</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">135,830</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Bruno Baillavoine</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">55,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">78,330</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">133,330</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Robert Watson </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">78,330</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">135,830</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Gail K. Naughton</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">104,032</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">154,032</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(1)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The fair value of stock issued for services.</p></td></tr><tr style="height:15px"><td></td><td></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(2)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The fair value of options granted computed in accordance with ASC 718-10-30-3 on the date of grant which represents their grant date fair value.</p></td></tr><tr style="height:15px"><td></td><td></td></tr><tr style="height:15px"><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Directors&#8217; fees paid to Geert Kersten are included in the Executive Compensation table.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">64</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Employment Contracts</span></strong>&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Geert Kersten</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On August 31, 2019, CEL-SCI entered into a four-year employment agreement with Geert Kersten, CEL-SCI&#8217;s Chief Executive Officer. The employment agreement with Mr. Kersten, which is essentially the same as Mr. Kersten&#8217;s prior employment agreement, as amended on August 30, 2016, provided that, during the term of the agreement, CEL-SCI would pay Mr. Kersten an annual salary of $559,052, plus any increases in proportion to salary increases granted to other senior executive officers of CEL-SCI, as well any increases approved by the Board of Directors during the term of the employment agreement. On October 26, 2023, CEL-SCI agreed that the term of the employment agreement would be extended to August 31, 2027. All other terms of the employment agreement remain the same.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">During the employment term, Mr. Kersten will be entitled to receive any other benefits which are provided to CEL-SCI's executive officers or other full time employees in accordance with CEL-SCI's policies and practices and subject to Mr. Kersten&#8217;s satisfaction of any applicable conditions of eligibility.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If Mr. Kersten resigns after the occurrence of any of the following events:(i) a reduction in Mr. Kersten&#8217;s salary(ii) a relocation (or demand for relocation) of Mr. Kersten&#8217;s place of employment to a location more than ten(10) miles from his current place of employment, (iii) a significant and material reduction in Mr. Kersten&#8217;s authority, job duties or level of responsibility or the imposition of significant and material limitations on Mr. Kersten&#8217;s autonomy in his position, or (iv) a Change in Control, then the employment agreement will be terminated and Mr. Kersten will be entitled to receive a lump-sum payment from CEL-SCI equal to 24 months of salary ($1,288,182) and the unvested portion of any stock options would vest immediately. For purposes of the employment agreement a change in the control of CEL-SCI means: (1) the merger of CEL-SCI with another entity if after such merger the shareholders of CEL-SCI do not own at least 50% of voting capital stock of the surviving corporation; (2) the sale of substantially all of the assets of CEL-SCI; (3) the acquisition by any person of more than 50% of CEL-SCI's common stock; or (4) a change in a majority of CEL-SCI's directors which has not been approved by the incumbent directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The employment agreement will also terminate upon the death of Mr. Kersten or Mr. Kersten&#8217;s physical or mental disability. If the employment agreement is terminated for any of these reasons, Mr. Kersten, or his legal representatives, as the case may be, will be paid the salary provided by the employment agreement through the date of termination, any options or bonus shares of CEL-SCI then held by Mr. Kersten will become fully vested and the expiration date of any options which would expire during the four year period following his termination of employment will be extended to the date which is four years after his termination of employment. The employment agreement will also terminate upon the willful misconduct, an act of fraud against CEL-SCI, or a breach of the employment agreement by Mr. Kersten, in which case Mr. Kersten will be paid the salary provided by the employment agreement through the date of termination.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Patricia B. Prichep / Eyal Talor, Ph.D.</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On August 31, 2019, CEL-SCI entered into a four-year employment agreement with Patricia B. Prichep, CEL-SCI&#8217;s Senior Vice President of Operations. The employment agreement with Ms. Prichep, which is essentially the same as Ms. Prichep&#8217;s prior employment agreement entered into on August 30, 2016 provided that, during the term of the agreement, CEL-SCI would pay Ms. Prichep an annual salary of $245,804 plus any increases approved by the Board of Directors during the period of the employment agreement. On August 31, 2023, CEL-SCI agreed that the term of the employment agreement would be extended to August 31, 2027. All other terms of the employment agreement remain the same.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">65</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On August 31, 2019, CEL-SCI entered into a four-year employment agreement with Eyal Talor, Ph.D., CEL-SCI&#8217;s Chief Scientific Officer. The employment agreement with Dr. Talor, which is essentially the same as Dr. Talor&#8217;s prior employment agreement entered into on August 30, 2016, provided that, during the term of the agreement, CEL-SCI would pay Dr. Talor an annual salary of $303,453 plus any increases approved by the Board of Directors during the period of the employment agreement. On August 31, 2023, CEL-SCI agreed that the term of the employment agreement would be extended to August 31, 2027. All other terms of the employment agreement remain the same.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If Ms. Prichep or Dr. Talor resigns after the occurrence of any of the following events: (i) a relocation (or demand for relocation) of employee&#8217;s place of employment to a location more than ten (10) miles from the employee&#8217;s current place of employment, (ii) a significant and material reduction in the employee&#8217;s authority, job duties or level of responsibility, (iii) the imposition of significant and material limitations on the employee&#8217;s autonomy in her or his position, or (iv) there is a change in the control of CEL-SCI, the employment agreements with Ms. Prichep and Dr. Talor allow Ms. Prichep and/or Dr. Talor (as the case may be) to resign from her or his position at CEL-SCI and receive a lump-sum payment from CEL-SCI equal to 18 months of salary ($424,790 and $524,419, respectively). In addition, the unvested portion of any stock options held by the employee will vest immediately. For purposes of the employment agreements, a change in the control of CEL-SCI means: (1) the merger of CEL-SCI with another entity if after such merger the shareholders of CEL-SCI do not own at least 50% of voting capital stock of the surviving corporation; (2) the sale of substantially all of the assets of CEL-SCI; (3) the acquisition by any person of more than 50% of CEL-SCI's common stock; or (4) a change in a majority of CEL-SCI's directors which has not been approved by the incumbent directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The employment agreements with Ms. Prichep and Dr. Talor will also terminate upon the death of the employee, the employee&#8217;s physical or mental disability, willful misconduct, an act of fraud against CEL-SCI, or a breach of the employment agreement by the employee. If the employment agreement is terminated for any of these reasons the employee, or her or his legal representatives, as the case may be, will be paid the salary provided by the employment agreement through the date of termination.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Compensation Committee Interlocks and Insider Participation</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has a compensation committee comprised of Mr. Bruno Baillavoine, Dr. Peter Young and Mr. Robert Watson, all of whom are independent directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">During the year ended September 30, 2023, no director of CEL-SCI was also an executive officer of another entity, which had an executive officer of CEL-SCI serving as a director of such entity or as a member of the compensation committee of such entity.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Stock Option, Bonus and Compensation Plans</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Bonus Plans, Stock Compensation Plans and an Incentive Stock Bonus Plan. All Stock Option, Bonus and Compensation Plans have been approved by CEL-SCI&#8217;s stockholders. A summary description of these Plans follows. In some cases these Plans are collectively referred to as the "Plans".</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">66</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><span style="text-decoration:underline">Incentive Stock Option Plan</span><span style="text-decoration:underline">s</span>. The Incentive Stock Option Plans authorize the issuance of shares of CEL-SCI's common stock to persons who exercise options granted pursuant to the Plans. Only CEL-SCI&#8217;s employees may be granted options pursuant to the Incentive Stock Option Plans.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Options may not be exercised until one year following the date of grant. Options granted to an employee then owning more than 10% of the common stock of CEL-SCI may not be exercisable by its terms after five years from the date of grant. Any other option granted pursuant to the Plans may not be exercisable by its terms after ten years from the date of grant.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The option exercise price is determined by CEL-SCI&#8217;s Compensation Committee but cannot be less than the fair market value of the common stock on the date of the grant of the option (or 110% of the fair market value in the case of a person owning more than 10% of CEL-SCI's outstanding shares).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><span style="text-decoration:underline">Non-Qualified Stock Option Plans</span>. The Non-Qualified Stock Option Plans authorize the issuance of shares of CEL-SCI's common stock to persons that exercise options granted pursuant to the Plans. CEL-SCI's employees, directors, officers, consultants and advisors are eligible to be granted options pursuant to the Plans, provided however that bona fide services must be rendered by such consultants or advisors and such services must not be in connection with a capital-raising transaction or promoting CEL-SCI&#8217;s common stock. The option exercise price is determined by CEL-SCI&#8217;s Compensation Committee.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><span style="text-decoration:underline">Stock Bonus Plan</span><span style="text-decoration:underline">s</span>. Under the Stock Bonus Plans shares of CEL-SCI&#8217;s common stock may be issued to CEL-SCI's employees, directors, officers, consultants and advisors, provided however that bona fide services must be rendered by consultants or advisors and such services must not be in connection with&#160; a capital-raising transaction or promoting CEL-SCI&#8217;s common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><span style="text-decoration:underline">Stock Compensation Plan</span><span style="text-decoration:underline">s</span>.&#160; Under the Stock Compensation Plans, shares of CEL-SCI&#8217;s common stock may be issued to CEL-SCI&#8217;s employees, directors, officers, consultants and advisors in payment of salaries, fees and other compensation owed to these persons.&#160; However, bona fide services must be rendered by consultants or advisors and such services must not be in connection with a capital-raising transaction or promoting CEL-SCI&#8217;s common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><span style="text-decoration:underline">Incentive Stock Bonus</span><span style="text-decoration:underline"> Plan</span>.&#160; Under the 2014 Incentive Stock Bonus Plan, shares of CEL-SCI&#8217;s common stock may be issued to executive officers and other employees who contribute significantly to the success of CEL-SCI. The purpose of the Plan is to provide long term incentive for outstanding service to CEL-SCI and its shareholders, to assist in recruiting and retaining people of outstanding ability and initiative in executive and management positions to allow officers and employees to participate in CEL-SCI's future prosperity and growth, and to align the interests of CEL-SCI's officers and employees with those of its shareholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><span style="text-decoration:underline">Other Information Regarding the Plans</span>.&#160; The Plans are administered by CEL-SCI's Compensation Committee (&#8220;the Committee&#8221;), each member of which is a director of CEL-SCI.&#160; The members of the Committee were selected by CEL-SCI's Board of Directors and serve for a one-year tenure and until their successors are elected.&#160; A member of the Committee may be removed at any time by action of the Board of Directors. Any vacancies which may occur on the Committee will be filled by the Board of Directors.&#160; The Committee is vested with the authority to interpret the provisions of the Plans and supervise the administration of the Plans. In addition, the Committee is empowered to select those persons to whom shares or options are to be granted, to determine the number of shares subject to each grant of a stock bonus or an option and to determine when, and upon what conditions, shares or options granted under the Plans will vest or otherwise be subject to forfeiture and cancellation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">67</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In the discretion of the Committee, any option granted pursuant to the Plans may include installment exercise terms such that the option becomes fully exercisable in a series of cumulating portions. The Committee may also accelerate the date upon which any option (or any part of any options) is first exercisable. Any shares issued pursuant to the Stock Bonus Plans or Stock Compensation Plans and any options granted pursuant to the Incentive Stock Option Plans or the Non-Qualified Stock Option Plans will be forfeited if the "vesting" schedule established by the Committee administering the Plans at the time of the grant is not met. For this purpose, vesting means the period during which the employee must remain an employee of CEL-SCI or the period of time a non-employee must provide services to CEL-SCI. At the time an employee ceases working for CEL-SCI (or at the time a non-employee ceases to perform services for CEL-SCI), any shares or options not fully vested will be forfeited and cancelled. At the discretion of the Committee payment for the shares of common stock underlying options may be paid through the delivery of shares of CEL-SCI's common stock having an aggregate fair market value equal to the option price, provided such shares have been owned by the option holder for at least one year prior to such exercise. A combination of cash and shares of common stock may also be permitted at the discretion of the Committee.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Options are generally non-transferable except upon the death of the option holder. Shares issued pursuant to the Stock Bonus Plans will generally not be transferable until the person receiving the shares satisfies the vesting requirements imposed by the Committee when the shares were issued. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The Board of Directors of CEL-SCI may at any time, and from time to time, amend, terminate, or suspend one or more of the Plans in any manner &#160;it deems appropriate, provided that such amendment, termination or suspension may not adversely affect rights or obligations with respect to shares or options previously granted.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">During fiscal year ended September 30, 2022, CEL-SCI granted 250,000 performance-based stock options from the 2020 Non-Qualified Stock Option Plan to officers. Each option entitles the holder to purchase one share of CEL-SCI&#8217;s common stock at a price of $10.48 per share, the fair value on the date of issuance. The stock options will vest 100% upon approval of the first marketing application for any pharmaceutical based upon CEL-SCI&#8217;s Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia. As of September 30, 2023, none of the options were exercisable. All options which have not vested as of November 18, 2031 will be canceled.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Stock Options</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table shows information concerning the options granted during the fiscal year ended September 30, 2023, to the persons named below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span style="text-decoration:underline">Options Granted</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Name&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Grant Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options Granted</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Geert Kersten</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">8/8/2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">250,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.36</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8/7/2033</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patricia Prichep</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">8/8/2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">167,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.36</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8/7/2033</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Eyal Talor</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">8/8/2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">182,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.36</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8/7/2033</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">John Cipriano</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">8/8/2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.36</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8/7/2033</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Bruno Baillavoine</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">8/8/2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.36</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8/7/2033</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Peter Young</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">8/8/2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.36</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8/7/2033</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Robert Watson</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">8/8/2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.36</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8/7/2033</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Gail Naughton</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">8/8/2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.36</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8/7/2033</p></td><td style="width:1%;">&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">68</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table shows the outstanding options held by the persons named below on September 30, 2023:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares underlying unexercised</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Option which are:</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration</p></td><td>&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Name</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercisable</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Unexercisable</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Price ($)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Date</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Geert R. Kersten</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,600</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">02/25/24</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">180,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.18</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">07/27/27</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">530,121</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.45</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/30/28</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">813,180</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/10/29</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">148,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">444,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/19/30</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">592,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">05/13/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.48</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">11/18/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">83,334</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">166,666</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">06/12/32</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">250,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.36</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">08/07/33</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patricia B. Prichep</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">02/25/24</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.18</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">07/27/27</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">222,607</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.45</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/30/28</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">405,631</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/10/29</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">72,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">216,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/19/30</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">288,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">05/13/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.48</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">11/18/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">55,667</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">111,333</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">06/12/32</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">167,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.36</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">08/07/33</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Eyal Talor, Ph.D</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">02/25/24</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.18</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">07/27/27</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">193,934</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.45</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/30/28</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">100,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.55</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">09/20/28</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">382,712</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/10/29</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">72,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">216,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/19/30</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">318,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">05/13/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.48</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">11/18/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">60,667</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">121,333</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">06/12/32</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">182,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.36</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">08/07/33</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Dan Zimmerman, Ph.D</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,800</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">02/25/24</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">08/05/24</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">06/25/25</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">07/21/26</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.87</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">06/28/27</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.59</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">09/17/27</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">126,194</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.45</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/30/28</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">211,459</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/10/29</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/19/30</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">160,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">05/13/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.48</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">11/18/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,667</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">53,333</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">06/12/32</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">John Cipriano</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,800</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">02/25/24</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">90,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.18</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">07/27/27</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">148,347</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.45</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/30/28</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">206,880</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/10/29</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/19/30</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">130,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">05/13/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.48</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">11/18/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,667</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,333</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">06/12/32</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.36</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">08/07/33</p></td><td style="width:1%;">&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">69</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><span style="text-decoration:underline">Summary</span>. The following shows certain information as of September 30, 2023 concerning the stock options and stock bonuses granted by CEL-SCI. Each option represents the right to purchase one share of CEL-SCI's common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Name of Plan</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total Shares Reserved Under Plans</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Option Plans&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,787,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Bonus Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,283,760</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Compensation Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">634,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Bonus Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">640,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Of the shares issued pursuant to CEL-SCI's Stock Bonus Plans, 430,650 shares were issued as part of CEL-SCI's contribution to its 401(k) plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The following table shows the weighted average exercise price of the outstanding options granted pursuant to CEL-SCI&#8217;s Incentive and Non-Qualified Stock Option Plans as of September 30, 2023, CEL-SCI&#8217;s most recent fiscal year end. CEL-SCI's Incentive and Non-Qualified Stock Option Plans have been approved by CEL-SCI's shareholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Plan category</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number of Securities to be Issued Upon Exercise of Outstanding Options (a)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted-Average Exercise Price of Outstanding Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number of Securities Remaining Available For Future Issuance Under Equity Compensation Plans, Excluding Securities </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Reflected in Column (a)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Option Plans&#160;&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">45,446</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.21</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,712,112</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7.78</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">636,138</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">70</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 12. <span style="text-decoration:underline">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table shows, as of December 1, 2023, information with respect to the only persons owning beneficially 5% or more of CEL-SCI&#8217;s outstanding common stock and the number and percentage of outstanding shares owned by each director and officer of CEL-SCI and by the officers and directors as a group. Unless otherwise indicated, each owner has sole voting and investment powers over his shares of common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Name and Address</p></td><td style="BORDER-BOTTOM: #000000 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">Number of Shares (1)</p></td><td style="BORDER-BOTTOM: #000000 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">Percent of Class (2)</p></td><td style="BORDER-BOTTOM: #000000 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Geert R. Kersten </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">8229 Boone Blvd., Suite 802</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vienna, VA&#160; 22182</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,908,278</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">(3)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7.4</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Patricia B. Prichep</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">8229 Boone Blvd., Suite 802</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vienna, VA&#160; 22182</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,110,306</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.2</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Eyal Talor, Ph.D.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">8229 Boone Blvd., Suite 802</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vienna, VA&#160; 22182</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,039,890</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Daniel H. Zimmerman, Ph.D.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">8229 Boone Blvd., Suite 802</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vienna, VA&#160; 22182</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">568,346</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">John Cipriano</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">8229 Boone Blvd., Suite 802</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vienna, VA&#160; 22182</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">571,802</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Peter R. Young, Ph.D.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">208 Hewitt Drive, Suite 103-143</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Waco, TX 76712</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">366,448</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Bruno Baillavoine</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">8229 Boone Blvd., Suite 802</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vienna, VA 22182</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">336,807</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Robert Watson</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">245 N. Highland Ave. NE</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Suite 230-296</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Atlanta, GA 30307</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">307,765</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Gail Naughton, Ph.D.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">8229 Boone Blvd., Suite 802</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vienna, VA 22182</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,334</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">All Officers and Directors</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">as a Group (9 persons)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,230,976</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14.56</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">*</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less than 1%</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(1)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Includes shares issuable prior to February 28, 2024 upon the exercise of options or warrants granted to the following persons:</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options or Warrants Exercisable</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Prior to February 28, 2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Geert R. Kersten, Esq.</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,755,643</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">(3)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Patricia B. Prichep</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">896,864</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Eyal Talor, Ph.D.</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">931,713</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Daniel Zimmerman, Ph.D.</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">448,120</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">John Cipriano</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">508,694</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Peter R. Young, Ph.D.</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">337,534</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Bruno Baillavoine</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">330,834</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Robert Watson</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">303,334</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Gail Naughton, Ph.D.</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,334</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(2)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Amount includes shares referred to in (1) above but excludes shares which may be issued upon the exercise of options and warrants previously issued by CEL-SCI.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(3)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Amount includes 346,421 shares and 390,928 warrants held in the de Clara Trust, of which Mr. Kersten is a trustee and beneficiary.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">71</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 13. </strong><strong><span style="text-decoration:underline">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">During the years ended September 30, 2023 and 2022, no shares of the Company&#8217;s common stock were purchased by officers or directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">See Note 11 to the financial statements included as part of this report for additional information concerning related party transactions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 14</strong>. <strong><span style="text-decoration:underline">PRINCIPAL ACCOUNTING FEES AND SERVICES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">BDO USA, P.C.&#160;served as CEL-SCI&#8217;s independent registered public accountant for the two years ended September 30, 2023. The following table shows the aggregate fees billed to CEL-SCI for these years by BDO USA, P.C.:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;&#160;&#160; Year Ended September 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Audit Fees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">342,287</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">358,899</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Audit Related Fees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Tax Fees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">All Other Fees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Audit fees represent amounts billed for professional services rendered for the audit of CEL-SCI&#8217;s annual financial statements and the reviews of the financial statements included in CEL-SCI&#8217;s 10-Q reports for the fiscal year and all regulatory filings.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Before BDO USA, P.C. was engaged by CEL-SCI to render audit or non-audit services, the engagement was approved by CEL-SCI&#8217;s audit committee. CEL-SCI&#8217;s Board of Directors is of the opinion that the audit fees charged by BDO USA, P.C. are consistent with BDO USA, P.C. maintaining its independence from CEL-SCI.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">72</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">ITEM 15. </span></strong><strong><span style="text-decoration:underline">EXHIBITS</span></strong><strong><span style="text-decoration:underline">AND</span></strong><strong><span style="text-decoration:underline">FINANCIAL STATEMENT SCHEDULES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:7%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Exhibits</strong></p></td><td style="width:30%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3(a)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Articles of Incorporation</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 3(a) of CEL-SCI's combined Registration Statement on Form S-1 and Post-Effective Amendment ("Registration Statement"), Registration Nos. 2-85547-D and 33-7531.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3(b)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Amended Articles</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 3(a) of CEL-SCI's Registration Statement on Form S-1, Registration Nos. 2-85547-D and 33-7531.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3(c)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Amended Articles (Name change only)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 3(c) of CEL-SCI's &#160;Registration Statement on Form S-1 Registration Statement (No. 33-34878).</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3(d)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Bylaws (as amended)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;Incorporated by reference to Exhibit 3(d) of CEL-SCI's Post-Effective Amendment No. 3 to Registration Statement on Form S-1 (No. 333-229295).</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495420011660/cvm_ex4.htm">4</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495420011660/cvm_ex4.htm">Shareholders Rights Agreement, as Amended</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 4&#160;filed with CEL-SCI&#8217;s 8-K report dated October 30, 2020.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495416002720/cvi_ex4b.htm">4(b)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495416002720/cvi_ex4b.htm">Incentive Stock Option Plan</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 4 (b) filed on October 7, 2016 with CEL-SCI&#8217;s registration statement on Form S&#172;8 (File number 333-214031).</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495422009162/cvm_ex4b.htm">4(c)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495422009162/cvm_ex4b.htm">Non-Qualified Stock Option Plan</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 4 (b) filed on July 1, 2022 with CEL-SCI&#8217;s registration statement on Form S&#172;8 (File number 333-265994).</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495418001297/cvm_ex4c.htm">4(d)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495418001297/cvm_ex4c.htm">Stock Bonus Plan</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 4 (c) filed on February 9, 2018 with CEL-SCI&#8217;s registration statement on Form S&#172;8 (File number 333-222969).</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495420000735/cvm_ex4c.htm">4(e)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495420000735/cvm_ex4c.htm">Stock Compensation Plan</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 4 (c) filed on January 24, 2020 with CEL-SCI&#8217;s registration statement on Form S&#172;8 (File number 333-236063).</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815003367/cvm_ex4f.htm">4(f)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815003367/cvm_ex4f.htm">2014 Incentive Stock Bonus Plan</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Filed with Amendment No. 2 to CEL-SCI&#8217;s annual report on Form 10-K for the year ended September 30, 2014.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487810000213/exh10m11-10.txt">10(l)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487810000213/exh10m11-10.txt">First Amendment to Development Supply&#160;and Distribution Agreement with Orient&#160;Europharma.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(m)&#160;filed with CEL-SCI&#8217;s 10-K report for the&#160;year ended September 30, 2010.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487810000213/exh10n11-10.txt">10(m)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487810000213/exh10n11-10.txt">Exclusive License and Distribution&#160;Agreement with Teva&#160;Pharmaceutical Industries&#160;Ltd.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(n)&#160;filed with CEL-SCI&#8217;s 10-K report for the&#160;year ended September 30, 2010.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487810000213/exh10o11-10.txt">10(n)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487810000213/exh10o11-10.txt">Lease Agreement</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(o)&#160;filed with CEL-SCI&#8217;s 10-K report for the&#160;year ended September 30, 2010.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">10(p)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Licensing Agreement with Byron&#160;Biopharma</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(i) of&#160;CEL-SCI&#8217;s report on Form 8-K dated March&#160;27, 2009</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487804000009/sept03amnd10kex10z.txt">10(z)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487804000009/sept03amnd10kex10z.txt">Development, Supply and Distribution&#160;Agreement with Orient Europharma</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit&#160;10(z)&#160;filed with CEL-SCI&#8217;s report on Form&#160;10-K for the year ended September 30, 2003.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10rr.htm">10 (rr)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10rr.htm">Assignment and Assumption Agreement with Teva Pharmaceutical Industries, Ltd. and GCP Clinical Studies, Ltd.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(rr) of CEL-SCI&#8217;s report on Form 10-K/A report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10ss.htm">10 (ss)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10ss.htm">Service Agreement with GCP Clinical Studies,&#160;Ltd., together with Amendment 1 thereto*</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(ss) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10tt.htm">10 (tt)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10tt.htm">Joinder Agreement with PLIVA Hrvatska d.o.o.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(tt) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10uu.htm">10 (uu)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10uu.htm">Master Service Agreement with Ergomed Clinical Research, Ltd.,&#160;&#160;and Clinical Trial Orders thereunder</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(uu) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10vv.htm">10 (vv)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10vv.htm">Co-Development and Revenue Sharing Agreement with Ergomed Clinical Research Ltd., dated April 19, 2013, as amended</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(vv) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10ww.htm">10 (ww)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10ww.htm">Co-Development and Revenue Sharing Agreement II:&#160;&#160;Cervical Intraepithelial Neoplasia in HIV/HPV co-infected women, with Ergomed Clinical Research Ltd., dated October 10, 2013, as amended</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(ww) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">73</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="width:7%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10xx.htm">10(xx)</a></p></td><td style="width:30%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10xx.htm">Co-Development and Revenue Sharing Agreement III: Anal warts and anal intraepithelial neoplasia in HIV/HPV co-infected patients, with Ergomed Clinical Research Ltd., dated October 24, 2013</a></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(xx) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10yy.htm">10 (yy)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10yy.htm">Master Services Agreement with Aptiv Solutions, Inc.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(yy) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10zz.htm">10 (zz)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10zz.htm">Project Agreement Number 1 with Aptiv Solutions, Inc. together with Amendments 1 and 2 thereto*</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(zz) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10aaa.htm">10 (aaa)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10aaa.htm">Second Amendment to Development Supply&#160;and Distribution Agreement with Orient Europharma</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(aaa) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815005519/cvm_ex10iii.htm">10 (iii)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815005519/cvm_ex10iii.htm">Amendment to Co-Development and Revenue Sharing Agreement with Ergomed Clinical Research, Ltd., dated&#160; September 15, 2015</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10 (iii)&#160;filed with CEL-SCI&#8217;s 10-K report for the&#160;year ended September 30, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495419010199/cvm_ex107.htm">10 (mmm)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495419010199/cvm_ex107.htm">Employment Agreement with Geert Kersten (2019-2023)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(10.7) of CEL-SCI&#8217;s report on Form 8-K dated August 31, 2019.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495419010199/cvm_ex108.htm">10 (nnn)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495419010199/cvm_ex108.htm">Employment Agreement with Patricia Prichep (2019-2022)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(10.8) of CEL-SCI&#8217;s report on Form 8-K dated August 31, 2019.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495419010199/cvm_ex109.htm">10 (ooo)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495419010199/cvm_ex109.htm">Employment Agreement with Eyal Taylor (2019-2022)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(10.9) of CEL-SCI&#8217;s report on Form 8-K dated August 31, 2019.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423011434/cvm_ex1010.htm">10 (ppp)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423011434/cvm_ex1010.htm">Extension of Employment Agreement with Patricia Prichep (2023-2027)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(10.10) of CEL-SCI&#8217;s report on Form 8-K dated August 31, 2023.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423011434/cvm_ex1011.htm">10 (qqq)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423011434/cvm_ex1011.htm">Extension of Employment Agreement with Eyal Talor (2023-2027)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(10.11) of CEL-SCI&#8217;s report on Form 8-K dated August 31, 2023.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="width:7%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex231.htm">23.1</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex231.htm">Consent of BDO USA, P.C.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex31.htm">31</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex31.htm">Rule 13a-14(a) Certifications</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex32.htm">32</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex32.htm">Section 1350 Certifications</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex97.htm">97</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex97.htm">Policy relating to Recovery of Erroneously Awarded Compensation</a></p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">* Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the Commission under Rule 24b-2 of the Securities Exchange Act of 1934. The omitted confidential material has been filed separately with the Commission. The location of the omitted confidential information is indicated in the exhibit with asterisks (*)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">74</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 480px; text-align:justify;"><strong>CEL-SCI CORPORATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 480px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 480px; text-align:justify;"><strong>Financial Statements for the Years</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 480px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 480px; text-align:justify;"><strong>Ended September 30, </strong><strong>2023 and 2022</strong><strong>, and</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 480px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 480px; text-align:justify;"><strong>Report of Independent Registered Public Accounting Firm</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 480px; text-align:justify;">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI CORPORATION</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><span class="atag" style="display: inline" id="toc2">TABLE OF CONTENTS</span></strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Page</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="#re">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB ID: <ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:AuditorFirmId">243</ix:nonNumeric>)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">F- 2</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">FINANCIAL STATEMENTS FOR THE YEARS ENDED SEPTEMBER 30, 2023 and 2022:</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"><a href="#bs">Balance Sheets</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">F- 4</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"><a href="#op">Statements of Operations</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">F- 5</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"><a href="#ew">Statements of Stockholders&#8217; Equity</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">F- 6</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"><a href="#cf">Statements of Cash Flows</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">F- 7</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"><a href="#fs">Notes to Financial Statements</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">F- 9 </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-1</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="re">Report of Independent Registered Public Accounting Firm</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Stockholders and Board of Directors</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI Corporation</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vienna, Virginia</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Opinion on the Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">We have audited the accompanying balance sheets of CEL-SCI Corporation (the &#8220;Company&#8221;) as of September 30, 2023 and 2022, the related statements of operations, stockholders&#8217; equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at September 30, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Going Concern Uncertainty</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations and has future liquidity needs that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"><strong>Basis for Opinion</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits. we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"><strong>Critical Audit Matter</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-2</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Evaluation of Liquidity&#160;- See also Going Concern Uncertainty explanatory paragraph above</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">As described in Note 2 to the financial statements, the Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and participation in clinical trials. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring its lead product candidate to market.&#160;&#160;However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We identified management&#8217;s evaluation of the Company&#8217;s liquidity as a critical audit matter due to certain significant judgments and assumptions used by management in&#160;preparing its forecast of cash expenditures that are used to support the Company&#8217;s liquidity disclosure. Auditing the timing and amount of&#160;forecasted cash expenditures involved especially challenging auditor judgment due to the nature and extent of audit effort required to address these matters.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The primary procedures we performed to address this critical audit matter included:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Assessing the reasonableness of the timing and amount of forecasted cash expenditures by comparing (i) the timing of the Company&#8217;s forecasted cash expenditures with the ongoing drug development pipeline and (ii) the disaggregated actual current year expenditures with historical forecasted expenditures.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Testing the completeness and accuracy of underlying data used in the forecasted cash expenditures by inspecting contractual arrangements with third-party clinical research organizations and suppliers.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160; </p><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ <ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:AuditorName">BDO USA, P.C.</ix:nonNumeric></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have served as the Company's auditor since 2005.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:AuditorLocation">Potomac, Maryland</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">December 21, 2023</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-3</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45pt; text-align:center;"><span class="atag" style="display: inline" id="bs">CEL-SCI CORPORATION&#160;</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45pt; text-align:center;">BALANCE SHEETS&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45pt; text-align:center;">SEPTEMBER 30, 2023 AND 2022</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>ASSETS</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Current assets:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1271" contextRef="AsOf2023-09-30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,145,735</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1272" contextRef="AsOf2022-09-30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,672,138</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Prepaid expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1273" contextRef="AsOf2023-09-30" name="us-gaap:PrepaidExpenseCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">520,368</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1274" contextRef="AsOf2022-09-30" name="us-gaap:PrepaidExpenseCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">762,063</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Supplies used for R&amp;D and manufacturing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1275" contextRef="AsOf2023-09-30" name="us-gaap:InventoryNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,248,072</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1276" contextRef="AsOf2022-09-30" name="us-gaap:InventoryNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,001,715</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1277" contextRef="AsOf2023-09-30" name="us-gaap:DepositsAssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,245</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1278" contextRef="AsOf2022-09-30" name="us-gaap:DepositsAssetsCurrent" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Total current assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1279" contextRef="AsOf2023-09-30" name="us-gaap:AssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,918,420</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1280" contextRef="AsOf2022-09-30" name="us-gaap:AssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,435,916</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finance lease right of use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1281" contextRef="AsOf2023-09-30" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,131,987</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1282" contextRef="AsOf2022-09-30" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,937,797</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating lease right of use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1283" contextRef="AsOf2023-09-30" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,698,243</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1284" contextRef="AsOf2022-09-30" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,884,464</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Property and equipment, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1285" contextRef="AsOf2023-09-30" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,188,126</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1286" contextRef="AsOf2022-09-30" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,889,029</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patent costs, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1287" contextRef="AsOf2023-09-30" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">197,704</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1288" contextRef="AsOf2022-09-30" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">212,201</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1460" contextRef="AsOf2023-09-30" name="us-gaap:DepositsAssetsNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,319,101</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1462" contextRef="AsOf2022-09-30" name="us-gaap:DepositsAssetsNoncurrent" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Supplies used for R&amp;D and manufacturing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1289" contextRef="AsOf2023-09-30" name="us-gaap:InventoryNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,669</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1290" contextRef="AsOf2022-09-30" name="us-gaap:InventoryNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">164,299</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1291" contextRef="AsOf2023-09-30" name="us-gaap:Assets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,528,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1292" contextRef="AsOf2022-09-30" name="us-gaap:Assets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,523,706</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>LIABILITIES AND STOCKHOLDERS' EQUITY</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Current Liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1295" contextRef="AsOf2023-09-30" name="us-gaap:AccountsPayableCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,009,786</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1296" contextRef="AsOf2022-09-30" name="us-gaap:AccountsPayableCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,618,290</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1297" contextRef="AsOf2023-09-30" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,049,581</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1298" contextRef="AsOf2022-09-30" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">842,492</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Due to employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1299" contextRef="AsOf2023-09-30" name="cvm:AmountsDueToEmployeesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">557,244</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1300" contextRef="AsOf2022-09-30" name="cvm:AmountsDueToEmployeesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">471,488</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Finance lease obligation, current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1301" contextRef="AsOf2023-09-30" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,771,804</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1302" contextRef="AsOf2022-09-30" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,560,553</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Operating lease obligation, current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1303" contextRef="AsOf2023-09-30" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">197,431</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1304" contextRef="AsOf2022-09-30" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">170,928</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Total current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1305" contextRef="AsOf2023-09-30" name="us-gaap:LiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,585,846</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1306" contextRef="AsOf2022-09-30" name="us-gaap:LiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,663,751</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Finance lease liabilities, net of current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1307" contextRef="AsOf2023-09-30" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,949,565</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1308" contextRef="AsOf2022-09-30" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,721,368</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Operating lease liabilities, net of current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1461" contextRef="AsOf2023-09-30" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,652,949</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1463" contextRef="AsOf2022-09-30" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,850,380</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Other liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1311" contextRef="AsOf2023-09-30" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1312" contextRef="AsOf2022-09-30" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1313" contextRef="AsOf2023-09-30" name="us-gaap:Liabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,313,360</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1314" contextRef="AsOf2022-09-30" name="us-gaap:Liabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,360,499</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Commitments and contingencies</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">STOCKHOLDERS' EQUITY</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Preferred stock, $<ix:nonFraction id="fid_1452" contextRef="AsOf2023-09-30" name="us-gaap:PreferredStockParOrStatedValuePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction> par value; <ix:nonFraction id="fid_1453" contextRef="AsOf2023-09-30" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">200,000</ix:nonFraction> shares authorized; <ix:nonFraction id="fid_1454" contextRef="AsOf2023-09-30" name="us-gaap:PreferredStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">0</ix:nonFraction> shares issued and outstanding Common stock, $<ix:nonFraction id="fid_1442" contextRef="AsOf2023-09-30" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction> par value; <ix:nonFraction id="fid_1444" contextRef="AsOf2023-09-30" name="us-gaap:CommonStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">600,000,000</ix:nonFraction> shares authorized; <ix:nonFraction id="fid_1447" contextRef="AsOf2023-09-30" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">47,422,304</ix:nonFraction> and <ix:nonFraction id="fid_1446" contextRef="AsOf2022-09-30" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">43,448,317</ix:nonFraction> shares issued and outstanding at September 30, 2023 and September 30, 2022, respectively</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1317" contextRef="AsOf2023-09-30" name="us-gaap:CommonStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">474,223</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1318" contextRef="AsOf2022-09-30" name="us-gaap:CommonStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">434,484</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Additional paid-in capital</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1319" contextRef="AsOf2023-09-30" name="us-gaap:AdditionalPaidInCapital" format="ixt:numdotdecimal" decimals="0" unitRef="USD">499,832,063</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1320" contextRef="AsOf2022-09-30" name="us-gaap:AdditionalPaidInCapital" format="ixt:numdotdecimal" decimals="0" unitRef="USD">486,625,816</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accumulated deficit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1321" contextRef="AsOf2023-09-30" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">487,091,396</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1322" contextRef="AsOf2022-09-30" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">454,897,093</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total stockholders' equity</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1323" contextRef="AsOf2023-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,214,890</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1324" contextRef="AsOf2022-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,163,207</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1325" contextRef="AsOf2023-09-30" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,528,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1326" contextRef="AsOf2022-09-30" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,523,706</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-4</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 63pt; text-align:center;"><span class="atag" style="display: inline" id="op">CEL-SCI CORPORATION&#160;</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 63pt; text-align:center;">STATEMENTS OF OPERATIONS&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 63pt; text-align:center;">YEARS ENDED SEPTEMBER 30, 2023 AND 2022</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating expenses:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1328" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,471,496</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1329" contextRef="From2021-10-01to2022-09-30" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,355,346</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">General &amp; administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1330" contextRef="From2022-10-01to2023-09-30" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,004,578</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1331" contextRef="From2021-10-01to2022-09-30" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,707,447</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total operating expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1332" contextRef="From2022-10-01to2023-09-30" name="us-gaap:OperatingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,476,074</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1333" contextRef="From2021-10-01to2022-09-30" name="us-gaap:OperatingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,062,793</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1334" contextRef="From2022-10-01to2023-09-30" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">31,476,074</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1335" contextRef="From2021-10-01to2022-09-30" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">36,062,793</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Gain on derivative instruments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1336" contextRef="From2022-10-01to2023-09-30" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1337" contextRef="From2021-10-01to2022-09-30" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">366,791</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other non-operating losses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1338" contextRef="From2022-10-01to2023-09-30" name="us-gaap:OtherNonoperatingGainsLosses" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1339" contextRef="From2021-10-01to2022-09-30" name="us-gaap:OtherNonoperatingGainsLosses" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">30,793</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Interest expense, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1340" contextRef="From2022-10-01to2023-09-30" name="us-gaap:InterestExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">675,416</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1341" contextRef="From2021-10-01to2022-09-30" name="us-gaap:InterestExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,081,034</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other (expense) income &#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1342" contextRef="From2022-10-01to2023-09-30" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">42,813</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1343" contextRef="From2021-10-01to2022-09-30" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,148</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1344" contextRef="From2022-10-01to2023-09-30" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">32,194,303</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1345" contextRef="From2021-10-01to2022-09-30" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">36,700,681</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Modification of warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1346" contextRef="From2022-10-01to2023-09-30" name="cvm:ModificationOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">171,552</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1347" contextRef="From2021-10-01to2022-09-30" name="cvm:ModificationOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">929,122</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss available to common shareholders</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1348" contextRef="From2022-10-01to2023-09-30" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">32,365,855</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1349" contextRef="From2021-10-01to2022-09-30" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">37,629,803</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss per common share &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1350" contextRef="From2022-10-01to2023-09-30" name="cvm:EarningPerShareBasicAndDiluted" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.73</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1351" contextRef="From2021-10-01to2022-09-30" name="cvm:EarningPerShareBasicAndDiluted" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.87</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average common shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1352" contextRef="From2022-10-01to2023-09-30" name="cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">44,479,865</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1353" contextRef="From2021-10-01to2022-09-30" name="cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">43,148,888</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-5</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="ew">CEL-SCI CORPORATION</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">STATEMENT OF STOCKHOLDERS' EQUITY</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">YEARS ENDED SEPTEMBER 30, 2023 AND 2022</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Common Stock</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Additional &#160;Paid-In</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Accumulated</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Amount</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Capital</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Deficit</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCE,&#160;SEPTEMBER 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1465" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">43,207,183</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1466" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">432,072</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1467" contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">474,298,566</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1468" contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">418,196,412</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1469" contextRef="AsOf2021-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,534,226</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrant exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1470" contextRef="From2021-10-01to2022-09-30_us-gaap_CommonStockMember" name="cvm:WarrantExercisesShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">25,205</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1471" contextRef="From2021-10-01to2022-09-30_us-gaap_CommonStockMember" name="cvm:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1472" contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember" name="cvm:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">171,562</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1473" contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember" name="cvm:WarrantExercisesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1474" contextRef="From2021-10-01to2022-09-30" name="cvm:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">171,814</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">401(k) contributions paid in common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1475" contextRef="From2021-10-01to2022-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">52,882</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1476" contextRef="From2021-10-01to2022-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">528</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1477" contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">222,515</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1478" contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1479" contextRef="From2021-10-01to2022-09-30" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">223,043</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock issued to nonemployees for service</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1480" contextRef="From2021-10-01to2022-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">156,547</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1481" contextRef="From2021-10-01to2022-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,567</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1482" contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">691,926</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1483" contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1484" contextRef="From2021-10-01to2022-09-30" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">693,493</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity based compensation - employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1485" contextRef="From2021-10-01to2022-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1486" contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,389,932</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1487" contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1488" contextRef="From2021-10-01to2022-09-30" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,389,932</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Option exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1489" contextRef="From2021-10-01to2022-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">6,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1490" contextRef="From2021-10-01to2022-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1491" contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,770</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1492" contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1493" contextRef="From2021-10-01to2022-09-30" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,835</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Share issuance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1494" contextRef="From2021-10-01to2022-09-30_us-gaap_CommonStockMember" name="cvm:IncreaseDecreaseFromStockIssuanceCosts" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1495" contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember" name="cvm:IncreaseDecreaseFromStockIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD">178,455</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1496" contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember" name="cvm:IncreaseDecreaseFromStockIssuanceCosts" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1497" contextRef="From2021-10-01to2022-09-30" name="cvm:IncreaseDecreaseFromStockIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD">178,455</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1498" contextRef="From2021-10-01to2022-09-30_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1499" contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1500" contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">36,700,681</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1501" contextRef="From2021-10-01to2022-09-30" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">36,700,681</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCE, SEPTEMBER 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1502" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">43,448,317</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1503" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">434,484</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1504" contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">486,625,816</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1505" contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">454,897,093</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1506" contextRef="AsOf2022-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,163,207</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrant exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1507" contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember" name="cvm:WarrantExercisesShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">217,752</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1508" contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember" name="cvm:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,177</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1509" contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" name="cvm:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">445,114</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1510" contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember" name="cvm:WarrantExercisesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1511" contextRef="From2022-10-01to2023-09-30" name="cvm:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">447,291</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">401(k) contributions paid in common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1512" contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">97,004</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1513" contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">970</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1514" contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">206,623</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1515" contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1516" contextRef="From2022-10-01to2023-09-30" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">207,593</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock issued to nonemployees for service</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1517" contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">249,997</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1518" contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1519" contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">563,480</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1520" contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1521" contextRef="From2022-10-01to2023-09-30" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">565,980</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds from the sale of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1522" contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,413,234</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1523" contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,132</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1524" contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,518,365</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1525" contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1526" contextRef="From2022-10-01to2023-09-30" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,552,497</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2014 Incentive Stock Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1527" contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember" name="cvm:IncentiveStockForfeitedShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares" sign="-">4,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1528" contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember" name="cvm:IncentiveStockForfeitedAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">40</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1529" contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" name="cvm:IncentiveStockForfeitedAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">22,160</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1530" contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember" name="cvm:IncentiveStockForfeitedAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1531" contextRef="From2022-10-01to2023-09-30" name="cvm:IncentiveStockForfeitedAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">22,200</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity based compensation - employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1532" contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1533" contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,308,431</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1534" contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1535" contextRef="From2022-10-01to2023-09-30" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,308,431</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Share issuance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1536" contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember" name="cvm:IncreaseDecreaseFromStockIssuanceCosts" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1537" contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" name="cvm:IncreaseDecreaseFromStockIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD">813,606</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1538" contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember" name="cvm:IncreaseDecreaseFromStockIssuanceCosts" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1539" contextRef="From2022-10-01to2023-09-30" name="cvm:IncreaseDecreaseFromStockIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD">813,606</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1540" contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1541" contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1542" contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">32,194,303</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1543" contextRef="From2022-10-01to2023-09-30" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">32,194,303</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCE, SEPTEMBER 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1544" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">47,422,304</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1545" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">474,223</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1546" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">499,832,063</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1547" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">487,091,396</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1548" contextRef="AsOf2023-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,214,890</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-6</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="cf">CEL-SCI CORPORATION</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">STATEMENTS OF CASH FLOWS</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">YEARS ENDED SEPTEMBER 30, 2023 AND 2022</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH FLOWS FROM OPERATING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1355" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ProfitLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">32,194,303</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1356" contextRef="From2021-10-01to2022-09-30" name="us-gaap:ProfitLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">36,700,681</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1358" contextRef="From2022-10-01to2023-09-30" name="us-gaap:DepreciationAndAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,958,334</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1359" contextRef="From2021-10-01to2022-09-30" name="us-gaap:DepreciationAndAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,828,917</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Non-cash lease expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1360" contextRef="From2022-10-01to2023-09-30" name="us-gaap:OtherNoncashExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,292</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1361" contextRef="From2021-10-01to2022-09-30" name="us-gaap:OtherNoncashExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,469</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Share-based payments for services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1362" contextRef="From2022-10-01to2023-09-30" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:numdotdecimal" decimals="0" unitRef="USD">655,740</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1363" contextRef="From2021-10-01to2022-09-30" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:numdotdecimal" decimals="0" unitRef="USD">762,261</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Equity based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1364" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,286,231</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1365" contextRef="From2021-10-01to2022-09-30" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,389,932</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Common stock contributed to 401(k) plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1366" contextRef="From2022-10-01to2023-09-30" name="cvm:CommonStockContributedToEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">207,593</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1367" contextRef="From2021-10-01to2022-09-30" name="cvm:CommonStockContributedToEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">223,043</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Gain on short term investments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1368" contextRef="From2022-10-01to2023-09-30" name="us-gaap:GainLossOnInvestments" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1369" contextRef="From2021-10-01to2022-09-30" name="us-gaap:GainLossOnInvestments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">615</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Gain on derivative instruments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1370" contextRef="From2022-10-01to2023-09-30" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1371" contextRef="From2021-10-01to2022-09-30" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">366,791</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Impairment loss on abandonment of patents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1372" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1373" contextRef="From2021-10-01to2022-09-30" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,793</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Loss on Receivables</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1374" contextRef="From2022-10-01to2023-09-30" name="cvm:GainLossOnReceivables" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1375" contextRef="From2021-10-01to2022-09-30" name="cvm:GainLossOnReceivables" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">54,922</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">(Increase)/decrease in assets:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Prepaid expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1377" contextRef="From2022-10-01to2023-09-30" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,935</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1378" contextRef="From2021-10-01to2022-09-30" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">167,651</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Supplies used for R&amp;D and manufacturing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1379" contextRef="From2022-10-01to2023-09-30" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">156,727</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1380" contextRef="From2021-10-01to2022-09-30" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">159,430</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1381" contextRef="From2022-10-01to2023-09-30" name="us-gaap:IncreaseDecreaseInDeposits" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,323,346</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1382" contextRef="From2021-10-01to2022-09-30" name="us-gaap:IncreaseDecreaseInDeposits" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,910,917</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Increase/(decrease) in liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1384" contextRef="From2022-10-01to2023-09-30" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">257,845</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1385" contextRef="From2021-10-01to2022-09-30" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">374,890</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1386" contextRef="From2022-10-01to2023-09-30" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">207,089</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1387" contextRef="From2021-10-01to2022-09-30" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">16,724</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Due to employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1388" contextRef="From2022-10-01to2023-09-30" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,756</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1389" contextRef="From2021-10-01to2022-09-30" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">205,495</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:60px">Net cash used in operating activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1390" contextRef="From2022-10-01to2023-09-30" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">22,848,561</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1391" contextRef="From2021-10-01to2022-09-30" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">18,240,951</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH FLOWS FROM INVESTING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Proceeds from maturity of U.S. Treasury Bills</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1393" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1394" contextRef="From2021-10-01to2022-09-30" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,152,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Purchases of property and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1395" contextRef="From2022-10-01to2023-09-30" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">361,892</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1396" contextRef="From2021-10-01to2022-09-30" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">637,892</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Expenditures for patent costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1397" contextRef="From2022-10-01to2023-09-30" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,370</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1398" contextRef="From2021-10-01to2022-09-30" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,741</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:60px">Net cash (used in) provided by investing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1399" contextRef="From2022-10-01to2023-09-30" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">372,262</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1400" contextRef="From2021-10-01to2022-09-30" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,491,367</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH FLOWS FROM FINANCING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Proceeds from issuance of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1402" contextRef="From2022-10-01to2023-09-30" name="cvm:ProceedsFromIssuanceOfCommonStocks" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,552,497</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1403" contextRef="From2021-10-01to2022-09-30" name="cvm:ProceedsFromIssuanceOfCommonStocks" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Payments of stock issuance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1404" contextRef="From2022-10-01to2023-09-30" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD">744,913</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1405" contextRef="From2021-10-01to2022-09-30" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD">169,445</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Proceeds from the exercise of warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1406" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:numdotdecimal" decimals="0" unitRef="USD">447,291</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1407" contextRef="From2021-10-01to2022-09-30" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,225</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Proceeds from the exercise of options</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1408" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1409" contextRef="From2021-10-01to2022-09-30" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,835</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Proceeds from landlord funding of lease improvements</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1410" contextRef="From2022-10-01to2023-09-30" name="cvm:ProceedsFromLandlordFundingOfLeaseImprovements" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1411" contextRef="From2021-10-01to2022-09-30" name="cvm:ProceedsFromLandlordFundingOfLeaseImprovements" format="ixt:numdotdecimal" decimals="0" unitRef="USD">786,454</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Payments on obligations under finance leases</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1412" contextRef="From2022-10-01to2023-09-30" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,560,455</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1413" contextRef="From2021-10-01to2022-09-30" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,386,495</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:60px">Net cash provided by (used in) financing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1414" contextRef="From2022-10-01to2023-09-30" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,694,420</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1415" contextRef="From2021-10-01to2022-09-30" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">638,426</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">NET DECREASE IN CASH AND CASH EQUIVALENTS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1416" contextRef="From2022-10-01to2023-09-30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">18,526,403</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1417" contextRef="From2021-10-01to2022-09-30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">13,388,010</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1418" contextRef="AsOf2022-09-30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,672,138</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1419" contextRef="AsOf2021-09-30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,060,148</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH AND CASH EQUIVALENTS, END OF YEAR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1420" contextRef="AsOf2023-09-30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,145,735</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1421" contextRef="AsOf2022-09-30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,672,138</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-7</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">STATEMENTS OF CASH FLOWS</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">YEARS ENDED SEPTEMBER 30, 2023 AND 2022</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="4" style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Property and equipment purchases included in current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1422" contextRef="From2022-10-01to2023-09-30" name="cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,650</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1423" contextRef="From2021-10-01to2022-09-30" name="cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Capitalized patent costs included in current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1424" contextRef="From2022-10-01to2023-09-30" name="cvm:CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,211</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1425" contextRef="From2021-10-01to2022-09-30" name="cvm:CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Assets purchased under finance leases</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1426" contextRef="From2022-10-01to2023-09-30" name="cvm:AssetsPurchasedUnderFinanceLeases" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1427" contextRef="From2021-10-01to2022-09-30" name="cvm:AssetsPurchasedUnderFinanceLeases" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,409</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Changes to right of use assets and liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1428" contextRef="From2022-10-01to2023-09-30" name="cvm:IncreaseDecreaseToRightOfUseAssetsAndLiabilities" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1429" contextRef="From2021-10-01to2022-09-30" name="cvm:IncreaseDecreaseToRightOfUseAssetsAndLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,268</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finance lease obligation included in accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1430" contextRef="From2022-10-01to2023-09-30" name="cvm:FinanceLeaseObligationIncludedInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,451</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1431" contextRef="From2021-10-01to2022-09-30" name="cvm:FinanceLeaseObligationIncludedInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,354</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Prepaid consulting services paid with issuance of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1432" contextRef="From2022-10-01to2023-09-30" name="cvm:ConsultingFeePaidWithIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">565,980</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1433" contextRef="From2021-10-01to2022-09-30" name="cvm:ConsultingFeePaidWithIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,143</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Financing costs included in current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1434" contextRef="From2022-10-01to2023-09-30" name="cvm:FinancingCostsIncludedInCurrentLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,703</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1435" contextRef="From2021-10-01to2022-09-30" name="cvm:FinancingCostsIncludedInCurrentLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,010</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercise of derivative liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1436" contextRef="From2022-10-01to2023-09-30" name="cvm:DerivativeLiabilitiesExercised" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1437" contextRef="From2021-10-01to2022-09-30" name="cvm:DerivativeLiabilitiesExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,589</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued consulting services to be paid with common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1438" contextRef="From2022-10-01to2023-09-30" name="cvm:AccruedConsultingServicesToBePaid" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1439" contextRef="From2021-10-01to2022-09-30" name="cvm:AccruedConsultingServicesToBePaid" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash paid for interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1440" contextRef="From2022-10-01to2023-09-30" name="us-gaap:InterestPaidNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,062,564</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1441" contextRef="From2021-10-01to2022-09-30" name="us-gaap:InterestPaidNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,157,069</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-8</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"><strong><span class="atag" style="display: inline" id="fs">CEL-SCI CORPORATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"><strong>NOTES TO FINANCIAL STATEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><ix:nonNumeric id="fid_1563" contextRef="From2022-10-01to2023-09-30" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1. ORGANIZATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">CEL-SCI Corporation (the Company) was incorporated on March 22, 1983, in the state of Colorado, to finance research and development in biomedical science and ultimately to engage in marketing and selling products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company has announced results from its Phase III study for its lead investigational therapy, Multikine&#174; (Leukocyte Interleukin, Injection), involving head and neck cancer, for which the Company has received Orphan Drug Status from the United States Food and Drug Administration (FDA). Unlike other immune therapies, Multikine is administered locally at the site of the tumor as a first line treatment right after diagnosis, before surgery and radiation. The goal is to help the intact immune system kill the micro metastases that usually cause recurrence of the cancer to improve outcomes and better overall survival rates for patients suffering from head and neck cancer. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">CEL-SCI is also investigating a peptide-based immunotherapy (CEL-4000) as a vaccine for rheumatoid arthritis using its LEAPS technology platform. CEL-SCI is in the process of completing pre-IND studies for CEL-4000.&#160; </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1549" contextRef="From2022-10-01to2023-09-30" name="cvm:LiquiditydisclosureTextblock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>2</strong><strong>.</strong>&#160; <strong>LIQUIDITY </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and participation in clinical trials.&#160; The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities.&#160; The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine to market.&#160; The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from the U.S. Food and Drug Administration (FDA) or from the regulators in Canada, the UK or Europe for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings.&#160; The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase III study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all.&#160; If the Company does not raise the necessary amounts of funding, it may have to curtail its operations until such time as it is able to raise the required funding.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Due to the Company&#8217;s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern.&#160; The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-9</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1550" contextRef="From2022-10-01to2023-09-30" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="cont_caff3a"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>3</strong><strong>. </strong><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1564" contextRef="From2022-10-01to2023-09-30" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Cash and Cash Equivalents </em>&#8211; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds.&#160; The Company considers all highly liquid investments with a maturity when purchased of less than three months as cash and cash equivalents.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1565" contextRef="From2022-10-01to2023-09-30" name="cvm:USTreasuryBillsPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>U.S. Treasury Bills &#8211; </em>U.S. Treasury Bills (&#8220;T-bills&#8221;) are highly liquid short-term investments with maturity dates of greater than 3 months, but less than one year. These investments are recorded at fair value.&#160; </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1566" contextRef="From2022-10-01to2023-09-30" name="us-gaap:InventoryPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Supplies used for R&amp;D and manufacturing</em> &#8211; Supplies are consumable items kept on hand to support the Company&#8217;s R&amp;D and manufacturing operations.&#160; Supplies are recorded at cost and are charged to expense as they are used in operations.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1567" contextRef="From2022-10-01to2023-09-30" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment are reviewed on a quarterly basis to determine if any of the assets are impaired.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1568" contextRef="From2022-10-01to2023-09-30" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Patents</em> &#8211; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (<ix:nonNumeric id="fid_1852" contextRef="From2021-10-01to2022-09-30_us-gaap_PatentsMember" name="cvm:FiniteLivedIntangibleAssetsUsefulLife" format="ixt-sec:duryear">17</ix:nonNumeric> years).&#160; In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment to the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset.&#160; The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1569" contextRef="From2022-10-01to2023-09-30" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Leases</em> &#8211; The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material. For purposes of calculating the finance and operating lease liabilities, lease and non-lease components are combined. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1570" contextRef="From2022-10-01to2023-09-30" name="us-gaap:DerivativesPolicyTextBlock" escape="true" continuedAt="cont_878e7d"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Derivative Instruments</em> &#8211; The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, <em>Accounting for Derivative Instruments and Hedging Activities</em>. In accordance with ASC 815, derivative instruments and hybrid instruments are recognized as either assets or liabilities on the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each&#160;reporting period. </p></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-10</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_caff3a" continuedAt="cont_25a98b"><ix:continuation id="cont_878e7d"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company adopted Accounting Standards Update (ASU) 2020-06 <em>Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</em> effective October 1, 2021<em>.</em>&#160;The amendments in this Update simplify and clarify the guidance in Subtopic 815-40. &#160;There was no financial impact upon adoption.&#160;&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company adopted ASU 2021-04,&#160;<em>Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</em>. This standard was issued to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 was effective for fiscal years beginning after December 15, 2021, however, as permitted, the Company elected to prospectively adopt the standard, effective as of October 1, 2021. Adoption of this standard had no impact on the Company&#8217;s financial statements.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1571" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Stock-Based Compensation</em> &#8211; Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, <em>Compensation &#8211; Stock Compensation</em>. The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized using the straight-line allocation method as expense over the requisite service or vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the "Plans". All Plans have been approved by the Company&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the assumption for stock price volatility is based on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the 2021 and 2020 Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant-dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1572" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Research and Development Costs</em> - Research and development costs are expensed as incurred.&#160; Management accrues Clinical Research Organization (CRO) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. </p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-11</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_25a98b" continuedAt="cont_6bb5fb"><ix:nonNumeric id="fid_1573" contextRef="From2022-10-01to2023-09-30" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Net Loss Per Common Share</em> &#8211; The Company calculates net loss per common share in accordance with ASC 260 <em>Earnings Per Share</em> (ASC 260).&#160; Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period.&#160; The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1574" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Concentration of Credit Risk</em> &#8211; Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents.&#160; The Company maintains its cash and cash equivalents with high quality financial institutions.&#160; At times, these accounts may exceed federally insured limits.&#160; The Company has not experienced any losses in such bank accounts.&#160; The Company believes it is not exposed to significant credit risk related to cash and cash equivalents.&#160; All non-interest bearing cash balances were fully insured up to $<ix:nonFraction id="fid_1853" contextRef="AsOf2023-09-30" name="us-gaap:CashFDICInsuredAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction> at September 30, 2023 and September 30, 2022. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1575" contextRef="From2022-10-01to2023-09-30" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Income Taxes</em> &#8211;The Company follows ASC 740-10-25 for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related assets or liability is expected to be realized or settled.&#160; The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160; The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of September 30, 2023 and 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company adopted ASU&#160; 2019-12,&#160;<em>Income Taxes (Topic&#160;740): Simplifying the Accounting for Income Taxes</em>, effective October 1, 2021. The new standard includes several provisions that simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. The adoption of ASU 2019-12 had no impact on the Company&#8217;s financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On August 16, 2022, the Inflation Reduction Act of 2022 (the &#8220;IR Act&#8221;) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly traded foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself, not its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the &#8220;Treasury&#8221;) has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax.&#160;&#160;&#160;&#160;&#160; </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2060" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Impairment of long-lived assets</em> &#8211; CEL-SCI&#8217;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#8217;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets in accordance with ASC 360-10-35-21 to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-12</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_6bb5fb"><ix:nonNumeric id="fid_1576" contextRef="From2022-10-01to2023-09-30" name="us-gaap:UseOfEstimates" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures.&#160; These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, obsolescence of supplies used for research and development (R&amp;D) and manufacturing, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities,&#160;deferred tax assets and the related valuation allowance, and the valuation of derivative liabilities. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.&#160; The Company considers the estimates used in valuing the derivative liabilities and the lease assets and liabilities to be significant. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>New Accounting Pronouncements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1577" contextRef="From2022-10-01to2023-09-30" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In June 2016, the Financial Accounting Standards Board issued ASU 2016-13, <em>Financial Instruments&#8211;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</em> (ASU 2016-13), as amended. The amendments in ASU 2016-13 require, among other things, financial assets measured at amortized cost basis to be presented at the net amount expected to be collected as compared to previous U.S. GAAP which delayed recognition until it was probable a loss had been incurred. The amendments in ASU 2016-13 are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, with early adoption permitted. The Company currently does not have any such financial assets reported as of September 30, 2023, however, the Company will continue to evaluate the impact that adoption of ASU 2016-13 will have on its financial statements and related disclosures.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Other accounting standard updates effective for interim and annual periods beginning after September 30, 2023 are not expected to have a material impact on the Company&#8217;s financial statements.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1551" contextRef="From2022-10-01to2023-09-30" name="cvm:WarrantsAndNonEmployeeOptionsDisclosureTextBlock" escape="true" continuedAt="cont_3e74b2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>4.&#160;&#160; WARRANTS AND NON-EMPLOYEE OPTIONS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following warrants and non-employee options are outstanding at September 30, 2023:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1578" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" escape="true" continuedAt="cont_feb8c6"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">Warrant/Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;">Shares Issuable upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;">of Warrants/ Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.95pt; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:14%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1854" contextRef="From2022-10-01to2023-09-30_cvm_SeriesNMember" name="cvm:Issuedate2">8/18/2008</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1873" contextRef="AsOf2023-09-30_cvm_SeriesNMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">85,339</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1891" contextRef="AsOf2023-09-30_cvm_SeriesNMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:14%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1910" contextRef="From2022-10-01to2023-09-30_cvm_SeriesNMember" name="cvm:ExpirationDate1">8/18/2024</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1865" contextRef="From2022-10-01to2023-09-30_cvm_SeriesUUMember" name="cvm:Issuedate2">6/11/2018</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1874" contextRef="AsOf2023-09-30_cvm_SeriesUUMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">93,603</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1892" contextRef="AsOf2023-09-30_cvm_SeriesUUMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.80</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1911" contextRef="From2022-10-01to2023-09-30_cvm_SeriesUUMember" name="cvm:ExpirationDate1">6/30/2024</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1856" contextRef="From2022-10-01to2023-09-30_cvm_SeriesXMember" name="cvm:Issuedate2">1/13/2016</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1875" contextRef="AsOf2023-09-30_cvm_SeriesXMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">120,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1893" contextRef="AsOf2023-09-30_cvm_SeriesXMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.25</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1912" contextRef="From2022-10-01to2023-09-30_cvm_SeriesXMember" name="cvm:ExpirationDate1">7/13/2024</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1857" contextRef="From2022-10-01to2023-09-30_cvm_SeriesYMember" name="cvm:Issuedate2">2/15/2016</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1876" contextRef="AsOf2023-09-30_cvm_SeriesYMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">26,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1894" contextRef="AsOf2023-09-30_cvm_SeriesYMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1913" contextRef="From2022-10-01to2023-09-30_cvm_SeriesYMember" name="cvm:ExpirationDate1">8/15/2024</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1858" contextRef="From2022-10-01to2023-09-30_cvm_SeriesMMMember" name="cvm:Issuedate2">6/22/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1877" contextRef="AsOf2023-09-30_cvm_SeriesMMMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">333,432</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1895" contextRef="AsOf2023-09-30_cvm_SeriesMMMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.86</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1914" contextRef="From2022-10-01to2023-09-30_cvm_SeriesMMMember" name="cvm:ExpirationDate1">6/22/2024</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1859" contextRef="From2022-10-01to2023-09-30_cvm_SeriesNNMember" name="cvm:Issuedate2">7/24/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1878" contextRef="AsOf2023-09-30_cvm_SeriesNNMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">200,087</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1896" contextRef="AsOf2023-09-30_cvm_SeriesNNMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.52</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1915" contextRef="From2022-10-01to2023-09-30_cvm_SeriesNNMember" name="cvm:ExpirationDate1">7/24/2024</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1871" contextRef="From2022-10-01to2023-09-30_cvm_SeriesRRMember" name="cvm:Issuedate2">10/30/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1879" contextRef="AsOf2023-09-30_cvm_SeriesRRMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">234,009</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1897" contextRef="AsOf2023-09-30_cvm_SeriesRRMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.65</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1916" contextRef="From2022-10-01to2023-09-30_cvm_SeriesRRMember" name="cvm:ExpirationDate1">10/30/2024</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultant Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"><ix:nonNumeric id="fid_1863" contextRef="From2022-10-01to2023-09-30_cvm_ConsultantsMember_srt_MinimumMember" name="cvm:Issuedate2">7/28/2017</ix:nonNumeric> &#8211; <ix:nonNumeric id="fid_1929" contextRef="From2022-10-01to2023-09-30_cvm_ConsultantsOneMember_srt_MaximumMember" name="cvm:Issuedate2">9/2/2023</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1880" contextRef="AsOf2023-09-30_cvm_ConsultantsMember_srt_MinimumMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">110,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>$</td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"><ix:nonFraction id="fid_1898" contextRef="AsOf2023-09-30_cvm_ConsultantsMember_srt_MinimumMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.39</ix:nonFraction> - $<ix:nonFraction id="fid_1930" contextRef="AsOf2023-09-30_cvm_ConsultantsOneMember_srt_MaximumMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.18</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1917" contextRef="From2022-10-01to2023-09-30_cvm_ConsultantsMember_srt_MinimumMember" name="cvm:ExpirationDate1">7/27/2027</ix:nonNumeric> &#8211; <ix:nonNumeric id="fid_1931" contextRef="From2022-10-01to2023-09-30_cvm_ConsultantsOneMember_srt_MaximumMember" name="cvm:ExpirationDate1">9/1/2028</ix:nonNumeric></p></td><td>&#160;</td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-13</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_3e74b2" continuedAt="cont_99ddb5"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following warrants and non-employee options are outstanding at September 30, 2022:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_feb8c6"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">Warrant/Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;">Shares Issuable upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;">of Warrants/ Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.95pt; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:14%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1864" contextRef="From2021-10-01to2022-09-30_cvm_SeriesNMember" name="cvm:Issuedate2">8/18/2008</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1881" contextRef="AsOf2022-09-30_cvm_SeriesNMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">85,339</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1899" contextRef="AsOf2022-09-30_cvm_SeriesNMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:14%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1918" contextRef="From2021-10-01to2022-09-30_cvm_SeriesNMember" name="cvm:ExpirationDate1">8/18/2024</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1855" contextRef="From2021-10-01to2022-09-30_cvm_SeriesUUMember" name="cvm:Issuedate2">6/11/2018</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1882" contextRef="AsOf2022-09-30_cvm_SeriesUUMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">93,603</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1900" contextRef="AsOf2022-09-30_cvm_SeriesUUMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.80</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1919" contextRef="From2021-10-01to2022-09-30_cvm_SeriesUUMember" name="cvm:ExpirationDate1">6/30/2024</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1867" contextRef="From2021-10-01to2022-09-30_cvm_SeriesXMember" name="cvm:Issuedate2">1/13/2016</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1883" contextRef="AsOf2022-09-30_cvm_SeriesXMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">120,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1902" contextRef="AsOf2022-09-30_cvm_SeriesXMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.25</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1921" contextRef="From2021-10-01to2022-09-30_cvm_SeriesXMember" name="cvm:ExpirationDate1">7/13/2024</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1868" contextRef="From2021-10-01to2022-09-30_cvm_SeriesYMember" name="cvm:Issuedate2">2/15/2016</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1884" contextRef="AsOf2022-09-30_cvm_SeriesYMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">26,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1903" contextRef="AsOf2022-09-30_cvm_SeriesYMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1922" contextRef="From2021-10-01to2022-09-30_cvm_SeriesYMember" name="cvm:ExpirationDate1">8/15/2024</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1869" contextRef="From2021-10-01to2022-09-30_cvm_SeriesMMMember" name="cvm:Issuedate2">6/22/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1885" contextRef="AsOf2022-09-30_cvm_SeriesMMMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">333,432</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1904" contextRef="AsOf2022-09-30_cvm_SeriesMMMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.86</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1923" contextRef="From2021-10-01to2022-09-30_cvm_SeriesMMMember" name="cvm:ExpirationDate1">6/22/2024</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1870" contextRef="From2021-10-01to2022-09-30_cvm_SeriesNNMember" name="cvm:Issuedate2">7/24/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1886" contextRef="AsOf2022-09-30_cvm_SeriesNNMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">200,087</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1905" contextRef="AsOf2022-09-30_cvm_SeriesNNMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.52</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1924" contextRef="From2021-10-01to2022-09-30_cvm_SeriesNNMember" name="cvm:ExpirationDate1">7/24/2024</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1860" contextRef="From2021-10-01to2022-09-30_cvm_SeriesRRMember" name="cvm:Issuedate2">10/30/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1887" contextRef="AsOf2022-09-30_cvm_SeriesRRMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">251,761</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1906" contextRef="AsOf2022-09-30_cvm_SeriesRRMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.65</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1925" contextRef="From2021-10-01to2022-09-30_cvm_SeriesRRMember" name="cvm:ExpirationDate1">10/30/2022</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series SS</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1861" contextRef="From2021-10-01to2022-09-30_cvm_SeriesSSMember" name="cvm:Issuedate2">12/19/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1888" contextRef="AsOf2022-09-30_cvm_SeriesSSMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">200,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1907" contextRef="AsOf2022-09-30_cvm_SeriesSSMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.09</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1926" contextRef="From2021-10-01to2022-09-30_cvm_SeriesSSMember" name="cvm:ExpirationDate1">12/18/2022</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series TT</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1862" contextRef="From2021-10-01to2022-09-30_cvm_SeriesTTMember" name="cvm:Issuedate2">2/5/2018</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1889" contextRef="AsOf2022-09-30_cvm_SeriesTTMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">600</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1908" contextRef="AsOf2022-09-30_cvm_SeriesTTMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.24</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1927" contextRef="From2021-10-01to2022-09-30_cvm_SeriesTTMember" name="cvm:ExpirationDate1">2/5/2023</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultant Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.95pt; text-align:right;"><ix:nonNumeric id="fid_1872" contextRef="From2021-10-01to2022-09-30_cvm_ConsultantsMember_srt_MinimumMember" name="cvm:Issuedate2">7/28/2017</ix:nonNumeric> &#8211; <ix:nonNumeric id="fid_1866" contextRef="From2021-10-01to2022-09-30_cvm_ConsultantsOneMember_srt_MaximumMember" name="cvm:Issuedate2">11/18/2020</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1890" contextRef="AsOf2022-09-30_cvm_ConsultantsMember_srt_MinimumMember" name="cvm:SharesIssuableUponExerciseOfwarrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>$</td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"><ix:nonFraction id="fid_1909" contextRef="AsOf2022-09-30_cvm_ConsultantsMember_srt_MinimumMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.18</ix:nonFraction> - $<ix:nonFraction id="fid_1901" contextRef="AsOf2022-09-30_cvm_ConsultantsOneMember_srt_MaximumMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.61</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:right;"><ix:nonNumeric id="fid_1928" contextRef="From2021-10-01to2022-09-30_cvm_ConsultantsMember_srt_MinimumMember" name="cvm:ExpirationDate1">11/17/2022</ix:nonNumeric> - <ix:nonNumeric id="fid_1920" contextRef="From2021-10-01to2022-09-30_cvm_ConsultantsOneMember_srt_MaximumMember" name="cvm:ExpirationDate1">7/27/2027</ix:nonNumeric></p></td><td>&#160;</td></tr></tbody></table></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>A.&#160; Warrant Liabilities</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">There were no warrant liabilities outstanding at September 30, 2023 and 2022.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The gains/(losses) on the warrant liabilities for the years ended September 30 are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1580" contextRef="From2022-10-01to2023-09-30" name="cvm:ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05in; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05in; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series W warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1932" contextRef="From2022-10-01to2023-09-30_cvm_SeriesWMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1933" contextRef="From2021-10-01to2022-09-30_cvm_SeriesWMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Z warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1934" contextRef="From2022-10-01to2023-09-30_cvm_SeriesZMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1935" contextRef="From2021-10-01to2022-09-30_cvm_SeriesZMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,787</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series ZZ warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1936" contextRef="From2022-10-01to2023-09-30_cvm_SeriesZZMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1937" contextRef="From2021-10-01to2022-09-30_cvm_SeriesZZMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series AA warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1938" contextRef="From2022-10-01to2023-09-30_cvm_SeriesAAMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1939" contextRef="From2021-10-01to2022-09-30_cvm_SeriesAAMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">276,035</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series BB warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1940" contextRef="From2022-10-01to2023-09-30_cvm_SeriesBBMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1941" contextRef="From2021-10-01to2022-09-30_cvm_SeriesBBMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series CC warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1942" contextRef="From2022-10-01to2023-09-30_cvm_SeriesCCMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1943" contextRef="From2021-10-01to2022-09-30_cvm_SeriesCCMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,372</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series HH warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1944" contextRef="From2022-10-01to2023-09-30_cvm_SeriesHHMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1945" contextRef="From2021-10-01to2022-09-30_cvm_SeriesHHMember" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,597</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss on warrant liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1947" contextRef="From2022-10-01to2023-09-30" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1946" contextRef="From2021-10-01to2022-09-30" name="cvm:NetLossGainOnWarrantLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">366,791</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company reviews all outstanding warrants in accordance with the requirements of ASC 815 , <em>Accounting for Derivative Instruments and Hedging Activities</em>.&#160; This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument&#8217;s contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain dilutive events.&#160; Under the provisions of ASC 815, the warrants are not considered indexed to the Company&#8217;s stock because future equity offerings or sales of the Company&#8217;s stock are not an input to the fair value of a &#8220;fixed-for-fixed&#8221; option on equity shares, and equity classification is therefore precluded.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration.&#160; Any change in fair value between the respective reporting periods is recognized as a gain or loss in the statement of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Changes in Warrant Liabilities</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In February 2022, <ix:nonFraction id="fid_1974" contextRef="From2022-02-01to2022-02-28_cvm_SeriesAAWarrantsMember" name="cvm:WarrantsExpired" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">100,000</ix:nonFraction> Series AA warrants, with an exercise price of $<ix:nonFraction id="fid_1978" contextRef="From2022-02-01to2022-02-28_cvm_SeriesAAWarrantsMember" name="cvm:ExercisePriceWarrants" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.75</ix:nonFraction> and <ix:nonFraction id="fid_1975" contextRef="From2022-02-01to2022-02-28_cvm_SeriesHHWarrantsMember" name="cvm:WarrantsExpired" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">200</ix:nonFraction> Series HH warrants with an exercise price of $<ix:nonFraction id="fid_1979" contextRef="From2022-02-01to2022-02-28_cvm_SeriesHHWarrantsMember" name="cvm:ExercisePriceWarrants" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.13</ix:nonFraction>, expired. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-14</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_99ddb5" continuedAt="cont_89d6c0"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In December 2021, <ix:nonFraction id="fid_1972" contextRef="From2021-12-01to2021-12-31_cvm_SeriesCCWarrantsMember" name="cvm:WarrantsExpired" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">640</ix:nonFraction> Series CC warrants, with an exercise price of $<ix:nonFraction id="fid_1976" contextRef="From2021-12-01to2021-12-31_cvm_SeriesCCWarrantsMember" name="cvm:ExercisePriceWarrants" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.00</ix:nonFraction>, expired. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2021, <ix:nonFraction id="fid_1973" contextRef="From2021-11-01to2021-11-30_cvm_SeriesZWarrantsMember" name="cvm:WarrantsExpired" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">184,800</ix:nonFraction> Series Z warrants, with an exercise price of $<ix:nonFraction id="fid_1977" contextRef="From2021-11-01to2021-11-30_cvm_SeriesZWarrantsMember" name="cvm:ExercisePriceWarrants" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.75</ix:nonFraction>, expired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Exercise of Warrant Liabilities</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">No warrants recorded as liabilities were exercised during the year ended September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following warrants recorded as liabilities were exercised during the year ended September 30, 2022:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1581" contextRef="From2022-10-01to2023-09-30" name="cvm:ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Proceeds</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series CC</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1949" contextRef="From2021-10-01to2022-09-30_cvm_SeriesCCMember" name="cvm:WarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,205</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1950" contextRef="From2021-10-01to2022-09-30_cvm_SeriesCCMember" name="cvm:ExercisePriceWarrants" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1948" contextRef="From2021-10-01to2022-09-30_cvm_SeriesCCMember" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,025</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>B. Equity Warrants</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Changes in Equity Warrants</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024.&#160; The incremental cost of this extension was approximately $<ix:nonFraction id="fid_2063" contextRef="From2022-10-01to2022-10-28_cvm_SeriesRRMember" name="cvm:IncrementalCostDeemedDividend" format="ixt:numdotdecimal" decimals="0" unitRef="USD">172,000</ix:nonFraction>, which was recorded as a deemed dividend. The Series RR warrants are held by Geert Kersten, Patricia Prichep (current officers of the Company) and the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On June 13, 2022, the expiration dates of the Series N, Series X, Series Y, Series UU, Series MM and Series NN warrants were extended two years. The incremental costs of the Series N, Series X and Series Y warrant extensions were recorded as a deemed dividend and totaled approximately $<ix:nonFraction id="fid_1980" contextRef="From2022-10-01to2023-09-30" name="cvm:DeemedDividendAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294,000</ix:nonFraction> for the year ended September 30, 2022.&#160; The Series N and Series X warrants are held by the de Clara Trust.&#160; The incremental cost of the Series MM, Series NN and Series UU warrant extensions of approximately $<ix:nonFraction id="fid_1971" contextRef="From2022-10-01to2023-09-30" name="cvm:DeemedDividend11" format="ixt:numdotdecimal" decimals="0" unitRef="USD">635,000</ix:nonFraction> was recorded as a deemed dividend because there were no longer any notes payable associated with these warrants at the time of modification. The Series UU warrants and a portion of the Series MM and Series NN warrants are held by Geert Kersten, Patricia Prichep (current officers of the Company) and the de Clara Trust.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Exercise of Equity Warrants </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following equity warrants were exercised during the year ended September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1582" contextRef="From2022-10-01to2023-09-30" name="cvm:ScheduleOfEquityWarrantsWereExercisedTableTextBlock" escape="true" continuedAt="cont_1b5a8c"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Proceeds</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1951" contextRef="From2022-10-01to2023-09-30_cvm_SeriesRRMember" name="cvm:EquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">17,752</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1957" contextRef="From2022-10-01to2023-09-30_cvm_SeriesRRMember" name="cvm:EquityWarrantsExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.65</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1954" contextRef="From2022-10-01to2023-09-30_cvm_SeriesRRMember" name="cvm:ProceedsFromEquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,291</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1952" contextRef="From2022-10-01to2023-09-30_cvm_SeriesSSMember" name="cvm:EquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">200,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1958" contextRef="From2022-10-01to2023-09-30_cvm_SeriesSSMember" name="cvm:EquityWarrantsExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.09</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1955" contextRef="From2022-10-01to2023-09-30_cvm_SeriesSSMember" name="cvm:ProceedsFromEquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">418,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1961" contextRef="From2022-10-01to2023-09-30" name="cvm:EquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">217,752</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1960" contextRef="From2022-10-01to2023-09-30" name="cvm:ProceedsFromEquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">447,291</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following equity warrants were exercised during the year ended September 30, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_1b5a8c"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Proceeds</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1953" contextRef="From2021-10-01to2022-09-30_cvm_SeriesNNMember" name="cvm:EquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1959" contextRef="From2021-10-01to2022-09-30_cvm_SeriesNNMember" name="cvm:EquityWarrantsExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.52</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1956" contextRef="From2021-10-01to2022-09-30_cvm_SeriesNNMember" name="cvm:ProceedsFromEquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,200</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:continuation></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-15</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_89d6c0"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>C.</strong>&#160; <strong>Options and Shares Issued to Consultants</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company typically enters into consulting arrangements in exchange for common stock or stock options. During the years ended September 30, 2023 and 2022, the Company issued <ix:nonFraction id="fid_1963" contextRef="From2022-10-01to2023-09-30" name="cvm:CommonStockIssuedForServiceShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">249,997</ix:nonFraction> and <ix:nonFraction id="fid_1962" contextRef="From2021-10-01to2022-09-30" name="cvm:CommonStockIssuedForServiceShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">156,547</ix:nonFraction> shares, respectively, of common stock to consultants, all of which were restricted shares.&#160; Under these arrangements, during the periods presented, the common stock was issued with stock prices ranging from $<ix:nonFraction id="fid_1970" contextRef="AsOf2023-09-30_srt_MinimumMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.26</ix:nonFraction> to $<ix:nonFraction id="fid_1981" contextRef="AsOf2023-09-30_srt_MaximumMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.20</ix:nonFraction> per share. The weighted average grant price was $<ix:nonFraction id="fid_1965" contextRef="From2022-10-01to2023-09-30_srt_MaximumMember_cvm_RestrictedStocksMember_cvm_ConsultantsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.83</ix:nonFraction> and $<ix:nonFraction id="fid_1964" contextRef="From2021-10-01to2022-09-30_srt_MaximumMember_cvm_RestrictedStocksMember_cvm_ConsultantsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.59</ix:nonFraction>, respectively, for stock issued during the years ended September 30, 2023 and 2022. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the years ended September 30, 2023 and 2022, the Company recorded total expense of approximately $<ix:nonFraction id="fid_1967" contextRef="From2022-10-01to2023-09-30_cvm_ConsultingAgreementsMember" name="us-gaap:CostsAndExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">656,000</ix:nonFraction> and $<ix:nonFraction id="fid_1966" contextRef="From2021-10-01to2022-09-30_cvm_ConsultingAgreementsMember" name="us-gaap:CostsAndExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">762,000</ix:nonFraction>, respectively, relating to these consulting agreements. At September 30, 2023 and 2022, costs of approximately $<ix:nonFraction id="fid_1968" contextRef="AsOf2023-09-30_cvm_ConsultingAgreementsMember" name="cvm:PrepaidExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">205,000</ix:nonFraction> and $<ix:nonFraction id="fid_1969" contextRef="AsOf2022-09-30_cvm_ConsultingAgreementsMember" name="cvm:PrepaidExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,000</ix:nonFraction>, respectively, are included in prepaid expenses. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the year ended September 30, 2023, the Company issued <ix:nonFraction id="fid_2064" contextRef="From2022-10-01to2023-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember" name="cvm:StockIssuedDuringPeriodToPurchaseCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">100,000</ix:nonFraction> options to a consultant to purchase common stock with an exercise price of $<ix:nonFraction id="fid_2065" contextRef="From2022-10-01to2023-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember" name="cvm:StockOptionExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.39</ix:nonFraction>. These options vest <ix:nonFraction id="fid_2066" contextRef="From2022-10-01to2023-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember_cvm_TwoSeptemberTwoThousendTwentyFourMember" name="cvm:VestedOptions" decimals="INF" unitRef="Pure" scale="-2">50</ix:nonFraction>% on September 2, 2024 and <ix:nonFraction id="fid_2068" contextRef="From2022-10-01to2023-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember_cvm_TwoSeptemberTwoThousendTwentyFiveMember" name="cvm:VestedOptions" decimals="INF" unitRef="Pure" scale="-2">50</ix:nonFraction>% on September 2, 2025 and expire on September 1, 2028. No options were issued to consultants during the year ended September 30, 2022. As of September 30, 2023, <ix:nonFraction id="fid_2069" contextRef="AsOf2023-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember" name="cvm:IssuedStockOfOptionsOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">110,000</ix:nonFraction> options issued to consultants as payment for services remained outstanding, all of which were issued from the Non-Qualified Stock Option Plan.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1552" contextRef="From2022-10-01to2023-09-30" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>5</strong><strong>. </strong><strong>PROPERTY AND </strong><strong>EQUIPMENT</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Property and equipment consisted of the following at September 30:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1583" contextRef="From2022-10-01to2023-09-30" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Research equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1598" contextRef="AsOf2023-09-30" name="us-gaap:FixturesAndEquipmentGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,109,070</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1599" contextRef="AsOf2022-09-30" name="us-gaap:FixturesAndEquipmentGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,095,022</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Furniture and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1600" contextRef="AsOf2023-09-30" name="us-gaap:FurnitureAndFixturesGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,296</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1601" contextRef="AsOf2022-09-30" name="us-gaap:FurnitureAndFixturesGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,296</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Leasehold improvements</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1602" contextRef="AsOf2023-09-30" name="us-gaap:LeaseholdImprovementsGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,924,724</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1603" contextRef="AsOf2022-09-30" name="us-gaap:LeaseholdImprovementsGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,544,394</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1604" contextRef="AsOf2023-09-30" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,133,090</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1605" contextRef="AsOf2022-09-30" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,738,712</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accumulated depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1606" contextRef="AsOf2023-09-30" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,944,964</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1607" contextRef="AsOf2022-09-30" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,849,683</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net property and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1608" contextRef="AsOf2023-09-30" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,188,126</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1609" contextRef="AsOf2022-09-30" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,889,029</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Depreciation expense for the years ended September 30, 2023 and 2022 totaled approximately $<ix:nonFraction id="fid_1610" contextRef="From2022-10-01to2023-09-30" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,114,000</ix:nonFraction> and $<ix:nonFraction id="fid_1611" contextRef="From2021-10-01to2022-09-30" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,977,000</ix:nonFraction> respectively.&#160; </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1553" contextRef="From2022-10-01to2023-09-30" name="us-gaap:IntangibleAssetsDisclosureTextBlock" escape="true" continuedAt="cont_8a8d36"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>6</strong><strong>. PATENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Patents consist of the following at September 30:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1584" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1612" contextRef="AsOf2023-09-30" name="us-gaap:FiniteLivedPatentsGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">853,445</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1613" contextRef="AsOf2022-09-30" name="us-gaap:FiniteLivedPatentsGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">893,833</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accumulated amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1615" contextRef="AsOf2023-09-30" name="cvm:AccumulatedAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">655,741</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1614" contextRef="AsOf2022-09-30" name="cvm:AccumulatedAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">681,632</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patents, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1617" contextRef="AsOf2023-09-30" name="us-gaap:OtherIntangibleAssetsNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">197,704</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1616" contextRef="AsOf2022-09-30" name="us-gaap:OtherIntangibleAssetsNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">212,201</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-16</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_8a8d36"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the years ended September 30, 2023 and 2022, there was no impairment of patent costs. The weighted average amortization period for patents&#160;is approximately <ix:nonNumeric id="fid_2062" contextRef="From2022-10-01to2023-09-30" name="cvm:PatentsWeightedAverageAmortizationPeriod" format="ixt-sec:duryear">8</ix:nonNumeric> years. Amortization expense for the years ended September 30, 2023 and 2022 totaled approximately $<ix:nonFraction id="fid_1625" contextRef="From2022-10-01to2023-09-30" name="cvm:AmortizationOfPatentCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,000</ix:nonFraction> and &#160;$<ix:nonFraction id="fid_1626" contextRef="From2021-10-01to2022-09-30" name="cvm:AmortizationOfPatentCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,000</ix:nonFraction>, respectively.&#160;&#160; The total estimated future amortization is as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1585" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="4"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Years ending September 30, </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1619" contextRef="AsOf2022-09-30" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1620" contextRef="AsOf2022-09-30" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1621" contextRef="AsOf2022-09-30" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1622" contextRef="AsOf2022-09-30" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1618" contextRef="AsOf2022-09-30" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1623" contextRef="AsOf2022-09-30" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1624" contextRef="AsOf2022-09-30" name="cvm:Total" format="ixt:numdotdecimal" decimals="0" unitRef="USD">198,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1554" contextRef="From2022-10-01to2023-09-30" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="cont_0d5dfa"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>7</strong><strong>. INCOME TAXES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">At September 30, 2023 and 2022, the Company had net deferred tax assets of $<ix:nonFraction id="fid_1677" contextRef="AsOf2023-09-30" name="cvm:DeferredTaxAssets" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">60.0</ix:nonFraction> million and $<ix:nonFraction id="fid_1676" contextRef="AsOf2022-09-30" name="cvm:DeferredTaxAssets" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">52.9</ix:nonFraction> million, respectively. Due to uncertainties surrounding the Company&#8217;s ability to generate future taxable income to realize these assets, a full valuation allowance has been established to offset the net deferred tax assets. In assessing the realization of deferred tax assets, management considered whether it was more likely than not that some, or all, of the deferred tax assets will be realized.&#160; The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income.&#160; Management has considered the history of the Company&#8217;s operating losses and believes that the realization of the benefit of the deferred tax assets cannot be reasonably assured.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Pursuant to Section 382 of the Internal Revenue Code, or IRC, annual use of the Company&#8217;s <ix:nonNumeric id="fid_1674" contextRef="From2022-10-01to2023-09-30_cvm_IncomeTaxMember" name="cvm:CumulativeChangeInOwnershipPercentage">net operating loss (NOL) carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period</ix:nonNumeric>. Such ownership change could result in annual limitations on the utilization of tax attributes, including NOL carryforwards and tax credits. The Company performed an estimated analysis to determine if any additional ownership changes occurred during the year ended September 30, 2023 and no such changes were identified. If changes in ownership occur after year end, NOL and tax credit carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company had federal NOL carryforwards of approximately $<ix:nonFraction id="fid_1672" contextRef="AsOf2023-09-30_cvm_IncomeTaxMember" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">123.1</ix:nonFraction> million and $<ix:nonFraction id="fid_1671" contextRef="AsOf2022-09-30_cvm_IncomeTaxMember" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">100.2</ix:nonFraction> million at September 30, 2023 and 2022, respectively. <ix:nonNumeric id="fid_1675" contextRef="From2022-10-01to2023-09-30_cvm_IncomeTaxMember" name="us-gaap:TaxCreditCarryforwardDescription">Approximately $19.2 million of the NOL carryforwards begin to expire during the year ended September 30, 2023 and become fully expired by 2038 and approximately $103.9 million of NOL carryforwards</ix:nonNumeric>, which were generated after the enactment of Tax Cuts and Jobs Act, have an indefinite life.&#160; In addition, the Company has a general business credit as a result of the credit for increasing research activities (&#8220;R&amp;D credit&#8221;) of approximately $<ix:nonFraction id="fid_1670" contextRef="AsOf2023-09-30_cvm_IncomeTaxMember" name="cvm:ResearchAndDevelopmentCredit" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.2</ix:nonFraction> million at September 30, 2023 and 2022.&#160;&#160;<ix:nonNumeric id="fid_1673" contextRef="From2022-10-01to2023-09-30_cvm_IncomeTaxMember" name="cvm:ResearchAndDevelopmentCreditDescription">The R&amp;D credit expires during the fiscal year ended 2029</ix:nonNumeric>.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Significant components of the Company&#8217;s deferred tax assets and liabilities as of September 30, 2023 and 2022 are listed below:&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1586" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">NOL carryforwards</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1627" contextRef="AsOf2023-09-30" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,829,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1628" contextRef="AsOf2022-09-30" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,346,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Capitalized R&amp;D</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1635" contextRef="AsOf2023-09-30" name="cvm:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,196,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1636" contextRef="AsOf2022-09-30" name="cvm:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,042,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock-based compensation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1633" contextRef="AsOf2023-09-30" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,579,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1634" contextRef="AsOf2022-09-30" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,442,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1629" contextRef="AsOf2023-09-30" name="cvm:LeaseLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,400,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1630" contextRef="AsOf2022-09-30" name="cvm:LeaseLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,872,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">R&amp;D credit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1631" contextRef="AsOf2023-09-30" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,221,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1632" contextRef="AsOf2022-09-30" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,221,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vacation and other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1637" contextRef="AsOf2023-09-30" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" format="ixt:numdotdecimal" decimals="0" unitRef="USD">298,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1638" contextRef="AsOf2022-09-30" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" format="ixt:numdotdecimal" decimals="0" unitRef="USD">307,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fixed assets and intangibles</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1653" contextRef="AsOf2023-09-30" name="cvm:FixedAssetsAndIntangiblesAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1654" contextRef="AsOf2022-09-30" name="cvm:FixedAssetsAndIntangiblesAssets" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total deferred tax assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1639" contextRef="AsOf2023-09-30" name="us-gaap:DeferredTaxAssetsGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,691,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1640" contextRef="AsOf2022-09-30" name="us-gaap:DeferredTaxAssetsGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,230,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Right of use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1641" contextRef="AsOf2023-09-30" name="cvm:RightOfUseAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,713,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1642" contextRef="AsOf2022-09-30" name="cvm:RightOfUseAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">3,244,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fixed assets and intangibles</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1643" contextRef="AsOf2023-09-30" name="cvm:FixedAssetsAndIntangibles" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1644" contextRef="AsOf2022-09-30" name="cvm:FixedAssetsAndIntangibles" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">44,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total deferred tax liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1645" contextRef="AsOf2023-09-30" name="us-gaap:DeferredTaxLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,713,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1646" contextRef="AsOf2022-09-30" name="us-gaap:DeferredTaxLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,288,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net deferred tax asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1647" contextRef="AsOf2023-09-30" name="us-gaap:DeferredTaxAssetsNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,978,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1648" contextRef="AsOf2022-09-30" name="us-gaap:DeferredTaxAssetsNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,942,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1649" contextRef="AsOf2023-09-30" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,978,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1650" contextRef="AsOf2022-09-30" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,942,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ending balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1651" contextRef="AsOf2023-09-30" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1652" contextRef="AsOf2022-09-30" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-17</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_0d5dfa"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has no federal or state current or deferred tax expense or benefit.&#160; The Company&#8217;s effective tax rate differs from the applicable federal statutory tax rate.&#160; The reconciliation of these rates is as follows for the years ended September 30:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1587" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Federal rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1655" contextRef="From2022-10-01to2023-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" decimals="INF" unitRef="Pure" scale="-2">21.00</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1656" contextRef="From2021-10-01to2022-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" decimals="INF" unitRef="Pure" scale="-2">21.00</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">State rate change </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1658" contextRef="From2022-10-01to2023-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" decimals="INF" unitRef="Pure" sign="-" scale="-2">1.58</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1657" contextRef="From2021-10-01to2022-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" decimals="INF" unitRef="Pure" sign="-" scale="-2">1.67</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">State tax rate, net of federal benefit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1660" contextRef="From2022-10-01to2023-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" decimals="INF" unitRef="Pure" scale="-2">4.05</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1659" contextRef="From2021-10-01to2022-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" decimals="INF" unitRef="Pure" scale="-2">4.34</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other adjustments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1662" contextRef="From2022-10-01to2023-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" decimals="INF" unitRef="Pure" sign="-" scale="-2">1.62</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1661" contextRef="From2021-10-01to2022-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" decimals="INF" unitRef="Pure" sign="-" scale="-2">0.28</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Permanent differences</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1664" contextRef="From2022-10-01to2023-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" decimals="INF" unitRef="Pure" scale="-2">0.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1663" contextRef="From2021-10-01to2022-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" decimals="INF" unitRef="Pure" scale="-2">0.21</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Change in valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1666" contextRef="From2022-10-01to2023-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" decimals="INF" unitRef="Pure" sign="-" scale="-2">21.85</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1665" contextRef="From2021-10-01to2022-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" decimals="INF" unitRef="Pure" sign="-" scale="-2">23.61</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Effective tax rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1667" contextRef="From2021-10-01to2022-09-30" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" decimals="INF" unitRef="Pure" scale="-2">0.00</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1668" contextRef="From2022-10-01to2023-09-30" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" decimals="INF" unitRef="Pure" scale="-2">0.00</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company applies the provisions of ASC 740, <em>Accounting for Uncertainty in Income Taxes,</em> which requires financial statement benefits to be recognized for positions taken for tax return purposes when it is more likely than not that the position will be sustained.&#160; The Company has elected to reflect any tax penalties or interest resulting from tax assessments on uncertain tax positions as a component of tax expense.&#160; The Company has generated federal net operating losses in tax years ending September 30, 1999 through 2023.&#160;&#160;The Company files income tax returns in the U.S. federal jurisdiction and various states. With few exceptions, the Company is no longer subject to U.S. federal and state income tax examinations by tax authorities for years before September 30, 2020. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1555" contextRef="From2022-10-01to2023-09-30" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="cont_fda28e"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>8</strong><strong>.</strong>&#160; <strong>EQUITY-BASED</strong><strong> </strong><strong>COMPENSATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company recognized the following expenses for options issued or vested and restricted stock awarded during the year:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1588" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Year Ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1679" contextRef="From2022-10-01to2023-09-30" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,286,231</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1678" contextRef="From2021-10-01to2022-09-30" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,389,932</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1681" contextRef="From2022-10-01to2023-09-30" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:numdotdecimal" decimals="0" unitRef="USD">655,740</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1680" contextRef="From2021-10-01to2022-09-30" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:numdotdecimal" decimals="0" unitRef="USD">762,261</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As of September 30, 2023, the total compensation cost related to non-vested options and restricted stock awarded to employees and non-employees not yet recognized was approximately $<ix:nonFraction id="fid_2072" contextRef="From2022-10-01to2023-09-30_cvm_NonVestedOptionsMember" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">6.9</ix:nonFraction> million and $<ix:nonFraction id="fid_2070" contextRef="From2022-10-01to2023-09-30_cvm_RestrictedStockAwardsMember" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.3</ix:nonFraction> million, respectively, and the weighted-average period over which it is expected to be recognized is <ix:nonNumeric id="fid_2074" contextRef="From2022-10-01to2023-09-30_cvm_NonVestedOptionsMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear">1.78</ix:nonNumeric> and <ix:nonNumeric id="fid_2073" contextRef="From2022-10-01to2023-09-30_cvm_RestrictedStockAwardsMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear">0.94</ix:nonNumeric> years, respectively.</p></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-18</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_fda28e" continuedAt="cont_60b0f2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the years ended September 30, 2023 and 2022 the fair value of each option grant was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1589" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected stock price volatility</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_1683" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" decimals="INF" unitRef="Pure" scale="-2">99.18</ix:nonFraction> &#8211; <ix:nonFraction id="fid_1685" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" decimals="INF" unitRef="Pure" scale="-2">100.18</ix:nonFraction>%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_1682" contextRef="From2021-10-01to2022-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" decimals="INF" unitRef="Pure" scale="-2">96.37</ix:nonFraction> &#8211; <ix:nonFraction id="fid_1684" contextRef="From2021-10-01to2022-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" decimals="INF" unitRef="Pure" scale="-2">99.26</ix:nonFraction>%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_1687" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" decimals="INF" unitRef="Pure" scale="-2">3.41</ix:nonFraction> &#8211; <ix:nonFraction id="fid_1689" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" decimals="INF" unitRef="Pure" scale="-2">4.25</ix:nonFraction>%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_1686" contextRef="From2021-10-01to2022-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" decimals="INF" unitRef="Pure" scale="-2">1.50</ix:nonFraction> &#8211; <ix:nonFraction id="fid_1688" contextRef="From2021-10-01to2022-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" decimals="INF" unitRef="Pure" scale="-2">3.43</ix:nonFraction>%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected life of options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric id="fid_1691" contextRef="From2022-10-01to2023-09-30" name="cvm:ExpectedLifeOfOptionsMin1" format="ixt-sec:duryear">9.63</ix:nonNumeric> &#8211; <ix:nonNumeric id="fid_1692" contextRef="From2022-10-01to2023-09-30" name="cvm:ExpectedLifeOfOptionsMax" format="ixt-sec:duryear">9.66</ix:nonNumeric> years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric id="fid_1690" contextRef="From2021-10-01to2022-09-30" name="cvm:ExpectedLifeOfOptionsMin1" format="ixt-sec:duryear">9.67</ix:nonNumeric> &#8211; <ix:nonNumeric id="fid_1693" contextRef="From2021-10-01to2022-09-30" name="cvm:ExpectedLifeOfOptionsMax" format="ixt-sec:duryear">9.69</ix:nonNumeric> years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected dividend yield</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="width:1%;vertical-align:bottom;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_1694" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:zerodash" decimals="INF" unitRef="Pure" scale="-2">-</ix:nonFraction></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="width:1%;vertical-align:bottom;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_1695" contextRef="From2021-10-01to2022-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:zerodash" decimals="INF" unitRef="Pure" scale="-2">-</ix:nonFraction></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Non-Qualified Stock Option Plan</span><span style="text-decoration:underline">s</span>&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the year ended September 30, 2023, the Company adopted the 2023 Non-Qualified Stock Option Plan, which provides for the issuance of up to <ix:nonFraction id="fid_1791" contextRef="AsOf2023-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,000,000</ix:nonFraction> options to purchase shares of common stock.&#160; On August 8, 2023, the Company granted <ix:nonFraction id="fid_1788" contextRef="AsOf2023-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="cvm:PerformanceBasedStockOptionsSharesGranted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,958,500</ix:nonFraction> options to purchase shares of common stock from the 2023 Non-Qualified Stock Option Plan to officers, directors and employees.&#160; Each option entitles the holder to purchase one share of the Company&#8217;s common stock at a price of $<ix:nonFraction id="fid_1783" contextRef="From2022-10-01to2023-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="us-gaap:OptionIndexedToIssuersEquityStrikePrice1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.36</ix:nonFraction> per share, vests in three equal annual installments commencing one year after the grant date and expires on August 7, 2033.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the year ended September 30, 2022, the Company adopted the 2022 Non-Qualified Stock Option Plan, which provides for the issuance of up to <ix:nonFraction id="fid_1792" contextRef="AsOf2022-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,000,000</ix:nonFraction> options to purchase shares of common stock.&#160; On November 19, 2021, the Company granted <ix:nonFraction id="fid_1782" contextRef="AsOf2022-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="cvm:PerformanceBasedStockOptionsSharesGranted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">250,000</ix:nonFraction> performance-based stock options from the 2020 Non-Qualified Stock Option Plan to officers. Each option entitles the holder to purchase one share of the Company&#8217;s common stock at a price of $<ix:nonFraction id="fid_1784" contextRef="From2021-10-01to2022-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="us-gaap:OptionIndexedToIssuersEquityStrikePrice1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.48</ix:nonFraction> per share, the fair value on the date of issuance. <ix:nonNumeric id="fid_1790" contextRef="From2021-10-01to2022-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="us-gaap:ConversionOfStockDescription">The stock options will vest 100% upon approval of the first marketing application for any pharmaceutical based upon the Company&#8217;s Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia</ix:nonNumeric>.&#160; None of the options will be exercisable before November 19, 2022.&#160; All options which have not vested as of November 18, 2031 will be canceled.&#160; On the grant date, the options were valued using a Monte Carlo Simulation approach. A Monte Carlo Simulation is a statistical technique that is used to model probabilistic systems and establish the probabilities for a variety of outcomes. However, because attainment of the performance condition cannot be considered probable, no compensation cost was recognized relating to these options as of September 30, 2023.&#160; Management will re-assess the probability of achieving the performance condition at each reporting date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">At September 30, 2023, the Company has collectively authorized the issuance of <ix:nonFraction id="fid_1777" contextRef="AsOf2023-09-30_cvm_NonQualifiedStockOptionsPlansMember" name="us-gaap:CommonStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,787,200</ix:nonFraction> options to purchase shares of common stock under its Non-Qualified Stock Option Plans. Options typically vest over a three-year period and expire no later than ten years after the grant date. Terms of the options were determined by the Company&#8217;s Compensation Committee which administers the plans. The Company&#8217;s employees, directors, officers, and consultants or advisors are eligible to be granted options under the Non-Qualified Stock Option Plans.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Incentive Stock Option Plan</span><span style="text-decoration:underline">s</span> &#8211; At September 30, 2023, the Company had collectively authorized the issuance of <ix:nonFraction id="fid_1778" contextRef="AsOf2023-09-30_cvm_IncentiveStockOptionPlansMember" name="us-gaap:CommonStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">138,400</ix:nonFraction> options to purchase shares of common stock under its Incentive Stock Option Plans.&#160; Options typically vest over a three-year period and expire no later than ten years after the grant date.&#160; Terms of the options were determined by the Company&#8217;s Compensation Committee which administers the Plans.&#160; Only the Company&#8217;s employees are eligible to be granted options under the Incentive Stock Option Plans.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-19</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_60b0f2" continuedAt="cont_6787b8"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Activity in the Company&#8217;s Non-Qualified and Incentive Stock Option Plans for the two years ended September 30, 2023 is summarized as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Non-Qualified and Incentive Stock Option Plans</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1590" contextRef="From2022-10-01to2023-09-30" name="cvm:ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="14"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Outstanding</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="14"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercisable</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Remaining Contractual Term (Years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Remaining Contractual Term (Years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at September 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1698" contextRef="AsOf2021-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">11,049,709</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1712" contextRef="AsOf2021-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.08</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1721" contextRef="From2021-10-01to2022-09-30_cvm_OutstandingMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear">7.93</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2077" contextRef="AsOf2021-09-30_cvm_OutstandingMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,843,283</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1699" contextRef="AsOf2021-09-30_cvm_ExercisableMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,540,028</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1713" contextRef="AsOf2021-09-30_cvm_ExercisableMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.77</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1722" contextRef="From2021-10-01to2022-09-30_cvm_ExercisableMember" name="cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" format="ixt-sec:duryear">6.96</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2081" contextRef="AsOf2021-09-30_cvm_ExercisableMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,589,598</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1743" contextRef="AsOf2021-09-30_cvm_ExercisableMember" name="cvm:NumberOfOptionsVested" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,547,703</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1745" contextRef="AsOf2021-09-30_cvm_ExercisableMember" name="cvm:WeightedAverageExercisePriceVested" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.60</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Granted(a)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1734" contextRef="From2021-10-01to2022-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,040,750</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1739" contextRef="From2021-10-01to2022-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.24</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1703" contextRef="From2021-10-01to2022-09-30_cvm_OutstandingMember" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">6,500</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1715" contextRef="From2021-10-01to2022-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.59</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td class="ffcell" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_2079" contextRef="From2021-10-01to2022-09-30_cvm_OutstandingMember" name="cvm:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,725</ix:nonFraction></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1704" contextRef="From2021-10-01to2022-09-30_cvm_ExercisableMember" name="cvm:NumberOfOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares" sign="-">6,500</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1716" contextRef="From2021-10-01to2022-09-30_cvm_ExercisableMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.59</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1733" contextRef="From2021-10-01to2022-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">106,331</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1738" contextRef="From2021-10-01to2022-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.53</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1707" contextRef="From2021-10-01to2022-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">13,614</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1719" contextRef="From2021-10-01to2022-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">97.50</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1708" contextRef="From2021-10-01to2022-09-30_cvm_ExercisableMember" name="cvm:NumberOfOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares" sign="-">13,614</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1720" contextRef="From2021-10-01to2022-09-30_cvm_ExercisableMember" name="cvm:WeightedAverageExercisePriceExpired" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">97.50</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1696" contextRef="AsOf2022-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">12,964,014</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1710" contextRef="AsOf2022-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.06</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1724" contextRef="From2021-10-01to2022-09-30_cvm_OutstandingMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear">7.35</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2078" contextRef="AsOf2022-09-30_cvm_OutstandingMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,866,240</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1697" contextRef="AsOf2022-09-30_cvm_ExercisableMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">7,067,617</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1711" contextRef="AsOf2022-09-30_cvm_ExercisableMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.21</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1723" contextRef="From2021-10-01to2022-09-30_cvm_ExercisableMember" name="cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" format="ixt-sec:duryear">6.21</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2083" contextRef="AsOf2022-09-30_cvm_ExercisableMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,866,105</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1700" contextRef="AsOf2022-09-30_cvm_ExercisableMember" name="cvm:NumberOfOptionsVested" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">952,256</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1714" contextRef="AsOf2022-09-30_cvm_ExercisableMember" name="cvm:WeightedAverageExercisePriceVested" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.41</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Granted (b)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1736" contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,065,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1741" contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.37</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1735" contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">213,165</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1740" contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.19</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1705" contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">58,791</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1717" contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">61.05</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1706" contextRef="From2022-10-01to2023-09-30_cvm_ExercisableMember" name="cvm:NumberOfOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares" sign="-">58,791</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1718" contextRef="From2022-10-01to2023-09-30_cvm_ExercisableMember" name="cvm:WeightedAverageExercisePriceExpired" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">61.05</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1746" contextRef="AsOf2023-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">14,757,558</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1747" contextRef="AsOf2023-09-30_cvm_OutstandingMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.78</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1725" contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear">6.81</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2076" contextRef="AsOf2023-09-30_cvm_OutstandingMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1709" contextRef="AsOf2023-09-30_cvm_ExercisableMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">7,961,082</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1748" contextRef="AsOf2023-09-30_cvm_ExercisableMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.07</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1726" contextRef="From2022-10-01to2023-09-30_cvm_ExercisableMember" name="cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" format="ixt-sec:duryear">5.60</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2082" contextRef="AsOf2023-09-30_cvm_ExercisableMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(a)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The weighted average grant date fair value was $3.01.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(b)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Includes 1,965,500 performance based options issued to officers and directors, 100,000 options issued to consultants. The weighted average grant date fair value was $1.22.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">A summary of the status of the Company&#8217;s un-vested options for the two years ended September 30, 2023 is presented below:&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1592" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Options</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Grant Date Fair Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested at September 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1750" contextRef="AsOf2021-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,509,681</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1761" contextRef="AsOf2021-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.17</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1753" contextRef="From2021-10-01to2022-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,547,703</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td class="ffcell" style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_2085" contextRef="From2021-10-01to2022-09-30" name="cvm:WeightedAverageGrantDateFairValueVested" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.37</ix:nonFraction></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1755" contextRef="From2021-10-01to2022-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,040,750</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1757" contextRef="From2021-10-01to2022-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">106,331</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested at September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1751" contextRef="AsOf2022-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,896,397</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1760" contextRef="AsOf2022-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.63</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1752" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">952,256</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td class="ffcell" style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_2084" contextRef="From2022-10-01to2023-09-30" name="cvm:WeightedAverageGrantDateFairValueVested" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.30</ix:nonFraction></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1754" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,065,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1756" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">213,165</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested at September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1758" contextRef="AsOf2023-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">6,796,476</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1762" contextRef="AsOf2023-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.25</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Incentive Stock Bonus Plan</span> &#8211; On September 30, 2023, <ix:nonFraction id="fid_1779" contextRef="AsOf2023-09-30_cvm_IncentiveStockBonusPlanMember" name="us-gaap:CommonStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">610,500</ix:nonFraction> of the shares granted under the 2014 Incentive Stock Bonus Plan remain outstanding, of which <ix:nonFraction id="fid_1786" contextRef="From2022-10-01to2023-09-30_cvm_IncentiveStockBonusPlanMember" name="cvm:VestedShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">463,250</ix:nonFraction> shares are fully vested.&#160; During the year ended September 30, 2023, <ix:nonFraction id="fid_1793" contextRef="From2022-10-01to2023-09-30_cvm_IncentiveStockBonusPlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,000</ix:nonFraction> unvested shares were forfeited. The shares are being earned upon the achievement of certain milestones leading to the commercialization of the Company&#8217;s Multikine technology, or specified increases in the market price of the Company&#8217;s stock.&#160; The fair value of the shares on the grant date was calculated using the market value on the grant-date for issuances where the attainment of performance criteria is likely and using a Monte Carlo Simulation for issuances where the attainment of performance criteria is uncertain.&#160; The grant date fair value of shares issued that remain outstanding as of September 30, 2023 was approximately $<ix:nonFraction id="fid_1785" contextRef="AsOf2023-09-30_cvm_IncentiveStockBonusPlanMember" name="cvm:RemainingOutstandingFairValueOfShares" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">8.6</ix:nonFraction> million.&#160; The total value of the shares, if earned, is being expensed over the requisite service periods for each milestone, provided the requisite service periods are rendered, regardless of whether the market conditions are met.&#160; No compensation cost is recognized for awards where the requisite service period is not rendered.&#160; During the years ended September 30, 2023 and 2022, the Company recorded expense relating to the issuance of restricted stock pursuant to the plan of approximately $(<ix:nonFraction id="fid_1787" contextRef="AsOf2023-09-30_cvm_IncentiveStockBonusPlanMember" name="us-gaap:DeferredCompensationEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,000</ix:nonFraction>) and $<ix:nonFraction id="fid_1789" contextRef="AsOf2022-09-30_cvm_IncentiveStockBonusPlanMember" name="us-gaap:DeferredCompensationEquity" format="ixt:numdotdecimal" decimals="-3" unitRef="USD" scale="3">45,000</ix:nonFraction>, respectively.&#160; As of September 30, 2023, all compensation expense related to the 2014 Incentive Stock Bonus Plan has been fully recognized. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-20</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_6787b8"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">A summary of the status of the Company&#8217;s restricted common stock issued from the Incentive Stock Bonus Plan for the two years ended September 30, 2023 is presented below: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2061" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number of </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted Average Grant Date Fair Value</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unvested at September 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1764" contextRef="AsOf2021-09-30_cvm_RestrictedStockAwardsMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">151,250</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1772" contextRef="AsOf2021-09-30_cvm_RestrictedStockAwardsMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.75</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0px; text-align:justify;">Unvested at September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1765" contextRef="AsOf2022-09-30_cvm_RestrictedStockAwardsMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">151,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1773" contextRef="AsOf2023-09-30_cvm_RestrictedStockAwardsMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.75</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1766" contextRef="From2022-10-01to2023-09-30_cvm_RestrictedStockAwardsMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unvested at September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1770" contextRef="AsOf2023-09-30_cvm_RestrictedStockAwardsMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">147,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1774" contextRef="AsOf2022-09-30_cvm_RestrictedStockAwardsMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.75</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Stock Bonus Plans</span><span style="text-decoration:underline"> </span>&#8211; As of September 30, 2023, the Company authorized to issue up to <ix:nonFraction id="fid_1780" contextRef="AsOf2023-09-30_cvm_StockBonusPlansMember" name="us-gaap:CommonStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,283,760</ix:nonFraction> shares of common stock from the Stock Bonus Plans and has issued a total of <ix:nonFraction id="fid_1775" contextRef="AsOf2023-09-30_cvm_StockBonusPlansMember" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">512,972</ix:nonFraction> shares of common stock under its Stock Bonus Plans.&#160; All employees, directors, officers, consultants, and advisors are eligible to be granted shares.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Stock Compensation Plans</span> &#8211; On September 30, 2023, <ix:nonFraction id="fid_1781" contextRef="AsOf2023-09-30_cvm_StockCompensationPlansMember" name="us-gaap:CommonStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">634,000</ix:nonFraction> shares were authorized for issuance pursuant to the &#160;Company&#8217;s Stock Compensation Plans, of which <ix:nonFraction id="fid_1776" contextRef="AsOf2023-09-30_cvm_StockCompensationPlansMember" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">153,195</ix:nonFraction> shares were issued and outstanding.&#160; No shares were issued from the Stock Compensation Plans during the years ended September 30, 2023 and 2022.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1556" contextRef="From2022-10-01to2023-09-30" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>9</strong><strong>. EMPLOYEE BENEFIT PLAN</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company maintains a defined contribution retirement plan, qualifying under Section 401(k) of the Internal Revenue Code, subject to the Employee Retirement Income Security Act of 1974, as amended, and covering substantially all Company employees. Each participant&#8217;s contribution is matched by the Company with shares of common stock that have a value equal to 100% of the participant&#8217;s contribution, not to exceed the lesser of $<ix:nonFraction id="fid_1984" contextRef="From2022-10-01to2023-09-30" name="cvm:TotalCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction> or <ix:nonFraction id="fid_1985" contextRef="From2022-10-01to2023-09-30" name="cvm:ParticipantCompensation" decimals="INF" unitRef="Pure" scale="-2">6</ix:nonFraction>% of the participant&#8217;s total compensation. The Company&#8217;s contribution of common stock is valued each quarter based upon the closing bid price of the Company&#8217;s common stock. During the year ended September 30, 2023, <ix:nonFraction id="fid_1987" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ConversionOfStockSharesIssued1" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">97,004</ix:nonFraction> shares were issued to the Company&#8217;s 401(k) plan for a cost of approximately $<ix:nonFraction id="fid_1983" contextRef="From2022-10-01to2023-09-30" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">208,000</ix:nonFraction>. During the year ended September 30, 2022, <ix:nonFraction id="fid_1986" contextRef="From2021-10-01to2022-09-30" name="us-gaap:ConversionOfStockSharesIssued1" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">52,882</ix:nonFraction> shares were issued to the Company&#8217;s 401(k) plan for a cost of approximately $<ix:nonFraction id="fid_1982" contextRef="From2021-10-01to2022-09-30" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">223,000</ix:nonFraction>.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-21</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1557" contextRef="From2022-10-01to2023-09-30" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="cont_c769a1"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>10</strong><strong>. COMMITMENTS AND CONTINGENCIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Clinical Research Agreements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In April 2013, the Company entered into a co-development and revenue sharing agreement with Ergomed. Under the agreement, Ergomed will contribute up to $<ix:nonFraction id="fid_2013" contextRef="From2022-10-01to2023-09-30_cvm_ErgomedMember" name="cvm:ClinicalServiceTrial" format="ixt:numdotdecimal" decimals="-6" unitRef="USD" scale="6">10</ix:nonFraction> million towards the Company&#8217;s Phase III clinical study in the form of offering discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. In October 2015, the Company entered into a second co-development and revenue sharing agreement with Ergomed for an additional $<ix:nonFraction id="fid_2014" contextRef="From2022-10-01to2023-09-30_cvm_ErgomedMember" name="cvm:AdditionalClinicalTrial" format="ixt:numdotdecimal" decimals="-6" unitRef="USD" scale="6">2</ix:nonFraction> million, for a total of $<ix:nonFraction id="fid_2035" contextRef="AsOf2022-09-30_us-gaap_OperatingExpenseMember" name="cvm:CashPaymentForOperatingLeases" format="ixt:numdotdecimal" decimals="-6" unitRef="USD" scale="6">12</ix:nonFraction> million. The Company accounted for the co-development and revenue sharing agreement in accordance with ASC 808, <em>Collaborative Arrangements</em>. The Company determined the payments to Ergomed are within the scope of ASC 730, <em>Research and Development</em>. Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its Statements of Operations. Since the Company entered into the co-development and revenue sharing agreement with Ergomed, it has incurred research and development expenses of approximately $<ix:nonFraction id="fid_2015" contextRef="From2022-10-01to2023-09-30" name="us-gaap:OtherResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">35.7</ix:nonFraction> million related to Ergomed&#8217;s services. This amount is net of Ergomed&#8217;s discount of approximately $<ix:nonFraction id="fid_2016" contextRef="From2022-10-01to2023-09-30" name="cvm:NetOfDiscount" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">11.8</ix:nonFraction> million. During the years ended September 30, 2023 and 2022, the Company recorded approximately $<ix:nonFraction id="fid_2008" contextRef="From2022-10-01to2023-09-30_cvm_ErgomedMember" name="us-gaap:OtherResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.2</ix:nonFraction> million and $<ix:nonFraction id="fid_2009" contextRef="From2021-10-01to2022-09-30_cvm_ErgomedMember" name="us-gaap:OtherResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.5</ix:nonFraction> million, respectively, as research and development expense related to Ergomed&#8217;s services. These amounts were net of Ergomed&#8217;s discount of approximately $<ix:nonFraction id="fid_2010" contextRef="From2022-10-01to2023-09-30_cvm_ErgomedMember" name="cvm:NetOfDiscount" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.1</ix:nonFraction> million during both the years ended September 30, 2023 and 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Lease Agreements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#8217;s specifications so that it can be used by the Company to manufacture Multikine for the Company&#8217;s Phase III clinical trial and sales of the drug if approved by the FDA or regulators in Canada, the UK or Europe. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. &#160;The renewal options are not included in the calculation of the right of use asset and lease liability because exercise of those options is not reasonably certain.&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of September 30, 2023 and 2022, respectively, the net book value of the finance lease right of use asset is approximately $<ix:nonFraction id="fid_2018" contextRef="From2022-10-01to2023-09-30_us-gaap_LeaseAgreementsMember" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">9.1</ix:nonFraction> million and $<ix:nonFraction id="fid_2019" contextRef="From2021-10-01to2022-09-30_us-gaap_LeaseAgreementsMember" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">10.9</ix:nonFraction> million and the balance of the finance lease liability is approximately $<ix:nonFraction id="fid_2020" contextRef="AsOf2023-09-30_us-gaap_LeaseAgreementsMember" name="us-gaap:FinanceLeaseLiability" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">11.7</ix:nonFraction> million and $<ix:nonFraction id="fid_2021" contextRef="AsOf2022-09-30_us-gaap_LeaseAgreementsMember" name="us-gaap:FinanceLeaseLiability" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">13.3</ix:nonFraction> million, of which approximately $<ix:nonFraction id="fid_2022" contextRef="AsOf2023-09-30_us-gaap_LeaseAgreementsMember" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.8</ix:nonFraction> million and $<ix:nonFraction id="fid_2023" contextRef="AsOf2022-09-30_us-gaap_LeaseAgreementsMember" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.6</ix:nonFraction> million is current.&#160; These amounts include the San Tomas lease as well as several other smaller finance leases for office equipment.&#160; During the years ended September 30, 2023 and 2022, the finance right of use assets are being depreciated using a straight-line method over the underlying lease terms and depreciation expense totaled approximately $<ix:nonFraction id="fid_2025" contextRef="From2021-10-01to2022-09-30_us-gaap_LeaseAgreementsMember" name="us-gaap:Depreciation" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.8</ix:nonFraction> million and $<ix:nonFraction id="fid_2024" contextRef="From2022-10-01to2023-09-30_us-gaap_LeaseAgreementsMember" name="us-gaap:Depreciation" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.8</ix:nonFraction> million, respectively. Total cash paid related to finance leases during the years ended September 30, 2023 and 2022, respectively, was approximately $<ix:nonFraction id="fid_2027" contextRef="AsOf2023-09-30_us-gaap_LeaseAgreementsMember" name="cvm:CashPaymentToLeaseLiability" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">2.6</ix:nonFraction> million and $<ix:nonFraction id="fid_2028" contextRef="AsOf2022-09-30_us-gaap_LeaseAgreementsMember" name="cvm:CashPaymentToLeaseLiability" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">2.5</ix:nonFraction> million, of which approximately $<ix:nonFraction id="fid_2026" contextRef="From2022-10-01to2023-09-30_us-gaap_LeaseAgreementsMember" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.1</ix:nonFraction> million and $<ix:nonFraction id="fid_2029" contextRef="From2021-10-01to2022-09-30_us-gaap_LeaseAgreementsMember" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.2</ix:nonFraction> million was for interest in both years. The weighted average discount rate of the Company&#8217;s finance leases is <ix:nonFraction id="fid_2030" contextRef="From2022-10-01to2023-09-30_us-gaap_LeaseAgreementsMember" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" decimals="INF" unitRef="Pure" scale="-2">8.44</ix:nonFraction>% and the weighted average time to maturity is <ix:nonNumeric id="fid_2017" contextRef="From2022-10-01to2023-09-30_us-gaap_LeaseAgreementsMember" name="cvm:WeightedAverageMaturityYear" format="ixt-sec:duryear">5.09</ix:nonNumeric> years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In August 2020, the Company entered into an amendment to the San Tomas lease agreement under which the landlord agreed to allow the Company to substantially upgrade the manufacturing facility in preparation for the potential commercial production of Multikine. The upgrades were completed and the improvements were placed in service in October 2021.&#160; The total cost of the upgrades was $<ix:nonFraction id="fid_2011" contextRef="From2022-10-01to2023-09-30_cvm_LandlordMember" name="cvm:FinancingLeaseContractualArrangement" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">11.1</ix:nonFraction> million. &#160;The landlord agreed to finance the final $<ix:nonFraction id="fid_2012" contextRef="From2022-10-01to2023-09-30_cvm_LandlordMember" name="cvm:PaymentsMadeToLandlord" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">2.4</ix:nonFraction> million of the costs incurred which will be repaid through increased lease payments over the remaining lease term starting on March 1, 2021.&#160; <ix:nonNumeric id="fid_2031" contextRef="From2022-10-01to2023-09-30_cvm_LandlordMember" name="us-gaap:DescriptionOfLesseeLeasingArrangementsCapitalLeases">The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year</ix:nonNumeric>.&#160; The Company remeasured the lease liability to account for the modified payments using an <ix:nonFraction id="fid_2032" contextRef="From2022-10-01to2023-09-30_cvm_LandlordMember" name="cvm:IncrementalBorrowingDerivativeVariableRate" decimals="INF" unitRef="Pure" scale="-2">8.45</ix:nonFraction>% incremental borrowing rate (IBR).&#160;The rate was determined using a synthetic credit rating analysis prepared by an outside valuation specialist.&#160; Additionally, this financing is considered to be a lease incentive from the landlord and has been included in the calculation of the lease liability as it is realized.&#160; The entire $<ix:nonFraction id="fid_2045" contextRef="From2021-10-01to2022-09-30_us-gaap_OperatingExpenseMember" name="us-gaap:OtherExpenses" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">2.4</ix:nonFraction> million was received from the landlord as of September 30, 2022. The leasehold improvements are recorded in property and equipment and are being amortized over the remaining lease term.&#160; </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-22</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_c769a1" continuedAt="cont_71be65"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">During June 2021, the Company determined that it used an incorrect discount rate to calculate the opening ROU asset and lease liability balances upon adoption of ASC 842. Management engaged an outside valuation specialist to perform a synthetic credit rating analysis which resulted in a revised rate to be used upon adoption of ASC 842 of 10.19% compared to the previously used rate of 8.80%. This change resulted in an immaterial difference to the September 30, 2020 financial statements, and was corrected in the quarterly period ended June 30, 2021 as an out of period adjustment.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company was required to deposit the equivalent of one year of base rent in accordance with the original lease.&#160; Because the Company met the minimum cash balance required by the lease, the full balance of the deposit was returned to the Company in January 2022. However, on January 11, 2023, the Company was required to deposit approximately $<ix:nonFraction id="fid_2033" contextRef="From2023-01-01to2023-01-11_cvm_LandlordMember" name="cvm:PaymentsMadeToLandlord" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">2.3</ix:nonFraction>&#160;million to its landlord, equivalent to one year&#8217;s rent, for falling back below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Approximate future minimum lease payments under finance leases as of September 30, 2023 are as follows:&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1593" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1988" contextRef="AsOf2023-09-30" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,655,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1989" contextRef="AsOf2023-09-30" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,740,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1990" contextRef="AsOf2023-09-30" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,832,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1991" contextRef="AsOf2023-09-30" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,923,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1996" contextRef="AsOf2023-09-30" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,015,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1992" contextRef="AsOf2023-09-30" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1993" contextRef="AsOf2023-09-30" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,417,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1994" contextRef="AsOf2023-09-30" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,696,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of lease finance lease obligations &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1995" contextRef="AsOf2023-09-30" name="us-gaap:CapitalLeaseObligationsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,772,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of lease finance lease obligations &#8211; non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1997" contextRef="AsOf2023-09-30" name="us-gaap:CapitalLeaseObligationsNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,949,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company leases two facilities under operating leases.&#160; The lease for the Company&#8217;s office headquarters will expire on November 30, 2025.&#160; The lease for its research and development laboratory and will expire on February 29, 2032. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of September 30, 2023, the net book value of the operating lease right of use asset is approximately $<ix:nonFraction id="fid_2041" contextRef="From2022-10-01to2023-09-30_us-gaap_OperatingExpenseMember" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.7</ix:nonFraction> million and the balance of the operating lease liability is approximately $<ix:nonFraction id="fid_2039" contextRef="AsOf2023-09-30_us-gaap_OperatingExpenseMember" name="us-gaap:OperatingLeaseLiability" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.9</ix:nonFraction> million, of which approximately $<ix:nonFraction id="fid_2037" contextRef="AsOf2023-09-30_us-gaap_OperatingExpenseMember" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.2</ix:nonFraction> million is current.&#160; As of September 30, 2022, the net book value of the operating lease right of use asset is approximately $<ix:nonFraction id="fid_2042" contextRef="From2021-10-01to2022-09-30_us-gaap_OperatingExpenseMember" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.9</ix:nonFraction> million and the balance of the operating lease liability is approximately $<ix:nonFraction id="fid_2040" contextRef="AsOf2022-09-30_us-gaap_OperatingExpenseMember" name="us-gaap:OperatingLeaseLiability" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">2.1</ix:nonFraction> million, of which approximately $<ix:nonFraction id="fid_2038" contextRef="AsOf2022-09-30_us-gaap_OperatingExpenseMember" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.2</ix:nonFraction> million is current.&#160; During the years ended September 30, 2023 and 2022 the Company incurred lease expense under operating leases of approximately $<ix:nonFraction id="fid_2044" contextRef="From2022-10-01to2023-09-30_us-gaap_OperatingExpenseMember" name="us-gaap:OtherExpenses" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.4</ix:nonFraction> million each year. Total cash paid related to operating leases during the years ended September 30, 2023 and 2022 was approximately $<ix:nonFraction id="fid_2034" contextRef="AsOf2023-09-30_us-gaap_OperatingExpenseMember" name="cvm:CashPaymentForOperatingLeases" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.3</ix:nonFraction> million each year.&#160; The weighted average discount rate of the Company&#8217;s operating leases is <ix:nonFraction id="fid_2036" contextRef="From2022-10-01to2023-09-30_us-gaap_OperatingExpenseMember" name="cvm:WeightedAverageOperatingLeaseDiscountRate" decimals="INF" unitRef="Pure" scale="-2">10.2</ix:nonFraction>% and the weighted average time to maturity is <ix:nonNumeric id="fid_2043" contextRef="From2022-10-01to2023-09-30_us-gaap_OperatingExpenseMember" name="cvm:WeightedAverageOperatingLeaseMaturityYear" format="ixt-sec:duryear">7.74</ix:nonNumeric> years. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-23</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_71be65"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of September 30, 2023, future minimum lease payments on operating leases are as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1594" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1998" contextRef="AsOf2022-09-30" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:numdotdecimal" decimals="0" unitRef="USD">357,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1999" contextRef="AsOf2022-09-30" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:numdotdecimal" decimals="0" unitRef="USD">366,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2000" contextRef="AsOf2022-09-30" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:numdotdecimal" decimals="0" unitRef="USD">287,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2001" contextRef="AsOf2022-09-30" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:numdotdecimal" decimals="0" unitRef="USD">277,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2006" contextRef="AsOf2022-09-30" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">285,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2002" contextRef="AsOf2022-09-30" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,040,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2003" contextRef="AsOf2022-09-30" name="cvm:LesseeOperatingLeaseLiabilityPayments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,612,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2004" contextRef="AsOf2022-09-30" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">762,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligation &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2007" contextRef="AsOf2022-09-30" name="us-gaap:CapitalLeaseObligationsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">197,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligation &#8211; non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2005" contextRef="AsOf2022-09-30" name="us-gaap:CapitalLeaseObligationsNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,653,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Vendor Obligations</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has contingent obligations with vendors for work that will be completed in relation to the Phase III clinical trial.&#160; The timing of these obligations cannot be determined at this time.&#160; The Company estimates it will incur additional expenses of approximately $<ix:nonFraction id="fid_2046" contextRef="From2022-10-01to2023-09-30" name="cvm:AdditionalExpenses" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.7</ix:nonFraction> million for the remainder of the Phase III clinical trial and the filing of the clinical study report with the FDA.&#160; This estimate is based only on the information currently available from the Clinical Research Organizations responsible for managing the Phase III clinical trial and does not include other related costs.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1558" contextRef="From2022-10-01to2023-09-30" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1</strong><strong>1</strong><strong>. </strong><strong>RELATED PARTY TRANSACTIONS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the year ended September 30, 2023, no restricted shares of the Company&#8217;s common stock were purchased by related parties.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024 (Note 4).&#160; The incremental cost of this extension was approximately $<ix:nonFraction id="fid_1796" contextRef="From2021-10-01to2022-09-30_cvm_OfficerAndDirectorMember" name="cvm:DeemedDividendFromModificationOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">172,000</ix:nonFraction>, which was recorded as a deemed dividend. The Series RR warrants are held by Geert Kersten, Patricia Prichep (current officers of the Company) and the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On June 13, 2022, the expiration dates of the Series N, Series X, Series Y, Series UU, Series MM and Series NN warrants were extended two years (Note 4).&#160; The incremental costs of the warrant extensions were recorded consistent with the accounting for the initial warrant issuances.&#160; The incremental costs of the Series N, Series X and Series Y warrant extensions were recorded as a deemed dividend and totaled approximately $<ix:nonFraction id="fid_1794" contextRef="From2021-10-01to2022-09-30_cvm_SeriesNAndXAndYWarrantsMember" name="cvm:DeemedDividendFromModificationOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294,000</ix:nonFraction> for the year ended September 30, 2022.&#160; The Series N and Series X warrants are held by the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a trustee and beneficiary.&#160; The incremental cost of the Series MM, Series NN and Series UU warrant extensions of approximately $<ix:nonFraction id="fid_1795" contextRef="From2021-10-01to2022-09-30_cvm_SeriesMMAndNNAndUUWarrantMember" name="cvm:Warrant" format="ixt:numdotdecimal" decimals="0" unitRef="USD">635,000</ix:nonFraction> was recorded as a deemed dividend because there are no longer any notes payable associated with these warrants at the time of modification.&#160; The Series UU warrants and a portion of the Series MM and Series NN warrants are held by Geert Kersten, Patricia Prichep and the de Clara Trust.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1559" contextRef="From2022-10-01to2023-09-30" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="cont_a8836e"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1</strong><strong>2</strong><strong>.</strong> <strong>STOCKHOLDERS&#8217; EQUITY&#160; </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Exercise of Warrants</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the years ended September 30, 2023 and 2022, the Company received proceeds of approximately $<ix:nonFraction id="fid_1802" contextRef="From2022-10-01to2023-09-30" name="cvm:ProceedFromIssuanceOrSaleOfEquity" format="ixt:numdotdecimal" decimals="-4" unitRef="USD" scale="5">0.4</ix:nonFraction> million and $<ix:nonFraction id="fid_1801" contextRef="From2021-10-01to2022-09-30" name="cvm:ProceedFromIssuanceOrSaleOfEquity" format="ixt:numdotdecimal" decimals="-4" unitRef="USD" scale="5">0.1</ix:nonFraction> million, respectively, from the exercise of warrants, as detailed in Note 4.&#160; Upon exercise, <ix:nonFraction id="fid_1804" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">217,752</ix:nonFraction> and <ix:nonFraction id="fid_1803" contextRef="From2021-10-01to2022-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">25,205</ix:nonFraction> shares of common stock were issued during the years ended September 30, 2023 and 2022, respectively. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-24</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_a8836e"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Sales of Securities</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On May 2, 2023, the Company sold <ix:nonFraction id="fid_1797" contextRef="AsOf2023-05-02" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">913,234</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction id="fid_1799" contextRef="AsOf2023-05-02" name="us-gaap:SaleOfStockPricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.70</ix:nonFraction> per share and received aggregate proceeds of approximately $<ix:nonFraction id="fid_1806" contextRef="From2023-04-30to2023-05-02" name="cvm:AggregateNetProceedsFromSaleOfSecurities" format="ixt:numdotdecimal" decimals="-4" unitRef="USD" scale="6">1.55</ix:nonFraction> million.&#160; On July 20, 2023, the Company sold <ix:nonFraction id="fid_1798" contextRef="AsOf2023-07-20" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,500,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction id="fid_1800" contextRef="AsOf2023-07-20" name="us-gaap:SaleOfStockPricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.00</ix:nonFraction> per share and received aggregate proceeds of approximately $<ix:nonFraction id="fid_1807" contextRef="From2023-07-01to2023-07-20" name="cvm:AggregateNetProceedsFromSaleOfSecurities" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">5.0</ix:nonFraction> million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">There were no sales of securities during the fiscal year ended September 30, 2022.&#160; &#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Other Equity Transactions</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company entered into Securities Purchase Agreements (SPA) with Ergomed plc, one of the Company&#8217;s Clinical Research Organizations responsible for managing the Company&#8217;s Phase III clinical trial, to facilitate payment of amounts due Ergomed.&#160; Under the Agreements, the Company issued Ergomed shares of common stock and the net proceeds from the sales of those shares reduces outstanding amounts due Ergomed.&#160; Upon issuance, the Company expenses the full value of the shares as Other non-operating gain/loss and subsequently offsets the expense as amounts are realized through the sale by Ergomed and reduces accounts payable to Ergomed.&#160;&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the years ended September 30, 2023 and 2022, CEL-SCI did not issue Ergomed any shares of common stock. Additionally, no shares were sold during the years ended September 30, 2023 and 2022. All outstanding shares have been resold as of September 30, 2023 and 2022 and the Company had approximately $<ix:nonFraction id="fid_1808" contextRef="AsOf2023-09-30_cvm_ErgomedMember" name="cvm:PrepaidAmountOfResold" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction> and $<ix:nonFraction id="fid_1805" contextRef="AsOf2022-09-30_cvm_ErgomedMember" name="cvm:PrepaidAmountOfResold" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,000</ix:nonFraction> in amounts remaining in prepaid to Ergomed as of September 30, 2023 and 2022, respectively.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1560" contextRef="From2022-10-01to2023-09-30" name="us-gaap:FairValueDisclosuresTextBlock" escape="true" continuedAt="cont_cd8d10"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1</strong><strong>3</strong><strong>. FAIR VALUE MEASUREMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In accordance with the provisions of ASC 820, &#8220;<em>Fair Value Measurements</em>,&#8221; the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160; The Company generally applies the income approach to determine fair value.&#160; This method uses valuation techniques to convert future amounts to a single present amount.&#160; The measurement is based on the value indicated by current market expectations with respect to the future amounts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value.&#160; The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&#160; The Company classifies fair value balances based on the observability of those inputs.&#160; The three levels of the fair value hierarchy are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">o</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Level 1 &#8211; Observable inputs such as quoted prices in active markets for identical assets or liabilities</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">o</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 2 &#8211; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs other than quoted prices that are observable for the asset or liability are observable in active markets</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">o</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Level 3 &#8211; Unobservable inputs that reflect management&#8217;s assumptions</p></td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-25</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_cd8d10"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement.&#160; The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company purchased short-term T-bills during the year ended September 30, 2021 that are classified as trading securities.&#160; Quoted market prices were applied to determine the fair value of short-term investments, therefore they were categorized as Level 1 on the fair value hierarchy. The T-bills were recorded at fair market value, which includes an unrealized gain of approximately $<ix:nonFraction id="fid_1819" contextRef="From2022-10-01to2023-09-30" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction>.&#160; The T-bills matured in December 2021 and yield a weighted average interest rate of <ix:nonFraction id="fid_1820" contextRef="From2022-10-01to2023-09-30" name="cvm:WeightedAverageRiskFreeInterestRate" decimals="INF" unitRef="Pure" scale="-2">0.10</ix:nonFraction>%. The Company is not holding any T-bills as of September 30, 2023 and September 30, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of September 30, 2023 and 2022, there were no derivative liabilities&#160;outstanding.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following sets forth the reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3), as of September 30:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1595" contextRef="From2022-10-01to2023-09-30" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;&#160;&#160;&#160; 2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;&#160;&#160;&#160; 2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Beginning balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1816" contextRef="AsOf2022-09-30" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1815" contextRef="AsOf2021-09-30" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">437,380</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Issuances</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1809" contextRef="From2021-10-01to2022-09-30" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1810" contextRef="From2022-10-01to2023-09-30" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1812" contextRef="From2022-10-01to2023-09-30" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1811" contextRef="From2021-10-01to2022-09-30" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,589</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Net realized and unrealized derivative loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1814" contextRef="From2022-10-01to2023-09-30" name="cvm:FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1813" contextRef="From2021-10-01to2022-09-30" name="cvm:FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">366,791</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Ending balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1818" contextRef="AsOf2023-09-30" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1817" contextRef="AsOf2022-09-30" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The fair values of the Company&#8217;s derivative instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such as historical price and volatility of the Company&#8217;s stock were used.&#160; </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1561" contextRef="From2022-10-01to2023-09-30" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1</strong><strong>4</strong><strong>. NET LOSS PER COMMON SHARE</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, common stock warrants and restricted stock&#160;are not included in the computation of diluted net loss per share&#160;if their effect&#160;would be anti-dilutive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following table provides a reconciliation of the numerators and denominators of the basic and diluted per-share computations: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1596" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Year ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Loss per share &#8211; basic and diluted</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Net loss available to common shareholders &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2048" contextRef="From2022-10-01to2023-09-30" name="cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">32,365,855</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2049" contextRef="From2021-10-01to2022-09-30" name="cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">37,629,803</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Weighted average shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2050" contextRef="From2022-10-01to2023-09-30" name="cvm:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">44,479,865</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2051" contextRef="From2021-10-01to2022-09-30" name="cvm:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">43,148,888</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Basic and diluted loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2052" contextRef="From2022-10-01to2023-09-30" name="cvm:EarningPerShareBasicAndDiluted" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.73</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2053" contextRef="From2021-10-01to2022-09-30" name="cvm:EarningPerShareBasicAndDiluted" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.87</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In accordance with the contingently issuable shares guidance of ASC 260, <em>Earnings Per Share</em>, the calculation of diluted net loss per share excludes the following dilutive securities because their inclusion would have been anti-dilutive as of September 30: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1597" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;&#160;&#160;&#160;&#160;&#160;&#160; 2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options and warrants&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2055" contextRef="From2022-10-01to2023-09-30_cvm_OptionsMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,850,028</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2054" contextRef="From2021-10-01to2022-09-30_cvm_OptionsMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">14,274,836</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested restricted stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2057" contextRef="From2022-10-01to2023-09-30_cvm_UnvestedRestrictedStockMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">147,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2056" contextRef="From2021-10-01to2022-09-30_cvm_UnvestedRestrictedStockMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">151,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2058" contextRef="From2022-10-01to2023-09-30" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,997,278</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2059" contextRef="From2021-10-01to2022-09-30" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">14,426,086</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1562" contextRef="From2022-10-01to2023-09-30" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>15.&#160; SUBSEQUENT EVENTS </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On November 20, 2023, the Company sold <ix:nonFraction id="fid_1848" contextRef="From2023-11-01to2023-11-20_us-gaap_SubsequentEventMember" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,490,000</ix:nonFraction> shares of common stock to a single investor at a public offering price of $<ix:nonFraction id="fid_1849" contextRef="AsOf2023-11-20_us-gaap_SubsequentEventMember" name="us-gaap:SaleOfStockPricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.00</ix:nonFraction> per share for aggregate net proceeds of approximately $<ix:nonFraction id="fid_1850" contextRef="From2023-11-01to2023-11-20_us-gaap_SubsequentEventMember" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">4.5</ix:nonFraction> million.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-26</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In accordance with Section 13 or 15(a) of the Securities Exchange Act of 1934, the Registrant has caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized on the 21st day of December 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI CORPORATION</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="width:50%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:35%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Geert Kersten</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Geert Kersten, Chief Executive Officer</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Pursuant to the requirements of the Securities Act of l934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Signature</p></td><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Title</p></td><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Date</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Geert Kersten</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Chief Executive, Principal</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">December 21, 2023</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Geert R. Kersten</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Accounting and Financial Officer and a Director</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Peter Young</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">December 21, 2023</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Dr. Peter R. Young</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Bruno Baillavoine</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">December 21, 2023</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Bruno Baillavoine</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Robert Watson</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Director</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">December 21, 2023</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Robert Watson</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Gail Naughton</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">December 21, 2023</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Gail Naughton</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CEL-SCI CORPORATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FORM 10-K</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>EXHIBITS</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>cvm_ex231.htm
<DESCRIPTION>CONSENT
<TEXT>
<html><head><title>cvm_ex231.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 23.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (File numbers 333-162039, 333-161504, 333-162792, 333-184094, 333-186103, 333-196243, 333-205444, 333-226558 and 333-265995) and Form S-8 (File numbers 333-117088, 333-140792, 333-162265, 333-179477, 333-184092, 333-198244, 333-206538, 333-214031, 333-222969, 333-228252, 333-236063, 333-237845 and 333-265994) of CEL-SCI Corporation (the Company)&nbsp;of our report dated December 21, 2023, relating to the financial statements, which appear in this Annual Report on&nbsp;Form 10-K. Our report contains an explanatory paragraph regarding the Company&#8217;s ability to continue as a going concern.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">/s/ BDO USA, P.C.&nbsp;&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Potomac, Maryland</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">December 21, 2023</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>3
<FILENAME>cvm_ex31.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>cvm_ex31.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATIONS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, Geert Kersten, of CEL-SCI Corporation, certify that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">1. </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I have reviewed this annual report on Form 10-K of CEL-SCI Corporation; </p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3. </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">4. </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">a) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">b) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">designed such internal control over financial reporting, or cause such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">c) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;&nbsp; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">d)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">5. </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): </p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">a)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">b) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">any fraud, whether or not material, that involves management or other employees who have significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">December 21, 2023 </p></td> <td style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">/s/ Geert Kersten</p></td> <td style="width:12%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Geert R. Kersten</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Principal Executive Officer</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATIONS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, Geert Kersten, of CEL-SCI Corporation, certify that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">1. </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I have reviewed this annual report on Form 10-K of CEL-SCI Corporation; </p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3. </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">4. </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">a) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">b) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">designed such internal control over financial reporting, or cause such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">c) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;&nbsp; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">d)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">5. </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): </p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">a)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">b) </p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">any fraud, whether or not material, that involves management or other employees who have significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">December 21, 2023 </p></td> <td style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">/s/ Geert Kersten</p></td> <td style="width:12%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Geert R. Kersten</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Principal Financial Officer</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>cvm_ex32.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>cvm_ex32.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 32</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In connection with the Annual Report of CEL-SCI Corporation (the &#8220;Company&#8221;) on Form 10-K for the period ending September 30, 2023 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), Geert Kersten, the Chief Executive and Principal Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(1)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">(2)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The information contained in the Report fairly presents, in all material respects the financial condition and results of the Company.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;"> <p style="margin:0px">December 21, 2023 </p></td> <td style="width:3%;"> <p style="margin:0px">By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;"> <p style="MARGIN: 0px; text-align:justify;">/s/ Geert Kersten</p></td> <td style="width:12%;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">Geert Kersten, Chief Executive and Principal</p> <p style="MARGIN: 0px; text-align:justify;">Financial and Accounting Officer</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>5
<FILENAME>cvm_ex97.htm
<DESCRIPTION>COMPENSATION RECOVERY POLICY
<TEXT>
<html><head><title>cvm_ex97.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 97</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CEL-SCI CORPORATION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Compensation Recovery Policy</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">1</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong></strong>&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>TABLE OF CONTENTS</strong> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px;background-color:#cceeff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Overview</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:9%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">3</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Section 1. Recovery Requirement</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">3</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Section 2. Incentive-Based Compensation Subject to this Policy</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">4</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Section 3. Definitions</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">4</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Section 4. Exceptions to Recovery</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Section 5. Right to Adjust Unvested Incentive-Based Compensation</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Section 6. Additional Actions in Case of Misconduct/Excessive Risk Taking/Violation of Company Policies</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Section 7. No Right to Indemnification or Insurance</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Section 8. Award Agreements and Plan Documents</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Section 9. Interpretation and Amendment of this Policy</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">7</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Section 10. Filing Requirement</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">7</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>OVERVIEW</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">This Compensation Recovery Policy (this &#8220;Policy&#8221;) of Cel-Sci Corporation (the &#8220;Company&#8221;) is effective on and after November 16, 2023 (the &#8220;Effective Date&#8221;) and was adopted in compliance with Section 811 of The NYSE American Company Guide. Certain terms shall have the meanings set forth in &#8220;Section 3. Definitions&#8221; below. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>SECTION 1. RECOVERY REQUIREMENT </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Subject to Section 4 of this Policy, in the event the Company is required to prepare an Accounting Restatement, then the Board of Directors (the &#8220;Board&#8221;) and the Compensation Committee (the &#8220;Committee&#8221;) of the Board hereby direct the Company, to the fullest extent permitted by Applicable Law, to recover from each Executive Officer (i) the amount received by an Executive Officer, if any, of Erroneously Awarded Compensation, with such recovery occurring reasonably promptly after the Restatement Date relating to such Restatement and (ii) the amount of any Incentive-Based Compensation required to be repaid by an Executive Officer in accordance with any other Applicable Law, including, without limitation, any federal or state banking law. Any recovery pursuant to this Policy shall be made on a &#8220;no fault&#8221; basis, without regard to whether the Executive Officer engaged in any misconduct or whether the Executive Officer had any personal responsibility for, or involvement in, preparation of the financial statements relating to the Accounting Restatement. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Board or the Committee may effect recovery in any manner consistent with Applicable Law including, but not limited to, (a) seeking reimbursement of all or part of Erroneously Awarded Compensation previously paid to an Executive Officer and to the extent that the Executive Officer does not reimburse such Erroneously Awarded Compensation, suing and enforcing recovery against the Executive Officer for repayment of the Erroneously Awarded Compensation, (b) cancelling prior grants of Incentive-Based Compensation, whether vested or unvested, restricted or deferred, or paid or unpaid, and the forfeiture of previously vested equity awards, (c) cancelling or setting-off against planned future grants of Incentive Based Compensation, (d) deducting all or any portion of such Erroneously Awarded Compensation from any other remuneration payable by the Company to such Executive Officer, and (e) any other method authorized by Applicable Law or contract. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Recovery of Erroneously Awarded Compensation may include the cancellation of unvested, restricted, or deferred equity awards previously granted to an Executive Officer and the required forfeiture of previously vested equity awards to the extent they constitute Erroneously Awarded Compensation subject to recovery under this Policy. The Company&#8217;s right to recovery pursuant to this Policy is not dependent on if or when the Accounting Restatement is filed with the Securities and Exchange Commission. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Without by implication limiting the foregoing, following a restatement of the Company&#8217;s financial statements, the Company also shall be entitled to recover any compensation received by the Chief Executive Officer and Chief Financial Officer that is required to be recovered by Section 304 of the Sarbanes-Oxley Act of 2002. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>SECTION 2. INCENTIVE-BASED COMPENSATION SUBJECT TO THIS POLICY </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">This Policy applies to all Incentive-Based Compensation received by each Executive Officer: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(i)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">if such Incentive-Based Compensation was received on and after the date such person became an Executive Officer of the Company;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(ii)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">if such Executive Officer served as an Executive Officer at any time during the performance period for that Incentive-Based Compensation;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(iii)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">while the Company has a class of securities listed on a national securities exchange or a national securities association; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(iv)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">during the three completed fiscal years immediately preceding the date that the Company is required to prepare an Accounting Restatement (including any transition period that results from a change in the Company&#8217;s fiscal year that is within or immediately following those three completed fiscal years; provided that a transition period of nine to 12 months is deemed to be a completed fiscal year); provided, further that notwithstanding clause (iv), this Policy applies only to Incentive-Based Compensation received by an Executive Officer on or after the Effective Date.</p></td></tr></table>&nbsp; <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This Policy shall also apply to any bonus, incentive or equity compensation paid or granted to any employee, independent contractor or outside director of the Company who is not an Executive Officer to the extent that the applicable plan document or award agreement relating to such bonus, incentive or equity compensation provides that this Policy will apply (in which case, all references to Executive Officer in this Policy shall include such employee, independent contractor or outside director). This Policy shall apply and govern Incentive-Based Compensation received by any Executive Officer, notwithstanding any contrary or supplemental term or condition in any document, plan or agreement including without limitation any employment contract, indemnification agreement, equity agreement, or equity plan document. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>SECTION 3. DEFINITIONS </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For purposes of this Policy, </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">&#8220;Accounting Restatement&#8221; means an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error (i) in previously issued financial statements that is material to the previously issued financial statements (commonly referred to as a &#8220;Big R&#8221; restatement) or (ii) that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (commonly referred to as a &#8220;little r&#8221; restatement).</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">&#8220;Applicable Law&#8221; means all legal requirements relating to the payment of compensation to any employee, outside director or independent contractor under applicable corporate laws, applicable securities laws, the rules of any exchange or inter-dealer quotation system upon which the Company&#8217;s securities are listed or quoted, any federal or state banking laws, and any other applicable law, rule or restriction.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">&#8220;Erroneously Awarded Compensation&#8221; means the amount of Incentive-Based Compensation received that exceeds the amount of Incentive-Based Compensation that otherwise would have been received by the Executive Officer had it been determined based on the restated amounts (computed without regard to any taxes paid). For Incentive-Based Compensation based on stock price or total shareholder return (&#8220;TSR&#8221;), where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in the Accounting Restatement the Company shall: (i) base the calculation of the amount on a reasonable estimate of the effect of the Accounting Restatement on the stock price or TSR upon which the Incentive-Based Compensation was received; and (ii) retain documentation of the determination of that reasonable estimate and provide such documentation to The NYSE American Stock Exchange or, if a class of securities of the Company are no longer listed on The NYSE American Stock Exchange, such other national securities exchange or national securities association on which a class of the Company&#8217;s securities are then listed for trading.</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">&#8220;Executive Officer&#8221; means the Company&#8217;s Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer, Chief Operating Officer, any vice-president of the Company, or any other person <em>who performs similar significant a policy-making function for the Company (including executive officers of a parent or subsidiary), including any executive officers identified pursuant to Item 401(b) of Regulation S-K, as determined by the Committee or the Board. </em></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"><em>&#8220;Financial Reporting Measures&#8221; means measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and any measures</em> that are derived wholly or in part from such measures. Stock price and TSR are also Financial Reporting Measures. A Financial Reporting Measure need not be presented within the Company&#8217;s financial statements or included in any of the Company&#8217;s filings with the Securities and Exchange Commission.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">&#8220;Incentive-Based Compensation&#8221; means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure (including, without limitation, any cash bonuses, restricted stock awards or restricted stock unit awards that vest based on achievement of a Financial Reporting Measure). Equity awards that vest exclusively upon completion of a specified employment period, without any performance condition, and bonus awards that are discretionary or based on subjective goals or goals unrelated to Financial Reporting Measures, do not constitute Incentive-Based Compensation.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">&#8220;received&#8221;: An Executive Officer shall be deemed to have &#8220;received&#8221; Incentive-Based Compensation in the Company&#8217;s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the payment or grant of the Incentive-Based Compensation occurs after the end of that fiscal period.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">&#8220;Restatement Date&#8221; means the earlier to occur of (i) the date the Board or the Committee (or an officer or officers of the Company authorized to take such action if Board action is not required) 5 | P a g e concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement and (ii) the date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement.</td></tr></table>&nbsp; <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>SECTION 4. EXCEPTIONS TO RECOVERY </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Notwithstanding the foregoing, the Company is not required to recover Erroneously Awarded Compensation if the Committee has made a determination that recovery would be impracticable and that: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(I)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">after the Company has made a reasonable attempt to recover such Erroneously Awarded Compensation (which has been documented and such documentation has been provided to the NYSE American Stock Exchange), the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(ii)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and regulations thereunder.</p></td></tr></table>&nbsp; <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>SECTION 5. RIGHT TO ADJUST UNVESTED INCENTIVE-BASED COMPENSATION </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If the Board or the Committee, in its sole discretion, determines that the performance metrics of outstanding but unvested Incentive-Based Compensation were established using Financial Reporting Measures that were impacted by the Accounting Restatement, the Board or the Committee, in its sole discretion, may adjust such Financial Reporting Measures or modify such Incentive-Based Compensation, in such manner as the Board or the Committee determines, in its sole discretion, is appropriate. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>SECTION 6. ADDITIONAL ACTIONS IN CASE OF MISCONDUCT/EXCESSIVE RISK TAKING/VIOLATION OF COMPANY POLICIES </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If the Board or the Committee learns of any of the following actions or inactions by an Executive Officer or other employee, outside director or independent contractor of the Company or any of its subsidiaries, then the Board and the Committee shall take, and directs the Company to take, all such actions as they deem reasonably necessary to remedy the action or inaction, prevent its recurrence and, if appropriate, based on all relevant facts and circumstances, take remedial action against the wrongdoer: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(I)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">any misconduct by an Executive Officer or other employee, outside director, or independent contractor that contributed to the Company&#8217;s having to restate its financial statements;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(ii)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">any conduct or other behavior by an Executive Officer, employee, outside director, or independent contractor in the performance of his or her duties for the Company or its subsidiaries that the Board or the Committee, in its sole discretion, has determined would constitute excessive-risk taking or that would expose the Company to inappropriate risks could lead to material financial loss (regardless of whether such material financial loss has yet occurred); or</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(iii)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">any failure by an Executive Officer, employee, outside director, or independent contractor to comply with the Company&#8217;s policies, procedures, and/or regulations (including, without limitation, the Company&#8217;s Code of Business Conduct and Ethics) in such a manner that the Board or the Committee determines, in its sole discretion, that could lead to financial or reputational damage to the Company (regardless of whether such reputational damage has yet occurred).</p></td></tr></table>&nbsp; <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In determining whether remedial action is appropriate, the Board or Committee shall take into account such factors as it deems relevant, including whether the misconduct, action, or failure to comply reflected negligence, excessive risk taking, recklessness or intentional wrongdoing. Remedial action may include dismissal and initiating legal action against the officer, termination of employment, and/or forfeiture of existing awards or clawback prior amounts paid or shares vested. In determining what action to take or to require the Company to take, the Board and the Committee may consider, among other things, penalties or punishments imposed by third parties, such as law enforcement agencies, regulators or other authorities, the impact upon the Company in any related proceeding or investigation of taking remedial action against an officer, and the cost and likely outcome of taking remedial action. The Board&#8217;s and the Committee&#8217;s power to determine the appropriate remedial action is in addition to, and not in replacement of, remedies imposed by such authorities. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>SECTION 7. NO RIGHT TO INDEMNIFICATION OR INSURANCE </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company shall not indemnify any Executive Officer against the loss of Erroneously Awarded Compensation. In addition, the Company shall not pay, or reimburse any Executive Officer for, any premiums for a third-party insurance policy purchased by the Executive Officer or any other party that would fund any of the Executive Officer&#8217;s potential recovery obligations under this Policy. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>SECTION 8. AWARD AGREEMENTS AND PLAN DOCUMENTS </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Board further directs the Company to include clawback language in each of the Company&#8217;s incentive compensation plans such that each individual who receives Incentive-Based Compensation under those plans understands and agrees that all or any portion of such Incentive-Based Compensation may be subject to recovery by the Company, and such individual may be required to repay all or any portion of such Incentive-Based Compensation, if (i) recovery of such Incentive-Based Compensation is required by this Policy, (ii) such Incentive-Based Compensation is determined to be based on materially inaccurate financial and/or performance information (which includes, but is not limited to, statements of earnings, revenues or gains); or (iii) repayment of such Incentive-Based Compensation is required by Applicable Law. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>SECTION 9. INTERPRETATION AND AMENDMENT OF THIS POLICY </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Committee (or if applicable, the Board), in its discretion, shall have the sole authority to interpret and make any determinations regarding this Policy. Any interpretation, determination, or other action made or taken by the Committee (or, if applicable, the Board) shall be final, binding, and conclusive on all interested parties. The determination of the Committee (or, if applicable, the Board) need not be uniform with respect to one or more officers. This Policy may be amended from time to time in the discretion of the Committee (or, if applicable, the Board). </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>SECTION 10. FILING REQUIREMENT </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company shall file this Policy as an exhibit to its Annual Report on Form 10-K.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">7</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cvm-20230930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 12/21/2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:cvm="http://cvm.com/20230930" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cvm.com/20230930">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://cvm.com/role/Cover" id="Cover">
        <link:definition>000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/BalanceSheets" id="BalanceSheets">
        <link:definition>000002 - Statement - BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
        <link:definition>000003 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StatementsOfOperations" id="StatementsOfOperations">
        <link:definition>000004 - Statement - STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
        <link:definition>000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
        <link:definition>000006 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/ORGANIZATION" id="ORGANIZATION">
        <link:definition>000007 - Disclosure - ORGANIZATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LIQUIDITY" id="LIQUIDITY">
        <link:definition>000008 - Disclosure - LIQUIDITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptions" id="WarrantsAndNonemployeeOptions">
        <link:definition>000010 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
        <link:definition>000011 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PATENTS" id="PATENTS">
        <link:definition>000012 - Disclosure - PATENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>000013 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/EquityBasedCompensation" id="EquityBasedCompensation">
        <link:definition>000014 - Disclosure - EQUITY-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/EmployeeBenefitPlan" id="EmployeeBenefitPlan">
        <link:definition>000015 - Disclosure - EMPLOYEE BENEFIT PLAN</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>000016 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>000017 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>000018 - Disclosure - STOCKHOLDERS EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>000019 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/NetLossPerCommonShare" id="NetLossPerCommonShare">
        <link:definition>000020 - Disclosure - NET LOSS PER COMMON SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>000021 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsTables" id="WarrantsAndNonemployeeOptionsTables">
        <link:definition>000023 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PlantPropertyAndEquipmentTables" id="PlantPropertyAndEquipmentTables">
        <link:definition>000024 - Disclosure - PLANT PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsTables" id="PatentsTables">
        <link:definition>000025 - Disclosure - PATENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <link:definition>000026 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/EquityBasedCompensationTables" id="EquityBasedCompensationTables">
        <link:definition>000027 - Disclosure - EQUITY-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
        <link:definition>000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
        <link:definition>000029 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/NetLossPerCommonShareTables" id="NetLossPerCommonShareTables">
        <link:definition>000030 - Disclosure - NET LOSS PER COMMON SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
        <link:definition>000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" id="WarrantsAndNonemployeeOptionsDetails">
        <link:definition>000032 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1" id="WarrantsAndNonemployeeOptionsDetails1">
        <link:definition>000033 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails2" id="WarrantsAndNonemployeeOptionsDetails2">
        <link:definition>000034 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails3" id="WarrantsAndNonemployeeOptionsDetails3">
        <link:definition>000035 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative" id="WarrantsAndNonemployeeOptionsDetailsNarrative">
        <link:definition>000036 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PropertyAndEquipmentDetails" id="PropertyAndEquipmentDetails">
        <link:definition>000037 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
        <link:definition>000038 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsDetails" id="PatentsDetails">
        <link:definition>000039 - Disclosure - PATENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsDetails1" id="PatentsDetails1">
        <link:definition>000040 - Disclosure - PATENTS (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsDetailsNarrative" id="PatentsDetailsNarrative">
        <link:definition>000041 - Disclosure - PATENTS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
        <link:definition>000042 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
        <link:definition>000043 - Disclosure - INCOME TAXES (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
        <link:definition>000044 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/EquityBasedCompensationDetails" id="EquityBasedCompensationDetails">
        <link:definition>000045 - Disclosure - EQUITY-BASED COMPENSATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/EquityBasedCompensationDetails1" id="EquityBasedCompensationDetails1">
        <link:definition>000046 - Disclosure - EQUITY-BASED COMPENSATION (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/EquityBasedCompensationDetails2" id="EquityBasedCompensationDetails2">
        <link:definition>000047 - Disclosure - EQUITY-BASED COMPENSATION (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/EquityBasedCompensationDetails3" id="EquityBasedCompensationDetails3">
        <link:definition>000048 - Disclosure - EQUITY-BASED COMPENSATION (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/EquityBasedCompensationDetails4" id="EquityBasedCompensationDetails4">
        <link:definition>000049 - Disclosure - EQUITY-BASED COMPENSATION (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/EquityBasedCompensationDetailsNarrative" id="EquityBasedCompensationDetailsNarrative">
        <link:definition>000050 - Disclosure - EQUITY-BASED COMPENSATION (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/EmployeeBenefitPlanDetailNarrative" id="EmployeeBenefitPlanDetailNarrative">
        <link:definition>000051 - Disclosure - EMPLOYEE BENEFIT PLAN (Detail Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <link:definition>000052 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
        <link:definition>000053 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
        <link:definition>000054 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
        <link:definition>000055 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
        <link:definition>000056 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/FairValueMeasurementsDetails" id="FairValueMeasurementsDetails">
        <link:definition>000057 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/FairValueMeasurementsDetailsNarrative" id="FairValueMeasurementsDetailsNarrative">
        <link:definition>000058 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/NetLossPerCommonShareDetails" id="NetLossPerCommonShareDetails">
        <link:definition>000059 - Disclosure - NET LOSS PER COMMON SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/NetLossPerCommonShareDetails1" id="NetLossPerCommonShareDetails1">
        <link:definition>000060 - Disclosure - NET LOSS PER COMMON SHARE (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
        <link:definition>000061 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20230930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20230930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20230930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20230930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
  <import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
  <import namespace="http://fasb.org/srt-roles/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd" />
  <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
  <import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
  <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <element id="cvm_AmountsDueToEmployeesCurrent" name="AmountsDueToEmployeesCurrent" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ModificationOfWarrants" name="ModificationOfWarrants" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_EarningPerShareBasicAndDiluted" name="EarningPerShareBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" name="WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantExercisesShares" name="WarrantExercisesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantExercisesAmount" name="WarrantExercisesAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncreaseDecreaseFromStockIssuanceCosts" name="IncreaseDecreaseFromStockIssuanceCosts" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncentiveStockForfeitedShares" name="IncentiveStockForfeitedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncentiveStockForfeitedAmount" name="IncentiveStockForfeitedAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CommonStockContributedToEmployeeBenefitPlan" name="CommonStockContributedToEmployeeBenefitPlan" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_GainLossOnReceivables" name="GainLossOnReceivables" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ProceedsFromIssuanceOfCommonStocks" name="ProceedsFromIssuanceOfCommonStocks" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ProceedsFromLandlordFundingOfLeaseImprovements" name="ProceedsFromLandlordFundingOfLeaseImprovements" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" name="PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable" name="CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_AssetsPurchasedUnderFinanceLeases" name="AssetsPurchasedUnderFinanceLeases" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncreaseDecreaseToRightOfUseAssetsAndLiabilities" name="IncreaseDecreaseToRightOfUseAssetsAndLiabilities" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinanceLeaseObligationIncludedInAccountsPayable" name="FinanceLeaseObligationIncludedInAccountsPayable" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ConsultingFeePaidWithIssuanceOfCommonStock" name="ConsultingFeePaidWithIssuanceOfCommonStock" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinancingCostsIncludedInCurrentLiabilities" name="FinancingCostsIncludedInCurrentLiabilities" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_DerivativeLiabilitiesExercised" name="DerivativeLiabilitiesExercised" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_AccruedConsultingServicesToBePaid" name="AccruedConsultingServicesToBePaid" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LiquiditydisclosureTextblock" name="LiquiditydisclosureTextblock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantsAndNonEmployeeOptionsDisclosureTextBlock" name="WarrantsAndNonEmployeeOptionsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_USTreasuryBillsPolicyTextBlock" name="USTreasuryBillsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock" name="ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock" name="ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock" name="ScheduleOfEquityWarrantsWereExercisedTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock" name="ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FiniteLivedIntangibleAssetsUsefulLife" name="FiniteLivedIntangibleAssetsUsefulLife" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_Issuedate2" name="Issuedate2" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_SharesIssuableUponExerciseOfwarrant" name="SharesIssuableUponExerciseOfwarrant" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExercisePrice" name="ExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExpirationDate1" name="ExpirationDate1" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NetLossGainOnWarrantLiabilities" name="NetLossGainOnWarrantLiabilities" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantsExercised" name="WarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExercisePriceWarrants" name="ExercisePriceWarrants" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_EquityWarrantsExercised" name="EquityWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ProceedsFromEquityWarrantsExercised" name="ProceedsFromEquityWarrantsExercised" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_EquityWarrantsExercisePrice" name="EquityWarrantsExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncrementalCostDeemedDividend" name="IncrementalCostDeemedDividend" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_StockIssuedDuringPeriodToPurchaseCommonStock" name="StockIssuedDuringPeriodToPurchaseCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_DeemedDividend11" name="DeemedDividend11" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_DeemedDividendAmount" name="DeemedDividendAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_StockOptionExercisePrice" name="StockOptionExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_VestedOptions" name="VestedOptions" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IssuedStockOfOptionsOutstanding" name="IssuedStockOfOptionsOutstanding" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CommonStockIssuedForServiceShares" name="CommonStockIssuedForServiceShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantsExpired" name="WarrantsExpired" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PrepaidExpenses" name="PrepaidExpenses" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_AccumulatedAmortization" name="AccumulatedAmortization" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_Total" name="Total" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PatentsWeightedAverageAmortizationPeriod" name="PatentsWeightedAverageAmortizationPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_AmortizationOfPatentCosts" name="AmortizationOfPatentCosts" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" name="DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LeaseLiabilities" name="LeaseLiabilities" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FixedAssetsAndIntangiblesAssets" name="FixedAssetsAndIntangiblesAssets" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_RightOfUseAssets" name="RightOfUseAssets" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FixedAssetsAndIntangibles" name="FixedAssetsAndIntangibles" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ResearchAndDevelopmentCredit" name="ResearchAndDevelopmentCredit" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ResearchAndDevelopmentCreditDescription" name="ResearchAndDevelopmentCreditDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CumulativeChangeInOwnershipPercentage" name="CumulativeChangeInOwnershipPercentage" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_DeferredTaxAssets" name="DeferredTaxAssets" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExpectedLifeOfOptionsMin1" name="ExpectedLifeOfOptionsMin1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExpectedLifeOfOptionsMax" name="ExpectedLifeOfOptionsMax" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NumberOfOptionsVested" name="NumberOfOptionsVested" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NumberOfOptionsExercised" name="NumberOfOptionsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NumberOfOptions" name="NumberOfOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageExercisePriceVested" name="WeightedAverageExercisePriceVested" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageExercisePriceExpired" name="WeightedAverageExercisePriceExpired" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" name="WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" name="WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageGrantDateFairValueVested" name="WeightedAverageGrantDateFairValueVested" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PerformanceBasedStockOptionsSharesGranted" name="PerformanceBasedStockOptionsSharesGranted" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_RemainingOutstandingFairValueOfShares" name="RemainingOutstandingFairValueOfShares" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_VestedShares" name="VestedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_TotalCompensation" name="TotalCompensation" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ParticipantCompensation" name="ParticipantCompensation" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LesseeOperatingLeaseLiabilityPayments" name="LesseeOperatingLeaseLiabilityPayments" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncrementalBorrowingDerivativeVariableRate" name="IncrementalBorrowingDerivativeVariableRate" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NetOfDiscount" name="NetOfDiscount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_AdditionalExpenses" name="AdditionalExpenses" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinancingLeaseContractualArrangement" name="FinancingLeaseContractualArrangement" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageMaturityYear" name="WeightedAverageMaturityYear" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CashPaymentToLeaseLiability" name="CashPaymentToLeaseLiability" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CashPaymentForOperatingLeases" name="CashPaymentForOperatingLeases" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageOperatingLeaseDiscountRate" name="WeightedAverageOperatingLeaseDiscountRate" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageOperatingLeaseMaturityYear" name="WeightedAverageOperatingLeaseMaturityYear" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PaymentsMadeToLandlord" name="PaymentsMadeToLandlord" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ClinicalServiceTrial" name="ClinicalServiceTrial" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_AdditionalClinicalTrial" name="AdditionalClinicalTrial" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_DeemedDividendFromModificationOfWarrants" name="DeemedDividendFromModificationOfWarrants" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_Warrant" name="Warrant" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_AggregateNetProceedsFromSaleOfSecurities" name="AggregateNetProceedsFromSaleOfSecurities" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ProceedFromIssuanceOrSaleOfEquity" name="ProceedFromIssuanceOrSaleOfEquity" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PrepaidAmountOfResold" name="PrepaidAmountOfResold" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings" name="FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageRiskFreeInterestRate" name="WeightedAverageRiskFreeInterestRate" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" name="NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" name="WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LIQUIDITYAbstract" name="LIQUIDITYAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantsAndNonemployeeOptionsAbstract" name="WarrantsAndNonemployeeOptionsAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element name="IncomeTaxMember" id="cvm_IncomeTaxMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesYMember" id="cvm_SeriesYMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesZMember" id="cvm_SeriesZMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesCCMember" id="cvm_SeriesCCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesHHMember" id="cvm_SeriesHHMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesAAMember" id="cvm_SeriesAAMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesMMMember" id="cvm_SeriesMMMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesNNMember" id="cvm_SeriesNNMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesRRMember" id="cvm_SeriesRRMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesSSMember" id="cvm_SeriesSSMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesTTMember" id="cvm_SeriesTTMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesWMember" id="cvm_SeriesWMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OutstandingMember" id="cvm_OutstandingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesZZMember" id="cvm_SeriesZZMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesBBMember" id="cvm_SeriesBBMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ExercisableMember" id="cvm_ExercisableMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="RestrictedStockAwardsMember" id="cvm_RestrictedStockAwardsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockBonusPlansMember" id="cvm_StockBonusPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockCompensationPlansMember" id="cvm_StockCompensationPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NonQualifiedStockOptionsPlansMember" id="cvm_NonQualifiedStockOptionsPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="IncentiveStockOptionPlansMember" id="cvm_IncentiveStockOptionPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="IncentiveStockBonusPlanMember" id="cvm_IncentiveStockBonusPlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesNAndXAndYWarrantsMember" id="cvm_SeriesNAndXAndYWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesMMAndNNAndUUWarrantMember" id="cvm_SeriesMMAndNNAndUUWarrantMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OfficerAndDirectorMember" id="cvm_OfficerAndDirectorMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OptionsMember" id="cvm_OptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="UnvestedRestrictedStockMember" id="cvm_UnvestedRestrictedStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesNMember" id="cvm_SeriesNMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesUUMember" id="cvm_SeriesUUMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesXMember" id="cvm_SeriesXMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultantsMember" id="cvm_ConsultantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultantsOneMember" id="cvm_ConsultantsOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="RestrictedStocksMember" id="cvm_RestrictedStocksMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultingAgreementsMember" id="cvm_ConsultingAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ErgomedMember" id="cvm_ErgomedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="LandlordMember" id="cvm_LandlordMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesCCWarrantsMember" id="cvm_SeriesCCWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesZWarrantsMember" id="cvm_SeriesZWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesAAWarrantsMember" id="cvm_SeriesAAWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesHHWarrantsMember" id="cvm_SeriesHHWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultantMember" id="cvm_ConsultantMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TwoSeptemberTwoThousendTwentyFourMember" id="cvm_TwoSeptemberTwoThousendTwentyFourMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TwoSeptemberTwoThousendTwentyFiveMember" id="cvm_TwoSeptemberTwoThousendTwentyFiveMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NonVestedOptionsMember" id="cvm_NonVestedOptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>cvm-20230930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 12/21/2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Fin Stmt Error Correction Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address Address Line 2</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm Id</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security 12b Title</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl_74165a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl_74165a" xml:lang="en-US">BALANCE SHEETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl_e03fe1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl_e03fe1" xml:lang="en-US">ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl_e1cbd2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl_e1cbd2" xml:lang="en-US">Current assets:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_cce343" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_cce343" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl_1090d0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl_1090d0" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl_b53d4a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl_b53d4a" xml:lang="en-US">Supplies used for R&amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl_1e4053" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl_1e4053" xml:lang="en-US">Deposits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_8d96c4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl_8d96c4" xml:lang="en-US">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl_8" xml:lang="en-US">[Assets, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl_433dfb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl_433dfb" xml:lang="en-US">Finance lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl_22c712" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl_22c712" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_73668d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_73668d" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_f64d51" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_f64d51" xml:lang="en-US">Patent costs, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl_36de15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl_36de15" xml:lang="en-US">Deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl_13" xml:lang="en-US">[Deposits Assets, Noncurrent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNoncurrent" xlink:to="us-gaap_InventoryNoncurrent_lbl_f4c876" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryNoncurrent_lbl_f4c876" xml:lang="en-US">Supplies used for R&amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNoncurrent" xlink:to="us-gaap_InventoryNoncurrent_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNoncurrent_lbl_14" xml:lang="en-US">[Inventory, Noncurrent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_7d1891" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl_7d1891" xml:lang="en-US">Total assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl_15" xml:lang="en-US">[Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_84fc8c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_84fc8c" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl_621c9e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl_621c9e" xml:lang="en-US">Current Liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl_41b4d1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl_41b4d1" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl_aa6000" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl_aa6000" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_AmountsDueToEmployeesCurrent" xlink:label="cvm_AmountsDueToEmployeesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AmountsDueToEmployeesCurrent" xlink:to="cvm_AmountsDueToEmployeesCurrent_lbl_377acc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AmountsDueToEmployeesCurrent_lbl_377acc" xml:lang="en-US">Due to employees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl_021650" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl_021650" xml:lang="en-US">Finance lease obligation, current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_7650a8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_7650a8" xml:lang="en-US">Operating lease obligation, current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_b39c27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl_b39c27" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl_23" xml:lang="en-US">[Liabilities, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl_11fae3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl_11fae3" xml:lang="en-US">Finance lease liabilities, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_44053c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_44053c" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl_300f60" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl_300f60" xml:lang="en-US">Other liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_01fb0e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl_01fb0e" xml:lang="en-US">Total liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl_27" xml:lang="en-US">[Liabilities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_0f86a6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_0f86a6" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl_ead4a7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl_ead4a7" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl_03275d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl_03275d" xml:lang="en-US">Preferred stock, $.01 par value; 200,000 shares authorized; 0 shares issued and outstanding Common stock, $.01 par value; 600,000,000 shares authorized; 47,422,304 and 43,448,317 shares issued and outstanding at September 30, 2023 and September 30, 2022, respectively</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl_48473d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl_48473d" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_48f9ee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_48f9ee" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_2b59a0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl_2b59a0" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl_33" xml:lang="en-US">[Stockholders' Equity Attributable to Parent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_8afa93" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_8afa93" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_34" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_34" xml:lang="en-US">[Liabilities and Equity]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl_a7351f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl_a7351f" xml:lang="en-US">Common stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl_725d3d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl_725d3d" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_8739c1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl_8739c1" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl_11d932" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl_11d932" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_75eb82" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_75eb82" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl_3a57b4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl_3a57b4" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl_28c36f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl_28c36f" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl_c0b54e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl_c0b54e" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl_0b177c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl_0b177c" xml:lang="en-US">STATEMENTS OF OPERATIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl_b00e35" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl_b00e35" xml:lang="en-US">Operating expenses:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl_66b6ad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl_66b6ad" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl_3a5889" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl_3a5889" xml:lang="en-US">General &amp; administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_bd6ead" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl_bd6ead" xml:lang="en-US">Total operating expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl_5" xml:lang="en-US">[Operating Expenses]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_a1ef7a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl_a1ef7a" xml:lang="en-US">Operating loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl_6" xml:lang="en-US">[Operating Income (Loss)]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl_29fc59" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl_29fc59" xml:lang="en-US">Gain on derivative instruments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingGainsLosses" xlink:label="us-gaap_OtherNonoperatingGainsLosses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingGainsLosses" xlink:to="us-gaap_OtherNonoperatingGainsLosses_lbl_dd1d02" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingGainsLosses_lbl_dd1d02" xml:lang="en-US">Other non-operating losses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl_5e269c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl_5e269c" xml:lang="en-US">Interest expense, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl_9" xml:lang="en-US">[Interest Expense]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl_82fe94" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl_82fe94" xml:lang="en-US">Other (expense) income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_e0491a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_e0491a" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl_11" xml:lang="en-US">[Net Income (Loss) Attributable to Parent]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ModificationOfWarrants" xlink:label="cvm_ModificationOfWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ModificationOfWarrants" xlink:to="cvm_ModificationOfWarrants_lbl_2397a0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ModificationOfWarrants_lbl_2397a0" xml:lang="en-US">Modification of warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_3d4265" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_3d4265" xml:lang="en-US">Net loss available to common shareholders</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_13" xml:lang="en-US">[Net Income (Loss) Available to Common Stockholders, Basic]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_EarningPerShareBasicAndDiluted" xlink:label="cvm_EarningPerShareBasicAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_EarningPerShareBasicAndDiluted" xlink:to="cvm_EarningPerShareBasicAndDiluted_lbl_deeb36" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_EarningPerShareBasicAndDiluted_lbl_deeb36" xml:lang="en-US">Net loss per common share - basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" xlink:label="cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" xlink:to="cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted_lbl_1b366e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted_lbl_1b366e" xml:lang="en-US">Weighted average common shares outstanding - basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl_6c782d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl_6c782d" xml:lang="en-US">STATEMENTS OF STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl_4a0f56" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl_4a0f56" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl_b89096" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl_b89096" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl_6235b6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl_6235b6" xml:lang="en-US">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl_789c86" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl_789c86" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl_dbb7a1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl_dbb7a1" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl_0e1972" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl_0e1972" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_70f5e4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl_70f5e4" xml:lang="en-US">Balance, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl_2" xml:lang="en-US">[Shares, Issued]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_9eb68d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl_9eb68d" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WarrantExercisesShares" xlink:label="cvm_WarrantExercisesShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantExercisesShares" xlink:to="cvm_WarrantExercisesShares_lbl_d8a012" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantExercisesShares_lbl_d8a012" xml:lang="en-US">Warrant exercises, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WarrantExercisesAmount" xlink:label="cvm_WarrantExercisesAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantExercisesAmount" xlink:to="cvm_WarrantExercisesAmount_lbl_b6bee9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantExercisesAmount_lbl_b6bee9" xml:lang="en-US">Warrant exercises, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl_d6b882" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl_d6b882" xml:lang="en-US">401(k) contributions paid in common stock, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl_fc3d8c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl_fc3d8c" xml:lang="en-US">401(k) contributions paid in common stock, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_b37599" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_b37599" xml:lang="en-US">Stock issued to nonemployees for service, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl_b40b7d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl_b40b7d" xml:lang="en-US">Stock issued to nonemployees for service, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl_a20772" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl_a20772" xml:lang="en-US">Equity based compensation - employees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_032a90" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_032a90" xml:lang="en-US">Option exercises, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl_0471b1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl_0471b1" xml:lang="en-US">Option exercises, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IncreaseDecreaseFromStockIssuanceCosts" xlink:label="cvm_IncreaseDecreaseFromStockIssuanceCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncreaseDecreaseFromStockIssuanceCosts" xlink:to="cvm_IncreaseDecreaseFromStockIssuanceCosts_lbl_adf231" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncreaseDecreaseFromStockIssuanceCosts_lbl_adf231" xml:lang="en-US">Share issuance costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_8964aa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_8964aa" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl_dc25f0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl_dc25f0" xml:lang="en-US">Proceeds from the sale of common stock, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl_6c6934" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl_6c6934" xml:lang="en-US">Proceeds from the sale of common stock, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IncentiveStockForfeitedShares" xlink:label="cvm_IncentiveStockForfeitedShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockForfeitedShares" xlink:to="cvm_IncentiveStockForfeitedShares_lbl_fe8df1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncentiveStockForfeitedShares_lbl_fe8df1" xml:lang="en-US">2014 Incentive Stock Forfeited, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IncentiveStockForfeitedAmount" xlink:label="cvm_IncentiveStockForfeitedAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockForfeitedAmount" xlink:to="cvm_IncentiveStockForfeitedAmount_lbl_78f03e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncentiveStockForfeitedAmount_lbl_78f03e" xml:lang="en-US">2014 Incentive Stock Forfeited, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_50bfc9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl_50bfc9" xml:lang="en-US">Balance, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_a77a23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl_a77a23" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl_c0163f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl_c0163f" xml:lang="en-US">STATEMENTS OF CASH FLOWS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_24dbab" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_24dbab" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl_bad1a4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl_bad1a4" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl_3" xml:lang="en-US">[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_e43ca6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_e43ca6" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl_ca430d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl_ca430d" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl_edb06b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl_edb06b" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_629e49" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_629e49" xml:lang="en-US">Share-based payments for services</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_cddcbc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl_cddcbc" xml:lang="en-US">Equity based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:label="cvm_CommonStockContributedToEmployeeBenefitPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:to="cvm_CommonStockContributedToEmployeeBenefitPlan_lbl_7a6003" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CommonStockContributedToEmployeeBenefitPlan_lbl_7a6003" xml:lang="en-US">Common stock contributed to 401(k) plan</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl_89364d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnInvestments_lbl_89364d" xml:lang="en-US">Gain on short term investments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnInvestments_lbl_10" xml:lang="en-US">[Gain (Loss) on Investments]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl_20a25a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl_20a25a" xml:lang="en-US">Gain on derivative instruments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl_8c22bc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl_8c22bc" xml:lang="en-US">Impairment loss on abandonment of patents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_GainLossOnReceivables" xlink:to="cvm_GainLossOnReceivables_lbl_f4f5e5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvm_GainLossOnReceivables_lbl_f4f5e5" xml:lang="en-US">Loss on Receivables</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_GainLossOnReceivables" xlink:label="cvm_GainLossOnReceivables" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_GainLossOnReceivables" xlink:to="cvm_GainLossOnReceivables_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_GainLossOnReceivables_lbl_13" xml:lang="en-US">[Loss on Receivables]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl_7e1698" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl_7e1698" xml:lang="en-US">(Increase)/decrease in assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_639173" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_639173" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_15" xml:lang="en-US">[Increase (Decrease) in Prepaid Expense]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl_fe77d4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl_fe77d4" xml:lang="en-US">Supplies used for R&amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl_16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl_16" xml:lang="en-US">[Increase (Decrease) in Inventories]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeposits" xlink:to="us-gaap_IncreaseDecreaseInDeposits_lbl_3dd1a1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeposits_lbl_3dd1a1" xml:lang="en-US">Deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeposits" xlink:label="us-gaap_IncreaseDecreaseInDeposits" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeposits" xlink:to="us-gaap_IncreaseDecreaseInDeposits_lbl_17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeposits_lbl_17" xml:lang="en-US">[Increase (Decrease) in Deposits]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl_a82b00" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl_a82b00" xml:lang="en-US">Increase/(decrease) in liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_64e6ce" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_64e6ce" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_19" xml:lang="en-US">[Increase (Decrease) in Accounts Payable]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_b1d39d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_b1d39d" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_20" xml:lang="en-US">[Increase (Decrease) in Accrued Liabilities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_512192" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_512192" xml:lang="en-US">Due to employees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_21" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_21" xml:lang="en-US">[Increase (Decrease) in Employee Related Liabilities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_b10d6e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_b10d6e" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_22" xml:lang="en-US">[Net Cash Provided by (Used in) Operating Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_6f4e43" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_6f4e43" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_lbl_0c4622" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_lbl_0c4622" xml:lang="en-US">Proceeds from maturity of U.S. Treasury Bills</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_1d63cf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_1d63cf" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_25" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_25" xml:lang="en-US">[Payments to Acquire Property, Plant, and Equipment]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_935d2d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_935d2d" xml:lang="en-US">Expenditures for patent costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_26" xml:lang="en-US">[Payments to Acquire Intangible Assets]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_2598cd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_2598cd" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_27" xml:lang="en-US">[Net Cash Provided by (Used in) Investing Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_4d3365" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_4d3365" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ProceedsFromIssuanceOfCommonStocks" xlink:label="cvm_ProceedsFromIssuanceOfCommonStocks" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ProceedsFromIssuanceOfCommonStocks" xlink:to="cvm_ProceedsFromIssuanceOfCommonStocks_lbl_7bd8ea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ProceedsFromIssuanceOfCommonStocks_lbl_7bd8ea" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl_775d31" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl_775d31" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl_30" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl_30" xml:lang="en-US">[Payments of Stock Issuance Costs]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl_81afb9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl_81afb9" xml:lang="en-US">Proceeds from the exercise of warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl_9d1485" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl_9d1485" xml:lang="en-US">Proceeds from the exercise of options</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ProceedsFromLandlordFundingOfLeaseImprovements" xlink:label="cvm_ProceedsFromLandlordFundingOfLeaseImprovements" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ProceedsFromLandlordFundingOfLeaseImprovements" xlink:to="cvm_ProceedsFromLandlordFundingOfLeaseImprovements_lbl_b5c655" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ProceedsFromLandlordFundingOfLeaseImprovements_lbl_b5c655" xml:lang="en-US">Proceeds from landlord funding of lease improvements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_6ed500" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_6ed500" xml:lang="en-US">Payments on obligations under finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_34" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_34" xml:lang="en-US">[Repayments of Debt and Lease Obligation]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_62fa60" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_62fa60" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_35" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_35" xml:lang="en-US">[Net Cash Provided by (Used in) Financing Activities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_2cf182" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_2cf182" xml:lang="en-US">NET DECREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_36" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_36" xml:lang="en-US">[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_819d1b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_819d1b" xml:lang="en-US">CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_8159f4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_8159f4" xml:lang="en-US">CASH AND CASH EQUIVALENTS, END OF YEAR</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl_531b27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl_531b27" xml:lang="en-US">SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" xlink:label="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" xlink:to="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities_lbl_8c27d1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities_lbl_8c27d1" xml:lang="en-US">Property and equipment purchases included in current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable" xlink:label="cvm_CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable" xlink:to="cvm_CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable_lbl_adf884" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable_lbl_adf884" xml:lang="en-US">Capitalized patent costs included in current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_AssetsPurchasedUnderFinanceLeases" xlink:label="cvm_AssetsPurchasedUnderFinanceLeases" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AssetsPurchasedUnderFinanceLeases" xlink:to="cvm_AssetsPurchasedUnderFinanceLeases_lbl_e6f7f5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AssetsPurchasedUnderFinanceLeases_lbl_e6f7f5" xml:lang="en-US">Assets purchased under finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IncreaseDecreaseToRightOfUseAssetsAndLiabilities" xlink:label="cvm_IncreaseDecreaseToRightOfUseAssetsAndLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncreaseDecreaseToRightOfUseAssetsAndLiabilities" xlink:to="cvm_IncreaseDecreaseToRightOfUseAssetsAndLiabilities_lbl_334d9d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncreaseDecreaseToRightOfUseAssetsAndLiabilities_lbl_334d9d" xml:lang="en-US">Changes to right of use assets and liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_FinanceLeaseObligationIncludedInAccountsPayable" xlink:label="cvm_FinanceLeaseObligationIncludedInAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseObligationIncludedInAccountsPayable" xlink:to="cvm_FinanceLeaseObligationIncludedInAccountsPayable_lbl_009c26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinanceLeaseObligationIncludedInAccountsPayable_lbl_009c26" xml:lang="en-US">Finance lease obligation included in accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ConsultingFeePaidWithIssuanceOfCommonStock" xlink:label="cvm_ConsultingFeePaidWithIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultingFeePaidWithIssuanceOfCommonStock" xlink:to="cvm_ConsultingFeePaidWithIssuanceOfCommonStock_lbl_8b636e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultingFeePaidWithIssuanceOfCommonStock_lbl_8b636e" xml:lang="en-US">Prepaid consulting services paid with issuance of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_FinancingCostsIncludedInCurrentLiabilities" xlink:label="cvm_FinancingCostsIncludedInCurrentLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinancingCostsIncludedInCurrentLiabilities" xlink:to="cvm_FinancingCostsIncludedInCurrentLiabilities_lbl_2e0f19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinancingCostsIncludedInCurrentLiabilities_lbl_2e0f19" xml:lang="en-US">Financing costs included in current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_DerivativeLiabilitiesExercised" xlink:label="cvm_DerivativeLiabilitiesExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_DerivativeLiabilitiesExercised" xlink:to="cvm_DerivativeLiabilitiesExercised_lbl_b8a5e7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_DerivativeLiabilitiesExercised_lbl_b8a5e7" xml:lang="en-US">Exercise of derivative liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_AccruedConsultingServicesToBePaid" xlink:label="cvm_AccruedConsultingServicesToBePaid" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AccruedConsultingServicesToBePaid" xlink:to="cvm_AccruedConsultingServicesToBePaid_lbl_ecd967" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AccruedConsultingServicesToBePaid_lbl_ecd967" xml:lang="en-US">Accrued consulting services to be paid with common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl_5c42cf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl_5c42cf" xml:lang="en-US">Cash paid for interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_67cdf1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_67cdf1" xml:lang="en-US">ORGANIZATION</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_1dbc8e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_1dbc8e" xml:lang="en-US">ORGANIZATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_2" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_LIQUIDITYAbstract" xlink:label="cvm_LIQUIDITYAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LIQUIDITYAbstract" xlink:to="cvm_LIQUIDITYAbstract_lbl_533da3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LIQUIDITYAbstract_lbl_533da3" xml:lang="en-US">LIQUIDITY</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LiquiditydisclosureTextblock" xlink:to="cvm_LiquiditydisclosureTextblock_lbl_cef047" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_LiquiditydisclosureTextblock_lbl_cef047" xml:lang="en-US">LIQUIDITY</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_LiquiditydisclosureTextblock" xlink:label="cvm_LiquiditydisclosureTextblock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LiquiditydisclosureTextblock" xlink:to="cvm_LiquiditydisclosureTextblock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LiquiditydisclosureTextblock_lbl_2" xml:lang="en-US">[LIQUIDITY]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl_87bcc2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl_87bcc2" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_66c723" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_66c723" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_2" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WarrantsAndNonemployeeOptionsAbstract" xlink:label="cvm_WarrantsAndNonemployeeOptionsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantsAndNonemployeeOptionsAbstract" xlink:to="cvm_WarrantsAndNonemployeeOptionsAbstract_lbl_1d8eaf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantsAndNonemployeeOptionsAbstract_lbl_1d8eaf" xml:lang="en-US">WARRANTS AND NONEMPLOYEE OPTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WarrantsAndNonEmployeeOptionsDisclosureTextBlock" xlink:label="cvm_WarrantsAndNonEmployeeOptionsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantsAndNonEmployeeOptionsDisclosureTextBlock" xlink:to="cvm_WarrantsAndNonEmployeeOptionsDisclosureTextBlock_lbl_a6b367" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantsAndNonEmployeeOptionsDisclosureTextBlock_lbl_a6b367" xml:lang="en-US">WARRANTS AND NON-EMPLOYEE OPTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl_a0ba70" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl_a0ba70" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl_72460c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl_72460c" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl_2" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl_c9f62b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl_c9f62b" xml:lang="en-US">PATENTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_0c2506" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_0c2506" xml:lang="en-US">PATENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_2" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl_091cac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl_091cac" xml:lang="en-US">INCOME TAXES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl_530e7d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl_530e7d" xml:lang="en-US">INCOME TAXES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl_2" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl_5072f9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl_5072f9" xml:lang="en-US">EQUITY-BASED COMPENSATION</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl_484407" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl_484407" xml:lang="en-US">EQUITY-BASED COMPENSATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl_2" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract_lbl_2af8da" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract_lbl_2af8da" xml:lang="en-US">EMPLOYEE BENEFIT PLAN</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl_c198ae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl_c198ae" xml:lang="en-US">EMPLOYEE BENEFIT PLAN</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl_2" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_fc8c4e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_fc8c4e" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_2" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl_ae68f8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl_ae68f8" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_5598fe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_5598fe" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_2" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl_b3f08d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl_b3f08d" xml:lang="en-US">STOCKHOLDERS EQUITY</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_6be148" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_6be148" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_2" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl_d9933b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl_d9933b" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl_8b9f0f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl_8b9f0f" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl_2" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl_78733b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl_78733b" xml:lang="en-US">NET LOSS PER COMMON SHARE</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl_726d54" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl_726d54" xml:lang="en-US">NET LOSS PER COMMON SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl_2" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl_d00613" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl_d00613" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_7541d9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_7541d9" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_2" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_ba8aa6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_ba8aa6" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_USTreasuryBillsPolicyTextBlock" xlink:label="cvm_USTreasuryBillsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_USTreasuryBillsPolicyTextBlock" xlink:to="cvm_USTreasuryBillsPolicyTextBlock_lbl_f77a69" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_USTreasuryBillsPolicyTextBlock_lbl_f77a69" xml:lang="en-US">U.S. Treasury Bills</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl_acddd2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl_acddd2" xml:lang="en-US">Supplies used for R&amp;amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_398b68" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_398b68" xml:lang="en-US">Property and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl_5a4879" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl_5a4879" xml:lang="en-US">Patents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl_b9fa1e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl_b9fa1e" xml:lang="en-US">Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl_559fa4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl_559fa4" xml:lang="en-US">Derivative Instruments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_2fde65" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_2fde65" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_3f52a9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_3f52a9" xml:lang="en-US">Research and Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl_eb2d15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl_eb2d15" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl_677587" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl_677587" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl_0148dc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl_0148dc" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl_5ee103" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl_5ee103" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl_f915b3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl_f915b3" xml:lang="en-US">Use of Estimates</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_d6b2d9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_d6b2d9" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl_bd60a7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl_bd60a7" xml:lang="en-US">Schedule of warrants and non-employee options</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock" xlink:label="cvm_ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock" xlink:to="cvm_ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock_lbl_97a35b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock_lbl_97a35b" xml:lang="en-US">Schedule of (losses)/gains on the warrant liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock" xlink:label="cvm_ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock" xlink:to="cvm_ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock_lbl_595471" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock_lbl_595471" xml:lang="en-US">Schedule of warrants recorded as liabilities were exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock" xlink:label="cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock" xlink:to="cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock_lbl_d69494" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock_lbl_d69494" xml:lang="en-US">Schedule of equity warrants were exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl_9cb290" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl_9cb290" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl_f57663" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl_f57663" xml:lang="en-US">Schedule of patents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl_d19735" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl_d19735" xml:lang="en-US">Schedule of total estimated future amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl_cf1848" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl_cf1848" xml:lang="en-US">Schedule of components of the Company's deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl_4428d3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl_4428d3" xml:lang="en-US">Schedule of federal or state current or deferred tax expense or benefit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl_196504" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl_196504" xml:lang="en-US">Schedule of expenses for options issued or vested and restricted stock awarded</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl_e1e9ea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl_e1e9ea" xml:lang="en-US">Schedule of assumptions used for fair value of each option granted</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock" xlink:label="cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock" xlink:to="cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock_lbl_ddc75d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock_lbl_ddc75d" xml:lang="en-US">Schedule of non-qualified and incentive stock option plans</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl_5b4527" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl_5b4527" xml:lang="en-US">Schedule of non vested options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl_ff4bf9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl_ff4bf9" xml:lang="en-US">Schedule of restricted common stock issued from the incentive stock bonus plan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl_52da33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl_52da33" xml:lang="en-US">Schedule of future minimum payments under finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl_5cb5e0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl_5cb5e0" xml:lang="en-US">Schedule of future minimum payments under operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl_a6bb43" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl_a6bb43" xml:lang="en-US">Schedule of fair value measurements using significant unobservable inputs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl_3795e9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl_3795e9" xml:lang="en-US">Schedule of earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl_03f22a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl_03f22a" xml:lang="en-US">Schedule of anti-dilutive securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl_0a4dac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl_0a4dac" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl_6fd1c7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl_6fd1c7" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_FiniteLivedIntangibleAssetsUsefulLife" xlink:label="cvm_FiniteLivedIntangibleAssetsUsefulLife" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FiniteLivedIntangibleAssetsUsefulLife" xlink:to="cvm_FiniteLivedIntangibleAssetsUsefulLife_lbl_eb30f0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FiniteLivedIntangibleAssetsUsefulLife_lbl_eb30f0" xml:lang="en-US">Patent Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl_c0efed" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl_c0efed" xml:lang="en-US">Fully insured amount of non-interest bearing cash balances</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl_7a679d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl_7a679d" xml:lang="en-US">Derivative Instrument Risk Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_4e9f0f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_4e9f0f" xml:lang="en-US">Related Party Transactions By Related Party Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl_05f020" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl_05f020" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesYMember" xlink:label="cvm_SeriesYMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesYMember" xlink:to="cvm_SeriesYMember_lbl_72a23c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesYMember_lbl_72a23c" xml:lang="en-US">Series Y [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesMMMember" xlink:label="cvm_SeriesMMMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesMMMember" xlink:to="cvm_SeriesMMMember_lbl_c1b54e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesMMMember_lbl_c1b54e" xml:lang="en-US">Series MM [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesNNMember" xlink:label="cvm_SeriesNNMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesNNMember" xlink:to="cvm_SeriesNNMember_lbl_03ea3f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesNNMember_lbl_03ea3f" xml:lang="en-US">Series NN [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesRRMember" xlink:label="cvm_SeriesRRMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesRRMember" xlink:to="cvm_SeriesRRMember_lbl_4e8bbd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesRRMember_lbl_4e8bbd" xml:lang="en-US">Series RR [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesSSMember" xlink:label="cvm_SeriesSSMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesSSMember" xlink:to="cvm_SeriesSSMember_lbl_698ac6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesSSMember_lbl_698ac6" xml:lang="en-US">Series SS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesTTMember" xlink:label="cvm_SeriesTTMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesTTMember" xlink:to="cvm_SeriesTTMember_lbl_e494ad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesTTMember_lbl_e494ad" xml:lang="en-US">Series TT [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesNMember" xlink:label="cvm_SeriesNMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesNMember" xlink:to="cvm_SeriesNMember_lbl_59b343" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesNMember_lbl_59b343" xml:lang="en-US">Series N [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesUUMember" xlink:label="cvm_SeriesUUMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesUUMember" xlink:to="cvm_SeriesUUMember_lbl_066a18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesUUMember_lbl_066a18" xml:lang="en-US">Series UU [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesXMember" xlink:label="cvm_SeriesXMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesXMember" xlink:to="cvm_SeriesXMember_lbl_8dfb35" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesXMember_lbl_8dfb35" xml:lang="en-US">Series X [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ConsultantsMember" xlink:label="cvm_ConsultantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantsMember" xlink:to="cvm_ConsultantsMember_lbl_767b67" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultantsMember_lbl_767b67" xml:lang="en-US">Consultants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl_0b387e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl_0b387e" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ConsultantsOneMember" xlink:label="cvm_ConsultantsOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantsOneMember" xlink:to="cvm_ConsultantsOneMember_lbl_d37db6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultantsOneMember_lbl_d37db6" xml:lang="en-US">Consultants 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl_f3364a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl_f3364a" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_Issuedate2" xlink:label="cvm_Issuedate2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_Issuedate2" xlink:to="cvm_Issuedate2_lbl_e1da1b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_Issuedate2_lbl_e1da1b" xml:lang="en-US">Issue Date</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SharesIssuableUponExerciseOfwarrant" xlink:label="cvm_SharesIssuableUponExerciseOfwarrant" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SharesIssuableUponExerciseOfwarrant" xlink:to="cvm_SharesIssuableUponExerciseOfwarrant_lbl_218b3c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SharesIssuableUponExerciseOfwarrant_lbl_218b3c" xml:lang="en-US">Shares Issuable upon Exercise of Warrant</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ExercisePrice" xlink:label="cvm_ExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExercisePrice" xlink:to="cvm_ExercisePrice_lbl_3b544f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExercisePrice_lbl_3b544f" xml:lang="en-US">Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ExpirationDate1" xlink:label="cvm_ExpirationDate1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExpirationDate1" xlink:to="cvm_ExpirationDate1_lbl_dee73d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExpirationDate1_lbl_dee73d" xml:lang="en-US">Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl_632bc4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl_632bc4" xml:lang="en-US">Class Of Warrant Or Right Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesZMember" xlink:label="cvm_SeriesZMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesZMember" xlink:to="cvm_SeriesZMember_lbl_da465a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesZMember_lbl_da465a" xml:lang="en-US">Series Z [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesCCMember" xlink:label="cvm_SeriesCCMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesCCMember" xlink:to="cvm_SeriesCCMember_lbl_9e03a3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesCCMember_lbl_9e03a3" xml:lang="en-US">Series CC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesHHMember" xlink:label="cvm_SeriesHHMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesHHMember" xlink:to="cvm_SeriesHHMember_lbl_5e0d98" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesHHMember_lbl_5e0d98" xml:lang="en-US">Series HH [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesAAMember" xlink:label="cvm_SeriesAAMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesAAMember" xlink:to="cvm_SeriesAAMember_lbl_d2320a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesAAMember_lbl_d2320a" xml:lang="en-US">Series AA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesWMember" xlink:label="cvm_SeriesWMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesWMember" xlink:to="cvm_SeriesWMember_lbl_5c4794" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesWMember_lbl_5c4794" xml:lang="en-US">Series W [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesZZMember" xlink:label="cvm_SeriesZZMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesZZMember" xlink:to="cvm_SeriesZZMember_lbl_e9b202" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesZZMember_lbl_e9b202" xml:lang="en-US">Series ZZ [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesBBMember" xlink:label="cvm_SeriesBBMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesBBMember" xlink:to="cvm_SeriesBBMember_lbl_0b7955" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesBBMember_lbl_0b7955" xml:lang="en-US">Series BB [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_NetLossGainOnWarrantLiabilities" xlink:label="cvm_NetLossGainOnWarrantLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NetLossGainOnWarrantLiabilities" xlink:to="cvm_NetLossGainOnWarrantLiabilities_lbl_6fa9e1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NetLossGainOnWarrantLiabilities_lbl_6fa9e1" xml:lang="en-US">Net (loss) gain on warrant liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl_15abd8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl_15abd8" xml:lang="en-US">Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WarrantsExercised" xlink:label="cvm_WarrantsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantsExercised" xlink:to="cvm_WarrantsExercised_lbl_91730c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantsExercised_lbl_91730c" xml:lang="en-US">Warrants Exercised</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExercisePriceWarrants" xlink:to="cvm_ExercisePriceWarrants_lbl_e5ca01" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_ExercisePriceWarrants_lbl_e5ca01" xml:lang="en-US">Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ExercisePriceWarrants" xlink:label="cvm_ExercisePriceWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExercisePriceWarrants" xlink:to="cvm_ExercisePriceWarrants_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExercisePriceWarrants_lbl_4" xml:lang="en-US">[Exercise Price]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_EquityWarrantsExercised" xlink:label="cvm_EquityWarrantsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_EquityWarrantsExercised" xlink:to="cvm_EquityWarrantsExercised_lbl_83b1cb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_EquityWarrantsExercised_lbl_83b1cb" xml:lang="en-US">Equity Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ProceedsFromEquityWarrantsExercised" xlink:label="cvm_ProceedsFromEquityWarrantsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ProceedsFromEquityWarrantsExercised" xlink:to="cvm_ProceedsFromEquityWarrantsExercised_lbl_dff9a3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ProceedsFromEquityWarrantsExercised_lbl_dff9a3" xml:lang="en-US">Proceeds from Equity Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_EquityWarrantsExercisePrice" xlink:label="cvm_EquityWarrantsExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_EquityWarrantsExercisePrice" xlink:to="cvm_EquityWarrantsExercisePrice_lbl_d14f2d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_EquityWarrantsExercisePrice_lbl_d14f2d" xml:lang="en-US">Equity Warrants Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl_bcf193" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl_bcf193" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl_bf69a6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl_bf69a6" xml:lang="en-US">Plan Name Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl_c99d94" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl_c99d94" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl_3ce4a0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl_3ce4a0" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl_3fff91" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_MaximumMember_lbl_3fff91" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_RestrictedStocksMember" xlink:label="cvm_RestrictedStocksMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_RestrictedStocksMember" xlink:to="cvm_RestrictedStocksMember_lbl_4a0ac4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_RestrictedStocksMember_lbl_4a0ac4" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantsMember" xlink:to="cvm_ConsultantsMember_lbl_33ba4c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_ConsultantsMember_lbl_33ba4c" xml:lang="en-US">Consultants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ConsultingAgreementsMember" xlink:label="cvm_ConsultingAgreementsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultingAgreementsMember" xlink:to="cvm_ConsultingAgreementsMember_lbl_73b1fd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultingAgreementsMember_lbl_73b1fd" xml:lang="en-US">Consulting Agreements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl_648673" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_MinimumMember_lbl_648673" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesCCWarrantsMember" xlink:label="cvm_SeriesCCWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesCCWarrantsMember" xlink:to="cvm_SeriesCCWarrantsMember_lbl_e0494d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesCCWarrantsMember_lbl_e0494d" xml:lang="en-US">Series CC Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesZWarrantsMember" xlink:label="cvm_SeriesZWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesZWarrantsMember" xlink:to="cvm_SeriesZWarrantsMember_lbl_945ac9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesZWarrantsMember_lbl_945ac9" xml:lang="en-US">Series Z Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesAAWarrantsMember" xlink:label="cvm_SeriesAAWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesAAWarrantsMember" xlink:to="cvm_SeriesAAWarrantsMember_lbl_686150" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesAAWarrantsMember_lbl_686150" xml:lang="en-US">Series AA Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesHHWarrantsMember" xlink:label="cvm_SeriesHHWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesHHWarrantsMember" xlink:to="cvm_SeriesHHWarrantsMember_lbl_2919ef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesHHWarrantsMember_lbl_2919ef" xml:lang="en-US">Series HH Warrants [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesRRMember" xlink:to="cvm_SeriesRRMember_lbl_434a9b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_SeriesRRMember_lbl_434a9b" xml:lang="en-US">Series RR [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="cvm_NonQualifiedStockOptionsPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NonQualifiedStockOptionsPlansMember" xlink:to="cvm_NonQualifiedStockOptionsPlansMember_lbl_1506fa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NonQualifiedStockOptionsPlansMember_lbl_1506fa" xml:lang="en-US">Non Qualified Stock Options Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ConsultantMember" xlink:label="cvm_ConsultantMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantMember" xlink:to="cvm_ConsultantMember_lbl_8f7d14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultantMember_lbl_8f7d14" xml:lang="en-US">Consultant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_TwoSeptemberTwoThousendTwentyFourMember" xlink:label="cvm_TwoSeptemberTwoThousendTwentyFourMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_TwoSeptemberTwoThousendTwentyFourMember" xlink:to="cvm_TwoSeptemberTwoThousendTwentyFourMember_lbl_2a061a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_TwoSeptemberTwoThousendTwentyFourMember_lbl_2a061a" xml:lang="en-US">September 2, 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_TwoSeptemberTwoThousendTwentyFiveMember" xlink:label="cvm_TwoSeptemberTwoThousendTwentyFiveMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_TwoSeptemberTwoThousendTwentyFiveMember" xlink:to="cvm_TwoSeptemberTwoThousendTwentyFiveMember_lbl_1454f3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_TwoSeptemberTwoThousendTwentyFiveMember_lbl_1454f3" xml:lang="en-US">September 2, 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IncrementalCostDeemedDividend" xlink:label="cvm_IncrementalCostDeemedDividend" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncrementalCostDeemedDividend" xlink:to="cvm_IncrementalCostDeemedDividend_lbl_090a8f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncrementalCostDeemedDividend_lbl_090a8f" xml:lang="en-US">Incremental cost</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_StockIssuedDuringPeriodToPurchaseCommonStock" xlink:label="cvm_StockIssuedDuringPeriodToPurchaseCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockIssuedDuringPeriodToPurchaseCommonStock" xlink:to="cvm_StockIssuedDuringPeriodToPurchaseCommonStock_lbl_0da33e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockIssuedDuringPeriodToPurchaseCommonStock_lbl_0da33e" xml:lang="en-US">Issued options to purchase common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_DeemedDividend11" xlink:label="cvm_DeemedDividend11" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_DeemedDividend11" xlink:to="cvm_DeemedDividend11_lbl_d1bad9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_DeemedDividend11_lbl_d1bad9" xml:lang="en-US">Deemed dividend</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_DeemedDividendAmount" xlink:label="cvm_DeemedDividendAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_DeemedDividendAmount" xlink:to="cvm_DeemedDividendAmount_lbl_c2e676" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_DeemedDividendAmount_lbl_c2e676" xml:lang="en-US">Total Deemed dividend</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_StockOptionExercisePrice" xlink:label="cvm_StockOptionExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockOptionExercisePrice" xlink:to="cvm_StockOptionExercisePrice_lbl_8f7c56" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockOptionExercisePrice_lbl_8f7c56" xml:lang="en-US">Exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_VestedOptions" xlink:label="cvm_VestedOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_VestedOptions" xlink:to="cvm_VestedOptions_lbl_b821c5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_VestedOptions_lbl_b821c5" xml:lang="en-US">Options vested</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IssuedStockOfOptionsOutstanding" xlink:label="cvm_IssuedStockOfOptionsOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IssuedStockOfOptionsOutstanding" xlink:to="cvm_IssuedStockOfOptionsOutstanding_lbl_7042bb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IssuedStockOfOptionsOutstanding_lbl_7042bb" xml:lang="en-US">Options issued of payment for services remained outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_CommonStockIssuedForServiceShares" xlink:label="cvm_CommonStockIssuedForServiceShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CommonStockIssuedForServiceShares" xlink:to="cvm_CommonStockIssuedForServiceShares_lbl_ae027f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CommonStockIssuedForServiceShares_lbl_ae027f" xml:lang="en-US">Common stock issued for service, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WarrantsExpired" xlink:label="cvm_WarrantsExpired" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantsExpired" xlink:to="cvm_WarrantsExpired_lbl_c7cf51" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantsExpired_lbl_c7cf51" xml:lang="en-US">Warrants expired</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExercisePriceWarrants" xlink:to="cvm_ExercisePriceWarrants_lbl_95d9a2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvm_ExercisePriceWarrants_lbl_95d9a2" xml:lang="en-US">Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl_d6c08f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl_d6c08f" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl_90473b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl_90473b" xml:lang="en-US">Total expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PrepaidExpenses" xlink:to="cvm_PrepaidExpenses_lbl_2c297d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_PrepaidExpenses_lbl_2c297d" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_PrepaidExpenses" xlink:label="cvm_PrepaidExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PrepaidExpenses" xlink:to="cvm_PrepaidExpenses_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PrepaidExpenses_lbl_14" xml:lang="en-US">[Prepaid expenses]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl_6afe4d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl_6afe4d" xml:lang="en-US">Stock prices per share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FixturesAndEquipmentGross" xlink:label="us-gaap_FixturesAndEquipmentGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FixturesAndEquipmentGross" xlink:to="us-gaap_FixturesAndEquipmentGross_lbl_8d84bd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FixturesAndEquipmentGross_lbl_8d84bd" xml:lang="en-US">Research equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl_d98522" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl_d98522" xml:lang="en-US">Furniture and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl_4c6114" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl_4c6114" xml:lang="en-US">Leasehold improvements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl_2b8ffd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl_2b8ffd" xml:lang="en-US">Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_a1bb7d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_a1bb7d" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_6" xml:lang="en-US">[Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_5fa6e7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_5fa6e7" xml:lang="en-US">Net property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl_1d423a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl_1d423a" xml:lang="en-US">Depreciation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedPatentsGross_lbl_3d5280" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedPatentsGross_lbl_3d5280" xml:lang="en-US">Patents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="us-gaap_FiniteLivedPatentsGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedPatentsGross_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedPatentsGross_lbl_2" xml:lang="en-US">[Finite-Lived Patents, Gross]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_AccumulatedAmortization" xlink:label="cvm_AccumulatedAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AccumulatedAmortization" xlink:to="cvm_AccumulatedAmortization_lbl_b55a35" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AccumulatedAmortization_lbl_b55a35" xml:lang="en-US">Accumulated amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="us-gaap_OtherIntangibleAssetsNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsNet" xlink:to="us-gaap_OtherIntangibleAssetsNet_lbl_c55132" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl_c55132" xml:lang="en-US">Patents, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_def733" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_def733" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_79acad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_79acad" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_c7c121" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_c7c121" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_e54e21" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_e54e21" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_8102d8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_8102d8" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_2c71d7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_2c71d7" xml:lang="en-US">Thereafter</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_Total" xlink:to="cvm_Total_lbl_6c835d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_Total_lbl_6c835d" xml:lang="en-US">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_Total" xlink:label="cvm_Total" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_Total" xlink:to="cvm_Total_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_Total_lbl_8" xml:lang="en-US">[Total]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_PatentsWeightedAverageAmortizationPeriod" xlink:label="cvm_PatentsWeightedAverageAmortizationPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PatentsWeightedAverageAmortizationPeriod" xlink:to="cvm_PatentsWeightedAverageAmortizationPeriod_lbl_218270" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PatentsWeightedAverageAmortizationPeriod_lbl_218270" xml:lang="en-US">Weighted average amortization period for patents</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_AmortizationOfPatentCosts" xlink:label="cvm_AmortizationOfPatentCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AmortizationOfPatentCosts" xlink:to="cvm_AmortizationOfPatentCosts_lbl_972990" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AmortizationOfPatentCosts_lbl_972990" xml:lang="en-US">Amortization of patent costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl_a2e8f9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl_a2e8f9" xml:lang="en-US">NOL carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" xlink:label="cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" xlink:to="cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd_lbl_f54ffe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd_lbl_f54ffe" xml:lang="en-US">Capitalized R&amp;D</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl_c10108" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl_c10108" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_LeaseLiabilities" xlink:label="cvm_LeaseLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LeaseLiabilities" xlink:to="cvm_LeaseLiabilities_lbl_d0cd0d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LeaseLiabilities_lbl_d0cd0d" xml:lang="en-US">Lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl_fbcfde" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl_fbcfde" xml:lang="en-US">R&amp;D credit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl_b82001" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl_b82001" xml:lang="en-US">Vacation and other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FixedAssetsAndIntangiblesAssets" xlink:to="cvm_FixedAssetsAndIntangiblesAssets_lbl_fc3159" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_FixedAssetsAndIntangiblesAssets_lbl_fc3159" xml:lang="en-US">Fixed assets and intangibles</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_FixedAssetsAndIntangiblesAssets" xlink:label="cvm_FixedAssetsAndIntangiblesAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FixedAssetsAndIntangiblesAssets" xlink:to="cvm_FixedAssetsAndIntangiblesAssets_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FixedAssetsAndIntangiblesAssets_lbl_8" xml:lang="en-US">[Fixed assets and intangibles]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl_92afaf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl_92afaf" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_RightOfUseAssets" xlink:label="cvm_RightOfUseAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_RightOfUseAssets" xlink:to="cvm_RightOfUseAssets_lbl_f753e2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_RightOfUseAssets_lbl_f753e2" xml:lang="en-US">Right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_FixedAssetsAndIntangibles" xlink:label="cvm_FixedAssetsAndIntangibles" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FixedAssetsAndIntangibles" xlink:to="cvm_FixedAssetsAndIntangibles_lbl_73cb7f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FixedAssetsAndIntangibles_lbl_73cb7f" xml:lang="en-US">Fixed assets and intangibles</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl_9f3eb8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl_9f3eb8" xml:lang="en-US">Total deferred tax liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl_12" xml:lang="en-US">[Deferred Tax Liabilities, Net]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl_948cb1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl_948cb1" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl_587fc4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl_587fc4" xml:lang="en-US">Valuation allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl_14" xml:lang="en-US">[Deferred Tax Assets, Valuation Allowance]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl_3c9425" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl_3c9425" xml:lang="en-US">Ending Balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl_d4fcb1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl_d4fcb1" xml:lang="en-US">Federal Rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl_fc2121" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl_fc2121" xml:lang="en-US">State tax rate change</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl_46580e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl_46580e" xml:lang="en-US">State tax rate, net of federal benefit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl_5487ad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl_5487ad" xml:lang="en-US">Other adjustments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl_8a91ee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl_8a91ee" xml:lang="en-US">Permanent differences</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl_6e9ed1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl_6e9ed1" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl_2fdca7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl_2fdca7" xml:lang="en-US">Effective tax rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl_cb8335" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl_cb8335" xml:lang="en-US">Tax Credit Carryforward Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IncomeTaxMember" xlink:label="cvm_IncomeTaxMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncomeTaxMember" xlink:to="cvm_IncomeTaxMember_lbl_5aeafa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncomeTaxMember_lbl_5aeafa" xml:lang="en-US">Income Tax [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ResearchAndDevelopmentCredit" xlink:label="cvm_ResearchAndDevelopmentCredit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ResearchAndDevelopmentCredit" xlink:to="cvm_ResearchAndDevelopmentCredit_lbl_fc28d7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ResearchAndDevelopmentCredit_lbl_fc28d7" xml:lang="en-US">Research and development credit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl_5e8908" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl_5e8908" xml:lang="en-US">NOL carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ResearchAndDevelopmentCreditDescription" xlink:label="cvm_ResearchAndDevelopmentCreditDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ResearchAndDevelopmentCreditDescription" xlink:to="cvm_ResearchAndDevelopmentCreditDescription_lbl_8c80ff" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ResearchAndDevelopmentCreditDescription_lbl_8c80ff" xml:lang="en-US">Research and development credit, description</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_CumulativeChangeInOwnershipPercentage" xlink:label="cvm_CumulativeChangeInOwnershipPercentage" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CumulativeChangeInOwnershipPercentage" xlink:to="cvm_CumulativeChangeInOwnershipPercentage_lbl_aa59b5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CumulativeChangeInOwnershipPercentage_lbl_aa59b5" xml:lang="en-US">Cumulative change in ownership percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="us-gaap_TaxCreditCarryforwardDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl_d7ce27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl_d7ce27" xml:lang="en-US">Net operating loss carryforwards, description</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_DeferredTaxAssets" xlink:label="cvm_DeferredTaxAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_DeferredTaxAssets" xlink:to="cvm_DeferredTaxAssets_lbl_1cdce9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_DeferredTaxAssets_lbl_1cdce9" xml:lang="en-US">Deferred tax asset</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl_d1042d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl_d1042d" xml:lang="en-US">Employees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_aa4526" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_aa4526" xml:lang="en-US">Non-employees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl_a7464d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl_a7464d" xml:lang="en-US">Expected stock price volatility, min</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl_539e24" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl_539e24" xml:lang="en-US">Expected stock price volatility, max</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl_cb9218" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl_cb9218" xml:lang="en-US">Risk-free interest rate, min</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl_8b4dd9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl_8b4dd9" xml:lang="en-US">Risk-free interest rate, max</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ExpectedLifeOfOptionsMin1" xlink:label="cvm_ExpectedLifeOfOptionsMin1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExpectedLifeOfOptionsMin1" xlink:to="cvm_ExpectedLifeOfOptionsMin1_lbl_1dc9ed" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExpectedLifeOfOptionsMin1_lbl_1dc9ed" xml:lang="en-US">Expected life of options, min</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ExpectedLifeOfOptionsMax" xlink:label="cvm_ExpectedLifeOfOptionsMax" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExpectedLifeOfOptionsMax" xlink:to="cvm_ExpectedLifeOfOptionsMax_lbl_9501bc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExpectedLifeOfOptionsMax_lbl_9501bc" xml:lang="en-US">Expected life of options, max</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl_cd47c1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl_cd47c1" xml:lang="en-US">Expected dividend yield</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl_faca80" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl_faca80" xml:lang="en-US">Option Indexed To Issuers Equity Equity Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl_52e472" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl_52e472" xml:lang="en-US">Subsidiary Sale Of Stock Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_OutstandingMember" xlink:label="cvm_OutstandingMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OutstandingMember" xlink:to="cvm_OutstandingMember_lbl_0f0180" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OutstandingMember_lbl_0f0180" xml:lang="en-US">Outstanding [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ExercisableMember" xlink:label="cvm_ExercisableMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExercisableMember" xlink:to="cvm_ExercisableMember_lbl_c9169b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExercisableMember_lbl_c9169b" xml:lang="en-US">Exercisable [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_4eec46" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_4eec46" xml:lang="en-US">Number of Options Outstanding, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_2" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_cfff82" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_cfff82" xml:lang="en-US">Number of Options Granted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_c9763b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_c9763b" xml:lang="en-US">Number of Options Exercised</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_90a266" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_90a266" xml:lang="en-US">Number of Options Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_5" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_406f55" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_406f55" xml:lang="en-US">Number of Options Forfeited</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_d27d9d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_d27d9d" xml:lang="en-US">Number of Options Outstanding, Ending</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_81f013" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_81f013" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_8" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_2546f1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_2546f1" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_f5e8e8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_f5e8e8" xml:lang="en-US">Weighted Average Exercise Price Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl_e57e87" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl_e57e87" xml:lang="en-US">Weighted Average Exercise Price Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl_d158cd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl_d158cd" xml:lang="en-US">Weighted Average Exercise Price Expired</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_50e337" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_50e337" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Ending</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl_1b1077" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl_1b1077" xml:lang="en-US">Weighted Average Remaining Contractual Life Term (Years) Outstanding, Beginning</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl_32fa56" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl_32fa56" xml:lang="en-US">Weighted Average Remaining Contractual Life Term (Years) Outstanding, Ending</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl_15" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl_48e71e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl_48e71e" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl_16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl_16" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised" xlink:label="cvm_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised" xlink:to="cvm_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised_lbl_eb0dc0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised_lbl_eb0dc0" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Exercised</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl_38ecb4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl_38ecb4" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Ending</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NumberOfOptionsVested" xlink:to="cvm_NumberOfOptionsVested_lbl_9567d7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="cvm_NumberOfOptionsVested_lbl_9567d7" xml:lang="en-US">Number of Options Vested</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_NumberOfOptionsVested" xlink:label="cvm_NumberOfOptionsVested" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NumberOfOptionsVested" xlink:to="cvm_NumberOfOptionsVested_lbl_19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NumberOfOptionsVested_lbl_19" xml:lang="en-US">[Number of Options Vested]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NumberOfOptionsExercised" xlink:to="cvm_NumberOfOptionsExercised_lbl_46a60a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_NumberOfOptionsExercised_lbl_46a60a" xml:lang="en-US">Number of Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_NumberOfOptionsExercised" xlink:label="cvm_NumberOfOptionsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NumberOfOptionsExercised" xlink:to="cvm_NumberOfOptionsExercised_lbl_20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NumberOfOptionsExercised_lbl_20" xml:lang="en-US">[Number of Options Exercised]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NumberOfOptions" xlink:to="cvm_NumberOfOptions_lbl_386496" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_NumberOfOptions_lbl_386496" xml:lang="en-US">Number of Options Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_NumberOfOptions" xlink:label="cvm_NumberOfOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NumberOfOptions" xlink:to="cvm_NumberOfOptions_lbl_21" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NumberOfOptions_lbl_21" xml:lang="en-US">[Number of Options Expired]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageExercisePriceVested" xlink:to="cvm_WeightedAverageExercisePriceVested_lbl_82139a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="cvm_WeightedAverageExercisePriceVested_lbl_82139a" xml:lang="en-US">Weighted Average Exercise Price Vested</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageExercisePriceVested" xlink:label="cvm_WeightedAverageExercisePriceVested" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageExercisePriceVested" xlink:to="cvm_WeightedAverageExercisePriceVested_lbl_22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageExercisePriceVested_lbl_22" xml:lang="en-US">[Weighted Average Exercise Price Vested]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageExercisePriceExpired" xlink:to="cvm_WeightedAverageExercisePriceExpired_lbl_c2a16b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_WeightedAverageExercisePriceExpired_lbl_c2a16b" xml:lang="en-US">Weighted Average Exercise Price Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageExercisePriceExpired" xlink:label="cvm_WeightedAverageExercisePriceExpired" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageExercisePriceExpired" xlink:to="cvm_WeightedAverageExercisePriceExpired_lbl_23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageExercisePriceExpired_lbl_23" xml:lang="en-US">[Weighted Average Exercise Price Expired]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" xlink:to="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning_lbl_1a2a08" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning_lbl_1a2a08" xml:lang="en-US">Weighted Average Remaining Contractual Life Term (Years) Outstanding, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" xlink:label="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" xlink:to="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning_lbl_24" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning_lbl_24" xml:lang="en-US">[Weighted Average Remaining Contractual Life Term (Years) Outstanding, Beginning]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" xlink:label="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" xlink:to="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding_lbl_dfc878" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding_lbl_dfc878" xml:lang="en-US">Weighted Average Remaining Contractual Life Term (Years) Outstanding, Ending</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl_638c75" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl_638c75" xml:lang="en-US">Number of unvested options, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl_2" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl_165a4d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl_165a4d" xml:lang="en-US">Vested options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl_3" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl_14d8d9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl_14d8d9" xml:lang="en-US">Granted options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl_0a7ea2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl_0a7ea2" xml:lang="en-US">Forfeited options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl_5" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl_c02a20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl_c02a20" xml:lang="en-US">Number of unvested options, Ending</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl_5ec007" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl_5ec007" xml:lang="en-US">Weighted Average Grant Date Fair Value, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl_7" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageGrantDateFairValueVested" xlink:label="cvm_WeightedAverageGrantDateFairValueVested" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageGrantDateFairValueVested" xlink:to="cvm_WeightedAverageGrantDateFairValueVested_lbl_50ad7d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageGrantDateFairValueVested_lbl_50ad7d" xml:lang="en-US">Weighted Average Grant Date Fair Value, vested</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl_93d549" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl_93d549" xml:lang="en-US">Weighted Average Grant Date Fair Value, Ending</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_RestrictedStockAwardsMember" xlink:label="cvm_RestrictedStockAwardsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_RestrictedStockAwardsMember" xlink:to="cvm_RestrictedStockAwardsMember_lbl_048882" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_RestrictedStockAwardsMember_lbl_048882" xml:lang="en-US">Restricted Stock Awards [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl_eb4de6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl_eb4de6" xml:lang="en-US">Number of unvested shares, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl_2" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl_c387c9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl_c387c9" xml:lang="en-US">Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl_3" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl_04e947" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl_04e947" xml:lang="en-US">Vested shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl_ebef10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl_ebef10" xml:lang="en-US">Number of unvested shares, Ending</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl_f2b04d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl_f2b04d" xml:lang="en-US">Weighted Average Grant Date Fair Value, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl_6" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl_6b8b7f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl_6b8b7f" xml:lang="en-US">Weighted Average Grant Date Fair Value, Ending</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_StockBonusPlansMember" xlink:label="cvm_StockBonusPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockBonusPlansMember" xlink:to="cvm_StockBonusPlansMember_lbl_cc86db" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockBonusPlansMember_lbl_cc86db" xml:lang="en-US">Stock Bonus Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_StockCompensationPlansMember" xlink:label="cvm_StockCompensationPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockCompensationPlansMember" xlink:to="cvm_StockCompensationPlansMember_lbl_9908bf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockCompensationPlansMember_lbl_9908bf" xml:lang="en-US">Stock Compensation Plans [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NonQualifiedStockOptionsPlansMember" xlink:to="cvm_NonQualifiedStockOptionsPlansMember_lbl_7fd8bb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_NonQualifiedStockOptionsPlansMember_lbl_7fd8bb" xml:lang="en-US">Non-Qualified Stock Options Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IncentiveStockOptionPlansMember" xlink:label="cvm_IncentiveStockOptionPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockOptionPlansMember" xlink:to="cvm_IncentiveStockOptionPlansMember_lbl_4c17c6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncentiveStockOptionPlansMember_lbl_4c17c6" xml:lang="en-US">Incentive Stock Option Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IncentiveStockBonusPlanMember" xlink:label="cvm_IncentiveStockBonusPlanMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockBonusPlanMember" xlink:to="cvm_IncentiveStockBonusPlanMember_lbl_1ee75b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncentiveStockBonusPlanMember_lbl_1ee75b" xml:lang="en-US">Incentive Stock Bonus Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_NonVestedOptionsMember" xlink:label="cvm_NonVestedOptionsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NonVestedOptionsMember" xlink:to="cvm_NonVestedOptionsMember_lbl_250842" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NonVestedOptionsMember_lbl_250842" xml:lang="en-US">Non Vested Options [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl_7fdd01" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl_7fdd01" xml:lang="en-US">Total compensation cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl_ba0d26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl_ba0d26" xml:lang="en-US">Weighted-average period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_618cd9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl_618cd9" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl_f88b1c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl_f88b1c" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl_57e9fc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl_57e9fc" xml:lang="en-US">Issuance of common stock options authorized shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_PerformanceBasedStockOptionsSharesGranted" xlink:label="cvm_PerformanceBasedStockOptionsSharesGranted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PerformanceBasedStockOptionsSharesGranted" xlink:to="cvm_PerformanceBasedStockOptionsSharesGranted_lbl_e62858" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PerformanceBasedStockOptionsSharesGranted_lbl_e62858" xml:lang="en-US">Performance based stock options shares granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:to="us-gaap_OptionIndexedToIssuersEquityStrikePrice1_lbl_852887" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1_lbl_852887" xml:lang="en-US">Stock price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockDescription" xlink:label="us-gaap_ConversionOfStockDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockDescription" xlink:to="us-gaap_ConversionOfStockDescription_lbl_9db560" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockDescription_lbl_9db560" xml:lang="en-US">Stock options vest description</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_RemainingOutstandingFairValueOfShares" xlink:label="cvm_RemainingOutstandingFairValueOfShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_RemainingOutstandingFairValueOfShares" xlink:to="cvm_RemainingOutstandingFairValueOfShares_lbl_432d9c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_RemainingOutstandingFairValueOfShares_lbl_432d9c" xml:lang="en-US">Grant date fair value remaining outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_VestedShares" xlink:to="cvm_VestedShares_lbl_06fd17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_VestedShares_lbl_06fd17" xml:lang="en-US">Vested shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_VestedShares" xlink:label="cvm_VestedShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_VestedShares" xlink:to="cvm_VestedShares_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_VestedShares_lbl_12" xml:lang="en-US">[Vested shares]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationEquity" xlink:label="us-gaap_DeferredCompensationEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationEquity" xlink:to="us-gaap_DeferredCompensationEquity_lbl_3f4f11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationEquity_lbl_3f4f11" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl_37f066" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl_37f066" xml:lang="en-US">Expense for Company's contribution to employee benefit plan</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_TotalCompensation" xlink:label="cvm_TotalCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_TotalCompensation" xlink:to="cvm_TotalCompensation_lbl_3f476d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_TotalCompensation_lbl_3f476d" xml:lang="en-US">Total compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ParticipantCompensation" xlink:label="cvm_ParticipantCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ParticipantCompensation" xlink:to="cvm_ParticipantCompensation_lbl_a258c7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ParticipantCompensation_lbl_a258c7" xml:lang="en-US">Participant compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl_83d151" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl_83d151" xml:lang="en-US">Shares issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_600260" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_600260" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_2" xml:lang="en-US">[Finance Lease, Liability, to be Paid, Year One]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_89ea09" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_89ea09" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_3" xml:lang="en-US">[Finance Lease, Liability, to be Paid, Year Two]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_308844" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_308844" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_4" xml:lang="en-US">[Finance Lease, Liability, to be Paid, Year Three]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl_58d2fa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl_58d2fa" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl_5" xml:lang="en-US">[Finance Lease, Liability, to be Paid, Year Four]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl_1ab2cf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl_1ab2cf" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl_6" xml:lang="en-US">[Finance Lease, Liability, to be Paid, Year Five]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl_6f17cc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl_6f17cc" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_lbl_7" xml:lang="en-US">[Finance Lease, Liability, to be Paid, after Year Five]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_0b0720" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_0b0720" xml:lang="en-US">Total Future Minimum Lease Obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_c9794e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_c9794e" xml:lang="en-US">Less: Imputed Interest On Financing Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_9" xml:lang="en-US">[Finance Lease, Liability, Undiscounted Excess Amount]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl_ba8665" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl_ba8665" xml:lang="en-US">Net present value of lease finance lease obligations - current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent_lbl_8ba307" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl_8ba307" xml:lang="en-US">Net present value of lease finance lease obligations - non-current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_cbb4d9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_cbb4d9" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_2" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year One]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_55ca17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_55ca17" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_3" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Two]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_aa72df" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_aa72df" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_4" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Three]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_39d163" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_39d163" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_5" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Four]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_070a8e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_070a8e" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_6" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Five]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_75b2e2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_75b2e2" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_7" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, after Year Five]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LesseeOperatingLeaseLiabilityPayments" xlink:to="cvm_LesseeOperatingLeaseLiabilityPayments_lbl_25f730" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_LesseeOperatingLeaseLiabilityPayments_lbl_25f730" xml:lang="en-US">Total Future Minimum Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_LesseeOperatingLeaseLiabilityPayments" xlink:label="cvm_LesseeOperatingLeaseLiabilityPayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LesseeOperatingLeaseLiabilityPayments" xlink:to="cvm_LesseeOperatingLeaseLiabilityPayments_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LesseeOperatingLeaseLiabilityPayments_lbl_8" xml:lang="en-US">[Total Future Minimum Lease Obligation]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_9899c6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_9899c6" xml:lang="en-US">Less Imputed Interest On Operating Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_9" xml:lang="en-US">[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent_lbl_659102" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl_659102" xml:lang="en-US">Net present value of operating lease obligation - non-current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl_78e3ba" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl_78e3ba" xml:lang="en-US">Net present value of operating lease obligation - current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl_554cc0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl_554cc0" xml:lang="en-US">Title Of Individual Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl_9d8470" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl_9d8470" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ErgomedMember" xlink:label="cvm_ErgomedMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ErgomedMember" xlink:to="cvm_ErgomedMember_lbl_cae2f1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ErgomedMember_lbl_cae2f1" xml:lang="en-US">Ergomed [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_LandlordMember" xlink:label="cvm_LandlordMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LandlordMember" xlink:to="cvm_LandlordMember_lbl_d3d051" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LandlordMember_lbl_d3d051" xml:lang="en-US">Landlord [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAgreementsMember" xlink:to="us-gaap_LeaseAgreementsMember_lbl_44d3a8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAgreementsMember_lbl_44d3a8" xml:lang="en-US">Lease Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenseMember" xlink:to="us-gaap_OperatingExpenseMember_lbl_844729" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenseMember_lbl_844729" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IncrementalBorrowingDerivativeVariableRate" xlink:label="cvm_IncrementalBorrowingDerivativeVariableRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncrementalBorrowingDerivativeVariableRate" xlink:to="cvm_IncrementalBorrowingDerivativeVariableRate_lbl_c2c0c8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncrementalBorrowingDerivativeVariableRate_lbl_c2c0c8" xml:lang="en-US">Incremental borrowing, derivative variable rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl_44ffae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl_44ffae" xml:lang="en-US">Research and development expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_NetOfDiscount" xlink:label="cvm_NetOfDiscount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NetOfDiscount" xlink:to="cvm_NetOfDiscount_lbl_ee4dc8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NetOfDiscount_lbl_ee4dc8" xml:lang="en-US">Net of discount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases" xlink:label="us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases" xlink:to="us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases_lbl_db95ba" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases_lbl_db95ba" xml:lang="en-US">Lease description</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_AdditionalExpenses" xlink:label="cvm_AdditionalExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AdditionalExpenses" xlink:to="cvm_AdditionalExpenses_lbl_d255c9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AdditionalExpenses_lbl_d255c9" xml:lang="en-US">Additional expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_FinancingLeaseContractualArrangement" xlink:label="cvm_FinancingLeaseContractualArrangement" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinancingLeaseContractualArrangement" xlink:to="cvm_FinancingLeaseContractualArrangement_lbl_94cc13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinancingLeaseContractualArrangement_lbl_94cc13" xml:lang="en-US">Financing arrangement</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageMaturityYear" xlink:label="cvm_WeightedAverageMaturityYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageMaturityYear" xlink:to="cvm_WeightedAverageMaturityYear_lbl_ea6c72" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageMaturityYear_lbl_ea6c72" xml:lang="en-US">Weighted average maturity year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl_4bfccf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl_4bfccf" xml:lang="en-US">Finance lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl_9" xml:lang="en-US">[Finance Lease, Right-of-Use Asset, Amortization]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl_926b69" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl_926b69" xml:lang="en-US">Finance lease liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl_89b1c2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl_89b1c2" xml:lang="en-US">Finance lease liability, current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl_104e9f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl_104e9f" xml:lang="en-US">Depreciation expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl_0ef396" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl_0ef396" xml:lang="en-US">Interest payment to lease liability</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_CashPaymentToLeaseLiability" xlink:label="cvm_CashPaymentToLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CashPaymentToLeaseLiability" xlink:to="cvm_CashPaymentToLeaseLiability_lbl_bab511" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CashPaymentToLeaseLiability_lbl_bab511" xml:lang="en-US">Cash payment to lease liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:label="us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:to="us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_lbl_e6af9a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_lbl_e6af9a" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_CashPaymentForOperatingLeases" xlink:label="cvm_CashPaymentForOperatingLeases" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CashPaymentForOperatingLeases" xlink:to="cvm_CashPaymentForOperatingLeases_lbl_944f6c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CashPaymentForOperatingLeases_lbl_944f6c" xml:lang="en-US">Cash payment for operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageOperatingLeaseDiscountRate" xlink:label="cvm_WeightedAverageOperatingLeaseDiscountRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageOperatingLeaseDiscountRate" xlink:to="cvm_WeightedAverageOperatingLeaseDiscountRate_lbl_05250a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageOperatingLeaseDiscountRate_lbl_05250a" xml:lang="en-US">Weighted average operating lease discount rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_227416" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_227416" xml:lang="en-US">Operating lease liability, current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl_782700" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl_782700" xml:lang="en-US">Operating lease liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl_ae6816" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl_ae6816" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl_20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl_20" xml:lang="en-US">[Operating Lease, Right-of-Use Asset, Amortization Expense]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageOperatingLeaseMaturityYear" xlink:label="cvm_WeightedAverageOperatingLeaseMaturityYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageOperatingLeaseMaturityYear" xlink:to="cvm_WeightedAverageOperatingLeaseMaturityYear_lbl_4979b6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageOperatingLeaseMaturityYear_lbl_4979b6" xml:lang="en-US">Weighted average operating lease maturity year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl_340e83" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl_340e83" xml:lang="en-US">Lease expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_PaymentsMadeToLandlord" xlink:label="cvm_PaymentsMadeToLandlord" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PaymentsMadeToLandlord" xlink:to="cvm_PaymentsMadeToLandlord_lbl_024847" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PaymentsMadeToLandlord_lbl_024847" xml:lang="en-US">Payments Made to Landlord</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ClinicalServiceTrial" xlink:label="cvm_ClinicalServiceTrial" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ClinicalServiceTrial" xlink:to="cvm_ClinicalServiceTrial_lbl_c64452" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ClinicalServiceTrial_lbl_c64452" xml:lang="en-US">Clinical service trial</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_AdditionalClinicalTrial" xlink:label="cvm_AdditionalClinicalTrial" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AdditionalClinicalTrial" xlink:to="cvm_AdditionalClinicalTrial_lbl_f4538e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AdditionalClinicalTrial_lbl_f4538e" xml:lang="en-US">Additional clinical trial</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesNAndXAndYWarrantsMember" xlink:label="cvm_SeriesNAndXAndYWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesNAndXAndYWarrantsMember" xlink:to="cvm_SeriesNAndXAndYWarrantsMember_lbl_e36a30" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesNAndXAndYWarrantsMember_lbl_e36a30" xml:lang="en-US">Series N and X and Y Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesMMAndNNAndUUWarrantMember" xlink:label="cvm_SeriesMMAndNNAndUUWarrantMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesMMAndNNAndUUWarrantMember" xlink:to="cvm_SeriesMMAndNNAndUUWarrantMember_lbl_3697dc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesMMAndNNAndUUWarrantMember_lbl_3697dc" xml:lang="en-US">Series MM and NN and UU Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_OfficerAndDirectorMember" xlink:label="cvm_OfficerAndDirectorMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OfficerAndDirectorMember" xlink:to="cvm_OfficerAndDirectorMember_lbl_1a0f9c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OfficerAndDirectorMember_lbl_1a0f9c" xml:lang="en-US">Officer and Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_DeemedDividendFromModificationOfWarrants" xlink:label="cvm_DeemedDividendFromModificationOfWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_DeemedDividendFromModificationOfWarrants" xlink:to="cvm_DeemedDividendFromModificationOfWarrants_lbl_0d1c54" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_DeemedDividendFromModificationOfWarrants_lbl_0d1c54" xml:lang="en-US">Deemed dividend from modification of warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_Warrant" xlink:label="cvm_Warrant" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_Warrant" xlink:to="cvm_Warrant_lbl_2989ea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_Warrant_lbl_2989ea" xml:lang="en-US">Warrant extensions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_a28e74" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl_a28e74" xml:lang="en-US">Common stock shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_AggregateNetProceedsFromSaleOfSecurities" xlink:label="cvm_AggregateNetProceedsFromSaleOfSecurities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AggregateNetProceedsFromSaleOfSecurities" xlink:to="cvm_AggregateNetProceedsFromSaleOfSecurities_lbl_0b00ed" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AggregateNetProceedsFromSaleOfSecurities_lbl_0b00ed" xml:lang="en-US">Aggregate net proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl_085d5a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl_085d5a" xml:lang="en-US">Public offering price per share</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ProceedFromIssuanceOrSaleOfEquity" xlink:label="cvm_ProceedFromIssuanceOrSaleOfEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ProceedFromIssuanceOrSaleOfEquity" xlink:to="cvm_ProceedFromIssuanceOrSaleOfEquity_lbl_21c311" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ProceedFromIssuanceOrSaleOfEquity_lbl_21c311" xml:lang="en-US">Proceeds from issuance of warrant</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl_26024f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl_26024f" xml:lang="en-US">Warrants exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_PrepaidAmountOfResold" xlink:label="cvm_PrepaidAmountOfResold" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PrepaidAmountOfResold" xlink:to="cvm_PrepaidAmountOfResold_lbl_a20082" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PrepaidAmountOfResold_lbl_a20082" xml:lang="en-US">Prepaid of resold amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl_0ab144" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl_0ab144" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl_2" xml:lang="en-US">[Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl_cc3ec5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl_cc3ec5" xml:lang="en-US">Issuances</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_lbl_17f602" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_lbl_17f602" xml:lang="en-US">Exercises</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_lbl_4" xml:lang="en-US">[Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings" xlink:label="cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings" xlink:to="cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings_lbl_68e3ab" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings_lbl_68e3ab" xml:lang="en-US">Net realized and unrealized derivative loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl_39d636" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl_39d636" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl_51e55c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl_51e55c" xml:lang="en-US">Unrealized gain on short-term T-bills</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageRiskFreeInterestRate" xlink:label="cvm_WeightedAverageRiskFreeInterestRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageRiskFreeInterestRate" xlink:to="cvm_WeightedAverageRiskFreeInterestRate_lbl_1f19d7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageRiskFreeInterestRate_lbl_1f19d7" xml:lang="en-US">Weighted average risk free interest rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl_e57d0a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl_e57d0a" xml:lang="en-US">Loss per share - basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:label="cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:to="cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_lbl_de02bd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_lbl_de02bd" xml:lang="en-US">Net loss available to common shareholders - basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:label="cvm_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:to="cvm_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_lbl_e0bb97" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_lbl_e0bb97" xml:lang="en-US">Weighted average shares outstanding - basic and diluted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_EarningPerShareBasicAndDiluted" xlink:to="cvm_EarningPerShareBasicAndDiluted_lbl_220d7d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_EarningPerShareBasicAndDiluted_lbl_220d7d" xml:lang="en-US">Basic and diluted loss per common share</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_OptionsMember" xlink:label="cvm_OptionsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OptionsMember" xlink:to="cvm_OptionsMember_lbl_0180b0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OptionsMember_lbl_0180b0" xml:lang="en-US">Options and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_UnvestedRestrictedStockMember" xlink:label="cvm_UnvestedRestrictedStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_UnvestedRestrictedStockMember" xlink:to="cvm_UnvestedRestrictedStockMember_lbl_4a1a30" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_UnvestedRestrictedStockMember_lbl_4a1a30" xml:lang="en-US">Unvested Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_05836a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_05836a" xml:lang="en-US">Antidilutive securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl_ef5346" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl_ef5346" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl_720286" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl_720286" xml:lang="en-US">Subsequent Event Member</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl_7dab32" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl_7dab32" xml:lang="en-US">Sale of common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl_facc1e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl_facc1e" xml:lang="en-US">Share public offering price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_fc750b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_fc750b" xml:lang="en-US">Aggregate net proceeds from sale of common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="cvm_NetLossGainOnWarrantLiabilities" xlink:to="cvm_NetLossGainOnWarrantLiabilities_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="cvm_NetLossGainOnWarrantLiabilities_d">Amount of increase in the fair value of derivatives recognized in the income statement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="cvm_CommonStockIssuedForServiceShares" xlink:to="cvm_CommonStockIssuedForServiceShares_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="cvm_CommonStockIssuedForServiceShares_d">Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="cvm_WarrantsExpired" xlink:to="cvm_WarrantsExpired_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="cvm_WarrantsExpired_d">Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>cvm-20230930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 12/21/2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cvm.com/role/Cover" xlink:href="cvm-20230930.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BalanceSheets" xlink:href="cvm-20230930.xsd#BalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BalanceSheetsParenthetical" xlink:href="cvm-20230930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfOperations" xlink:href="cvm-20230930.xsd#StatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfStockholdersEquity" xlink:href="cvm-20230930.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfCashFlows" xlink:href="cvm-20230930.xsd#StatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/ORGANIZATION" xlink:href="cvm-20230930.xsd#ORGANIZATION" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LIQUIDITY" xlink:href="cvm-20230930.xsd#LIQUIDITY" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="cvm-20230930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptions" xlink:href="cvm-20230930.xsd#WarrantsAndNonemployeeOptions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PropertyAndEquipment" xlink:href="cvm-20230930.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PATENTS" xlink:href="cvm-20230930.xsd#PATENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxes" xlink:href="cvm-20230930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensation" xlink:href="cvm-20230930.xsd#EquityBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EmployeeBenefitPlan" xlink:href="cvm-20230930.xsd#EmployeeBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingencies" xlink:href="cvm-20230930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactions" xlink:href="cvm-20230930.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquity" xlink:href="cvm-20230930.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurements" xlink:href="cvm-20230930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShare" xlink:href="cvm-20230930.xsd#NetLossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEvents" xlink:href="cvm-20230930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20230930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsTables" xlink:href="cvm-20230930.xsd#WarrantsAndNonemployeeOptionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PlantPropertyAndEquipmentTables" xlink:href="cvm-20230930.xsd#PlantPropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsTables" xlink:href="cvm-20230930.xsd#PatentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesTables" xlink:href="cvm-20230930.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationTables" xlink:href="cvm-20230930.xsd#EquityBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20230930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsTables" xlink:href="cvm-20230930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareTables" xlink:href="cvm-20230930.xsd#NetLossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="cvm-20230930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" xlink:href="cvm-20230930.xsd#WarrantsAndNonemployeeOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1" xlink:href="cvm-20230930.xsd#WarrantsAndNonemployeeOptionsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails2" xlink:href="cvm-20230930.xsd#WarrantsAndNonemployeeOptionsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails3" xlink:href="cvm-20230930.xsd#WarrantsAndNonemployeeOptionsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative" xlink:href="cvm-20230930.xsd#WarrantsAndNonemployeeOptionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PropertyAndEquipmentDetails" xlink:href="cvm-20230930.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="cvm-20230930.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails" xlink:href="cvm-20230930.xsd#PatentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails1" xlink:href="cvm-20230930.xsd#PatentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetailsNarrative" xlink:href="cvm-20230930.xsd#PatentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesDetails" xlink:href="cvm-20230930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesDetails1" xlink:href="cvm-20230930.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesDetailsNarrative" xlink:href="cvm-20230930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails" xlink:href="cvm-20230930.xsd#EquityBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails1" xlink:href="cvm-20230930.xsd#EquityBasedCompensationDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails2" xlink:href="cvm-20230930.xsd#EquityBasedCompensationDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails3" xlink:href="cvm-20230930.xsd#EquityBasedCompensationDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails4" xlink:href="cvm-20230930.xsd#EquityBasedCompensationDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetailsNarrative" xlink:href="cvm-20230930.xsd#EquityBasedCompensationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EmployeeBenefitPlanDetailNarrative" xlink:href="cvm-20230930.xsd#EmployeeBenefitPlanDetailNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20230930.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20230930.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20230930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cvm-20230930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:href="cvm-20230930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsDetails" xlink:href="cvm-20230930.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsDetailsNarrative" xlink:href="cvm-20230930.xsd#FairValueMeasurementsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareDetails" xlink:href="cvm-20230930.xsd#NetLossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareDetails1" xlink:href="cvm-20230930.xsd#NetLossPerCommonShareDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:href="cvm-20230930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/BalanceSheets" xlink:title="000002 - Statement - BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDepositsAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaapInventoryNoncurrent" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapInventoryNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_AmountsDueToEmployeesCurrent" xlink:label="loc_cvmAmountsDueToEmployeesCurrent" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_cvmAmountsDueToEmployeesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
    <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
    <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
    <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
    <link:calculationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/BalanceSheetsParenthetical" xlink:title="000003 - Statement - BALANCE SHEETS (Parenthetical)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfOperations" xlink:title="000004 - Statement - STATEMENTS OF OPERATIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingGainsLosses" xlink:label="loc_us-gaapOtherNonoperatingGainsLosses" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingGainsLosses" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ModificationOfWarrants" xlink:label="loc_cvmModificationOfWarrants" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_cvmModificationOfWarrants" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfStockholdersEquity" xlink:title="000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfCashFlows" xlink:title="000006 - Statement - STATEMENTS OF CASH FLOWS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOtherNoncashExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:label="loc_cvmCommonStockContributedToEmployeeBenefitPlan" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cvmCommonStockContributedToEmployeeBenefitPlan" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_GainLossOnReceivables" xlink:label="loc_cvmGainLossOnReceivables" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cvmGainLossOnReceivables" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeposits" xlink:label="loc_us-gaapIncreaseDecreaseInDeposits" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeposits" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfOtherInvestments" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfOtherInvestments" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
    <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ProceedsFromLandlordFundingOfLeaseImprovements" xlink:label="loc_cvmProceedsFromLandlordFundingOfLeaseImprovements" />
    <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_cvmProceedsFromLandlordFundingOfLeaseImprovements" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" />
    <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ProceedsFromIssuanceOfCommonStocks" xlink:label="loc_cvmProceedsFromIssuanceOfCommonStocks" />
    <link:calculationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_cvmProceedsFromIssuanceOfCommonStocks" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:calculationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/ORGANIZATION" xlink:title="000007 - Disclosure - ORGANIZATION" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LIQUIDITY" xlink:title="000008 - Disclosure - LIQUIDITY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptions" xlink:title="000010 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PropertyAndEquipment" xlink:title="000011 - Disclosure - PROPERTY AND EQUIPMENT" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PATENTS" xlink:title="000012 - Disclosure - PATENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxes" xlink:title="000013 - Disclosure - INCOME TAXES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensation" xlink:title="000014 - Disclosure - EQUITY-BASED COMPENSATION" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/EmployeeBenefitPlan" xlink:title="000015 - Disclosure - EMPLOYEE BENEFIT PLAN" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingencies" xlink:title="000016 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactions" xlink:title="000017 - Disclosure - RELATED PARTY TRANSACTIONS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquity" xlink:title="000018 - Disclosure - STOCKHOLDERS EQUITY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurements" xlink:title="000019 - Disclosure - FAIR VALUE MEASUREMENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShare" xlink:title="000020 - Disclosure - NET LOSS PER COMMON SHARE" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEvents" xlink:title="000021 - Disclosure - SUBSEQUENT EVENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsTables" xlink:title="000023 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PlantPropertyAndEquipmentTables" xlink:title="000024 - Disclosure - PLANT PROPERTY AND EQUIPMENT (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsTables" xlink:title="000025 - Disclosure - PATENTS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesTables" xlink:title="000026 - Disclosure - INCOME TAXES (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationTables" xlink:title="000027 - Disclosure - EQUITY-BASED COMPENSATION (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:title="000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsTables" xlink:title="000029 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareTables" xlink:title="000030 - Disclosure - NET LOSS PER COMMON SHARE (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" xlink:title="000032 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1" xlink:title="000033 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails2" xlink:title="000034 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details 2)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails3" xlink:title="000035 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details 3)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative" xlink:title="000036 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PropertyAndEquipmentDetails" xlink:title="000037 - Disclosure - PROPERTY AND EQUIPMENT (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="000038 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails" xlink:title="000039 - Disclosure - PATENTS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails1" xlink:title="000040 - Disclosure - PATENTS (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetailsNarrative" xlink:title="000041 - Disclosure - PATENTS (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesDetails" xlink:title="000042 - Disclosure - INCOME TAXES (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesDetails1" xlink:title="000043 - Disclosure - INCOME TAXES (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesDetailsNarrative" xlink:title="000044 - Disclosure - INCOME TAXES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails" xlink:title="000045 - Disclosure - EQUITY-BASED COMPENSATION (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails1" xlink:title="000046 - Disclosure - EQUITY-BASED COMPENSATION (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails2" xlink:title="000047 - Disclosure - EQUITY-BASED COMPENSATION (Details 2)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails3" xlink:title="000048 - Disclosure - EQUITY-BASED COMPENSATION (Details 3)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails4" xlink:title="000049 - Disclosure - EQUITY-BASED COMPENSATION (Details 4)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetailsNarrative" xlink:title="000050 - Disclosure - EQUITY-BASED COMPENSATION (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/EmployeeBenefitPlanDetailNarrative" xlink:title="000051 - Disclosure - EMPLOYEE BENEFIT PLAN (Detail Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:title="000052 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:title="000053 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000054 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="000055 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:title="000056 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsDetails" xlink:title="000057 - Disclosure - FAIR VALUE MEASUREMENTS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="000058 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareDetails" xlink:title="000059 - Disclosure - NET LOSS PER COMMON SHARE (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareDetails1" xlink:title="000060 - Disclosure - NET LOSS PER COMMON SHARE (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:title="000061 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>cvm-20230930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 12/21/2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cvm.com/role/Cover" xlink:href="cvm-20230930.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BalanceSheets" xlink:href="cvm-20230930.xsd#BalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BalanceSheetsParenthetical" xlink:href="cvm-20230930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfOperations" xlink:href="cvm-20230930.xsd#StatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfStockholdersEquity" xlink:href="cvm-20230930.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfCashFlows" xlink:href="cvm-20230930.xsd#StatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/ORGANIZATION" xlink:href="cvm-20230930.xsd#ORGANIZATION" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LIQUIDITY" xlink:href="cvm-20230930.xsd#LIQUIDITY" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="cvm-20230930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptions" xlink:href="cvm-20230930.xsd#WarrantsAndNonemployeeOptions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PropertyAndEquipment" xlink:href="cvm-20230930.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PATENTS" xlink:href="cvm-20230930.xsd#PATENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxes" xlink:href="cvm-20230930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensation" xlink:href="cvm-20230930.xsd#EquityBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EmployeeBenefitPlan" xlink:href="cvm-20230930.xsd#EmployeeBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingencies" xlink:href="cvm-20230930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactions" xlink:href="cvm-20230930.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquity" xlink:href="cvm-20230930.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurements" xlink:href="cvm-20230930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShare" xlink:href="cvm-20230930.xsd#NetLossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEvents" xlink:href="cvm-20230930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20230930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsTables" xlink:href="cvm-20230930.xsd#WarrantsAndNonemployeeOptionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PlantPropertyAndEquipmentTables" xlink:href="cvm-20230930.xsd#PlantPropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsTables" xlink:href="cvm-20230930.xsd#PatentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesTables" xlink:href="cvm-20230930.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationTables" xlink:href="cvm-20230930.xsd#EquityBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20230930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsTables" xlink:href="cvm-20230930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareTables" xlink:href="cvm-20230930.xsd#NetLossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="cvm-20230930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" xlink:href="cvm-20230930.xsd#WarrantsAndNonemployeeOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1" xlink:href="cvm-20230930.xsd#WarrantsAndNonemployeeOptionsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails2" xlink:href="cvm-20230930.xsd#WarrantsAndNonemployeeOptionsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails3" xlink:href="cvm-20230930.xsd#WarrantsAndNonemployeeOptionsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative" xlink:href="cvm-20230930.xsd#WarrantsAndNonemployeeOptionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PropertyAndEquipmentDetails" xlink:href="cvm-20230930.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="cvm-20230930.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails" xlink:href="cvm-20230930.xsd#PatentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails1" xlink:href="cvm-20230930.xsd#PatentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetailsNarrative" xlink:href="cvm-20230930.xsd#PatentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesDetails" xlink:href="cvm-20230930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesDetails1" xlink:href="cvm-20230930.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesDetailsNarrative" xlink:href="cvm-20230930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails" xlink:href="cvm-20230930.xsd#EquityBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails1" xlink:href="cvm-20230930.xsd#EquityBasedCompensationDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails2" xlink:href="cvm-20230930.xsd#EquityBasedCompensationDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails3" xlink:href="cvm-20230930.xsd#EquityBasedCompensationDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails4" xlink:href="cvm-20230930.xsd#EquityBasedCompensationDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetailsNarrative" xlink:href="cvm-20230930.xsd#EquityBasedCompensationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EmployeeBenefitPlanDetailNarrative" xlink:href="cvm-20230930.xsd#EmployeeBenefitPlanDetailNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20230930.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20230930.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20230930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cvm-20230930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:href="cvm-20230930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsDetails" xlink:href="cvm-20230930.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsDetailsNarrative" xlink:href="cvm-20230930.xsd#FairValueMeasurementsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareDetails" xlink:href="cvm-20230930.xsd#NetLossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareDetails1" xlink:href="cvm-20230930.xsd#NetLossPerCommonShareDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:href="cvm-20230930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/BalanceSheets" xlink:title="000002 - Statement - BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_2e40f6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_a398ff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_2e40f6" xlink:to="loc_us-gaapAssetsAbstract_a398ff" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_5162f5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract_a398ff" xlink:to="loc_us-gaapAssetsCurrentAbstract_5162f5" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f05344" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_5162f5" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f05344" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_713e94" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_5162f5" xlink:to="loc_us-gaapPrepaidExpenseCurrent_713e94" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet_4f452e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_5162f5" xlink:to="loc_us-gaapInventoryNet_4f452e" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent_e4fe09" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_5162f5" xlink:to="loc_us-gaapDepositsAssetsCurrent_e4fe09" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_87f0be" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_5162f5" xlink:to="loc_us-gaapAssetsCurrent_87f0be" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset_9b2903" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_5162f5" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset_9b2903" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_c99eeb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_5162f5" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_c99eeb" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_2dcd7f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_5162f5" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_2dcd7f" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_f50130" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_5162f5" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_f50130" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent_61e052" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_5162f5" xlink:to="loc_us-gaapDepositsAssetsNoncurrent_61e052" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaapInventoryNoncurrent_18e224" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_5162f5" xlink:to="loc_us-gaapInventoryNoncurrent_18e224" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_80e324" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_5162f5" xlink:to="loc_us-gaapAssets_80e324" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_74876d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_5162f5" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_74876d" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_9df810" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_74876d" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_9df810" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_6dd0dd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_9df810" xlink:to="loc_us-gaapAccountsPayableCurrent_6dd0dd" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_9f6aa0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_9df810" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_9f6aa0" order="18" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_AmountsDueToEmployeesCurrent" xlink:label="loc_cvmAmountsDueToEmployeesCurrent_d8ca15" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_9df810" xlink:to="loc_cvmAmountsDueToEmployeesCurrent_d8ca15" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent_8fd165" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_9df810" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent_8fd165" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_65ef4a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_9df810" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_65ef4a" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_eb52bf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_9df810" xlink:to="loc_us-gaapLiabilitiesCurrent_eb52bf" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent_8c0274" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_9df810" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent_8c0274" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_757841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_9df810" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_757841" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent_afa9db" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_9df810" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent_afa9db" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_e31bfb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_9df810" xlink:to="loc_us-gaapLiabilities_e31bfb" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_1d0ed2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_9df810" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_1d0ed2" order="27" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_c10dc9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_1d0ed2" xlink:to="loc_us-gaapStockholdersEquityAbstract_c10dc9" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_7d5928" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_c10dc9" xlink:to="loc_us-gaapCommonStockValue_7d5928" order="29" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_a31e74" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_c10dc9" xlink:to="loc_us-gaapAdditionalPaidInCapital_a31e74" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_e25804" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_c10dc9" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_e25804" order="31" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_fccab5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_c10dc9" xlink:to="loc_us-gaapStockholdersEquity_fccab5" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_95a06c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_c10dc9" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_95a06c" order="33" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/BalanceSheetsParenthetical" xlink:title="000003 - Statement - BALANCE SHEETS (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_7ee78a" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_6a8f1d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_7ee78a" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_6a8f1d" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_1422b7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_7ee78a" xlink:to="loc_us-gaapCommonStockSharesAuthorized_1422b7" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_631678" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_7ee78a" xlink:to="loc_us-gaapCommonStockSharesIssued_631678" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_af9207" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_7ee78a" xlink:to="loc_us-gaapCommonStockSharesOutstanding_af9207" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_8926b1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_7ee78a" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_8926b1" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_86b209" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_7ee78a" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_86b209" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_f1c89b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_7ee78a" xlink:to="loc_us-gaapPreferredStockSharesIssued_f1c89b" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_606133" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_7ee78a" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_606133" order="8" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfOperations" xlink:title="000004 - Statement - STATEMENTS OF OPERATIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract_fe578a" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_93c498" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_fe578a" xlink:to="loc_us-gaapOperatingExpensesAbstract_93c498" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_335575" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_93c498" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_335575" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_df0c57" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_93c498" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_df0c57" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_f95173" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_93c498" xlink:to="loc_us-gaapOperatingExpenses_f95173" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_5d4027" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_93c498" xlink:to="loc_us-gaapOperatingIncomeLoss_5d4027" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet_a36698" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_93c498" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet_a36698" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingGainsLosses" xlink:label="loc_us-gaapOtherNonoperatingGainsLosses_67d774" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_93c498" xlink:to="loc_us-gaapOtherNonoperatingGainsLosses_67d774" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_6d3476" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_93c498" xlink:to="loc_us-gaapInterestExpense_6d3476" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_f7819c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_93c498" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_f7819c" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_11681f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_93c498" xlink:to="loc_us-gaapNetIncomeLoss_11681f" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ModificationOfWarrants" xlink:label="loc_cvmModificationOfWarrants_53e6a5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_93c498" xlink:to="loc_cvmModificationOfWarrants_53e6a5" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_3012ba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_93c498" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_3012ba" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_EarningPerShareBasicAndDiluted" xlink:label="loc_cvmEarningPerShareBasicAndDiluted_c2cd1a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_93c498" xlink:to="loc_cvmEarningPerShareBasicAndDiluted_c2cd1a" order="13" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" xlink:label="loc_cvmWeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted_2fc6df" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_93c498" xlink:to="loc_cvmWeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted_2fc6df" order="14" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfStockholdersEquity" xlink:title="000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract_8d7f72" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_b566f0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract_8d7f72" xlink:to="loc_us-gaapStatementTable_b566f0" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_d71b32" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_b566f0" xlink:to="loc_us-gaapStatementLineItems_d71b32" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis_7bf3b7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_b566f0" xlink:to="loc_us-gaapStatementEquityComponentsAxis_7bf3b7" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_8bb7ae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis_7bf3b7" xlink:to="loc_us-gaapEquityComponentDomain_8bb7ae" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_db55c0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_8bb7ae" xlink:to="loc_us-gaapCommonStockMember_db55c0" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_b7a4c7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_8bb7ae" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_b7a4c7" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_e7e0d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_8bb7ae" xlink:to="loc_us-gaapRetainedEarningsMember_e7e0d9" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_d18f60" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d71b32" xlink:to="loc_us-gaapSharesIssued_d18f60" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_55d8ba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d71b32" xlink:to="loc_us-gaapStockholdersEquity_55d8ba" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WarrantExercisesShares" xlink:label="loc_cvmWarrantExercisesShares_74be03" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d71b32" xlink:to="loc_cvmWarrantExercisesShares_74be03" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WarrantExercisesAmount" xlink:label="loc_cvmWarrantExercisesAmount_101b33" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d71b32" xlink:to="loc_cvmWarrantExercisesAmount_101b33" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_b402de" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d71b32" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_b402de" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_2b001c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d71b32" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_2b001c" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_61e4b2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d71b32" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_61e4b2" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_d0ad50" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d71b32" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_d0ad50" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_2ef3c7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d71b32" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_2ef3c7" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_d1ba53" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d71b32" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_d1ba53" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_5d4d39" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d71b32" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_5d4d39" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IncreaseDecreaseFromStockIssuanceCosts" xlink:label="loc_cvmIncreaseDecreaseFromStockIssuanceCosts_7eb121" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d71b32" xlink:to="loc_cvmIncreaseDecreaseFromStockIssuanceCosts_7eb121" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_9ed236" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d71b32" xlink:to="loc_us-gaapNetIncomeLoss_9ed236" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_9e6e6d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d71b32" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_9e6e6d" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_869167" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d71b32" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_869167" order="15" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IncentiveStockForfeitedShares" xlink:label="loc_cvmIncentiveStockForfeitedShares_1795ed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d71b32" xlink:to="loc_cvmIncentiveStockForfeitedShares_1795ed" order="16" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IncentiveStockForfeitedAmount" xlink:label="loc_cvmIncentiveStockForfeitedAmount_eaa2ff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d71b32" xlink:to="loc_cvmIncentiveStockForfeitedAmount_eaa2ff" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_a32d2f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d71b32" xlink:to="loc_us-gaapSharesIssued_a32d2f" order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_e689ff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d71b32" xlink:to="loc_us-gaapStockholdersEquity_e689ff" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfCashFlows" xlink:title="000006 - Statement - STATEMENTS OF CASH FLOWS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract_bd8db7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_f51517" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_bd8db7" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_f51517" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_7d4011" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_f51517" xlink:to="loc_us-gaapProfitLoss_7d4011" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1e9a4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_f51517" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1e9a4" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_a59338" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1e9a4" xlink:to="loc_us-gaapDepreciationAndAmortization_a59338" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense_32ec39" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1e9a4" xlink:to="loc_us-gaapOtherNoncashExpense_32ec39" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_70d9e4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1e9a4" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_70d9e4" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_491c2f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1e9a4" xlink:to="loc_us-gaapShareBasedCompensation_491c2f" order="7" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:label="loc_cvmCommonStockContributedToEmployeeBenefitPlan_5f5f9d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1e9a4" xlink:to="loc_cvmCommonStockContributedToEmployeeBenefitPlan_5f5f9d" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments_160f65" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1e9a4" xlink:to="loc_us-gaapGainLossOnInvestments_160f65" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet_b1726b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1e9a4" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet_b1726b" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived_f1413a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1e9a4" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived_f1413a" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_GainLossOnReceivables" xlink:label="loc_cvmGainLossOnReceivables_2b4844" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1e9a4" xlink:to="loc_cvmGainLossOnReceivables_2b4844" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_4e99b1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1e9a4" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_4e99b1" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense_1fa92c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_4e99b1" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense_1fa92c" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories_73d5cd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_4e99b1" xlink:to="loc_us-gaapIncreaseDecreaseInInventories_73d5cd" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeposits" xlink:label="loc_us-gaapIncreaseDecreaseInDeposits_33f9d4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_4e99b1" xlink:to="loc_us-gaapIncreaseDecreaseInDeposits_33f9d4" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_8e73f1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_4e99b1" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_8e73f1" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable_5555bf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_8e73f1" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable_5555bf" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_685038" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_8e73f1" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_685038" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities_3ba408" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_8e73f1" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities_3ba408" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_4ab77b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_8e73f1" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_4ab77b" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_7cea6e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_8e73f1" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_7cea6e" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfOtherInvestments_045641" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_7cea6e" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfOtherInvestments_045641" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_3b6f23" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_7cea6e" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_3b6f23" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets_863285" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_7cea6e" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets_863285" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_345286" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_7cea6e" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_345286" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_b1090f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_7cea6e" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_b1090f" order="27" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ProceedsFromIssuanceOfCommonStocks" xlink:label="loc_cvmProceedsFromIssuanceOfCommonStocks_6f33de" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_b1090f" xlink:to="loc_cvmProceedsFromIssuanceOfCommonStocks_6f33de" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_635747" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_b1090f" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_635747" order="29" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_c1b3a8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_b1090f" xlink:to="loc_us-gaapProceedsFromWarrantExercises_c1b3a8" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised_600922" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_b1090f" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised_600922" order="31" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ProceedsFromLandlordFundingOfLeaseImprovements" xlink:label="loc_cvmProceedsFromLandlordFundingOfLeaseImprovements_715f4b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_b1090f" xlink:to="loc_cvmProceedsFromLandlordFundingOfLeaseImprovements_715f4b" order="32" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations_5b23b0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_b1090f" xlink:to="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations_5b23b0" order="33" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_4fceb4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_b1090f" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_4fceb4" order="34" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_60e61a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_b1090f" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_60e61a" order="35" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_08753e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_b1090f" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_08753e" order="36" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5958bf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_b1090f" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5958bf" order="37" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_76b5d8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_b1090f" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_76b5d8" order="38" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" xlink:label="loc_cvmPropertyAndEquipmentPurchasesIncludedInCurrentLiabilities_dc6b12" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_76b5d8" xlink:to="loc_cvmPropertyAndEquipmentPurchasesIncludedInCurrentLiabilities_dc6b12" order="39" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable" xlink:label="loc_cvmCapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable_68af0f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_76b5d8" xlink:to="loc_cvmCapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable_68af0f" order="40" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_AssetsPurchasedUnderFinanceLeases" xlink:label="loc_cvmAssetsPurchasedUnderFinanceLeases_cc8e8a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_76b5d8" xlink:to="loc_cvmAssetsPurchasedUnderFinanceLeases_cc8e8a" order="41" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IncreaseDecreaseToRightOfUseAssetsAndLiabilities" xlink:label="loc_cvmIncreaseDecreaseToRightOfUseAssetsAndLiabilities_d510c0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_76b5d8" xlink:to="loc_cvmIncreaseDecreaseToRightOfUseAssetsAndLiabilities_d510c0" order="42" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_FinanceLeaseObligationIncludedInAccountsPayable" xlink:label="loc_cvmFinanceLeaseObligationIncludedInAccountsPayable_7a97d4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_76b5d8" xlink:to="loc_cvmFinanceLeaseObligationIncludedInAccountsPayable_7a97d4" order="43" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ConsultingFeePaidWithIssuanceOfCommonStock" xlink:label="loc_cvmConsultingFeePaidWithIssuanceOfCommonStock_44ecf3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_76b5d8" xlink:to="loc_cvmConsultingFeePaidWithIssuanceOfCommonStock_44ecf3" order="44" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_FinancingCostsIncludedInCurrentLiabilities" xlink:label="loc_cvmFinancingCostsIncludedInCurrentLiabilities_1bc946" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_76b5d8" xlink:to="loc_cvmFinancingCostsIncludedInCurrentLiabilities_1bc946" order="45" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_DerivativeLiabilitiesExercised" xlink:label="loc_cvmDerivativeLiabilitiesExercised_eb8152" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_76b5d8" xlink:to="loc_cvmDerivativeLiabilitiesExercised_eb8152" order="46" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_AccruedConsultingServicesToBePaid" xlink:label="loc_cvmAccruedConsultingServicesToBePaid_683732" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_76b5d8" xlink:to="loc_cvmAccruedConsultingServicesToBePaid_683732" order="47" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet_5b414d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_76b5d8" xlink:to="loc_us-gaapInterestPaidNet_5b414d" order="48" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/ORGANIZATION" xlink:title="000007 - Disclosure - ORGANIZATION">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e0aace" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_99b6d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e0aace" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_99b6d9" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LIQUIDITY" xlink:title="000008 - Disclosure - LIQUIDITY">
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_LIQUIDITYAbstract" xlink:label="loc_cvmLIQUIDITYAbstract_da7dd7" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_LiquiditydisclosureTextblock" xlink:label="loc_cvmLiquiditydisclosureTextblock_89597a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmLIQUIDITYAbstract_da7dd7" xlink:to="loc_cvmLiquiditydisclosureTextblock_89597a" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_4f3c93" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock_9ea183" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_4f3c93" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock_9ea183" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptions" xlink:title="000010 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS">
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WarrantsAndNonemployeeOptionsAbstract" xlink:label="loc_cvmWarrantsAndNonemployeeOptionsAbstract_8aee1c" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WarrantsAndNonEmployeeOptionsDisclosureTextBlock" xlink:label="loc_cvmWarrantsAndNonEmployeeOptionsDisclosureTextBlock_6a5e80" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmWarrantsAndNonemployeeOptionsAbstract_8aee1c" xlink:to="loc_cvmWarrantsAndNonEmployeeOptionsDisclosureTextBlock_6a5e80" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PropertyAndEquipment" xlink:title="000011 - Disclosure - PROPERTY AND EQUIPMENT">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_c30940" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock_113612" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_c30940" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock_113612" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PATENTS" xlink:title="000012 - Disclosure - PATENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_d71eee" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock_42f2f9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_d71eee" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock_42f2f9" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxes" xlink:title="000013 - Disclosure - INCOME TAXES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract_029ec1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock_b3d13d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_029ec1" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock_b3d13d" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensation" xlink:title="000014 - Disclosure - EQUITY-BASED COMPENSATION">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_867c86" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9d8f7c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_867c86" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9d8f7c" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/EmployeeBenefitPlan" xlink:title="000015 - Disclosure - EMPLOYEE BENEFIT PLAN">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationAbstract_9ba61d" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock_287717" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationAbstract_9ba61d" xlink:to="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock_287717" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingencies" xlink:title="000016 - Disclosure - COMMITMENTS AND CONTINGENCIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_c6c3b3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_5c6c1c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_c6c3b3" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_5c6c1c" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactions" xlink:title="000017 - Disclosure - RELATED PARTY TRANSACTIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_8cd0b0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_a93df7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_8cd0b0" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_a93df7" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquity" xlink:title="000018 - Disclosure - STOCKHOLDERS EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_c64ae6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_f1f9ae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_c64ae6" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_f1f9ae" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurements" xlink:title="000019 - Disclosure - FAIR VALUE MEASUREMENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_c0a65a" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock_c19e4d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_c0a65a" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock_c19e4d" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShare" xlink:title="000020 - Disclosure - NET LOSS PER COMMON SHARE">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_13d88c" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock_070223" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_13d88c" xlink:to="loc_us-gaapEarningsPerShareTextBlock_070223" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEvents" xlink:title="000021 - Disclosure - SUBSEQUENT EVENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_78c21d" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock_b70a78" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_78c21d" xlink:to="loc_us-gaapSubsequentEventsTextBlock_b70a78" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_b99095" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_e5afa6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_b99095" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_e5afa6" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_USTreasuryBillsPolicyTextBlock" xlink:label="loc_cvmUSTreasuryBillsPolicyTextBlock_3f971a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_b99095" xlink:to="loc_cvmUSTreasuryBillsPolicyTextBlock_3f971a" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock_e2fd62" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_b99095" xlink:to="loc_us-gaapInventoryPolicyTextBlock_e2fd62" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_7b6872" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_b99095" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_7b6872" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy_5c4f12" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_b99095" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy_5c4f12" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock_121e13" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_b99095" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock_121e13" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaapDerivativesPolicyTextBlock_658d2c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_b99095" xlink:to="loc_us-gaapDerivativesPolicyTextBlock_658d2c" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy_223e69" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_b99095" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy_223e69" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy_c741cc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_b99095" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy_c741cc" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock_e02731" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_b99095" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock_e02731" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk_da1d1e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_b99095" xlink:to="loc_us-gaapConcentrationRiskCreditRisk_da1d1e" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock_82d5f4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_b99095" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock_82d5f4" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_c728f4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_b99095" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_c728f4" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates_6ede10" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_b99095" xlink:to="loc_us-gaapUseOfEstimates_6ede10" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_40edef" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_b99095" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_40edef" order="15" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsTables" xlink:title="000023 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Tables)">
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WarrantsAndNonemployeeOptionsAbstract" xlink:label="loc_cvmWarrantsAndNonemployeeOptionsAbstract_633d50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_80b88e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmWarrantsAndNonemployeeOptionsAbstract_633d50" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_80b88e" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock" xlink:label="loc_cvmScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock_6de0de" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmWarrantsAndNonemployeeOptionsAbstract_633d50" xlink:to="loc_cvmScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock_6de0de" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock" xlink:label="loc_cvmScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock_71f0b4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmWarrantsAndNonemployeeOptionsAbstract_633d50" xlink:to="loc_cvmScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock_71f0b4" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock" xlink:label="loc_cvmScheduleOfEquityWarrantsWereExercisedTableTextBlock_81ff36" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmWarrantsAndNonemployeeOptionsAbstract_633d50" xlink:to="loc_cvmScheduleOfEquityWarrantsWereExercisedTableTextBlock_81ff36" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PlantPropertyAndEquipmentTables" xlink:title="000024 - Disclosure - PLANT PROPERTY AND EQUIPMENT (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_ac529c" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock_e78ec6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_ac529c" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock_e78ec6" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsTables" xlink:title="000025 - Disclosure - PATENTS (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_05a607" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_3a2ef8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_05a607" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_3a2ef8" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_c59219" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_05a607" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_c59219" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesTables" xlink:title="000026 - Disclosure - INCOME TAXES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract_0ec230" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0793a4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_0ec230" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0793a4" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_f270de" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_0ec230" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_f270de" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationTables" xlink:title="000027 - Disclosure - EQUITY-BASED COMPENSATION (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dcbb93" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_d9f923" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dcbb93" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_d9f923" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3075b4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dcbb93" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3075b4" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock" xlink:label="loc_cvmScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock_9067bf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dcbb93" xlink:to="loc_cvmScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock_9067bf" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5b3ad2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dcbb93" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5b3ad2" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_aef461" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dcbb93" xlink:to="loc_us-gaapScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_aef461" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:title="000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_c9a5b3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_7434fb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_c9a5b3" xlink:to="loc_us-gaapScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_7434fb" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_5a5aa5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_c9a5b3" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_5a5aa5" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsTables" xlink:title="000029 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_65030e" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1f4fca" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_65030e" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1f4fca" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareTables" xlink:title="000030 - Disclosure - NET LOSS PER COMMON SHARE (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_6c9ea4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_79c70f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_6c9ea4" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_79c70f" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f59555" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_6c9ea4" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f59555" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_c7a283" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_c3e15e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c7a283" xlink:to="loc_us-gaapStatementTable_c3e15e" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_4423b7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c3e15e" xlink:to="loc_us-gaapStatementLineItems_4423b7" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_fe42f4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c3e15e" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_fe42f4" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_f6d04e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_fe42f4" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_f6d04e" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_a14342" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_f6d04e" xlink:to="loc_us-gaapPatentsMember_a14342" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_FiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_cvmFiniteLivedIntangibleAssetsUsefulLife_a10717" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4423b7" xlink:to="loc_cvmFiniteLivedIntangibleAssetsUsefulLife_a10717" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_104c0f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4423b7" xlink:to="loc_us-gaapCashFDICInsuredAmount_104c0f" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" xlink:title="000032 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details)">
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WarrantsAndNonemployeeOptionsAbstract" xlink:label="loc_cvmWarrantsAndNonemployeeOptionsAbstract_18daa0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_095f9b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmWarrantsAndNonemployeeOptionsAbstract_18daa0" xlink:to="loc_us-gaapStatementTable_095f9b" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_bbaaa1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_095f9b" xlink:to="loc_us-gaapStatementLineItems_bbaaa1" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis_d9d492" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_095f9b" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis_d9d492" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_003b6a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis_d9d492" xlink:to="loc_us-gaapDerivativeContractTypeDomain_003b6a" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_3407d5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_095f9b" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_3407d5" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_125069" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_3407d5" xlink:to="loc_us-gaapRelatedPartyDomain_125069" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis_1fa793" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_095f9b" xlink:to="loc_srtRangeAxis_1fa793" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_6d10df" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis_1fa793" xlink:to="loc_srtRangeMember_6d10df" order="60" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesYMember" xlink:label="loc_cvmSeriesYMember_617314" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_003b6a" xlink:to="loc_cvmSeriesYMember_617314" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesMMMember" xlink:label="loc_cvmSeriesMMMember_75e357" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_003b6a" xlink:to="loc_cvmSeriesMMMember_75e357" order="62" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesNNMember" xlink:label="loc_cvmSeriesNNMember_1e0151" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_003b6a" xlink:to="loc_cvmSeriesNNMember_1e0151" order="63" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember_f1c4cf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_003b6a" xlink:to="loc_cvmSeriesRRMember_f1c4cf" order="64" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesSSMember" xlink:label="loc_cvmSeriesSSMember_b8ab9e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_003b6a" xlink:to="loc_cvmSeriesSSMember_b8ab9e" order="65" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesTTMember" xlink:label="loc_cvmSeriesTTMember_d89658" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_003b6a" xlink:to="loc_cvmSeriesTTMember_d89658" order="66" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesNMember" xlink:label="loc_cvmSeriesNMember_34642d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_003b6a" xlink:to="loc_cvmSeriesNMember_34642d" order="67" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesUUMember" xlink:label="loc_cvmSeriesUUMember_59df6d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_003b6a" xlink:to="loc_cvmSeriesUUMember_59df6d" order="68" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesXMember" xlink:label="loc_cvmSeriesXMember_9b13b6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_003b6a" xlink:to="loc_cvmSeriesXMember_9b13b6" order="69" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember_f8b493" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_125069" xlink:to="loc_cvmConsultantsMember_f8b493" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_461580" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_6d10df" xlink:to="loc_srtMinimumMember_461580" order="71" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ConsultantsOneMember" xlink:label="loc_cvmConsultantsOneMember_b20aae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_125069" xlink:to="loc_cvmConsultantsOneMember_b20aae" order="72" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_8f5d66" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_6d10df" xlink:to="loc_srtMaximumMember_8f5d66" order="73" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_Issuedate2" xlink:label="loc_cvmIssuedate2_ca4cf8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bbaaa1" xlink:to="loc_cvmIssuedate2_ca4cf8" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SharesIssuableUponExerciseOfwarrant" xlink:label="loc_cvmSharesIssuableUponExerciseOfwarrant_30dbd1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bbaaa1" xlink:to="loc_cvmSharesIssuableUponExerciseOfwarrant_30dbd1" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ExercisePrice" xlink:label="loc_cvmExercisePrice_9a1860" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bbaaa1" xlink:to="loc_cvmExercisePrice_9a1860" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ExpirationDate1" xlink:label="loc_cvmExpirationDate1_b4e4d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bbaaa1" xlink:to="loc_cvmExpirationDate1_b4e4d2" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1" xlink:title="000033 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details 1)">
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WarrantsAndNonemployeeOptionsAbstract" xlink:label="loc_cvmWarrantsAndNonemployeeOptionsAbstract_552b76" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_ae8ecc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmWarrantsAndNonemployeeOptionsAbstract_552b76" xlink:to="loc_us-gaapStatementTable_ae8ecc" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_676c55" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ae8ecc" xlink:to="loc_us-gaapStatementLineItems_676c55" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_37587d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ae8ecc" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_37587d" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_6c0316" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_37587d" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_6c0316" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesZMember" xlink:label="loc_cvmSeriesZMember_b29751" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_6c0316" xlink:to="loc_cvmSeriesZMember_b29751" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesCCMember" xlink:label="loc_cvmSeriesCCMember_5a5c3c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_6c0316" xlink:to="loc_cvmSeriesCCMember_5a5c3c" order="22" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesHHMember" xlink:label="loc_cvmSeriesHHMember_f603bf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_6c0316" xlink:to="loc_cvmSeriesHHMember_f603bf" order="23" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesAAMember" xlink:label="loc_cvmSeriesAAMember_0c41ed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_6c0316" xlink:to="loc_cvmSeriesAAMember_0c41ed" order="24" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesWMember" xlink:label="loc_cvmSeriesWMember_76e530" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_6c0316" xlink:to="loc_cvmSeriesWMember_76e530" order="25" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesZZMember" xlink:label="loc_cvmSeriesZZMember_093755" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_6c0316" xlink:to="loc_cvmSeriesZZMember_093755" order="26" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesBBMember" xlink:label="loc_cvmSeriesBBMember_80a542" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_6c0316" xlink:to="loc_cvmSeriesBBMember_80a542" order="27" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_NetLossGainOnWarrantLiabilities" xlink:label="loc_cvmNetLossGainOnWarrantLiabilities_ad0f06" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_676c55" xlink:to="loc_cvmNetLossGainOnWarrantLiabilities_ad0f06" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails2" xlink:title="000034 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details 2)">
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WarrantsAndNonemployeeOptionsAbstract" xlink:label="loc_cvmWarrantsAndNonemployeeOptionsAbstract_bf7e54" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_c09f11" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmWarrantsAndNonemployeeOptionsAbstract_bf7e54" xlink:to="loc_us-gaapStatementTable_c09f11" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_230fe3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c09f11" xlink:to="loc_us-gaapStatementLineItems_230fe3" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_2d8876" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c09f11" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_2d8876" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_ea99e1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_2d8876" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_ea99e1" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesCCMember" xlink:label="loc_cvmSeriesCCMember_4d750a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_ea99e1" xlink:to="loc_cvmSeriesCCMember_4d750a" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_9512db" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_230fe3" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_9512db" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WarrantsExercised" xlink:label="loc_cvmWarrantsExercised_a0acc6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_230fe3" xlink:to="loc_cvmWarrantsExercised_a0acc6" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ExercisePriceWarrants" xlink:label="loc_cvmExercisePriceWarrants_76d1d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_230fe3" xlink:to="loc_cvmExercisePriceWarrants_76d1d2" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails3" xlink:title="000035 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details 3)">
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WarrantsAndNonemployeeOptionsAbstract" xlink:label="loc_cvmWarrantsAndNonemployeeOptionsAbstract_b8a515" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_479840" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmWarrantsAndNonemployeeOptionsAbstract_b8a515" xlink:to="loc_us-gaapStatementTable_479840" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_8d5e0b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_479840" xlink:to="loc_us-gaapStatementLineItems_8d5e0b" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis_711daf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_479840" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis_711daf" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_cd4e28" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis_711daf" xlink:to="loc_us-gaapDerivativeContractTypeDomain_cd4e28" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesNNMember" xlink:label="loc_cvmSeriesNNMember_bd32d7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_cd4e28" xlink:to="loc_cvmSeriesNNMember_bd32d7" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember_f82ee0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_cd4e28" xlink:to="loc_cvmSeriesRRMember_f82ee0" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesSSMember" xlink:label="loc_cvmSeriesSSMember_21a61c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_cd4e28" xlink:to="loc_cvmSeriesSSMember_21a61c" order="13" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_EquityWarrantsExercised" xlink:label="loc_cvmEquityWarrantsExercised_fcffde" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8d5e0b" xlink:to="loc_cvmEquityWarrantsExercised_fcffde" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ProceedsFromEquityWarrantsExercised" xlink:label="loc_cvmProceedsFromEquityWarrantsExercised_40417e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8d5e0b" xlink:to="loc_cvmProceedsFromEquityWarrantsExercised_40417e" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_EquityWarrantsExercisePrice" xlink:label="loc_cvmEquityWarrantsExercisePrice_c28a33" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8d5e0b" xlink:to="loc_cvmEquityWarrantsExercisePrice_c28a33" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative" xlink:title="000036 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WarrantsAndNonemployeeOptionsAbstract" xlink:label="loc_cvmWarrantsAndNonemployeeOptionsAbstract_c656cc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_0059a2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmWarrantsAndNonemployeeOptionsAbstract_c656cc" xlink:to="loc_us-gaapStatementTable_0059a2" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_893a11" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0059a2" xlink:to="loc_us-gaapStatementLineItems_893a11" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis_b72b97" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0059a2" xlink:to="loc_srtRangeAxis_b72b97" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_e081c7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis_b72b97" xlink:to="loc_srtRangeMember_e081c7" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d368ad" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0059a2" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d368ad" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_f48872" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d368ad" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_f48872" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_5dd297" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0059a2" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_5dd297" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_f4db10" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_5dd297" xlink:to="loc_us-gaapRelatedPartyDomain_f4db10" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_889112" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0059a2" xlink:to="loc_us-gaapPlanNameAxis_889112" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_4d9730" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_889112" xlink:to="loc_us-gaapPlanNameDomain_4d9730" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_931c14" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0059a2" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_931c14" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_d18fbe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_931c14" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_d18fbe" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_1eaa73" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0059a2" xlink:to="loc_us-gaapAwardTypeAxis_1eaa73" order="90" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_458074" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_1eaa73" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_458074" order="90" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis_a42b48" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0059a2" xlink:to="loc_us-gaapAwardDateAxis_a42b48" order="110" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_7e1ce1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis_a42b48" xlink:to="loc_us-gaapAwardDateDomain_7e1ce1" order="110" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_cf4332" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_e081c7" xlink:to="loc_srtMaximumMember_cf4332" order="111" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_RestrictedStocksMember" xlink:label="loc_cvmRestrictedStocksMember_ab64ea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_f48872" xlink:to="loc_cvmRestrictedStocksMember_ab64ea" order="112" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember_73fb9c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_f4db10" xlink:to="loc_cvmConsultantsMember_73fb9c" order="113" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ConsultingAgreementsMember" xlink:label="loc_cvmConsultingAgreementsMember_3de23f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_4d9730" xlink:to="loc_cvmConsultingAgreementsMember_3de23f" order="114" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0204ca" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_e081c7" xlink:to="loc_srtMinimumMember_0204ca" order="115" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesCCWarrantsMember" xlink:label="loc_cvmSeriesCCWarrantsMember_e1ddf3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_d18fbe" xlink:to="loc_cvmSeriesCCWarrantsMember_e1ddf3" order="116" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesZWarrantsMember" xlink:label="loc_cvmSeriesZWarrantsMember_f41a8d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_d18fbe" xlink:to="loc_cvmSeriesZWarrantsMember_f41a8d" order="117" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesAAWarrantsMember" xlink:label="loc_cvmSeriesAAWarrantsMember_6b4c16" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_d18fbe" xlink:to="loc_cvmSeriesAAWarrantsMember_6b4c16" order="118" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesHHWarrantsMember" xlink:label="loc_cvmSeriesHHWarrantsMember_cde817" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_d18fbe" xlink:to="loc_cvmSeriesHHWarrantsMember_cde817" order="119" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember_614db0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_d18fbe" xlink:to="loc_cvmSeriesRRMember_614db0" order="120" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="loc_cvmNonQualifiedStockOptionsPlansMember_e6c379" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_458074" xlink:to="loc_cvmNonQualifiedStockOptionsPlansMember_e6c379" order="121" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ConsultantMember" xlink:label="loc_cvmConsultantMember_d6a8d4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_f4db10" xlink:to="loc_cvmConsultantMember_d6a8d4" order="122" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_TwoSeptemberTwoThousendTwentyFourMember" xlink:label="loc_cvmTwoSeptemberTwoThousendTwentyFourMember_70a6e6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_7e1ce1" xlink:to="loc_cvmTwoSeptemberTwoThousendTwentyFourMember_70a6e6" order="123" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_TwoSeptemberTwoThousendTwentyFiveMember" xlink:label="loc_cvmTwoSeptemberTwoThousendTwentyFiveMember_ee6c1b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_7e1ce1" xlink:to="loc_cvmTwoSeptemberTwoThousendTwentyFiveMember_ee6c1b" order="124" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IncrementalCostDeemedDividend" xlink:label="loc_cvmIncrementalCostDeemedDividend_eebd69" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_893a11" xlink:to="loc_cvmIncrementalCostDeemedDividend_eebd69" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_StockIssuedDuringPeriodToPurchaseCommonStock" xlink:label="loc_cvmStockIssuedDuringPeriodToPurchaseCommonStock_ea1270" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_893a11" xlink:to="loc_cvmStockIssuedDuringPeriodToPurchaseCommonStock_ea1270" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_DeemedDividend11" xlink:label="loc_cvmDeemedDividend11_11276f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_893a11" xlink:to="loc_cvmDeemedDividend11_11276f" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_DeemedDividendAmount" xlink:label="loc_cvmDeemedDividendAmount_88dca1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_893a11" xlink:to="loc_cvmDeemedDividendAmount_88dca1" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_StockOptionExercisePrice" xlink:label="loc_cvmStockOptionExercisePrice_f12e3f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_893a11" xlink:to="loc_cvmStockOptionExercisePrice_f12e3f" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_VestedOptions" xlink:label="loc_cvmVestedOptions_0de108" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_893a11" xlink:to="loc_cvmVestedOptions_0de108" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IssuedStockOfOptionsOutstanding" xlink:label="loc_cvmIssuedStockOfOptionsOutstanding_c3aa52" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_893a11" xlink:to="loc_cvmIssuedStockOfOptionsOutstanding_c3aa52" order="7" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_CommonStockIssuedForServiceShares" xlink:label="loc_cvmCommonStockIssuedForServiceShares_5ab040" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_893a11" xlink:to="loc_cvmCommonStockIssuedForServiceShares_5ab040" order="8" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WarrantsExpired" xlink:label="loc_cvmWarrantsExpired_8a4e75" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_893a11" xlink:to="loc_cvmWarrantsExpired_8a4e75" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ExercisePriceWarrants" xlink:label="loc_cvmExercisePriceWarrants_0c495b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_893a11" xlink:to="loc_cvmExercisePriceWarrants_0c495b" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ac34ad" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_893a11" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ac34ad" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses_61ed01" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_893a11" xlink:to="loc_us-gaapCostsAndExpenses_61ed01" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_PrepaidExpenses" xlink:label="loc_cvmPrepaidExpenses_b9405b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_893a11" xlink:to="loc_cvmPrepaidExpenses_b9405b" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_a3f76e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_893a11" xlink:to="loc_us-gaapSharePrice_a3f76e" order="14" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PropertyAndEquipmentDetails" xlink:title="000037 - Disclosure - PROPERTY AND EQUIPMENT (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_67b551" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FixturesAndEquipmentGross" xlink:label="loc_us-gaapFixturesAndEquipmentGross_91ef4a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_67b551" xlink:to="loc_us-gaapFixturesAndEquipmentGross_91ef4a" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaapFurnitureAndFixturesGross_825644" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_67b551" xlink:to="loc_us-gaapFurnitureAndFixturesGross_825644" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross_a83c19" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_67b551" xlink:to="loc_us-gaapLeaseholdImprovementsGross_a83c19" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_dac45e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_67b551" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_dac45e" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_87080c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_67b551" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_87080c" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_dfc50f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_67b551" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_dfc50f" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="000038 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_e8b9bd" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization_96265c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_e8b9bd" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization_96265c" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails" xlink:title="000039 - Disclosure - PATENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_46ce3b" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="loc_us-gaapFiniteLivedPatentsGross_3633ba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_46ce3b" xlink:to="loc_us-gaapFiniteLivedPatentsGross_3633ba" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_AccumulatedAmortization" xlink:label="loc_cvmAccumulatedAmortization_6510f0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_46ce3b" xlink:to="loc_cvmAccumulatedAmortization_6510f0" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaapOtherIntangibleAssetsNet_f5bad2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_46ce3b" xlink:to="loc_us-gaapOtherIntangibleAssetsNet_f5bad2" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails1" xlink:title="000040 - Disclosure - PATENTS (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_650529" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_49db31" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_650529" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_49db31" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_7550df" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_650529" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_7550df" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_531dee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_650529" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_531dee" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_5fcd99" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_650529" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_5fcd99" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_aab65b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_650529" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_aab65b" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_af027a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_650529" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_af027a" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_Total" xlink:label="loc_cvmTotal_eeef90" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_650529" xlink:to="loc_cvmTotal_eeef90" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetailsNarrative" xlink:title="000041 - Disclosure - PATENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_05a8bf" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_PatentsWeightedAverageAmortizationPeriod" xlink:label="loc_cvmPatentsWeightedAverageAmortizationPeriod_c6435c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_05a8bf" xlink:to="loc_cvmPatentsWeightedAverageAmortizationPeriod_c6435c" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_AmortizationOfPatentCosts" xlink:label="loc_cvmAmortizationOfPatentCosts_2eca84" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_05a8bf" xlink:to="loc_cvmAmortizationOfPatentCosts_2eca84" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesDetails" xlink:title="000042 - Disclosure - INCOME TAXES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract_9b684d" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_603aea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_9b684d" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_603aea" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" xlink:label="loc_cvmDeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd_0b1812" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_9b684d" xlink:to="loc_cvmDeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd_0b1812" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_18716a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_9b684d" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_18716a" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_LeaseLiabilities" xlink:label="loc_cvmLeaseLiabilities_8f2d0e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_9b684d" xlink:to="loc_cvmLeaseLiabilities_8f2d0e" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_bab788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_9b684d" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_bab788" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_70fc80" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_9b684d" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_70fc80" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_FixedAssetsAndIntangiblesAssets" xlink:label="loc_cvmFixedAssetsAndIntangiblesAssets_ce862c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_9b684d" xlink:to="loc_cvmFixedAssetsAndIntangiblesAssets_ce862c" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross_e9523a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_9b684d" xlink:to="loc_us-gaapDeferredTaxAssetsGross_e9523a" order="8" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_RightOfUseAssets" xlink:label="loc_cvmRightOfUseAssets_4e993d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_9b684d" xlink:to="loc_cvmRightOfUseAssets_4e993d" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_FixedAssetsAndIntangibles" xlink:label="loc_cvmFixedAssetsAndIntangibles_4aede3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_9b684d" xlink:to="loc_cvmFixedAssetsAndIntangibles_4aede3" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities_c145f6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_9b684d" xlink:to="loc_us-gaapDeferredTaxLiabilities_c145f6" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet_d3f64f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_9b684d" xlink:to="loc_us-gaapDeferredTaxAssetsNet_d3f64f" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_8f8069" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_9b684d" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_8f8069" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet_ec7bba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_9b684d" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet_ec7bba" order="14" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesDetails1" xlink:title="000043 - Disclosure - INCOME TAXES (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract_30ccc8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_01ccd8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_30ccc8" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_01ccd8" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_227bd7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_30ccc8" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_227bd7" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_3f8c0e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_30ccc8" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_3f8c0e" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments_e11a74" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_30ccc8" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments_e11a74" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense_0c1427" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_30ccc8" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense_0c1427" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_f2e6a4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_30ccc8" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_f2e6a4" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_1b0e8a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_30ccc8" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_1b0e8a" order="7" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesDetailsNarrative" xlink:title="000044 - Disclosure - INCOME TAXES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract_f04f66" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_074a48" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_f04f66" xlink:to="loc_us-gaapStatementTable_074a48" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_381095" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_074a48" xlink:to="loc_us-gaapStatementLineItems_381095" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis_3cfe24" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_074a48" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis_3cfe24" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain_f66f52" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis_3cfe24" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain_f66f52" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IncomeTaxMember" xlink:label="loc_cvmIncomeTaxMember_e5590d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain_f66f52" xlink:to="loc_cvmIncomeTaxMember_e5590d" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ResearchAndDevelopmentCredit" xlink:label="loc_cvmResearchAndDevelopmentCredit_b8a0d5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_381095" xlink:to="loc_cvmResearchAndDevelopmentCredit_b8a0d5" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_dca45b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_381095" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_dca45b" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ResearchAndDevelopmentCreditDescription" xlink:label="loc_cvmResearchAndDevelopmentCreditDescription_3fba87" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_381095" xlink:to="loc_cvmResearchAndDevelopmentCreditDescription_3fba87" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_CumulativeChangeInOwnershipPercentage" xlink:label="loc_cvmCumulativeChangeInOwnershipPercentage_17c0f0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_381095" xlink:to="loc_cvmCumulativeChangeInOwnershipPercentage_17c0f0" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="loc_us-gaapTaxCreditCarryforwardDescription_efd00b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_381095" xlink:to="loc_us-gaapTaxCreditCarryforwardDescription_efd00b" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_DeferredTaxAssets" xlink:label="loc_cvmDeferredTaxAssets_840e03" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_381095" xlink:to="loc_cvmDeferredTaxAssets_840e03" order="6" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails" xlink:title="000045 - Disclosure - EQUITY-BASED COMPENSATION (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e66fb3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_4189a5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e66fb3" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_4189a5" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_585217" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e66fb3" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_585217" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails1" xlink:title="000046 - Disclosure - EQUITY-BASED COMPENSATION (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_efde76" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_9958e9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_efde76" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_9958e9" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_6de58b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_efde76" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_6de58b" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b9b32a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_efde76" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b9b32a" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_87b24c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_efde76" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_87b24c" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ExpectedLifeOfOptionsMin1" xlink:label="loc_cvmExpectedLifeOfOptionsMin1_ede025" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_efde76" xlink:to="loc_cvmExpectedLifeOfOptionsMin1_ede025" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ExpectedLifeOfOptionsMax" xlink:label="loc_cvmExpectedLifeOfOptionsMax_c0f084" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_efde76" xlink:to="loc_cvmExpectedLifeOfOptionsMax_c0f084" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f5fb30" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_efde76" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f5fb30" order="7" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails2" xlink:title="000047 - Disclosure - EQUITY-BASED COMPENSATION (Details 2)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_85dc32" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_c392b3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_85dc32" xlink:to="loc_us-gaapStatementTable_c392b3" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_2f449e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c392b3" xlink:to="loc_us-gaapStatementLineItems_2f449e" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis_b10800" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c392b3" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis_b10800" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_58961a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis_b10800" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_58961a" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis_b7dd40" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c392b3" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis_b7dd40" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_590dae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis_b7dd40" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_590dae" order="40" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_OutstandingMember" xlink:label="loc_cvmOutstandingMember_96d9df" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_58961a" xlink:to="loc_cvmOutstandingMember_96d9df" order="41" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ExercisableMember" xlink:label="loc_cvmExercisableMember_8b7d90" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain_590dae" xlink:to="loc_cvmExercisableMember_8b7d90" order="42" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_98d9d0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2f449e" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_98d9d0" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_caa5ba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2f449e" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_caa5ba" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_91288d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2f449e" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_91288d" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_850f26" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2f449e" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_850f26" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7f7026" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2f449e" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7f7026" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a2606c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2f449e" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a2606c" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6a11e2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2f449e" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6a11e2" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2632f0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2f449e" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2632f0" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e402fb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2f449e" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e402fb" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e3d8f3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2f449e" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e3d8f3" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6428f1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2f449e" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6428f1" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7d51c3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2f449e" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7d51c3" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_69c0cb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2f449e" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_69c0cb" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_eaad86" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2f449e" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_eaad86" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_94399f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2f449e" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_94399f" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised" xlink:label="loc_cvmSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised_96a72d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2f449e" xlink:to="loc_cvmSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised_96a72d" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_1ca640" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2f449e" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_1ca640" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_NumberOfOptionsVested" xlink:label="loc_cvmNumberOfOptionsVested_f14b22" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2f449e" xlink:to="loc_cvmNumberOfOptionsVested_f14b22" order="18" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_NumberOfOptionsExercised" xlink:label="loc_cvmNumberOfOptionsExercised_b84163" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2f449e" xlink:to="loc_cvmNumberOfOptionsExercised_b84163" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_NumberOfOptions" xlink:label="loc_cvmNumberOfOptions_def7b9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2f449e" xlink:to="loc_cvmNumberOfOptions_def7b9" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageExercisePriceVested" xlink:label="loc_cvmWeightedAverageExercisePriceVested_2ab7dc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2f449e" xlink:to="loc_cvmWeightedAverageExercisePriceVested_2ab7dc" order="21" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageExercisePriceExpired" xlink:label="loc_cvmWeightedAverageExercisePriceExpired_95461f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2f449e" xlink:to="loc_cvmWeightedAverageExercisePriceExpired_95461f" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" xlink:label="loc_cvmWeightedAverageRemainingContractualLifeInYearsOutstandingBeginning_25227f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2f449e" xlink:to="loc_cvmWeightedAverageRemainingContractualLifeInYearsOutstandingBeginning_25227f" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" xlink:label="loc_cvmWeightedAverageRemainingContractualLifeInYearsOutstandingEnding_9b23aa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2f449e" xlink:to="loc_cvmWeightedAverageRemainingContractualLifeInYearsOutstandingEnding_9b23aa" order="24" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails3" xlink:title="000048 - Disclosure - EQUITY-BASED COMPENSATION (Details 3)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_81c5ea" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a2a6ca" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_81c5ea" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a2a6ca" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_dea852" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_81c5ea" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_dea852" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4d6923" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_81c5ea" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4d6923" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_580c38" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_81c5ea" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_580c38" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2ac03c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_81c5ea" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2ac03c" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8e5634" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_81c5ea" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8e5634" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageGrantDateFairValueVested" xlink:label="loc_cvmWeightedAverageGrantDateFairValueVested_9dff4a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_81c5ea" xlink:to="loc_cvmWeightedAverageGrantDateFairValueVested_9dff4a" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_586e47" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_81c5ea" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_586e47" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails4" xlink:title="000049 - Disclosure - EQUITY-BASED COMPENSATION (Details 4)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6eabc3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_acc82d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6eabc3" xlink:to="loc_us-gaapStatementTable_acc82d" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_f82399" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_acc82d" xlink:to="loc_us-gaapStatementLineItems_f82399" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_b200c2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_acc82d" xlink:to="loc_us-gaapAwardTypeAxis_b200c2" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16101b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_b200c2" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16101b" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_RestrictedStockAwardsMember" xlink:label="loc_cvmRestrictedStockAwardsMember_69db1c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16101b" xlink:to="loc_cvmRestrictedStockAwardsMember_69db1c" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_70e4ef" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f82399" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_70e4ef" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_36e13e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f82399" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_36e13e" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c2858b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f82399" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c2858b" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_012081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f82399" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_012081" order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_151d0e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f82399" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_151d0e" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_6c67ec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f82399" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_6c67ec" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetailsNarrative" xlink:title="000050 - Disclosure - EQUITY-BASED COMPENSATION (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5a4b5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_61cc21" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5a4b5" xlink:to="loc_us-gaapStatementTable_61cc21" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_59da5b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_61cc21" xlink:to="loc_us-gaapStatementLineItems_59da5b" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_3c4acd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_61cc21" xlink:to="loc_us-gaapAwardTypeAxis_3c4acd" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_001f13" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_3c4acd" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_001f13" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis_f39888" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_61cc21" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis_f39888" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_dc5fa9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis_f39888" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_dc5fa9" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_35b362" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_61cc21" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_35b362" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_48fd17" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_35b362" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_48fd17" order="30" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_RestrictedStockAwardsMember" xlink:label="loc_cvmRestrictedStockAwardsMember_6d6371" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_001f13" xlink:to="loc_cvmRestrictedStockAwardsMember_6d6371" order="31" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_StockBonusPlansMember" xlink:label="loc_cvmStockBonusPlansMember_b68c38" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_dc5fa9" xlink:to="loc_cvmStockBonusPlansMember_b68c38" order="32" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_StockCompensationPlansMember" xlink:label="loc_cvmStockCompensationPlansMember_2dba77" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_48fd17" xlink:to="loc_cvmStockCompensationPlansMember_2dba77" order="33" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="loc_cvmNonQualifiedStockOptionsPlansMember_3eb485" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_dc5fa9" xlink:to="loc_cvmNonQualifiedStockOptionsPlansMember_3eb485" order="34" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IncentiveStockOptionPlansMember" xlink:label="loc_cvmIncentiveStockOptionPlansMember_6a2370" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_dc5fa9" xlink:to="loc_cvmIncentiveStockOptionPlansMember_6a2370" order="35" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IncentiveStockBonusPlanMember" xlink:label="loc_cvmIncentiveStockBonusPlanMember_36a6ec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_dc5fa9" xlink:to="loc_cvmIncentiveStockBonusPlanMember_36a6ec" order="36" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_NonVestedOptionsMember" xlink:label="loc_cvmNonVestedOptionsMember_e4d671" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_001f13" xlink:to="loc_cvmNonVestedOptionsMember_e4d671" order="37" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_f57875" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_59da5b" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_f57875" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_240284" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_59da5b" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_240284" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_844034" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_59da5b" xlink:to="loc_us-gaapCommonStockSharesIssued_844034" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_bed329" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_59da5b" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_bed329" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_7b6931" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_59da5b" xlink:to="loc_us-gaapCommonStockSharesAuthorized_7b6931" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_58159a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_59da5b" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_58159a" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_PerformanceBasedStockOptionsSharesGranted" xlink:label="loc_cvmPerformanceBasedStockOptionsSharesGranted_419328" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_59da5b" xlink:to="loc_cvmPerformanceBasedStockOptionsSharesGranted_419328" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityStrikePrice1_de6303" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_59da5b" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityStrikePrice1_de6303" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockDescription" xlink:label="loc_us-gaapConversionOfStockDescription_976eaa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_59da5b" xlink:to="loc_us-gaapConversionOfStockDescription_976eaa" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_RemainingOutstandingFairValueOfShares" xlink:label="loc_cvmRemainingOutstandingFairValueOfShares_b14ff0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_59da5b" xlink:to="loc_cvmRemainingOutstandingFairValueOfShares_b14ff0" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_VestedShares" xlink:label="loc_cvmVestedShares_fd4e25" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_59da5b" xlink:to="loc_cvmVestedShares_fd4e25" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationEquity" xlink:label="loc_us-gaapDeferredCompensationEquity_61f4e9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_59da5b" xlink:to="loc_us-gaapDeferredCompensationEquity_61f4e9" order="12" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/EmployeeBenefitPlanDetailNarrative" xlink:title="000051 - Disclosure - EMPLOYEE BENEFIT PLAN (Detail Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationAbstract_7e2d56" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount_2b4b1e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationAbstract_7e2d56" xlink:to="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount_2b4b1e" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_TotalCompensation" xlink:label="loc_cvmTotalCompensation_7209b4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationAbstract_7e2d56" xlink:to="loc_cvmTotalCompensation_7209b4" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ParticipantCompensation" xlink:label="loc_cvmParticipantCompensation_feb056" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationAbstract_7e2d56" xlink:to="loc_cvmParticipantCompensation_feb056" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_11c594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationAbstract_7e2d56" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_11c594" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:title="000052 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_e5346b" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_e18526" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_e5346b" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_e18526" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo_a64f54" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_e5346b" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo_a64f54" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree_8298a5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_e5346b" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree_8298a5" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour_da259b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_e5346b" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour_da259b" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive_d1e826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_e5346b" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive_d1e826" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueAfterYearFive_aa05e3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_e5346b" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueAfterYearFive_aa05e3" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue_fac2aa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_e5346b" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue_fac2aa" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount_995225" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_e5346b" xlink:to="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount_995225" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsCurrent_31d5e9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_e5346b" xlink:to="loc_us-gaapCapitalLeaseObligationsCurrent_31d5e9" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsNoncurrent_fd1659" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_e5346b" xlink:to="loc_us-gaapCapitalLeaseObligationsNoncurrent_fd1659" order="10" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:title="000053 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_d5d1d7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_456e3e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_d5d1d7" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_456e3e" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_016809" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_d5d1d7" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_016809" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_3cc0d7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_d5d1d7" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_3cc0d7" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour_176236" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_d5d1d7" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour_176236" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive_f5c0fe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_d5d1d7" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive_f5c0fe" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9ab5ae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_d5d1d7" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9ab5ae" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_LesseeOperatingLeaseLiabilityPayments" xlink:label="loc_cvmLesseeOperatingLeaseLiabilityPayments_e9504e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_d5d1d7" xlink:to="loc_cvmLesseeOperatingLeaseLiabilityPayments_e9504e" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d486b1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_d5d1d7" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d486b1" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsNoncurrent_9647d5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_d5d1d7" xlink:to="loc_us-gaapCapitalLeaseObligationsNoncurrent_9647d5" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsCurrent_8c1c91" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_d5d1d7" xlink:to="loc_us-gaapCapitalLeaseObligationsCurrent_8c1c91" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000054 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_7ef162" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_fc9a18" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_7ef162" xlink:to="loc_us-gaapStatementTable_fc9a18" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_20f0e2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_fc9a18" xlink:to="loc_us-gaapStatementLineItems_20f0e2" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_1a5541" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_fc9a18" xlink:to="loc_us-gaapPlanNameAxis_1a5541" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_362ebb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_1a5541" xlink:to="loc_us-gaapPlanNameDomain_362ebb" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis_c890e4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_fc9a18" xlink:to="loc_srtTitleOfIndividualAxis_c890e4" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_fb2d2f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis_c890e4" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_fb2d2f" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_40cd5b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_fc9a18" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_40cd5b" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_fa1d9a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_40cd5b" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_fa1d9a" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis_bda457" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_fc9a18" xlink:to="loc_us-gaapIncomeStatementLocationAxis_bda457" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_91341c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis_bda457" xlink:to="loc_us-gaapIncomeStatementLocationDomain_91341c" order="60" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ErgomedMember" xlink:label="loc_cvmErgomedMember_874de6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_362ebb" xlink:to="loc_cvmErgomedMember_874de6" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_LandlordMember" xlink:label="loc_cvmLandlordMember_b0a132" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_fb2d2f" xlink:to="loc_cvmLandlordMember_b0a132" order="62" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaapLeaseAgreementsMember_d006e7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_fa1d9a" xlink:to="loc_us-gaapLeaseAgreementsMember_d006e7" order="63" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaapOperatingExpenseMember_4496b5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain_91341c" xlink:to="loc_us-gaapOperatingExpenseMember_4496b5" order="64" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IncrementalBorrowingDerivativeVariableRate" xlink:label="loc_cvmIncrementalBorrowingDerivativeVariableRate_b40664" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_20f0e2" xlink:to="loc_cvmIncrementalBorrowingDerivativeVariableRate_b40664" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_eb8418" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_20f0e2" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_eb8418" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_NetOfDiscount" xlink:label="loc_cvmNetOfDiscount_a6a930" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_20f0e2" xlink:to="loc_cvmNetOfDiscount_a6a930" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases" xlink:label="loc_us-gaapDescriptionOfLesseeLeasingArrangementsCapitalLeases_843a70" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_20f0e2" xlink:to="loc_us-gaapDescriptionOfLesseeLeasingArrangementsCapitalLeases_843a70" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_AdditionalExpenses" xlink:label="loc_cvmAdditionalExpenses_25d6b1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_20f0e2" xlink:to="loc_cvmAdditionalExpenses_25d6b1" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_FinancingLeaseContractualArrangement" xlink:label="loc_cvmFinancingLeaseContractualArrangement_754954" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_20f0e2" xlink:to="loc_cvmFinancingLeaseContractualArrangement_754954" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageMaturityYear" xlink:label="loc_cvmWeightedAverageMaturityYear_d1a6ee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_20f0e2" xlink:to="loc_cvmWeightedAverageMaturityYear_d1a6ee" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization_37994c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_20f0e2" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization_37994c" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability_f053be" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_20f0e2" xlink:to="loc_us-gaapFinanceLeaseLiability_f053be" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent_a4058f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_20f0e2" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent_a4058f" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_3b5ce0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_20f0e2" xlink:to="loc_us-gaapDepreciation_3b5ce0" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="loc_us-gaapFinanceLeaseInterestPaymentOnLiability_153004" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_20f0e2" xlink:to="loc_us-gaapFinanceLeaseInterestPaymentOnLiability_153004" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_CashPaymentToLeaseLiability" xlink:label="loc_cvmCashPaymentToLeaseLiability_149c33" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_20f0e2" xlink:to="loc_cvmCashPaymentToLeaseLiability_149c33" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:label="loc_us-gaapLongTermDebtWeightedAverageInterestRateOverTime_ba45e9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_20f0e2" xlink:to="loc_us-gaapLongTermDebtWeightedAverageInterestRateOverTime_ba45e9" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_CashPaymentForOperatingLeases" xlink:label="loc_cvmCashPaymentForOperatingLeases_163723" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_20f0e2" xlink:to="loc_cvmCashPaymentForOperatingLeases_163723" order="15" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageOperatingLeaseDiscountRate" xlink:label="loc_cvmWeightedAverageOperatingLeaseDiscountRate_19c97f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_20f0e2" xlink:to="loc_cvmWeightedAverageOperatingLeaseDiscountRate_19c97f" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_806a09" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_20f0e2" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_806a09" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_c204be" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_20f0e2" xlink:to="loc_us-gaapOperatingLeaseLiability_c204be" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense_d861ab" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_20f0e2" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense_d861ab" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageOperatingLeaseMaturityYear" xlink:label="loc_cvmWeightedAverageOperatingLeaseMaturityYear_8cbc5b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_20f0e2" xlink:to="loc_cvmWeightedAverageOperatingLeaseMaturityYear_8cbc5b" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses_310264" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_20f0e2" xlink:to="loc_us-gaapOtherExpenses_310264" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_PaymentsMadeToLandlord" xlink:label="loc_cvmPaymentsMadeToLandlord_ce1adb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_20f0e2" xlink:to="loc_cvmPaymentsMadeToLandlord_ce1adb" order="22" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ClinicalServiceTrial" xlink:label="loc_cvmClinicalServiceTrial_ee8db4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_20f0e2" xlink:to="loc_cvmClinicalServiceTrial_ee8db4" order="23" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_AdditionalClinicalTrial" xlink:label="loc_cvmAdditionalClinicalTrial_4aa734" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_20f0e2" xlink:to="loc_cvmAdditionalClinicalTrial_4aa734" order="24" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="000055 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_f5354e" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_acfde6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_f5354e" xlink:to="loc_us-gaapStatementTable_acfde6" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_23dcea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_acfde6" xlink:to="loc_us-gaapStatementLineItems_23dcea" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_e140c9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_acfde6" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_e140c9" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_ec9ca4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_e140c9" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_ec9ca4" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_f547aa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_acfde6" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_f547aa" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_d9c6ad" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_f547aa" xlink:to="loc_us-gaapRelatedPartyDomain_d9c6ad" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesNAndXAndYWarrantsMember" xlink:label="loc_cvmSeriesNAndXAndYWarrantsMember_33e4b7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_ec9ca4" xlink:to="loc_cvmSeriesNAndXAndYWarrantsMember_33e4b7" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesMMAndNNAndUUWarrantMember" xlink:label="loc_cvmSeriesMMAndNNAndUUWarrantMember_883b43" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_ec9ca4" xlink:to="loc_cvmSeriesMMAndNNAndUUWarrantMember_883b43" order="22" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_OfficerAndDirectorMember" xlink:label="loc_cvmOfficerAndDirectorMember_dda259" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_d9c6ad" xlink:to="loc_cvmOfficerAndDirectorMember_dda259" order="23" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_DeemedDividendFromModificationOfWarrants" xlink:label="loc_cvmDeemedDividendFromModificationOfWarrants_465fca" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_23dcea" xlink:to="loc_cvmDeemedDividendFromModificationOfWarrants_465fca" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_Warrant" xlink:label="loc_cvmWarrant_4c7b99" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_23dcea" xlink:to="loc_cvmWarrant_4c7b99" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:title="000056 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_8d1f33" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_dd5cf3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_8d1f33" xlink:to="loc_us-gaapStatementTable_dd5cf3" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_d6a683" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_dd5cf3" xlink:to="loc_us-gaapStatementLineItems_d6a683" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_a7fb8c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_dd5cf3" xlink:to="loc_us-gaapPlanNameAxis_a7fb8c" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_24f1e3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_a7fb8c" xlink:to="loc_us-gaapPlanNameDomain_24f1e3" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ErgomedMember" xlink:label="loc_cvmErgomedMember_84413b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_24f1e3" xlink:to="loc_cvmErgomedMember_84413b" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_2ff961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d6a683" xlink:to="loc_us-gaapCommonStockSharesIssued_2ff961" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_AggregateNetProceedsFromSaleOfSecurities" xlink:label="loc_cvmAggregateNetProceedsFromSaleOfSecurities_b249f1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d6a683" xlink:to="loc_cvmAggregateNetProceedsFromSaleOfSecurities_b249f1" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_f09ee1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d6a683" xlink:to="loc_us-gaapSaleOfStockPricePerShare_f09ee1" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ProceedFromIssuanceOrSaleOfEquity" xlink:label="loc_cvmProceedFromIssuanceOrSaleOfEquity_f037d6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d6a683" xlink:to="loc_cvmProceedFromIssuanceOrSaleOfEquity_f037d6" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_baa7d4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d6a683" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_baa7d4" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_PrepaidAmountOfResold" xlink:label="loc_cvmPrepaidAmountOfResold_3eb776" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d6a683" xlink:to="loc_cvmPrepaidAmountOfResold_3eb776" order="6" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsDetails" xlink:title="000057 - Disclosure - FAIR VALUE MEASUREMENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_e5a59a" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3e52bc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_e5a59a" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3e52bc" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_edc623" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_e5a59a" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_edc623" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_96af73" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_e5a59a" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_96af73" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings" xlink:label="loc_cvmFairValueMeasuredOnRecurringBasisGainLossIncludedEarnings_d06d5e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_e5a59a" xlink:to="loc_cvmFairValueMeasuredOnRecurringBasisGainLossIncludedEarnings_d06d5e" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_60a213" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_e5a59a" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_60a213" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="000058 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_dfd718" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaapUnrealizedGainLossOnInvestments_ce14ff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_dfd718" xlink:to="loc_us-gaapUnrealizedGainLossOnInvestments_ce14ff" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageRiskFreeInterestRate" xlink:label="loc_cvmWeightedAverageRiskFreeInterestRate_d9b1bd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_dfd718" xlink:to="loc_cvmWeightedAverageRiskFreeInterestRate_d9b1bd" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareDetails" xlink:title="000059 - Disclosure - NET LOSS PER COMMON SHARE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_d2af29" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract_c30ef2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_d2af29" xlink:to="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract_c30ef2" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:label="loc_cvmNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_d72d78" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract_c30ef2" xlink:to="loc_cvmNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_d72d78" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:label="loc_cvmWeightedAverageNumberOfSharesOutstandingBasicAndDiluted_687c54" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract_c30ef2" xlink:to="loc_cvmWeightedAverageNumberOfSharesOutstandingBasicAndDiluted_687c54" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_EarningPerShareBasicAndDiluted" xlink:label="loc_cvmEarningPerShareBasicAndDiluted_0918ad" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract_c30ef2" xlink:to="loc_cvmEarningPerShareBasicAndDiluted_0918ad" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareDetails1" xlink:title="000060 - Disclosure - NET LOSS PER COMMON SHARE (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_096190" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_358a2b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_096190" xlink:to="loc_us-gaapStatementTable_358a2b" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_243fec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_358a2b" xlink:to="loc_us-gaapStatementLineItems_243fec" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_04cbea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_358a2b" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_04cbea" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_a40a9a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_04cbea" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_a40a9a" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_OptionsMember" xlink:label="loc_cvmOptionsMember_1fdf4c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_a40a9a" xlink:to="loc_cvmOptionsMember_1fdf4c" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_UnvestedRestrictedStockMember" xlink:label="loc_cvmUnvestedRestrictedStockMember_875ad9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_a40a9a" xlink:to="loc_cvmUnvestedRestrictedStockMember_875ad9" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b566ac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_243fec" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b566ac" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:title="000061 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_b54d36" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_0cea46" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_b54d36" xlink:to="loc_us-gaapStatementTable_0cea46" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_1d8230" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0cea46" xlink:to="loc_us-gaapStatementLineItems_1d8230" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis_9fcbce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0cea46" xlink:to="loc_us-gaapSubsequentEventTypeAxis_9fcbce" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_100a61" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis_9fcbce" xlink:to="loc_us-gaapSubsequentEventTypeDomain_100a61" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_503c21" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain_100a61" xlink:to="loc_us-gaapSubsequentEventMember_503c21" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_f4a173" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1d8230" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_f4a173" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_28766f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1d8230" xlink:to="loc_us-gaapSaleOfStockPricePerShare_28766f" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_80ae2c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1d8230" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_80ae2c" order="3" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>cvm-20230930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 12/21/2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cvm.com/role/Cover" xlink:href="cvm-20230930.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BalanceSheets" xlink:href="cvm-20230930.xsd#BalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BalanceSheetsParenthetical" xlink:href="cvm-20230930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfOperations" xlink:href="cvm-20230930.xsd#StatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfStockholdersEquity" xlink:href="cvm-20230930.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfCashFlows" xlink:href="cvm-20230930.xsd#StatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/ORGANIZATION" xlink:href="cvm-20230930.xsd#ORGANIZATION" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LIQUIDITY" xlink:href="cvm-20230930.xsd#LIQUIDITY" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="cvm-20230930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptions" xlink:href="cvm-20230930.xsd#WarrantsAndNonemployeeOptions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PropertyAndEquipment" xlink:href="cvm-20230930.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PATENTS" xlink:href="cvm-20230930.xsd#PATENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxes" xlink:href="cvm-20230930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensation" xlink:href="cvm-20230930.xsd#EquityBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EmployeeBenefitPlan" xlink:href="cvm-20230930.xsd#EmployeeBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingencies" xlink:href="cvm-20230930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactions" xlink:href="cvm-20230930.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquity" xlink:href="cvm-20230930.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurements" xlink:href="cvm-20230930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShare" xlink:href="cvm-20230930.xsd#NetLossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEvents" xlink:href="cvm-20230930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20230930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsTables" xlink:href="cvm-20230930.xsd#WarrantsAndNonemployeeOptionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PlantPropertyAndEquipmentTables" xlink:href="cvm-20230930.xsd#PlantPropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsTables" xlink:href="cvm-20230930.xsd#PatentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesTables" xlink:href="cvm-20230930.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationTables" xlink:href="cvm-20230930.xsd#EquityBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20230930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsTables" xlink:href="cvm-20230930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareTables" xlink:href="cvm-20230930.xsd#NetLossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="cvm-20230930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" xlink:href="cvm-20230930.xsd#WarrantsAndNonemployeeOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1" xlink:href="cvm-20230930.xsd#WarrantsAndNonemployeeOptionsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails2" xlink:href="cvm-20230930.xsd#WarrantsAndNonemployeeOptionsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails3" xlink:href="cvm-20230930.xsd#WarrantsAndNonemployeeOptionsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative" xlink:href="cvm-20230930.xsd#WarrantsAndNonemployeeOptionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PropertyAndEquipmentDetails" xlink:href="cvm-20230930.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="cvm-20230930.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails" xlink:href="cvm-20230930.xsd#PatentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails1" xlink:href="cvm-20230930.xsd#PatentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetailsNarrative" xlink:href="cvm-20230930.xsd#PatentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesDetails" xlink:href="cvm-20230930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesDetails1" xlink:href="cvm-20230930.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesDetailsNarrative" xlink:href="cvm-20230930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails" xlink:href="cvm-20230930.xsd#EquityBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails1" xlink:href="cvm-20230930.xsd#EquityBasedCompensationDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails2" xlink:href="cvm-20230930.xsd#EquityBasedCompensationDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails3" xlink:href="cvm-20230930.xsd#EquityBasedCompensationDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails4" xlink:href="cvm-20230930.xsd#EquityBasedCompensationDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetailsNarrative" xlink:href="cvm-20230930.xsd#EquityBasedCompensationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EmployeeBenefitPlanDetailNarrative" xlink:href="cvm-20230930.xsd#EmployeeBenefitPlanDetailNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20230930.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20230930.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20230930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cvm-20230930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:href="cvm-20230930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsDetails" xlink:href="cvm-20230930.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsDetailsNarrative" xlink:href="cvm-20230930.xsd#FairValueMeasurementsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareDetails" xlink:href="cvm-20230930.xsd#NetLossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareDetails1" xlink:href="cvm-20230930.xsd#NetLossPerCommonShareDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:href="cvm-20230930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/BalanceSheets" xlink:title="000002 - Statement - BALANCE SHEETS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/BalanceSheetsParenthetical" xlink:title="000003 - Statement - BALANCE SHEETS (Parenthetical)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfOperations" xlink:title="000004 - Statement - STATEMENTS OF OPERATIONS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfStockholdersEquity" xlink:title="000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WarrantExercisesShares" xlink:label="loc_cvmWarrantExercisesShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantExercisesShares" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WarrantExercisesAmount" xlink:label="loc_cvmWarrantExercisesAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantExercisesAmount" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IncreaseDecreaseFromStockIssuanceCosts" xlink:label="loc_cvmIncreaseDecreaseFromStockIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIncreaseDecreaseFromStockIssuanceCosts" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" order="15" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IncentiveStockForfeitedShares" xlink:label="loc_cvmIncentiveStockForfeitedShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIncentiveStockForfeitedShares" order="16" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IncentiveStockForfeitedAmount" xlink:label="loc_cvmIncentiveStockForfeitedAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIncentiveStockForfeitedAmount" order="17" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfCashFlows" xlink:title="000006 - Statement - STATEMENTS OF CASH FLOWS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/ORGANIZATION" xlink:title="000007 - Disclosure - ORGANIZATION" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LIQUIDITY" xlink:title="000008 - Disclosure - LIQUIDITY" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptions" xlink:title="000010 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PropertyAndEquipment" xlink:title="000011 - Disclosure - PROPERTY AND EQUIPMENT" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PATENTS" xlink:title="000012 - Disclosure - PATENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxes" xlink:title="000013 - Disclosure - INCOME TAXES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensation" xlink:title="000014 - Disclosure - EQUITY-BASED COMPENSATION" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/EmployeeBenefitPlan" xlink:title="000015 - Disclosure - EMPLOYEE BENEFIT PLAN" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingencies" xlink:title="000016 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactions" xlink:title="000017 - Disclosure - RELATED PARTY TRANSACTIONS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquity" xlink:title="000018 - Disclosure - STOCKHOLDERS EQUITY" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurements" xlink:title="000019 - Disclosure - FAIR VALUE MEASUREMENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShare" xlink:title="000020 - Disclosure - NET LOSS PER COMMON SHARE" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEvents" xlink:title="000021 - Disclosure - SUBSEQUENT EVENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsTables" xlink:title="000023 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PlantPropertyAndEquipmentTables" xlink:title="000024 - Disclosure - PLANT PROPERTY AND EQUIPMENT (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsTables" xlink:title="000025 - Disclosure - PATENTS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesTables" xlink:title="000026 - Disclosure - INCOME TAXES (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationTables" xlink:title="000027 - Disclosure - EQUITY-BASED COMPENSATION (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:title="000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsTables" xlink:title="000029 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareTables" xlink:title="000030 - Disclosure - NET LOSS PER COMMON SHARE (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_FiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_cvmFiniteLivedIntangibleAssetsUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmFiniteLivedIntangibleAssetsUsefulLife" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" order="2" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" xlink:title="000032 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesYMember" xlink:label="loc_cvmSeriesYMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesYMember" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesMMMember" xlink:label="loc_cvmSeriesMMMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesMMMember" order="62" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesNNMember" xlink:label="loc_cvmSeriesNNMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesNNMember" order="63" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesRRMember" order="64" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesSSMember" xlink:label="loc_cvmSeriesSSMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesSSMember" order="65" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesTTMember" xlink:label="loc_cvmSeriesTTMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesTTMember" order="66" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesNMember" xlink:label="loc_cvmSeriesNMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesNMember" order="67" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesUUMember" xlink:label="loc_cvmSeriesUUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesUUMember" order="68" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesXMember" xlink:label="loc_cvmSeriesXMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesXMember" order="69" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantsMember" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" order="71" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ConsultantsOneMember" xlink:label="loc_cvmConsultantsOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantsOneMember" order="72" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" order="73" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_Issuedate2" xlink:label="loc_cvmIssuedate2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIssuedate2" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SharesIssuableUponExerciseOfwarrant" xlink:label="loc_cvmSharesIssuableUponExerciseOfwarrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmSharesIssuableUponExerciseOfwarrant" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ExercisePrice" xlink:label="loc_cvmExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExercisePrice" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ExpirationDate1" xlink:label="loc_cvmExpirationDate1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExpirationDate1" order="4" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1" xlink:title="000033 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesZMember" xlink:label="loc_cvmSeriesZMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesZMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesCCMember" xlink:label="loc_cvmSeriesCCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesCCMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesHHMember" xlink:label="loc_cvmSeriesHHMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesHHMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesAAMember" xlink:label="loc_cvmSeriesAAMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesAAMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesWMember" xlink:label="loc_cvmSeriesWMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesWMember" order="25" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesZZMember" xlink:label="loc_cvmSeriesZZMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesZZMember" order="26" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesBBMember" xlink:label="loc_cvmSeriesBBMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesBBMember" order="27" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_NetLossGainOnWarrantLiabilities" xlink:label="loc_cvmNetLossGainOnWarrantLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNetLossGainOnWarrantLiabilities" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails2" xlink:title="000034 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details 2)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesCCMember" xlink:label="loc_cvmSeriesCCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesCCMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WarrantsExercised" xlink:label="loc_cvmWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantsExercised" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ExercisePriceWarrants" xlink:label="loc_cvmExercisePriceWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExercisePriceWarrants" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails3" xlink:title="000035 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details 3)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesNNMember" xlink:label="loc_cvmSeriesNNMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesNNMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesRRMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesSSMember" xlink:label="loc_cvmSeriesSSMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesSSMember" order="13" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_EquityWarrantsExercised" xlink:label="loc_cvmEquityWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmEquityWarrantsExercised" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ProceedsFromEquityWarrantsExercised" xlink:label="loc_cvmProceedsFromEquityWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmProceedsFromEquityWarrantsExercised" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_EquityWarrantsExercisePrice" xlink:label="loc_cvmEquityWarrantsExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmEquityWarrantsExercisePrice" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative" xlink:title="000036 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="80" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="90" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="90" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="110" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" order="110" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="120" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" order="130" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" order="111" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_RestrictedStocksMember" xlink:label="loc_cvmRestrictedStocksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmRestrictedStocksMember" order="112" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantsMember" order="113" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ConsultingAgreementsMember" xlink:label="loc_cvmConsultingAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmConsultingAgreementsMember" order="114" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" order="115" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesCCWarrantsMember" xlink:label="loc_cvmSeriesCCWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesCCWarrantsMember" order="116" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesZWarrantsMember" xlink:label="loc_cvmSeriesZWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesZWarrantsMember" order="117" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesAAWarrantsMember" xlink:label="loc_cvmSeriesAAWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesAAWarrantsMember" order="118" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesHHWarrantsMember" xlink:label="loc_cvmSeriesHHWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesHHWarrantsMember" order="119" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesRRMember" order="120" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="loc_cvmNonQualifiedStockOptionsPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmNonQualifiedStockOptionsPlansMember" order="121" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ConsultantMember" xlink:label="loc_cvmConsultantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantMember" order="122" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_TwoSeptemberTwoThousendTwentyFourMember" xlink:label="loc_cvmTwoSeptemberTwoThousendTwentyFourMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_cvmTwoSeptemberTwoThousendTwentyFourMember" order="123" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_TwoSeptemberTwoThousendTwentyFiveMember" xlink:label="loc_cvmTwoSeptemberTwoThousendTwentyFiveMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_cvmTwoSeptemberTwoThousendTwentyFiveMember" order="124" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IncrementalCostDeemedDividend" xlink:label="loc_cvmIncrementalCostDeemedDividend" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIncrementalCostDeemedDividend" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_StockIssuedDuringPeriodToPurchaseCommonStock" xlink:label="loc_cvmStockIssuedDuringPeriodToPurchaseCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmStockIssuedDuringPeriodToPurchaseCommonStock" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_DeemedDividend11" xlink:label="loc_cvmDeemedDividend11" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmDeemedDividend11" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_DeemedDividendAmount" xlink:label="loc_cvmDeemedDividendAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmDeemedDividendAmount" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_StockOptionExercisePrice" xlink:label="loc_cvmStockOptionExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmStockOptionExercisePrice" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_VestedOptions" xlink:label="loc_cvmVestedOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmVestedOptions" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IssuedStockOfOptionsOutstanding" xlink:label="loc_cvmIssuedStockOfOptionsOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIssuedStockOfOptionsOutstanding" order="7" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_CommonStockIssuedForServiceShares" xlink:label="loc_cvmCommonStockIssuedForServiceShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmCommonStockIssuedForServiceShares" order="8" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WarrantsExpired" xlink:label="loc_cvmWarrantsExpired" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantsExpired" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ExercisePriceWarrants" xlink:label="loc_cvmExercisePriceWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExercisePriceWarrants" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostsAndExpenses" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_PrepaidExpenses" xlink:label="loc_cvmPrepaidExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmPrepaidExpenses" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" order="14" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PropertyAndEquipmentDetails" xlink:title="000037 - Disclosure - PROPERTY AND EQUIPMENT (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="000038 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails" xlink:title="000039 - Disclosure - PATENTS (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails1" xlink:title="000040 - Disclosure - PATENTS (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetailsNarrative" xlink:title="000041 - Disclosure - PATENTS (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesDetails" xlink:title="000042 - Disclosure - INCOME TAXES (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesDetails1" xlink:title="000043 - Disclosure - INCOME TAXES (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesDetailsNarrative" xlink:title="000044 - Disclosure - INCOME TAXES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IncomeTaxMember" xlink:label="loc_cvmIncomeTaxMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_cvmIncomeTaxMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ResearchAndDevelopmentCredit" xlink:label="loc_cvmResearchAndDevelopmentCredit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmResearchAndDevelopmentCredit" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ResearchAndDevelopmentCreditDescription" xlink:label="loc_cvmResearchAndDevelopmentCreditDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmResearchAndDevelopmentCreditDescription" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_CumulativeChangeInOwnershipPercentage" xlink:label="loc_cvmCumulativeChangeInOwnershipPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmCumulativeChangeInOwnershipPercentage" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="loc_us-gaapTaxCreditCarryforwardDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardDescription" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_DeferredTaxAssets" xlink:label="loc_cvmDeferredTaxAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmDeferredTaxAssets" order="6" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails" xlink:title="000045 - Disclosure - EQUITY-BASED COMPENSATION (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails1" xlink:title="000046 - Disclosure - EQUITY-BASED COMPENSATION (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails2" xlink:title="000047 - Disclosure - EQUITY-BASED COMPENSATION (Details 2)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_OutstandingMember" xlink:label="loc_cvmOutstandingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_cvmOutstandingMember" order="41" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ExercisableMember" xlink:label="loc_cvmExercisableMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_cvmExercisableMember" order="42" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="15" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised" xlink:label="loc_cvmSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised" order="16" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_NumberOfOptionsVested" xlink:label="loc_cvmNumberOfOptionsVested" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNumberOfOptionsVested" order="18" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_NumberOfOptionsExercised" xlink:label="loc_cvmNumberOfOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNumberOfOptionsExercised" order="19" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_NumberOfOptions" xlink:label="loc_cvmNumberOfOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNumberOfOptions" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageExercisePriceVested" xlink:label="loc_cvmWeightedAverageExercisePriceVested" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageExercisePriceVested" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageExercisePriceExpired" xlink:label="loc_cvmWeightedAverageExercisePriceExpired" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageExercisePriceExpired" order="22" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" xlink:label="loc_cvmWeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" order="23" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" xlink:label="loc_cvmWeightedAverageRemainingContractualLifeInYearsOutstandingEnding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageRemainingContractualLifeInYearsOutstandingEnding" order="24" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails3" xlink:title="000048 - Disclosure - EQUITY-BASED COMPENSATION (Details 3)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails4" xlink:title="000049 - Disclosure - EQUITY-BASED COMPENSATION (Details 4)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_RestrictedStockAwardsMember" xlink:label="loc_cvmRestrictedStockAwardsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmRestrictedStockAwardsMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetailsNarrative" xlink:title="000050 - Disclosure - EQUITY-BASED COMPENSATION (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_RestrictedStockAwardsMember" xlink:label="loc_cvmRestrictedStockAwardsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmRestrictedStockAwardsMember" order="31" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_StockBonusPlansMember" xlink:label="loc_cvmStockBonusPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_cvmStockBonusPlansMember" order="32" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_StockCompensationPlansMember" xlink:label="loc_cvmStockCompensationPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmStockCompensationPlansMember" order="33" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="loc_cvmNonQualifiedStockOptionsPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_cvmNonQualifiedStockOptionsPlansMember" order="34" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IncentiveStockOptionPlansMember" xlink:label="loc_cvmIncentiveStockOptionPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_cvmIncentiveStockOptionPlansMember" order="35" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IncentiveStockBonusPlanMember" xlink:label="loc_cvmIncentiveStockBonusPlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_cvmIncentiveStockBonusPlanMember" order="36" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_NonVestedOptionsMember" xlink:label="loc_cvmNonVestedOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmNonVestedOptionsMember" order="37" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_PerformanceBasedStockOptionsSharesGranted" xlink:label="loc_cvmPerformanceBasedStockOptionsSharesGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmPerformanceBasedStockOptionsSharesGranted" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityStrikePrice1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityStrikePrice1" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockDescription" xlink:label="loc_us-gaapConversionOfStockDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockDescription" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_RemainingOutstandingFairValueOfShares" xlink:label="loc_cvmRemainingOutstandingFairValueOfShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmRemainingOutstandingFairValueOfShares" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_VestedShares" xlink:label="loc_cvmVestedShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmVestedShares" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationEquity" xlink:label="loc_us-gaapDeferredCompensationEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredCompensationEquity" order="12" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/EmployeeBenefitPlanDetailNarrative" xlink:title="000051 - Disclosure - EMPLOYEE BENEFIT PLAN (Detail Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:title="000052 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:title="000053 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000054 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ErgomedMember" xlink:label="loc_cvmErgomedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmErgomedMember" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_LandlordMember" xlink:label="loc_cvmLandlordMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_cvmLandlordMember" order="62" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaapLeaseAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLeaseAgreementsMember" order="63" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaapOperatingExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapOperatingExpenseMember" order="64" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_IncrementalBorrowingDerivativeVariableRate" xlink:label="loc_cvmIncrementalBorrowingDerivativeVariableRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIncrementalBorrowingDerivativeVariableRate" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_NetOfDiscount" xlink:label="loc_cvmNetOfDiscount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNetOfDiscount" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases" xlink:label="loc_us-gaapDescriptionOfLesseeLeasingArrangementsCapitalLeases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDescriptionOfLesseeLeasingArrangementsCapitalLeases" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_AdditionalExpenses" xlink:label="loc_cvmAdditionalExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmAdditionalExpenses" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_FinancingLeaseContractualArrangement" xlink:label="loc_cvmFinancingLeaseContractualArrangement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmFinancingLeaseContractualArrangement" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageMaturityYear" xlink:label="loc_cvmWeightedAverageMaturityYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageMaturityYear" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiability" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciation" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="loc_us-gaapFinanceLeaseInterestPaymentOnLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseInterestPaymentOnLiability" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_CashPaymentToLeaseLiability" xlink:label="loc_cvmCashPaymentToLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmCashPaymentToLeaseLiability" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:label="loc_us-gaapLongTermDebtWeightedAverageInterestRateOverTime" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebtWeightedAverageInterestRateOverTime" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_CashPaymentForOperatingLeases" xlink:label="loc_cvmCashPaymentForOperatingLeases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmCashPaymentForOperatingLeases" order="15" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageOperatingLeaseDiscountRate" xlink:label="loc_cvmWeightedAverageOperatingLeaseDiscountRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageOperatingLeaseDiscountRate" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" order="19" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_WeightedAverageOperatingLeaseMaturityYear" xlink:label="loc_cvmWeightedAverageOperatingLeaseMaturityYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageOperatingLeaseMaturityYear" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherExpenses" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_PaymentsMadeToLandlord" xlink:label="loc_cvmPaymentsMadeToLandlord" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmPaymentsMadeToLandlord" order="22" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ClinicalServiceTrial" xlink:label="loc_cvmClinicalServiceTrial" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmClinicalServiceTrial" order="23" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_AdditionalClinicalTrial" xlink:label="loc_cvmAdditionalClinicalTrial" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmAdditionalClinicalTrial" order="24" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="000055 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesNAndXAndYWarrantsMember" xlink:label="loc_cvmSeriesNAndXAndYWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesNAndXAndYWarrantsMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_SeriesMMAndNNAndUUWarrantMember" xlink:label="loc_cvmSeriesMMAndNNAndUUWarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesMMAndNNAndUUWarrantMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_OfficerAndDirectorMember" xlink:label="loc_cvmOfficerAndDirectorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmOfficerAndDirectorMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_DeemedDividendFromModificationOfWarrants" xlink:label="loc_cvmDeemedDividendFromModificationOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmDeemedDividendFromModificationOfWarrants" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_Warrant" xlink:label="loc_cvmWarrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrant" order="2" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:title="000056 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ErgomedMember" xlink:label="loc_cvmErgomedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmErgomedMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_AggregateNetProceedsFromSaleOfSecurities" xlink:label="loc_cvmAggregateNetProceedsFromSaleOfSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmAggregateNetProceedsFromSaleOfSecurities" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_ProceedFromIssuanceOrSaleOfEquity" xlink:label="loc_cvmProceedFromIssuanceOrSaleOfEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmProceedFromIssuanceOrSaleOfEquity" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_PrepaidAmountOfResold" xlink:label="loc_cvmPrepaidAmountOfResold" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmPrepaidAmountOfResold" order="6" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsDetails" xlink:title="000057 - Disclosure - FAIR VALUE MEASUREMENTS (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="000058 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareDetails" xlink:title="000059 - Disclosure - NET LOSS PER COMMON SHARE (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareDetails1" xlink:title="000060 - Disclosure - NET LOSS PER COMMON SHARE (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_OptionsMember" xlink:label="loc_cvmOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmOptionsMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20230930.xsd#cvm_UnvestedRestrictedStockMember" xlink:label="loc_cvmUnvestedRestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmUnvestedRestrictedStockMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:title="000061 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" order="3" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>cvm_10kimg16.jpg
<TEXT>
begin 644 cvm_10kimg16.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" $7 BX# 2(  A$! Q$!_\0
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MA.%(4G 'H!FFZ]X>DU[6=$FGNPFGZ9=&]DM@N3<2JN(LG/"JQ+8P<D+Z5U-
M'ADOB#QQX?U7QG>:QXS;4=-\(16]U);0Z7!')>H\7F,F[/RGC (KN=9^(-IH
MT]U#+IL\IM_#\OB E74;DC(!B_WCGKTJU<>"M#O)?$C7D,DZ>)84@OXFD.UD
M2,Q@+CE?E/KUK)M_A7H,8OFNM6UO4Y+S2I-%DEO;WS&6V<@E5X 4C'7&?7-
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MK2Y[.(FW^6TEDG>;,8S\J+O 4#GY>U>NT4 >8-X#U23QM;:Y/?6LBP7WVGS
MKK))"86C\DJ"$/+9W'<6QSBHK?X:WD>@Z5H_VZTL4T^VN[,7%G$5DE66'REE
M(XPXZGD_6O5** /-+CPWK']B6'AV/2],@CEO+9I[K3U\I(HH&5R[ \EV*!5
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M.0#TXJ#2?AWXD4^&])UW5M-ET+PON6R-E;/'<W/[EH4\PDE4PCDG;G<<=.E
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MQ9Z+IMO80?W((PN?<XZGW-:Q&?I3LVES?@'*Y)<S^XEHHHK0U"BBB@ HHHH
M**** "BBB@ HHHH **** $HI*\K^(WQ*C\.QOH^C2)+JKCYWZBW!_FWMVZFL
M*U:%&+G-Z$RDHJ[-#QU\0M/\(6AM;=A=:M(O[N#=PG^T_P#AU/ZU\XZOK&I:
MYJ<NH:I=/<W$AY9CT'8 =A["JUS=7%Y=275U,\TTK%G=SDL3W)JUHVCZAKVK
M0Z;IENT]Q*< #H!W)/8#UKY6OBJF*G9;=%_74\V=251D6FZ;>ZMJ$=CI]N\]
MQ(=JJ@Y-?1G@+X:V7A>W34-11+O5FY+XRL'LGO[_ )>^KX)\":;X1TX*JK<7
M\BCSKDCD_P"ROHO\^]=K7KX+ *E:=367Y'72H\OO2W'4445[1TG*^--<NM!\
M.&XTV&.?4KJ>*RLDE^YYTKA$+8YV@G<<=@:Y3Q?\6M%\ W]OH>L-)J>IPVB7
M-VT;10?(<C<JNPW,2K$(N3Q]*[/Q9H/_  DGAR?3H[HV=TKI<6MRJ[C!/&P>
M-\=P&49'<9%96H>![/7;NWU34KJ]T[6/LZV]U<:/>RVHG4<[#@Y902V,\C)Y
MYH TM6\4Z;HGA%_%%PMQ-9>7')&D,>993(56-%4X^9F90 <<GG%4?#/B^YUW
M6=4T34O#MWH>H:=##.\=Q-%*'27?M(:-F'\!S2:YX-L=4TG6+11)<-J-K%;B
M&\NIF@0Q9,; !LHP."64AB0#G(KG/"OPWOM/M/$+^(M<N;V]UN.&"26UO)P\
M4<6[;ME=B^XECTP!TQU) /5Z\L&M_$[_ (6-_P (H;SPSY?V#^T?-^PW&=GG
M>7LQYW7'.?TKL-+T22QU?5]6N-4N+M]1DC\N)V/EVT2(%5$7)&2=S%NI+>PJ
MW_8>G_\ "4_\)+L?^T?LGV'=O.WRM^_&WIG=WH \O_X6IKUM8ZTVH:?8QS+<
MR?V0R;_+N88[L6\JODY\U,AN."&!QP:L1_$+7KSXE:IX9@U'2;**SU-;&.&7
M2;R>25?+1RQF1A$I.\CGICFNKU#X<^%-4T2+1;VRD>UAU ZI$?.8.DYD,A8-
MUP2Q!'3!Q6[I>BV>DS:E-9HZOJ=T;RXW.6!D**A(!Z#"+Q0!DV/CKP_J5W8V
M]I-/(=1D>.R<P,%N@@)=T..4&WENG(]1F/0=9U+_ (2[7?#.K/'/+:"*\M;B
M./9YEM+N"JPR?F1D=2>XVG YJ"R^'NBZ?>VEU9SZA ;/>MI&MTVRUC=MSQHO
M0*Q SU.  " *O:)H=U9>(=;\0ZI*EQ?ZBZ11K"I"06T>?+C&>2<L[,>Y;@8
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MD_+'/- %<C'52>JX/4''6LWQ=XJL?"+Z,;K33/;7UR;669"JBTB",[2,".4
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M;%#KP4N1R5^W4.23CS6T.5\,_#_3/!JV5GX9N9]/TJ":XNIK-3D7$TN!N8]
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M9P2,0@AC'^L SCYB2<^U=U7'> O$5UXF\'VFLWT<45Q(\J21PYVJ4D9>Y)Z
M5VE8TK<J:=[Z_>8T>7D3B[IZ_>.HHHK8V,+5M!L=8>(WD;GRR#\C;=W7@GKW
M[5=ATG3;=%6WL880HV@QH%('U%:%% &5=:/:W41CF42H>JRJ'!_.L6;P=8FR
MBLX;2"*VCN!=". &/Y_PKK:*5E>YGRQOS6U.*C\*M;ZA)>0W]U;22.6P!D<G
M)^85=D_M*)U:"&.Y4#+2;P&'X\-745')!#,N)8U<>XKBJT/:2YE)IFZE8R;4
MWBP[IKEC(WS%2 RJ/0=_S-1MJXCV;E#*SA-ZY!&>^#V'4\]*X;Q%\:/ /AG7
MWT&\NIGN(SMF:"'>D)]&/J/0 UV-C;Z?K.FVVI:?J3SVDT8>&2+9AU(X.=O-
M&&4N=QJ3O;L;5\/6I4XU)1<5+9M63-^*2.:/?&ZNOJIR*\?^('P+TOQOXC.O
M1ZM+IE[(%6;;&)%DVC .,C!P .O:O3$TJ2%B]O?2I(<9+ $'Z@8J6/\ M195
M298YHB<%U.T@>M=M6E"I'E;NC+"XRMA:GM*;<9;76IS_ ()\'Z?X'\,1:'IK
M22)&QD>20_-(YZL?R''H!78K\V*CCFS_ *R-T/N,C\QQ3UDCD!V.&'J#FE&*
MBE&.PJLYU9RJ5'>3=VSRSX@:QX9^%Z77C*'25FUO40MO'&K;1(5'7T4 8R0,
MG@5F?"WXR-\0+ZZTF]T<6=]#'YZM"Y>-T! /49!!(^M=AXX\$Q>-(]$AN1#)
M:65\MQ<Q3;OWL6TAE!'(/(].E5]/T'P#\+]/N+K3[./3EN/E9@S233$<A 6)
M)^G2N>U3VETTHK\32-;#TJ$HU(^]>Z=[*W6YL^+O#MOXJ\+WN@W5U<6D5TH5
MI;=]KC!!_$<<CN*Y?2-4\/\ P_\ #=MX7TN\N]=N;4,-JL)&!)R=S?=4#/3L
M.U<WXF\:7NI%FOIY=-L&_P!780-B:8?]-&'0>W3Z]:X&[U^ZEA-K9(MA:?\
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M!HEQ?&]LIM;-G;VVC6T4OE0!\$7$,B"=< $M*'"C@@$=?4?$'C::"\DL]-C
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ML+V[%X;B%@'B)&#U!!!XR#Z"H_ /PWT'X=V5Q:Z3YT\MR0T]Q.07DQG X
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M52NYV7#1J?[N.^/7-=+ES'!&-CI_!]OX9FTRW6SU.#7+I")3<3MOE#CN%;E
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M;+\_4X:^(J5Y^TJ.[.5M?A_X1MK9(/[%BFVY^>7+,><\FI_^$#\(?]"_:_\
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MXGUK^UM05V9KC!&%/1<GEL>I]?:NP[;J2]Z.JM<SE3A"H[6DD][:.QYE\/\
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MI]O[I_2O5J* /CQA?Z1J;*?.LKVV?!P2KHPKVCP#\3AJ1AT/Q ZI>'Y8;HG
MF/96]&]^_P!>NS\0/ UOXCTUKZT58M4MURK@?ZU?[K>OUKYWDCE@G>*53'+&
MQ5E/52* /LKJ*Q-'\/Z;H$5S'IL'E"YF:9_J>P]AV%<I\,?&#>(-%;3[Z0-J
M-D "2?FEC[-]1T/X>M>C4 <#XLT'P7J%Y!J.O*T&HPH8XKJUNI;:X$9.2F^%
ME<KGL3C-9]OX+^'>M6=A9V*W"MIKRS6[V^HW,-PK2X$C&0.';=@9))K5\3>#
MSK5R+ZWO/*E*A61QE3CT]*@\.^"VTG44O[J\#O'G:D8('(QR3]>E>,ZN*5?D
M4%RWWOT[G>J>']CSN;YNUNO8OQ_#WPC#X=O?#JZ##)IU\WF72RL\DEP_&'>1
MB79Q@88MD8&",59\/>#="\+S7$VEVLOVBY"K-<W-S+<S.J_=4R2LS;1DX7.!
MDUU%%>R<!DZKI=CK6ESZ7J5OY]G<KLECW%=P],@@T^^U.QTV+S+VY2%3P-YY
M/T'4U=/3%<EXH\,MKD\=Q%=>3*B[<,,@CK^!KAQ-2M3IN5&/-+HF[&]",)U%
M&I+ECW)8)O"^N>(;+5DD6;5+&.6*WD+,K(DFW> IP#G:O8]*W9H8KJWDMYXU
MEAD4HZ.H974C!!!Z@BN(T;P+-8ZC#>W=T&\I@ZK'GDCIDGM7H87I6&!JXBK3
M<L1%1E?IV+Q,*=.=J4N9'$Z;\,_!NEW=I=V.FW,8LY!+:VS:A</;6[#H4A+F
M-<=L+@9XJS8_#[POINK)J.GVMU;&.4SI;1WTZVJ2$DEA!O\ +!R2?N]3FNRH
MKU3E.1L_!OAK39=+FLM-$)TF2YELSYCGRFG),QY/.XL>N<=L5<;Q5H<4WDR:
M@F\''&2/S Q6E=6RW5I-:N2$E4H2IP0",<5Y[-\.;HSGRKV,Q$\%E.['T_\
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M@8]!G:&'3@4 9.F^-O%.JOINE:)#IAN(-$LM4O[G6+AHS-YRGB,1KVV-N?&
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ML$CTP2R2$1LTB2%IT7.%R7+*!@\&K6E?$[Q5J'AZUL;B#3M/UR?Q%)X?:]N
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M/1/"6F76B^"]$TB^8/=65C#;RL#D;E0 X/<9%=!56]OK73[1[J\F6*)!DDT
M9?B?6K?0="FOYY F%(7Z_P"?UQ7RS?7DNH:C<7TW^LF<N1Z>@_ 8%=7X^\:2
M^*M3,5OE-.A;]VO]\C^+Z?Y]*XN@#3\/V$FJ>)-/L(EW--.BX]L\G\LFOK@
M*H4< <5XO\'?"\GG2^*+Q"J &&U!_B/\3_T'XU[50 4444 %%%% !1110 44
M44 %%%1NZ1H6D8*HZDG H =3)IHX8S)*P51W-8E_XBM;<%+?]\_K_"/\:YB]
MU*ZOI-TTAQV4=!7!6QD(:1U9T0H2EOH:6L:X]WFWM<I#W/=JR;6UFO+A885+
M,U3:?IESJ$P6-"$_B8]!7:V&FV^GP[8ERY^\_<UP4Z53$2YY[?UL;RG&DN6(
M:;I\>GVPC7!;^)O6KW:BC'%>U&*@E&.QPMMN['4445H(**** "BBB@ HHHH
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MYW##XW(ZL5=3@D9# C@D<<$BNEH **** "BBB@ HHHH **** "BBB@ HHHH
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MXJU">S\ W<_Q*\.V>KQ?:8UAL-'6>Z65OX?,!0$ 'DD@@ 9Y.!7+:?8Z+#\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M&'#I>FV^I76L6]JD=W=JC3S(,-*%X7=ZD XSUQQ6Y110!R\GA/PO<>(%\3S:
M);2ZGN#K=,NYE8#:& / ('?&:U9+>":_MTEA626 F>-G4$QL002#V."1QV)H
MHH TZ*** "L;4-)T[5(8&U"TCN8[>=;J-9!D+(O*MCU!Y'OS110!LT444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
$4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>cvm_10kimg9.jpg
<TEXT>
begin 644 cvm_10kimg9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %W 9T# 2(  A$! Q$!_\0
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MY'7OQ6!??$'Q;KFHV7BG3[Q=.OKSX;WNJ"".1_L\4RS [PN3\P4'!.><9XH
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M@:UCNV3,B1,<L@/H3VKG)?A3\-9["VT^;P3I#6MM))-!"ULI6)GQOVCL#@9
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M_:K?_GXB_P"^Q1]JM_\ GXB_[[% $U%0_:K?_GXB_P"^Q1]JM_\ GXB_[[%
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M]]BC[5;_ //Q%_WV* )J*A^U6_\ S\1?]]BC[5;_ //Q%_WV* )J*A^U6_\
MS\1?]]BC[5;_ //Q%_WV* )J*A^U6_\ S\1?]]BC[5;_ //Q%_WV* )J*A^U
M6_\ S\1?]]BC[5;_ //Q'_WV* )J*.HHH **** "BBB@ HHHH **** "BBD)
M !)X'K0 M5))OF\J%=[]_1?K_A1N>X^6(E(O^>G=OI_C5B.-(T"HNT4 01P;
M27<^9(>K,/T'H*L>6G]Q?RIU% #?+3^XOY4>6G]Q?RIU% #?+3^XOY4>6G]Q
M?RIU% #?+3^XOY4>6G]Q?RIU% #?+3^XOY4>6G]Q?RIU% #?+3^XOY4>6G]Q
M?RIU% #?+3^XOY4>6G]Q?RIU% #?+3^XOY4>6G]Q?RIU% #?+3^XOY4>6G]Q
M?RIU% #?+3^XOY4>6G]Q?RIU% #?+3^XOY4>6G]Q?RIU% #?+3^XOY4>6G]Q
M?RIU% #?+3^XOY4>6G]Q?RKS#XL>)-5TF?PGH>B7.HPW>K:DQG&EQ)+=-:PP
MO)*(U<$9)\M<]MU/M8/B7'\#K*.XN))?'?V:,RO"UN'#EP2"9%,6X)P3C!(.
M.U 'IGEI_<7\J/+3^XOY5Y7H%I\3KCX6^)K/7+FXA\430W"Z;+<26NY&,.(R
M&MU51A^Y&1],5ROPDL_%GA.34)+CPGXCMM)OGTRS6RO+E9Y8KK8RWEY\TC8B
MW%"2#\V,A>U 'OWEI_<7\J/+3^XOY5\F:?X-^+2Z;XEAL;'7;+7)-(O(=3O)
M[_\ =ZM=M>*\36Q,A"G[.)%# )MW >]7M6\-^,A\%O$-AHOA[Q=8PW6O1S:'
MI"76ZYMX B;Q.3*Q$)=92$W'YBI[T ?4OEI_<7\J/+3^XOY5X?XJ\%MXZ^)7
MA'4K?P[JFDQB./5-4U&>>2%TCC_U5D$60IYC,?GXX5>N37N5 #?+3^XOY4>6
MG]Q?RIU% #?+3^XOY4>6G]Q?RIU% #?+3^XOY4>6G]Q?RIU% !1110 4444
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MP?RJ6D4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!155ILL5AC,A'4@X ]LT_P VX_Y]3_WV* )Z*@\VX_Y]3_WV*/-N/^?4_P#?
M8H GHJ#S;C_GU/\ WV*/-N/^?4_]]B@">BH/-N/^?4_]]BCS;C_GU/\ WV*
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MG&SN>CA*M2=2TW?0]DJIJ7_(+N_^N+_^@FG^;<?\^I_[[%5-0EG_ ++N\VI
M\E_XQ_=->&CU67;?_CUB_P!T?RJ:J5O+<?98O]%/W!_&/2IO-N/^?4_]]BD]
MP1/14'FW'_/J?^^Q1YMQ_P ^I_[[% R>BH/-N/\ GU/_ 'V*/-N/^?4_]]B@
M">BH/-N/^?4_]]BCS;C_ )]3_P!]B@">B@=/2B@ HHHH **** "BBB@ HHHH
M ***ADF6/ P6<_=0=30!(S*BEF8!1U)JK^^N#W2'\F?_  'ZT1PL[B28Y(Y5
M!]U?\3[U<H :JJBA54*HZ 4ZBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "@]**#TH ^*O'/_)0=?_Z_Y_\ T8U9ECH^K:M'))I>FW=\D7#M
M!"SA?J0*T_'/_)0=?_Z_Y_\ T8U6_A[IZR:R-6O/$D5K8Z;.+B/36OT@DO+@
M ;0 [ !>F6/;@=Z^X^L2H86$H]D?'2@JE9Q?=F'8Z#KFJ1S2:;H][>+ =LAA
MA9Q&?0X'!]JC@T?5KJRN+ZUTNZFM;7_72QPLR1^NXXXKMO"MO<7'CC4_$VM>
M(K*V%E?27B:3!JD:"[N6P0%)8+Y8R 7YSC'K5+0_&5Y#K\^AZI9VD=Y/J%W(
MM_'?!+6W^T+B9G RLJJN2N".<"L_[4KW:A%.UO\ @^ILL-"RYG:YQTMK=006
M]Q/;R117*EX79<"50<$KZC((S7->(?\ 66WT;^E>SW%UX'\1>&+C4U^RP^1:
MW-M;B6Z*7-H(2JV<<<.?F#C+,<'ECR*\8\0_?MO]UOZ5UT<7]8IRYDTU_F8>
MR]E46M[F'7VK^SK_ ,D:L_\ KZG_ /0J^*J^U?V=?^2-6?\ U]3_ /H5>1FO
M\'YK]3V,%_$^1Z]534O^07=_]<7_ /035NJFI?\ (+N_^N+_ /H)KY='LLEM
M_P#CUB_W1_*IJAM_^/:+_='\JFH>X(****!A1110 4444 %%%% !1110 53N
MII;>VEFCMY+IT7*Q18W.?09('YFKE9FJ'4O[+N6T?[/]OV'R/M)(C#>K8&<4
M 8*^+84AN%N-+NHM2@N8[3[#N1F>210R;6#;<%3DDGC!STJ.;QM:6]D)O[.N
MGN(VG%S;#9NMQ  9226P<!E(P3D,,55M_#NL+I,+?9[5-2MK]-1:62Z:4WLF
M"K[V\M=F5.!@$+@#&!5V'PKYVEWS:M9VEWJ5S=2WJ1L6,43LH54W8!9=JJ&X
MYYXH W+/45U"\NDMU8QVSK&9#C:[%0Q [\ C/OQV-:U<!;^#[^U\2V-Y#=1F
M* QN]PS,)LA7\U N-I$COO)SUSP<#'?T 5))F9S%" S#[S'[J_XGVJ6*%8P6
MY9V^\QZFI%544*JA0.PIU !1110 4444 %%%% !1110 4444 %%%% !1110
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MUJR6I'J4+!FS]Y1CO7JNE^--:O/C1JO@F\TVVMM-M])BU*TG28O-.'D*'>.
MF"K#;R>,YYP-BX^'_@F^724O/">DS)HX T]7LT(M0"" @Q\HR <>HJ>/P3X/
MA\7OXNC\-V*>('SNU$0CSSE=A^;K]WCZ4 =-1110 4444 %%%% !0>E%!Z4
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ML+3$S!=H (&.&//S"N]KYA^ O_)1Y_\ KPE_]#2OIZ@ HHHH **** "BBB@
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MQ_Z,:N<S7Z;@?X$/1?D?&5?CEZCJ*;FC-=YD.KN? /\ J=0_WD_D:X3-=UX
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MY\;OAW87LMG)KC2O$VUGAMW="?9@,'ZCBKITJE7^'%OT(E4C#XG8].JA<_\
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MU;_OM:/-N/\ GU;_ +[6K-% %;S;C_GU;_OM:7SI\?\ 'HW_ 'TO^-6*#TH
M^%?'C$_$?Q(67:?[2N..O_+1JYK-='\0#_Q<GQ+_ -A*X_\ 1C5S.:_2L%_
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MP1],2[J-U1;J-U %76F_XD5[_P!<S7G)->@ZRW_$CO/^N9KSLF@#V#]GD_\
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M5\F?LZG_ (NA<?\ 8.E_]#CKZSH **** "BBB@ HHHH **** "BBB@ HHHH
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MKRLU_P!VG\OS1VX+^+'Y_D=7NHW5%NHW5\*?2$NZC=46ZC=0!6U=O^)+=_\
M7,UP!-=WJ[?\26[_ .N9K@>6.!R: /8OV=]S?$ZXVN4_XETO(Q_?C]:^L?)E
M_P"?J3_OE?\ "OBOX<V/BNW\0"[\-RR6UU(AA:15SA203G\A7UMX8T_7+6P1
MM;U22[G(YSVH WO)E_Y^I/\ OE?\*/)E_P"?J3_OE?\ "IJ* (?)E_Y^I/\
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MUO%&_P!Y40G"C^7;%==10!RUKX0TN&&TAEDN[U+6.:!/MDYES'*%#*V>HPH
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MFS:^)UJ:![^WO/+'R6JAV<D8QE3&4_X&AKLO!GP^T/P,UZVCRW<AO GF?:)
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MU&WE0-+,!\ZQ;@0=O=B,9R.<'&E<^%5OX0NH:M=7,_V&YT]YV5%9UF*Y8@*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cvm_10kimg18.jpg
<TEXT>
begin 644 cvm_10kimg18.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %5 F\# 2(  A$! Q$!_\0
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M]/\ ^OZ#_P!"K7K$UJ6.2+3BDBG=>P,,'J-U;?:@ HJ+SH?^>J?]]"CSH?\
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MF_\ 1K4NK?\ ']H__7W_ .TWI/#O_(%7_KM-_P"C6H UJ*** "BBB@ HHHH
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M<'DGI774 %<->?$+P[9ZAJ%G))=M<6$JQ2HENS$_*69E]5558L>P!//%=S7
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M0 5D^'?^0*O_ %VF_P#1K5K5D^'?^0*O_7:;_P!&M0!K4444 %%%% !1110
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MM'Q!_P! %?\ P*7_  K;HHU[ASQ_E7X_YF)_:/B#_H K_P"!2_X4?VCX@_Z
M*_\ @4O^%;=%&O<.>/\ *OQ_S,3^T-?[Z"N/^OI?\*R(=1\1:3;6UO<:!:BV
M#^4)!? $9SC@KC]:[+-1R)'(A21593V89%)I]PYXO[*_'_,P/[>U3_H&VW_@
M<G^%*NMZM(P6/2H'8]%6]0D_I6U]CM/^?6'_ +]BJEUI\<T<;6L4,,T<BR*Q
MCXX/3C!H][N'M(_RK\?\RK_:'B#_ * *_P#@4O\ A1_:/B#_ * 2_P#@2O\
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M0 4444 %%%% !63X=_Y J_\ 7:;_ -&M6M63X=_Y J_]=IO_ $:U &M1110
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M_FW<YU)@5DN(HP2 1MP<[<$X+%B?HS_A!_#O_/K)C&?]<_\ K/\ GMU_UO\
MTT^][TO_  @_AW_GUDSU_P!<_P#K/^>W7_6_]-/O>])<RMIMYA:EKJ]?(\!U
M+XC>(_[ L_$$.L1MXDAT'7I+LRZ;;I-IUY"T)^S*"K,J1DXP6.\!6;=QC2UC
MXA>.=*FOM'/BB-+>+7H;236]0:WLA:Q26"W 1I?LTD2 RG:&:%C@[2<D,/;#
MX&\.X_X]I/[W^N?_ %G_ #VZ_P"M_P"FGWO>D_X0?P[G_CWDZ;O]>_\ K/\
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MQ_W^B_\ BZ/[3UC_ *%VX_[_ $7_ ,71=![.7=?>C<HK#_M/6/\ H7;C_O\
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M^_T7_P 71_:>L?\ 0NW'_?Z+_P"+HN@]G+NOO1N45A_VGK'_ $+MQ_W^B_\
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M,\_=[U8_L6;^T/M7]M:AL\O9Y.]=F<_>^[UK;HI<J%RHS_[-D_Z"5Y_WTO\
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MC)/3(I-0\9Z#I6K2:;?7,D<D4?F22^4QB0[2X0N!C>55F"]2!0!K?\(_HO\
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M ($C_P")H W:*Y2Q\/WC6$1OM>U=;C!W@7*^OLOI5[_A'&_Z&#6/_ D?_$T
M1Z3_ ,A[7O\ KY3_ -$QUOUQ]GX9N([F_DEUK5(_-GW*RW"Y=0B@$_+UX(^@
M%:9\.M_T,&L?^!(_^)I+1%3ES2NNR-^BN7B\/WAU"Y$FO:N+<*GE'[2O)YW?
MP_2K?_".-_T,&L?^!(_^)IDF[17*R>'[S^TK=8]>U<VY1_-/VE>&XV_PY_O5
M=_X1QO\ H8-8_P# D?\ Q- &[17*WOAV]"0?8]>U<DS(),W"\1Y^;JOI5W_A
M'&_Z&#6/_ D?_$T ;M%<KJ'AZ]6PD-CKVKM<?+M!N5]1GJOIFKO_  CC?]#!
MK'_@2/\ XF@#=HK ;PZ^QMNOZP6QQ_I(_P#B:K6?AZZ;3[<WFO:N+CRU\T"Y
M'WL<]%]: .HHK"_X1QO^A@UC_P "1_\ $U4M/#]X1/\ :=>U8'SF\O%RO*?P
M_P - '445A?\(XW_ $,&L?\ @2/_ (FJT/A^[-W=";7M7$(9?)/VA>1M&?X?
M7- '345A?\(XW_0P:Q_X$C_XFJQ\.W?]I*HU[5OLOE')^TC._(Q_#Z9H Z:B
ML+_A'&_Z&#6/_ D?_$U5N/#UV)+;[/KVKE3+^]S<KPFT_P"SZXH Z>BL+_A'
M&_Z&#6/_  )'_P 356\\/7:VZ_9->U=I/,3.;E?N[ANZK_=S0!T]%87_  CC
M?]#!K'_@2/\ XFH+CP[<"TF-OK^KF78VP&Y'WL<?P^M '25D^'?^0*O_ %VF
M_P#1K51M_#MP;6$S:_JXEV#>/M(^]CG^'UK5TZQBTZPCLX7DD5,G?*VYF)))
M)/<Y)H OT444 %%%% !1110 4444 %'>BCO0 4444 %%%% !1110 4444 %<
MIXQDU.+PZ3I;72#SXQ</9IOG2#=^\:,8.6Q['O75T4 8>@-J4GAW3VUA=FH-
M;H;@8 P^T9X'0YJUJTVI6^CW5QI%FE]?I&3!;O((UD?L"QZ"M*B@#E?!,VO3
M>"K)_%$4T>K_ +Q;@3!0Q(D8 X3@ C& .V*ZJBB@#@/A[>^*+G^W?^$BCO1B
M\+6WVN$1[4.?D7@9Q@=,KR,,><=\<XXZTM% 'EUK<>*EU?1;/4M0U?[1_:%S
MYDHL@+:2!9F"^9M4X+)M"\@ 98GU]1HHH \F\3S?$*WU*Z73YKZ>S_M16C-O
M  QB\A2L2D*?E\S<"[#&>I KU@9QSUI:* /+?$UUXD_X2R]BTN\UU+*)8Q="
M&TRHB8KDVQV'+KR2<DG<0!\O'>Z"^I2>'=.DUA FHM;H;A0,8DVC=^M:M% '
M >+KK7+?Q'IC:'_:4MSM:1;>.+%I+CJDLFTX+< 9("\M]=+P'/XCN/"$$GBJ
MWE@U833+*LH4$@2MM("\ ;<8]L5UM% '$>-KC4H[2P33;K4[>XFG"*]C;^:J
MGKNEPK$1CG@?>.!D=:K?#^]\47AUK_A(H[U2+PM;_:H1'M0_P#@9QCME>>&/
M->@44 <QXN:Z3PQ=FSN+^WGX"26$7F2@YXX"L=N<9(!(&:PO"=YX@O/$5PVI
M7&J1HEE$)K:^M?+C,Y"DF)@H&%Y!^8[B3TVUZ)10!FZB6_LN[:-IU<1.5-NH
M:0'!^Z#P6] >]>8^&[WQW)XLT>.]_M672%\Q T\.PRIND_>2DH.@\H -M8G)
M /->P44 (<X.!D^E>.1ZE\3I;R=M2TV]L'.H$VL4 CEB((AV1LRY_=!?.)8X
MRWI@"O9** "O'_%&J?%E-5\3+HN@SBV6V0:?)#+"P4!GW2*&^](V!\I^Z".O
M?T/6/$VBZ!-;0ZM>?9I+H[81Y3OO/H-H//M6I#*D\*31DE'4,I((X/L: "W:
M1[:)YHS'(R@LA.2IQR*\[\<:EX^MO$=O#X?TNY;1UL[C?<6OER,TQB;864\@
M*0,  [B?;!]*9@JEF( '))[5&DB31K)&P=& 964Y!'J* .;\$S:M/X-TYM<\
M\WX5ED>X38[X8A6((!Y&#R ?4 U2\;3Z];W&B'17O"1<%I8+>!F6X' VNXXC
M !9N>#MQ7<5"[K'&TC<*H+' SQ0!R/@6?4KC2[RXU"ZU*='NCY":E;F*>-<
M'/RJ,$Y8 #Y0<9.*E\=3:I'X8*Z/<75M=&9/FM+=IG90<[<+RH; 7=VS75QL
MLD89>589';BLYM:TN/3#JCW\0LPYC\[/R[@VPCZ[@10!Q_@6X\87&M:U)XH@
MN8<L#'$_^J@^9L(AVC=\FTEE)!/7!KH_%3ZQ'X3U1_#XSJ@MV^SX7<0V.H'<
M^@]:DM?$V@WTVEQVNJV\SZM"UQ9!&R;B-0"S+[#</SK7D=(HVDD8(B@EF)P
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M8>9=+L=Q@'(4JI R6&".WIBNUHH X'XB7GB2TT:P_P"$;2]\]KQ3*]I%YAV
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MRV_B) B8^SI(T@^SDJI=U(SSY@)'3@XR._37GAO4H?#&FZ?"RW4UKJ$EPX'
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
,* "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cvm_10kimg17.jpg
<TEXT>
begin 644 cvm_10kimg17.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %/ >4# 2(  A$! Q$!_\0
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M4Y+)*YZ#]J@^?]^G[O[_ ,P^7Z^E-^T0[D02H6<94;AEAZCUKE/^$-\-\_\
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M\,\^*O$;>UJO_D+/]::$SK:***LD**** "BBB@ HHHH **** "BBB@ HHHH
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MB/Q,WI+;+_Y+H?ZU!NJ7PASK7B=O^GN ?^2L7^-- SL****HD**** "BBB@
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M** "BBB@ HHHH **** "BBB@#@]:./B!-_V"X?\ T=)2;J373CQ_-_V"XO\
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M1I@1)CY<\DD\DX/3TK3_ .$)\#?]";H?_@OB_P#B:7_A"? O_0FZ'_X+XO\
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MH:GVCWI?/]ZRO/\ >CS_ 'I\@>T.8\12;OB"#_U"4_\ 1[U#NJ'6I-WC[/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ=<G/_,/C_\ 1KUO;JY;29-WBN[_ .O"/_T:]=)NKY7&*U>7]=#ZW N]&/\
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M!)-&?WJ_45ZI\-O^2:Z*?[T3-^;L:\HC_P!:G^\*]8^&X_XMEX?;UM%;\^:
M.MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M,J;1=*EM+VSDL87M[YS)<QLN1*Q !)]\*/R%0V^@Z-;6EO:PZ9"L%NDB1QE,
M@!_O\'J6[D\G)]36W10!EZ;I=CI-H+73;5;>');:O<GJ23R3]:U*** "BBB@
M HHHH **** "BBB@!M<)\6N?A+KC>B1-^4J&N[KA/BY_R2+Q#[6X;\G4UI1_
MB1]485_X<O1GRXT_S'GO2>?[UFM-\Q^M)Y]?IL(>Z?F4ZGO&GY_O1Y_O69Y]
M'GU7(9^T-/S_ 'H\_P!ZS//H\^CD#VAI^?[T>?[UF>?1Y]'('M#3\_WI?/\
M>LOSZ//HY ]H:GVBCSZR_/H\ZCV8>T.Q\&OO\1:C_P!><7_HQZ[JO// 3[]?
MU3VM(?\ T-Z]#K\^S16Q$UZ?DC]%RIWPT'Z_F%%%%>:>F%%%% !1110 4444
M %%%% #XO]<G^\*]<^'7_)+_  U_V#X3_P".BO(H_P#6I]17L'P_7;\-/#(_
MZAMO_P"BQ0!T]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.:Z[P?XJU*#P)H$*1V^V/3X%'R'H(P!WKCY/]4_^Z?Y5H^&!CP;H@_Z<8/\
MT6* .[_X3+5/^>=O_P!\'_&C_A,M4_YYV_\ WP?\:YNB@#I/^$RU3_GG;_\
M?!_QH_X3+5/^>=O_ -\'_&N;HH Z3_A,M4_YYV__ 'P?\:/^$RU3_GG;_P#?
M!_QKFZ* .D_X3+5/^>=O_P!\'_&MKP]KDFJ22PW6Q95&Y=HQD=_Z?K7 U;TV
M\>QU"&Y3JK=/44 >L45%#*D\*31G*.H93[&I: "BBB@ HHHH **** "BBB@
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M)^N_^"V?_P"(I_7,/_/'[T'U+$?R/[F8.**WO^$-\9?]"?KO_@MG_P#B*/\
MA#/&7_0H:[_X+9__ (BE]=P_\\?O0_J6(_D?W,UOAM_R&M6_Z]8?_0WKTO-<
M-X&\/^)-+U749M0\+ZY!');Q(A.F7!W$,Y(X3W%=W]GU#_H ZW_X*;G_ .-U
M\!F4XSQ$I1=UH?H&60E##PC)6>HW-&:=]GU'_H ZW_X*;G_XW1]GU'_H ZW_
M ."FY_\ C=>8>H-S1FG?9]1_Z .M_P#@IN?_ (W1]GU'_H ZW_X*;G_XW0 W
M-&:=]GU'_H ZW_X*;G_XW1]GU'_H ZW_ ."FY_\ C= #<T9IWV?4?^@#K?\
MX*;G_P"-T?9]1_Z .M_^"FY_^-T -S1FG?9]1_Z .M_^"FY_^-T?9]1_Z .M
M_P#@IN?_ (W0!#,V+:8^B,?TK7\.#;X2T8>EC!_Z+6LFYM=3:SG5- ULLT;
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D@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cvm_10kimg10.jpg
<TEXT>
begin 644 cvm_10kimg10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %& 94# 2(  A$! Q$!_\0
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M#Z-HKYK\3?$;QEX!\0'X=>$]).NMX?TNWN;F\U61I9K_ '9+.9&E3RQP<O\
M/@\8 %6/$7QVUK2_'=K9Z3:6%_I7V^QL;V%K619;5KA5.#<>9L9QN. L;# Y
M:@#Z,HKR?P'XR\:>+_&'BR.\MM%A\.:%K%YI"&(2_:Y'B*;&.24 VL<GJ3T
MQSYGXDUR\U35?C!J&O>/=4\.ZEX4.-$LK74&M8XD$.^*0Q @3>:^!\P;K@8R
M* /J2BOFR?XU>.M'M-'T74M'L'\2>(]'TJYT-)(9%66YF=8[E)@&XV9+X&W
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MVYXKHZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &,
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MQA0Q&>2!^-/_ .$B\*_\)1_PBW]LZ5_;FSS/[.\Z/[1MQG.S.>G/3IS7B_Q
M^'OQ"\9:A/JT?AC2UN?$/AQ="N[>?4%<:/(+DR><K;/WJ[3T4 Y45:B^&/C*
M+XD1+]DM)-(C\5#Q1_;C7(\]D%KY/V4Q[=V2PZYV[??B@#U+0?&7@?Q1?SV'
MAOQ%I&KW4">9)#9SQRLBYQD@=!D@5U?V:W_Y]X_^^17BOPG\"^*?"OC"^G.E
MR>&O"GV'R(]%EU@ZD&N3+N,T;$#RDVY&WN3G KV^@"+[-;_\^\?_ 'R*/LUO
M_P ^\?\ WR*EHH B^S6__/O'_P!\BC[-;_\ /O'_ -\BI:* (OLUO_S[Q_\
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M\J/_ *#4_P#WU'_\36GBC%%V%C,\J/\ Z#4__?4?_P 31Y4?_0:G_P"^H_\
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M>R?]]5*"" 1R#2T4 %%%% !1110 5@:YK*Z+%;[;=KB:[G%O#&'5 7()Y9B
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M\H$--F5W#R9XW ,%&,\#Z =B0",$9% %3]Y/]W,<7KT9OIZ"K*HL:A44*HZ
M4^B@ IDDBQIN<X'\ZBDFV-Y:C?(?X1V]SZ"B.'#>9(V]_7LOTH 38TW,HVQ]
MH_7Z_P"%6>@HHH **KM<1J2OS,1P=JEL?E3OM,?]V3_OVW^% $U%0_:8_P"[
M)_W[;_"C[3'_ '9/^_;?X4 345#]IC_N2_\ ?IO\*/M,?]R7_OTW^% $U9]Y
M_P A73?]Z3_T U:^TQ_W)?\ OTW^%59O+EN[:?\ >CR"QQY3<Y&/2FA,T**A
M^TQ_W)?^_3?X4?:8_P"Y+_WZ;_"D,FHJ'[3'_<E_[]-_A1]IC_NR_P#?IO\
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M#\=-UY>>(CJL>O:F=3MI?/:R31EA)MF5<>5C.S:5^8L3G-5OBIXBU[5O$/\
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M2] MV"M$"!NN)AGC9'A@#T&"/2L_[6BIN,H[?UJ-8:;BI7W/*/LMM_S[Q_\
M?-<SK"JFILJ*%4*O Z=*]+U[PGJ'AVTM;R:ZL;^RN7:*.ZL+CSHS(OWD)P,$
M<_D:\VUK_D+/_NK_ "KOJUZ<Z"J4W=7)I1DJG*S-K=\,VMTNM66J)&/)M)TF
MRW <JP.!^53:7X>9]MQJ"E5ZK#W/U_PKIU554*JA5 P !@"OSS.L\A1O2HOF
MEU?1>G=GW^59).K:I6TCT75^O8]H_P"%]7W_ $+<7_@0?\*/^%\WW_0N1?\
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MVH9C&'40HR @ E7!;'/&!CK4*>+M8>XTW4Y+=HM.GM8+EXDMF=61XF:1O-Z
MJP50O4Y'7(QU6K:%;:Q)%)+-<VT\:O$)[64QN8WQN0GT.![@@$8J9M(L6L;*
MQ6,QVMDT;11(<+^[^X#Z@$ X]0* ,_0=>AU2'[-)<!M1B4O,BQ,BCYBI"$C#
MA6!3<,\K[UTC-M0MM+8[#J:Q-+\/Z=I5_/>6?G%Y 442.66)"Y<J@[ LQ/Y=
M@*WZ *@B:1@]QT'*QCH/KZFK=%% !5:2;:WEJN^0]%'\SZ"@RM-E8?N]Y.P^
MGK4D<:QKA1R>23U)]Z &QPG?YDK;W[>B_2IZ*:S*JEF( '4GM0 E>.?M ?\
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M1?K_ (4 222K&!GDG[JCJ:B6)I&#W';E4'0?7U-+'&(R68EW/5SU_P#K"K-
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M9=%>,?\ "]HO^A;/_@7_ /84?\+WB_Z%L_\ @7_]A7V9\4>OW*[K295&248
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M+T?YHV,T9IF:,U^ G[?<?FC-,S1FD%Q^:,TS-&: N/8_(WT->8C+,%52S$\
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MJ^4:^M/@U_R2?2O]^;_T:U '<_9O^FTW_?='V;_IM-_WW5BB@"O]F_Z;3?\
M?='V;_IM-_WW5BB@"O\ 9O\ IM-_WW1]F_Z;3?\ ?=6** (/('_/:7_ONI@,
M #KBEHH **** "JL[3"W=K=5DE .U7;:"?<X./RJU10!YY;V[ZIXKEDDM['6
M?L=X6'VG5&=K/#8!6W\H*K#L>O\ M=ZW_$]O;SV$'VI-0Q'<)(DFG(7EB< X
M; !..W0]:YR*3P[K7BD7&M>(H&U"QOWCM;$2QP-$ZN54?*=[YP#@M@Y^[7H]
M 'FT+:S#/8:QK6FW]^C6=Y:*BVX>8!I5:+S$7A6>-0"<8!'.,TB^%+ZUT?1G
M2XN$U 0VD,L4:JRQS)&4\TMU 168XS@E5]>?2J* .'\(MKD-]<Z=>6\T6GVT
M7EQI) (UB99&55C;_EHIC"DL<\]^<#M67<A7<5SW'44^B@!D<:1KM1<#^=/H
MJ&298\+]YS]U!U- $CNL:EG8*H[FJO[R?[V8XO[O1F^OH*='&S$23$,XZ ?=
M7Z?XU:H :JJJA5  '0"G457DF.XQPKOD[^B_6@":O%/VC/\ D2-+_P"P@/\
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MPR-R]N.OIWKG;U'N+5HT;#5K/XJU1K^#5%T?3AJ8XGNL/NN%*%"&&[ R#R0
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MWE\CXOB#:/S_ $-#?1OJ#=1NK[(^(+ >EWU7#4NZ@"??1OJ#=1NH S?$[?\
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M1FE88_-&:9FC-%A#F/R-]#5ZQ;_B76W_ %S7^59S'Y&^AJW9-_Q+[;_KFO\
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M6%#F4J@[ LQ/?MV KK*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
1BB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>cvm_10kimg11.jpg
<TEXT>
begin 644 cvm_10kimg11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" #F A4# 2(  A$! Q$!_\0
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M^&#K6J2K:V$=TB">/:I4W2?W2#D)U&>: -/;^TY_SV^&_P#WQ>_XT;?VG/\
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M(=I68[4VLK+WY4_6@!-O[3G_ #V^&_\ WQ>_XT;?VG/^>WPW_P"^+W_&N/\
MBC\6O&L/P]T+5]!\*Z_X<OI=>CLKR*[6.)AM/^J4MD.LF2 Z\#8<X[]2WC"W
MM?C9:R>()M<T.2/P>^JWFG2W:/8VB+*=Y=5SNE7&-P.,=* )]O[3G_/;X;_]
M\7O^-&W]IS_GM\-_^^+W_&J.G?'^UN+C2=2U7P3K>C^%=;NA::?KMUY?E2,Q
M(0N@.Y%;'!.?7I4.K?M"+8W7BVWTSX>ZYJQ\*7DL&I3P/&L,,4?'FESZX8A
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M4 >-[?VG/^>WPW_[XO?\:-O[3G_/;X;_ /?%[_C7LE% 'C>W]IS_ )[?#?\
M[XO?\:-O[3G_ #V^&_\ WQ>_XU[)10!XWM_:<_Y[?#?_ +XO?\:-O[3G_/;X
M;_\ ?%[_ (U[)10!XWM_:<_Y[?#?_OB]_P :-O[3G_/;X;_]\7O^->R44 >-
M[?VG/^>WPW_[XO?\:-O[3G_/;X;_ /?%[_C7LE% 'C>W]IS_ )[?#?\ [XO?
M\:-O[3G_ #V^&_\ WQ>_XU[)10!XWM_:<_Y[?#?_ +XO?\:-O[3G_/;X;_\
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MUG^S?%?_ $,EK_X+_P#[91_9OBO_ *&2U_\ !?\ _;*/9Q_F7X_Y![67\K_
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MKX9TF^T[Q/!KFH1Z9#)!;F./(")G<SN <;FVY_G[%_9OBO\ Z&2V_P#!?_\
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M-_;ZHB7.DVLEG9OY2'RH7WAEP1S_ *QN3D\U/%X^\80^%?\ A&8]>(T[R#:
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M+PGK5CXAOM8\%_!V^T6QD\'7>EIIVI.HCGO/,C8AE60D!E! ;*F0CMUK'O/
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M^&:?&'_12G_[]2__ !=')#^?\ ]K5_D_$^G\CU%&1ZBOF#_AFGQA_P!%*?\
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MH? O0^0D[3;\SWI_"OPTU#7;JQ;38='MM,\2OI:NNHL?M\1@E=%=G)"!I$5
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M90O<7$I!(1%&6; !)P!VK@_^&@/A'_T-R_\ @%<__&ZW/BQ_R17QI_V!KO\
M]%-7YY&1@,!CFN["X95T[NUCSL7BI4'&RO<^\/\ AH#X1?\ 0W+_ . 5S_\
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MKKYAX'$9VYY/?UI1E13T82C6DK-'#:YKCZY<PW$FE:7IIB3R]FFVHMT?G.6
M)R?>LBO0];^&D>BZ5KTC>*+6YU7P]#;R:EIR6\BF)IF5559#\KXW<D=^/>O/
M>PKT:<HR7N[''5C*,O>W9WOP9_Y+9X1_Z_C_ .BWK]!Q]^OSY^#7_);?"/\
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M.014E1*JQH$10JJ,  8 %2T %%%% !4%PK-;2JHRQ4@=NU3U!=<VLW^XW\J
M/)/@[\']/^&^E"^U+R;[Q-<Q[;BZ1<I O_/*+/('J>K'V  ]@KY4^"/Q@DTW
M2+#PYXLOFETK(@MM1F?<UF_:.5C_ ,LSQM<_=Z'C!7ZJ[9K6K&<9>_N84IPD
MO<V'T445D;GP%^VG_P EET?_ + L?_HZ6BC]M/\ Y++H_P#V!8__ $=+10!]
M)^/O^3H?@Y_UQU?_ -)TKVD]#7BWC[_DZ'X.?]<=7_\ 2=*]I/0T ?ET&(48
M.*-[?WC2?PBCO7U-/X4?(U/B8NYO[QIT99I40L<,P'YFF9I58JZL.JD$?A70
M9+?4[/6/!-Y'\3=1\$^'Y&NWMKAXXY;EUC 1%W,\C<!0!DD^@ITGPW\0(%EB
MU#2[FRDCBGBO8+O?!-$\PA,BMC[J2%5?(!7<"1@U<O/BE?W/B%O$D'A70+/6
M))&>XN8XI6-RK*4DCD5I"I5U)!P ?0BJT/Q+UBTUS2]0T[2]+LK'2[:6TMM)
M2%FM1%*=T@8,Q9B6PV2>JKZ5Y5ZUE9'5:EK=]3,\0>#=>\,64UUJS6\7E70L
MFC67<_G>4)&4#'.P,H8]BP'-=SJ7PMTNW\(_VE;S:Y!<1Z);:P]]=0H-/F:3
M9FW1Q@B3Y^!SG%<#XH\8:UXN73O[9>)FL83&'C7:9G8Y>:3UD;"Y;OM%-U[Q
M9K&O'3EO9MD.GVEO:16\;N(L0KM5BA)&X@<D4FJK2UMW*4J47+2_8[7Q-X!\
M-VMYXETGPSJ6KR:OX842W,-_'&8[J(.J,T3)R&!=?E8<@\5S-CX1N6\+>*=2
MU:*^TZ\T:"VFA@FB,?FB6;RSN##..N,=ZN>(/B9JVO0ZH(]'TG1Y=7=9-0NK
M")UFNMK!@&=W8JNX X7&2!5+2?'VL:>NJQ:I;P>)H=4AB@GCUB2:;Y8WWIA@
MX888YZUI%5%'7R_2Y$G!RT\_0@M_">H7'P_O?&2:E8?9;.:.)[19MUP-[% Q
M0?=7(.-V,X.*YS<V-VXUV4?CQ8?#NM:':^#=#M[75V5IF19]RE,^7M)D/W"2
M1G/)YS7%>U;P<G?F,:BBK<K]1=[?WC1O;^\:;176<QZ9\""3\>?"F>?WT_\
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M &/^0C/_ /%U[!3:TC.4?A=C64(S^)7/(O\ AG3X4?\ 0%O/_!C/_P#%T?\
M#.GPH_Z MY_X,9__ (NO7_PH_"K]M4_F?WF?L:?\J^X\@_X9S^%'_0$O/_!C
M/_\ %T?\,Z?"C_H"WG_@QG_^+KUZBCVM3^9_>/V-/^5?<>0_\,Y_"C_H"7G_
M (,9_P#XNC_AG3X4?] 6\_\ !C/_ /%UZ]11[:I_,_O%[&G_ "K[CX4^/'@G
MP[X#\;:?IOANWEM;2?3Q<2++</+\_F.N<N3CA17>_ WX&M<&U\;>-K+$7$NG
M:9,O+=UFE4]NZH?J>PKV/Q!\+M'\5?%'3O&FO8NX-,M%@M]/9,HTHD9Q(_\
M> W#"],\GIBO1^QYK:6+DZ:IKYLYX82"J.HUZ(EHHHKD.\Y'X@:M?Z'\-_$V
MM:;,(;VPTVXN8)"H8*Z1EE.#P>1T-?'G_#07Q: Y\6*/^X?;?_$5]=?%C_DB
MOC7_ + UW_Z*:OBSX4V=C=>.W6ZM(+V]AT^ZGTNSN &CN;U$S$A!X;N0.Y K
MTL)"FX2E-7L>7C)U%*,82M>YMI^T%\6I&VQ^*@[>BZ=;D_\ H%-_X:#^+/\
MT-B_^"^W_P#B*ZGP#JWQ"U_XC^%+SQEI;FSAO+N&/4)M.2WF#?9)<P@A5RH
M) QP1UXK)T'P'X&\56_AG5M.M[W2K.Y74?M-I/>>:]T;559=KA,J7#9;:IP
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M* "BBB@ HHHH **** "BBB@#X"_;3_Y++H__ &!8_P#T=+11^VG_ ,EET?\
M[ L?_HZ6B@#V;]HSQDWPY^(_PW\='31J2:<NHJ;;SO*+F2.-/O;3C&<UQ?\
MPW&O_1-S_P"#3_[5110 ?\-QK_T3<_\ @T_^U4?\-QK_ -$W/_@T_P#M5%%
M!_PW&O\ T3<_^#3_ .U4?\-QK_T3<_\ @T_^U444 '_#<:_]$W/_ (-/_M5'
M_#<:_P#1-S_X-/\ [5110 ?\-QK_ -$W/_@T_P#M5'_#<:_]$W/_ (-/_M5%
M% !_PW&O_1-S_P"#3_[51_PW&O\ T3<_^#3_ .U444 '_#<:_P#1-S_X-/\
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H >0_$CQPOQU\70^(ETDZ']ALH[,P_:?-W_/(^[(0?WL=.U%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>cvm_10kimg14.jpg
<TEXT>
begin 644 cvm_10kimg14.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" 'O @L# 2(  A$! Q$!_\0
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MI(Y'?O77ZE\8+ZZ\;ZCX+^'_ ()D\5ZAI4,<M]))J45A''YBAE5"X)<X(S@
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M%A\Z:^TRR6:"W7=C$CEUVG_$4 >$ZY\)=0U;PY\:[V\\"_:]=O\ 6#-H=Q)
MK3R1F0'="W4 C).,9'6MV;PCXF\/>//"GCC5_ =WXSTR+PK;:4]C"(Y;C3;E
M47<?*D8 Y^8$@_Q'\>WO?CQIMIX N/&C>#/$UKIT<EJL)U"U2V^UK.2%>([R
M& X)Z<$>M>PQRK)G;@L/O*#RI]#0!\X_\*Y?Q)\9? ^I:U\+X-.\,V^@SQS:
M;/%%/;64S32LB,!\N[#!L 8!;VKE?&'PK\36OQ0\:75_H?B34O#WB%8UM)?#
M<=E*1$$V^1(LXW1A1@ J0,#\OKI98FD:-9%+KU4'D?A7)>-?&\?@C38+^X\,
MZ_KD+[S(=&LQ<&W51DM)EEVC'?V- '@/B'PK\1K6U\(:!#X7U8Z!#X>6SD>P
MM["\U&.<$@0333#:L8!7E,#KC/;%L_AOXFA^ W@'3]4\'^)%U?1[Z^N5?2U@
MDFL7:7,9>WF(656'/!&W;[U[_P##WXLZ7\1IEET?POXEL["2%IHM2U"Q6*UE
MVMM*K(';+9SQ_LGTKT6.:&4%HI4D ZE6!Q0!\B:M\.?B]KWPHT&YUC1U^VZ9
MXB;4)-/L8;6TN[FUV*JS.@!@,XVMP0>",YQ4-U\+_%FK?#OX@KX<\/\ BBVN
M]82RE=-?>T@?4&AE+/&D4& ORXY/WCQ7UZMU#)M\N5'W E=K Y ZTY+BWD8+
M',C$YP%8'.* /G#P3H&NW7[1>F^*X?AK?>#M#M_#9T\K/'$B^:'](R?H,\D+
MGCBMGXW>"?%'B[XF_#&XT&/4;:UL;J<W>IV 7?8!O+P_S9&>#V/0U[P)8S*8
MA(ID R4SR!]*YKPYXX\-^*M7US2=&O&FN]#NC9WB.A3;(,Y"Y^\.#R.* /,=
M9^%.G^$?ASK5KIOA*Z^(UWK]_'/KBZC>*EU=H-Q\Q'^4!D)RH&#R:Y#X6?#G
M7]%^+*:QX3\.^)/"/@M+.9+[3M=ND?[5,RL$6*-68X!*G<Q_A//.*]E^('Q1
MT?X=S:-;:II6K:G=:W.UO9P:9;K-))(NWY<%EY.X8QFIO OQ.\._$";4K/3(
M-0T_5-*D$=]INI6_D7-N3G&Y<D8.#T)H ^6]'^"OCS3_ (1:+KS:3JNHZGI6
MM-=77@W4;@FTO(=_#)$#M#\Y/7(SZ8/U;KMUKNK_  OU&ZT'1 FMW>G.;?3=
M4C4 2LG^JE4G:?0@G!^E=<LT,B%HY491U96! IBSPNP5)D9BNX ,"2/7Z4 ?
M(W@7P;\0IOC9\/O%&M>&=<MA917,>I3W=E9VMO;N86 6)+?!\O+8!?D]N]9F
MJ?!G7+CX$>+)%^'[-XQE\323V<GD+]K:V,BD%7SG9@MQGUK[-^T0[6;SDVH<
M,=PPI]#7&+\0K%OC,?AF-/G-[_9?]K?:]R^5LW[-N.N: /$/&/@SQ9:_$_XB
M:E-\/+KQ9%XIT-+72;R 0O\ 8'$&QD;S&&SYAG(Y.!C)/'M'P:T?4M!^"?A;
M1M6LY++4+6R$<UO*,-&VX\&N[2>&1F6.9'9?O!6!(KCM+^(6@^(K;Q(WAL2Z
MK?>'YY;2>S0")Y9XP3L0N0IR1@-G'/6@#P;X4_ .]UGP9+:_$B;7]/T^/6Y;
MS_A'#(D=M<X"[)'P"Q!R1]X?=_&K'Q,\"P^(O&6LW&I?!G7WU=6V:7K_ (;O
M8T6Y0*%B:8,X"%> 203@>@KZ0T75+C4=!M=2U+3)-&GE3=):7$J.T!SC!9"5
M/X'O6FTT:H)&D54;&&)X.>E 'RIJG@_XG:'I_P %-0US1]4\5ZIX;N+FXU/[
M"RSRQH60QQEF8!F"_+G./E//<]UX1\->+/%7Q\N/BMXC\/S^&].L],_LS3;&
M[D1KF;)):20(2%'S-QGN/2O<5DC<LJ,K%3A@#G!]ZFH \+_:"\':YXSC\!VF
MCV%_<1V_B"&:\FL7V26L/1I W\)&<@]B*YKPSX+\<?#OQ]X[TFVT&;Q2=?L9
M)M(\2ZBWVABXC.RUNW8_=R ,X )QGAOE^F:* /C/PEX)^)%Y\5?ASX@USPKK
M<$FFW$RZE)/8V5K:6P*8"PK!ABG.,OU[=ZW='^'?C"WT+XM> 8_!\]AJ&NWE
M[>:7KBK$MJT+E2L'F [EW@8QC R<XQ7U?10!\A_#WX=^(+3Q9X1N;_PCXPAU
M/0H)+>9[N2P@L(D,#(RI)$!)*K' '<9SG@Y/ACX'^('ASX@:!8Z'X3U/3_#M
MM=-<:C!XDL[*5;,'J;:Z0F21N6 ("]L\9KZ\HH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BN7G\8:#;>/K3P+-=/'K=W9M?0QF,[)(U8@@-TW<$XZX!--T7QGX?\
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MMHM0O;C4+YO);>+J&1 L;K( V6P 057@@5]0;5R#M&1T]J0(@<N% 8]3CDT
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M18^/+S2+V)9]-CU"2QM8C/.NY VU5 !8\^W'I6)\/?B)K'Q%OGU33[#2M/\
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M99S]YVY+5/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?\EF\,_]?7_LIKQ<0[TI^C_(]"E\<?5'WM1117PA]*9^L?\ (!O_ /KWD_\
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M,W__ #S@_P"^V_PH M455S?_ //.#_OMO\*,W_\ SS@_[[;_  H M455S?\
M_/.#_OMO\*,W_P#SS@_[[;_"@"U157-__P \X/\ OMO\*,W_ /SS@_[[;_"@
M"U157-__ ,\X/^^V_P *,W__ #S@_P"^V_PH M455S?_ //.#_OMO\*,W_\
MSS@_[[;_  H M455S?\ _/.#_OMO\*,W_P#SS@_[[;_"@"U157-__P \X/\
MOMO\*,W_ /SS@_[[;_"@"U157-__ ,\X/^^V_P *,W__ #S@_P"^V_PH M45
M5S?_ //.#_OMO\*,W_\ SS@_[[;_  H \[^-G_)+[O\ Z[1?^A5\JU]2_&@W
M7_"L[OS%B"^?%]UB3][Z5\M5]YP]_!?J_P D?+9I_&^2"BBBOJCR@HHHH *P
M?$7WK;Z-_2MZL'Q%UMOHW]*Y<5_"9K1^-&%7>_!S_DLWAG_KZ_\ 937!5W?P
M?W_\+B\,^6 6^U?Q=/NFOG*_\*7H_P CU:?QQ]4??%%5<W__ #S@_P"^V_PH
MS?\ _/.#_OMO\*^&/I"+6/\ D W_ /U[R?\ H)JW#_J4_P!T5F:N;W^P[_<D
M&/L\G1C_ '3[59B-_P"2G[NW^Z/XF_PJNA/4O455S?\ _/.#_OMO\*,W_P#S
MS@_[[;_"I*+5%5<W_P#SS@_[[;_"C-__ ,\X/^^V_P * +5%5<W_ /SS@_[[
M;_"C-_\ \\X/^^V_PH M455S?_\ /.#_ +[;_"C-_P#\\X/^^V_PH M455S?
M_P#/.#_OMO\ "I(O.P?.51Z;"30!-1110 4444 %%%% !1110 4444 %%%%
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MC_KZ_P#937A5_P"%+T?Y'I4OC7J??%%%%?$'T10UC_D W_\ U[R?^@FK4/\
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M^6_QHQ?_ -^W_P"^6_QJS10!6Q?_ -^W_P"^6_QHQ?\ ]^W_ .^6_P :LT4
M5L7_ /?M_P#OEO\ &C%__?M_^^6_QJS10!6Q?_W[?_OEO\:,7_\ ?M_^^6_Q
MJS10!Y3\<!=?\*LO/,:,KY\/W5(/WOK7R?7UO\<_^24W?_7:+_T*OD?-?=Y#
M_NK_ ,3_ "1\YF'\7Y"T4F:,U[]SS!:*3-&:+@+6'KWWK?Z-_2MO-8>O?>M_
MHW]*Y\3_  V:4?C1C9KN_@[O_P"%R^&?+(#?:_XNGW37!UWOP;_Y+/X8_P"O
MO_V4U\[6_AR]&>E3^->I][XO_P"_;_\ ?+?XT8O_ ._;_P#?+?XU9HKX\^@,
M?5A??V'?[G@Q]GD_A;^Z?>K48OO)7#P?='\+?XTFL?\ (!O_ /KWD_\ 035J
M'_4I_NBJZ$_:(\7_ /?M_P#OEO\ &C%__?M_^^6_QJS14E%;%_\ W[?_ +Y;
M_&C%_P#W[?\ [Y;_ !JS10!6Q?\ ]^W_ .^6_P :,7_]^W_[Y;_&K-% %;%_
M_?M_^^6_QHQ?_P!^W_[Y;_&K-% %;%__ '[?_OEO\:?'YV#YQ4GML!%344 %
M%%% !1110!@>*-0NM(\)ZIJ-F(C/;6[2)YIP@('4^PZX[]*Y[0YFEU2QW?$;
M3=549*VL%O;H9 1T7:Q8>O'I70^*K]=-\(ZI?26:7BP0,Y@E&4?'][_9[GV!
MKC[&SN-!\1:))<-H.I?VE,8E%GIR02P'RV??&P8ED&W!S_>'- 'I]%%% !11
M10 4444 %%%5))CYOEP+YDG?T3ZG^E #YIHX5!?J>%4<ECZ 5"L,DS![E?E'
M*Q#H/KZG]*EB@",9';S)3U8]O8>@JS0 4444 %%%% !112;A0 44W<M)N7UH
M%S(H7'_(Q:?_ -<)_P"<=:556CB:=)BH\Q 55NX!QG^0_*K&ZGV$F.HIOF+Z
MT;E]:8[H?1114C,V;_D8K7_KVF_]"CK1K.F_Y&*U_P"O:;_T*.M&A]"5U%HH
MHH*"BBB@ HHHH **** "BBB@#RWXZ?\ )*[S_KO#_P"A5\D5];?'7_DE-[_U
MVA_]"KY)K[C(?X+]7^2/G,P_B_(****^B/,"BBB@ K$UW[UO]&_I6W6)KOWK
M?Z-_2N7$?PV:4OC1C5WOP:_Y+3X8_P"OO_V4UP-=[\&?^2U>%_\ K[_]E:O
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MN;O[7K"37T*21KM!=)'5 H[ 8& :ZI;-K72_L.ELMJ8HO*@,BF18\#"Y&06
M^OXU@>'_  ]K6B:1J&GR:]%-]HDEFAFAL_+:"21V=FPSL&&6X&.W>@##\,WE
MS"?L]Q?>(?\ A(OL+2I8ZNP$4[A1N*8&" Q'?(!Z5FZ1XDUB.QN$AU2\OIKF
MU@CWW\6S[-J#[O-495?D1 79>0H7KS7:6/AW4O\ A(+;6M<UE-1N+2)X;9(;
M;R$CWXWN1N8LQV@=0 .U6;_08M5U5[B^F+P"SDM(H0N/+,G$CY]2N /09]:
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M7*^$;"WNM9BU3P[X3M?#UBC,EW<2QJTT\@RKPQ '"H&&"_?;@#O0!ZI1110
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MG51U?_D$S_A_.KU4=7_Y!,_X?SKKJ/\ =R]"(?$CDJ!R<'I12C[PKYFML>M
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MO^1BM?\ KUF_]"CK0_B-9\W_ ",5K_UZS?\ H4=:'\1I/H"ZCJ***!A1110
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M_CTF_P"N;?RKX"SS7U&0_%/Y'AYE]GY_H/S1NJ/=1NK[.YX9)NHW5'NHW47
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M.M?3%?,W[.)SXMUC_KR_]J+7TS0 4444 %%%% !1110 4444 %%%% !1110
M445C>(]5?0_"^IZQ'$LSV5N\X1FVABHS@GM0!LT5P]KXDU>'0K_7-2CTBYLK
M.U>XQI=R\K%E7=M.5 '&:BA\7:E!:ZE!J&F6XU:W%O\ 9X;><ND[3Y$:Y(!!
M!4[N.@S0!WM%01EC&I?;NQ\VWIGOBIZ "J\DL<*;G;'8#N3Z"FRS[6\N-?,D
M_N]A[D]J2&WVOYDS>9+_ 'NR^P':@!/+DN3NF^6+M%Z_[W^%7.@HHH ****
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MU0+$V<*9*\__ .&=/&?_ #]6?_?7_P!>OJO[4O\ SQG_ ._34?:U_P">4_\
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M (9-\6;MW]HVO^?QJ0_LI>+MNT:E:X_S[U]C?:U_YY3_ /?IJ/M:_P#/*?\
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MJQ<)RNF7##4X2YHK4^>/^%/^-O\ GE8_]_31_P *?\;?\\K'_OZ:^A_M:_\
M/*?_ +]-1]K7_GE/_P!^FKB.@^>/^%/^-O\ GE8_]_31_P *?\;?\\K'_OZ:
M^A_M:_\ /*?_ +]-1]K7_GE/_P!^FH ^>/\ A3_C;_GE8_\ ?TT?\*?\;?\
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3 HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>cvm_10kimg15.jpg
<TEXT>
begin 644 cvm_10kimg15.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" $& C$# 2(  A$! Q$!_\0
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M !\2?]]FJ_LVB^_WA]<J^1]J_P#"TM$_Z!NJ?]^5_P#BJ/\ A:6B?] W4_\
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MW/\ S\2_]]FC^RJ?G]X?7*GD?:O_  M+0?\ H&ZI_P" Z_\ Q5'_  M+0?\
MH&ZI_P" Z_\ Q5?%7VFY_P"?B7_OLT?:;G_GXE_[[-']E4_/[P^N5/(^U?\
MA:6@_P#0-U3_ ,!U_P#BJ/\ A:6@_P#0-U3_ ,!U_P#BJ^*OM-S_ ,_$O_?9
MH^TW/_/Q+_WV:/[*I^?WA]<J>1]J_P#"TM!_Z!NJ?^ Z_P#Q5'_"TM!_Z!NJ
M?^ Z_P#Q5?%7VFY_Y^)?^^S1]IN?^?B7_OLT?V53\_O#ZY4\C[5_X6EH/_0-
MU3_P'7_XJC_A:6@_] W5/_ =?_BJ^*OM-S_S\2_]]FC[3<_\_$O_ 'V:/[*I
M^?WA]<J>1]J_\+2T'_H&ZI_X#K_\51_PM+0?^@;JG_@.O_Q5?%7VFY_Y^)?^
M^S1]IN?^?B7_ +[-']E4_/[P^N5/(^U?^%I:#_T#=4_\!U_^*H_X6EH/_0-U
M3_P'7_XJOBK[3<_\_$O_ 'V:/M-S_P _$O\ WV:/[*I^?WA]<J>1]J_\+2T'
M_H&ZI_X#K_\ %4?\+2T'_H&ZI_X#K_\ %5\5?:;G_GXE_P"^S1]IN?\ GXE_
M[[-']E4_/[P^N5/(^U?^%I:#_P! W5/_  '7_P"*H_X6EH/_ $#=4_\  =?_
M (JOBK[3<_\ /Q+_ -]FC[3<_P#/Q+_WV:/[*I^?WA]<J>1]J_\ "TM!_P"@
M;JG_ (#K_P#%4?\ "TM!_P"@;JG_ (#K_P#%5\5?:;G_ )^)?^^S1]IN?^?B
M7_OLT?V53\_O#ZY4\C[5_P"%I:#_ - W5/\ P'7_ .*H_P"%I:#_ - W5/\
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M<F0?E()R. <^PQD:/#8P?$'5+>);8/$UXFF+<;3#]H!80@[OE/MGC=MS7(X
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M!FM-.@N[K4+&"2>V^UI:O(PE,9R5.-N,MCA<YZ=,UW]Y>6$<#7%G#=7/AG[
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M^=F_#%-\4> =%\::OHFI:[<:C)#H\PN8M/2Y*6LLH(*/+&/OE2..>YZ@UW-
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MOI=,T1X)V?=Y=G;R1E3^\?)QD9(+'.:36M+71M5ET[[8MV\)*R.D3Q@,"00
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MNH[7Q'-K7B*VU*RU"0?8(([L3;I?/5DE1!_J51 X.0OWMN#5K6KZYU&[N?\
MA$_$EKITD6L7EQ=.;Y;;S2TN8KC<2/,0)Q@9Q@\?-7(_\(7XM_Z%?5O_  !E
M_P#B:/\ A"_%O_0KZM_X R__ !-9\L-^9$WEV.Q_M3PW/J4>I136@TNU\1RW
M3QL%4A'AC59A">63S%+;0#@#!%5;._\ [-@7_A-M8@UU9-4M;B&)+H7K *Y,
MTW!.U&7 VG!;CCBN8_X0OQ;_ -"OJW_@#+_\33X?"/C*WGCG@\-ZQ%+&P='2
MRE!5@<@@[>M3:G;X@O+L=.)-9_X1SQ8VK^)+?5HY#:S(8[P7 ;-TG[U<9\M2
M.,':>@Q\O$NKWUQJ-]-_PBOB*VTYX=8O+BZ;[<MMYI:;=%<;B1YB!/EP,D8/
M'S<XM]IGQ#U&T>UN/#VHK!)()94@TDPB9QG#/L0;B,GKZUE?\(7XM_Z%?5O_
M  !E_P#B:T7+NVOTV!WV29VGABZL[._T::XUN.ZL)))?M\TNJ>1#$SNZLGV;
M W*P*MDK@[OX<<<=XA6.30?#4T-Q!*L6G?9)$296>.19920RYR.&4@]#G@TS
M_A"_%O\ T*^K?^ ,O_Q-'_"%^+?^A7U;_P  9?\ XFE'D4N;F$^9JUCIO^$J
MFC\23K%K2BPC\.B&./S 83,MFA4;?NF02@8)&=RCTJ31->LY-,TA]6U(SZH+
M74+6"XFNRDD#L\;1[I2&,>090K'H6/3J.5_X0SQ;_P!"OJW_ ( R_P#Q-'_"
M&>+?^A7U;_P!E_\ B:S_ '?</?['6QZM;P/!I\L\%CJ@M+I+*^GU07CV<C[0
MJ/*%VH"%?:<G89,_+FJ5GJ.KZ-;ZH=2\2P3WXT>2*U"WBW$EN6N(CL$@R-Q&
MY@ Q(QGBN?\ ^$+\6_\ 0KZM_P" ,O\ \31_PA?BW_H5]6_\ 9?_ (FMOW?=
M#][L=+:WT>H:9I-Q-K,DNL0:7+"(_P"T/LTEQ_I38CDF)R,1G< 2"P  -6]4
MUR&UTW4+G3]5A349=#M+9WAN_/D\U;HAU$G5G$8'S==O0D<UQ_\ PA?BW_H5
M]6_\ 9?_ (FC_A"_%O\ T*^K?^ ,O_Q-'[N_Q![W8Z9]8@N-%$LVJ6TFH2:-
M81.]U)OWRQWV<29R6VH%)SD[16E%J44'B"SUJ_U9;2\-Q=2_8VU1;ZV):VEQ
M,G)\L%RJA6)SD8Z5P_\ PA?BW_H5]6_\ 9?_ (FC_A"_%O\ T*^K?^ ,O_Q-
M5^[U]X+R[&E_PE6L+X(TE5U^Y_M&/5)I'D\\^>L>R)E!;.[9OWG&<9SQ3_MV
MCV_Q=N]0DE@_L[^T;AXIPN^)"V_RY,#.55RK<=A67_PAGBW_ *%?5_\ P!E_
M^)H_X0SQ;_T*^K_^ ,O_ ,32O35]=[_B3[W8Z:POKK38]/C\2>((;V].MVES
M;.E\+EK=%8^?*9 3L1P5&,C.,X&*YF":&_\ B LVI:O+!;O?,3?>82T:[R58
M,<X'3!Z#.>U)_P (7XM_Z%?5O_ &7_XFE_X0SQ=_T*^K_P#@#+_\351]FKOF
MW&^9VT.VM]4T^WL],;6KJWAO+;57=!+J7]I-;![=U28GGY!*(V(&?N@X'&<W
M1+G6M,\2:1_;WBZWE5Y+E4']IB<QL\#*)&D!(1&8J.6'(R0,9KFO^$+\6_\
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M)H_X0SQ;_P!"OJW_ ( R_P#Q-'M8=PY9=C HK?\ ^$,\6_\ 0KZM_P" ,O\
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M-T?4*W=?C_D'UJGV9]545\J_\+TUC_H.ZG_X"VO_ ,;H_P"%Z:Q_T'=3_P#
M6U_^-T?4*W=?C_D'UJGV9]545\J_\+TUC_H.ZG_X"VO_ ,;H_P"%Z:Q_T'=3
M_P# 6U_^-T?4*W=?C_D'UNGV9]4_+1\M?*W_  O+6/\ H.ZG_P" MK_\;H_X
M7EK'_0=U/_P%M?\ XW5?V?6[K\?\A?7*?9GU3\M'RU\K?\+RUC_H.ZG_ . M
MK_\ &Z/^%Y:Q_P!!W4__  %M?_C=']GUNZ_'_(/KE/LSZJHKY5_X7IK'_0=U
M/_P%M?\ XW1_PO36/^@[J?\ X"VO_P ;J?J%;NOQ_P A_6J?9GU/17RQ_P +
MRUC_ *#NI_\ @+:__&Z/^%Z:Q_T'=3_\!;7_ .-T_J%;NOQ_R%]9I]F?4]/K
MY5_X7IK'_0=U/_P%M?\ XW1_PO36/^@[J?\ X"VO_P ;I?4*W=?C_D/ZU3[,
M^IOEJ2OE7_A>FL?]!W4__ 6U_P#C='_"]-8_Z#NI_P#@+:__ !NCZA6[K\?\
M@^M4^S/JCY:7Y:^5O^%Y:Q_T'=3_ / 6U_\ C='_  O+6/\ H.ZG_P" MK_\
M;H^H5NZ_'_(7URGV9]545\J_\+TUC_H.ZG_X"VO_ ,;H_P"%Z:Q_T'=3_P#
M6U_^-T?4*W=?C_D/ZW3[,^J?EHX_R*^5O^%Y:Q_T'=3_ / 6U_\ C='_  O+
M6/\ H.ZG_P" MK_\;JO[/K=U^/\ D+ZY3[,^J?EH^6OE;_A>6L?]!W4__ 6U
M_P#C='_"\M8_Z#NI_P#@+:__ !NC^SZW=?C_ )!]<I]F?55%?*O_  O36/\
MH.ZG_P" MK_\;H_X7IK'_0=U/_P%M?\ XW2_L^MW7X_Y#^MT^S/JFBOE;_A>
M6L?]!W4__ 6U_P#C='_"\M8_Z#NI_P#@+:__ !NE]0K=U^/^0OK=/LSZH^6E
M^6OE;_A>6L?]!W4__ 6U_P#C='_"\M8_Z#NI_P#@+:__ !NG]0K=U^/^0?7*
M?9GU317RM_PO+6/^@[J?_@+:_P#QNC_A>6L?]!W4_P#P%M?_ (W3_L^MW7X_
MY!];I]F?5/RTW"_W:^6/^%Y:Q_T'=3_\!;7_ .-T?\+RUC_H.ZG_ . MK_\
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MF,RW&I7"SRQKMV^4C!00G?G.2!TKG*ZX<UO>,Y6OH%;W@O\ Y*!X=_["5O\
M^C%K!K>\%_\ )0/#O_82M_\ T8M15_AL2/MJBBBOFCK.@HHHKS#VPHHHH **
M** "BBB@ K(M_P#D;[__ *\[?_T.:M>LBW_Y&^__ .O.W_\ 0YJ:ZDOH:O>N
M7^('_)-O$G_8-N/_ $6:ZCO7+_$#_DFWB3_L&W'_ *+-%+XX^HI_"SX6N/\
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MKL $<-M()Z#!ZGI7=QZLUU'K4DD%C:II.L6DEB(;>-!:J;AT8 XR5*XSN)Y
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M\#6\OA73H[V]ENYH]2Q;)<2*N%\E&# [8B-Y)X!.<G@5VN5M_B$+R-+>*?\
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M2+R./6?!6B)9V7V'4=/C2^WVR,]T'>5?G8C(( &,$8/-3[?R#V?F>9[E!P2
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MF1)()O.$CB7.[S QW9]<]:0DDEB223DD]2:&&UF4,& )&Y>A]Q25U$!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !6]X+_ .2@>'?^PE;_ /HQ:P:WO!?_ "4#P[_V$K?_ -&+
M6=7^'($?;5%%%?,'6=!1117F'MA1110 4444 %%%% !61;_\C??_ /7G;_\
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2_OD445-V;V1+M3^[1112)/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387586394128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 08, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CEL-SCI CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000725363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well Known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,980,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,639,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Fin Stmt Error Correction Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-11889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-0916344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">8229 Boone Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line 2</a></td>
<td class="text">Suite 802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Vienna<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">VA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">22182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">Icfr Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">BDO USA, P.C.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Potomac, Maryland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm Id</a></td>
<td class="text">243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">506-9460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CVM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">CO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387584774528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,145,735<span></span>
</td>
<td class="nump">$ 22,672,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">520,368<span></span>
</td>
<td class="nump">762,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Supplies used for R&amp;D and manufacturing</a></td>
<td class="nump">2,248,072<span></span>
</td>
<td class="nump">2,001,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits</a></td>
<td class="nump">4,245<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">6,918,420<span></span>
</td>
<td class="nump">25,435,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right of use assets</a></td>
<td class="nump">9,131,987<span></span>
</td>
<td class="nump">10,937,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">1,698,243<span></span>
</td>
<td class="nump">1,884,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10,188,126<span></span>
</td>
<td class="nump">11,889,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patent costs, net</a></td>
<td class="nump">197,704<span></span>
</td>
<td class="nump">212,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">2,319,101<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Supplies used for R&amp;D and manufacturing</a></td>
<td class="nump">74,669<span></span>
</td>
<td class="nump">164,299<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">30,528,250<span></span>
</td>
<td class="nump">50,523,706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,009,786<span></span>
</td>
<td class="nump">1,618,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,049,581<span></span>
</td>
<td class="nump">842,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_AmountsDueToEmployeesCurrent', window );">Due to employees</a></td>
<td class="nump">557,244<span></span>
</td>
<td class="nump">471,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease obligation, current portion</a></td>
<td class="nump">1,771,804<span></span>
</td>
<td class="nump">1,560,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease obligation, current portion</a></td>
<td class="nump">197,431<span></span>
</td>
<td class="nump">170,928<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,585,846<span></span>
</td>
<td class="nump">4,663,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="nump">9,949,565<span></span>
</td>
<td class="nump">11,721,368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">1,652,949<span></span>
</td>
<td class="nump">1,850,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">17,313,360<span></span>
</td>
<td class="nump">18,360,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Preferred stock, $.01 par value; 200,000 shares authorized; 0 shares issued and outstanding Common stock, $.01 par value; 600,000,000 shares authorized; 47,422,304 and 43,448,317 shares issued and outstanding at September 30, 2023 and September 30, 2022, respectively</a></td>
<td class="nump">474,223<span></span>
</td>
<td class="nump">434,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">499,832,063<span></span>
</td>
<td class="nump">486,625,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(487,091,396)<span></span>
</td>
<td class="num">(454,897,093)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">13,214,890<span></span>
</td>
<td class="nump">32,163,207<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 30,528,250<span></span>
</td>
<td class="nump">$ 50,523,706<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AmountsDueToEmployeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AmountsDueToEmployeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387585666656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">47,422,304<span></span>
</td>
<td class="nump">43,448,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">47,422,304<span></span>
</td>
<td class="nump">43,448,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387584663472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 22,471,496<span></span>
</td>
<td class="nump">$ 25,355,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General &amp; administrative</a></td>
<td class="nump">9,004,578<span></span>
</td>
<td class="nump">10,707,447<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">31,476,074<span></span>
</td>
<td class="nump">36,062,793<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(31,476,074)<span></span>
</td>
<td class="num">(36,062,793)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain on derivative instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">366,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingGainsLosses', window );">Other non-operating losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(30,793)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="num">(675,416)<span></span>
</td>
<td class="num">(1,081,034)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income</a></td>
<td class="num">(42,813)<span></span>
</td>
<td class="nump">107,148<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(32,194,303)<span></span>
</td>
<td class="num">(36,700,681)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ModificationOfWarrants', window );">Modification of warrants</a></td>
<td class="num">(171,552)<span></span>
</td>
<td class="num">(929,122)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common shareholders</a></td>
<td class="num">$ (32,365,855)<span></span>
</td>
<td class="num">$ (37,629,803)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EarningPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted</a></td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (0.87)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding - basic and diluted</a></td>
<td class="nump">44,479,865<span></span>
</td>
<td class="nump">43,148,888<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_EarningPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_EarningPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ModificationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ModificationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7,9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387581316080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,207,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2021</a></td>
<td class="nump">$ 56,534,226<span></span>
</td>
<td class="nump">$ 432,072<span></span>
</td>
<td class="nump">$ 474,298,566<span></span>
</td>
<td class="num">$ (418,196,412)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WarrantExercisesShares', window );">Warrant exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WarrantExercisesAmount', window );">Warrant exercises, amount</a></td>
<td class="nump">171,814<span></span>
</td>
<td class="nump">$ 252<span></span>
</td>
<td class="nump">171,562<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, amount</a></td>
<td class="nump">223,043<span></span>
</td>
<td class="nump">$ 528<span></span>
</td>
<td class="nump">222,515<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service, amount</a></td>
<td class="nump">693,493<span></span>
</td>
<td class="nump">$ 1,567<span></span>
</td>
<td class="nump">691,926<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity based compensation - employees</a></td>
<td class="nump">11,389,932<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">11,389,932<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Option exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Option exercises, amount</a></td>
<td class="nump">29,835<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">29,770<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncreaseDecreaseFromStockIssuanceCosts', window );">Share issuance costs</a></td>
<td class="nump">178,455<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">178,455<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(36,700,681)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(36,700,681)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,448,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2022</a></td>
<td class="nump">32,163,207<span></span>
</td>
<td class="nump">$ 434,484<span></span>
</td>
<td class="nump">486,625,816<span></span>
</td>
<td class="num">(454,897,093)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WarrantExercisesShares', window );">Warrant exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WarrantExercisesAmount', window );">Warrant exercises, amount</a></td>
<td class="nump">447,291<span></span>
</td>
<td class="nump">$ 2,177<span></span>
</td>
<td class="nump">445,114<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, amount</a></td>
<td class="nump">207,593<span></span>
</td>
<td class="nump">$ 970<span></span>
</td>
<td class="nump">206,623<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service, amount</a></td>
<td class="nump">565,980<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">563,480<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity based compensation - employees</a></td>
<td class="nump">6,308,431<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,308,431<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncreaseDecreaseFromStockIssuanceCosts', window );">Share issuance costs</a></td>
<td class="nump">813,606<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">813,606<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(32,194,303)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(32,194,303)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from the sale of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,413,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from the sale of common stock, amount</a></td>
<td class="nump">6,552,497<span></span>
</td>
<td class="nump">$ 34,132<span></span>
</td>
<td class="nump">6,518,365<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncentiveStockForfeitedShares', window );">2014 Incentive Stock Forfeited, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncentiveStockForfeitedAmount', window );">2014 Incentive Stock Forfeited, amount</a></td>
<td class="num">(22,200)<span></span>
</td>
<td class="num">$ (40)<span></span>
</td>
<td class="num">(22,160)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,422,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2023</a></td>
<td class="nump">$ 13,214,890<span></span>
</td>
<td class="nump">$ 474,223<span></span>
</td>
<td class="nump">$ 499,832,063<span></span>
</td>
<td class="num">$ (487,091,396)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncentiveStockForfeitedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncentiveStockForfeitedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncentiveStockForfeitedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncentiveStockForfeitedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncreaseDecreaseFromStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncreaseDecreaseFromStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantExercisesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantExercisesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantExercisesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantExercisesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387586403040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (32,194,303)<span></span>
</td>
<td class="num">$ (36,700,681)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,958,334<span></span>
</td>
<td class="nump">3,828,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash lease expense</a></td>
<td class="nump">15,292<span></span>
</td>
<td class="nump">54,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Share-based payments for services</a></td>
<td class="nump">655,740<span></span>
</td>
<td class="nump">762,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity based compensation</a></td>
<td class="nump">6,286,231<span></span>
</td>
<td class="nump">11,389,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommonStockContributedToEmployeeBenefitPlan', window );">Common stock contributed to 401(k) plan</a></td>
<td class="nump">207,593<span></span>
</td>
<td class="nump">223,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain on short term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(615)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain on derivative instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(366,791)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment loss on abandonment of patents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_GainLossOnReceivables', window );">Loss on Receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">54,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase)/decrease in assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">151,935<span></span>
</td>
<td class="nump">167,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Supplies used for R&amp;D and manufacturing</a></td>
<td class="num">(156,727)<span></span>
</td>
<td class="num">(159,430)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeposits', window );">Deposits</a></td>
<td class="num">(2,323,346)<span></span>
</td>
<td class="nump">1,910,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase/(decrease) in liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">257,845<span></span>
</td>
<td class="nump">374,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">207,089<span></span>
</td>
<td class="num">(16,724)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Due to employees</a></td>
<td class="nump">85,756<span></span>
</td>
<td class="nump">205,495<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(22,848,561)<span></span>
</td>
<td class="num">(18,240,951)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from maturity of U.S. Treasury Bills</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,152,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(361,892)<span></span>
</td>
<td class="num">(637,892)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Expenditures for patent costs</a></td>
<td class="num">(10,370)<span></span>
</td>
<td class="num">(22,741)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(372,262)<span></span>
</td>
<td class="nump">5,491,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ProceedsFromIssuanceOfCommonStocks', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">6,552,497<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="num">(744,913)<span></span>
</td>
<td class="num">(169,445)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of warrants</a></td>
<td class="nump">447,291<span></span>
</td>
<td class="nump">101,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">29,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ProceedsFromLandlordFundingOfLeaseImprovements', window );">Proceeds from landlord funding of lease improvements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">786,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Payments on obligations under finance leases</a></td>
<td class="num">(1,560,455)<span></span>
</td>
<td class="num">(1,386,495)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">4,694,420<span></span>
</td>
<td class="num">(638,426)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(18,526,403)<span></span>
</td>
<td class="num">(13,388,010)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR</a></td>
<td class="nump">22,672,138<span></span>
</td>
<td class="nump">36,060,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, END OF YEAR</a></td>
<td class="nump">4,145,735<span></span>
</td>
<td class="nump">22,672,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities', window );">Property and equipment purchases included in current liabilities</a></td>
<td class="nump">51,650<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable', window );">Capitalized patent costs included in current liabilities</a></td>
<td class="nump">13,211<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_AssetsPurchasedUnderFinanceLeases', window );">Assets purchased under finance leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncreaseDecreaseToRightOfUseAssetsAndLiabilities', window );">Changes to right of use assets and liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinanceLeaseObligationIncludedInAccountsPayable', window );">Finance lease obligation included in accounts payable</a></td>
<td class="nump">1,451<span></span>
</td>
<td class="nump">1,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ConsultingFeePaidWithIssuanceOfCommonStock', window );">Prepaid consulting services paid with issuance of common stock</a></td>
<td class="nump">565,980<span></span>
</td>
<td class="nump">295,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinancingCostsIncludedInCurrentLiabilities', window );">Financing costs included in current liabilities</a></td>
<td class="nump">77,703<span></span>
</td>
<td class="nump">9,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_DerivativeLiabilitiesExercised', window );">Exercise of derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">70,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_AccruedConsultingServicesToBePaid', window );">Accrued consulting services to be paid with common stock</a></td>
<td class="nump">55,000<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 1,062,564<span></span>
</td>
<td class="nump">$ 1,157,069<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AccruedConsultingServicesToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AccruedConsultingServicesToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AssetsPurchasedUnderFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AssetsPurchasedUnderFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommonStockContributedToEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommonStockContributedToEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ConsultingFeePaidWithIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ConsultingFeePaidWithIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_DerivativeLiabilitiesExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_DerivativeLiabilitiesExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinanceLeaseObligationIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinanceLeaseObligationIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinancingCostsIncludedInCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinancingCostsIncludedInCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_GainLossOnReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_GainLossOnReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncreaseDecreaseToRightOfUseAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncreaseDecreaseToRightOfUseAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ProceedsFromIssuanceOfCommonStocks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ProceedsFromIssuanceOfCommonStocks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ProceedsFromLandlordFundingOfLeaseImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ProceedsFromLandlordFundingOfLeaseImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481160/942-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387589775936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>ORGANIZATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1. ORGANIZATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">CEL-SCI Corporation (the Company) was incorporated on March 22, 1983, in the state of Colorado, to finance research and development in biomedical science and ultimately to engage in marketing and selling products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company has announced results from its Phase III study for its lead investigational therapy, Multikine&#174; (Leukocyte Interleukin, Injection), involving head and neck cancer, for which the Company has received Orphan Drug Status from the United States Food and Drug Administration (FDA). Unlike other immune therapies, Multikine is administered locally at the site of the tumor as a first line treatment right after diagnosis, before surgery and radiation. The goal is to help the intact immune system kill the micro metastases that usually cause recurrence of the cancer to improve outcomes and better overall survival rates for patients suffering from head and neck cancer. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">CEL-SCI is also investigating a peptide-based immunotherapy (CEL-4000) as a vaccine for rheumatoid arthritis using its LEAPS technology platform. CEL-SCI is in the process of completing pre-IND studies for CEL-4000.&#160; </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387586933792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_LIQUIDITYAbstract', window );"><strong>LIQUIDITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_LiquiditydisclosureTextblock', window );">LIQUIDITY</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>2</strong><strong>.</strong>&#160; <strong>LIQUIDITY </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and participation in clinical trials.&#160; The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities.&#160; The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine to market.&#160; The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from the U.S. Food and Drug Administration (FDA) or from the regulators in Canada, the UK or Europe for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings.&#160; The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase III study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all.&#160; If the Company does not raise the necessary amounts of funding, it may have to curtail its operations until such time as it is able to raise the required funding.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Due to the Company&#8217;s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern.&#160; The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LIQUIDITYAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LIQUIDITYAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LiquiditydisclosureTextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LiquiditydisclosureTextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387587507248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>3</strong><strong>. </strong><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Cash and Cash Equivalents </em>&#8211; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds.&#160; The Company considers all highly liquid investments with a maturity when purchased of less than three months as cash and cash equivalents.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>U.S. Treasury Bills &#8211; </em>U.S. Treasury Bills (&#8220;T-bills&#8221;) are highly liquid short-term investments with maturity dates of greater than 3 months, but less than one year. These investments are recorded at fair value.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Supplies used for R&amp;D and manufacturing</em> &#8211; Supplies are consumable items kept on hand to support the Company&#8217;s R&amp;D and manufacturing operations.&#160; Supplies are recorded at cost and are charged to expense as they are used in operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment are reviewed on a quarterly basis to determine if any of the assets are impaired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Patents</em> &#8211; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years).&#160; In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment to the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset.&#160; The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Leases</em> &#8211; The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material. For purposes of calculating the finance and operating lease liabilities, lease and non-lease components are combined. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Derivative Instruments</em> &#8211; The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, <em>Accounting for Derivative Instruments and Hedging Activities</em>. In accordance with ASC 815, derivative instruments and hybrid instruments are recognized as either assets or liabilities on the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each&#160;reporting period. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company adopted Accounting Standards Update (ASU) 2020-06 <em>Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</em> effective October 1, 2021<em>.</em>&#160;The amendments in this Update simplify and clarify the guidance in Subtopic 815-40. &#160;There was no financial impact upon adoption.&#160;&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company adopted ASU 2021-04,&#160;<em>Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</em>. This standard was issued to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 was effective for fiscal years beginning after December 15, 2021, however, as permitted, the Company elected to prospectively adopt the standard, effective as of October 1, 2021. Adoption of this standard had no impact on the Company&#8217;s financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Stock-Based Compensation</em> &#8211; Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, <em>Compensation &#8211; Stock Compensation</em>. The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized using the straight-line allocation method as expense over the requisite service or vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the "Plans". All Plans have been approved by the Company&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the assumption for stock price volatility is based on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the 2021 and 2020 Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant-dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Research and Development Costs</em> - Research and development costs are expensed as incurred.&#160; Management accrues Clinical Research Organization (CRO) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Net Loss Per Common Share</em> &#8211; The Company calculates net loss per common share in accordance with ASC 260 <em>Earnings Per Share</em> (ASC 260).&#160; Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period.&#160; The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Concentration of Credit Risk</em> &#8211; Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents.&#160; The Company maintains its cash and cash equivalents with high quality financial institutions.&#160; At times, these accounts may exceed federally insured limits.&#160; The Company has not experienced any losses in such bank accounts.&#160; The Company believes it is not exposed to significant credit risk related to cash and cash equivalents.&#160; All non-interest bearing cash balances were fully insured up to $250,000 at September 30, 2023 and September 30, 2022. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Income Taxes</em> &#8211;The Company follows ASC 740-10-25 for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related assets or liability is expected to be realized or settled.&#160; The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160; The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of September 30, 2023 and 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company adopted ASU&#160; 2019-12,&#160;<em>Income Taxes (Topic&#160;740): Simplifying the Accounting for Income Taxes</em>, effective October 1, 2021. The new standard includes several provisions that simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. The adoption of ASU 2019-12 had no impact on the Company&#8217;s financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On August 16, 2022, the Inflation Reduction Act of 2022 (the &#8220;IR Act&#8221;) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly traded foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself, not its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the &#8220;Treasury&#8221;) has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax.&#160;&#160;&#160;&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Impairment of long-lived assets</em> &#8211; CEL-SCI&#8217;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#8217;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets in accordance with ASC 360-10-35-21 to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures.&#160; These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, obsolescence of supplies used for research and development (R&amp;D) and manufacturing, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities,&#160;deferred tax assets and the related valuation allowance, and the valuation of derivative liabilities. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.&#160; The Company considers the estimates used in valuing the derivative liabilities and the lease assets and liabilities to be significant. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>New Accounting Pronouncements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In June 2016, the Financial Accounting Standards Board issued ASU 2016-13, <em>Financial Instruments&#8211;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</em> (ASU 2016-13), as amended. The amendments in ASU 2016-13 require, among other things, financial assets measured at amortized cost basis to be presented at the net amount expected to be collected as compared to previous U.S. GAAP which delayed recognition until it was probable a loss had been incurred. The amendments in ASU 2016-13 are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, with early adoption permitted. The Company currently does not have any such financial assets reported as of September 30, 2023, however, the Company will continue to evaluate the impact that adoption of ASU 2016-13 will have on its financial statements and related disclosures.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Other accounting standard updates effective for interim and annual periods beginning after September 30, 2023 are not expected to have a material impact on the Company&#8217;s financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387588521440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS AND NONEMPLOYEE OPTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WarrantsAndNonemployeeOptionsAbstract', window );"><strong>WARRANTS AND NONEMPLOYEE OPTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WarrantsAndNonEmployeeOptionsDisclosureTextBlock', window );">WARRANTS AND NON-EMPLOYEE OPTIONS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>4.&#160;&#160; WARRANTS AND NON-EMPLOYEE OPTIONS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following warrants and non-employee options are outstanding at September 30, 2023:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">Warrant/Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;">Shares Issuable upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;">of Warrants/ Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.95pt; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:14%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2008</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:14%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2024</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/11/2018</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">93,603</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.80</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/30/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1/13/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">120,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9.25</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/13/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/15/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">26,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">12.00</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/15/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">333,432</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.86</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">200,087</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.52</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">234,009</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.65</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultant Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">7/28/2017 &#8211; 9/2/2023</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">110,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>$</td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;">1.39 - $2.18</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/27/2027 &#8211; 9/1/2028</p></td><td>&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following warrants and non-employee options are outstanding at September 30, 2022:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">Warrant/Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;">Shares Issuable upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;">of Warrants/ Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.95pt; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:14%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2008</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:14%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2024</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/11/2018</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">93,603</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.80</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/30/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1/13/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">120,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9.25</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/13/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/15/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">26,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">12.00</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/15/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">333,432</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.86</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">200,087</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.52</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">251,761</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.65</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2022</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series SS</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12/19/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">200,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.09</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12/18/2022</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series TT</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/5/2018</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">600</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.24</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/5/2023</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultant Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.95pt; text-align:right;">7/28/2017 &#8211; 11/18/2020</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">15,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>$</td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">2.18 - $11.61</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:right;">11/17/2022 - 7/27/2027</p></td><td>&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>A.&#160; Warrant Liabilities</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">There were no warrant liabilities outstanding at September 30, 2023 and 2022.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The gains/(losses) on the warrant liabilities for the years ended September 30 are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05in; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05in; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series W warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Z warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,787</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series ZZ warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series AA warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">276,035</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series BB warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series CC warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,372</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series HH warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,597</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss on warrant liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">366,791</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company reviews all outstanding warrants in accordance with the requirements of ASC 815 , <em>Accounting for Derivative Instruments and Hedging Activities</em>.&#160; This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument&#8217;s contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain dilutive events.&#160; Under the provisions of ASC 815, the warrants are not considered indexed to the Company&#8217;s stock because future equity offerings or sales of the Company&#8217;s stock are not an input to the fair value of a &#8220;fixed-for-fixed&#8221; option on equity shares, and equity classification is therefore precluded.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration.&#160; Any change in fair value between the respective reporting periods is recognized as a gain or loss in the statement of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Changes in Warrant Liabilities</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In February 2022, 100,000 Series AA warrants, with an exercise price of $13.75 and 200 Series HH warrants with an exercise price of $3.13, expired. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In December 2021, 640 Series CC warrants, with an exercise price of $5.00, expired. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2021, 184,800 Series Z warrants, with an exercise price of $13.75, expired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Exercise of Warrant Liabilities</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">No warrants recorded as liabilities were exercised during the year ended September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following warrants recorded as liabilities were exercised during the year ended September 30, 2022:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Proceeds</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series CC</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,205</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">76,025</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>B. Equity Warrants</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Changes in Equity Warrants</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024.&#160; The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend. The Series RR warrants are held by Geert Kersten, Patricia Prichep (current officers of the Company) and the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On June 13, 2022, the expiration dates of the Series N, Series X, Series Y, Series UU, Series MM and Series NN warrants were extended two years. The incremental costs of the Series N, Series X and Series Y warrant extensions were recorded as a deemed dividend and totaled approximately $294,000 for the year ended September 30, 2022.&#160; The Series N and Series X warrants are held by the de Clara Trust.&#160; The incremental cost of the Series MM, Series NN and Series UU warrant extensions of approximately $635,000 was recorded as a deemed dividend because there were no longer any notes payable associated with these warrants at the time of modification. The Series UU warrants and a portion of the Series MM and Series NN warrants are held by Geert Kersten, Patricia Prichep (current officers of the Company) and the de Clara Trust.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Exercise of Equity Warrants </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following equity warrants were exercised during the year ended September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Proceeds</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,752</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,291</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">200,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">418,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">217,752</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">447,291</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following equity warrants were exercised during the year ended September 30, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Proceeds</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>C.</strong>&#160; <strong>Options and Shares Issued to Consultants</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company typically enters into consulting arrangements in exchange for common stock or stock options. During the years ended September 30, 2023 and 2022, the Company issued 249,997 and 156,547 shares, respectively, of common stock to consultants, all of which were restricted shares.&#160; Under these arrangements, during the periods presented, the common stock was issued with stock prices ranging from $1.26 to $11.20 per share. The weighted average grant price was $1.83 and $4.59, respectively, for stock issued during the years ended September 30, 2023 and 2022. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the years ended September 30, 2023 and 2022, the Company recorded total expense of approximately $656,000 and $762,000, respectively, relating to these consulting agreements. At September 30, 2023 and 2022, costs of approximately $205,000 and $295,000, respectively, are included in prepaid expenses. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the year ended September 30, 2023, the Company issued 100,000 options to a consultant to purchase common stock with an exercise price of $1.39. These options vest 50% on September 2, 2024 and 50% on September 2, 2025 and expire on September 1, 2028. No options were issued to consultants during the year ended September 30, 2022. As of September 30, 2023, 110,000 options issued to consultants as payment for services remained outstanding, all of which were issued from the Non-Qualified Stock Option Plan.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantsAndNonEmployeeOptionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantsAndNonEmployeeOptionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantsAndNonemployeeOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantsAndNonemployeeOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387587080176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>5</strong><strong>. </strong><strong>PROPERTY AND </strong><strong>EQUIPMENT</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Property and equipment consisted of the following at September 30:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Research equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,109,070</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,095,022</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Furniture and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">99,296</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">99,296</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Leasehold improvements</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">13,924,724</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">13,544,394</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,133,090</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,738,712</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accumulated depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,944,964</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(5,849,683</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net property and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">10,188,126</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">11,889,029</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Depreciation expense for the years ended September 30, 2023 and 2022 totaled approximately $2,114,000 and $1,977,000 respectively.&#160; </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387585654688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PATENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">PATENTS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>6</strong><strong>. PATENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Patents consist of the following at September 30:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">853,445</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">893,833</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accumulated amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(655,741</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(681,632</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patents, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">197,704</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">212,201</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the years ended September 30, 2023 and 2022, there was no impairment of patent costs. The weighted average amortization period for patents&#160;is approximately 8 years. Amortization expense for the years ended September 30, 2023 and 2022 totaled approximately $38,000 and &#160;$49,000, respectively.&#160;&#160; The total estimated future amortization is as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="4" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Years ending September 30, </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">32,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">71,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">198,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387588325712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>7</strong><strong>. INCOME TAXES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">At September 30, 2023 and 2022, the Company had net deferred tax assets of $60.0 million and $52.9 million, respectively. Due to uncertainties surrounding the Company&#8217;s ability to generate future taxable income to realize these assets, a full valuation allowance has been established to offset the net deferred tax assets. In assessing the realization of deferred tax assets, management considered whether it was more likely than not that some, or all, of the deferred tax assets will be realized.&#160; The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income.&#160; Management has considered the history of the Company&#8217;s operating losses and believes that the realization of the benefit of the deferred tax assets cannot be reasonably assured.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Pursuant to Section 382 of the Internal Revenue Code, or IRC, annual use of the Company&#8217;s net operating loss (NOL) carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. Such ownership change could result in annual limitations on the utilization of tax attributes, including NOL carryforwards and tax credits. The Company performed an estimated analysis to determine if any additional ownership changes occurred during the year ended September 30, 2023 and no such changes were identified. If changes in ownership occur after year end, NOL and tax credit carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company had federal NOL carryforwards of approximately $123.1 million and $100.2 million at September 30, 2023 and 2022, respectively. Approximately $19.2 million of the NOL carryforwards begin to expire during the year ended September 30, 2023 and become fully expired by 2038 and approximately $103.9 million of NOL carryforwards, which were generated after the enactment of Tax Cuts and Jobs Act, have an indefinite life.&#160; In addition, the Company has a general business credit as a result of the credit for increasing research activities (&#8220;R&amp;D credit&#8221;) of approximately $1.2 million at September 30, 2023 and 2022.&#160;&#160;The R&amp;D credit expires during the fiscal year ended 2029.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Significant components of the Company&#8217;s deferred tax assets and liabilities as of September 30, 2023 and 2022 are listed below:&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">NOL carryforwards</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,829,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,346,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Capitalized R&amp;D</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,196,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,042,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock-based compensation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,579,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,442,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,400,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,872,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">R&amp;D credit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,221,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,221,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vacation and other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">298,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">307,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fixed assets and intangibles</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">168,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total deferred tax assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">62,691,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">56,230,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Right of use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,713,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,244,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fixed assets and intangibles</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(44,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total deferred tax liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,713,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,288,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net deferred tax asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">59,978,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">52,942,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(59,978,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(52,942,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ending balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has no federal or state current or deferred tax expense or benefit.&#160; The Company&#8217;s effective tax rate differs from the applicable federal statutory tax rate.&#160; The reconciliation of these rates is as follows for the years ended September 30:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Federal rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">State rate change </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1.58</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1.67</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">State tax rate, net of federal benefit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.05</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.34</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other adjustments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1.62</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.28</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Permanent differences</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.21</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Change in valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(21.85</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(23.61</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Effective tax rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company applies the provisions of ASC 740, <em>Accounting for Uncertainty in Income Taxes,</em> which requires financial statement benefits to be recognized for positions taken for tax return purposes when it is more likely than not that the position will be sustained.&#160; The Company has elected to reflect any tax penalties or interest resulting from tax assessments on uncertain tax positions as a component of tax expense.&#160; The Company has generated federal net operating losses in tax years ending September 30, 1999 through 2023.&#160;&#160;The Company files income tax returns in the U.S. federal jurisdiction and various states. With few exceptions, the Company is no longer subject to U.S. federal and state income tax examinations by tax authorities for years before September 30, 2020. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387581018592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>EQUITY-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">EQUITY-BASED COMPENSATION</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>8</strong><strong>.</strong>&#160; <strong>EQUITY-BASED</strong><strong> </strong><strong>COMPENSATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company recognized the following expenses for options issued or vested and restricted stock awarded during the year:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Year Ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,286,231</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,389,932</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">655,740</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">762,261</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As of September 30, 2023, the total compensation cost related to non-vested options and restricted stock awarded to employees and non-employees not yet recognized was approximately $6.9 million and $0.3 million, respectively, and the weighted-average period over which it is expected to be recognized is 1.78 and 0.94 years, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the years ended September 30, 2023 and 2022 the fair value of each option grant was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected stock price volatility</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">99.18 &#8211; 100.18%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">96.37 &#8211; 99.26%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3.41 &#8211; 4.25%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.50 &#8211; 3.43%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected life of options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">9.63 &#8211; 9.66 years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">9.67 &#8211; 9.69 years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected dividend yield</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="width:1%;vertical-align:bottom;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="width:1%;vertical-align:bottom;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Non-Qualified Stock Option Plan</span><span style="text-decoration:underline">s</span>&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the year ended September 30, 2023, the Company adopted the 2023 Non-Qualified Stock Option Plan, which provides for the issuance of up to 2,000,000 options to purchase shares of common stock.&#160; On August 8, 2023, the Company granted 1,958,500 options to purchase shares of common stock from the 2023 Non-Qualified Stock Option Plan to officers, directors and employees.&#160; Each option entitles the holder to purchase one share of the Company&#8217;s common stock at a price of $1.36 per share, vests in three equal annual installments commencing one year after the grant date and expires on August 7, 2033.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the year ended September 30, 2022, the Company adopted the 2022 Non-Qualified Stock Option Plan, which provides for the issuance of up to 2,000,000 options to purchase shares of common stock.&#160; On November 19, 2021, the Company granted 250,000 performance-based stock options from the 2020 Non-Qualified Stock Option Plan to officers. Each option entitles the holder to purchase one share of the Company&#8217;s common stock at a price of $10.48 per share, the fair value on the date of issuance. The stock options will vest 100% upon approval of the first marketing application for any pharmaceutical based upon the Company&#8217;s Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia.&#160; None of the options will be exercisable before November 19, 2022.&#160; All options which have not vested as of November 18, 2031 will be canceled.&#160; On the grant date, the options were valued using a Monte Carlo Simulation approach. A Monte Carlo Simulation is a statistical technique that is used to model probabilistic systems and establish the probabilities for a variety of outcomes. However, because attainment of the performance condition cannot be considered probable, no compensation cost was recognized relating to these options as of September 30, 2023.&#160; Management will re-assess the probability of achieving the performance condition at each reporting date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">At September 30, 2023, the Company has collectively authorized the issuance of 15,787,200 options to purchase shares of common stock under its Non-Qualified Stock Option Plans. Options typically vest over a three-year period and expire no later than ten years after the grant date. Terms of the options were determined by the Company&#8217;s Compensation Committee which administers the plans. The Company&#8217;s employees, directors, officers, and consultants or advisors are eligible to be granted options under the Non-Qualified Stock Option Plans.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Incentive Stock Option Plan</span><span style="text-decoration:underline">s</span> &#8211; At September 30, 2023, the Company had collectively authorized the issuance of 138,400 options to purchase shares of common stock under its Incentive Stock Option Plans.&#160; Options typically vest over a three-year period and expire no later than ten years after the grant date.&#160; Terms of the options were determined by the Company&#8217;s Compensation Committee which administers the Plans.&#160; Only the Company&#8217;s employees are eligible to be granted options under the Incentive Stock Option Plans.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Activity in the Company&#8217;s Non-Qualified and Incentive Stock Option Plans for the two years ended September 30, 2023 is summarized as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Non-Qualified and Incentive Stock Option Plans</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Outstanding</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercisable</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Remaining Contractual Term (Years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Remaining Contractual Term (Years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at September 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">11,049,709</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">10.08</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">54,843,283</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5,540,028</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.77</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.96</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">43,589,598</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,547,703</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">8.60</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Granted(a)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,040,750</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.24</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(6,500</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.59</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td class="ffcell" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">45,725</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(6,500</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.59</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(106,331</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">11.53</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(13,614</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">97.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(13,614</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">97.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">12,964,014</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9.06</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,866,240</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">7,067,617</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.21</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.21</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,866,105</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">952,256</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">8.41</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Granted (b)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,065,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1.37</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">213,165</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9.19</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(58,791</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">61.05</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(58,791</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">61.05</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">14,757,558</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.78</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.81</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">7,961,082</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.07</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.60</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(a)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The weighted average grant date fair value was $3.01.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(b)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Includes 1,965,500 performance based options issued to officers and directors, 100,000 options issued to consultants. The weighted average grant date fair value was $1.22.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">A summary of the status of the Company&#8217;s un-vested options for the two years ended September 30, 2023 is presented below:&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Options</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Grant Date Fair Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested at September 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,509,681</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.17</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,547,703</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td class="ffcell" style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7.37</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,040,750</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(106,331</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested at September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,896,397</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.63</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(952,256</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td class="ffcell" style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7.30</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,065,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(213,165</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested at September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6,796,476</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Incentive Stock Bonus Plan</span> &#8211; On September 30, 2023, 610,500 of the shares granted under the 2014 Incentive Stock Bonus Plan remain outstanding, of which 463,250 shares are fully vested.&#160; During the year ended September 30, 2023, 4,000 unvested shares were forfeited. The shares are being earned upon the achievement of certain milestones leading to the commercialization of the Company&#8217;s Multikine technology, or specified increases in the market price of the Company&#8217;s stock.&#160; The fair value of the shares on the grant date was calculated using the market value on the grant-date for issuances where the attainment of performance criteria is likely and using a Monte Carlo Simulation for issuances where the attainment of performance criteria is uncertain.&#160; The grant date fair value of shares issued that remain outstanding as of September 30, 2023 was approximately $8.6 million.&#160; The total value of the shares, if earned, is being expensed over the requisite service periods for each milestone, provided the requisite service periods are rendered, regardless of whether the market conditions are met.&#160; No compensation cost is recognized for awards where the requisite service period is not rendered.&#160; During the years ended September 30, 2023 and 2022, the Company recorded expense relating to the issuance of restricted stock pursuant to the plan of approximately $(22,000) and $45,000, respectively.&#160; As of September 30, 2023, all compensation expense related to the 2014 Incentive Stock Bonus Plan has been fully recognized. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">A summary of the status of the Company&#8217;s restricted common stock issued from the Incentive Stock Bonus Plan for the two years ended September 30, 2023 is presented below: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number of </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted Average Grant Date Fair Value</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unvested at September 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">151,250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0px; text-align:justify;">Unvested at September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">151,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unvested at September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">147,250</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Stock Bonus Plans</span><span style="text-decoration:underline"> </span>&#8211; As of September 30, 2023, the Company authorized to issue up to 1,283,760 shares of common stock from the Stock Bonus Plans and has issued a total of 512,972 shares of common stock under its Stock Bonus Plans.&#160; All employees, directors, officers, consultants, and advisors are eligible to be granted shares.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Stock Compensation Plans</span> &#8211; On September 30, 2023, 634,000 shares were authorized for issuance pursuant to the &#160;Company&#8217;s Stock Compensation Plans, of which 153,195 shares were issued and outstanding.&#160; No shares were issued from the Stock Compensation Plans during the years ended September 30, 2023 and 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387585654688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLAN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract', window );"><strong>EMPLOYEE BENEFIT PLAN</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">EMPLOYEE BENEFIT PLAN</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>9</strong><strong>. EMPLOYEE BENEFIT PLAN</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company maintains a defined contribution retirement plan, qualifying under Section 401(k) of the Internal Revenue Code, subject to the Employee Retirement Income Security Act of 1974, as amended, and covering substantially all Company employees. Each participant&#8217;s contribution is matched by the Company with shares of common stock that have a value equal to 100% of the participant&#8217;s contribution, not to exceed the lesser of $10,000 or 6% of the participant&#8217;s total compensation. The Company&#8217;s contribution of common stock is valued each quarter based upon the closing bid price of the Company&#8217;s common stock. During the year ended September 30, 2023, 97,004 shares were issued to the Company&#8217;s 401(k) plan for a cost of approximately $208,000. During the year ended September 30, 2022, 52,882 shares were issued to the Company&#8217;s 401(k) plan for a cost of approximately $223,000.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387588517920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>10</strong><strong>. COMMITMENTS AND CONTINGENCIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Clinical Research Agreements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In April 2013, the Company entered into a co-development and revenue sharing agreement with Ergomed. Under the agreement, Ergomed will contribute up to $10 million towards the Company&#8217;s Phase III clinical study in the form of offering discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. In October 2015, the Company entered into a second co-development and revenue sharing agreement with Ergomed for an additional $2 million, for a total of $12 million. The Company accounted for the co-development and revenue sharing agreement in accordance with ASC 808, <em>Collaborative Arrangements</em>. The Company determined the payments to Ergomed are within the scope of ASC 730, <em>Research and Development</em>. Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its Statements of Operations. Since the Company entered into the co-development and revenue sharing agreement with Ergomed, it has incurred research and development expenses of approximately $35.7 million related to Ergomed&#8217;s services. This amount is net of Ergomed&#8217;s discount of approximately $11.8 million. During the years ended September 30, 2023 and 2022, the Company recorded approximately $0.2 million and $0.5 million, respectively, as research and development expense related to Ergomed&#8217;s services. These amounts were net of Ergomed&#8217;s discount of approximately $0.1 million during both the years ended September 30, 2023 and 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Lease Agreements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#8217;s specifications so that it can be used by the Company to manufacture Multikine for the Company&#8217;s Phase III clinical trial and sales of the drug if approved by the FDA or regulators in Canada, the UK or Europe. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. &#160;The renewal options are not included in the calculation of the right of use asset and lease liability because exercise of those options is not reasonably certain.&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of September 30, 2023 and 2022, respectively, the net book value of the finance lease right of use asset is approximately $9.1 million and $10.9 million and the balance of the finance lease liability is approximately $11.7 million and $13.3 million, of which approximately $1.8 million and $1.6 million is current.&#160; These amounts include the San Tomas lease as well as several other smaller finance leases for office equipment.&#160; During the years ended September 30, 2023 and 2022, the finance right of use assets are being depreciated using a straight-line method over the underlying lease terms and depreciation expense totaled approximately $1.8 million and $1.8 million, respectively. Total cash paid related to finance leases during the years ended September 30, 2023 and 2022, respectively, was approximately $2.6 million and $2.5 million, of which approximately $1.1 million and $1.2 million was for interest in both years. The weighted average discount rate of the Company&#8217;s finance leases is 8.44% and the weighted average time to maturity is 5.09 years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In August 2020, the Company entered into an amendment to the San Tomas lease agreement under which the landlord agreed to allow the Company to substantially upgrade the manufacturing facility in preparation for the potential commercial production of Multikine. The upgrades were completed and the improvements were placed in service in October 2021.&#160; The total cost of the upgrades was $11.1 million. &#160;The landlord agreed to finance the final $2.4 million of the costs incurred which will be repaid through increased lease payments over the remaining lease term starting on March 1, 2021.&#160; The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year.&#160; The Company remeasured the lease liability to account for the modified payments using an 8.45% incremental borrowing rate (IBR).&#160;The rate was determined using a synthetic credit rating analysis prepared by an outside valuation specialist.&#160; Additionally, this financing is considered to be a lease incentive from the landlord and has been included in the calculation of the lease liability as it is realized.&#160; The entire $2.4 million was received from the landlord as of September 30, 2022. The leasehold improvements are recorded in property and equipment and are being amortized over the remaining lease term.&#160; </p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">During June 2021, the Company determined that it used an incorrect discount rate to calculate the opening ROU asset and lease liability balances upon adoption of ASC 842. Management engaged an outside valuation specialist to perform a synthetic credit rating analysis which resulted in a revised rate to be used upon adoption of ASC 842 of 10.19% compared to the previously used rate of 8.80%. This change resulted in an immaterial difference to the September 30, 2020 financial statements, and was corrected in the quarterly period ended June 30, 2021 as an out of period adjustment.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company was required to deposit the equivalent of one year of base rent in accordance with the original lease.&#160; Because the Company met the minimum cash balance required by the lease, the full balance of the deposit was returned to the Company in January 2022. However, on January 11, 2023, the Company was required to deposit approximately $2.3&#160;million to its landlord, equivalent to one year&#8217;s rent, for falling back below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Approximate future minimum lease payments under finance leases as of September 30, 2023 are as follows:&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,655,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,740,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,832,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,923,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,015,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">252,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,417,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,696,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of lease finance lease obligations &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,772,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of lease finance lease obligations &#8211; non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,949,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company leases two facilities under operating leases.&#160; The lease for the Company&#8217;s office headquarters will expire on November 30, 2025.&#160; The lease for its research and development laboratory and will expire on February 29, 2032. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of September 30, 2023, the net book value of the operating lease right of use asset is approximately $1.7 million and the balance of the operating lease liability is approximately $1.9 million, of which approximately $0.2 million is current.&#160; As of September 30, 2022, the net book value of the operating lease right of use asset is approximately $1.9 million and the balance of the operating lease liability is approximately $2.1 million, of which approximately $0.2 million is current.&#160; During the years ended September 30, 2023 and 2022 the Company incurred lease expense under operating leases of approximately $0.4 million each year. Total cash paid related to operating leases during the years ended September 30, 2023 and 2022 was approximately $0.3 million each year.&#160; The weighted average discount rate of the Company&#8217;s operating leases is 10.2% and the weighted average time to maturity is 7.74 years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of September 30, 2023, future minimum lease payments on operating leases are as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">357,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">366,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">287,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">277,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">285,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,040,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,612,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(762,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligation &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">197,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligation &#8211; non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,653,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Vendor Obligations</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has contingent obligations with vendors for work that will be completed in relation to the Phase III clinical trial.&#160; The timing of these obligations cannot be determined at this time.&#160; The Company estimates it will incur additional expenses of approximately $0.7 million for the remainder of the Phase III clinical trial and the filing of the clinical study report with the FDA.&#160; This estimate is based only on the information currently available from the Clinical Research Organizations responsible for managing the Phase III clinical trial and does not include other related costs.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387588325712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1</strong><strong>1</strong><strong>. </strong><strong>RELATED PARTY TRANSACTIONS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the year ended September 30, 2023, no restricted shares of the Company&#8217;s common stock were purchased by related parties.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024 (Note 4).&#160; The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend. The Series RR warrants are held by Geert Kersten, Patricia Prichep (current officers of the Company) and the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On June 13, 2022, the expiration dates of the Series N, Series X, Series Y, Series UU, Series MM and Series NN warrants were extended two years (Note 4).&#160; The incremental costs of the warrant extensions were recorded consistent with the accounting for the initial warrant issuances.&#160; The incremental costs of the Series N, Series X and Series Y warrant extensions were recorded as a deemed dividend and totaled approximately $294,000 for the year ended September 30, 2022.&#160; The Series N and Series X warrants are held by the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a trustee and beneficiary.&#160; The incremental cost of the Series MM, Series NN and Series UU warrant extensions of approximately $635,000 was recorded as a deemed dividend because there are no longer any notes payable associated with these warrants at the time of modification.&#160; The Series UU warrants and a portion of the Series MM and Series NN warrants are held by Geert Kersten, Patricia Prichep and the de Clara Trust.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387587050720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1</strong><strong>2</strong><strong>.</strong> <strong>STOCKHOLDERS&#8217; EQUITY&#160; </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Exercise of Warrants</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the years ended September 30, 2023 and 2022, the Company received proceeds of approximately $0.4 million and $0.1 million, respectively, from the exercise of warrants, as detailed in Note 4.&#160; Upon exercise, 217,752 and 25,205 shares of common stock were issued during the years ended September 30, 2023 and 2022, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Sales of Securities</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On May 2, 2023, the Company sold 913,234 shares of common stock at a public offering price of $1.70 per share and received aggregate proceeds of approximately $1.55 million.&#160; On July 20, 2023, the Company sold 2,500,000 shares of common stock at a public offering price of $2.00 per share and received aggregate proceeds of approximately $5.0 million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">There were no sales of securities during the fiscal year ended September 30, 2022.&#160; &#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Other Equity Transactions</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company entered into Securities Purchase Agreements (SPA) with Ergomed plc, one of the Company&#8217;s Clinical Research Organizations responsible for managing the Company&#8217;s Phase III clinical trial, to facilitate payment of amounts due Ergomed.&#160; Under the Agreements, the Company issued Ergomed shares of common stock and the net proceeds from the sales of those shares reduces outstanding amounts due Ergomed.&#160; Upon issuance, the Company expenses the full value of the shares as Other non-operating gain/loss and subsequently offsets the expense as amounts are realized through the sale by Ergomed and reduces accounts payable to Ergomed.&#160;&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the years ended September 30, 2023 and 2022, CEL-SCI did not issue Ergomed any shares of common stock. Additionally, no shares were sold during the years ended September 30, 2023 and 2022. All outstanding shares have been resold as of September 30, 2023 and 2022 and the Company had approximately $0 and $22,000 in amounts remaining in prepaid to Ergomed as of September 30, 2023 and 2022, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387589792432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1</strong><strong>3</strong><strong>. FAIR VALUE MEASUREMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In accordance with the provisions of ASC 820, &#8220;<em>Fair Value Measurements</em>,&#8221; the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160; The Company generally applies the income approach to determine fair value.&#160; This method uses valuation techniques to convert future amounts to a single present amount.&#160; The measurement is based on the value indicated by current market expectations with respect to the future amounts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value.&#160; The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&#160; The Company classifies fair value balances based on the observability of those inputs.&#160; The three levels of the fair value hierarchy are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">o</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Level 1 &#8211; Observable inputs such as quoted prices in active markets for identical assets or liabilities</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">o</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 2 &#8211; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs other than quoted prices that are observable for the asset or liability are observable in active markets</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">o</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Level 3 &#8211; Unobservable inputs that reflect management&#8217;s assumptions</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement.&#160; The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company purchased short-term T-bills during the year ended September 30, 2021 that are classified as trading securities.&#160; Quoted market prices were applied to determine the fair value of short-term investments, therefore they were categorized as Level 1 on the fair value hierarchy. The T-bills were recorded at fair market value, which includes an unrealized gain of approximately $6,000.&#160; The T-bills matured in December 2021 and yield a weighted average interest rate of 0.10%. The Company is not holding any T-bills as of September 30, 2023 and September 30, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of September 30, 2023 and 2022, there were no derivative liabilities&#160;outstanding.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following sets forth the reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3), as of September 30:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;&#160;&#160;&#160; 2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;&#160;&#160;&#160; 2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Beginning balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">437,380</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Issuances</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(70,589</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Net realized and unrealized derivative loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(366,791</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Ending balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The fair values of the Company&#8217;s derivative instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such as historical price and volatility of the Company&#8217;s stock were used.&#160; </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387581028944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER COMMON SHARE</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1</strong><strong>4</strong><strong>. NET LOSS PER COMMON SHARE</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, common stock warrants and restricted stock&#160;are not included in the computation of diluted net loss per share&#160;if their effect&#160;would be anti-dilutive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following table provides a reconciliation of the numerators and denominators of the basic and diluted per-share computations: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Year ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Loss per share &#8211; basic and diluted</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Net loss available to common shareholders &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(32,365,855</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(37,629,803</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Weighted average shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">44,479,865</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,148,888</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Basic and diluted loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.73</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.87</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In accordance with the contingently issuable shares guidance of ASC 260, <em>Earnings Per Share</em>, the calculation of diluted net loss per share excludes the following dilutive securities because their inclusion would have been anti-dilutive as of September 30: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;&#160;&#160;&#160;&#160;&#160;&#160; 2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options and warrants&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,850,028</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,274,836</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested restricted stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">151,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">15,997,278</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">14,426,086</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387588492160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>15.&#160; SUBSEQUENT EVENTS </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On November 20, 2023, the Company sold 2,490,000 shares of common stock to a single investor at a public offering price of $2.00 per share for aggregate net proceeds of approximately $4.5 million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387584787456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Cash and Cash Equivalents </em>&#8211; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds.&#160; The Company considers all highly liquid investments with a maturity when purchased of less than three months as cash and cash equivalents.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_USTreasuryBillsPolicyTextBlock', window );">U.S. Treasury Bills</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>U.S. Treasury Bills &#8211; </em>U.S. Treasury Bills (&#8220;T-bills&#8221;) are highly liquid short-term investments with maturity dates of greater than 3 months, but less than one year. These investments are recorded at fair value.&#160; </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Supplies used for R&amp;amp;D and manufacturing</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Supplies used for R&amp;D and manufacturing</em> &#8211; Supplies are consumable items kept on hand to support the Company&#8217;s R&amp;D and manufacturing operations.&#160; Supplies are recorded at cost and are charged to expense as they are used in operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment are reviewed on a quarterly basis to determine if any of the assets are impaired.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patents</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Patents</em> &#8211; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years).&#160; In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment to the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset.&#160; The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Leases</em> &#8211; The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material. For purposes of calculating the finance and operating lease liabilities, lease and non-lease components are combined. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Derivative Instruments</em> &#8211; The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, <em>Accounting for Derivative Instruments and Hedging Activities</em>. In accordance with ASC 815, derivative instruments and hybrid instruments are recognized as either assets or liabilities on the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each&#160;reporting period. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company adopted Accounting Standards Update (ASU) 2020-06 <em>Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</em> effective October 1, 2021<em>.</em>&#160;The amendments in this Update simplify and clarify the guidance in Subtopic 815-40. &#160;There was no financial impact upon adoption.&#160;&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company adopted ASU 2021-04,&#160;<em>Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</em>. This standard was issued to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 was effective for fiscal years beginning after December 15, 2021, however, as permitted, the Company elected to prospectively adopt the standard, effective as of October 1, 2021. Adoption of this standard had no impact on the Company&#8217;s financial statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Stock-Based Compensation</em> &#8211; Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, <em>Compensation &#8211; Stock Compensation</em>. The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized using the straight-line allocation method as expense over the requisite service or vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the "Plans". All Plans have been approved by the Company&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the assumption for stock price volatility is based on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the 2021 and 2020 Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant-dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Research and Development Costs</em> - Research and development costs are expensed as incurred.&#160; Management accrues Clinical Research Organization (CRO) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Net Loss Per Common Share</em> &#8211; The Company calculates net loss per common share in accordance with ASC 260 <em>Earnings Per Share</em> (ASC 260).&#160; Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period.&#160; The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Concentration of Credit Risk</em> &#8211; Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents.&#160; The Company maintains its cash and cash equivalents with high quality financial institutions.&#160; At times, these accounts may exceed federally insured limits.&#160; The Company has not experienced any losses in such bank accounts.&#160; The Company believes it is not exposed to significant credit risk related to cash and cash equivalents.&#160; All non-interest bearing cash balances were fully insured up to $250,000 at September 30, 2023 and September 30, 2022. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Income Taxes</em> &#8211;The Company follows ASC 740-10-25 for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related assets or liability is expected to be realized or settled.&#160; The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160; The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of September 30, 2023 and 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company adopted ASU&#160; 2019-12,&#160;<em>Income Taxes (Topic&#160;740): Simplifying the Accounting for Income Taxes</em>, effective October 1, 2021. The new standard includes several provisions that simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. The adoption of ASU 2019-12 had no impact on the Company&#8217;s financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On August 16, 2022, the Inflation Reduction Act of 2022 (the &#8220;IR Act&#8221;) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly traded foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself, not its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the &#8220;Treasury&#8221;) has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax.&#160;&#160;&#160;&#160;&#160; </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Impairment of long-lived assets</em> &#8211; CEL-SCI&#8217;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#8217;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets in accordance with ASC 360-10-35-21 to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures.&#160; These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, obsolescence of supplies used for research and development (R&amp;D) and manufacturing, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities,&#160;deferred tax assets and the related valuation allowance, and the valuation of derivative liabilities. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.&#160; The Company considers the estimates used in valuing the derivative liabilities and the lease assets and liabilities to be significant. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In June 2016, the Financial Accounting Standards Board issued ASU 2016-13, <em>Financial Instruments&#8211;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</em> (ASU 2016-13), as amended. The amendments in ASU 2016-13 require, among other things, financial assets measured at amortized cost basis to be presented at the net amount expected to be collected as compared to previous U.S. GAAP which delayed recognition until it was probable a loss had been incurred. The amendments in ASU 2016-13 are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, with early adoption permitted. The Company currently does not have any such financial assets reported as of September 30, 2023, however, the Company will continue to evaluate the impact that adoption of ASU 2016-13 will have on its financial statements and related disclosures.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Other accounting standard updates effective for interim and annual periods beginning after September 30, 2023 are not expected to have a material impact on the Company&#8217;s financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_USTreasuryBillsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_USTreasuryBillsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387579975344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS AND NONEMPLOYEE OPTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WarrantsAndNonemployeeOptionsAbstract', window );"><strong>WARRANTS AND NONEMPLOYEE OPTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants and non-employee options</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">Warrant/Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;">Shares Issuable upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;">of Warrants/ Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.95pt; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:14%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2008</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:14%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2024</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/11/2018</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">93,603</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.80</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/30/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1/13/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">120,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9.25</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/13/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/15/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">26,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">12.00</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/15/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">333,432</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.86</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">200,087</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.52</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">234,009</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.65</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultant Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">7/28/2017 &#8211; 9/2/2023</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">110,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>$</td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;">1.39 - $2.18</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/27/2027 &#8211; 9/1/2028</p></td><td>&#160;</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">Warrant/Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;">Shares Issuable upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;">of Warrants/ Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.95pt; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:14%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2008</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:14%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2024</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/11/2018</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">93,603</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.80</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/30/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1/13/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">120,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9.25</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/13/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/15/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">26,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">12.00</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/15/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">333,432</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.86</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">200,087</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.52</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">251,761</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.65</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2022</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series SS</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12/19/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">200,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.09</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12/18/2022</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series TT</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/5/2018</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">600</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.24</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/5/2023</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultant Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.95pt; text-align:right;">7/28/2017 &#8211; 11/18/2020</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">15,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>$</td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">2.18 - $11.61</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:right;">11/17/2022 - 7/27/2027</p></td><td>&#160;</td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock', window );">Schedule of (losses)/gains on the warrant liabilities</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05in; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05in; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series W warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Z warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,787</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series ZZ warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series AA warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">276,035</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series BB warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series CC warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,372</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series HH warrants&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,597</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss on warrant liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">366,791</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock', window );">Schedule of warrants recorded as liabilities were exercised</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Proceeds</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series CC</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,205</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">76,025</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock', window );">Schedule of equity warrants were exercised</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Proceeds</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,752</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,291</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">200,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">418,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">217,752</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">447,291</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Proceeds</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantsAndNonemployeeOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantsAndNonemployeeOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387584777184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PLANT PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Research equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,109,070</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,095,022</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Furniture and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">99,296</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">99,296</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Leasehold improvements</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">13,924,724</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">13,544,394</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,133,090</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,738,712</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accumulated depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,944,964</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(5,849,683</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net property and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">10,188,126</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">11,889,029</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387587064016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PATENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of patents</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">853,445</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">893,833</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accumulated amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(655,741</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(681,632</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patents, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">197,704</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">212,201</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of total estimated future amortization</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="4" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Years ending September 30, </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">32,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">71,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">198,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387586374912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of components of the Company's deferred tax assets</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">NOL carryforwards</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,829,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,346,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Capitalized R&amp;D</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,196,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,042,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock-based compensation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,579,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,442,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,400,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,872,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">R&amp;D credit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,221,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,221,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vacation and other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">298,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">307,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fixed assets and intangibles</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">168,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total deferred tax assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">62,691,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">56,230,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Right of use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,713,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,244,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fixed assets and intangibles</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(44,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total deferred tax liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,713,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,288,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net deferred tax asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">59,978,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">52,942,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(59,978,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(52,942,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ending balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of federal or state current or deferred tax expense or benefit</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Federal rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">State rate change </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1.58</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1.67</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">State tax rate, net of federal benefit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.05</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.34</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other adjustments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1.62</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.28</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Permanent differences</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.21</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Change in valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(21.85</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(23.61</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Effective tax rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387584599072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>EQUITY-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of expenses for options issued or vested and restricted stock awarded</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Year Ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,286,231</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,389,932</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">655,740</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">762,261</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used for fair value of each option granted</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected stock price volatility</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">99.18 &#8211; 100.18%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">96.37 &#8211; 99.26%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3.41 &#8211; 4.25%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.50 &#8211; 3.43%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected life of options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">9.63 &#8211; 9.66 years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">9.67 &#8211; 9.69 years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected dividend yield</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="width:1%;vertical-align:bottom;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="width:1%;vertical-align:bottom;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock', window );">Schedule of non-qualified and incentive stock option plans</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Outstanding</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercisable</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Remaining Contractual Term (Years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Remaining Contractual Term (Years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at September 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">11,049,709</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">10.08</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">54,843,283</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5,540,028</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.77</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.96</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">43,589,598</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,547,703</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">8.60</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Granted(a)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,040,750</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.24</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(6,500</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.59</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td class="ffcell" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">45,725</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(6,500</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.59</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(106,331</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">11.53</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(13,614</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">97.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(13,614</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">97.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">12,964,014</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9.06</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,866,240</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">7,067,617</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.21</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.21</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,866,105</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">952,256</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">8.41</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Granted (b)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,065,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1.37</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">213,165</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9.19</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(58,791</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">61.05</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(58,791</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">61.05</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">14,757,558</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.78</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.81</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">7,961,082</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.07</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.60</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of non vested options</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number of </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted Average Grant Date Fair Value</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unvested at September 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">151,250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0px; text-align:justify;">Unvested at September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">151,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unvested at September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">147,250</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Schedule of restricted common stock issued from the incentive stock bonus plan</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Options</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Grant Date Fair Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested at September 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,509,681</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.17</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,547,703</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td class="ffcell" style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7.37</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,040,750</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(106,331</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested at September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,896,397</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.63</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(952,256</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$</p></td><td class="ffcell" style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7.30</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,065,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(213,165</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested at September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6,796,476</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387586936528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock', window );">Schedule of future minimum payments under finance leases</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,655,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,740,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,832,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,923,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,015,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">252,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,417,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,696,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of lease finance lease obligations &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,772,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of lease finance lease obligations &#8211; non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,949,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum payments under operating leases</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">357,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">366,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">287,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">277,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">285,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,040,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,612,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(762,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligation &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">197,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligation &#8211; non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,653,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481161/840-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387587133584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of fair value measurements using significant unobservable inputs</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;&#160;&#160;&#160; 2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;&#160;&#160;&#160; 2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Beginning balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">437,380</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Issuances</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(70,589</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;">Net realized and unrealized derivative loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(366,791</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Ending balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387586392336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of earnings per share</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Year ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Loss per share &#8211; basic and diluted</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Net loss available to common shareholders &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(32,365,855</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(37,629,803</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Weighted average shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">44,479,865</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,148,888</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Basic and diluted loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.73</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.87</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of anti-dilutive securities</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;&#160;&#160;&#160;&#160;&#160;&#160; 2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options and warrants&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,850,028</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,274,836</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested restricted stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">151,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">15,997,278</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">14,426,086</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387585603424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Fully insured amount of non-interest bearing cash balances</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FiniteLivedIntangibleAssetsUsefulLife', window );">Patent Useful Life</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FiniteLivedIntangibleAssetsUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FiniteLivedIntangibleAssetsUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387586680768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS AND NONEMPLOYEE OPTIONS (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember', window );">Consultants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">7/28/2017<span></span>
</td>
<td class="text">7/28/2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.39<span></span>
</td>
<td class="nump">$ 2.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">7/27/2027<span></span>
</td>
<td class="text">11/17/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsOneMember', window );">Consultants 1 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">9/2/2023<span></span>
</td>
<td class="text">11/18/2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.18<span></span>
</td>
<td class="nump">$ 11.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">9/1/2028<span></span>
</td>
<td class="text">7/27/2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesYMember', window );">Series Y [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">2/15/2016<span></span>
</td>
<td class="text">2/15/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">26,000<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">8/15/2024<span></span>
</td>
<td class="text">8/15/2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesMMMember', window );">Series MM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">6/22/2017<span></span>
</td>
<td class="text">6/22/2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">333,432<span></span>
</td>
<td class="nump">333,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.86<span></span>
</td>
<td class="nump">$ 1.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">6/22/2024<span></span>
</td>
<td class="text">6/22/2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesNNMember', window );">Series NN [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">7/24/2017<span></span>
</td>
<td class="text">7/24/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">200,087<span></span>
</td>
<td class="nump">200,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.52<span></span>
</td>
<td class="nump">$ 2.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">7/24/2024<span></span>
</td>
<td class="text">7/24/2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesRRMember', window );">Series RR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">10/30/2017<span></span>
</td>
<td class="text">10/30/2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">234,009<span></span>
</td>
<td class="nump">251,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="nump">$ 1.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">10/30/2024<span></span>
</td>
<td class="text">10/30/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesSSMember', window );">Series SS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12/19/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12/18/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesTTMember', window );">Series TT [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2/5/2018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2/5/2023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesNMember', window );">Series N [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">8/18/2008<span></span>
</td>
<td class="text">8/18/2008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">85,339<span></span>
</td>
<td class="nump">85,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">8/18/2024<span></span>
</td>
<td class="text">8/18/2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesUUMember', window );">Series UU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">6/11/2018<span></span>
</td>
<td class="text">6/11/2018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">93,603<span></span>
</td>
<td class="nump">93,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.80<span></span>
</td>
<td class="nump">$ 2.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">6/30/2024<span></span>
</td>
<td class="text">6/30/2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesXMember', window );">Series X [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">1/13/2016<span></span>
</td>
<td class="text">1/13/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 9.25<span></span>
</td>
<td class="nump">$ 9.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">7/13/2024<span></span>
</td>
<td class="text">7/13/2024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_Issuedate2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_Issuedate2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SharesIssuableUponExerciseOfwarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SharesIssuableUponExerciseOfwarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesMMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesMMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesNNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesNNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesRRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesRRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesSSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesSSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesTTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesTTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesUUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesUUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387675396000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS AND NONEMPLOYEE OPTIONS (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NetLossGainOnWarrantLiabilities', window );">Net (loss) gain on warrant liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 366,791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZMember', window );">Series Z [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NetLossGainOnWarrantLiabilities', window );">Net (loss) gain on warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">64,787<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesCCMember', window );">Series CC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NetLossGainOnWarrantLiabilities', window );">Net (loss) gain on warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,372<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesHHMember', window );">Series HH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NetLossGainOnWarrantLiabilities', window );">Net (loss) gain on warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesAAMember', window );">Series AA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NetLossGainOnWarrantLiabilities', window );">Net (loss) gain on warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">276,035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesWMember', window );">Series W [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NetLossGainOnWarrantLiabilities', window );">Net (loss) gain on warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZZMember', window );">Series ZZ [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NetLossGainOnWarrantLiabilities', window );">Net (loss) gain on warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesBBMember', window );">Series BB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NetLossGainOnWarrantLiabilities', window );">Net (loss) gain on warrant liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NetLossGainOnWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NetLossGainOnWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesCCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesCCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesHHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesHHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesAAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesAAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesWMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesWMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZZMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZZMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesBBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesBBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387587521776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS AND NONEMPLOYEE OPTIONS (Details 2) - Series CC [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds | $</a></td>
<td class="nump">$ 76,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WarrantsExercised', window );">Warrants Exercised | shares</a></td>
<td class="nump">15,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePriceWarrants', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 5.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExercisePriceWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExercisePriceWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesCCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesCCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387584787024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS AND NONEMPLOYEE OPTIONS (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised</a></td>
<td class="nump">217,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ProceedsFromEquityWarrantsExercised', window );">Proceeds from Equity Warrants Exercised</a></td>
<td class="nump">$ 447,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesNNMember', window );">Series NN [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ProceedsFromEquityWarrantsExercised', window );">Proceeds from Equity Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercisePrice', window );">Equity Warrants Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesRRMember', window );">Series RR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised</a></td>
<td class="nump">17,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ProceedsFromEquityWarrantsExercised', window );">Proceeds from Equity Warrants Exercised</a></td>
<td class="nump">$ 29,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercisePrice', window );">Equity Warrants Exercise Price</a></td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesSSMember', window );">Series SS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ProceedsFromEquityWarrantsExercised', window );">Proceeds from Equity Warrants Exercised</a></td>
<td class="nump">$ 418,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercisePrice', window );">Equity Warrants Exercise Price</a></td>
<td class="nump">$ 2.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_EquityWarrantsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_EquityWarrantsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_EquityWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_EquityWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ProceedsFromEquityWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ProceedsFromEquityWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesNNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesNNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesRRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesRRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesSSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesSSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387579759472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS AND NONEMPLOYEE OPTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 28, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_DeemedDividend11', window );">Deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 635,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_DeemedDividendAmount', window );">Total Deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 294,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommonStockIssuedForServiceShares', window );">Common stock issued for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249,997<span></span>
</td>
<td class="nump">156,547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesCCWarrantsMember', window );">Series CC Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WarrantsExpired', window );">Warrants expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePriceWarrants', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZWarrantsMember', window );">Series Z Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WarrantsExpired', window );">Warrants expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePriceWarrants', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesAAWarrantsMember', window );">Series AA Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WarrantsExpired', window );">Warrants expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePriceWarrants', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesHHWarrantsMember', window );">Series HH Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WarrantsExpired', window );">Warrants expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePriceWarrants', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember', window );">Series RR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncrementalCostDeemedDividend', window );">Incremental cost</a></td>
<td class="nump">$ 172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember', window );">Consulting Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 656,000<span></span>
</td>
<td class="nump">$ 762,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_PrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205,000<span></span>
</td>
<td class="nump">$ 295,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantMember', window );">Consultant [Member] | Non Qualified Stock Options Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_StockIssuedDuringPeriodToPurchaseCommonStock', window );">Issued options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_StockOptionExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssuedStockOfOptionsOutstanding', window );">Options issued of payment for services remained outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantMember', window );">Consultant [Member] | Non Qualified Stock Options Plans [Member] | September 2, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_VestedOptions', window );">Options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantMember', window );">Consultant [Member] | Non Qualified Stock Options Plans [Member] | September 2, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_VestedOptions', window );">Options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock prices per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Restricted Stock [Member] | Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.83<span></span>
</td>
<td class="nump">$ 4.59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock prices per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommonStockIssuedForServiceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommonStockIssuedForServiceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_DeemedDividend11">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_DeemedDividend11</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_DeemedDividendAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_DeemedDividendAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExercisePriceWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExercisePriceWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncrementalCostDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncrementalCostDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IssuedStockOfOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IssuedStockOfOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_StockIssuedDuringPeriodToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_StockIssuedDuringPeriodToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_StockOptionExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_StockOptionExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_VestedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_VestedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesCCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesCCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesZWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesAAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesAAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesHHWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesHHWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cvm_TwoSeptemberTwoThousendTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cvm_TwoSeptemberTwoThousendTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cvm_TwoSeptemberTwoThousendTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cvm_TwoSeptemberTwoThousendTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_RestrictedStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_RestrictedStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387579852240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FixturesAndEquipmentGross', window );">Research equipment</a></td>
<td class="nump">$ 4,109,070<span></span>
</td>
<td class="nump">$ 4,095,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture and equipment</a></td>
<td class="nump">99,296<span></span>
</td>
<td class="nump">99,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">13,924,724<span></span>
</td>
<td class="nump">13,544,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross</a></td>
<td class="nump">18,133,090<span></span>
</td>
<td class="nump">17,738,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(7,944,964)<span></span>
</td>
<td class="num">(5,849,683)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net property and equipment</a></td>
<td class="nump">$ 10,188,126<span></span>
</td>
<td class="nump">$ 11,889,029<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FixturesAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of fixtures and equipment. Includes, but is not limited to, machinery, equipment, and engines.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FixturesAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387587277424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">$ 2,114,000<span></span>
</td>
<td class="nump">$ 1,977,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387590596176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PATENTS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedPatentsGross', window );">Patents</a></td>
<td class="nump">$ 853,445<span></span>
</td>
<td class="nump">$ 893,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_AccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(655,741)<span></span>
</td>
<td class="num">(681,632)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">$ 197,704<span></span>
</td>
<td class="nump">$ 212,201<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedPatentsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedPatentsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387579868464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PATENTS (Details 1)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 32,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">29,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">22,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">19,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive', window );">Thereafter</a></td>
<td class="nump">71,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_Total', window );">Total</a></td>
<td class="nump">$ 198,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_Total">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_Total</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387590576208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PATENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_PatentsWeightedAverageAmortizationPeriod', window );">Weighted average amortization period for patents</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_AmortizationOfPatentCosts', window );">Amortization of patent costs</a></td>
<td class="nump">$ 38,000<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AmortizationOfPatentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AmortizationOfPatentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PatentsWeightedAverageAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PatentsWeightedAverageAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387581310496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 30,829,000<span></span>
</td>
<td class="nump">$ 25,346,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd', window );">Capitalized R&amp;D</a></td>
<td class="nump">15,196,000<span></span>
</td>
<td class="nump">15,042,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">11,579,000<span></span>
</td>
<td class="nump">10,442,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">3,400,000<span></span>
</td>
<td class="nump">3,872,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D credit</a></td>
<td class="nump">1,221,000<span></span>
</td>
<td class="nump">1,221,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences', window );">Vacation and other</a></td>
<td class="nump">298,000<span></span>
</td>
<td class="nump">307,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FixedAssetsAndIntangiblesAssets', window );">Fixed assets and intangibles</a></td>
<td class="nump">168,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">62,691,000<span></span>
</td>
<td class="nump">56,230,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_RightOfUseAssets', window );">Right of use assets</a></td>
<td class="num">(2,713,000)<span></span>
</td>
<td class="num">(3,244,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FixedAssetsAndIntangibles', window );">Fixed assets and intangibles</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(44,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liability</a></td>
<td class="num">(2,713,000)<span></span>
</td>
<td class="num">(3,288,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="nump">59,978,000<span></span>
</td>
<td class="nump">52,942,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(59,978,000)<span></span>
</td>
<td class="num">(52,942,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Ending Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FixedAssetsAndIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FixedAssetsAndIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FixedAssetsAndIntangiblesAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FixedAssetsAndIntangiblesAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_RightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_RightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387581596896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details 1)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal Rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">State tax rate change</a></td>
<td class="num">(1.58%)<span></span>
</td>
<td class="num">(1.67%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">State tax rate, net of federal benefit</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">4.34%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other adjustments</a></td>
<td class="num">(1.62%)<span></span>
</td>
<td class="num">(0.28%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.21%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(21.85%)<span></span>
</td>
<td class="num">(23.61%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387586464864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 30,829,000<span></span>
</td>
<td class="nump">$ 25,346,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_DeferredTaxAssets', window );">Deferred tax asset</a></td>
<td class="nump">60,000,000.0<span></span>
</td>
<td class="nump">52,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=cvm_IncomeTaxMember', window );">Income Tax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ResearchAndDevelopmentCredit', window );">Research and development credit</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">1,200,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 123,100,000<span></span>
</td>
<td class="nump">$ 100,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ResearchAndDevelopmentCreditDescription', window );">Research and development credit, description</a></td>
<td class="text">The R&D credit expires during the fiscal year ended 2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CumulativeChangeInOwnershipPercentage', window );">Cumulative change in ownership percentage</a></td>
<td class="text">net operating loss (NOL) carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Net operating loss carryforwards, description</a></td>
<td class="text">Approximately $19.2 million of the NOL carryforwards begin to expire during the year ended September 30, 2023 and become fully expired by 2038 and approximately $103.9 million of NOL carryforwards<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CumulativeChangeInOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CumulativeChangeInOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ResearchAndDevelopmentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ResearchAndDevelopmentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ResearchAndDevelopmentCreditDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ResearchAndDevelopmentCreditDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the origin, nature, and characteristics of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=cvm_IncomeTaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=cvm_IncomeTaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387590658000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>EQUITY-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Employees</a></td>
<td class="nump">$ 6,286,231<span></span>
</td>
<td class="nump">$ 11,389,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Non-employees</a></td>
<td class="nump">$ 655,740<span></span>
</td>
<td class="nump">$ 762,261<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387579647472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION (Details 1)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>EQUITY-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility, min</a></td>
<td class="nump">99.18%<span></span>
</td>
<td class="nump">96.37%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility, max</a></td>
<td class="nump">100.18%<span></span>
</td>
<td class="nump">99.26%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, min</a></td>
<td class="nump">3.41%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, max</a></td>
<td class="nump">4.25%<span></span>
</td>
<td class="nump">3.43%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpectedLifeOfOptionsMin1', window );">Expected life of options, min</a></td>
<td class="text">9 years 7 months 17 days<span></span>
</td>
<td class="text">9 years 8 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpectedLifeOfOptionsMax', window );">Expected life of options, max</a></td>
<td class="text">9 years 7 months 28 days<span></span>
</td>
<td class="text">9 years 8 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExpectedLifeOfOptionsMax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExpectedLifeOfOptionsMax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExpectedLifeOfOptionsMin1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExpectedLifeOfOptionsMin1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387586514480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cvm_ExercisableMember', window );">Exercisable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Beginning</a></td>
<td class="nump">7,067,617<span></span>
</td>
<td class="nump">5,540,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Ending</a></td>
<td class="nump">7,961,082<span></span>
</td>
<td class="nump">7,067,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Beginning</a></td>
<td class="nump">$ 6.21<span></span>
</td>
<td class="nump">$ 5.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Ending</a></td>
<td class="nump">$ 6.07<span></span>
</td>
<td class="nump">$ 6.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value Outstanding, Beginning</a></td>
<td class="nump">$ 1,866,105<span></span>
</td>
<td class="nump">$ 43,589,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value Outstanding, Ending</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,866,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NumberOfOptionsVested', window );">Number of Options Vested</a></td>
<td class="nump">952,256<span></span>
</td>
<td class="nump">1,547,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NumberOfOptionsExercised', window );">Number of Options Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NumberOfOptions', window );">Number of Options Expired</a></td>
<td class="num">(58,791)<span></span>
</td>
<td class="num">(13,614)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WeightedAverageExercisePriceVested', window );">Weighted Average Exercise Price Vested</a></td>
<td class="nump">$ 8.41<span></span>
</td>
<td class="nump">$ 8.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WeightedAverageExercisePriceExpired', window );">Weighted Average Exercise Price Expired</a></td>
<td class="nump">$ 61.05<span></span>
</td>
<td class="nump">$ 97.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning', window );">Weighted Average Remaining Contractual Life Term (Years) Outstanding, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 11 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding', window );">Weighted Average Remaining Contractual Life Term (Years) Outstanding, Ending</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">6 years 2 months 15 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_OutstandingMember', window );">Outstanding [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Beginning</a></td>
<td class="nump">12,964,014<span></span>
</td>
<td class="nump">11,049,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Granted</a></td>
<td class="nump">2,065,500<span></span>
</td>
<td class="nump">2,040,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Options Expired</a></td>
<td class="num">(58,791)<span></span>
</td>
<td class="num">(13,614)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options Forfeited</a></td>
<td class="nump">213,165<span></span>
</td>
<td class="nump">106,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Ending</a></td>
<td class="nump">14,757,558<span></span>
</td>
<td class="nump">12,964,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Beginning</a></td>
<td class="nump">$ 9.06<span></span>
</td>
<td class="nump">$ 10.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">1.37<span></span>
</td>
<td class="nump">4.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeited</a></td>
<td class="nump">9.19<span></span>
</td>
<td class="nump">11.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Expired</a></td>
<td class="nump">61.05<span></span>
</td>
<td class="nump">97.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Ending</a></td>
<td class="nump">$ 7.78<span></span>
</td>
<td class="nump">$ 9.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life Term (Years) Outstanding, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 11 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life Term (Years) Outstanding, Ending</a></td>
<td class="text">6 years 9 months 21 days<span></span>
</td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value Outstanding, Beginning</a></td>
<td class="nump">$ 1,866,240<span></span>
</td>
<td class="nump">$ 54,843,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised', window );">Aggregate Intrinsic Value Outstanding, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value Outstanding, Ending</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,866,240<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NumberOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NumberOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NumberOfOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NumberOfOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NumberOfOptionsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NumberOfOptionsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageExercisePriceExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageExercisePriceExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageExercisePriceVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageExercisePriceVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cvm_ExercisableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cvm_ExercisableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_OutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_OutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387586402160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION (Details 3) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>EQUITY-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of unvested options, Beginning</a></td>
<td class="nump">5,896,397<span></span>
</td>
<td class="nump">5,509,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested options</a></td>
<td class="num">(952,256)<span></span>
</td>
<td class="num">(1,547,703)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted options</a></td>
<td class="nump">2,065,500<span></span>
</td>
<td class="nump">2,040,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited options</a></td>
<td class="num">(213,165)<span></span>
</td>
<td class="num">(106,331)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of unvested options, Ending</a></td>
<td class="nump">6,796,476<span></span>
</td>
<td class="nump">5,896,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Beginning</a></td>
<td class="nump">$ 3.63<span></span>
</td>
<td class="nump">$ 5.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WeightedAverageGrantDateFairValueVested', window );">Weighted Average Grant Date Fair Value, vested</a></td>
<td class="nump">7.30<span></span>
</td>
<td class="nump">7.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Ending</a></td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="nump">$ 3.63<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageGrantDateFairValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageGrantDateFairValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387675397136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION (Details 4) - Restricted Stock Awards [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of unvested shares, Beginning</a></td>
<td class="nump">151,250<span></span>
</td>
<td class="nump">151,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of unvested shares, Ending</a></td>
<td class="nump">147,250<span></span>
</td>
<td class="nump">151,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Beginning</a></td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="nump">$ 13.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Ending</a></td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="nump">$ 13.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_RestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_RestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387586546448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jul. 20, 2023</div></th>
<th class="th"><div>May 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">47,422,304<span></span>
</td>
<td class="nump">43,448,317<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">913,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_StockCompensationPlansMember', window );">Stock Compensation Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">153,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">634,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_StockBonusPlansMember', window );">Stock Bonus Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">512,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,283,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_NonQualifiedStockOptionsPlansMember', window );">Non-Qualified Stock Options Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">15,787,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Issuance of common stock options authorized shares</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_PerformanceBasedStockOptionsSharesGranted', window );">Performance based stock options shares granted</a></td>
<td class="nump">1,958,500<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityStrikePrice1', window );">Stock price</a></td>
<td class="nump">$ 1.36<span></span>
</td>
<td class="nump">$ 10.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockDescription', window );">Stock options vest description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The stock options will vest 100% upon approval of the first marketing application for any pharmaceutical based upon the Company&#8217;s Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_IncentiveStockOptionPlansMember', window );">Incentive Stock Option Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">138,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_IncentiveStockBonusPlanMember', window );">Incentive Stock Bonus Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">610,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_RemainingOutstandingFairValueOfShares', window );">Grant date fair value remaining outstanding</a></td>
<td class="nump">$ 8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_VestedShares', window );">Vested shares</a></td>
<td class="nump">463,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationEquity', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="nump">$ 45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_RestrictedStockAwardsMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total compensation cost</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average period</a></td>
<td class="text">11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_NonVestedOptionsMember', window );">Non Vested Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total compensation cost</a></td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average period</a></td>
<td class="text">1 year 9 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PerformanceBasedStockOptionsSharesGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PerformanceBasedStockOptionsSharesGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_RemainingOutstandingFairValueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_RemainingOutstandingFairValueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_VestedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_VestedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued under share-based plans to employees or officers which is the unearned portion, accounted for under the fair value method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityStrikePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise or strike price stated in the contract for options indexed to the issuer's equity shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481648/480-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)(2)<br> -SubTopic 40<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityStrikePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_StockCompensationPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_StockCompensationPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_StockBonusPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_StockBonusPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_NonQualifiedStockOptionsPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_NonQualifiedStockOptionsPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_IncentiveStockOptionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_IncentiveStockOptionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_IncentiveStockBonusPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_IncentiveStockBonusPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_RestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_RestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_NonVestedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_NonVestedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387590504848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLAN (Detail Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract', window );"><strong>EMPLOYEE BENEFIT PLAN</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Expense for Company's contribution to employee benefit plan</a></td>
<td class="nump">$ 208,000<span></span>
</td>
<td class="nump">$ 223,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_TotalCompensation', window );">Total compensation</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ParticipantCompensation', window );">Participant compensation</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued</a></td>
<td class="nump">97,004<span></span>
</td>
<td class="nump">52,882<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ParticipantCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ParticipantCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_TotalCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_TotalCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387586400304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 2,655,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">2,740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">2,832,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">2,923,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">3,015,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">252,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total Future Minimum Lease Obligation</a></td>
<td class="nump">14,417,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed Interest On Financing Lease Obligation</a></td>
<td class="num">(2,696,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Net present value of lease finance lease obligations - current portion</a></td>
<td class="nump">1,772,000<span></span>
</td>
<td class="nump">$ 197,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Net present value of lease finance lease obligations - non-current portion</a></td>
<td class="nump">$ 9,949,000<span></span>
</td>
<td class="nump">$ 1,653,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481161/840-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481192/840-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481161/840-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481192/840-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387586456032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 357,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,040,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_LesseeOperatingLeaseLiabilityPayments', window );">Total Future Minimum Lease Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,612,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less Imputed Interest On Operating Lease Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(762,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Net present value of operating lease obligation - non-current portion</a></td>
<td class="nump">$ 9,949,000<span></span>
</td>
<td class="nump">1,653,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Net present value of operating lease obligation - current portion</a></td>
<td class="nump">$ 1,772,000<span></span>
</td>
<td class="nump">$ 197,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LesseeOperatingLeaseLiabilityPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LesseeOperatingLeaseLiabilityPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481161/840-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481192/840-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481161/840-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481192/840-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387584703248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 11, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NetOfDiscount', window );">Net of discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_AdditionalExpenses', window );">Additional expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,771,804<span></span>
</td>
<td class="nump">$ 1,560,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,431<span></span>
</td>
<td class="nump">170,928<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CashPaymentForOperatingLeases', window );">Cash payment for operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WeightedAverageOperatingLeaseDiscountRate', window );">Weighted average operating lease discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WeightedAverageOperatingLeaseMaturityYear', window );">Weighted average operating lease maturity year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 8 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Lease expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember', window );">Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WeightedAverageMaturityYear', window );">Weighted average maturity year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Finance lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,100,000<span></span>
</td>
<td class="nump">10,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,700,000<span></span>
</td>
<td class="nump">13,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Interest payment to lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CashPaymentToLeaseLiability', window );">Cash payment to lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime', window );">Weighted average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.44%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvm_LandlordMember', window );">Landlord [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncrementalBorrowingDerivativeVariableRate', window );">Incremental borrowing, derivative variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases', window );">Lease description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinancingLeaseContractualArrangement', window );">Financing arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_PaymentsMadeToLandlord', window );">Payments Made to Landlord</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_ErgomedMember', window );">Ergomed [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NetOfDiscount', window );">Net of discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ClinicalServiceTrial', window );">Clinical service trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_AdditionalClinicalTrial', window );">Additional clinical trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AdditionalClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AdditionalClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AdditionalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AdditionalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CashPaymentForOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CashPaymentForOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CashPaymentToLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CashPaymentToLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ClinicalServiceTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ClinicalServiceTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinancingLeaseContractualArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinancingLeaseContractualArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncrementalBorrowingDerivativeVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncrementalBorrowingDerivativeVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NetOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NetOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PaymentsMadeToLandlord">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PaymentsMadeToLandlord</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageMaturityYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageMaturityYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageOperatingLeaseMaturityYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageOperatingLeaseMaturityYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A general description of the lessee's leasing arrangements including, but not limited to, the following: a) the basis on which contingent rental payments are determined; (b) the existence and terms of renewal or purchase options and escalation clauses; (c) restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481440/840-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482673/440-10-25-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated over time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtWeightedAverageInterestRateOverTime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvm_LandlordMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvm_LandlordMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_ErgomedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_ErgomedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387584650672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative )<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_OfficerAndDirectorMember', window );">Officer and Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_DeemedDividendFromModificationOfWarrants', window );">Deemed dividend from modification of warrants</a></td>
<td class="nump">$ 172,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNAndXAndYWarrantsMember', window );">Series N and X and Y Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_DeemedDividendFromModificationOfWarrants', window );">Deemed dividend from modification of warrants</a></td>
<td class="nump">294,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesMMAndNNAndUUWarrantMember', window );">Series MM and NN and UU Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_Warrant', window );">Warrant extensions</a></td>
<td class="nump">$ 635,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_DeemedDividendFromModificationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_DeemedDividendFromModificationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_Warrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_Warrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_OfficerAndDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_OfficerAndDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNAndXAndYWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNAndXAndYWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesMMAndNNAndUUWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesMMAndNNAndUUWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387579727504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 02, 2023</div></th>
<th class="th"><div>Jul. 20, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">913,234<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">47,422,304<span></span>
</td>
<td class="nump">43,448,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_AggregateNetProceedsFromSaleOfSecurities', window );">Aggregate net proceeds</a></td>
<td class="nump">$ 1,550,000<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price per share</a></td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ProceedFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,752<span></span>
</td>
<td class="nump">25,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_ErgomedMember', window );">Ergomed [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_PrepaidAmountOfResold', window );">Prepaid of resold amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AggregateNetProceedsFromSaleOfSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AggregateNetProceedsFromSaleOfSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PrepaidAmountOfResold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PrepaidAmountOfResold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ProceedFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ProceedFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_ErgomedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_ErgomedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387581609088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 437,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuances</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales', window );">Exercises</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(70,589)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings', window );">Net realized and unrealized derivative loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(366,791)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387590643104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain on short-term T-bills</a></td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WeightedAverageRiskFreeInterestRate', window );">Weighted average risk free interest rate</a></td>
<td class="nump">0.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387587521648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Loss per share - basic and diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted', window );">Net loss available to common shareholders - basic and diluted</a></td>
<td class="num">$ (32,365,855)<span></span>
</td>
<td class="num">$ (37,629,803)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted', window );">Weighted average shares outstanding - basic and diluted</a></td>
<td class="nump">44,479,865<span></span>
</td>
<td class="nump">43,148,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EarningPerShareBasicAndDiluted', window );">Basic and diluted loss per common share</a></td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (0.87)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_EarningPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_EarningPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387579635584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">15,997,278<span></span>
</td>
<td class="nump">14,426,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember', window );">Options and Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">15,850,028<span></span>
</td>
<td class="nump">14,274,836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember', window );">Unvested Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">147,250<span></span>
</td>
<td class="nump">151,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140387590599328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 20, 2023</div></th>
<th class="th"><div>Jul. 20, 2023</div></th>
<th class="th"><div>May 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share public offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Sale of common stock</a></td>
<td class="nump">2,490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share public offering price</a></td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate net proceeds from sale of common stock</a></td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>cvm_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cvm="http://cvm.com/20230930"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cvm-20230930.xsd" xlink:type="simple"/>
    <context id="From2022-10-01to2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-20_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-20</instant>
        </period>
    </context>
    <context id="From2023-11-01to2023-11-20_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-20</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_UnvestedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_UnvestedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_ErgomedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_cvm_ErgomedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2023-07-01to2023-07-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="From2023-04-30to2023-05-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2023-04-30</startDate>
            <endDate>2023-05-02</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2023-07-20</instant>
        </period>
    </context>
    <context id="AsOf2023-05-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2023-05-02</instant>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_SeriesMMAndNNAndUUWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesMMAndNNAndUUWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_OfficerAndDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:OfficerAndDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_SeriesNAndXAndYWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNAndXAndYWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-01to2023-01-11_cvm_LandlordMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvm:LandlordMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-11</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_us-gaap_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_us-gaap_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_ErgomedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_ErgomedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_LandlordMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvm:LandlordMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_cvm_IncentiveStockBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:IncentiveStockBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_NonQualifiedStockOptionsPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_NonQualifiedStockOptionsPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_cvm_NonQualifiedStockOptionsPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_IncentiveStockBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:IncentiveStockBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_IncentiveStockOptionPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:IncentiveStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_NonQualifiedStockOptionsPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_StockCompensationPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:StockCompensationPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_IncentiveStockBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:IncentiveStockBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_StockBonusPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:StockBonusPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_NonVestedOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonVestedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_cvm_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_ExercisableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_ExercisableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_ExercisableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_ExercisableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_cvm_ExercisableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_OutstandingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_OutstandingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_OutstandingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_cvm_OutstandingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_cvm_OutstandingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_IncomeTaxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">cvm:IncomeTaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_IncomeTaxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">cvm:IncomeTaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_cvm_IncomeTaxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">cvm:IncomeTaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_srt_MaximumMember_cvm_RestrictedStocksMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_srt_MaximumMember_cvm_RestrictedStocksMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-02-01to2022-02-28_cvm_SeriesHHWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesHHWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="From2022-02-01to2022-02-28_cvm_SeriesAAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesAAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="From2021-11-01to2021-11-30_cvm_SeriesZWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="From2021-12-01to2021-12-31_cvm_SeriesCCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesCCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember_cvm_TwoSeptemberTwoThousendTwentyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:TwoSeptemberTwoThousendTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember_cvm_TwoSeptemberTwoThousendTwentyFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:TwoSeptemberTwoThousendTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2022-10-28_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-28</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_SeriesSSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesSSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_SeriesHHMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesHHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_SeriesHHMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesHHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_SeriesCCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesCCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_SeriesCCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesCCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_SeriesBBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesBBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_SeriesBBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesBBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_SeriesAAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesAAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_SeriesAAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesAAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_SeriesZZMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_SeriesZZMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_SeriesZMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_SeriesZMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_SeriesWMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesWMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_SeriesWMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesWMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_ConsultantsOneMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_cvm_ConsultantsOneMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_cvm_ConsultantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_cvm_SeriesTTMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesTTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_cvm_SeriesSSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesSSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_cvm_SeriesNNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_cvm_SeriesMMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesMMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_cvm_SeriesYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_cvm_SeriesXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_cvm_SeriesUUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesUUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_cvm_SeriesNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_ConsultantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_SeriesNNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_SeriesMMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesMMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_SeriesYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_SeriesXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_SeriesUUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesUUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_SeriesNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_ConsultantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_SeriesNNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_SeriesMMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesMMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_SeriesYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_SeriesXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_ConsultantsOneMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_ConsultantsOneMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_SeriesUUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesUUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_SeriesNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_ConsultantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_SeriesTTMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesTTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_SeriesSSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesSSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_SeriesNNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_SeriesMMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesMMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_SeriesYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_SeriesXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_cvm_SeriesUUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesUUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_SeriesNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2023-12-08</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-10-01to2023-09-30">0000725363</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-10-01to2023-09-30">false</dei:AmendmentFlag>
    <dei:EntityVoluntaryFilers contextRef="From2022-10-01to2023-09-30">No</dei:EntityVoluntaryFilers>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-10-01to2023-09-30">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2022-10-01to2023-09-30">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-10-01to2023-09-30">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2022-10-01to2023-09-30">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2022-10-01to2023-09-30">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-09-30"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-09-30" decimals="0" unitRef="Shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-09-30" decimals="0" unitRef="Shares">43448317</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-09-30" decimals="0" unitRef="Shares">47422304</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-09-30"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-09-30" decimals="0" unitRef="Shares">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2022-09-30" decimals="0" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2023-09-30" decimals="0" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2022-09-30" decimals="0" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CashFDICInsuredAmount contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <cvm:ResearchAndDevelopmentCredit
      contextRef="AsOf2022-09-30_cvm_IncomeTaxMember"
      decimals="0"
      unitRef="USD">1200000.0</cvm:ResearchAndDevelopmentCredit>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember"
      decimals="0"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <cvm:NumberOfOptionsExercised
      contextRef="From2022-10-01to2023-09-30_cvm_ExercisableMember"
      decimals="0"
      unitRef="Shares">0</cvm:NumberOfOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="From2021-10-01to2022-09-30_cvm_RestrictedStockAwardsMember"
      decimals="0"
      unitRef="Shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-10-01to2023-09-30_cvm_RestrictedStockAwardsMember"
      decimals="0"
      unitRef="Shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2021-10-01to2022-09-30_cvm_RestrictedStockAwardsMember"
      decimals="0"
      unitRef="Shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <dei:DocumentType contextRef="From2022-10-01to2023-09-30">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2022-10-01to2023-09-30">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-10-01to2023-09-30">2023-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2022-10-01to2023-09-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-10-01to2023-09-30">1-11889</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-10-01to2023-09-30">CEL-SCI CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-10-01to2023-09-30">CO</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-10-01to2023-09-30">84-0916344</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-10-01to2023-09-30">8229 Boone Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-10-01to2023-09-30">Suite 802</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-10-01to2023-09-30">Vienna</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-10-01to2023-09-30">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-10-01to2023-09-30">22182</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-10-01to2023-09-30">703</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-10-01to2023-09-30">506-9460</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-10-01to2023-09-30">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-10-01to2023-09-30">CVM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-10-01to2023-09-30">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2022-10-01to2023-09-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-10-01to2023-09-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-10-01to2023-09-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-10-01to2023-09-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-10-01to2023-09-30">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2022-10-01to2023-09-30">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="From2022-10-01to2023-09-30">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">97639295</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-12-08" decimals="INF" unitRef="Shares">49980804</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="From2022-10-01to2023-09-30">243</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2022-10-01to2023-09-30">BDO USA, P.C.</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2022-10-01to2023-09-30">Potomac, Maryland</dei:AuditorLocation>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1271"
      unitRef="USD">4145735</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1272"
      unitRef="USD">22672138</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1273"
      unitRef="USD">520368</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1274"
      unitRef="USD">762063</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:InventoryNet
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1275"
      unitRef="USD">2248072</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1276"
      unitRef="USD">2001715</us-gaap:InventoryNet>
    <us-gaap:DepositsAssetsCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1277"
      unitRef="USD">4245</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1278"
      unitRef="USD">0</us-gaap:DepositsAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1279"
      unitRef="USD">6918420</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1280"
      unitRef="USD">25435916</us-gaap:AssetsCurrent>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1281"
      unitRef="USD">9131987</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1282"
      unitRef="USD">10937797</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1283"
      unitRef="USD">1698243</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1284"
      unitRef="USD">1884464</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1285"
      unitRef="USD">10188126</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1286"
      unitRef="USD">11889029</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1287"
      unitRef="USD">197704</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1288"
      unitRef="USD">212201</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1460"
      unitRef="USD">2319101</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1462"
      unitRef="USD">0</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1289"
      unitRef="USD">74669</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1290"
      unitRef="USD">164299</us-gaap:InventoryNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1291"
      unitRef="USD">30528250</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1292"
      unitRef="USD">50523706</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1295"
      unitRef="USD">2009786</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1296"
      unitRef="USD">1618290</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1297"
      unitRef="USD">1049581</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1298"
      unitRef="USD">842492</us-gaap:AccruedLiabilitiesCurrent>
    <cvm:AmountsDueToEmployeesCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1299"
      unitRef="USD">557244</cvm:AmountsDueToEmployeesCurrent>
    <cvm:AmountsDueToEmployeesCurrent
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1300"
      unitRef="USD">471488</cvm:AmountsDueToEmployeesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1301"
      unitRef="USD">1771804</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1302"
      unitRef="USD">1560553</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1303"
      unitRef="USD">197431</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1304"
      unitRef="USD">170928</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1305"
      unitRef="USD">5585846</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1306"
      unitRef="USD">4663751</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1307"
      unitRef="USD">9949565</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1308"
      unitRef="USD">11721368</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1461"
      unitRef="USD">1652949</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1463"
      unitRef="USD">1850380</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1311"
      unitRef="USD">125000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1312"
      unitRef="USD">125000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1313"
      unitRef="USD">17313360</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1314"
      unitRef="USD">18360499</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="fid_1452"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1453"
      unitRef="Shares">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1454"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="fid_1442"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1444"
      unitRef="Shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1447"
      unitRef="Shares">47422304</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1446"
      unitRef="Shares">43448317</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1317"
      unitRef="USD">474223</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1318"
      unitRef="USD">434484</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1319"
      unitRef="USD">499832063</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1320"
      unitRef="USD">486625816</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1321"
      unitRef="USD">-487091396</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1322"
      unitRef="USD">-454897093</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1323"
      unitRef="USD">13214890</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1324"
      unitRef="USD">32163207</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1325"
      unitRef="USD">30528250</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1326"
      unitRef="USD">50523706</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1328"
      unitRef="USD">22471496</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1329"
      unitRef="USD">25355346</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1330"
      unitRef="USD">9004578</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1331"
      unitRef="USD">10707447</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1332"
      unitRef="USD">31476074</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1333"
      unitRef="USD">36062793</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1334"
      unitRef="USD">-31476074</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1335"
      unitRef="USD">-36062793</us-gaap:OperatingIncomeLoss>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1336"
      unitRef="USD">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1337"
      unitRef="USD">366791</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OtherNonoperatingGainsLosses
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1338"
      unitRef="USD">0</us-gaap:OtherNonoperatingGainsLosses>
    <us-gaap:OtherNonoperatingGainsLosses
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1339"
      unitRef="USD">-30793</us-gaap:OtherNonoperatingGainsLosses>
    <us-gaap:InterestExpense
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1340"
      unitRef="USD">675416</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1341"
      unitRef="USD">1081034</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1342"
      unitRef="USD">-42813</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1343"
      unitRef="USD">107148</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1344"
      unitRef="USD">-32194303</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1345"
      unitRef="USD">-36700681</us-gaap:NetIncomeLoss>
    <cvm:ModificationOfWarrants
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1346"
      unitRef="USD">-171552</cvm:ModificationOfWarrants>
    <cvm:ModificationOfWarrants
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1347"
      unitRef="USD">-929122</cvm:ModificationOfWarrants>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1348"
      unitRef="USD">-32365855</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1349"
      unitRef="USD">-37629803</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <cvm:EarningPerShareBasicAndDiluted
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1350"
      unitRef="USDPShares">-0.73</cvm:EarningPerShareBasicAndDiluted>
    <cvm:EarningPerShareBasicAndDiluted
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      id="fid_1351"
      unitRef="USDPShares">-0.87</cvm:EarningPerShareBasicAndDiluted>
    <cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1352"
      unitRef="Shares">44479865</cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted>
    <cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1353"
      unitRef="Shares">43148888</cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1465"
      unitRef="Shares">43207183</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1466"
      unitRef="USD">432072</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1467"
      unitRef="USD">474298566</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1468"
      unitRef="USD">-418196412</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1469"
      unitRef="USD">56534226</us-gaap:StockholdersEquity>
    <cvm:WarrantExercisesShares
      contextRef="From2021-10-01to2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1470"
      unitRef="Shares">25205</cvm:WarrantExercisesShares>
    <cvm:WarrantExercisesAmount
      contextRef="From2021-10-01to2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1471"
      unitRef="USD">252</cvm:WarrantExercisesAmount>
    <cvm:WarrantExercisesAmount
      contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1472"
      unitRef="USD">171562</cvm:WarrantExercisesAmount>
    <cvm:WarrantExercisesAmount
      contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1473"
      unitRef="USD">0</cvm:WarrantExercisesAmount>
    <cvm:WarrantExercisesAmount
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1474"
      unitRef="USD">171814</cvm:WarrantExercisesAmount>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2021-10-01to2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1475"
      unitRef="Shares">52882</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2021-10-01to2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1476"
      unitRef="USD">528</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1477"
      unitRef="USD">222515</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1478"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1479"
      unitRef="USD">223043</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2021-10-01to2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1480"
      unitRef="Shares">156547</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-10-01to2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1481"
      unitRef="USD">1567</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1482"
      unitRef="USD">691926</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1483"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1484"
      unitRef="USD">693493</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-10-01to2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1485"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1486"
      unitRef="USD">11389932</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1487"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1488"
      unitRef="USD">11389932</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-10-01to2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1489"
      unitRef="Shares">6500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-10-01to2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1490"
      unitRef="USD">65</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1491"
      unitRef="USD">29770</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1492"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1493"
      unitRef="USD">29835</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <cvm:IncreaseDecreaseFromStockIssuanceCosts
      contextRef="From2021-10-01to2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1494"
      unitRef="USD">0</cvm:IncreaseDecreaseFromStockIssuanceCosts>
    <cvm:IncreaseDecreaseFromStockIssuanceCosts
      contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1495"
      unitRef="USD">178455</cvm:IncreaseDecreaseFromStockIssuanceCosts>
    <cvm:IncreaseDecreaseFromStockIssuanceCosts
      contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1496"
      unitRef="USD">0</cvm:IncreaseDecreaseFromStockIssuanceCosts>
    <cvm:IncreaseDecreaseFromStockIssuanceCosts
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1497"
      unitRef="USD">178455</cvm:IncreaseDecreaseFromStockIssuanceCosts>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-01to2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1498"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1499"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1500"
      unitRef="USD">-36700681</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1501"
      unitRef="USD">-36700681</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1502"
      unitRef="Shares">43448317</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1503"
      unitRef="USD">434484</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1504"
      unitRef="USD">486625816</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1505"
      unitRef="USD">-454897093</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1506"
      unitRef="USD">32163207</us-gaap:StockholdersEquity>
    <cvm:WarrantExercisesShares
      contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1507"
      unitRef="Shares">217752</cvm:WarrantExercisesShares>
    <cvm:WarrantExercisesAmount
      contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1508"
      unitRef="USD">2177</cvm:WarrantExercisesAmount>
    <cvm:WarrantExercisesAmount
      contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1509"
      unitRef="USD">445114</cvm:WarrantExercisesAmount>
    <cvm:WarrantExercisesAmount
      contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1510"
      unitRef="USD">0</cvm:WarrantExercisesAmount>
    <cvm:WarrantExercisesAmount
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1511"
      unitRef="USD">447291</cvm:WarrantExercisesAmount>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1512"
      unitRef="Shares">97004</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1513"
      unitRef="USD">970</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1514"
      unitRef="USD">206623</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1515"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1516"
      unitRef="USD">207593</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1517"
      unitRef="Shares">249997</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1518"
      unitRef="USD">2500</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1519"
      unitRef="USD">563480</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1520"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1521"
      unitRef="USD">565980</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1522"
      unitRef="Shares">3413234</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1523"
      unitRef="USD">34132</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1524"
      unitRef="USD">6518365</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1525"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1526"
      unitRef="USD">6552497</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <cvm:IncentiveStockForfeitedShares
      contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1527"
      unitRef="Shares">-4000</cvm:IncentiveStockForfeitedShares>
    <cvm:IncentiveStockForfeitedAmount
      contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1528"
      unitRef="USD">-40</cvm:IncentiveStockForfeitedAmount>
    <cvm:IncentiveStockForfeitedAmount
      contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1529"
      unitRef="USD">-22160</cvm:IncentiveStockForfeitedAmount>
    <cvm:IncentiveStockForfeitedAmount
      contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1530"
      unitRef="USD">0</cvm:IncentiveStockForfeitedAmount>
    <cvm:IncentiveStockForfeitedAmount
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1531"
      unitRef="USD">-22200</cvm:IncentiveStockForfeitedAmount>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1532"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1533"
      unitRef="USD">6308431</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1534"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1535"
      unitRef="USD">6308431</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <cvm:IncreaseDecreaseFromStockIssuanceCosts
      contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1536"
      unitRef="USD">0</cvm:IncreaseDecreaseFromStockIssuanceCosts>
    <cvm:IncreaseDecreaseFromStockIssuanceCosts
      contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1537"
      unitRef="USD">813606</cvm:IncreaseDecreaseFromStockIssuanceCosts>
    <cvm:IncreaseDecreaseFromStockIssuanceCosts
      contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1538"
      unitRef="USD">0</cvm:IncreaseDecreaseFromStockIssuanceCosts>
    <cvm:IncreaseDecreaseFromStockIssuanceCosts
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1539"
      unitRef="USD">813606</cvm:IncreaseDecreaseFromStockIssuanceCosts>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1540"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1541"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1542"
      unitRef="USD">-32194303</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1543"
      unitRef="USD">-32194303</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1544"
      unitRef="Shares">47422304</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1545"
      unitRef="USD">474223</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1546"
      unitRef="USD">499832063</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1547"
      unitRef="USD">-487091396</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1548"
      unitRef="USD">13214890</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1355"
      unitRef="USD">-32194303</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1356"
      unitRef="USD">-36700681</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1358"
      unitRef="USD">3958334</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1359"
      unitRef="USD">3828917</us-gaap:DepreciationAndAmortization>
    <us-gaap:OtherNoncashExpense
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1360"
      unitRef="USD">15292</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1361"
      unitRef="USD">54469</us-gaap:OtherNoncashExpense>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1362"
      unitRef="USD">655740</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1363"
      unitRef="USD">762261</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1364"
      unitRef="USD">6286231</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1365"
      unitRef="USD">11389932</us-gaap:ShareBasedCompensation>
    <cvm:CommonStockContributedToEmployeeBenefitPlan
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1366"
      unitRef="USD">207593</cvm:CommonStockContributedToEmployeeBenefitPlan>
    <cvm:CommonStockContributedToEmployeeBenefitPlan
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1367"
      unitRef="USD">223043</cvm:CommonStockContributedToEmployeeBenefitPlan>
    <us-gaap:GainLossOnInvestments
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1368"
      unitRef="USD">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1369"
      unitRef="USD">615</us-gaap:GainLossOnInvestments>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1370"
      unitRef="USD">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1371"
      unitRef="USD">366791</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1372"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1373"
      unitRef="USD">30793</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <cvm:GainLossOnReceivables
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1374"
      unitRef="USD">0</cvm:GainLossOnReceivables>
    <cvm:GainLossOnReceivables
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1375"
      unitRef="USD">-54922</cvm:GainLossOnReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1377"
      unitRef="USD">151935</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1378"
      unitRef="USD">167651</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1379"
      unitRef="USD">-156727</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1380"
      unitRef="USD">-159430</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInDeposits
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1381"
      unitRef="USD">-2323346</us-gaap:IncreaseDecreaseInDeposits>
    <us-gaap:IncreaseDecreaseInDeposits
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1382"
      unitRef="USD">1910917</us-gaap:IncreaseDecreaseInDeposits>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1384"
      unitRef="USD">257845</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1385"
      unitRef="USD">374890</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1386"
      unitRef="USD">207089</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1387"
      unitRef="USD">-16724</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1388"
      unitRef="USD">85756</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1389"
      unitRef="USD">205495</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1390"
      unitRef="USD">-22848561</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1391"
      unitRef="USD">-18240951</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1393"
      unitRef="USD">0</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1394"
      unitRef="USD">6152000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1395"
      unitRef="USD">361892</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1396"
      unitRef="USD">637892</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1397"
      unitRef="USD">10370</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1398"
      unitRef="USD">22741</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1399"
      unitRef="USD">-372262</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1400"
      unitRef="USD">5491367</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <cvm:ProceedsFromIssuanceOfCommonStocks
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1402"
      unitRef="USD">6552497</cvm:ProceedsFromIssuanceOfCommonStocks>
    <cvm:ProceedsFromIssuanceOfCommonStocks
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1403"
      unitRef="USD">0</cvm:ProceedsFromIssuanceOfCommonStocks>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1404"
      unitRef="USD">744913</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1405"
      unitRef="USD">169445</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1406"
      unitRef="USD">447291</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1407"
      unitRef="USD">101225</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1408"
      unitRef="USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1409"
      unitRef="USD">29835</us-gaap:ProceedsFromStockOptionsExercised>
    <cvm:ProceedsFromLandlordFundingOfLeaseImprovements
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1410"
      unitRef="USD">0</cvm:ProceedsFromLandlordFundingOfLeaseImprovements>
    <cvm:ProceedsFromLandlordFundingOfLeaseImprovements
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1411"
      unitRef="USD">786454</cvm:ProceedsFromLandlordFundingOfLeaseImprovements>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1412"
      unitRef="USD">1560455</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1413"
      unitRef="USD">1386495</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1414"
      unitRef="USD">4694420</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1415"
      unitRef="USD">-638426</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1416"
      unitRef="USD">-18526403</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1417"
      unitRef="USD">-13388010</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1418"
      unitRef="USD">22672138</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1419"
      unitRef="USD">36060148</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1420"
      unitRef="USD">4145735</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1421"
      unitRef="USD">22672138</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1422"
      unitRef="USD">51650</cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities>
    <cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1423"
      unitRef="USD">0</cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities>
    <cvm:CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1424"
      unitRef="USD">13211</cvm:CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable>
    <cvm:CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1425"
      unitRef="USD">0</cvm:CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable>
    <cvm:AssetsPurchasedUnderFinanceLeases
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1426"
      unitRef="USD">0</cvm:AssetsPurchasedUnderFinanceLeases>
    <cvm:AssetsPurchasedUnderFinanceLeases
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1427"
      unitRef="USD">32409</cvm:AssetsPurchasedUnderFinanceLeases>
    <cvm:IncreaseDecreaseToRightOfUseAssetsAndLiabilities
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1428"
      unitRef="USD">0</cvm:IncreaseDecreaseToRightOfUseAssetsAndLiabilities>
    <cvm:IncreaseDecreaseToRightOfUseAssetsAndLiabilities
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1429"
      unitRef="USD">16268</cvm:IncreaseDecreaseToRightOfUseAssetsAndLiabilities>
    <cvm:FinanceLeaseObligationIncludedInAccountsPayable
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1430"
      unitRef="USD">1451</cvm:FinanceLeaseObligationIncludedInAccountsPayable>
    <cvm:FinanceLeaseObligationIncludedInAccountsPayable
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1431"
      unitRef="USD">1354</cvm:FinanceLeaseObligationIncludedInAccountsPayable>
    <cvm:ConsultingFeePaidWithIssuanceOfCommonStock
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1432"
      unitRef="USD">565980</cvm:ConsultingFeePaidWithIssuanceOfCommonStock>
    <cvm:ConsultingFeePaidWithIssuanceOfCommonStock
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1433"
      unitRef="USD">295143</cvm:ConsultingFeePaidWithIssuanceOfCommonStock>
    <cvm:FinancingCostsIncludedInCurrentLiabilities
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1434"
      unitRef="USD">77703</cvm:FinancingCostsIncludedInCurrentLiabilities>
    <cvm:FinancingCostsIncludedInCurrentLiabilities
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1435"
      unitRef="USD">9010</cvm:FinancingCostsIncludedInCurrentLiabilities>
    <cvm:DerivativeLiabilitiesExercised
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1436"
      unitRef="USD">0</cvm:DerivativeLiabilitiesExercised>
    <cvm:DerivativeLiabilitiesExercised
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1437"
      unitRef="USD">70589</cvm:DerivativeLiabilitiesExercised>
    <cvm:AccruedConsultingServicesToBePaid
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1438"
      unitRef="USD">55000</cvm:AccruedConsultingServicesToBePaid>
    <cvm:AccruedConsultingServicesToBePaid
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1439"
      unitRef="USD">55000</cvm:AccruedConsultingServicesToBePaid>
    <us-gaap:InterestPaidNet
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1440"
      unitRef="USD">1062564</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1441"
      unitRef="USD">1157069</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1563">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;1. ORGANIZATION&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;CEL-SCI Corporation (the Company) was incorporated on March 22, 1983, in the state of Colorado, to finance research and development in biomedical science and ultimately to engage in marketing and selling products.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company has announced results from its Phase III study for its lead investigational therapy, Multikine&#xae; (Leukocyte Interleukin, Injection), involving head and neck cancer, for which the Company has received Orphan Drug Status from the United States Food and Drug Administration (FDA). Unlike other immune therapies, Multikine is administered locally at the site of the tumor as a first line treatment right after diagnosis, before surgery and radiation. The goal is to help the intact immune system kill the micro metastases that usually cause recurrence of the cancer to improve outcomes and better overall survival rates for patients suffering from head and neck cancer. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;CEL-SCI is also investigating a peptide-based immunotherapy (CEL-4000) as a vaccine for rheumatoid arthritis using its LEAPS technology platform. CEL-SCI is in the process of completing pre-IND studies for CEL-4000.&#160; &lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <cvm:LiquiditydisclosureTextblock contextRef="From2022-10-01to2023-09-30" id="fid_1549">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;2&lt;/strong&gt;&lt;strong&gt;.&lt;/strong&gt;&#160; &lt;strong&gt;LIQUIDITY &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and participation in clinical trials.&#160; The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities.&#160; The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine to market.&#160; The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from the U.S. Food and Drug Administration (FDA) or from the regulators in Canada, the UK or Europe for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings.&#160; The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase III study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all.&#160; If the Company does not raise the necessary amounts of funding, it may have to curtail its operations until such time as it is able to raise the required funding.&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Due to the Company&#x2019;s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern.&#160; The financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;</cvm:LiquiditydisclosureTextblock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1550">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;3&lt;/strong&gt;&lt;strong&gt;. &lt;/strong&gt;&lt;strong&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Cash and Cash Equivalents &lt;/em&gt;&#x2013; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds.&#160; The Company considers all highly liquid investments with a maturity when purchased of less than three months as cash and cash equivalents.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;U.S. Treasury Bills &#x2013; &lt;/em&gt;U.S. Treasury Bills (&#x201c;T-bills&#x201d;) are highly liquid short-term investments with maturity dates of greater than 3 months, but less than one year. These investments are recorded at fair value.&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Supplies used for R&amp;amp;D and manufacturing&lt;/em&gt; &#x2013; Supplies are consumable items kept on hand to support the Company&#x2019;s R&amp;amp;D and manufacturing operations.&#160; Supplies are recorded at cost and are charged to expense as they are used in operations.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Property and Equipment&lt;/em&gt; &#x2013; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment are reviewed on a quarterly basis to determine if any of the assets are impaired.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Patents&lt;/em&gt; &#x2013; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years).&#160; In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment to the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset.&#160; The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Leases&lt;/em&gt; &#x2013; The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material. For purposes of calculating the finance and operating lease liabilities, lease and non-lease components are combined. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Derivative Instruments&lt;/em&gt; &#x2013; The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, &lt;em&gt;Accounting for Derivative Instruments and Hedging Activities&lt;/em&gt;. In accordance with ASC 815, derivative instruments and hybrid instruments are recognized as either assets or liabilities on the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each&#160;reporting period. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company adopted Accounting Standards Update (ASU) 2020-06 &lt;em&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/em&gt; effective October 1, 2021&lt;em&gt;.&lt;/em&gt;&#160;The amendments in this Update simplify and clarify the guidance in Subtopic 815-40. &#160;There was no financial impact upon adoption.&#160;&#160;&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company adopted ASU 2021-04,&#160;&lt;em&gt;Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options&lt;/em&gt;. This standard was issued to clarify and reduce diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 was effective for fiscal years beginning after December 15, 2021, however, as permitted, the Company elected to prospectively adopt the standard, effective as of October 1, 2021. Adoption of this standard had no impact on the Company&#x2019;s financial statements.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Stock-Based Compensation&lt;/em&gt; &#x2013; Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, &lt;em&gt;Compensation &#x2013; Stock Compensation&lt;/em&gt;. The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized using the straight-line allocation method as expense over the requisite service or vesting period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the "Plans". All Plans have been approved by the Company&#x2019;s stockholders.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company&#x2019;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the assumption for stock price volatility is based on the variance of daily closing prices of the Company&#x2019;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the 2021 and 2020 Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant-dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Research and Development Costs&lt;/em&gt; - Research and development costs are expensed as incurred.&#160; Management accrues Clinical Research Organization (CRO) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Net Loss Per Common Share&lt;/em&gt; &#x2013; The Company calculates net loss per common share in accordance with ASC 260 &lt;em&gt;Earnings Per Share&lt;/em&gt; (ASC 260).&#160; Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period.&#160; The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Concentration of Credit Risk&lt;/em&gt; &#x2013; Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents.&#160; The Company maintains its cash and cash equivalents with high quality financial institutions.&#160; At times, these accounts may exceed federally insured limits.&#160; The Company has not experienced any losses in such bank accounts.&#160; The Company believes it is not exposed to significant credit risk related to cash and cash equivalents.&#160; All non-interest bearing cash balances were fully insured up to $250,000 at September 30, 2023 and September 30, 2022. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Income Taxes&lt;/em&gt; &#x2013;The Company follows ASC 740-10-25 for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related assets or liability is expected to be realized or settled.&#160; The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160; The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of September 30, 2023 and 2022.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company adopted ASU&#160; 2019-12,&#160;&lt;em&gt;Income Taxes (Topic&#160;740): Simplifying the Accounting for Income Taxes&lt;/em&gt;, effective October 1, 2021. The new standard includes several provisions that simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. The adoption of ASU 2019-12 had no impact on the Company&#x2019;s financial statements.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On August 16, 2022, the Inflation Reduction Act of 2022 (the &#x201c;IR Act&#x201d;) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly traded foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself, not its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the &#x201c;Treasury&#x201d;) has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax.&#160;&#160;&#160;&#160;&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Impairment of long-lived assets&lt;/em&gt; &#x2013; CEL-SCI&#x2019;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#x2019;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets in accordance with ASC 360-10-35-21 to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Use of Estimates&lt;/em&gt; &#x2013; The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures.&#160; These estimates are based on management&#x2019;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, obsolescence of supplies used for research and development (R&amp;amp;D) and manufacturing, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities,&#160;deferred tax assets and the related valuation allowance, and the valuation of derivative liabilities. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.&#160; The Company considers the estimates used in valuing the derivative liabilities and the lease assets and liabilities to be significant. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;New Accounting Pronouncements&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In June 2016, the Financial Accounting Standards Board issued ASU 2016-13, &lt;em&gt;Financial Instruments&#x2013;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/em&gt; (ASU 2016-13), as amended. The amendments in ASU 2016-13 require, among other things, financial assets measured at amortized cost basis to be presented at the net amount expected to be collected as compared to previous U.S. GAAP which delayed recognition until it was probable a loss had been incurred. The amendments in ASU 2016-13 are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, with early adoption permitted. The Company currently does not have any such financial assets reported as of September 30, 2023, however, the Company will continue to evaluate the impact that adoption of ASU 2016-13 will have on its financial statements and related disclosures.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Other accounting standard updates effective for interim and annual periods beginning after September 30, 2023 are not expected to have a material impact on the Company&#x2019;s financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1564">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Cash and Cash Equivalents &lt;/em&gt;&#x2013; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds.&#160; The Company considers all highly liquid investments with a maturity when purchased of less than three months as cash and cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <cvm:USTreasuryBillsPolicyTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1565">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;U.S. Treasury Bills &#x2013; &lt;/em&gt;U.S. Treasury Bills (&#x201c;T-bills&#x201d;) are highly liquid short-term investments with maturity dates of greater than 3 months, but less than one year. These investments are recorded at fair value.&#160; &lt;/p&gt;</cvm:USTreasuryBillsPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1566">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Supplies used for R&amp;amp;D and manufacturing&lt;/em&gt; &#x2013; Supplies are consumable items kept on hand to support the Company&#x2019;s R&amp;amp;D and manufacturing operations.&#160; Supplies are recorded at cost and are charged to expense as they are used in operations.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1567">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Property and Equipment&lt;/em&gt; &#x2013; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment are reviewed on a quarterly basis to determine if any of the assets are impaired.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2022-10-01to2023-09-30" id="fid_1568">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Patents&lt;/em&gt; &#x2013; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years).&#160; In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment to the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset.&#160; The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value. &lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <cvm:FiniteLivedIntangibleAssetsUsefulLife
      contextRef="From2021-10-01to2022-09-30_us-gaap_PatentsMember"
      id="fid_1852">P17Y</cvm:FiniteLivedIntangibleAssetsUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1569">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Leases&lt;/em&gt; &#x2013; The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material. For purposes of calculating the finance and operating lease liabilities, lease and non-lease components are combined. &lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1570">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Derivative Instruments&lt;/em&gt; &#x2013; The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, &lt;em&gt;Accounting for Derivative Instruments and Hedging Activities&lt;/em&gt;. In accordance with ASC 815, derivative instruments and hybrid instruments are recognized as either assets or liabilities on the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each&#160;reporting period. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company adopted Accounting Standards Update (ASU) 2020-06 &lt;em&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/em&gt; effective October 1, 2021&lt;em&gt;.&lt;/em&gt;&#160;The amendments in this Update simplify and clarify the guidance in Subtopic 815-40. &#160;There was no financial impact upon adoption.&#160;&#160;&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company adopted ASU 2021-04,&#160;&lt;em&gt;Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options&lt;/em&gt;. This standard was issued to clarify and reduce diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 was effective for fiscal years beginning after December 15, 2021, however, as permitted, the Company elected to prospectively adopt the standard, effective as of October 1, 2021. Adoption of this standard had no impact on the Company&#x2019;s financial statements.&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2022-10-01to2023-09-30" id="fid_1571">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Stock-Based Compensation&lt;/em&gt; &#x2013; Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, &lt;em&gt;Compensation &#x2013; Stock Compensation&lt;/em&gt;. The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized using the straight-line allocation method as expense over the requisite service or vesting period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the "Plans". All Plans have been approved by the Company&#x2019;s stockholders.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company&#x2019;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the assumption for stock price volatility is based on the variance of daily closing prices of the Company&#x2019;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the 2021 and 2020 Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant-dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2022-10-01to2023-09-30" id="fid_1572">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Research and Development Costs&lt;/em&gt; - Research and development costs are expensed as incurred.&#160; Management accrues Clinical Research Organization (CRO) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. &lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1573">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Net Loss Per Common Share&lt;/em&gt; &#x2013; The Company calculates net loss per common share in accordance with ASC 260 &lt;em&gt;Earnings Per Share&lt;/em&gt; (ASC 260).&#160; Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period.&#160; The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2022-10-01to2023-09-30" id="fid_1574">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Concentration of Credit Risk&lt;/em&gt; &#x2013; Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents.&#160; The Company maintains its cash and cash equivalents with high quality financial institutions.&#160; At times, these accounts may exceed federally insured limits.&#160; The Company has not experienced any losses in such bank accounts.&#160; The Company believes it is not exposed to significant credit risk related to cash and cash equivalents.&#160; All non-interest bearing cash balances were fully insured up to $250,000 at September 30, 2023 and September 30, 2022. &lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1853"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1575">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Income Taxes&lt;/em&gt; &#x2013;The Company follows ASC 740-10-25 for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related assets or liability is expected to be realized or settled.&#160; The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160; The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of September 30, 2023 and 2022.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company adopted ASU&#160; 2019-12,&#160;&lt;em&gt;Income Taxes (Topic&#160;740): Simplifying the Accounting for Income Taxes&lt;/em&gt;, effective October 1, 2021. The new standard includes several provisions that simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. The adoption of ASU 2019-12 had no impact on the Company&#x2019;s financial statements.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On August 16, 2022, the Inflation Reduction Act of 2022 (the &#x201c;IR Act&#x201d;) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly traded foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself, not its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the &#x201c;Treasury&#x201d;) has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax.&#160;&#160;&#160;&#160;&#160; &lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_2060">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Impairment of long-lived assets&lt;/em&gt; &#x2013; CEL-SCI&#x2019;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#x2019;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets in accordance with ASC 360-10-35-21 to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2022-10-01to2023-09-30" id="fid_1576">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Use of Estimates&lt;/em&gt; &#x2013; The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures.&#160; These estimates are based on management&#x2019;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, obsolescence of supplies used for research and development (R&amp;amp;D) and manufacturing, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities,&#160;deferred tax assets and the related valuation allowance, and the valuation of derivative liabilities. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.&#160; The Company considers the estimates used in valuing the derivative liabilities and the lease assets and liabilities to be significant. &lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1577">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In June 2016, the Financial Accounting Standards Board issued ASU 2016-13, &lt;em&gt;Financial Instruments&#x2013;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/em&gt; (ASU 2016-13), as amended. The amendments in ASU 2016-13 require, among other things, financial assets measured at amortized cost basis to be presented at the net amount expected to be collected as compared to previous U.S. GAAP which delayed recognition until it was probable a loss had been incurred. The amendments in ASU 2016-13 are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, with early adoption permitted. The Company currently does not have any such financial assets reported as of September 30, 2023, however, the Company will continue to evaluate the impact that adoption of ASU 2016-13 will have on its financial statements and related disclosures.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Other accounting standard updates effective for interim and annual periods beginning after September 30, 2023 are not expected to have a material impact on the Company&#x2019;s financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <cvm:WarrantsAndNonEmployeeOptionsDisclosureTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1551">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;4.&#160;&#160; WARRANTS AND NON-EMPLOYEE OPTIONS&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The following warrants and non-employee options are outstanding at September 30, 2023:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"&gt;Warrant/Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"&gt;Issue Date&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"&gt;Shares Issuable upon Exercise &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"&gt;of Warrants/ Options&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.95pt; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Expiration Date&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series N&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:14%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2008&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;85,339&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:14%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series UU&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/11/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;93,603&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/30/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series X&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1/13/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;120,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;9.25&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/13/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Y&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/15/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;26,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;12.00&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/15/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;333,432&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;200,087&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;234,009&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Consultant Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;7/28/2017 &#x2013; 9/2/2023&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;110,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;$&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"&gt;1.39 - $2.18&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/27/2027 &#x2013; 9/1/2028&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"&gt;The following warrants and non-employee options are outstanding at September 30, 2022:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"&gt;Warrant/Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"&gt;Issue Date&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"&gt;Shares Issuable upon Exercise &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"&gt;of Warrants/ Options&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.95pt; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Expiration Date&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series N&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:14%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2008&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;85,339&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:14%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series UU&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/11/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;93,603&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/30/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series X&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1/13/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;120,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;9.25&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/13/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Y&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/15/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;26,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;12.00&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/15/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;333,432&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;200,087&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;251,761&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series SS&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12/19/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;200,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.09&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12/18/2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series TT&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/5/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;600&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.24&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/5/2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Consultant Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.95pt; text-align:right;"&gt;7/28/2017 &#x2013; 11/18/2020&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;15,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;$&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;2.18 - $11.61&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:right;"&gt;11/17/2022 - 7/27/2027&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;A.&#160; Warrant Liabilities&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;There were no warrant liabilities outstanding at September 30, 2023 and 2022.&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The gains/(losses) on the warrant liabilities for the years ended September 30 are as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05in; text-align:center;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05in; text-align:center;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series W warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Z warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;64,787&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series ZZ warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series AA warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;276,035&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series BB warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series CC warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;24,372&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series HH warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,597&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net loss on warrant liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;366,791&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company reviews all outstanding warrants in accordance with the requirements of ASC 815 , &lt;em&gt;Accounting for Derivative Instruments and Hedging Activities&lt;/em&gt;.&#160; This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument&#x2019;s contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain dilutive events.&#160; Under the provisions of ASC 815, the warrants are not considered indexed to the Company&#x2019;s stock because future equity offerings or sales of the Company&#x2019;s stock are not an input to the fair value of a &#x201c;fixed-for-fixed&#x201d; option on equity shares, and equity classification is therefore precluded.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration.&#160; Any change in fair value between the respective reporting periods is recognized as a gain or loss in the statement of operations.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Changes in Warrant Liabilities&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In February 2022, 100,000 Series AA warrants, with an exercise price of $13.75 and 200 Series HH warrants with an exercise price of $3.13, expired. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In December 2021, 640 Series CC warrants, with an exercise price of $5.00, expired. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In November 2021, 184,800 Series Z warrants, with an exercise price of $13.75, expired.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Exercise of Warrant Liabilities&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;No warrants recorded as liabilities were exercised during the year ended September 30, 2023.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The following warrants recorded as liabilities were exercised during the year ended September 30, 2022:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrants Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series CC&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,205&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;76,025&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;B. Equity Warrants&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Changes in Equity Warrants&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024.&#160; The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend. The Series RR warrants are held by Geert Kersten, Patricia Prichep (current officers of the Company) and the de Clara Trust, of which the Company&#x2019;s CEO, Geert Kersten, is a beneficiary.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On June 13, 2022, the expiration dates of the Series N, Series X, Series Y, Series UU, Series MM and Series NN warrants were extended two years. The incremental costs of the Series N, Series X and Series Y warrant extensions were recorded as a deemed dividend and totaled approximately $294,000 for the year ended September 30, 2022.&#160; The Series N and Series X warrants are held by the de Clara Trust.&#160; The incremental cost of the Series MM, Series NN and Series UU warrant extensions of approximately $635,000 was recorded as a deemed dividend because there were no longer any notes payable associated with these warrants at the time of modification. The Series UU warrants and a portion of the Series MM and Series NN warrants are held by Geert Kersten, Patricia Prichep (current officers of the Company) and the de Clara Trust.&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Exercise of Equity Warrants &lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The following equity warrants were exercised during the year ended September 30, 2023.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrants Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;17,752&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;29,291&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series SS&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;200,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.09&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;418,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;217,752&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;447,291&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The following equity warrants were exercised during the year ended September 30, 2022.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrants Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25,200&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;C.&lt;/strong&gt;&#160; &lt;strong&gt;Options and Shares Issued to Consultants&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company typically enters into consulting arrangements in exchange for common stock or stock options. During the years ended September 30, 2023 and 2022, the Company issued 249,997 and 156,547 shares, respectively, of common stock to consultants, all of which were restricted shares.&#160; Under these arrangements, during the periods presented, the common stock was issued with stock prices ranging from $1.26 to $11.20 per share. The weighted average grant price was $1.83 and $4.59, respectively, for stock issued during the years ended September 30, 2023 and 2022. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the years ended September 30, 2023 and 2022, the Company recorded total expense of approximately $656,000 and $762,000, respectively, relating to these consulting agreements. At September 30, 2023 and 2022, costs of approximately $205,000 and $295,000, respectively, are included in prepaid expenses. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the year ended September 30, 2023, the Company issued 100,000 options to a consultant to purchase common stock with an exercise price of $1.39. These options vest 50% on September 2, 2024 and 50% on September 2, 2025 and expire on September 1, 2028. No options were issued to consultants during the year ended September 30, 2022. As of September 30, 2023, 110,000 options issued to consultants as payment for services remained outstanding, all of which were issued from the Non-Qualified Stock Option Plan.&lt;/p&gt;</cvm:WarrantsAndNonEmployeeOptionsDisclosureTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1578">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"&gt;Warrant/Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"&gt;Issue Date&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"&gt;Shares Issuable upon Exercise &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"&gt;of Warrants/ Options&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.95pt; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Expiration Date&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series N&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:14%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2008&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;85,339&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:14%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series UU&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/11/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;93,603&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/30/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series X&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1/13/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;120,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;9.25&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/13/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Y&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/15/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;26,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;12.00&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/15/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;333,432&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;200,087&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;234,009&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Consultant Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;7/28/2017 &#x2013; 9/2/2023&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;110,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;$&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"&gt;1.39 - $2.18&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/27/2027 &#x2013; 9/1/2028&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"&gt;Warrant/Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"&gt;Issue Date&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"&gt;Shares Issuable upon Exercise &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"&gt;of Warrants/ Options&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.95pt; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Expiration Date&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series N&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:14%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2008&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;85,339&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:14%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series UU&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/11/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;93,603&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/30/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series X&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1/13/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;120,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;9.25&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/13/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Y&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/15/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;26,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;12.00&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/15/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;333,432&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;200,087&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;251,761&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series SS&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12/19/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;200,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.09&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12/18/2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series TT&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/5/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;600&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.24&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/5/2023&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Consultant Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.95pt; text-align:right;"&gt;7/28/2017 &#x2013; 11/18/2020&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;15,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;$&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;2.18 - $11.61&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:right;"&gt;11/17/2022 - 7/27/2027&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <cvm:Issuedate2
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesNMember"
      id="fid_1854">8/18/2008</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2023-09-30_cvm_SeriesNMember"
      decimals="0"
      id="fid_1873"
      unitRef="Shares">85339</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2023-09-30_cvm_SeriesNMember"
      decimals="INF"
      id="fid_1891"
      unitRef="USDPShares">3.00</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesNMember"
      id="fid_1910">8/18/2024</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesUUMember"
      id="fid_1865">6/11/2018</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2023-09-30_cvm_SeriesUUMember"
      decimals="0"
      id="fid_1874"
      unitRef="Shares">93603</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2023-09-30_cvm_SeriesUUMember"
      decimals="INF"
      id="fid_1892"
      unitRef="USDPShares">2.80</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesUUMember"
      id="fid_1911">6/30/2024</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesXMember"
      id="fid_1856">1/13/2016</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2023-09-30_cvm_SeriesXMember"
      decimals="0"
      id="fid_1875"
      unitRef="Shares">120000</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2023-09-30_cvm_SeriesXMember"
      decimals="INF"
      id="fid_1893"
      unitRef="USDPShares">9.25</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesXMember"
      id="fid_1912">7/13/2024</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesYMember"
      id="fid_1857">2/15/2016</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2023-09-30_cvm_SeriesYMember"
      decimals="0"
      id="fid_1876"
      unitRef="Shares">26000</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2023-09-30_cvm_SeriesYMember"
      decimals="INF"
      id="fid_1894"
      unitRef="USDPShares">12.00</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesYMember"
      id="fid_1913">8/15/2024</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesMMMember"
      id="fid_1858">6/22/2017</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2023-09-30_cvm_SeriesMMMember"
      decimals="0"
      id="fid_1877"
      unitRef="Shares">333432</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2023-09-30_cvm_SeriesMMMember"
      decimals="INF"
      id="fid_1895"
      unitRef="USDPShares">1.86</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesMMMember"
      id="fid_1914">6/22/2024</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesNNMember"
      id="fid_1859">7/24/2017</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2023-09-30_cvm_SeriesNNMember"
      decimals="0"
      id="fid_1878"
      unitRef="Shares">200087</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2023-09-30_cvm_SeriesNNMember"
      decimals="INF"
      id="fid_1896"
      unitRef="USDPShares">2.52</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesNNMember"
      id="fid_1915">7/24/2024</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesRRMember"
      id="fid_1871">10/30/2017</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2023-09-30_cvm_SeriesRRMember"
      decimals="0"
      id="fid_1879"
      unitRef="Shares">234009</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2023-09-30_cvm_SeriesRRMember"
      decimals="INF"
      id="fid_1897"
      unitRef="USDPShares">1.65</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesRRMember"
      id="fid_1916">10/30/2024</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2022-10-01to2023-09-30_cvm_ConsultantsMember_srt_MinimumMember"
      id="fid_1863">7/28/2017</cvm:Issuedate2>
    <cvm:Issuedate2
      contextRef="From2022-10-01to2023-09-30_cvm_ConsultantsOneMember_srt_MaximumMember"
      id="fid_1929">9/2/2023</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2023-09-30_cvm_ConsultantsMember_srt_MinimumMember"
      decimals="0"
      id="fid_1880"
      unitRef="Shares">110000</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2023-09-30_cvm_ConsultantsMember_srt_MinimumMember"
      decimals="INF"
      id="fid_1898"
      unitRef="USDPShares">1.39</cvm:ExercisePrice>
    <cvm:ExercisePrice
      contextRef="AsOf2023-09-30_cvm_ConsultantsOneMember_srt_MaximumMember"
      decimals="INF"
      id="fid_1930"
      unitRef="USDPShares">2.18</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2022-10-01to2023-09-30_cvm_ConsultantsMember_srt_MinimumMember"
      id="fid_1917">7/27/2027</cvm:ExpirationDate1>
    <cvm:ExpirationDate1
      contextRef="From2022-10-01to2023-09-30_cvm_ConsultantsOneMember_srt_MaximumMember"
      id="fid_1931">9/1/2028</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesNMember"
      id="fid_1864">8/18/2008</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2022-09-30_cvm_SeriesNMember"
      decimals="0"
      id="fid_1881"
      unitRef="Shares">85339</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2022-09-30_cvm_SeriesNMember"
      decimals="INF"
      id="fid_1899"
      unitRef="USDPShares">3.00</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesNMember"
      id="fid_1918">8/18/2024</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesUUMember"
      id="fid_1855">6/11/2018</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2022-09-30_cvm_SeriesUUMember"
      decimals="0"
      id="fid_1882"
      unitRef="Shares">93603</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2022-09-30_cvm_SeriesUUMember"
      decimals="INF"
      id="fid_1900"
      unitRef="USDPShares">2.80</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesUUMember"
      id="fid_1919">6/30/2024</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesXMember"
      id="fid_1867">1/13/2016</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2022-09-30_cvm_SeriesXMember"
      decimals="0"
      id="fid_1883"
      unitRef="Shares">120000</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2022-09-30_cvm_SeriesXMember"
      decimals="INF"
      id="fid_1902"
      unitRef="USDPShares">9.25</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesXMember"
      id="fid_1921">7/13/2024</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesYMember"
      id="fid_1868">2/15/2016</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2022-09-30_cvm_SeriesYMember"
      decimals="0"
      id="fid_1884"
      unitRef="Shares">26000</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2022-09-30_cvm_SeriesYMember"
      decimals="INF"
      id="fid_1903"
      unitRef="USDPShares">12.00</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesYMember"
      id="fid_1922">8/15/2024</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesMMMember"
      id="fid_1869">6/22/2017</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2022-09-30_cvm_SeriesMMMember"
      decimals="0"
      id="fid_1885"
      unitRef="Shares">333432</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2022-09-30_cvm_SeriesMMMember"
      decimals="INF"
      id="fid_1904"
      unitRef="USDPShares">1.86</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesMMMember"
      id="fid_1923">6/22/2024</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesNNMember"
      id="fid_1870">7/24/2017</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2022-09-30_cvm_SeriesNNMember"
      decimals="0"
      id="fid_1886"
      unitRef="Shares">200087</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2022-09-30_cvm_SeriesNNMember"
      decimals="INF"
      id="fid_1905"
      unitRef="USDPShares">2.52</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesNNMember"
      id="fid_1924">7/24/2024</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesRRMember"
      id="fid_1860">10/30/2017</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2022-09-30_cvm_SeriesRRMember"
      decimals="0"
      id="fid_1887"
      unitRef="Shares">251761</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2022-09-30_cvm_SeriesRRMember"
      decimals="INF"
      id="fid_1906"
      unitRef="USDPShares">1.65</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesRRMember"
      id="fid_1925">10/30/2022</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesSSMember"
      id="fid_1861">12/19/2017</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2022-09-30_cvm_SeriesSSMember"
      decimals="0"
      id="fid_1888"
      unitRef="Shares">200000</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2022-09-30_cvm_SeriesSSMember"
      decimals="INF"
      id="fid_1907"
      unitRef="USDPShares">2.09</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesSSMember"
      id="fid_1926">12/18/2022</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesTTMember"
      id="fid_1862">2/5/2018</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2022-09-30_cvm_SeriesTTMember"
      decimals="0"
      id="fid_1889"
      unitRef="Shares">600</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2022-09-30_cvm_SeriesTTMember"
      decimals="INF"
      id="fid_1908"
      unitRef="USDPShares">2.24</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesTTMember"
      id="fid_1927">2/5/2023</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2021-10-01to2022-09-30_cvm_ConsultantsMember_srt_MinimumMember"
      id="fid_1872">7/28/2017</cvm:Issuedate2>
    <cvm:Issuedate2
      contextRef="From2021-10-01to2022-09-30_cvm_ConsultantsOneMember_srt_MaximumMember"
      id="fid_1866">11/18/2020</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2022-09-30_cvm_ConsultantsMember_srt_MinimumMember"
      decimals="0"
      id="fid_1890"
      unitRef="Shares">15000</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2022-09-30_cvm_ConsultantsMember_srt_MinimumMember"
      decimals="INF"
      id="fid_1909"
      unitRef="USDPShares">2.18</cvm:ExercisePrice>
    <cvm:ExercisePrice
      contextRef="AsOf2022-09-30_cvm_ConsultantsOneMember_srt_MaximumMember"
      decimals="INF"
      id="fid_1901"
      unitRef="USDPShares">11.61</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2021-10-01to2022-09-30_cvm_ConsultantsMember_srt_MinimumMember"
      id="fid_1928">11/17/2022</cvm:ExpirationDate1>
    <cvm:ExpirationDate1
      contextRef="From2021-10-01to2022-09-30_cvm_ConsultantsOneMember_srt_MaximumMember"
      id="fid_1920">7/27/2027</cvm:ExpirationDate1>
    <cvm:ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1580">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05in; text-align:center;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05in; text-align:center;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series W warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Z warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;64,787&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series ZZ warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series AA warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;276,035&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series BB warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series CC warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;24,372&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series HH warrants&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,597&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net loss on warrant liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;366,791&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesWMember"
      decimals="0"
      id="fid_1932"
      unitRef="USD">0</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesWMember"
      decimals="0"
      id="fid_1933"
      unitRef="USD">0</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesZMember"
      decimals="0"
      id="fid_1934"
      unitRef="USD">0</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesZMember"
      decimals="0"
      id="fid_1935"
      unitRef="USD">64787</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesZZMember"
      decimals="0"
      id="fid_1936"
      unitRef="USD">0</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesZZMember"
      decimals="0"
      id="fid_1937"
      unitRef="USD">0</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesAAMember"
      decimals="0"
      id="fid_1938"
      unitRef="USD">0</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesAAMember"
      decimals="0"
      id="fid_1939"
      unitRef="USD">276035</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesBBMember"
      decimals="0"
      id="fid_1940"
      unitRef="USD">0</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesBBMember"
      decimals="0"
      id="fid_1941"
      unitRef="USD">0</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesCCMember"
      decimals="0"
      id="fid_1942"
      unitRef="USD">0</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesCCMember"
      decimals="0"
      id="fid_1943"
      unitRef="USD">24372</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesHHMember"
      decimals="0"
      id="fid_1944"
      unitRef="USD">0</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesHHMember"
      decimals="0"
      id="fid_1945"
      unitRef="USD">1597</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1947"
      unitRef="USD">0</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:NetLossGainOnWarrantLiabilities
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1946"
      unitRef="USD">366791</cvm:NetLossGainOnWarrantLiabilities>
    <cvm:WarrantsExpired
      contextRef="From2022-02-01to2022-02-28_cvm_SeriesAAWarrantsMember"
      decimals="0"
      id="fid_1974"
      unitRef="Shares">100000</cvm:WarrantsExpired>
    <cvm:ExercisePriceWarrants
      contextRef="From2022-02-01to2022-02-28_cvm_SeriesAAWarrantsMember"
      decimals="INF"
      id="fid_1978"
      unitRef="USDPShares">13.75</cvm:ExercisePriceWarrants>
    <cvm:WarrantsExpired
      contextRef="From2022-02-01to2022-02-28_cvm_SeriesHHWarrantsMember"
      decimals="0"
      id="fid_1975"
      unitRef="Shares">200</cvm:WarrantsExpired>
    <cvm:ExercisePriceWarrants
      contextRef="From2022-02-01to2022-02-28_cvm_SeriesHHWarrantsMember"
      decimals="INF"
      id="fid_1979"
      unitRef="USDPShares">3.13</cvm:ExercisePriceWarrants>
    <cvm:WarrantsExpired
      contextRef="From2021-12-01to2021-12-31_cvm_SeriesCCWarrantsMember"
      decimals="0"
      id="fid_1972"
      unitRef="Shares">640</cvm:WarrantsExpired>
    <cvm:ExercisePriceWarrants
      contextRef="From2021-12-01to2021-12-31_cvm_SeriesCCWarrantsMember"
      decimals="INF"
      id="fid_1976"
      unitRef="USDPShares">5.00</cvm:ExercisePriceWarrants>
    <cvm:WarrantsExpired
      contextRef="From2021-11-01to2021-11-30_cvm_SeriesZWarrantsMember"
      decimals="0"
      id="fid_1973"
      unitRef="Shares">184800</cvm:WarrantsExpired>
    <cvm:ExercisePriceWarrants
      contextRef="From2021-11-01to2021-11-30_cvm_SeriesZWarrantsMember"
      decimals="INF"
      id="fid_1977"
      unitRef="USDPShares">13.75</cvm:ExercisePriceWarrants>
    <cvm:ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1581">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrants Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series CC&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,205&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;76,025&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock>
    <cvm:WarrantsExercised
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesCCMember"
      decimals="0"
      id="fid_1949"
      unitRef="Shares">15205</cvm:WarrantsExercised>
    <cvm:ExercisePriceWarrants
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesCCMember"
      decimals="INF"
      id="fid_1950"
      unitRef="USDPShares">5.00</cvm:ExercisePriceWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesCCMember"
      decimals="0"
      id="fid_1948"
      unitRef="USD">76025</us-gaap:ProceedsFromIssuanceOfWarrants>
    <cvm:IncrementalCostDeemedDividend
      contextRef="From2022-10-01to2022-10-28_cvm_SeriesRRMember"
      decimals="0"
      id="fid_2063"
      unitRef="USD">172000</cvm:IncrementalCostDeemedDividend>
    <cvm:DeemedDividendAmount
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1980"
      unitRef="USD">294000</cvm:DeemedDividendAmount>
    <cvm:DeemedDividend11
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1971"
      unitRef="USD">635000</cvm:DeemedDividend11>
    <cvm:ScheduleOfEquityWarrantsWereExercisedTableTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1582">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrants Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;17,752&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;29,291&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series SS&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;200,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.09&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;418,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;217,752&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;447,291&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrants Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25,200&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfEquityWarrantsWereExercisedTableTextBlock>
    <cvm:EquityWarrantsExercised
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesRRMember"
      decimals="0"
      id="fid_1951"
      unitRef="Shares">17752</cvm:EquityWarrantsExercised>
    <cvm:EquityWarrantsExercisePrice
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesRRMember"
      decimals="INF"
      id="fid_1957"
      unitRef="USDPShares">1.65</cvm:EquityWarrantsExercisePrice>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesRRMember"
      decimals="0"
      id="fid_1954"
      unitRef="USD">29291</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:EquityWarrantsExercised
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesSSMember"
      decimals="0"
      id="fid_1952"
      unitRef="Shares">200000</cvm:EquityWarrantsExercised>
    <cvm:EquityWarrantsExercisePrice
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesSSMember"
      decimals="INF"
      id="fid_1958"
      unitRef="USDPShares">2.09</cvm:EquityWarrantsExercisePrice>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesSSMember"
      decimals="0"
      id="fid_1955"
      unitRef="USD">418000</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:EquityWarrantsExercised
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1961"
      unitRef="Shares">217752</cvm:EquityWarrantsExercised>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1960"
      unitRef="USD">447291</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:EquityWarrantsExercised
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesNNMember"
      decimals="0"
      id="fid_1953"
      unitRef="Shares">10000</cvm:EquityWarrantsExercised>
    <cvm:EquityWarrantsExercisePrice
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesNNMember"
      decimals="INF"
      id="fid_1959"
      unitRef="USDPShares">2.52</cvm:EquityWarrantsExercisePrice>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesNNMember"
      decimals="0"
      id="fid_1956"
      unitRef="USD">25200</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:CommonStockIssuedForServiceShares
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1963"
      unitRef="Shares">249997</cvm:CommonStockIssuedForServiceShares>
    <cvm:CommonStockIssuedForServiceShares
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1962"
      unitRef="Shares">156547</cvm:CommonStockIssuedForServiceShares>
    <us-gaap:SharePrice
      contextRef="AsOf2023-09-30_srt_MinimumMember"
      decimals="INF"
      id="fid_1970"
      unitRef="USDPShares">1.26</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2023-09-30_srt_MaximumMember"
      decimals="INF"
      id="fid_1981"
      unitRef="USDPShares">11.20</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-10-01to2023-09-30_srt_MaximumMember_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_1965"
      unitRef="USDPShares">1.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-10-01to2022-09-30_srt_MaximumMember_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_1964"
      unitRef="USDPShares">4.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:CostsAndExpenses
      contextRef="From2022-10-01to2023-09-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_1967"
      unitRef="USD">656000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2021-10-01to2022-09-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_1966"
      unitRef="USD">762000</us-gaap:CostsAndExpenses>
    <cvm:PrepaidExpenses
      contextRef="AsOf2023-09-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_1968"
      unitRef="USD">205000</cvm:PrepaidExpenses>
    <cvm:PrepaidExpenses
      contextRef="AsOf2022-09-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_1969"
      unitRef="USD">295000</cvm:PrepaidExpenses>
    <cvm:StockIssuedDuringPeriodToPurchaseCommonStock
      contextRef="From2022-10-01to2023-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember"
      decimals="0"
      id="fid_2064"
      unitRef="Shares">100000</cvm:StockIssuedDuringPeriodToPurchaseCommonStock>
    <cvm:StockOptionExercisePrice
      contextRef="From2022-10-01to2023-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember"
      decimals="INF"
      id="fid_2065"
      unitRef="USDPShares">1.39</cvm:StockOptionExercisePrice>
    <cvm:VestedOptions
      contextRef="From2022-10-01to2023-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember_cvm_TwoSeptemberTwoThousendTwentyFourMember"
      decimals="INF"
      id="fid_2066"
      unitRef="Pure">0.50</cvm:VestedOptions>
    <cvm:VestedOptions
      contextRef="From2022-10-01to2023-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember_cvm_TwoSeptemberTwoThousendTwentyFiveMember"
      decimals="INF"
      id="fid_2068"
      unitRef="Pure">0.50</cvm:VestedOptions>
    <cvm:IssuedStockOfOptionsOutstanding
      contextRef="AsOf2023-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember"
      decimals="0"
      id="fid_2069"
      unitRef="Shares">110000</cvm:IssuedStockOfOptionsOutstanding>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1552">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;5&lt;/strong&gt;&lt;strong&gt;. &lt;/strong&gt;&lt;strong&gt;PROPERTY AND &lt;/strong&gt;&lt;strong&gt;EQUIPMENT&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Property and equipment consisted of the following at September 30:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Research equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,109,070&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,095,022&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Furniture and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;99,296&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;99,296&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;13,924,724&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;13,544,394&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;18,133,090&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;17,738,712&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(7,944,964&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(5,849,683&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;10,188,126&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;11,889,029&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Depreciation expense for the years ended September 30, 2023 and 2022 totaled approximately $2,114,000 and $1,977,000 respectively.&#160; &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1583">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Research equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,109,070&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,095,022&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Furniture and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;99,296&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;99,296&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;13,924,724&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;13,544,394&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;18,133,090&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;17,738,712&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(7,944,964&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(5,849,683&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;10,188,126&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;11,889,029&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:FixturesAndEquipmentGross
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1598"
      unitRef="USD">4109070</us-gaap:FixturesAndEquipmentGross>
    <us-gaap:FixturesAndEquipmentGross
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1599"
      unitRef="USD">4095022</us-gaap:FixturesAndEquipmentGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1600"
      unitRef="USD">99296</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1601"
      unitRef="USD">99296</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1602"
      unitRef="USD">13924724</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1603"
      unitRef="USD">13544394</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1604"
      unitRef="USD">18133090</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1605"
      unitRef="USD">17738712</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1606"
      unitRef="USD">7944964</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1607"
      unitRef="USD">5849683</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1608"
      unitRef="USD">10188126</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1609"
      unitRef="USD">11889029</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1610"
      unitRef="USD">2114000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1611"
      unitRef="USD">1977000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1553">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;6&lt;/strong&gt;&lt;strong&gt;. PATENTS&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Patents consist of the following at September 30:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Patents&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;853,445&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;893,833&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(655,741&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(681,632&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Patents, net&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;197,704&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;212,201&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the years ended September 30, 2023 and 2022, there was no impairment of patent costs. The weighted average amortization period for patents&#160;is approximately 8 years. Amortization expense for the years ended September 30, 2023 and 2022 totaled approximately $38,000 and &#160;$49,000, respectively.&#160;&#160; The total estimated future amortization is as follows: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="4" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Years ending September 30, &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;32,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;29,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;22,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;19,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;71,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;198,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1584">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Patents&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;853,445&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;893,833&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(655,741&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(681,632&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Patents, net&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;197,704&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;212,201&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedPatentsGross
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1612"
      unitRef="USD">853445</us-gaap:FiniteLivedPatentsGross>
    <us-gaap:FiniteLivedPatentsGross
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1613"
      unitRef="USD">893833</us-gaap:FiniteLivedPatentsGross>
    <cvm:AccumulatedAmortization
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1615"
      unitRef="USD">-655741</cvm:AccumulatedAmortization>
    <cvm:AccumulatedAmortization
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1614"
      unitRef="USD">-681632</cvm:AccumulatedAmortization>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1617"
      unitRef="USD">197704</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1616"
      unitRef="USD">212201</us-gaap:OtherIntangibleAssetsNet>
    <cvm:PatentsWeightedAverageAmortizationPeriod contextRef="From2022-10-01to2023-09-30" id="fid_2062">P8Y</cvm:PatentsWeightedAverageAmortizationPeriod>
    <cvm:AmortizationOfPatentCosts
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1625"
      unitRef="USD">38000</cvm:AmortizationOfPatentCosts>
    <cvm:AmortizationOfPatentCosts
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1626"
      unitRef="USD">49000</cvm:AmortizationOfPatentCosts>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1585">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="4" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Years ending September 30, &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;32,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;29,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;22,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;19,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;71,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;198,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1619"
      unitRef="USD">32000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1620"
      unitRef="USD">29000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1621"
      unitRef="USD">25000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1622"
      unitRef="USD">22000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1618"
      unitRef="USD">19000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1623"
      unitRef="USD">71000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive>
    <cvm:Total
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1624"
      unitRef="USD">198000</cvm:Total>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1554">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;7&lt;/strong&gt;&lt;strong&gt;. INCOME TAXES&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;At September 30, 2023 and 2022, the Company had net deferred tax assets of $60.0 million and $52.9 million, respectively. Due to uncertainties surrounding the Company&#x2019;s ability to generate future taxable income to realize these assets, a full valuation allowance has been established to offset the net deferred tax assets. In assessing the realization of deferred tax assets, management considered whether it was more likely than not that some, or all, of the deferred tax assets will be realized.&#160; The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income.&#160; Management has considered the history of the Company&#x2019;s operating losses and believes that the realization of the benefit of the deferred tax assets cannot be reasonably assured.&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Pursuant to Section 382 of the Internal Revenue Code, or IRC, annual use of the Company&#x2019;s net operating loss (NOL) carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. Such ownership change could result in annual limitations on the utilization of tax attributes, including NOL carryforwards and tax credits. The Company performed an estimated analysis to determine if any additional ownership changes occurred during the year ended September 30, 2023 and no such changes were identified. If changes in ownership occur after year end, NOL and tax credit carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company had federal NOL carryforwards of approximately $123.1 million and $100.2 million at September 30, 2023 and 2022, respectively. Approximately $19.2 million of the NOL carryforwards begin to expire during the year ended September 30, 2023 and become fully expired by 2038 and approximately $103.9 million of NOL carryforwards, which were generated after the enactment of Tax Cuts and Jobs Act, have an indefinite life.&#160; In addition, the Company has a general business credit as a result of the credit for increasing research activities (&#x201c;R&amp;amp;D credit&#x201d;) of approximately $1.2 million at September 30, 2023 and 2022.&#160;&#160;The R&amp;amp;D credit expires during the fiscal year ended 2029.&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities as of September 30, 2023 and 2022 are listed below:&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;NOL carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;30,829,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25,346,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Capitalized R&amp;amp;D&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,196,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,042,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock-based compensation &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,579,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,442,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,400,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,872,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;R&amp;amp;D credit&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,221,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,221,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Vacation and other&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;298,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;307,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Fixed assets and intangibles&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;168,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;62,691,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;56,230,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Right of use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(2,713,000&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(3,244,000&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Fixed assets and intangibles&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(44,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,713,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(3,288,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net deferred tax asset&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;59,978,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;52,942,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(59,978,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(52,942,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company has no federal or state current or deferred tax expense or benefit.&#160; The Company&#x2019;s effective tax rate differs from the applicable federal statutory tax rate.&#160; The reconciliation of these rates is as follows for the years ended September 30:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Federal rate&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;State rate change &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1.58&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1.67&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;State tax rate, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.05&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.34&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Other adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1.62&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(0.28&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.21&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(21.85&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(23.61&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Effective tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company applies the provisions of ASC 740, &lt;em&gt;Accounting for Uncertainty in Income Taxes,&lt;/em&gt; which requires financial statement benefits to be recognized for positions taken for tax return purposes when it is more likely than not that the position will be sustained.&#160; The Company has elected to reflect any tax penalties or interest resulting from tax assessments on uncertain tax positions as a component of tax expense.&#160; The Company has generated federal net operating losses in tax years ending September 30, 1999 through 2023.&#160;&#160;The Company files income tax returns in the U.S. federal jurisdiction and various states. With few exceptions, the Company is no longer subject to U.S. federal and state income tax examinations by tax authorities for years before September 30, 2020. &lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <cvm:DeferredTaxAssets
      contextRef="AsOf2023-09-30"
      decimals="-5"
      id="fid_1677"
      unitRef="USD">60000000.0</cvm:DeferredTaxAssets>
    <cvm:DeferredTaxAssets
      contextRef="AsOf2022-09-30"
      decimals="-5"
      id="fid_1676"
      unitRef="USD">52900000</cvm:DeferredTaxAssets>
    <cvm:CumulativeChangeInOwnershipPercentage
      contextRef="From2022-10-01to2023-09-30_cvm_IncomeTaxMember"
      id="fid_1674">net operating loss (NOL) carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period</cvm:CumulativeChangeInOwnershipPercentage>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-09-30_cvm_IncomeTaxMember"
      decimals="-5"
      id="fid_1672"
      unitRef="USD">123100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2022-09-30_cvm_IncomeTaxMember"
      decimals="-5"
      id="fid_1671"
      unitRef="USD">100200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardDescription
      contextRef="From2022-10-01to2023-09-30_cvm_IncomeTaxMember"
      id="fid_1675">Approximately $19.2 million of the NOL carryforwards begin to expire during the year ended September 30, 2023 and become fully expired by 2038 and approximately $103.9 million of NOL carryforwards</us-gaap:TaxCreditCarryforwardDescription>
    <cvm:ResearchAndDevelopmentCredit
      contextRef="AsOf2023-09-30_cvm_IncomeTaxMember"
      decimals="-5"
      id="fid_1670"
      unitRef="USD">1200000</cvm:ResearchAndDevelopmentCredit>
    <cvm:ResearchAndDevelopmentCreditDescription
      contextRef="From2022-10-01to2023-09-30_cvm_IncomeTaxMember"
      id="fid_1673">The R&amp;D credit expires during the fiscal year ended 2029</cvm:ResearchAndDevelopmentCreditDescription>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1586">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;NOL carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;30,829,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25,346,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Capitalized R&amp;amp;D&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,196,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,042,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock-based compensation &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,579,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,442,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,400,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,872,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;R&amp;amp;D credit&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,221,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,221,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Vacation and other&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;298,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;307,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Fixed assets and intangibles&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;168,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;62,691,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;56,230,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Right of use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(2,713,000&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(3,244,000&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Fixed assets and intangibles&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(44,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,713,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(3,288,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net deferred tax asset&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;59,978,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;52,942,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(59,978,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(52,942,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1627"
      unitRef="USD">30829000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1628"
      unitRef="USD">25346000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <cvm:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1635"
      unitRef="USD">15196000</cvm:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd>
    <cvm:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1636"
      unitRef="USD">15042000</cvm:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1633"
      unitRef="USD">11579000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1634"
      unitRef="USD">10442000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <cvm:LeaseLiabilities
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1629"
      unitRef="USD">3400000</cvm:LeaseLiabilities>
    <cvm:LeaseLiabilities
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1630"
      unitRef="USD">3872000</cvm:LeaseLiabilities>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1631"
      unitRef="USD">1221000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1632"
      unitRef="USD">1221000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1637"
      unitRef="USD">298000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1638"
      unitRef="USD">307000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
    <cvm:FixedAssetsAndIntangiblesAssets
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1653"
      unitRef="USD">168000</cvm:FixedAssetsAndIntangiblesAssets>
    <cvm:FixedAssetsAndIntangiblesAssets
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1654"
      unitRef="USD">0</cvm:FixedAssetsAndIntangiblesAssets>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1639"
      unitRef="USD">62691000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1640"
      unitRef="USD">56230000</us-gaap:DeferredTaxAssetsGross>
    <cvm:RightOfUseAssets
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1641"
      unitRef="USD">-2713000</cvm:RightOfUseAssets>
    <cvm:RightOfUseAssets
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1642"
      unitRef="USD">-3244000</cvm:RightOfUseAssets>
    <cvm:FixedAssetsAndIntangibles
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1643"
      unitRef="USD">0</cvm:FixedAssetsAndIntangibles>
    <cvm:FixedAssetsAndIntangibles
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1644"
      unitRef="USD">-44000</cvm:FixedAssetsAndIntangibles>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1645"
      unitRef="USD">2713000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1646"
      unitRef="USD">3288000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1647"
      unitRef="USD">59978000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1648"
      unitRef="USD">52942000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1649"
      unitRef="USD">59978000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1650"
      unitRef="USD">52942000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1651"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1652"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1587">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 12.6pt; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Federal rate&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;State rate change &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1.58&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1.67&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;State tax rate, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.05&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.34&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Other adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1.62&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(0.28&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.21&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(21.85&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(23.61&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Effective tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1655"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      id="fid_1656"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1658"
      unitRef="Pure">-0.0158</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      id="fid_1657"
      unitRef="Pure">-0.0167</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1660"
      unitRef="Pure">0.0405</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      id="fid_1659"
      unitRef="Pure">0.0434</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1662"
      unitRef="Pure">-0.0162</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      id="fid_1661"
      unitRef="Pure">-0.0028</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1664"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      id="fid_1663"
      unitRef="Pure">0.0021</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1666"
      unitRef="Pure">-0.2185</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      id="fid_1665"
      unitRef="Pure">-0.2361</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      id="fid_1667"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1668"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1555">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;8&lt;/strong&gt;&lt;strong&gt;.&lt;/strong&gt;&#160; &lt;strong&gt;EQUITY-BASED&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&lt;strong&gt;COMPENSATION&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company recognized the following expenses for options issued or vested and restricted stock awarded during the year:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Year Ended September 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,286,231&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,389,932&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;655,740&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;762,261&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"&gt;As of September 30, 2023, the total compensation cost related to non-vested options and restricted stock awarded to employees and non-employees not yet recognized was approximately $6.9 million and $0.3 million, respectively, and the weighted-average period over which it is expected to be recognized is 1.78 and 0.94 years, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the years ended September 30, 2023 and 2022 the fair value of each option grant was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Expected stock price volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;99.18 &#x2013; 100.18%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;96.37 &#x2013; 99.26%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;3.41 &#x2013; 4.25%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.50 &#x2013; 3.43%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Expected life of options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;9.63 &#x2013; 9.66 years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;9.67 &#x2013; 9.69 years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Non-Qualified Stock Option Plan&lt;/span&gt;&lt;span style="text-decoration:underline"&gt;s&lt;/span&gt;&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the year ended September 30, 2023, the Company adopted the 2023 Non-Qualified Stock Option Plan, which provides for the issuance of up to 2,000,000 options to purchase shares of common stock.&#160; On August 8, 2023, the Company granted 1,958,500 options to purchase shares of common stock from the 2023 Non-Qualified Stock Option Plan to officers, directors and employees.&#160; Each option entitles the holder to purchase one share of the Company&#x2019;s common stock at a price of $1.36 per share, vests in three equal annual installments commencing one year after the grant date and expires on August 7, 2033.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the year ended September 30, 2022, the Company adopted the 2022 Non-Qualified Stock Option Plan, which provides for the issuance of up to 2,000,000 options to purchase shares of common stock.&#160; On November 19, 2021, the Company granted 250,000 performance-based stock options from the 2020 Non-Qualified Stock Option Plan to officers. Each option entitles the holder to purchase one share of the Company&#x2019;s common stock at a price of $10.48 per share, the fair value on the date of issuance. The stock options will vest 100% upon approval of the first marketing application for any pharmaceutical based upon the Company&#x2019;s Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia.&#160; None of the options will be exercisable before November 19, 2022.&#160; All options which have not vested as of November 18, 2031 will be canceled.&#160; On the grant date, the options were valued using a Monte Carlo Simulation approach. A Monte Carlo Simulation is a statistical technique that is used to model probabilistic systems and establish the probabilities for a variety of outcomes. However, because attainment of the performance condition cannot be considered probable, no compensation cost was recognized relating to these options as of September 30, 2023.&#160; Management will re-assess the probability of achieving the performance condition at each reporting date.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;At September 30, 2023, the Company has collectively authorized the issuance of 15,787,200 options to purchase shares of common stock under its Non-Qualified Stock Option Plans. Options typically vest over a three-year period and expire no later than ten years after the grant date. Terms of the options were determined by the Company&#x2019;s Compensation Committee which administers the plans. The Company&#x2019;s employees, directors, officers, and consultants or advisors are eligible to be granted options under the Non-Qualified Stock Option Plans.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Incentive Stock Option Plan&lt;/span&gt;&lt;span style="text-decoration:underline"&gt;s&lt;/span&gt; &#x2013; At September 30, 2023, the Company had collectively authorized the issuance of 138,400 options to purchase shares of common stock under its Incentive Stock Option Plans.&#160; Options typically vest over a three-year period and expire no later than ten years after the grant date.&#160; Terms of the options were determined by the Company&#x2019;s Compensation Committee which administers the Plans.&#160; Only the Company&#x2019;s employees are eligible to be granted options under the Incentive Stock Option Plans.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Activity in the Company&#x2019;s Non-Qualified and Incentive Stock Option Plans for the two years ended September 30, 2023 is summarized as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Non-Qualified and Incentive Stock Option Plans&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Outstanding&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Exercisable&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Number of Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Remaining Contractual Term (Years)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Aggregate Intrinsic Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Number of Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Remaining Contractual Term (Years)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Aggregate Intrinsic Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Outstanding at September 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;11,049,709&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;10.08&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;7.93&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;54,843,283&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;5,540,028&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;5.77&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6.96&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;43,589,598&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;-&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;1,547,703&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;8.60&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Granted(a)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;2,040,750&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;4.24&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;-&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;(6,500&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;4.59&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;45,725&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;(6,500&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;4.59&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;(106,331&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;11.53&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;-&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;(13,614&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;97.50&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;(13,614&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;97.50&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Outstanding at September 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;12,964,014&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;9.06&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;7.35&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;1,866,240&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;7,067,617&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6.21&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6.21&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;1,866,105&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;952,256&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;8.41&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Granted (b)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;2,065,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;1.37&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;213,165&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;9.19&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;-&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;(58,791&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;61.05&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;(58,791&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;61.05&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Outstanding at September 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"&gt;14,757,558&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;7.78&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6.81&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"&gt;7,961,082&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6.07&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;5.60&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;(a)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;The weighted average grant date fair value was $3.01.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;(b)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Includes 1,965,500 performance based options issued to officers and directors, 100,000 options issued to consultants. The weighted average grant date fair value was $1.22.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;A summary of the status of the Company&#x2019;s un-vested options for the two years ended September 30, 2023 is presented below:&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Number of &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Options&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Grant Date Fair Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested at September 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,509,681&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5.17&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1,547,703&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7.37&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,040,750&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(106,331&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested at September 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;5,896,397&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.63&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(952,256&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7.30&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,065,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(213,165&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested at September 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;6,796,476&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.25&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Incentive Stock Bonus Plan&lt;/span&gt; &#x2013; On September 30, 2023, 610,500 of the shares granted under the 2014 Incentive Stock Bonus Plan remain outstanding, of which 463,250 shares are fully vested.&#160; During the year ended September 30, 2023, 4,000 unvested shares were forfeited. The shares are being earned upon the achievement of certain milestones leading to the commercialization of the Company&#x2019;s Multikine technology, or specified increases in the market price of the Company&#x2019;s stock.&#160; The fair value of the shares on the grant date was calculated using the market value on the grant-date for issuances where the attainment of performance criteria is likely and using a Monte Carlo Simulation for issuances where the attainment of performance criteria is uncertain.&#160; The grant date fair value of shares issued that remain outstanding as of September 30, 2023 was approximately $8.6 million.&#160; The total value of the shares, if earned, is being expensed over the requisite service periods for each milestone, provided the requisite service periods are rendered, regardless of whether the market conditions are met.&#160; No compensation cost is recognized for awards where the requisite service period is not rendered.&#160; During the years ended September 30, 2023 and 2022, the Company recorded expense relating to the issuance of restricted stock pursuant to the plan of approximately $(22,000) and $45,000, respectively.&#160; As of September 30, 2023, all compensation expense related to the 2014 Incentive Stock Bonus Plan has been fully recognized. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;A summary of the status of the Company&#x2019;s restricted common stock issued from the Incentive Stock Bonus Plan for the two years ended September 30, 2023 is presented below: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Number of &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Weighted Average Grant Date Fair Value&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Unvested at September 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;151,250&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0px; text-align:justify;"&gt;Unvested at September 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;151,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(4,000&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Unvested at September 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;147,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Stock Bonus Plans&lt;/span&gt;&lt;span style="text-decoration:underline"&gt; &lt;/span&gt;&#x2013; As of September 30, 2023, the Company authorized to issue up to 1,283,760 shares of common stock from the Stock Bonus Plans and has issued a total of 512,972 shares of common stock under its Stock Bonus Plans.&#160; All employees, directors, officers, consultants, and advisors are eligible to be granted shares.&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Stock Compensation Plans&lt;/span&gt; &#x2013; On September 30, 2023, 634,000 shares were authorized for issuance pursuant to the &#160;Company&#x2019;s Stock Compensation Plans, of which 153,195 shares were issued and outstanding.&#160; No shares were issued from the Stock Compensation Plans during the years ended September 30, 2023 and 2022.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1588">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Year Ended September 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,286,231&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,389,932&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;655,740&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;762,261&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1679"
      unitRef="USD">6286231</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1678"
      unitRef="USD">11389932</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1681"
      unitRef="USD">655740</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1680"
      unitRef="USD">762261</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-10-01to2023-09-30_cvm_NonVestedOptionsMember"
      decimals="-5"
      id="fid_2072"
      unitRef="USD">6900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-10-01to2023-09-30_cvm_RestrictedStockAwardsMember"
      decimals="-5"
      id="fid_2070"
      unitRef="USD">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2022-10-01to2023-09-30_cvm_NonVestedOptionsMember"
      id="fid_2074">P1Y9M10D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2022-10-01to2023-09-30_cvm_RestrictedStockAwardsMember"
      id="fid_2073">P0Y11M8D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1589">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Expected stock price volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;99.18 &#x2013; 100.18%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;96.37 &#x2013; 99.26%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;3.41 &#x2013; 4.25%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.50 &#x2013; 3.43%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Expected life of options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;9.63 &#x2013; 9.66 years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;9.67 &#x2013; 9.69 years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1683"
      unitRef="Pure">0.9918</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1685"
      unitRef="Pure">1.0018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      id="fid_1682"
      unitRef="Pure">0.9637</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      id="fid_1684"
      unitRef="Pure">0.9926</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1687"
      unitRef="Pure">0.0341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1689"
      unitRef="Pure">0.0425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      id="fid_1686"
      unitRef="Pure">0.0150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      id="fid_1688"
      unitRef="Pure">0.0343</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <cvm:ExpectedLifeOfOptionsMin1 contextRef="From2022-10-01to2023-09-30" id="fid_1691">P9Y7M17D</cvm:ExpectedLifeOfOptionsMin1>
    <cvm:ExpectedLifeOfOptionsMax contextRef="From2022-10-01to2023-09-30" id="fid_1692">P9Y7M28D</cvm:ExpectedLifeOfOptionsMax>
    <cvm:ExpectedLifeOfOptionsMin1 contextRef="From2021-10-01to2022-09-30" id="fid_1690">P9Y8M1D</cvm:ExpectedLifeOfOptionsMin1>
    <cvm:ExpectedLifeOfOptionsMax contextRef="From2021-10-01to2022-09-30" id="fid_1693">P9Y8M8D</cvm:ExpectedLifeOfOptionsMax>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1694"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      id="fid_1695"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2023-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_1791"
      unitRef="Shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <cvm:PerformanceBasedStockOptionsSharesGranted
      contextRef="AsOf2023-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_1788"
      unitRef="Shares">1958500</cvm:PerformanceBasedStockOptionsSharesGranted>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1
      contextRef="From2022-10-01to2023-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="INF"
      id="fid_1783"
      unitRef="USDPShares">1.36</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2022-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_1792"
      unitRef="Shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <cvm:PerformanceBasedStockOptionsSharesGranted
      contextRef="AsOf2022-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_1782"
      unitRef="Shares">250000</cvm:PerformanceBasedStockOptionsSharesGranted>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1
      contextRef="From2021-10-01to2022-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="INF"
      id="fid_1784"
      unitRef="USDPShares">10.48</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
    <us-gaap:ConversionOfStockDescription
      contextRef="From2021-10-01to2022-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      id="fid_1790">The stock options will vest 100% upon approval of the first marketing application for any pharmaceutical based upon the Company&#x2019;s Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia</us-gaap:ConversionOfStockDescription>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_1777"
      unitRef="Shares">15787200</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-09-30_cvm_IncentiveStockOptionPlansMember"
      decimals="0"
      id="fid_1778"
      unitRef="Shares">138400</us-gaap:CommonStockSharesAuthorized>
    <cvm:ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1590">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Outstanding&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Exercisable&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Number of Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Remaining Contractual Term (Years)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Aggregate Intrinsic Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Number of Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Remaining Contractual Term (Years)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Aggregate Intrinsic Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Outstanding at September 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;11,049,709&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;10.08&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;7.93&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;54,843,283&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;5,540,028&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;5.77&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6.96&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;43,589,598&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;-&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;1,547,703&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;8.60&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Granted(a)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;2,040,750&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;4.24&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;-&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;(6,500&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;4.59&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;45,725&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;(6,500&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;4.59&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;(106,331&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;11.53&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;-&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;(13,614&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;97.50&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;(13,614&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;97.50&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Outstanding at September 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;12,964,014&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;9.06&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;7.35&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;1,866,240&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;7,067,617&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6.21&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6.21&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;1,866,105&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;952,256&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;8.41&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Granted (b)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;2,065,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;1.37&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;213,165&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;9.19&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;-&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;(58,791&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;61.05&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;(58,791&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;61.05&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Outstanding at September 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"&gt;14,757,558&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;7.78&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6.81&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"&gt;7,961,082&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6.07&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;5.60&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1698"
      unitRef="Shares">11049709</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1712"
      unitRef="USDPShares">10.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2021-10-01to2022-09-30_cvm_OutstandingMember"
      id="fid_1721">P7Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2021-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_2077"
      unitRef="USD">54843283</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_1699"
      unitRef="Shares">5540028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_cvm_ExercisableMember"
      decimals="INF"
      id="fid_1713"
      unitRef="USDPShares">5.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning
      contextRef="From2021-10-01to2022-09-30_cvm_ExercisableMember"
      id="fid_1722">P6Y11M15D</cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2021-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_2081"
      unitRef="USD">43589598</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <cvm:NumberOfOptionsVested
      contextRef="AsOf2021-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_1743"
      unitRef="Shares">1547703</cvm:NumberOfOptionsVested>
    <cvm:WeightedAverageExercisePriceVested
      contextRef="AsOf2021-09-30_cvm_ExercisableMember"
      decimals="INF"
      id="fid_1745"
      unitRef="USDPShares">8.60</cvm:WeightedAverageExercisePriceVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-10-01to2022-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1734"
      unitRef="Shares">2040750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-10-01to2022-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1739"
      unitRef="USDPShares">4.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-10-01to2022-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1703"
      unitRef="Shares">6500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-10-01to2022-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1715"
      unitRef="USDPShares">4.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <cvm:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised
      contextRef="From2021-10-01to2022-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_2079"
      unitRef="USD">45725</cvm:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised>
    <cvm:NumberOfOptionsExercised
      contextRef="From2021-10-01to2022-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_1704"
      unitRef="Shares">-6500</cvm:NumberOfOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-10-01to2022-09-30_cvm_ExercisableMember"
      decimals="INF"
      id="fid_1716"
      unitRef="USDPShares">4.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2021-10-01to2022-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1733"
      unitRef="Shares">106331</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2021-10-01to2022-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1738"
      unitRef="USDPShares">11.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2021-10-01to2022-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1707"
      unitRef="Shares">13614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-10-01to2022-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1719"
      unitRef="USDPShares">97.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <cvm:NumberOfOptions
      contextRef="From2021-10-01to2022-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_1708"
      unitRef="Shares">-13614</cvm:NumberOfOptions>
    <cvm:WeightedAverageExercisePriceExpired
      contextRef="From2021-10-01to2022-09-30_cvm_ExercisableMember"
      decimals="INF"
      id="fid_1720"
      unitRef="USDPShares">97.50</cvm:WeightedAverageExercisePriceExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1696"
      unitRef="Shares">12964014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1710"
      unitRef="USDPShares">9.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2021-10-01to2022-09-30_cvm_OutstandingMember"
      id="fid_1724">P7Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2022-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_2078"
      unitRef="USD">1866240</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_1697"
      unitRef="Shares">7067617</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_cvm_ExercisableMember"
      decimals="INF"
      id="fid_1711"
      unitRef="USDPShares">6.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding
      contextRef="From2021-10-01to2022-09-30_cvm_ExercisableMember"
      id="fid_1723">P6Y2M15D</cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2022-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_2083"
      unitRef="USD">1866105</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <cvm:NumberOfOptionsVested
      contextRef="AsOf2022-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_1700"
      unitRef="Shares">952256</cvm:NumberOfOptionsVested>
    <cvm:WeightedAverageExercisePriceVested
      contextRef="AsOf2022-09-30_cvm_ExercisableMember"
      decimals="INF"
      id="fid_1714"
      unitRef="USDPShares">8.41</cvm:WeightedAverageExercisePriceVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1736"
      unitRef="Shares">2065500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1741"
      unitRef="USDPShares">1.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1735"
      unitRef="Shares">213165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1740"
      unitRef="USDPShares">9.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1705"
      unitRef="Shares">58791</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1717"
      unitRef="USDPShares">61.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <cvm:NumberOfOptions
      contextRef="From2022-10-01to2023-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_1706"
      unitRef="Shares">-58791</cvm:NumberOfOptions>
    <cvm:WeightedAverageExercisePriceExpired
      contextRef="From2022-10-01to2023-09-30_cvm_ExercisableMember"
      decimals="INF"
      id="fid_1718"
      unitRef="USDPShares">61.05</cvm:WeightedAverageExercisePriceExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1746"
      unitRef="Shares">14757558</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1747"
      unitRef="USDPShares">7.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember"
      id="fid_1725">P6Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2023-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_2076"
      unitRef="USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_1709"
      unitRef="Shares">7961082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-09-30_cvm_ExercisableMember"
      decimals="INF"
      id="fid_1748"
      unitRef="USDPShares">6.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding
      contextRef="From2022-10-01to2023-09-30_cvm_ExercisableMember"
      id="fid_1726">P5Y7M6D</cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2023-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_2082"
      unitRef="USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1592">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Number of &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Options&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Grant Date Fair Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested at September 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,509,681&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5.17&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1,547,703&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7.37&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,040,750&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(106,331&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested at September 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;5,896,397&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.63&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(952,256&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7.30&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,065,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(213,165&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested at September 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;6,796,476&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.25&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1750"
      unitRef="Shares">5509681</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2021-09-30"
      decimals="INF"
      id="fid_1761"
      unitRef="USDPShares">5.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1753"
      unitRef="Shares">1547703</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <cvm:WeightedAverageGrantDateFairValueVested
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      id="fid_2085"
      unitRef="USDPShares">7.37</cvm:WeightedAverageGrantDateFairValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1755"
      unitRef="Shares">2040750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1757"
      unitRef="Shares">106331</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1751"
      unitRef="Shares">5896397</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-09-30"
      decimals="INF"
      id="fid_1760"
      unitRef="USDPShares">3.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1752"
      unitRef="Shares">952256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <cvm:WeightedAverageGrantDateFairValueVested
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_2084"
      unitRef="USDPShares">7.30</cvm:WeightedAverageGrantDateFairValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1754"
      unitRef="Shares">2065500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1756"
      unitRef="Shares">213165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1758"
      unitRef="Shares">6796476</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="fid_1762"
      unitRef="USDPShares">2.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-09-30_cvm_IncentiveStockBonusPlanMember"
      decimals="0"
      id="fid_1779"
      unitRef="Shares">610500</us-gaap:CommonStockSharesAuthorized>
    <cvm:VestedShares
      contextRef="From2022-10-01to2023-09-30_cvm_IncentiveStockBonusPlanMember"
      decimals="0"
      id="fid_1786"
      unitRef="Shares">463250</cvm:VestedShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="From2022-10-01to2023-09-30_cvm_IncentiveStockBonusPlanMember"
      decimals="0"
      id="fid_1793"
      unitRef="Shares">4000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <cvm:RemainingOutstandingFairValueOfShares
      contextRef="AsOf2023-09-30_cvm_IncentiveStockBonusPlanMember"
      decimals="-5"
      id="fid_1785"
      unitRef="USD">8600000</cvm:RemainingOutstandingFairValueOfShares>
    <us-gaap:DeferredCompensationEquity
      contextRef="AsOf2023-09-30_cvm_IncentiveStockBonusPlanMember"
      decimals="0"
      id="fid_1787"
      unitRef="USD">22000</us-gaap:DeferredCompensationEquity>
    <us-gaap:DeferredCompensationEquity
      contextRef="AsOf2022-09-30_cvm_IncentiveStockBonusPlanMember"
      decimals="-3"
      id="fid_1789"
      unitRef="USD">45000000</us-gaap:DeferredCompensationEquity>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_2061">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Number of &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Weighted Average Grant Date Fair Value&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Unvested at September 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;151,250&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0px; text-align:justify;"&gt;Unvested at September 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;151,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(4,000&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:justify;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Unvested at September 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;147,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2021-09-30_cvm_RestrictedStockAwardsMember"
      decimals="0"
      id="fid_1764"
      unitRef="Shares">151250</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2021-09-30_cvm_RestrictedStockAwardsMember"
      decimals="INF"
      id="fid_1772"
      unitRef="USDPShares">13.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2022-09-30_cvm_RestrictedStockAwardsMember"
      decimals="0"
      id="fid_1765"
      unitRef="Shares">151250</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-09-30_cvm_RestrictedStockAwardsMember"
      decimals="INF"
      id="fid_1773"
      unitRef="USDPShares">13.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="From2022-10-01to2023-09-30_cvm_RestrictedStockAwardsMember"
      decimals="0"
      id="fid_1766"
      unitRef="Shares">4000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2023-09-30_cvm_RestrictedStockAwardsMember"
      decimals="0"
      id="fid_1770"
      unitRef="Shares">147250</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-09-30_cvm_RestrictedStockAwardsMember"
      decimals="INF"
      id="fid_1774"
      unitRef="USDPShares">13.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-09-30_cvm_StockBonusPlansMember"
      decimals="0"
      id="fid_1780"
      unitRef="Shares">1283760</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-09-30_cvm_StockBonusPlansMember"
      decimals="0"
      id="fid_1775"
      unitRef="Shares">512972</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-09-30_cvm_StockCompensationPlansMember"
      decimals="0"
      id="fid_1781"
      unitRef="Shares">634000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-09-30_cvm_StockCompensationPlansMember"
      decimals="0"
      id="fid_1776"
      unitRef="Shares">153195</us-gaap:CommonStockSharesIssued>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1556">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;9&lt;/strong&gt;&lt;strong&gt;. EMPLOYEE BENEFIT PLAN&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company maintains a defined contribution retirement plan, qualifying under Section 401(k) of the Internal Revenue Code, subject to the Employee Retirement Income Security Act of 1974, as amended, and covering substantially all Company employees. Each participant&#x2019;s contribution is matched by the Company with shares of common stock that have a value equal to 100% of the participant&#x2019;s contribution, not to exceed the lesser of $10,000 or 6% of the participant&#x2019;s total compensation. The Company&#x2019;s contribution of common stock is valued each quarter based upon the closing bid price of the Company&#x2019;s common stock. During the year ended September 30, 2023, 97,004 shares were issued to the Company&#x2019;s 401(k) plan for a cost of approximately $208,000. During the year ended September 30, 2022, 52,882 shares were issued to the Company&#x2019;s 401(k) plan for a cost of approximately $223,000.&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <cvm:TotalCompensation
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1984"
      unitRef="USD">10000</cvm:TotalCompensation>
    <cvm:ParticipantCompensation
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1985"
      unitRef="Pure">0.06</cvm:ParticipantCompensation>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1987"
      unitRef="Shares">97004</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1983"
      unitRef="USD">208000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1986"
      unitRef="Shares">52882</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1982"
      unitRef="USD">223000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1557">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;10&lt;/strong&gt;&lt;strong&gt;. COMMITMENTS AND CONTINGENCIES&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Clinical Research Agreements&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In April 2013, the Company entered into a co-development and revenue sharing agreement with Ergomed. Under the agreement, Ergomed will contribute up to $10 million towards the Company&#x2019;s Phase III clinical study in the form of offering discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. In October 2015, the Company entered into a second co-development and revenue sharing agreement with Ergomed for an additional $2 million, for a total of $12 million. The Company accounted for the co-development and revenue sharing agreement in accordance with ASC 808, &lt;em&gt;Collaborative Arrangements&lt;/em&gt;. The Company determined the payments to Ergomed are within the scope of ASC 730, &lt;em&gt;Research and Development&lt;/em&gt;. Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its Statements of Operations. Since the Company entered into the co-development and revenue sharing agreement with Ergomed, it has incurred research and development expenses of approximately $35.7 million related to Ergomed&#x2019;s services. This amount is net of Ergomed&#x2019;s discount of approximately $11.8 million. During the years ended September 30, 2023 and 2022, the Company recorded approximately $0.2 million and $0.5 million, respectively, as research and development expense related to Ergomed&#x2019;s services. These amounts were net of Ergomed&#x2019;s discount of approximately $0.1 million during both the years ended September 30, 2023 and 2022.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Lease Agreements&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#x2019;s specifications so that it can be used by the Company to manufacture Multikine for the Company&#x2019;s Phase III clinical trial and sales of the drug if approved by the FDA or regulators in Canada, the UK or Europe. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. &#160;The renewal options are not included in the calculation of the right of use asset and lease liability because exercise of those options is not reasonably certain.&#160;&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;As of September 30, 2023 and 2022, respectively, the net book value of the finance lease right of use asset is approximately $9.1 million and $10.9 million and the balance of the finance lease liability is approximately $11.7 million and $13.3 million, of which approximately $1.8 million and $1.6 million is current.&#160; These amounts include the San Tomas lease as well as several other smaller finance leases for office equipment.&#160; During the years ended September 30, 2023 and 2022, the finance right of use assets are being depreciated using a straight-line method over the underlying lease terms and depreciation expense totaled approximately $1.8 million and $1.8 million, respectively. Total cash paid related to finance leases during the years ended September 30, 2023 and 2022, respectively, was approximately $2.6 million and $2.5 million, of which approximately $1.1 million and $1.2 million was for interest in both years. The weighted average discount rate of the Company&#x2019;s finance leases is 8.44% and the weighted average time to maturity is 5.09 years.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In August 2020, the Company entered into an amendment to the San Tomas lease agreement under which the landlord agreed to allow the Company to substantially upgrade the manufacturing facility in preparation for the potential commercial production of Multikine. The upgrades were completed and the improvements were placed in service in October 2021.&#160; The total cost of the upgrades was $11.1 million. &#160;The landlord agreed to finance the final $2.4 million of the costs incurred which will be repaid through increased lease payments over the remaining lease term starting on March 1, 2021.&#160; The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year.&#160; The Company remeasured the lease liability to account for the modified payments using an 8.45% incremental borrowing rate (IBR).&#160;The rate was determined using a synthetic credit rating analysis prepared by an outside valuation specialist.&#160; Additionally, this financing is considered to be a lease incentive from the landlord and has been included in the calculation of the lease liability as it is realized.&#160; The entire $2.4 million was received from the landlord as of September 30, 2022. The leasehold improvements are recorded in property and equipment and are being amortized over the remaining lease term.&#160; &lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px"&gt;During June 2021, the Company determined that it used an incorrect discount rate to calculate the opening ROU asset and lease liability balances upon adoption of ASC 842. Management engaged an outside valuation specialist to perform a synthetic credit rating analysis which resulted in a revised rate to be used upon adoption of ASC 842 of 10.19% compared to the previously used rate of 8.80%. This change resulted in an immaterial difference to the September 30, 2020 financial statements, and was corrected in the quarterly period ended June 30, 2021 as an out of period adjustment.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company was required to deposit the equivalent of one year of base rent in accordance with the original lease.&#160; Because the Company met the minimum cash balance required by the lease, the full balance of the deposit was returned to the Company in January 2022. However, on January 11, 2023, the Company was required to deposit approximately $2.3&#160;million to its landlord, equivalent to one year&#x2019;s rent, for falling back below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Approximate future minimum lease payments under finance leases as of September 30, 2023 are as follows:&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,655,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,740,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,832,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,923,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,015,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;252,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;14,417,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,696,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of lease finance lease obligations &#x2013; current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,772,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of lease finance lease obligations &#x2013; non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;9,949,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company leases two facilities under operating leases.&#160; The lease for the Company&#x2019;s office headquarters will expire on November 30, 2025.&#160; The lease for its research and development laboratory and will expire on February 29, 2032. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;As of September 30, 2023, the net book value of the operating lease right of use asset is approximately $1.7 million and the balance of the operating lease liability is approximately $1.9 million, of which approximately $0.2 million is current.&#160; As of September 30, 2022, the net book value of the operating lease right of use asset is approximately $1.9 million and the balance of the operating lease liability is approximately $2.1 million, of which approximately $0.2 million is current.&#160; During the years ended September 30, 2023 and 2022 the Company incurred lease expense under operating leases of approximately $0.4 million each year. Total cash paid related to operating leases during the years ended September 30, 2023 and 2022 was approximately $0.3 million each year.&#160; The weighted average discount rate of the Company&#x2019;s operating leases is 10.2% and the weighted average time to maturity is 7.74 years. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;As of September 30, 2023, future minimum lease payments on operating leases are as follows: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;357,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;366,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;287,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;277,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;285,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,040,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,612,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(762,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligation &#x2013; current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;197,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligation &#x2013; non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,653,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Vendor Obligations&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company has contingent obligations with vendors for work that will be completed in relation to the Phase III clinical trial.&#160; The timing of these obligations cannot be determined at this time.&#160; The Company estimates it will incur additional expenses of approximately $0.7 million for the remainder of the Phase III clinical trial and the filing of the clinical study report with the FDA.&#160; This estimate is based only on the information currently available from the Clinical Research Organizations responsible for managing the Phase III clinical trial and does not include other related costs.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <cvm:ClinicalServiceTrial
      contextRef="From2022-10-01to2023-09-30_cvm_ErgomedMember"
      decimals="-6"
      id="fid_2013"
      unitRef="USD">10000000</cvm:ClinicalServiceTrial>
    <cvm:AdditionalClinicalTrial
      contextRef="From2022-10-01to2023-09-30_cvm_ErgomedMember"
      decimals="-6"
      id="fid_2014"
      unitRef="USD">2000000</cvm:AdditionalClinicalTrial>
    <cvm:CashPaymentForOperatingLeases
      contextRef="AsOf2022-09-30_us-gaap_OperatingExpenseMember"
      decimals="-6"
      id="fid_2035"
      unitRef="USD">12000000</cvm:CashPaymentForOperatingLeases>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2022-10-01to2023-09-30"
      decimals="-5"
      id="fid_2015"
      unitRef="USD">35700000</us-gaap:OtherResearchAndDevelopmentExpense>
    <cvm:NetOfDiscount
      contextRef="From2022-10-01to2023-09-30"
      decimals="-5"
      id="fid_2016"
      unitRef="USD">11800000</cvm:NetOfDiscount>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2022-10-01to2023-09-30_cvm_ErgomedMember"
      decimals="-5"
      id="fid_2008"
      unitRef="USD">200000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2021-10-01to2022-09-30_cvm_ErgomedMember"
      decimals="-5"
      id="fid_2009"
      unitRef="USD">500000</us-gaap:OtherResearchAndDevelopmentExpense>
    <cvm:NetOfDiscount
      contextRef="From2022-10-01to2023-09-30_cvm_ErgomedMember"
      decimals="-5"
      id="fid_2010"
      unitRef="USD">100000</cvm:NetOfDiscount>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2022-10-01to2023-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_2018"
      unitRef="USD">9100000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2021-10-01to2022-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_2019"
      unitRef="USD">10900000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2023-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_2020"
      unitRef="USD">11700000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2022-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_2021"
      unitRef="USD">13300000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2023-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_2022"
      unitRef="USD">1800000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2022-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_2023"
      unitRef="USD">1600000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:Depreciation
      contextRef="From2021-10-01to2022-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_2025"
      unitRef="USD">1800000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2022-10-01to2023-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_2024"
      unitRef="USD">1800000</us-gaap:Depreciation>
    <cvm:CashPaymentToLeaseLiability
      contextRef="AsOf2023-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_2027"
      unitRef="USD">2600000</cvm:CashPaymentToLeaseLiability>
    <cvm:CashPaymentToLeaseLiability
      contextRef="AsOf2022-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_2028"
      unitRef="USD">2500000</cvm:CashPaymentToLeaseLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="From2022-10-01to2023-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_2026"
      unitRef="USD">1100000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="From2021-10-01to2022-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_2029"
      unitRef="USD">1200000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="From2022-10-01to2023-09-30_us-gaap_LeaseAgreementsMember"
      decimals="INF"
      id="fid_2030"
      unitRef="Pure">0.0844</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <cvm:WeightedAverageMaturityYear
      contextRef="From2022-10-01to2023-09-30_us-gaap_LeaseAgreementsMember"
      id="fid_2017">P5Y1M2D</cvm:WeightedAverageMaturityYear>
    <cvm:FinancingLeaseContractualArrangement
      contextRef="From2022-10-01to2023-09-30_cvm_LandlordMember"
      decimals="-5"
      id="fid_2011"
      unitRef="USD">11100000</cvm:FinancingLeaseContractualArrangement>
    <cvm:PaymentsMadeToLandlord
      contextRef="From2022-10-01to2023-09-30_cvm_LandlordMember"
      decimals="-5"
      id="fid_2012"
      unitRef="USD">2400000</cvm:PaymentsMadeToLandlord>
    <us-gaap:DescriptionOfLesseeLeasingArrangementsCapitalLeases
      contextRef="From2022-10-01to2023-09-30_cvm_LandlordMember"
      id="fid_2031">The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year</us-gaap:DescriptionOfLesseeLeasingArrangementsCapitalLeases>
    <cvm:IncrementalBorrowingDerivativeVariableRate
      contextRef="From2022-10-01to2023-09-30_cvm_LandlordMember"
      decimals="INF"
      id="fid_2032"
      unitRef="Pure">0.0845</cvm:IncrementalBorrowingDerivativeVariableRate>
    <us-gaap:OtherExpenses
      contextRef="From2021-10-01to2022-09-30_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="fid_2045"
      unitRef="USD">2400000</us-gaap:OtherExpenses>
    <cvm:PaymentsMadeToLandlord
      contextRef="From2023-01-01to2023-01-11_cvm_LandlordMember"
      decimals="-5"
      id="fid_2033"
      unitRef="USD">2300000</cvm:PaymentsMadeToLandlord>
    <us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1593">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,655,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,740,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,832,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,923,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,015,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;252,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;14,417,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,696,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of lease finance lease obligations &#x2013; current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,772,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of lease finance lease obligations &#x2013; non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;9,949,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1988"
      unitRef="USD">2655000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1989"
      unitRef="USD">2740000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1990"
      unitRef="USD">2832000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1991"
      unitRef="USD">2923000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1996"
      unitRef="USD">3015000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1992"
      unitRef="USD">252000</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1993"
      unitRef="USD">14417000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1994"
      unitRef="USD">2696000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:CapitalLeaseObligationsCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1995"
      unitRef="USD">1772000</us-gaap:CapitalLeaseObligationsCurrent>
    <us-gaap:CapitalLeaseObligationsNoncurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1997"
      unitRef="USD">9949000</us-gaap:CapitalLeaseObligationsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2022-10-01to2023-09-30_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="fid_2041"
      unitRef="USD">1700000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-09-30_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="fid_2039"
      unitRef="USD">1900000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-09-30_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="fid_2037"
      unitRef="USD">200000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2021-10-01to2022-09-30_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="fid_2042"
      unitRef="USD">1900000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2022-09-30_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="fid_2040"
      unitRef="USD">2100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2022-09-30_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="fid_2038"
      unitRef="USD">200000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherExpenses
      contextRef="From2022-10-01to2023-09-30_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="fid_2044"
      unitRef="USD">400000</us-gaap:OtherExpenses>
    <cvm:CashPaymentForOperatingLeases
      contextRef="AsOf2023-09-30_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="fid_2034"
      unitRef="USD">300000</cvm:CashPaymentForOperatingLeases>
    <cvm:WeightedAverageOperatingLeaseDiscountRate
      contextRef="From2022-10-01to2023-09-30_us-gaap_OperatingExpenseMember"
      decimals="INF"
      id="fid_2036"
      unitRef="Pure">0.102</cvm:WeightedAverageOperatingLeaseDiscountRate>
    <cvm:WeightedAverageOperatingLeaseMaturityYear
      contextRef="From2022-10-01to2023-09-30_us-gaap_OperatingExpenseMember"
      id="fid_2043">P7Y8M26D</cvm:WeightedAverageOperatingLeaseMaturityYear>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1594">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;357,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;366,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;287,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;277,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;285,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,040,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,612,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(762,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligation &#x2013; current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;197,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligation &#x2013; non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,653,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1998"
      unitRef="USD">357000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1999"
      unitRef="USD">366000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_2000"
      unitRef="USD">287000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_2001"
      unitRef="USD">277000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_2006"
      unitRef="USD">285000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_2002"
      unitRef="USD">1040000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <cvm:LesseeOperatingLeaseLiabilityPayments
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_2003"
      unitRef="USD">2612000</cvm:LesseeOperatingLeaseLiabilityPayments>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_2004"
      unitRef="USD">762000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:CapitalLeaseObligationsCurrent
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_2007"
      unitRef="USD">197000</us-gaap:CapitalLeaseObligationsCurrent>
    <us-gaap:CapitalLeaseObligationsNoncurrent
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_2005"
      unitRef="USD">1653000</us-gaap:CapitalLeaseObligationsNoncurrent>
    <cvm:AdditionalExpenses
      contextRef="From2022-10-01to2023-09-30"
      decimals="-5"
      id="fid_2046"
      unitRef="USD">700000</cvm:AdditionalExpenses>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1558">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;1&lt;/strong&gt;&lt;strong&gt;1&lt;/strong&gt;&lt;strong&gt;. &lt;/strong&gt;&lt;strong&gt;RELATED PARTY TRANSACTIONS&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the year ended September 30, 2023, no restricted shares of the Company&#x2019;s common stock were purchased by related parties.&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024 (Note 4).&#160; The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend. The Series RR warrants are held by Geert Kersten, Patricia Prichep (current officers of the Company) and the de Clara Trust, of which the Company&#x2019;s CEO, Geert Kersten, is a beneficiary.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On June 13, 2022, the expiration dates of the Series N, Series X, Series Y, Series UU, Series MM and Series NN warrants were extended two years (Note 4).&#160; The incremental costs of the warrant extensions were recorded consistent with the accounting for the initial warrant issuances.&#160; The incremental costs of the Series N, Series X and Series Y warrant extensions were recorded as a deemed dividend and totaled approximately $294,000 for the year ended September 30, 2022.&#160; The Series N and Series X warrants are held by the de Clara Trust, of which the Company&#x2019;s CEO, Geert Kersten, is a trustee and beneficiary.&#160; The incremental cost of the Series MM, Series NN and Series UU warrant extensions of approximately $635,000 was recorded as a deemed dividend because there are no longer any notes payable associated with these warrants at the time of modification.&#160; The Series UU warrants and a portion of the Series MM and Series NN warrants are held by Geert Kersten, Patricia Prichep and the de Clara Trust.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <cvm:DeemedDividendFromModificationOfWarrants
      contextRef="From2021-10-01to2022-09-30_cvm_OfficerAndDirectorMember"
      decimals="0"
      id="fid_1796"
      unitRef="USD">172000</cvm:DeemedDividendFromModificationOfWarrants>
    <cvm:DeemedDividendFromModificationOfWarrants
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesNAndXAndYWarrantsMember"
      decimals="0"
      id="fid_1794"
      unitRef="USD">294000</cvm:DeemedDividendFromModificationOfWarrants>
    <cvm:Warrant
      contextRef="From2021-10-01to2022-09-30_cvm_SeriesMMAndNNAndUUWarrantMember"
      decimals="0"
      id="fid_1795"
      unitRef="USD">635000</cvm:Warrant>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1559">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;1&lt;/strong&gt;&lt;strong&gt;2&lt;/strong&gt;&lt;strong&gt;.&lt;/strong&gt; &lt;strong&gt;STOCKHOLDERS&#x2019; EQUITY&#160; &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Exercise of Warrants&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the years ended September 30, 2023 and 2022, the Company received proceeds of approximately $0.4 million and $0.1 million, respectively, from the exercise of warrants, as detailed in Note 4.&#160; Upon exercise, 217,752 and 25,205 shares of common stock were issued during the years ended September 30, 2023 and 2022, respectively. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Sales of Securities&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On May 2, 2023, the Company sold 913,234 shares of common stock at a public offering price of $1.70 per share and received aggregate proceeds of approximately $1.55 million.&#160; On July 20, 2023, the Company sold 2,500,000 shares of common stock at a public offering price of $2.00 per share and received aggregate proceeds of approximately $5.0 million.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;There were no sales of securities during the fiscal year ended September 30, 2022.&#160; &#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Other Equity Transactions&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company entered into Securities Purchase Agreements (SPA) with Ergomed plc, one of the Company&#x2019;s Clinical Research Organizations responsible for managing the Company&#x2019;s Phase III clinical trial, to facilitate payment of amounts due Ergomed.&#160; Under the Agreements, the Company issued Ergomed shares of common stock and the net proceeds from the sales of those shares reduces outstanding amounts due Ergomed.&#160; Upon issuance, the Company expenses the full value of the shares as Other non-operating gain/loss and subsequently offsets the expense as amounts are realized through the sale by Ergomed and reduces accounts payable to Ergomed.&#160;&#160;&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the years ended September 30, 2023 and 2022, CEL-SCI did not issue Ergomed any shares of common stock. Additionally, no shares were sold during the years ended September 30, 2023 and 2022. All outstanding shares have been resold as of September 30, 2023 and 2022 and the Company had approximately $0 and $22,000 in amounts remaining in prepaid to Ergomed as of September 30, 2023 and 2022, respectively.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <cvm:ProceedFromIssuanceOrSaleOfEquity
      contextRef="From2022-10-01to2023-09-30"
      decimals="-4"
      id="fid_1802"
      unitRef="USD">40000</cvm:ProceedFromIssuanceOrSaleOfEquity>
    <cvm:ProceedFromIssuanceOrSaleOfEquity
      contextRef="From2021-10-01to2022-09-30"
      decimals="-4"
      id="fid_1801"
      unitRef="USD">10000</cvm:ProceedFromIssuanceOrSaleOfEquity>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1804"
      unitRef="Shares">217752</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1803"
      unitRef="Shares">25205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-05-02"
      decimals="0"
      id="fid_1797"
      unitRef="Shares">913234</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-05-02"
      decimals="INF"
      id="fid_1799"
      unitRef="USDPShares">1.70</us-gaap:SaleOfStockPricePerShare>
    <cvm:AggregateNetProceedsFromSaleOfSecurities
      contextRef="From2023-04-30to2023-05-02"
      decimals="-4"
      id="fid_1806"
      unitRef="USD">1550000</cvm:AggregateNetProceedsFromSaleOfSecurities>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-07-20"
      decimals="0"
      id="fid_1798"
      unitRef="Shares">2500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-07-20"
      decimals="INF"
      id="fid_1800"
      unitRef="USDPShares">2.00</us-gaap:SaleOfStockPricePerShare>
    <cvm:AggregateNetProceedsFromSaleOfSecurities
      contextRef="From2023-07-01to2023-07-20"
      decimals="-5"
      id="fid_1807"
      unitRef="USD">5000000.0</cvm:AggregateNetProceedsFromSaleOfSecurities>
    <cvm:PrepaidAmountOfResold
      contextRef="AsOf2023-09-30_cvm_ErgomedMember"
      decimals="0"
      id="fid_1808"
      unitRef="USD">0</cvm:PrepaidAmountOfResold>
    <cvm:PrepaidAmountOfResold
      contextRef="AsOf2022-09-30_cvm_ErgomedMember"
      decimals="0"
      id="fid_1805"
      unitRef="USD">22000</cvm:PrepaidAmountOfResold>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1560">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;1&lt;/strong&gt;&lt;strong&gt;3&lt;/strong&gt;&lt;strong&gt;. FAIR VALUE MEASUREMENTS&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In accordance with the provisions of ASC 820, &#x201c;&lt;em&gt;Fair Value Measurements&lt;/em&gt;,&#x201d; the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160; The Company generally applies the income approach to determine fair value.&#160; This method uses valuation techniques to convert future amounts to a single present amount.&#160; The measurement is based on the value indicated by current market expectations with respect to the future amounts.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value.&#160; The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&#160; The Company classifies fair value balances based on the observability of those inputs.&#160; The three levels of the fair value hierarchy are as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;o&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Level 1 &#x2013; Observable inputs such as quoted prices in active markets for identical assets or liabilities&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;o&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Level 2 &#x2013; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs other than quoted prices that are observable for the asset or liability are observable in active markets&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;o&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Level 3 &#x2013; Unobservable inputs that reflect management&#x2019;s assumptions&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement.&#160; The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company purchased short-term T-bills during the year ended September 30, 2021 that are classified as trading securities.&#160; Quoted market prices were applied to determine the fair value of short-term investments, therefore they were categorized as Level 1 on the fair value hierarchy. The T-bills were recorded at fair market value, which includes an unrealized gain of approximately $6,000.&#160; The T-bills matured in December 2021 and yield a weighted average interest rate of 0.10%. The Company is not holding any T-bills as of September 30, 2023 and September 30, 2022.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;As of September 30, 2023 and 2022, there were no derivative liabilities&#160;outstanding.&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The following sets forth the reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3), as of September 30:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&#160;&#160;&#160; 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&#160;&#160;&#160; 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Beginning balance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;437,380&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Issuances&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Exercises&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(70,589&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Net realized and unrealized derivative loss&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(366,791&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The fair values of the Company&#x2019;s derivative instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such as historical price and volatility of the Company&#x2019;s stock were used.&#160; &lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1819"
      unitRef="USD">6000</us-gaap:UnrealizedGainLossOnInvestments>
    <cvm:WeightedAverageRiskFreeInterestRate
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1820"
      unitRef="Pure">0.0010</cvm:WeightedAverageRiskFreeInterestRate>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1595">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&#160;&#160;&#160; 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&#160;&#160;&#160; 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Beginning balance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;437,380&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Issuances&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Exercises&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(70,589&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 15px; text-align:left;"&gt;Net realized and unrealized derivative loss&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(366,791&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1816"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1815"
      unitRef="USD">437380</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1809"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1810"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1812"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1811"
      unitRef="USD">70589</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales>
    <cvm:FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1814"
      unitRef="USD">0</cvm:FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings>
    <cvm:FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1813"
      unitRef="USD">-366791</cvm:FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1818"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1817"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1561">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;1&lt;/strong&gt;&lt;strong&gt;4&lt;/strong&gt;&lt;strong&gt;. NET LOSS PER COMMON SHARE&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, common stock warrants and restricted stock&#160;are not included in the computation of diluted net loss per share&#160;if their effect&#160;would be anti-dilutive.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The following table provides a reconciliation of the numerators and denominators of the basic and diluted per-share computations: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Year ended September 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Loss per share &#x2013; basic and diluted&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px"&gt;Net loss available to common shareholders &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(32,365,855&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(37,629,803&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px"&gt;Weighted average shares outstanding &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;44,479,865&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;43,148,888&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;Basic and diluted loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.73&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.87&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In accordance with the contingently issuable shares guidance of ASC 260, &lt;em&gt;Earnings Per Share&lt;/em&gt;, the calculation of diluted net loss per share excludes the following dilutive securities because their inclusion would have been anti-dilutive as of September 30: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options and warrants&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,850,028&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;14,274,836&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested restricted stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;147,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;151,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;15,997,278&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;14,426,086&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1596">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Year ended September 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Loss per share &#x2013; basic and diluted&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px"&gt;Net loss available to common shareholders &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(32,365,855&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(37,629,803&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px"&gt;Weighted average shares outstanding &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;44,479,865&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;43,148,888&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;Basic and diluted loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.73&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.87&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2048"
      unitRef="USD">-32365855</cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
    <cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_2049"
      unitRef="USD">-37629803</cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
    <cvm:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2050"
      unitRef="Shares">44479865</cvm:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <cvm:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_2051"
      unitRef="Shares">43148888</cvm:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <cvm:EarningPerShareBasicAndDiluted
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_2052"
      unitRef="USDPShares">-0.73</cvm:EarningPerShareBasicAndDiluted>
    <cvm:EarningPerShareBasicAndDiluted
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      id="fid_2053"
      unitRef="USDPShares">-0.87</cvm:EarningPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1597">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2022&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options and warrants&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,850,028&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;14,274,836&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested restricted stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;147,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;151,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;15,997,278&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;14,426,086&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-10-01to2023-09-30_cvm_OptionsMember"
      decimals="0"
      id="fid_2055"
      unitRef="Shares">15850028</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-10-01to2022-09-30_cvm_OptionsMember"
      decimals="0"
      id="fid_2054"
      unitRef="Shares">14274836</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-10-01to2023-09-30_cvm_UnvestedRestrictedStockMember"
      decimals="0"
      id="fid_2057"
      unitRef="Shares">147250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-10-01to2022-09-30_cvm_UnvestedRestrictedStockMember"
      decimals="0"
      id="fid_2056"
      unitRef="Shares">151250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2058"
      unitRef="Shares">15997278</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_2059"
      unitRef="Shares">14426086</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_1562">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;15.&#160; SUBSEQUENT EVENTS &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On November 20, 2023, the Company sold 2,490,000 shares of common stock to a single investor at a public offering price of $2.00 per share for aggregate net proceeds of approximately $4.5 million.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2023-11-01to2023-11-20_us-gaap_SubsequentEventMember"
      decimals="0"
      id="fid_1848"
      unitRef="Shares">2490000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-11-20_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="fid_1849"
      unitRef="USDPShares">2.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-11-01to2023-11-20_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="fid_1850"
      unitRef="USD">4500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>81
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M;5M@AL)JP/HEL#ZXFA/NIVI7)M'3^UH[ON!RV^I^TO$!J]KR,116XW-1\KD
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M^K^IM#JERO\=V->S(16AV2H3]N9^Z4#(N=7O#MV^]@(#N+0UK5/(OE/)OG-
MSJF?BFRG:.,%>@IEI-]VP2'[AW&UQ(Q*OJFT.K%*\AU8RY\$"?)SE^_Q@D=:
M6G" ]WRGA614ZDVEU2%54N_ !EX.JYLW?T78DC;O%N&@^Z_S&RTMHS)O*JU^
ML6LE\^Y1,C]EDHKB:OCL1"_9G3#783N0V'!^'*YJ?:7K*5S>K5S>/>HRGRGS
MN5AS42AJT3YZ/&52O#=*_H%D[T$+SZCCFTHKX/7V;@/(+D[);Z=(D)]Q*.X(
M*-\M;]D8YS<J]*JO%_=[*)U:ABQ!$7U1I=;9A=J=B^(6BN*%Y.O\IH(%E\K
M\J<K2@(JLB^HSU\XE[L7V0^4-[*,_@=02P,$%     @ \H&55R>_'!9K!@
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M*CQ=J@XCBNB.9CE]RQE2',$"* !?IE2PE.>P,9CYAS4)AMP-_,CW^Q&83,.
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M([ .Y7A/.3Z-\B3GFT*<1/D6,3A@R0]\3! *NBQ-=<.&3J20:3 +"8HC/U
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M(@S5#<9I7.H*K4M\*^.A7<<?:93-Q.M2&R,8U#VP6GB!H566I!*54AV11$&
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M#C.(QLP0=TS2G]GI/XTV21VER=_M6Q]9Z/^C;F@X3PD>E@,:,U,W9"7 [)7
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MNB]UL6GOG-T7=5UD[<<UCV 5"@/X_:$HZM<OX@_LKBV>_A]02P,$%     @
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M*\N&'!_ ?FUMV/W@ .-_3Y?_ E!+ P04    " #R@957H@+J>4X)  #)%@
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M$^)ZCN4 PQ,RL[V03,U&1_N1>&,W-+3>I"9UO5J'<$#[[AW(\CPDGA+?]ZW
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M'L9[]D^^=JKEEAL\5^4/4=CM/)@$4.":-Z6]4KO/V-4S='RY*HU_PJ[-3=(
M\L98575@4E )V;[Y0[</!X!)_ * =0#F=;<+>947W/+%3*L=:)=-;"[PI7HT
MB1/2'<JUU?15$,XN5LN;CU]OKF>1)3(W%>4=\*P%LA> "8-+)>W6P$=98/&4
M("(5O12VEW+&CC)>8SV - Z!Q2P]PI?VI:6>+WU]:2TP>Q[H^F!J:I[C/*"+
M;E#?8[!X^R89Q1^.R,IZ6=DQ]F.RC@*?ES6" 72,L.(6I360*^H98T&MP6X1
MUJJDUA-R ]P";;+%ZA8U[?34[[1[L!Y[ I-A&F;9T$6G:3A)4UCF>5,U)644
MP"NEK?C-?4N]&PV'X3A+X#V%DR0<I8S"CBH$29YR LGI.!S'&44L82&+$[AH
MM%/CM#TBUP;0W: GTMI+ %P67E[HDC7"CAN0"D15<Z')&GR-M5^/JC9D3W!#
MK#O?BT[M/6JREJ>J:]1"%;0MNH,:$ 9X76OU(*C/L7R$2:ML ,M#)#Z0%QKT
MT%>H!ZLL+YV<)VN<I),PCF.?=I*=NC@DGS,U>J<J']MB/!C06(\CW8UM]#\E
M.?VF.V@SA9][76Z;_Q/FCB)E?FD:#8&=[N,1L.$^'@/K<R9TB#Z^<:? UY;(
MQHF?<>?;EO%<:T0'QE2AWGC[=1>TD;;UJ'ZV=_AE:VQ_T]O?PR77&R$-E+@F
M:#P8#P/0K>6V ZMJ;W.WRI)I^G!+?RG4+H&^KY6R^X%;H/_O+?X 4$L#!!0
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MV(IXG1QY6(P/I5GR3UZFIBQ-SB^)GBE+"_#YS)@R/M !]6^@SO\+4$L#!!0
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MH#$SW+T@30*^7PFA]XYIT&WS^#]02P,$%     @ \H&55TW#1<>B @  ,P8
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M&^V?;.P8RY0K<5EFW]*Y7IT-X@',Q8)O,GU?;O\6=3S4Z)N5F;*?L*UDHV0
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M_S2=/3Q7NJ(93#P\'1K4(WC3-Z_"0?"^0VR_%=OO8I\N\3#F=0E$%J2H3:W
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MF6)25-,VF\+(RK6JM338^-QPBU\:H.P$O%](:0Z%7:#]=IG^ %!+ P04
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MNTIW8SC=J*Y\657V#U1N^3#A3*42KEF,\4L"5\MHM/A;+9?^4<8Y%F?0]CZ
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MP^AKO&8L06_^)H@O!NLDV9X91KQ<,]^-A^&6!?R;IS#RW81O1L]&O(V8N\I
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M43Z^6, /HGOU\;[89,F5Y_%=?!P&-Y8*IX+YC?E$5_946#L]G;7#U(UUJQN
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M^482;K-%R8]ADH1^]G'-W!6+T@#^_5,8)N\;Z0'*=>W3_P%02P,$%     @
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M*->N,Q5D8L-U<WW;U;;Y!\V=_Y/>O!Q3*M>,*RAQ9:#![;U1ETTW-H$6M>N
MI="FG]RT, \82IM@]E="Z$-@!=HG,?X-4$L#!!0    ( /*!E5?N,J+== ,
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MZYN&IY;SU+0\ T9]@#%'$T8CM!==*NP6Z&JUNMW &W1:_P?2.3F=HZ7S@ 7
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M<K ZE!&.XW'6HZ4AKY'\Y_>@3^>>X9[6EDQ\K$=70GY;<KP)+QO5LY,U>O,
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M85D-D]6+%H6=Q^9"TW1G'Q,:P%$: _J^$$*_O)@-ZI%^\B]02P,$%     @
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MSE2+!UP'J.<I8W([T2\P36/T!U!+ P04    " #R@957N+YTRMT%  ";'@
M&0   'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6R]66UOVS80_BN$-PPIT,KD
M2=1+YAA(G'0+L#19TZ0HAGU0;-H6JA>/HI/VWT]OEF2)9*(YW9=84H['YT[D
M/<^)DZ>$?TW7C GT+0KC]&2T%F)S/!ZG\S6+_-1(-BS._K-,>.2+[):OQNF&
M,W]1#(K",6!LCR,_B$?32?'LAD\GR5:$0<QN.$JW4>3S[V<L3)Y.1F2T>_ Q
M6*U%_F \G6S\%;MEXFYSP[.[<>UE$40L3H,D1IPM3T:GY'AFTGQ 87$?L*>T
M=8WR4!Z2Y&M^<[DX&>$<$0O97.0N_.SGD<U8&.:>,AS_5$Y']9SYP/;USOO[
M(O@LF <_9;,D_!PLQ/IDY([0@BW];2@^)D^_LRJ@ N \"=/B+WJJ;/$(S;>I
M2*)J<(8@"N+RU_]6):(U *AB %0#H#O 5@PPJP%F$6B)K CKW!?^=,*3)\1S
MZ\Q;?E'DIAB=11/$^6N\%3S[;Y"-$].+/^\N/WUY=W9Z>W&.9M=7-Q<?;D\_
M75Y_0$?G3/A!F")X@]ZAN]MS=/3SF\E89)/F0\?S:H*S<@)03$  726Q6*?H
M(EZPQ;Z#<8:VA@P[R&>@]7C+-@8R\5L$&$P)H-G+AX,&CEEGT"S\6:H,?F-\
M'J3^0\C07U<L>F#\;UF:M%[RW7J<;OPY.QEEVS%E_)&-IK_\1&S\JRS$5W*V
M%[!5!VQI _ZPS6-$R1)=;_*MF*+KK4B%'R^">/46G;%5$,?9I2P)I6=:>,XK
MS./4P;9C$V<R?FS'U[>CU,(8W-IN#SJMH=-#H%\4OS+<M(_;LPEVH8-;8M>)
M;P^W7>.VM;@_%]6(+=#I(^-9=475HF/HA@=S-N %E/,X+8"V :031=^(&HXB
M!*<.P3DHA-WM0H9:ZWKHWBF=>:WH+(-Z\NC<.CKW]5Z0>IFYDK>#NWM#9M1Z
MA7OXO1J_I\5_NEIQMO(%0Y>QX$'&TG-T[X?;(4NKG,%NX2*NG6T2VL'?M[-,
MZGK44VQN@ALNPZ\1A3K_E?\V-MQ!+S'IAKF/OL7$9&!QNF>ID&^(RE6[T'@4
M@-I=M'T[0BW'P:8"+31H82!:[0ZNO%%=9OLF[VR*L0)IP\]$3] RI)N *W":
M?1#4=;QNB939$=,FE@)M0ZY$SZ[/51+-FK!ZA<$UK!YPF96M0-WP*M$3Z_/5
M79UQVJ]GQ.A5#8F9YQBJ3=<0*QG(K!]9WOQD]0'-,MG*LS9CZX?HCV#)T"?&
M(W3TA?D\?3.@+NH1#&6O9^*QT?<<'R($1:7L)A0M_.^I1OB1AL/)0!+_3]G2
MU%_]]+0*SMG%9DM"J]*D][1+$PS(4J,%B%X,M(+5=@1Z-X,7QBMYVP^Z$1!$
MKR .Z0HJUWLL!9YMX58YK8*46!)L>0Y6"#AHQ /HQ4,_@-^X'RMJ;>6KC0.P
M3=ML5?6B,D,+.U1!:]#(!1@J%[0$#'TET,/:-]$0,#12 89+!24=@$0%R A8
M9J<A8&CD @R5"^\3OF2!:B7TA0 0D]A=_I+8$6R;ID*X0R,8X*!V7%ULH=]D
M$\NA#J5N%[O$LKL_]]$WP@$.$PXO+R(@$0@&[@IBB17!!E:T'M#H"#BL0]?5
M$KO7D!+#['9]$BO+ %7^&T:'']B6ZWT/)3 8TIA#P\9P6&NNW]UN#Y-G$*_[
M;OI6A!A4T6-!PZF@Y]0#5'7EN0U)IJHE9FI5;39<:NJY])4^AU2SM#>K8SC=
MZB2QVMOX^S$T_&KJ^?5_Z ST" 9_$];'X_0Z ^LYR6LV%&_J*?Y'-P;/3+^3
M\]XN-"#*SN 95[LT6;H>8S]+K9,"O;1XC:]LU13=[T]@==6<Q)!:KF6"JZA+
M9B,Y3+WD>.EW-AUWZ*<8O/;["L6B#J@*62-/3+T\.?B+8N5?]T518M)]HR7Z
M<>N8+V)\59Q^IFB>;&-1'I_53^L3UM/B7+'S_(P<S\ISTL9->6Q[Y?-L[:4H
M9,O,)3:<#!LO3T++&Y%LBL/$AT2()"HNU\Q?,)X;9/]?)HG8W>03U.?1TW\!
M4$L#!!0    ( /*!E5<-XC?,0 ,  (L*   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0X+GAM;*V6;6_:,!#'OXJ53=,FM<1)2 (=1 +:;GW1EI4^:"\-.4C4
M),YL ]VWG^U &D*@V]0W$#MW__O=V8ZOMZ;LF4<  KVD2<;[1B1$?F::?!9!
M2GB+YI#)-W/*4B+DD"U,GC,@H79*$]/&V#-3$F=&T--S8Q;TZ%(D<09CAO@R
M30G[/82$KON&96PG[N)%)-2$&?1RLH )B(=\S.3(+%7".(6,QS1##.9]8V"=
MC2SMH"T>8UCSRC-2J4PI?5:#J[!O8$4$"<R$DB#R;P4C2!*E)#E^;42-,J9R
MK#YOU2]U\C*9*>$PHLE3'(JH;W0,%,*<+!-Q1]??89.0J_1F-.'Z%ZT+6U=&
MG"VYH.G&68[3."O^R<NF$!4'RSO@8&\<[+I#^X"#LW%P=*(%F4[KG @2]!A=
M(Z:LI9IZT+71WC*;.%/+.!%,OHVEGP@N?CQ<W?\\'0XF%^=H='L]OKB9#.ZO
M;F_0YW,0)$XX<KZ@4_01F8A'A 'OF4+&5=[F;!-C6,2P#\2P;'1-,Q%Q=)&%
M$.X*F!*XI+:WU$/[J.($\A9R\ FRL>TT (W^WMT^@N.4172TGO.O16RJ52'5
M;I92I_:,YV0&?4,>2PYL!4;PZ8/EX:]->;Z3V$[6[3+K]C'UX&:93H$A.D?+
M; 5<0(AHKLXF/T%#6,19%F>+I@H4LJZ659^95>!VNI[3]7OFJII<@YV+NU['
M*NUVN-V2VSW*_;C#V@3H[@4^[;JV[7HUP 8[RVW[/G::";V2T#M*^(V1[ U$
M;R^TC3U9'EQ#;+)K8]_%S81^2>@?)92?T#G$;S#Z^^6Q+<?RW!IC@YV%/<<Y
ML,Z=DK'SW_M3?H@.;,[.'HSG=[VV7U_[?;OZ)MZ![I;0W:/03_K>D:B#%3!Y
MCR*]%Y#\M@.Z)#%#CR19PAL'K CA5]B<EN?4$M@W<EO6 7H+OUXG^%WXBP5I
MO$N* -T*F-^JPS<;':*O7(;6N] ?WCZ; -6RVBV[ON,;K'96J, W*]=Z"FRA
MNQV.9G29B>*N+&?+CFJ@^XC:_%!U6KI=>)4IVK1KPN0^XBB!N93$+5]N:%9T
M/L5 T%PW#U,J9"NB'R/9+0)3!O+]G%*Q':@ 9?\9_ %02P,$%     @ \H&5
M5_,7^-3. @  ,P@  !D   !X;"]W;W)K<VAE971S+W-H965T-#DN>&ULK99M
M;]HP$,>_RBG:BTUJFQ (H J0@+*M+VA9Z8.F:2],<A"KB<UL![IO/]L)&8^A
MFO:&^.'N[]_=)3XZ:RY>98RHX"U-F.PZL5++:]>588PID5=\B4SOS+E(B=)3
ML7#E4B")K%.:N+[G-=V44.;T.G9M(GH=GJF$,IP(D%F:$O%[@ E?=YV:LUEX
MH(M8F06WUUF2!4Y1/2TG0L_<4B6B*3)).0.!\Z[3KUT/V\;>&CQ37,NM,9A(
M9IR_FLEMU'4\ X0)ALHH$/U8X1"3Q AIC%^%IE,>:1RWQQOUSS9V'<N,2!SR
MY(5&*NXZ;0<BG),L40]\_16+> *C%_)$VE]8%[:> V$F%4\+9TV04I8_R5N1
MARV'6O.$@U\X^/L.C1,.]<*A;@/-R6Q8-T217D?P-0ACK=7,P.;&>NMH*#-5
MG"JA=ZGV4[W1MZ?;Q^^7@_YT= /#^_%D=#?M/][>W\''&U2$)A(:G^ 2'E J
M04.%$4P5#U^AOR8BDO!CC.D,Q4]M\@%<D#$1*#NNTFCF #<L, 8YAG\"H^;#
MF#,52QBQ"*-= 5?'5 ;F;P(;^)6*4UQ>0=V[ -_SZT> AN]W]RMPZF6>ZU:O
M<4+O+C-I CZ'C*UT+G4>\UQ=P  7E#'*%L?2EJL&5M5\D:M>+:CY@==Q5]O!
MG#7;@6Z4T(U*:/VAS)&J_7KD9(V#(R\;GK</=FAU@BDHF8)*IN?MY!WC"BI.
MS)FJ+':8FB53\U^+JU_G$Y5M'I:LT3JL[!&SBLJV2N)6)?&+O=XT9W^%0M_6
M\$40ID!?(0B?"17P3)(,S[R;^1&M;;3Z52O8"^"<U0Y_N^1O_Q?^T^EOOPO^
MG%4.[V[=ORF*A6U+$D*>,97?6.5JV?GZ]L+?6Q_HCI@WL+\R>3L=$Z$K(2'!
MN9;T-(,#(F]1^43QI;WE9USIGF&'L>[J*(R!WI]SKC83<T#Y/Z'W!U!+ P04
M    " #R@9575VK'+!$'  #1+P  &0   'AL+W=O<FMS:&5E=',O<VAE970U
M,"YX;6RU6FUOVS80_BN$NQ4KX,02Y=<T,9#8:I<.2=.Z:3$,^\!(M"U$$CV*
MBIO]^I&28IF2S%K%S1\2O?">HYXC3_=0/-\R_IBL*17H>Q3&R45G+<3FK-=+
MO#6-2'+*-C26=Y:,1T3(4[[J)1M.B9\916$/6]:P%Y$@[DS/LVMW?'K.4A$&
M,;WC*$FCB/#G*QJR[47'[KQ<^!RLUD)=Z$W/-V1%%U3<;^ZX/.OM4/P@HG$2
ML!AQNKSH7-IGKI,99"V^!G2;[!TC]2@/C#VJDVO_HF.I'M&0>D)!$/GOB<YH
M&"HDV8]_"M#.SJ<RW#]^07^7/;Q\F >2T!D+OP6^6%]TQAWDTR5)0_&9;7^G
MQ0,-%)['PB3[B[9YV\&P@[PT$2PJC&4/HB#._Y/O!1%[!KA_P  7!KAB,+8.
M&#B%@5,QL ]YZ!<&_:J!<\!@4!ADC][+GSTC;DX$F9YSMD5<M99HZB!C/[.6
M? 6Q&B@+P>7=0-J)J?OI_OK+GR=7EPMWCF8?;^[<V\7EE^N/M^BW.14D"!-T
M2S@G*IQOT FZ7\S1;[^\.>\)Z5Q!]+S"T57N"!]P9&-TPV*Q3I ;^]37 7JR
MU[NNXY>N7V$CXH)N3I%C=1&VL-/0H=GQYKC!?&XV_Y"&I]+TH'?7;'Y#GI&%
MFZPU+IQ=&)T,KG\ ;L:B2$X[.5R\QRY*UH33! 5)DE:9SHG-P089F$HE3]/^
MJ(^Q8_7/>T_[%#8T=/K]L6./](;S>D,\L-1/;^?6VTUL!SNE7^WQ^[O'[[=_
M?)**->/!O\T4]&L=&5K%K\+!T2WGQDZJE'^6;(A'+SHRIR>4/]'.]/4K>VB]
M;1H_0& :GX,=GP,CGPM%))*LRO=10K*,?A>2.$%_W=#H@?*_FQ@U0K9\^ADD
MV!P2S 4"T^(RW,5E"#G-A[61:P\<>S*H#'"CS[9<0X*Y0& :UZ,=UR/HG#*J
M9PJG7T\H1K]M^88$<X' -+['.[['1^2<*Q:GR1')QHC5-ME @LTAP5P@,"T@
MDUU )I#)9E(;_ ,;3T:X,OB-/MMR#0GF H%I7-M668=;T.FF0-3R.QX[HV$U
MX9A=MR4=%,V%0M-IWY,_MI'V6Q:??$I)&"P#ZJ,\!WW<J(KGF"QD!F^;AD#1
MYJ!H+A2:'B9<A@F#SP[<4/V,QB-<>Q^;?;?F'1+-A4+3>2]EI6W6E=<RW9/8
MHX@MD;<7 \2*.5+&H(A*8R@:U&&CU#JVX=S<[=8D Z'I))?BU3:KUSO*LQ4_
MQ;-:]/(K'!?#?<5)+ Z,];I&E67^>% GN-XPU^E5?D&E+!2:SF\I9NUCU.R&
M!QYM)"^W'NV3=^H,J\PUM+).^^,J<:!:$PI-)ZY4F[99;BZT8?A$$X%\FG@\
MR*XT<@DI_V8_Z-Z7-:W,E&T0AGD_;<OZ%:4;M12]V7#V1$*5PH2T6 9<WH\(
M?Z0BB%?J?AAX^2*'G(:(Q,]H(V=<)+N9"GDG+"9EAJ80U+J(;/7ZU1C;H[<)
MNDE#$3S*SB%!O77,0K9Z1D&<(15.[Q>7730C,?%)%]W_T47OJ9KPSUWTCJMY
MWT77@H3R=+$A0=Q%'XCTT$6R.Y=I(KBL3TCCNP94;4.AZ:.MU-NV67!?2QYB
MM<ZLE6''5&&0&G@&BC8'17.AT/0(E0K=-DOTGZG"QO4WDS/NUU],H!H<%,V%
M0M-9+V6X;=;AU7E1+I&89P6D.)Z!HLU!T5PH-/TK5*G<L5FYOV-\28,#E1FN
M:_23AB5!LXNV](*BN5!H.KVE0L=FA?X32:= U!9B;:M>#9L]MV8=5'!#H>FL
MEX(;FP7W>R4VD$^$+)A(P)$LH%**.%5[#U35Q%*1"!+[\K@Q CGZ<"\"XV&3
MXC-WHW4(0+4W%)H>@E)[8[/V_BKK6*.LQ@U?9X>.U'-5CB'%\AP4S85"TSDN
MI3<V2^_[F%./K>)L </;_]Y)OZOC1L%88.X/;HP;AG:]67_0N)IA[F1K2O\/
MM8U+M8W-:ONS'+92:HO=<NKEEG#?7,&;(=O6*J!H<U T%PI-#TZIZ/$/)#.3
M,E,?Z!Y+1&-,AK7AZS1F<-#/QZ!H+A2:SG:I:+%9T7[+MJE1_X0\44Y6%&TH
M#UASR6)&LFT4Y;NGQO*E_-ST.IB9(5H' E2X0J'I@2B%*S8+5W.)7I>HC25Z
MO5DMCX/*3B@TG;-2=F*S[+R5N:$H05X^B!E3.*C<!$6;@Z*Y4&CZ1K]2;CIF
MN=DBA1=(^RE\.&G*X6:7;>D&17.AT'2Z2_GIF.5GBQS^ R0;/5/"T>0ED]O6
MP51N1FH=#U!A"H66QZ.WMW4YHGR5[1E/Y(A.8Y%O!=Y=W>U+O\QV8U>N7]EG
MLWQW>0F3;W:_(7P5R.P5TJ6$M$Y',H7S?/]X?B+8)ML@_<"$8%%VN*;$IUPU
MD/>7C(F7$^5@MXM_^A]02P,$%     @ \H&55U\G"6?, @  \P<  !D   !X
M;"]W;W)K<VAE971S+W-H965T-3$N>&ULK55A;]HP$/TK5C9MK;01DT!@'40J
M--4JM1TJ[:9]-.$@5AT[LPVT_WZV UE*:;95^T)LY]Z[]\[D;K 1\EYE !H]
MY(RKH9=I79SXODHSR(EJB0*X>;,0,B?:;.725X4$,G>@G/D!QI&?$\J]>.#.
M)C(>B)5FE,-$(K7*<R(?1\#$9NBUO=W!#5UFVA[X\: @2YB"OBLFTNS\BF5.
M<^"*"HXD+(;>:?MDW+/Q+N ;A8VJK9%U,A/BWFXNYD,/6T' (-66@9C'&L;
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MNV5FIC)(&V#>+X30NXU-4,WY^!=02P,$%     @ \H&55T*4O8E* P  4@P
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M@>L!ZOF6,?G8T65E\S<B_@M02P,$%     @ \H&55X&W)IY  P  0PP  !D
M  !X;"]W;W)K<VAE971S+W-H965T-3,N>&ULK9=M;]HP%(7_BI5-4RNMS1M)
MH(-(+6TWI )5H=MG$RY@-;$SVX'NW\].TI2*)"W3OA [\3D^C_/B2W_'^)/8
M $CTG,14#(R-E.F%:8IH PD6YRP%JJZL&$^P5%V^-D7* 2]S41*;CF7Y9H()
M-<)^?NZ>AWV6R9A0N.=(9$F"^9\KB-EN8-C&RXD'LMY(?<(,^RE>PPSD8WK/
M5<^L7)8D 2H(HXC#:F!<VA=#V]&"?,1/ CNQUT8:9<'8D^Z,E@/#THD@ADAJ
M"ZP.6QA"'&LGE>-W:6I4<VKA?OO%_3:'5S ++&#(XE]D*3<#HVN@):QP%LL'
MMOL!)9"G_2(6B_P7[8JQ@66@*!.2):58)4@(+8[XN5R(/8'=:1 XI<#YJ, M
M!6X.6B3+L:ZQQ&&?LQWB>K1RTXU\;7*UHB%4W\:9Y.HJ43H9#J?C\6@^OIG,
M9^AR<HV&T\E\-/E^,QF.;F;HY!HD)K% ]BDZ0X^S:W3R^;1O2C6QEIM1.<E5
M,8G3,,D,TG/D6E^18SENC7SX<;GS5FXJW(K9J9B=W,]M8F9)0J1Z%J5 F"Y1
MQ*@D= TT(B#JZ J[3KV=?M$N1(HC&!CJ31+ MV"$7S[9OO6MCO4_F;TA=RMR
MM\T]5 O8J0-L51T+6)CYN9G^BFQ#UPLLR^J;VYKHG2IZY[WH7EWT5M6QT0LS
M;S^Z[S=&]ZKHWGO1_;KHK:ICHWL'T9UN\ZK[573_O>A!7?16U;'1_</H07/T
MH(H>O!>]6Q>]575L]*!FU;W&Z-TJ>K<U^GP#:DM>2>!U *W:8P&Z!P"VU;$:
M"7H50:^=@$D<H]M,9AS0F%"29 FZ [7?HNDB)FNL]_ ZN%;;8^%ZAW?'MYU&
M.-MZW32M5KP[$ *-DC23L$0CJFX4"(FF%$U3X%AO)A^";9_E6-K2;1_W+/!;
M</=J!+L5=Z+*R3P!E6B+XPP06R%6H<8Y*JM05:E &3V+,LZU(F6\<0'L@[VB
MU^OT]B.7;/;A<^I[;C/;:RU@MVZX_\#V$2[G@,L. J>&JV9@K^;;9^Y5>+J\
M'F.^)E2H>"LEM,X#M3*\J%B+CF1I7O0MF%0E9-[<J"H?N!Z@KJ\8DR\=74=6
M_QO"OU!+ P04    " #R@957TPK]TK0&  !#*   &0   'AL+W=O<FMS:&5E
M=',O<VAE970U-"YX;6RUFEMOVS88AO\*X:U#"W2Q2%D^9(F!U$JW#+,;-.EZ
M,>R"D1A;J X>1=O)OQ\IR9)E49^M@LU%;,GD2WZO>'A(\6J7\&_IBC&!7J(P
M3J][*R'6E_U^ZJU81-.+9,UB^<MSPB,JY"5?]M,U9]3/,D5AGUC6L!_1(.Y-
MK[)[]WQZE6Q$&,3LGJ-T$T64OWY@8;*[[N'>_L;G8+D2ZD9_>K6F2_; Q)?U
M/9=7_5+%#R(6IT$2(\Z>KWLW^-*U!RI#EN+O@.W2@^](A?*4)-_4Q9U_W;-4
MC5C(/*$DJ/S8LAD+0Z4DZ_%?(=HKRU09#[_OU3]FP<M@GFC*9DGX-?#%ZKHW
M[B&?/=--*#XGNS]8$9"C]+PD3+/_:)>G'5H]Y&U2D41%9EF#*(CS3_I2&'&0
M 0]:,I B SG*,&XKP2XRV.>6,"@R9%;W\U R'UPJZ/2*)SO$56JIIKYD9F:Y
M9?A!K)[[@^#RUT#F$]/9I_G\[G%^NWA\0#<+%\T^+1[O%K_?+F9WMP_HK<L$
M#<(4+2CG5#VA=^A7].7!16]_?G?5%[("2J;O%87-\L)(2V&8H'D2BU6*;F.?
M^76!OJQY67VRK_X' BK^2>,+A/%[1"QBZRH$9W]@ZPMD6ZW9W?.S$R :NWP8
M=J8W:-'[S%)&N;="-/9EX]W*7KF6?4P@]B+[><I2314_@))JV+A,U]1CUSTY
M+J2,;UEO^LM/>&C]IK,K%QMF8FK(V$YM9V2IOZO^]M 80Z76;!J4-@U FQ9R
M.$R>D1^D7K*)A<X44*"K*;F8<V *QF.=*89*K9GBE*8XH"DWOA^HD92&8&L!
M1;H:XS2,T;850V76;!F6M@Q!6SX&,8T]AD(F)P<4!O0I" /Q^EZ.K9PS?>,!
M%;MZ-&PVGM%(-I_!D4G#1L_#SM!R'+M,5XM_5,8_ N/_M&9JX(Z7G1P -;LZ
M,&HZ,!D-;'QD@";9R)J0L3[^<1G_^,SX;_->@?Z9L^B)\7]U<8-:7>,V*>8:
M$JMY."D]G( >SFBZ0FOZFDU%$C514F]4VH$&E.QJY:0Y+>D&FDFS"1&KGK!F
M +8J2K) "[YF_,A\1+<R]"4[MJ"<C)"\RW1^P 5T-:104Q]EK-8%MLB1(Z9*
MK=MV )?X!XP^L&AGJW"C\1!=XRG2.>WIZB:0R@3R?29H8P>U.L=.-&.O-OAF
M0H*AZ"NDQ3#3'D?/54=2^+:1%S1-F= .'[!J9Q^:7(NUJ%(DA RK^U Q*X:A
M]>0((M>P&RY;!7J5:P"M)4:A]D1U1UDU4C1&4;YB(T/DTU?=LW)-5:SN; 6^
M&";?OS+[(.B%!3H[YS0:TT#;EIIX3 906ZJ8%L-0FT=\L^2,97,RA#2P5.?8
M3:JYIM3J-E9HC&$V;G3)TUW0*!B?J)Y3=$&<=T%$VCN@H6K5?:P0&\.,75]C
MG3O &V7M0NVP3TZPME..FP.\!8[P%25C&)-;EIK:X(W2,=9P;\OTIDEIVT#T
MI")D A/R]RRT8<FN-A1JM>"TVS2ZA$/(A(IW"<R[+I,5]0*:;6E#,Q*LTSGR
M)KJV1'XZ83WR"G()#+EWL6"RIJ)<)XKDG(X JW;V08.[VE% EQ""?5+A+H%Q
MM[96/M,#HZA+FJA+AEH/FJA+',B#"G5)1]0]N3B&!3M;,- MCJWQX'C/S52Q
M=9\J<"4GP)7&?IAP'^0W6*.S-2;57%-J=?\J#"8P!M_%'L\ F(;H*>$ROUQ-
MO4<^X\$V>UF%MI3+GA>R]H9GE(X+M6;#R_M5\7>\\6FJ#G47*PHF,&;FBPF?
MI1X/UFKBTOID%'Q/U.AQ)1\8VP^B0>R%&UD]1+,7O$C!!-JM F^%9)UI*)^L
M_$T@^PUB5-Y4T(S6X2:5.8LY2:SD[]3S^"9/BNV+D?,&R05X&^F[I@*N/Y0*
MJ<DY2*TV!]2+UWB9-7/M@S&*T:2)T;AE!OT1&]*D8FT"L_9]WCA2-*<^4_/L
M?BS5>M3</B:Z_>,9:>+Q\8J]B-X0O]??$E>L;<.L?<N72<3@>0.6Z/Q>V*2:
M:TJM;E]%Z39,Z=_WFMTHL=LG-YL+IYJ;UQ"CV16OVS"OG_$.'5;H'+$&N;41
M&RJU[LO!"8P3_"YO!')604HZD.M9(0DBU-IC]N"%9N/9LK0&_8BC%W8%]S8,
M]P?G#+R]5^T>&>7Z0JWY)J=AD5&N[Q^<KHH87V:GU%*4]9O\I%)YMSP)=Y.=
M_SJZ/\.7;GZ>K9+)C]?-*5\&<2I7B\]2TI)TTLOWT?87(EEG9[B>$B&2*/NZ
M8G+JXRJ!_/TY2<3^0A50GAN<_@]02P,$%     @ \H&55R1$@%ZK @  1@<
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M>E=]O6&B[-JEH7AN.^6:*]UW[7"K'SH0QD&OIYRK@V$2U$]G^!M02P,$%
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MO^ZRB8*>A ?C\#64$^2<AH?_'XY'O'#:!' J/O<$WXKEN=JP*M&B)R2VA(-
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M\>IQJRHRX#I O4\8DZ\-/4!;XRW_!5!+ P04    " #R@957:*F5:K<"
M"   &0   'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6RME6UOVC 0Q[^*E4U3
M*ZU-2""D'40"2K5*HZI@=*_=Y "KCIW9YF'[]+.=D$*;ADW:&^)S[O[^W1'?
M];9</,L5@$*[C#+9=U9*Y=>N*Y,59%A>\AR8?K/@(L-*FV+IREP 3FU01EW?
M\T(WPX0Y<<_N/8BXQ]>*$@8/ LEUEF'Q:PB4;_M.R]EO3,ERI<R&&_=RO(09
MJ'G^(+3E5BHIR8!)PAD2L.@[@];U*#+^UN&1P%8>K)')Y(GS9V/<I7W',T!
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MG\\'KL(E-=!-=O0C2^\?H>_X9,)+E4ER5Z:0OB=P46LMV-\+'ODG&>=079+
M^TI\SP]:!(T_#O=/R GJ_ 6&+SC"]\"E)!7@O<BH $P5GJD\(;1,29JSM3KT
M;"U:SK"=4U_<:UG1!(8.WDP)8@-._.53)_*^M1G^3V3O[(>U_? 4>_R(=8;I
M%- -GA6Z8$ 4)PDO"KRB)B499RD(^=',V.4BLYRN0)OX(O"#J-OO=@?NIFF[
M+;(7^5=]+Z@CWWGJUIZZ)SV]F*L/*7H"@97,^I $:Z!4*#\O5Q]U8Q?J-C2&
M8=B[ZD>'9EH"@T[8QU^[EZCV$IWT,CI4:7=+']CF)K5IM\2]9GZ]RUYP(+PU
MJM\[4.TV"E0!8F7JMD0)ZU+9JU^/UD_#C:F(!^,C?#)LA?]'8]^;"16KO)2$
MP1(I42DF4]@:;CN*5Z8,+KC"HFJ:&3Y[('0 SB\Y5_N.7J!^2.._4$L#!!0
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M.\UT2P9A O3W)>=JOS 'U$T^_@-02P,$%     @ \H&55_?\XJCW @  $0H
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MA387?-%,3,V&T@:8]RLA]+9C)ZBKP-$?4$L#!!0    ( /*!E5<]KD%!, ,
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M>[[6>/V?I'HZGYNOE[\LOW;.;L(%YP2_$SW^!5!+ P04    " #R@957UDS
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MJS^.'Y]%9YK^,Y^-_^VY>@=02P$"% ,4    " #R@957!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M /*!E5> NP:$[0   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( /*!E5>97)PC$ 8  )PG   3
M  "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ \H&55^K=
M>J-Z!P  U#(  !@              ("!# @  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( /*!E5<GOQP6:P8  *09   8
M  " @;P/  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #R
M@957V*0RX;@"  "P"0  &               @(%=%@  >&PO=V]R:W-H965T
M<R]S:&5E=#,N>&UL4$L! A0#%     @ \H&55T1/].,V!   Z0T  !@
M         ("!2QD  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0
M   ( /*!E5? ;J+/[ 8  /(G   8              " @;<=  !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #R@957-:EX%D\)  #"*
M&               @('9)   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!
M A0#%     @ \H&55WP[*GYR!   9@D  !@              ("!7BX  'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( /*!E5>. D-^^ 4
M $D-   8              " @08S  !X;"]W;W)K<VAE971S+W-H965T."YX
M;6Q02P$"% ,4    " #R@957H@+J>4X)  #)%@  &               @($T
M.0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ \H&55T*/
MGF5$"0  2!P  !D              ("!N$(  'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q02P$"% ,4    " #R@9578\D(?0P#  ">!@  &0
M    @($S3   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (
M /*!E5<]W/2"& ,   ,'   9              " @79/  !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L! A0#%     @ \H&55UQ\Q-6Z!P  WQ(  !D
M             ("!Q5(  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"
M% ,4    " #R@957#L*ZF_L)  #5&P  &0              @(&V6@  >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( /*!E5<9:?%*A ,
M $<(   9              " @>AD  !X;"]W;W)K<VAE971S+W-H965T,34N
M>&UL4$L! A0#%     @ \H&55Q(I?1ZY#   #R4  !D              ("!
MHV@  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #R@957
M9:\&^B($  #O"@  &0              @(&3=0  >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;%!+ 0(4 Q0    ( /*!E5<0/YE/SP0   \,   9
M      " @>QY  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%
M  @ \H&55W]\$V<=!@  RP\  !D              ("!\GX  'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #R@957P_*[@ND#   $"0
M&0              @(%&A0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+
M 0(4 Q0    ( /*!E5?;,E7H;@(  %P%   9              " @6:)  !X
M;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ \H&55^0'WN8Z
M"@  :AX  !D              ("!"XP  'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6Q02P$"% ,4    " #R@957A!S-[G<$  "0#0  &0
M@(%\E@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( /*!
ME5<QN<+MN@(  -D%   9              " @2J;  !X;"]W;W)K<VAE971S
M+W-H965T,C0N>&UL4$L! A0#%     @ \H&55TW#1<>B @  ,P8  !D
M         ("!&YX  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
M    " #R@957@'87O]<#  #U"   &0              @('TH   >&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( /*!E5?2H)_R?04  ",/
M   9              " @0*E  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L! A0#%     @ \H&55[@&EH8^ P  QP@  !D              ("!MJH
M 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #R@95710!)
M28D"  "#!0  &0              @($KK@  >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;%!+ 0(4 Q0    ( /*!E5?U6I)^%P,  "<'   9
M  " @>NP  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @
M\H&55W$@%WZ: @  E@8  !D              ("!.;0  'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6Q02P$"% ,4    " #R@957IA4^!(T&  #C+@  &0
M            @($*MP  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4
M Q0    ( /*!E5?G9X(:70,  "T0   9              " @<Z]  !X;"]W
M;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ \H&55[V/Q+)1 @
M'@4  !D              ("!8L$  'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6Q02P$"% ,4    " #R@957[C*BW70#   ?$   &0              @('J
MPP  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( /*!E5?0
MA6NP_ <   Y-   9              " @97'  !X;"]W;W)K<VAE971S+W-H
M965T,S8N>&UL4$L! A0#%     @ \H&55WM)TI/> @  1P@  !D
M     ("!R,\  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /*!E5>V)J)%J@,  '<-   9              "
M@?K<  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ \H&5
M5],ON1T) P  R0D  !D              ("!V^   'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6Q02P$"% ,4    " #R@957*<ANQ]D#  #>"P  &0
M        @($;Y   >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0
M   ( /*!E5=*S7? 9P(  # &   9              " @2OH  !X;"]W;W)K
M<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ \H&55S.Z9"<5 P  0 H
M !D              ("!R>H  'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q0
M2P$"% ,4    " #R@957N+YTRMT%  ";'@  &0              @($5[@
M>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( /*!E5<-XC?,
M0 ,  (L*   9              " @2GT  !X;"]W;W)K<VAE971S+W-H965T
M-#@N>&UL4$L! A0#%     @ \H&55_,7^-3. @  ,P@  !D
M ("!H/<  'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " #R
M@9575VK'+!$'  #1+P  &0              @(&E^@  >&PO=V]R:W-H965T
M<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( /*!E5=?)PEGS (  /,'   9
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M970U-2YX;6Q02P$"% ,4    " #R@957F_T[09<#  #O#0  &0
M    @(&U%0$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    (
M /*!E5=HJ95JMP(    (   9              " @8,9 0!X;"]W;W)K<VAE
M971S+W-H965T-3<N>&UL4$L! A0#%     @ \H&55VTV4K!< @  0P4  !D
M             ("!<1P! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"
M% ,4    " #R@957;Y"63,D"  !4!P  &0              @($$'P$ >&PO
M=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( /*!E5="JY,,LP(
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M<F5L<R\N<F5L<U!+ 0(4 Q0    ( /*!E5=U2DK8QP0  #,H   /
M      "  6 L 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #R@957]4F2
MS $"  !>)   &@              @ %4,0$ >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " #R@957UDS DN !  #C(P  $P
M    @ &-,P$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     10!% -H2  ">
%-0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>151</ContextCount>
  <ElementCount>367</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>55</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000002 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/BalanceSheets</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000003 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000004 - Statement - STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StatementsOfOperations</Role>
      <ShortName>STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000006 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000007 - Disclosure - ORGANIZATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/ORGANIZATION</Role>
      <ShortName>ORGANIZATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000008 - Disclosure - LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LIQUIDITY</Role>
      <ShortName>LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000010 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/WarrantsAndNonemployeeOptions</Role>
      <ShortName>WARRANTS AND NONEMPLOYEE OPTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000011 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000012 - Disclosure - PATENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PATENTS</Role>
      <ShortName>PATENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000013 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000014 - Disclosure - EQUITY-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/EquityBasedCompensation</Role>
      <ShortName>EQUITY-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000015 - Disclosure - EMPLOYEE BENEFIT PLAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/EmployeeBenefitPlan</Role>
      <ShortName>EMPLOYEE BENEFIT PLAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000016 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000017 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000018 - Disclosure - STOCKHOLDERS EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000019 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/FairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000020 - Disclosure - NET LOSS PER COMMON SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/NetLossPerCommonShare</Role>
      <ShortName>NET LOSS PER COMMON SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000021 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000023 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/WarrantsAndNonemployeeOptionsTables</Role>
      <ShortName>WARRANTS AND NONEMPLOYEE OPTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/WarrantsAndNonemployeeOptions</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000024 - Disclosure - PLANT PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PlantPropertyAndEquipmentTables</Role>
      <ShortName>PLANT PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000025 - Disclosure - PATENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsTables</Role>
      <ShortName>PATENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/PATENTS</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>000026 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/IncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>000027 - Disclosure - EQUITY-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/EquityBasedCompensationTables</Role>
      <ShortName>EQUITY-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/EquityBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>000029 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/FairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/FairValueMeasurements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>000030 - Disclosure - NET LOSS PER COMMON SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/NetLossPerCommonShareTables</Role>
      <ShortName>NET LOSS PER COMMON SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/NetLossPerCommonShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>000032 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails</Role>
      <ShortName>WARRANTS AND NONEMPLOYEE OPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/WarrantsAndNonemployeeOptionsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>000033 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1</Role>
      <ShortName>WARRANTS AND NONEMPLOYEE OPTIONS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/WarrantsAndNonemployeeOptionsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>000034 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails2</Role>
      <ShortName>WARRANTS AND NONEMPLOYEE OPTIONS (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/WarrantsAndNonemployeeOptionsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>000035 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails3</Role>
      <ShortName>WARRANTS AND NONEMPLOYEE OPTIONS (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/WarrantsAndNonemployeeOptionsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>000036 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative</Role>
      <ShortName>WARRANTS AND NONEMPLOYEE OPTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/WarrantsAndNonemployeeOptionsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>000037 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/PropertyAndEquipment</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>000038 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/PropertyAndEquipment</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>000039 - Disclosure - PATENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsDetails</Role>
      <ShortName>PATENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/PatentsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>000040 - Disclosure - PATENTS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsDetails1</Role>
      <ShortName>PATENTS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/PatentsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>000041 - Disclosure - PATENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsDetailsNarrative</Role>
      <ShortName>PATENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/PatentsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>000042 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/IncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/IncomeTaxesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>000043 - Disclosure - INCOME TAXES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/IncomeTaxesDetails1</Role>
      <ShortName>INCOME TAXES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/IncomeTaxesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>000044 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/IncomeTaxesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>000045 - Disclosure - EQUITY-BASED COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/EquityBasedCompensationDetails</Role>
      <ShortName>EQUITY-BASED COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/EquityBasedCompensationTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>000046 - Disclosure - EQUITY-BASED COMPENSATION (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/EquityBasedCompensationDetails1</Role>
      <ShortName>EQUITY-BASED COMPENSATION (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/EquityBasedCompensationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>000047 - Disclosure - EQUITY-BASED COMPENSATION (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/EquityBasedCompensationDetails2</Role>
      <ShortName>EQUITY-BASED COMPENSATION (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/EquityBasedCompensationTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>000048 - Disclosure - EQUITY-BASED COMPENSATION (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/EquityBasedCompensationDetails3</Role>
      <ShortName>EQUITY-BASED COMPENSATION (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/EquityBasedCompensationTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>000049 - Disclosure - EQUITY-BASED COMPENSATION (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/EquityBasedCompensationDetails4</Role>
      <ShortName>EQUITY-BASED COMPENSATION (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/EquityBasedCompensationTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>000050 - Disclosure - EQUITY-BASED COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/EquityBasedCompensationDetailsNarrative</Role>
      <ShortName>EQUITY-BASED COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/EquityBasedCompensationTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>000051 - Disclosure - EMPLOYEE BENEFIT PLAN (Detail Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/EmployeeBenefitPlanDetailNarrative</Role>
      <ShortName>EMPLOYEE BENEFIT PLAN (Detail Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>000052 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>000053 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>000054 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>000055 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative )</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/RelatedPartyTransactions</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>000056 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquity</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>000057 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>000058 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/FairValueMeasurementsDetailsNarrative</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>000059 - Disclosure - NET LOSS PER COMMON SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/NetLossPerCommonShareDetails</Role>
      <ShortName>NET LOSS PER COMMON SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/NetLossPerCommonShareTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>000060 - Disclosure - NET LOSS PER COMMON SHARE (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/NetLossPerCommonShareDetails1</Role>
      <ShortName>NET LOSS PER COMMON SHARE (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/NetLossPerCommonShareTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>000061 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/SubsequentEvents</ParentRole>
      <Position>61</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cvm-20230930.xsd</File>
    <File>cvm-20230930_cal.xml</File>
    <File>cvm-20230930_def.xml</File>
    <File>cvm-20230930_lab.xml</File>
    <File>cvm-20230930_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="cvm_10k.htm">cvm_10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cvm_10kimg10.jpg</File>
    <File>cvm_10kimg11.jpg</File>
    <File>cvm_10kimg14.jpg</File>
    <File>cvm_10kimg15.jpg</File>
    <File>cvm_10kimg16.jpg</File>
    <File>cvm_10kimg17.jpg</File>
    <File>cvm_10kimg18.jpg</File>
    <File>cvm_10kimg9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="477">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>87
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cvm_10k.htm": {
   "nsprefix": "cvm",
   "nsuri": "http://cvm.com/20230930",
   "dts": {
    "schema": {
     "local": [
      "cvm-20230930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cvm-20230930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cvm-20230930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cvm-20230930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cvm-20230930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "cvm_10k.htm"
     ]
    }
   },
   "keyStandard": 266,
   "keyCustom": 101,
   "axisStandard": 16,
   "axisCustom": 0,
   "memberStandard": 9,
   "memberCustom": 44,
   "hidden": {
    "total": 24,
    "http://xbrl.sec.gov/dei/2023": 8,
    "http://fasb.org/us-gaap/2023": 14,
    "http://cvm.com/20230930": 2
   },
   "contextCount": 151,
   "entityCount": 1,
   "segmentCount": 55,
   "elementCount": 488,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 477,
    "http://xbrl.sec.gov/dei/2023": 38
   },
   "report": {
    "R1": {
     "role": "http://cvm.com/role/Cover",
     "longName": "000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://cvm.com/role/BalanceSheets",
     "longName": "000002 - Statement - BALANCE SHEETS",
     "shortName": "BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://cvm.com/role/BalanceSheetsParenthetical",
     "longName": "000003 - Statement - BALANCE SHEETS (Parenthetical)",
     "shortName": "BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://cvm.com/role/StatementsOfOperations",
     "longName": "000004 - Statement - STATEMENTS OF OPERATIONS",
     "shortName": "STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://cvm.com/role/StatementsOfStockholdersEquity",
     "longName": "000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2021-09-30_us-gaap_CommonStockMember",
      "name": "us-gaap:SharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-09-30_us-gaap_CommonStockMember",
      "name": "us-gaap:SharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://cvm.com/role/StatementsOfCashFlows",
     "longName": "000006 - Statement - STATEMENTS OF CASH FLOWS",
     "shortName": "STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://cvm.com/role/ORGANIZATION",
     "longName": "000007 - Disclosure - ORGANIZATION",
     "shortName": "ORGANIZATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://cvm.com/role/LIQUIDITY",
     "longName": "000008 - Disclosure - LIQUIDITY",
     "shortName": "LIQUIDITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "cvm:LiquiditydisclosureTextblock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "cvm:LiquiditydisclosureTextblock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://cvm.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://cvm.com/role/WarrantsAndNonemployeeOptions",
     "longName": "000010 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS",
     "shortName": "WARRANTS AND NONEMPLOYEE OPTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "cvm:WarrantsAndNonEmployeeOptionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "cvm:WarrantsAndNonEmployeeOptionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://cvm.com/role/PropertyAndEquipment",
     "longName": "000011 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://cvm.com/role/PATENTS",
     "longName": "000012 - Disclosure - PATENTS",
     "shortName": "PATENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://cvm.com/role/IncomeTaxes",
     "longName": "000013 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://cvm.com/role/EquityBasedCompensation",
     "longName": "000014 - Disclosure - EQUITY-BASED COMPENSATION",
     "shortName": "EQUITY-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://cvm.com/role/EmployeeBenefitPlan",
     "longName": "000015 - Disclosure - EMPLOYEE BENEFIT PLAN",
     "shortName": "EMPLOYEE BENEFIT PLAN",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://cvm.com/role/CommitmentsAndContingencies",
     "longName": "000016 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://cvm.com/role/RelatedPartyTransactions",
     "longName": "000017 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://cvm.com/role/StockholdersEquity",
     "longName": "000018 - Disclosure - STOCKHOLDERS EQUITY",
     "shortName": "STOCKHOLDERS EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://cvm.com/role/FairValueMeasurements",
     "longName": "000019 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://cvm.com/role/NetLossPerCommonShare",
     "longName": "000020 - Disclosure - NET LOSS PER COMMON SHARE",
     "shortName": "NET LOSS PER COMMON SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://cvm.com/role/SubsequentEvents",
     "longName": "000021 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://cvm.com/role/WarrantsAndNonemployeeOptionsTables",
     "longName": "000023 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Tables)",
     "shortName": "WARRANTS AND NONEMPLOYEE OPTIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cvm:WarrantsAndNonEmployeeOptionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cvm:WarrantsAndNonEmployeeOptionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://cvm.com/role/PlantPropertyAndEquipmentTables",
     "longName": "000024 - Disclosure - PLANT PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PLANT PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://cvm.com/role/PatentsTables",
     "longName": "000025 - Disclosure - PATENTS (Tables)",
     "shortName": "PATENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://cvm.com/role/IncomeTaxesTables",
     "longName": "000026 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://cvm.com/role/EquityBasedCompensationTables",
     "longName": "000027 - Disclosure - EQUITY-BASED COMPENSATION (Tables)",
     "shortName": "EQUITY-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesTables",
     "longName": "000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://cvm.com/role/FairValueMeasurementsTables",
     "longName": "000029 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://cvm.com/role/NetLossPerCommonShareTables",
     "longName": "000030 - Disclosure - NET LOSS PER COMMON SHARE (Tables)",
     "shortName": "NET LOSS PER COMMON SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
     "longName": "000032 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details)",
     "shortName": "WARRANTS AND NONEMPLOYEE OPTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30_cvm_ConsultantsMember_srt_MinimumMember",
      "name": "cvm:Issuedate2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "cvm:WarrantsAndNonEmployeeOptionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30_cvm_ConsultantsMember_srt_MinimumMember",
      "name": "cvm:Issuedate2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "cvm:WarrantsAndNonEmployeeOptionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1",
     "longName": "000033 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details 1)",
     "shortName": "WARRANTS AND NONEMPLOYEE OPTIONS (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "cvm:NetLossGainOnWarrantLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "cvm:NetLossGainOnWarrantLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails2",
     "longName": "000034 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details 2)",
     "shortName": "WARRANTS AND NONEMPLOYEE OPTIONS (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2021-10-01to2022-09-30_cvm_SeriesCCMember",
      "name": "us-gaap:ProceedsFromIssuanceOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2021-10-01to2022-09-30_cvm_SeriesCCMember",
      "name": "us-gaap:ProceedsFromIssuanceOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails3",
     "longName": "000035 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details 3)",
     "shortName": "WARRANTS AND NONEMPLOYEE OPTIONS (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "cvm:EquityWarrantsExercised",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfEquityWarrantsWereExercisedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "cvm:EquityWarrantsExercised",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfEquityWarrantsWereExercisedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative",
     "longName": "000036 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details Narrative)",
     "shortName": "WARRANTS AND NONEMPLOYEE OPTIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "cvm:DeemedDividend11",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "cvm:DeemedDividend11",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://cvm.com/role/PropertyAndEquipmentDetails",
     "longName": "000037 - Disclosure - PROPERTY AND EQUIPMENT (Details)",
     "shortName": "PROPERTY AND EQUIPMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:FixturesAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:FixturesAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://cvm.com/role/PropertyAndEquipmentDetailsNarrative",
     "longName": "000038 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)",
     "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://cvm.com/role/PatentsDetails",
     "longName": "000039 - Disclosure - PATENTS (Details)",
     "shortName": "PATENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:FiniteLivedPatentsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:FiniteLivedPatentsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://cvm.com/role/PatentsDetails1",
     "longName": "000040 - Disclosure - PATENTS (Details 1)",
     "shortName": "PATENTS (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2022-09-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-09-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://cvm.com/role/PatentsDetailsNarrative",
     "longName": "000041 - Disclosure - PATENTS (Details Narrative)",
     "shortName": "PATENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "cvm:PatentsWeightedAverageAmortizationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "cvm:PatentsWeightedAverageAmortizationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://cvm.com/role/IncomeTaxesDetails",
     "longName": "000042 - Disclosure - INCOME TAXES (Details)",
     "shortName": "INCOME TAXES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "cvm:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://cvm.com/role/IncomeTaxesDetails1",
     "longName": "000043 - Disclosure - INCOME TAXES (Details 1)",
     "shortName": "INCOME TAXES (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://cvm.com/role/IncomeTaxesDetailsNarrative",
     "longName": "000044 - Disclosure - INCOME TAXES (Details Narrative)",
     "shortName": "INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "cvm:DeferredTaxAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://cvm.com/role/EquityBasedCompensationDetails",
     "longName": "000045 - Disclosure - EQUITY-BASED COMPENSATION (Details)",
     "shortName": "EQUITY-BASED COMPENSATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://cvm.com/role/EquityBasedCompensationDetails1",
     "longName": "000046 - Disclosure - EQUITY-BASED COMPENSATION (Details 1)",
     "shortName": "EQUITY-BASED COMPENSATION (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://cvm.com/role/EquityBasedCompensationDetails2",
     "longName": "000047 - Disclosure - EQUITY-BASED COMPENSATION (Details 2)",
     "shortName": "EQUITY-BASED COMPENSATION (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2022-09-30_cvm_ExercisableMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-09-30_cvm_ExercisableMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://cvm.com/role/EquityBasedCompensationDetails3",
     "longName": "000048 - Disclosure - EQUITY-BASED COMPENSATION (Details 3)",
     "shortName": "EQUITY-BASED COMPENSATION (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2022-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://cvm.com/role/EquityBasedCompensationDetails4",
     "longName": "000049 - Disclosure - EQUITY-BASED COMPENSATION (Details 4)",
     "shortName": "EQUITY-BASED COMPENSATION (Details 4)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "AsOf2022-09-30_cvm_RestrictedStockAwardsMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-09-30_cvm_RestrictedStockAwardsMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://cvm.com/role/EquityBasedCompensationDetailsNarrative",
     "longName": "000050 - Disclosure - EQUITY-BASED COMPENSATION (Details Narrative)",
     "shortName": "EQUITY-BASED COMPENSATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30_cvm_StockCompensationPlansMember",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://cvm.com/role/EmployeeBenefitPlanDetailNarrative",
     "longName": "000051 - Disclosure - EMPLOYEE BENEFIT PLAN (Detail Narrative)",
     "shortName": "EMPLOYEE BENEFIT PLAN (Detail Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesDetails",
     "longName": "000052 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesDetails1",
     "longName": "000053 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2022-09-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-09-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "000054 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:OtherResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:OtherResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "000055 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative )",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "From2021-10-01to2022-09-30_cvm_OfficerAndDirectorMember",
      "name": "cvm:DeemedDividendFromModificationOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2021-10-01to2022-09-30_cvm_OfficerAndDirectorMember",
      "name": "cvm:DeemedDividendFromModificationOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://cvm.com/role/StockholdersEquityDetailsNarrative",
     "longName": "000056 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)",
     "shortName": "STOCKHOLDERS EQUITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "AsOf2023-05-02",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-04-30to2023-05-02",
      "name": "cvm:AggregateNetProceedsFromSaleOfSecurities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://cvm.com/role/FairValueMeasurementsDetails",
     "longName": "000057 - Disclosure - FAIR VALUE MEASUREMENTS (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "AsOf2022-09-30",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-09-30",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://cvm.com/role/FairValueMeasurementsDetailsNarrative",
     "longName": "000058 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:UnrealizedGainLossOnInvestments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:UnrealizedGainLossOnInvestments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://cvm.com/role/NetLossPerCommonShareDetails",
     "longName": "000059 - Disclosure - NET LOSS PER COMMON SHARE (Details)",
     "shortName": "NET LOSS PER COMMON SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://cvm.com/role/NetLossPerCommonShareDetails1",
     "longName": "000060 - Disclosure - NET LOSS PER COMMON SHARE (Details 1)",
     "shortName": "NET LOSS PER COMMON SHARE (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://cvm.com/role/SubsequentEventsDetailsNarrative",
     "longName": "000061 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "AsOf2023-07-20",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-11-01to2023-11-20_us-gaap_SubsequentEventMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of expenses for options issued or vested and restricted stock awarded",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_OtherIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIntangibleAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents, net",
        "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/ORGANIZATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ORGANIZATION",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r105",
      "r382",
      "r383"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Increase)/decrease in assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase/(decrease) in liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of non vested options",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r44"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expense",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r182"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of assumptions used for fair value of each option granted",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of unvested shares, Beginning",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares]",
        "periodEndLabel": "Number of unvested shares, Ending",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails4",
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares]",
        "documentation": "Number of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Beginning",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price]",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Ending",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses",
        "label": "[Increase (Decrease) in Prepaid Expense]",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Thereafter",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, after Year Five]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://cvm.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r219"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercises",
        "label": "[Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales]",
        "documentation": "Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuances",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited options",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period]",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted options",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r252"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2024",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year One]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Five]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of unvested options, Beginning",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number]",
        "periodEndLabel": "Number of unvested options, Ending",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r250"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Beginning",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value]",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Ending",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r250"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://cvm.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r405"
     ]
    },
    "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtWeightedAverageInterestRateOverTime",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average discount rate",
        "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://cvm.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r405",
      "r423",
      "r573",
      "r574"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested options",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period]",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Four]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward Axis",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Three]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Two]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets",
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "label": "[Stockholders' Equity Attributable to Parent]",
        "periodStartLabel": "Balance, amount",
        "periodEndLabel": "Balance, amount",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r72",
      "r73",
      "r87",
      "r407",
      "r423",
      "r447",
      "r448",
      "r483",
      "r495",
      "r512",
      "r518",
      "r558",
      "r573"
     ]
    },
    "cvm_DeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "DeferredTaxAssets",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease expenses",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Future Minimum Lease Obligation",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "cvm_SeriesSSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "SeriesSSMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series SS [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails",
      "http://cvm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NOL carryforwards",
        "verboseLabel": "NOL carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r554"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized gain on short-term T-bills",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "cvm_SeriesWMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "SeriesWMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series W [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share - basic and diluted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r338",
      "r339",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r422",
      "r424",
      "r453"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "EQUITY-BASED COMPENSATION"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Thereafter",
        "label": "[Finance Lease, Liability, to be Paid, after Year Five]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net deferred tax asset",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "PROPERTY AND EQUIPMENT",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r122",
      "r125",
      "r126"
     ]
    },
    "cvm_SeriesBBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "SeriesBBMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series BB [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "[Deferred Tax Assets, Valuation Allowance]",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2024",
        "label": "[Finance Lease, Liability, to be Paid, Year One]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "cvm_SeriesZZMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "SeriesZZMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series ZZ [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "[Finance Lease, Liability, to be Paid, Year Five]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_OutstandingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "OutstandingMember",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "[Finance Lease, Liability, to be Paid, Year Four]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "label": "[Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value]",
        "periodEndLabel": "Ending balance",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebtAndCapitalLeaseObligations",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on obligations under finance leases",
        "label": "[Repayments of Debt and Lease Obligation]",
        "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "[Finance Lease, Liability, to be Paid, Year Three]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "cvm_SeriesTTMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "SeriesTTMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series TT [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "[Finance Lease, Liability, to be Paid, Year Two]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "cvm_ProceedFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "ProceedFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of warrant"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_DeemedDividendFromModificationOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "DeemedDividendFromModificationOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deemed dividend from modification of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well Known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "cvm_Warrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "Warrant",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant extensions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "[Liabilities, Current]",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r130",
      "r155",
      "r188",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r302",
      "r305",
      "r306",
      "r317",
      "r483",
      "r522",
      "r561",
      "r562"
     ]
    },
    "cvm_AggregateNetProceedsFromSaleOfSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "AggregateNetProceedsFromSaleOfSecurities",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate net proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_PrepaidAmountOfResold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "PrepaidAmountOfResold",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid of resold amount"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest payment to lease liability",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r332"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected stock price volatility, min",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected stock price volatility, max",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAndDiluted",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding - basic and diluted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate, min",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net realized and unrealized derivative loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate, max",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WeightedAverageRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "WeightedAverageRiskFreeInterestRate",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average risk free interest rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "R&amp;D credit",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r554"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of federal or state current or deferred tax expense or benefit",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss available to common shareholders - basic and diluted"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r336",
      "r337",
      "r339",
      "r340",
      "r389",
      "r390",
      "r391",
      "r428",
      "r429",
      "r430",
      "r450",
      "r452"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "cvm_LIQUIDITYAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "LIQUIDITYAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "LIQUIDITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Total deferred tax liability",
        "label": "[Deferred Tax Liabilities, Net]",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r553"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vacation and other",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days)."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r554"
     ]
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "cvm_SeriesRRMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "SeriesRRMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails3",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series RR [Member]",
        "verboseLabel": "Series RR [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WarrantsAndNonemployeeOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "WarrantsAndNonemployeeOptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "WARRANTS AND NONEMPLOYEE OPTIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "cvm_IncomeTaxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "IncomeTaxMember",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r499",
      "r500",
      "r501"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "cvm_SeriesYMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "SeriesYMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series Y [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r499",
      "r500",
      "r501"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "NET LOSS PER COMMON SHARE",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r176",
      "r177",
      "r178"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less Imputed Interest On Operating Lease Obligation",
        "label": "[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "cvm_SeriesZMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "SeriesZMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series Z [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of earnings per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r554"
     ]
    },
    "us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of future minimum payments under finance leases",
        "documentation": "Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "cvm_SeriesCCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "SeriesCCMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series CC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss",
        "label": "[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r139",
      "r140",
      "r148",
      "r155",
      "r161",
      "r168",
      "r169",
      "r180",
      "r183",
      "r185",
      "r187",
      "r188",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r300",
      "r303",
      "r304",
      "r315",
      "r317",
      "r365",
      "r374",
      "r392",
      "r425",
      "r444",
      "r445",
      "r474",
      "r480",
      "r481",
      "r494",
      "r509",
      "r522"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets",
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease obligation, current portion",
        "verboseLabel": "Operating lease liability, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm Id",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r499",
      "r500",
      "r501"
     ]
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of future minimum payments under operating leases",
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "cvm_SeriesHHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "SeriesHHMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series HH [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://cvm.com/role/EmployeeBenefitPlanDetailNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of components of the Company's deferred tax assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "cvm_SeriesAAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "SeriesAAMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series AA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesMMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "SeriesMMMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series MM [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument Risk Axis",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r57",
      "r395",
      "r397",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r434",
      "r435",
      "r436",
      "r437",
      "r440",
      "r441",
      "r442",
      "r443",
      "r458",
      "r459",
      "r460",
      "r461",
      "r470",
      "r485",
      "r487"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesNNMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "SeriesNNMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series NN [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r280",
      "r569"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total expense",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "cvm_IssuedStockOfOptionsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "IssuedStockOfOptionsOutstanding",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options issued of payment for services remained outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ExpectedLifeOfOptionsMin1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "ExpectedLifeOfOptionsMin1",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life of options, min"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r393",
      "r513",
      "r514",
      "r515",
      "r557",
      "r573"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r397",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r434",
      "r435",
      "r436",
      "r437",
      "r440",
      "r441",
      "r442",
      "r443",
      "r458",
      "r459",
      "r460",
      "r461",
      "r485",
      "r487"
     ]
    },
    "cvm_NumberOfOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "NumberOfOptions",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of Options Expired",
        "label": "[Number of Options Expired]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NumberOfOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "NumberOfOptionsExercised",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of Options Exercised",
        "label": "[Number of Options Exercised]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r95",
      "r369",
      "r380",
      "r381",
      "r387",
      "r406",
      "r483"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplies used for R&amp;amp;D and manufacturing",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r131",
      "r135",
      "r191",
      "r192",
      "r193",
      "r346",
      "r472"
     ]
    },
    "us-gaap_FixturesAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FixturesAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research equipment",
        "documentation": "Amount before accumulated depreciation of fixtures and equipment. Includes, but is not limited to, machinery, equipment, and engines."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NumberOfOptionsVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "NumberOfOptionsVested",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Options Vested",
        "label": "[Number of Options Vested]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Due to employees",
        "label": "[Increase (Decrease) in Employee Related Liabilities]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_OtherNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashExpense",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash lease expense",
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r38"
     ]
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositsAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deposits",
        "label": "[Deposits Assets, Noncurrent]",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "cvm_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value Outstanding, Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_CommonStockIssuedForServiceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "CommonStockIssuedForServiceShares",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for service, shares",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WarrantsExpired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "WarrantsExpired",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants expired",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_PrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "PrepaidExpenses",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses",
        "label": "[Prepaid expenses]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "401(k) contributions paid in common stock, amount",
        "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_AccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "AccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Supplies used for R&amp;D and manufacturing",
        "label": "[Inventory, Noncurrent]",
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "401(k) contributions paid in common stock, shares",
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of long-lived assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r92"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General &amp; administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r427"
     ]
    },
    "cvm_Total": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "Total",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "label": "[Total]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_PatentsWeightedAverageAmortizationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "PatentsWeightedAverageAmortizationPeriod",
     "presentation": [
      "http://cvm.com/role/PatentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average amortization period for patents"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r208",
      "r232",
      "r234",
      "r262",
      "r263",
      "r264",
      "r344",
      "r345",
      "r376",
      "r396",
      "r397",
      "r454",
      "r455",
      "r456",
      "r457",
      "r462",
      "r466",
      "r467",
      "r475",
      "r476",
      "r477",
      "r484",
      "r487",
      "r520",
      "r524",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568"
     ]
    },
    "cvm_AmortizationOfPatentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "AmortizationOfPatentCosts",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of patent costs"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ExpectedLifeOfOptionsMax": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "ExpectedLifeOfOptionsMax",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life of options, max"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r499",
      "r500",
      "r501"
     ]
    },
    "cvm_ResearchAndDevelopmentCreditDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "ResearchAndDevelopmentCreditDescription",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development credit, description"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized R&amp;D"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r21",
      "r127",
      "r142",
      "r143",
      "r144",
      "r158",
      "r159",
      "r160",
      "r162",
      "r167",
      "r169",
      "r179",
      "r189",
      "r190",
      "r231",
      "r271",
      "r272",
      "r273",
      "r293",
      "r294",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r334",
      "r377",
      "r378",
      "r379",
      "r393",
      "r446"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "verboseLabel": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r208",
      "r234",
      "r345",
      "r376",
      "r396",
      "r397",
      "r454",
      "r455",
      "r456",
      "r457",
      "r462",
      "r466",
      "r467",
      "r475",
      "r476",
      "r477",
      "r484",
      "r524",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r208",
      "r232",
      "r234",
      "r262",
      "r263",
      "r264",
      "r344",
      "r345",
      "r376",
      "r396",
      "r397",
      "r454",
      "r455",
      "r456",
      "r457",
      "r462",
      "r466",
      "r467",
      "r475",
      "r476",
      "r477",
      "r484",
      "r487",
      "r520",
      "r524",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r158",
      "r159",
      "r160",
      "r162",
      "r167",
      "r169",
      "r189",
      "r190",
      "r271",
      "r272",
      "r273",
      "r293",
      "r294",
      "r307",
      "r309",
      "r310",
      "r312",
      "r314",
      "r377",
      "r379",
      "r393",
      "r573"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r127",
      "r142",
      "r143",
      "r144",
      "r158",
      "r159",
      "r160",
      "r162",
      "r167",
      "r169",
      "r179",
      "r189",
      "r190",
      "r231",
      "r271",
      "r272",
      "r273",
      "r293",
      "r294",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r334",
      "r377",
      "r378",
      "r379",
      "r393",
      "r446"
     ]
    },
    "cvm_FixedAssetsAndIntangiblesAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "FixedAssetsAndIntangiblesAssets",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fixed assets and intangibles",
        "label": "[Fixed assets and intangibles]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "verboseLabel": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r208",
      "r234",
      "r345",
      "r376",
      "r396",
      "r397",
      "r454",
      "r455",
      "r456",
      "r457",
      "r462",
      "r466",
      "r467",
      "r475",
      "r476",
      "r477",
      "r484",
      "r524",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r150",
      "r151"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_RightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "RightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fully insured amount of non-interest bearing cash balances",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual Axis"
       }
      }
     },
     "auth_ref": [
      "r517",
      "r559"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Supplies used for R&amp;D and manufacturing",
        "label": "[Increase (Decrease) in Inventories]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "cvm_FixedAssetsAndIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "FixedAssetsAndIntangibles",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed assets and intangibles"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://cvm.com/role/PlantPropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of property and equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense, net",
        "label": "[Interest Expense]",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r110",
      "r145",
      "r181",
      "r325",
      "r431",
      "r493",
      "r572"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued to nonemployees for service, shares",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r483",
      "r571"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued to nonemployees for service, amount",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ResearchAndDevelopmentCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "ResearchAndDevelopmentCredit",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development credit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenseMember",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expense [Member]",
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "cvm_WeightedAverageExercisePriceVested": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "WeightedAverageExercisePriceVested",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price Vested",
        "label": "[Weighted Average Exercise Price Vested]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ExercisableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "ExercisableMember",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r342"
     ]
    },
    "cvm_WeightedAverageExercisePriceExpired": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "WeightedAverageExercisePriceExpired",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Exercise Price Expired",
        "label": "[Weighted Average Exercise Price Expired]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "WeightedAverageRemainingContractualLifeInYearsOutstandingEnding",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life Term (Years) Outstanding, Ending"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WeightedAverageOperatingLeaseMaturityYear": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "WeightedAverageOperatingLeaseMaturityYear",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average operating lease maturity year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails1",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "cvm_StockOptionExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "StockOptionExercisePrice",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesUUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "SeriesUUMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series UU [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r240",
      "r259",
      "r260",
      "r261",
      "r262",
      "r265",
      "r274",
      "r275",
      "r276",
      "r277"
     ]
    },
    "cvm_AdditionalClinicalTrial": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "AdditionalClinicalTrial",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional clinical trial"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "ConsultantsMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultants [Member]",
        "verboseLabel": "Consultants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity based compensation - employees",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r68",
      "r69",
      "r95"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of stock issuance costs",
        "label": "[Payments of Stock Issuance Costs]",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "cvm_VestedOptions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "VestedOptions",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options vested"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ConsultantsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "ConsultantsOneMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultants 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r555"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary Sale Of Stock Axis",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/PATENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "PATENTS",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of common stock, amount",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r68",
      "r69",
      "r95",
      "r393",
      "r446",
      "r463",
      "r494"
     ]
    },
    "cvm_DeemedDividendAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "DeemedDividendAmount",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Deemed dividend"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ClinicalServiceTrial": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "ClinicalServiceTrial",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical service trial"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_DeemedDividend11": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "DeemedDividend11",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deemed dividend"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_StockIssuedDuringPeriodToPurchaseCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "StockIssuedDuringPeriodToPurchaseCommonStock",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued options to purchase common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r51",
      "r52",
      "r53",
      "r58",
      "r157"
     ]
    },
    "cvm_PaymentsMadeToLandlord": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "PaymentsMadeToLandlord",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments Made to Landlord"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesXMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "SeriesXMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series X [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockDescription",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options vest description",
        "documentation": "A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock prices per share",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of non-qualified and incentive stock option plans"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Remaining Contractual Life Term (Years) Outstanding, Beginning",
        "label": "[Weighted Average Remaining Contractual Life Term (Years) Outstanding, Beginning]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "ScheduleOfLlossesGainsOnTheWarrantLiabilitiesTableTextBlock",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of (losses)/gains on the warrant liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions By Related Party Axis",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r338",
      "r339",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r422",
      "r424",
      "r453",
      "r560"
     ]
    },
    "cvm_WeightedAverageGrantDateFairValueVested": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "WeightedAverageGrantDateFairValueVested",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value, vested"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "ScheduleOfWarrantsRecordedAsLiabilitiesWereExercisedTableTextBlock",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrants recorded as liabilities were exercised"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_PerformanceBasedStockOptionsSharesGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "PerformanceBasedStockOptionsSharesGranted",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance based stock options shares granted"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "ScheduleOfEquityWarrantsWereExercisedTableTextBlock",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of equity warrants were exercised"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_RestrictedStockAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "RestrictedStockAwardsMember",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails4",
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Awards [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 6.0
      },
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows",
      "http://cvm.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on derivative instruments",
        "negatedLabel": "Gain on derivative instruments",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r284",
      "r296"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option exercises, amount",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r21",
      "r95"
     ]
    },
    "cvm_FiniteLivedIntangibleAssetsUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "FiniteLivedIntangibleAssetsUsefulLife",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent Useful Life"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_RemainingOutstandingFairValueOfShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "RemainingOutstandingFairValueOfShares",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant date fair value remaining outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_Issuedate2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "Issuedate2",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State tax rate, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r555"
     ]
    },
    "cvm_VestedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "VestedShares",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested shares",
        "label": "[Vested shares]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "FAIR VALUE MEASUREMENTS",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "cvm_SharesIssuableUponExerciseOfwarrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "SharesIssuableUponExerciseOfwarrant",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issuable upon Exercise of Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "ExercisePrice",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent differences",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r555"
     ]
    },
    "cvm_StockBonusPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "StockBonusPlansMember",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Bonus Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_TotalCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "TotalCompensation",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/EmployeeBenefitPlanDetailNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 29.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "[Net Cash Provided by (Used in) Financing Activities]",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of common stock, shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r68",
      "r69",
      "r95",
      "r386",
      "r446",
      "r463"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ExpirationDate1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "ExpirationDate1",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 28.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by investing activities",
        "label": "[Net Cash Provided by (Used in) Investing Activities]",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from maturity of U.S. Treasury Bills",
        "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "cvm_StockCompensationPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "StockCompensationPlansMember",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Compensation Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/EquityBasedCompensationDetails2",
      "http://cvm.com/role/EquityBasedCompensationDetails4",
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative",
      "http://cvm.com/role/IncomeTaxesDetailsNarrative",
      "http://cvm.com/role/NetLossPerCommonShareDetails1",
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StatementsOfStockholdersEquity",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative",
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails2",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails3",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r179",
      "r350",
      "r384",
      "r394",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r405",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r424",
      "r426",
      "r427",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r446",
      "r488"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "[Net Cash Provided by (Used in) Operating Activities]",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r85"
     ]
    },
    "cvm_NetLossGainOnWarrantLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "NetLossGainOnWarrantLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net (loss) gain on warrant liabilities",
        "documentation": "Amount of increase in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ParticipantCompensation": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "ParticipantCompensation",
     "presentation": [
      "http://cvm.com/role/EmployeeBenefitPlanDetailNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Participant compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingGainsLosses",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other non-operating losses",
        "documentation": "Amount of gain (loss) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of common stock",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r68",
      "r69",
      "r95"
     ]
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of restricted common stock issued from the incentive stock bonus plan",
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "STOCKHOLDERS' EQUITY",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r154",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r313",
      "r449",
      "r451",
      "r464"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "cvm_WeightedAverageOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "WeightedAverageOperatingLeaseDiscountRate",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average operating lease discount rate"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NonQualifiedStockOptionsPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "NonQualifiedStockOptionsPlansMember",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Qualified Stock Options Plans [Member]",
        "verboseLabel": "Non-Qualified Stock Options Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "WarrantsExercised",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "[Assets]",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r134",
      "r155",
      "r180",
      "r184",
      "r186",
      "r188",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r301",
      "r305",
      "r317",
      "r367",
      "r417",
      "r483",
      "r495",
      "r522",
      "r523",
      "r561"
     ]
    },
    "cvm_IncentiveStockOptionPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "IncentiveStockOptionPlansMember",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Stock Option Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_LesseeOperatingLeaseLiabilityPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "LesseeOperatingLeaseLiabilityPayments",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total Future Minimum Lease Obligation",
        "label": "[Total Future Minimum Lease Obligation]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "[Operating Income (Loss)]",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r183",
      "r185",
      "r187",
      "r474"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "cvm_IncrementalBorrowingDerivativeVariableRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "IncrementalBorrowingDerivativeVariableRate",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental borrowing, derivative variable rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r351",
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "cvm_NetOfDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "NetOfDiscount",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net of discount"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_IncentiveStockBonusPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "IncentiveStockBonusPlanMember",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Stock Bonus Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ExercisePriceWarrants": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "ExercisePriceWarrants",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails2",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise Price",
        "label": "[Exercise Price]",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardDescription",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards, description",
        "documentation": "A description of the origin, nature, and characteristics of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "cvm_AdditionalExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "AdditionalExpenses",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional expenses"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesNAndXAndYWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "SeriesNAndXAndYWarrantsMember",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series N and X and Y Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37"
     ]
    },
    "cvm_EquityWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "EquityWarrantsExercised",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other adjustments",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r555"
     ]
    },
    "cvm_FinancingLeaseContractualArrangement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "FinancingLeaseContractualArrangement",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r342"
     ]
    },
    "cvm_SeriesMMAndNNAndUUWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "SeriesMMAndNNAndUUWarrantMember",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series MM and NN and UU Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WeightedAverageMaturityYear": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "WeightedAverageMaturityYear",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average maturity year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeBenefitsAndShareBasedCompensationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "EMPLOYEE BENEFIT PLAN"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://cvm.com/role/PatentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of total estimated future amortization",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "cvm_ProceedsFromEquityWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "ProceedsFromEquityWarrantsExercised",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Equity Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_OfficerAndDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "OfficerAndDirectorMember",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer and Director [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2",
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option exercises, shares",
        "negatedLabel": "Number of Options Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r68",
      "r69",
      "r95",
      "r246"
     ]
    },
    "cvm_EquityWarrantsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "EquityWarrantsExercisePrice",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Warrants Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_CashPaymentToLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "CashPaymentToLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash payment to lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesNMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "SeriesNMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series N [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_UnvestedRestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "UnvestedRestrictedStockMember",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested Restricted Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_OptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "OptionsMember",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options and Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_CashPaymentForOperatingLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "CashPaymentForOperatingLeases",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash payment for operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDeposits",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deposits",
        "label": "[Increase (Decrease) in Deposits]",
        "documentation": "The net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r64"
     ]
    },
    "cvm_IncrementalCostDeemedDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "IncrementalCostDeemedDividend",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental cost"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_AmountsDueToEmployeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "AmountsDueToEmployeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to employees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://cvm.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r343"
     ]
    },
    "cvm_AssetsPurchasedUnderFinanceLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "AssetsPurchasedUnderFinanceLeases",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets purchased under finance leases"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_FinanceLeaseObligationIncludedInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "FinanceLeaseObligationIncludedInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease obligation included in accounts payable"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_FinancingCostsIncludedInCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "FinancingCostsIncludedInCurrentLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing costs included in current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "[Payments to Acquire Property, Plant, and Equipment]",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r122",
      "r125",
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock options authorized shares",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "cvm_USTreasuryBillsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "USTreasuryBillsPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S. Treasury Bills"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options Expired",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period]",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "cvm_WarrantsAndNonEmployeeOptionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "WarrantsAndNonEmployeeOptionsDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WARRANTS AND NON-EMPLOYEE OPTIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right of use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "cvm_LiquiditydisclosureTextblock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "LiquiditydisclosureTextblock",
     "presentation": [
      "http://cvm.com/role/LIQUIDITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LIQUIDITY",
        "label": "[LIQUIDITY]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_AccruedConsultingServicesToBePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "AccruedConsultingServicesToBePaid",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued consulting services to be paid with common stock"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_DerivativeLiabilitiesExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "DerivativeLiabilitiesExercised",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of derivative liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "cvm_ConsultingFeePaidWithIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "ConsultingFeePaidWithIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid consulting services paid with issuance of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on short term investments",
        "label": "[Gain (Loss) on Investments]",
        "documentation": "Amount of realized and unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r506"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Options Outstanding, Beginning",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number]",
        "periodEndLabel": "Number of Options Outstanding, Ending",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://cvm.com/role/EmployeeBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "EMPLOYEE BENEFIT PLAN",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r99"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expenditures for patent costs",
        "label": "[Payments to Acquire Intangible Assets]",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price Outstanding, Beginning",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price]",
        "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease right of use assets",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "cvm_ModificationOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "ModificationOfWarrants",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Modification of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment purchases included in current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET DECREASE IN CASH AND CASH EQUIVALENTS",
        "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r83"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 1",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationEquity",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation expense",
        "documentation": "Value of stock issued under share-based plans to employees or officers which is the unearned portion, accounted for under the fair value method."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r41"
     ]
    },
    "cvm_EarningPerShareBasicAndDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "EarningPerShareBasicAndDiluted",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails",
      "http://cvm.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per common share - basic and diluted",
        "verboseLabel": "Basic and diluted loss per common share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 2",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted",
     "presentation": [
      "http://cvm.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding - basic and diluted"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WarrantExercisesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "WarrantExercisesShares",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercises, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://cvm.com/role/PatentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of patents",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails4",
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265"
     ]
    },
    "cvm_WarrantExercisesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "WarrantExercisesAmount",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercises, amount"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address City Or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets",
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF YEAR",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r83",
      "r152"
     ]
    },
    "cvm_IncreaseDecreaseFromStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "IncreaseDecreaseFromStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_IncentiveStockForfeitedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "IncentiveStockForfeitedShares",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2014 Incentive Stock Forfeited, shares"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_IncentiveStockForfeitedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "IncentiveStockForfeitedAmount",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2014 Incentive Stock Forfeited, amount"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_IncreaseDecreaseToRightOfUseAssetsAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "IncreaseDecreaseToRightOfUseAssetsAndLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes to right of use assets and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_CommonStockContributedToEmployeeBenefitPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "CommonStockContributedToEmployeeBenefitPlan",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock contributed to 401(k) plan"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_GainLossOnReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "GainLossOnReceivables",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on Receivables",
        "label": "[Loss on Receivables]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "cvm_CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "CapitalizablePatentCostsIncludedInAccruedExpensesAndAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized patent costs included in current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ProceedsFromIssuanceOfCommonStocks": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "ProceedsFromIssuanceOfCommonStocks",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r486",
      "r487",
      "r489",
      "r490",
      "r491",
      "r492",
      "r513",
      "r514",
      "r557",
      "r570",
      "r573"
     ]
    },
    "cvm_ProceedsFromLandlordFundingOfLeaseImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "ProceedsFromLandlordFundingOfLeaseImprovements",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from landlord funding of lease improvements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://cvm.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r219"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r203",
      "r204",
      "r465",
      "r521"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finance lease right of use assets",
        "label": "[Finance Lease, Right-of-Use Asset, Amortization]",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r331",
      "r482"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r202",
      "r430"
     ]
    },
    "us-gaap_FurnitureAndFixturesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesGross",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and equipment",
        "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r153"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r430"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Member",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r342"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityStrikePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionIndexedToIssuersEquityStrikePrice1",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock price",
        "documentation": "Exercise or strike price stated in the contract for options indexed to the issuer's equity shares."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r15"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssued",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "label": "[Shares, Issued]",
        "periodEndLabel": "Balance, shares",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r483"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/EmployeeBenefitPlanDetailNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense for Company's contribution to employee benefit plan",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "EQUITY-BASED COMPENSATION",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r268",
      "r269",
      "r270",
      "r478"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://cvm.com/role/BalanceSheetsParenthetical",
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "verboseLabel": "Common stock, shares issued",
        "terseLabel": "Common stock shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r281",
      "r285",
      "r286",
      "r291",
      "r295",
      "r297",
      "r298",
      "r299",
      "r388"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, $.01 par value; 200,000 shares authorized; 0 shares issued and outstanding Common stock, $.01 par value; 600,000,000 shares authorized; 47,422,304 and 43,448,317 shares issued and outstanding at September 30, 2023 and September 30, 2022, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r368",
      "r483"
     ]
    },
    "us-gaap_CapitalLeaseObligationsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalLeaseObligationsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails",
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net present value of lease finance lease obligations - current portion",
        "verboseLabel": "Net present value of operating lease obligation - current portion",
        "documentation": "Amount of capital lease obligation due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r116",
      "r117"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "[Liabilities]",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r155",
      "r188",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r302",
      "r305",
      "r306",
      "r317",
      "r404",
      "r473",
      "r495",
      "r522",
      "r561",
      "r562"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://cvm.com/role/BalanceSheetsParenthetical",
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "verboseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r405"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average period",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "[Liabilities and Equity]",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r108",
      "r370",
      "r483",
      "r512",
      "r518",
      "r558"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://cvm.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r69",
      "r405",
      "r423",
      "r573",
      "r574"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate net proceeds from sale of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease liabilities, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r282",
      "r283",
      "r286",
      "r287",
      "r290",
      "r292",
      "r385"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplies used for R&amp;D and manufacturing",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r468",
      "r483"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r333"
     ]
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails",
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payments for services",
        "verboseLabel": "Non-employees",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets",
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease obligation, current portion",
        "verboseLabel": "Finance lease liability, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_CapitalLeaseObligationsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalLeaseObligationsNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails",
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net present value of lease finance lease obligations - non-current portion",
        "verboseLabel": "Net present value of operating lease obligation - non-current portion",
        "documentation": "Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r116",
      "r117"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Imputed Interest On Financing Lease Obligation",
        "label": "[Finance Lease, Liability, Undiscounted Excess Amount]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the exercise of options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of anti-dilutive securities",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Common Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "[Increase (Decrease) in Accounts Payable]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "cvm_CumulativeChangeInOwnershipPercentage": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "CumulativeChangeInOwnershipPercentage",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative change in ownership percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "[Assets, Current]",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r138",
      "r155",
      "r188",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r301",
      "r305",
      "r317",
      "r483",
      "r522",
      "r523",
      "r561"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "PATENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "[Operating Expenses]",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent costs, net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r351"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "[Increase (Decrease) in Accrued Liabilities]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fin Stmt Error Correction Flag",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r499",
      "r500",
      "r501",
      "r503"
     ]
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedPatentsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedPatentsGross",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Patents",
        "label": "[Finite-Lived Patents, Gross]",
        "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://cvm.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value Outstanding, Beginning",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding]",
        "periodEndLabel": "Aggregate Intrinsic Value Outstanding, Ending",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseAgreementsMember",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Agreement [Member]",
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsGross",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold improvements",
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails1",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r132",
      "r373"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State tax rate change",
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets",
      "http://cvm.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "verboseLabel": "Net property and equipment",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r366",
      "r373",
      "r483"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r121"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated depreciation and amortization",
        "label": "[Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment]",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r133",
      "r372"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r499",
      "r500",
      "r501"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS PER COMMON SHARE"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2",
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r194",
      "r195",
      "r469"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative",
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails2",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Axis",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life Term (Years) Outstanding, Beginning",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Remaining Contractual Life Term (Years) Outstanding, Ending",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term]",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r119",
      "r120",
      "r123",
      "r124"
     ]
    },
    "cvm_NonVestedOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "NonVestedOptionsMember",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Vested Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionIndexedToIssuersEquityEquityAxis",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2",
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed To Issuers Equity Equity Axis",
        "documentation": "Information by type of options indexed to an issuer's equity."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r59",
      "r60",
      "r106"
     ]
    },
    "cvm_RestrictedStocksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "RestrictedStocksMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expenses",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r38"
     ]
    },
    "us-gaap_DescriptionOfLesseeLeasingArrangementsCapitalLeases": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DescriptionOfLesseeLeasingArrangementsCapitalLeases",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease description",
        "documentation": "A general description of the lessee's leasing arrangements including, but not limited to, the following: a) the basis on which contingent rental payments are determined; (b) the existence and terms of renewal or purchase options and escalation clauses; (c) restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name Axis",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550"
     ]
    },
    "cvm_ConsultingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "ConsultingAgreementsMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfOperations",
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "[Net Income (Loss) Attributable to Parent]",
        "verboseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r85",
      "r109",
      "r128",
      "r139",
      "r140",
      "r144",
      "r155",
      "r161",
      "r163",
      "r164",
      "r165",
      "r166",
      "r168",
      "r169",
      "r173",
      "r180",
      "r183",
      "r185",
      "r187",
      "r188",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r315",
      "r317",
      "r375",
      "r425",
      "r444",
      "r445",
      "r474",
      "r493",
      "r522"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/EquityBasedCompensationDetails2",
      "http://cvm.com/role/EquityBasedCompensationDetails4",
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative",
      "http://cvm.com/role/IncomeTaxesDetailsNarrative",
      "http://cvm.com/role/NetLossPerCommonShareDetails1",
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StatementsOfStockholdersEquity",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative",
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails2",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails3",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r179",
      "r350",
      "r384",
      "r394",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r405",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r424",
      "r426",
      "r427",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r446",
      "r488"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r347",
      "r348",
      "r349",
      "r351",
      "r471"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss available to common shareholders",
        "label": "[Net Income (Loss) Available to Common Stockholders, Basic]",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r163",
      "r164",
      "r165",
      "r166",
      "r171",
      "r172",
      "r174",
      "r175",
      "r180",
      "r183",
      "r185",
      "r187",
      "r474"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease right of use assets",
        "label": "[Operating Lease, Right-of-Use Asset, Amortization Expense]",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "cvm_LandlordMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "LandlordMember",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Landlord [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ErgomedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "ErgomedMember",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ergomed [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value measurements using significant unobservable inputs",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r62"
     ]
    },
    "cvm_SeriesCCWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "SeriesCCWarrantsMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series CC Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees",
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total compensation cost",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r278"
     ]
    },
    "cvm_SeriesZWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "SeriesZWarrantsMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series Z Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public offering price per share",
        "verboseLabel": "Share public offering price",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ending Balance",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "cvm_SeriesAAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "SeriesAAWarrantsMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series AA Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://cvm.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrants and non-employee options",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails4",
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "cvm_SeriesHHWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "SeriesHHWarrantsMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series HH Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PatentsMember",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative",
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails2",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other (expense) income",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "cvm_ConsultantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "ConsultantMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment loss on abandonment of patents",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r519"
     ]
    },
    "cvm_TwoSeptemberTwoThousendTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "TwoSeptemberTwoThousendTwentyFiveMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "September 2, 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_TwoSeptemberTwoThousendTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20230930",
     "localname": "TwoSeptemberTwoThousendTwentyFourMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "September 2, 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(2)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481648/480-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)(2)",
   "SubTopic": "40",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-8"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "63",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481620/480-10-55-63"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-4"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "230",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481160/942-230-45-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4,6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7,9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-3"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482673/440-10-25-3"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481440/840-10-50-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481192/840-30-45-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481161/840-30-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-30/tableOfContent"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>88
<FILENAME>0001654954-23-015877-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001654954-23-015877-xbrl.zip
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M9%:N 9,W-V(FLW(-F%PLQ$QFY1HPN5J)F<S*-6!RO18SF95KP.1F(V8R*]>
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M*9S=)DB/".O_G4Q_&$9WJ/[Z?U!+ P04    " #R@957[Z$GKE\0  #NP0
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M;W1IS$3^$X03*%T7(UV>J#%@B$1M#^>/01BD[<WX9A FD*PYWPC"")8WX0=
M" &2)GP""!M \DU6YA[* AR1 5O",OR@<VCU.C6Y4F^>66>IWNOB#="V#P"W
M_89X.P? VWE#O&<'P'OVAGBAT_!5?1EXTX=-.H"D.6Q0DU;IXC 1$M!XPL8'
M1:!;A22M#XH!3)-:ZG"Q(XP=N<#!D>A84D@<' N4+8"DF2@;QAY,V"A"':M
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ML$;QMAO&#_%@== @6EHS@[^PD.$U84[9B-2*G5B$,X.TL)PE^Y(Z0=&K<F:
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M-*V8W%P'B; IR"?!G>3ZN-0;!YG#6L%!R'>H):.U![/V8/8<#F8] )V'R-6
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MJ:HN8%WB:E ZDF2195.5WI[PJ8[=IH 5DE)HI/XX**AAAT$1AT2D)DUNFA)
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MH*M& A*@)A]X1#NZ)C_'?]RBS^\?_P]02P,$%     @ \H&55V[J#W7/:0
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M'X:$KEYDP\UO"(97OD,<:;R%JU!4T2J_!NIAP2^0,X =-=!*VP F#I@\( H
M:P"BHL%N_(HVF__R@Z_^(X)1X"/G)HKV*!2. J&\2CM2 SIO3P3"!C!'!I_
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M/B[%NLHHJ)GKY&"G<UZU-'/\(&2-=3K@F^(4&DF\K\G91G .+%(0"[I@1?5
MI%^1]_R"BUZ]XGW5,[K;DV1+:S<9'L7@R7J>G5B>&AIV4NF4I2<5QNP-IL9,
M9^ALQ]4H<CPM&B\$:-DYGN=B:[LG?0>I6)) S[7;(L6BE*[*A"T-*I//X2*A
MR$X<[?EB9$+ 6PO(U5&[!J8(.=3QB2Q#ZAHB$=) MQP\+J^H!$N8!0?NU(0S
M]2IL)::DLN!W*JW;EWW <^OYZ ;_4^3YX@EJ($@))I<D!RD6L;98#I9&$46
MKX(L1 -0%6,8PPPDGO=W@4^3)K]YM>3AZVC@415X+J5X"LD#N..I912[ZJ&*
MB98D*SLJ@]^)NF[297;AGVF:5T$;<.2TI$;(@Q3D0V!"[.KV8FDO3"!1#3Q!
MY@,J;V:*W4JZU.AH3[<KIE&E O,D6-8<FG $U !J10)>HGM^XX,+(Q/P5K),
M)*POT:Z85WQ)=F<1#9=S$Z*\9#!6)=&]U)E$M^;*?NGR^QQO))"JP(H="KW
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M'N73LZA*'D(38-(DSW"#5K[S&9)3YOA][=*;J?67%!J6H30%2?/*%;*4R!?
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ME4S2%269P2/RCG%EUKO.2E7TRF%W#7!X_?#T(EEF2\==+'2>A?12F=(B*?T
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M0@=OPT'1ID@=(Z-]U?G#HWEY[(6[R6CAF+7H.K4F50/%10X*\701A""*<:G
MWN.Q00[EP_Q 06Q2(G^WV",KQ@P:?J3T YX!0\_&,R ]TOCBDU>O\/;>69&V
MQ'O]AN.HHZ]H.>?JLH$$IU]=?(+2=KB<30<F7!_IM7*5KB@VU")ZE3@Y' ->
M%.WQ4,1_><7?)>Y5WP'A 0(>O?@; )+O:W=7\5HN>0B1-A!M+W:3(2))#=EK
M4+B"6_:WUB/SE(_H'9BG-T_=N&S_!192/41+9,)+AGW6K6I4PF,1QXO^+LG+
M^4KS<I*!"^V79,""9^)&[OF<XR[P_[*'&\_UD).]$I1I O:BFORA1]LB59^
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MN'PZ 28.B+SNQ'TP>KF^O+FX\>F&=K4E>3X$PT8@J_9E(2'8XDM")4$6?3U
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M#R@ DC-&5)0!&9#(\VAW<,M+)L,74>@CXD#+>80RO[.N=&=+J#.HOQY9:?V
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MJ E8^!_WV*GNHND C<>J)BW5QS3RM3_)15YWE*-N^K+JF\UJW&P/: L]<@)
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M(V>&YHR>S7V %R(@R!KT)<6+8):NPU>X9A6Z.VX'+(QP]7 8%]MJ(!4,$63
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M[-RM=Q$6H!W%!\R4_BM.R:5YIVW0R7S4!"@(JXIL;_X<M*6C*%P5![RQY(?
MEI/![G.+S3HER@8BYT+-G87="?@ZA*;HU^8NMQ9.7(53VY *[?Z\W4[B)DZ>
M</).5M.V8F2=AMO0#9C04X3G^>K "GYD.V8,:$8]!*^_A4ES4LB\$7"@@6U)
M"C*T(70=CL+!2Z*$D(ION*8D:FD;$K/1E$(OVUE,USCI8R\]OV=GG<5QM[/^
MG--A'FUUC]]P9G;&:/J.$_B,\U]F:O\-#)-?X6K#2@%PV8D Z.N&=,&=37(H
MF%:"LRYG1H@L%P/9Y0AFZG%:O(:<M 26BI$R-EVH"<P9TFL])/@-ABP*YPEZ
MCAH!SS64,6[I=3A*>;4N_/PUS'9>I[Z6=X^MC@?UP+8DB5_IM D>PR@8=_DB
MU@])_(:S*$ZR3/^Y"=\R'+N<0?OIES(0V:<9B!X>%P^SQ^7O>0:BV5^_S!_N
M9O?+?=ZA+MF&ADARGV/*W@/796",K$2%HUU35V#9GEDMYGD98#?AMS4A>UJ>
MV,])G#(.E-HNP%5Q8(CVL6M-=NJ*:@;9R];?GV^;) JS&9()%G-MXEM=%^!H
MIF5(\HS<EV^-('M9_7OS[1:3>^A+O$+SU[<D?M]Z,C0PKKX/@([N5SU_1LDY
M#I2]GA7.=P8TL(_=#R#H&Z8D]XZ>+.1$VNO=HG^8E^]O7C>YK\HU)F3VPYS(
MY,\KG%,[?V=)UN&_\I_78JIG^%!? (ZM.(HDP1T]16-PFAR>8CCU$G=[.XWP
M<S8)@7I)+;9[W.4:27H!%/BF(LF#V[GVD#+.P[/1B&K.,/0B9HI6IZ6"U"\Q
MJ]RJ$G8\UZM8*B\#C&??JL?&TQNXEF:9H]GP"V90UW$KO,+*!S^0LX!<,QGF
M";>R^J;+698?6:@]XB8D6@Z^)6L<S0D5HN?06^%IFN)U2O;)YI7&UQ\8EH_U
MBC7SXA!W7&JT2U [ -W2=4\2JT1+NM>8)M@X#XM)AH"%TL6O8:,DK6L: \M4
ME4"21_]>+.3 *-8^L5B_X(2"JW[9U?4 @>E!6<H=#K'N&H$*JP)P?(JIE&/,
M4)J.L8GZ/1]DEJF86C?7CW-"+&\ NZ>W>\+VY5>\>L=W<;1^X3OO.HP+#!=Y
MNB3/P"VYV'0L]B&'8+-^*Q"_8YA%A@PE(KOA@&V:"I+$FG!YR3BE@MCSN,/<
MR9<9+]X=!P2FKB(LB9E:D% <T4'L6T3[V6?A?$-*138>, ,?N9(\/XD1BB,R
MB'W8Z##YDL5Q$)D@;0&$GB6+!Y0@F2B3H5?(R(5EXC%>K;)$3\$:)T/+!VUL
M  -%L\=EFAE05I@D&3XR9AFOX8IN=\E_!3#&037_Z0BY44%TB&\9TWO1D5;/
M>B(RU$;M7NR;T(6T?,6$CE=17'IX &\Y<.(4?O1.G7N-U[@&<_8&OF7HLKSZ
MM*1T9=VU!CU\R'SY8XM@.Z'<;[S&YES7'&C8AXXD;G%]^=*,\E3/O=@^-X_(
M'_$2?L.,=SA#.]WBYO=7B[O99#G]VTSP8]P>P&%^S5L:HQ-P/<LQA+UR;\]'
M,K.M>"W><'9R1,^W<9I>D6/D(XB3+("&89IL,0BP%!W*DC.8ARDUK]WM 0^_
M\YW.XB;\1K;@?#Z'32-S:;Z";R&Y'X7_PNBQYO3J-A90/-61I991>V[VQRW6
M6E@1PPS\[F<[I>,H2BY"GW&$@W"=TL/HLA.BQ2H?X&M =6S5^NZV@R$I,WQR
ME=SU^C:$7KC*DZ33=X335L )-*1(8A+NM-9K$8DUY-&DYXK\/5P?'22/A,Z$
M1B_M%BAC(.!!SW8DR2TRZ-KC 2W64-=]Q]C_F!Q3'F&4SPH&'O0SP%8"WY'$
M8"1@KV:19'CS7>DB0N90OHOD/Z/OV0V=@(\=2Y/$]-!I"^<%.*0%4/#.T. &
M26\/L&MJ^G=WKSK&-GSFG#QU]"+XDF+6*CMM!0SLNKHD"34Z+:M:1,-GT:E=
MP2UW-&! C+ DM22&W<OVT$JI=01O16QMH;I<R[=L7S7,0))<R4-L131LI?0P
M8XM/JVRR3/=?6FN ], R)/$@&^ZP*2/KEV]F>!YER8FVA%VMXJ\P8B4]X>A,
M-&%'D25/\W <9 !MG^A&W@5;VI#:K=WCC@#[MB=+Y,QP0E #4ES"G.H#&-6%
M7^=Z 1/DQS_X&YBN^+[?[2;?&\PL"+"?.4OL)_A(EO@C]N/()Y*SE?SU#;F3
M)7"5Y6K:D#E\'#6N!SW X$!1?1^-P%!7,)&Z,(<DA%BO?1XD>?30_D?1<Y[5
MZP$G/C.51-^1@:;9'I*D_-59)86+"F)?YWA@W,0)#I^CHQ;7(>F8T3>D^N^U
M(%+3Z$ /''\,3SJ]Q86;$F+]_+DE?XK^9Y.N\YQ) ^PFI=$ 5E5H2^(%=?X=
MA(9<[&L@S]3OX^RFN2'-O!7>/5KT$P/:B$#Q54/[(QPF3/1B'PIYIG_UDB4_
MGD>]K 0#?P@$&K;@'V$?Z4*47L^%9Y*IJYB<A-&&W*5VSFST"B5,RM#& *JG
M8&<$9H4.DL#$>UIE0Z"!@1E-8/ 9&L2&% QN< @4([ $+<!]ON<E) =._?R/
MVP'%-J Q C- 05KJ0JK!M'_J$O3654W!S<&6?5N@.ZKBRE8]Y9C";&Y4H13*
MLR**)51'KNFWD,&9VBY ]P-<K90I/X.:$>WY)!&7#C686_*J5+R9;"&!+$6X
MFKG SSP*Q'XLK*ODNMV?6?5T3QH!;)JN(HD?"R_M*FX5=: *(@\8@%$XE4XC
M=(W?\2K.$R9NIUWC.L3H 3P'*DBV0Z1Z,%0HS@5*K,G^XF%.R(>&+&D1N'G9
M ^?!U"Y#%D*61%[CU$_"M_JLA)R=@1YXT)'$/#;4<J7A&SX Y6J;$9'HDH7Q
M9/$UPDGZ$K[MGG#@<TT16JZN0+5]:1)(MF%-.W1B#=74 YJ]N%A'>UGR<( 4
M9:2;)S>XX8L+5_9M^A*J- ..H6!%$E?:-LNE'LFI@?5BMK<L;?;ZHQ+1QXAT
M-T_-;UF*]^7OGSY/GV;7DZO%W</L_FFZG"_NQ8:]'^:X",K0'G&>W#;/+I"'
M,WJETHMILY&NW[@ $SW $_5<^_JVBC\P+A?VK=:F7.4?SQ,Q9"\'SU$60[Q-
MBY&#*T46UQ:Z+ZS0Y_D@,%3'A9)H'@/) ]V*?V;ZB55RLD+3V3/3(LCK3I/[
M75&L]U!\.ETD5RL8LLR;K88!IF-JJB2WX'.*3C>J#*D627*&49U5K?:'F"#/
M55F/L0!A6]1S5->:ROLRR>3VM7G=%EC.W"=\ OC7.%-D5D20LH?2NS *7S>O
MC#>5B\T!N*[I8$EB'0:2&OK;SN5)*O;\NP1@^$V\'&_G "R$34<2+7GL<GQ"
M4K&.PX,"?@S3?]PD&,^C-2:BL;[\;LR8 ?!<3]<D\0T:C0SS$%2L'_/YX5YT
M'V;, #BVIQF2I-08MP2?$+27=9MJ'RWV_MLP( 1:;*="%HY*$2/2OK8YP @K
MVG=B+J'RG O]\ 9L^C?AMS;\@=] ]CHB2R+7R[*G!%ZLB_%9[FS7X7N(<(38
M 9=G_S0(S,#3)7E=',V6SZ2D,%=IMJGKX%Y4,G79'4Q=VK]-70>9<TSDZZ)4
MJVZ>U[[N:M5'IE&N^(+Z]!5/ASURYVPM, Q7DBC7&@JSN5&%(MPY>WOCF)-=
M]AM&RSA['<%)NMU.M_]E>VKS]0>>JCA5B/*SKB4\P3[<K-DNR7>;7+GY^@/3
M<2U5$F-/2P:U9C(%MF F/VV\-$0A3#Z>X&K_C,E<I+5=@&<C9(QP738C*LP.
MHKATF%;F[+X(EN2VG9*#.[N5-BS#YKX@<X6'LAR%C;R@LY ?93]>4DT4B\TZ
M7<,(A=$S*[*BT@RX%G)EJ;+:<N.J&!_JT144'S#(8O8-)WZ89FN;1?%*,^ 0
M,9*EOED+H:68>NJ0%=0>VSO5SEQ5$J/[30UG^YHBZCX%7(=(K"S247_1']8P
MTTB-PP-^.W^EM]P[CN!(U@(S(_:ER\^Y/]=\5[.L(?'V&3X&? A-63(P7EHH
M6?00_!Z?;=OY(8FN-PE9--LIYFC2_)>+PL:9[]0'PR/-/-%V+."JFN-($I79
M6BBZPSV\8(\M06O?E3#[]A;NDHG,ZTM.#K3L*!\#CJD$FB09NR^]#;'H<7B2
M_J.)Y$V<!#A<;X@(G%\D*1\#=F K?U219-%#;':R46L 4+,42Q+/'?$:0$&-
M@]] %PU@%HUYERM1Y:2B<7$]>4A"5A*]"TT 6%!5L22Y402*+A>-NI:"&HE*
MF[92J\XDUL-- FB6KDD<NM]/M,] IUY%L,2+9P%*M(2VF@? AJ(%DH1>7%Q(
MNY&J5R4Q\7)*N8,+DM26,P%81TX@B>_2Q66U*[$$5UX;8(U6K!C"-M96,P&6
MH3E!Y?GP#R*N78E5*C\GI;A^+WJ7C4S5_U[WTH%I5"J9-U)+@M=,+*\UL1YQ
M]MI/?I[E#L\\<C=PM<3)J]8@W9>=#+!<7_''?,,51*]27<$QRFW)UX03.BUX
M;B ^=)@,P! B9\SO!(+H52J'.+:*Z9W)MG5XFT?I.MGDM[.\)-#R!48[@DZ?
MGY/\Z6Y.J!9&:>CG44VE_>$,PC_ K(!KZ*XKB;/AQ5;!D(0KEH,IQ&I,]8.\
M.%U8WBQD0N+F UP+VMK8/&+D(%DAV"+C@O^]5Y>W'-6'EG2A%&/8JPO"%2+=
M\86OEZ))W:FW+^K[J/Q?<;JNVT2I34&@&IXVMN?=1C0%GQQYSM23"3><>'6M
M@><8JC4VLQ /H()EKAQI_4_FR\4E@'!@>Y*D^^O!G#V.4ABA##QAV0)9.U]S
M/Z!!ST9C<]!J!ZU4E$:6/9$U^_Q]H@M'=QV!:QJ6.C;%M"6V@J>2U$+A, 5E
M283FT>\8)F7;YV?\'$81_>)<)4F'<8%F:IH]?FGH [T0%OXP!SF%95:G8O4A
MUVQGE/$T'8XM*FI W(6,[%.:29(>Z1!D7TJ/Y'1(CZ3_.SU2*4&/ZINX(NV2
M/^0WZO/W<?2>7WW.YN??=@H :M#R)=E6!I*981_^.U/T#QI%W$BO[>7_C %4
M+6= =$KHR%)C=9Q+H(:@K>M^C#]2L)%4Q\[M(J3_> ; 0):K26*V&Z?TUQ!T
MI,G'&^'NO(G%;N&520#347R]$@#R;SD>@J9_P)#O,=[E->@KNB2FXG$N@3J*
M'@+,1^K%>UYJG=AX\@/QFK!YGP);Z.IHG!UPL&GIWT>N?-$+AY_8_6+L+_#H
M4YU[BZ>\NL[ 14%@?,\&EPZT.,U\_^\-4K(U:SH6-KZ/^J;R;Y %L0]![4-<
M.B1Y+C%HSR5NA^<2X]_/)0>AMC#TJB%Y%]H^NU63@+[OR.*^/!#UZ5L*'?;(
MJTD$CJ:[LOF3'5.8S8TJ%.'5)/*#),L\S<Y'?]0,>&2^OB2/%VT804<QVHP#
M!S@1>EC!*,MOW9BI_@Q? ZJE*JHD(:MT'G>[>/6A13^IHJJ*C^0NEX19*:]M
MPOYL$BDK,SNC [!<Y*F2V.W.RHB*HLA#%1G2.O2(1STQ*2Z"O'532NWA/PAL
M!1M87C_#XABNWQ[.2)/OP%=C".J</@1=7&39$P"ZA55=EL(MHD28DT8C=[[H
M0:E?+[K=TKX&?,TQ'4EN89<65"9!)'"*^![.<D75%$?>_&!"SO*")JV=%61[
MJQV"-GT?'"XR!Z":*E+^Z.<Y/YGZ>2%\-[?4<<BVY5LVED6IEU>V"S(-FW%?
MDL>N>YADB2S?#W%1AT<O4^GPZ+4?\-^/7X?G%VA"PQ-5^Z/;XY>E^KXFR?UM
M(.KS/'X5L$?^^&6Z")JR:7?'%.9]_"J@C//Q2_<-Z$ORAMR&$704_W[\ZOO.
MH"AJ4$TZ*L/C5\'CRSU^%;00+%5\)>;KY82S1'V@NXXC2?1'FYV@);Q2VAO9
MF'DHF=V-F:62V\@W RB)<TE+!K5F,@6V8"9?K6":+H+?,E4C6B^2QTR%8R_2
MVBY -SW=DM,]A;DNFQ$5EFR9N-2T_AB=@.$$2)7$Q;>9^OQ,.X'7CVT7\ 5!
MEFY+HAF>]5[2SA=D1Y6">]U\0>@9A;./?8ZC39I-E,DW:E/@68XT@:<M3YH*
M#]@("^IWJT!>3_VR=/$QH:8'T) ';9DWL9/=B,Z )G0%'[J]HM*32L;17S=P
M%0;A;OGM++F-[.#H"'3L&4[%0#?.%=(&;\&GRY<3H/)X'OF$/N$[+LV[D;\-
MG8 %-=V6)'%S7][R8BWXVLWFS,&;_0[,SYF3+D"WH"7+\].P?*E#6G"E6U+W
MNEWQU[+/5<-&2&D+L(&L/^9]KH$@!;L$!7U.5_FX9!.G$F7V+?LCXT&'KS\(
M3-NQ)3GZ&.9_NI6Z'<2##ZT\W@5;UZ#I9OT2)^&_,/I"]J#D='<_RF/[F*V%
M4A;*G?">JW[9Q2<(-$/1'$ER';252-EH>/"Q%6("BE]?"?H,Z)8$^<'*2,=4
MTP$XAJ'(DOZBK4@T83HXG/YA*GJ-S:O?PTC7)#'W#[,CG8]&X\W$55FHAPV[
MQ8YUZ 1LSW*KAL!QB T/KJ[>GI+L7%VR:!P+/8^ #/XI8#JJZ4J2GZ?3;G06
M:AS<,X?2K1]P$L3)*R2Z?3Z=LC%M.XW<6[0NW1)W=V"HKJY)8I_G9F@GA&+3
M*+&L/$_K)/S']N[-*)7+.P) V-(52?Q\VJ[1UB /:8#$'-OD@I*D9,ID=\@D
M\!JG?A+F(%CG=GTOX-H6EKB21</!S0%LQ['*E;;/$_-.%2TIK7L?>L9-/G]6
MY>@*/-4( DG,^&TVR7;HSI (8FOB9#&@W ($R,#:V.R!=2!*F1G&=D6]WDWW
MR*"9[\'UFUI]'V"I@8%'JL)RP"H8O3=T72Z^YO5M%7]@_!E'. C7F2EO&PO#
M#*U1*Z$U=P^WB]]GL\GGV?WL9KZ</-Q.]V$U@J-J3B"FTZC&X-X<2--Z*&!C
M#9F"RB 3P2,2BG+K:NAM"E/M#D22,3#!V4]A\E%N-'V--Q$KG*C7N$#S#$^5
M)"BU.T/KEOH0E.GUTD,]19?Q&J[*>.A'::49L#7%]20Q70_%+";07D\.=$4<
M)NO0#]^(+MG,@9K&(,">4MU'1L^')KABTUE4E)'R"PA#SV;W ZKJF^YWMJ;:
M(3]8V2]\W<GLPN%Z&V 9Y?LTT6=PY(<XW84 TZX[VNEUYVIQ=S=?WLWNET^3
MZ7T63'R_G-__/+N_FL^>]M'$0FX[+(1[",TWG5;# &SJAE4)V+P,X)LPRDQX
MMYA([&T(O7!%;M9%%.WU!M\3Z5A^Q:MW?$=0O##>X]J.!+#JF)HDFW(WAE$7
M<6<Z=,WR)EY=;8*<U4Y=?HV[R\YN   M(S EV?LO*#*G\%LG3QN7I)!O,5S;
MN(< CN8Z4!)KUJ6EY8@ X_4RX<%Z$V\8]:UX1P (:J8K2=J$"TO+$?ZN"<I&
M(BPEFUQ'82$C *1BYP]X=ZG@'Z\72!/4:;#&27^).1H&0*B86)*7X0N*#9T(
M77-JR2\[W<4%!-#79'E]OJ"$['&+=1*A3O-+A C:S,2,T>R;C].TR<3?:AC@
MNJ8FRZ/KN5G>2(365:7D\2"%;^$:KG*\"V\5/N>L2Z\V249WAJV(V0_H*C)E
M>;L=4#HX4??R53D72^_CR._(U4-7$"#5,O\PC*4 K[B[2&3'/B1>*1FR]6Z&
M[(GZQS%E(Q.I2-#A?4M.$XP7;SCSEHB>!S!I=QT1&*:%9:D$T8V!U+7=FQ[C
M-7'S0F\T=;<<""BJY2BC/"8&$:53,HS7]-T*,=L$WGHHH/N^4MV7_UA2=$2(
M\9K$VV!FF\;;C@14V]*J"2S^4%)T1(?QFLI;068:0-N.! +35X(_[MVH0H?Q
MFM!Y(7.:TCL-!USHF?"/*TYT8@@SK5-=.+FPT!TZN;H"[)J*\1W)0&O@!ZOY
M=[6'M+>\=QH.(,.Q/$EB]2^UAS02X[NSQ ]CMG4MPT:C?*UAR@H_\(-)?FQ[
MS9E>:!Q?]=WO;_?@1%VRXO>7!XE> )@1?$;'EP"QH7Q"7@1L'*C5%/N7 =RQ
M_%7@NU"5)"5'-V)3%W0-RI%7N]*40,%REG H*,SF1A6*\&I710Y5=EF-<BN@
M0M,T)#D$V["!"D)P42+>(E4GJ6YU2\.>) [,5+(R&7 "XAPL2)-UB?SD;P?2
MD[^ 97; +X(Y48S>0[2!JQKQ)VVI38'ON J6)#J%:PTT(CE'%9FV7/@M7+_D
MQ1ZSV^=+^+:,9^007'_4K@X:*O8@(/ TI 6".=?(C6;F<<(47!SH)HS"-;XE
MUV T)^2-GD,BHM,TQ5F&[SOX/W&2%Z=@GSXM!@&&XB-)*V(R#Z<N&(LW*?EX
M>Y@PS^'6<B 00!7)DABQ"]_:"@"3"(*%8!X111L?;KC91S(&,!<THQ/P$#1,
M2=P7VBQ@'DS%6XU<O&I:GLQNP%5U0Y6DO </#]HP[P1B/_91W\MFR3/Y,&*5
M\SAJ AS;0%@2OXR:^WSE@8N.H*#F@,E[;F&$5F1<%CF/VP!/@6JUC)@$UT'.
M^UWU-9&.KZ"V(/-<;EJ>/B=X6]VEED'[YRQ*<X 4Q<*2' U=C^N:USL6W()U
M@G+[[!\5=V56FGA';P\,P[4\21[3^+9[*JL:T!6\JI@&NF]J9+))/DVX^APG
M2?R5?/P:)^%[_KKP*TS"['+R2+#0-SS^_L S%*LZ=6F21Q9&T\J>UP&BV!I!
MB_4+3AX)60E)7J81NL;O>!6_91 :ZSTU]P78<PQ97C6X^=@>WO 9Z.[Q>A%<
M[YPEZ,OIJ F %G2KMA7)*5V+0FP2N5("ZT6P=6C)#D:RELN%X<IOU0P5L\-@
MP#%T*$L%R;;+I@_>TR1S_=?1%*$PS]ZYVJW9&I^_:CN@F4@:!ZTV*XH!Y>#V
M.Q1]MP'7A:-7J2I8B=ETBO/T!+9IN++DWFK#@U;@AB\D<E*U[0ZN-PG1V#*7
M73HS&!T 4J&%)7%T;<,#'DSR9'[(2V$O@B_I5G>;OL;).OQ77=K9@^[',P#0
M;=<U)#&-M3U/VF)L[4(JC:L@-7D%'_/WS4&@F+HWMM7*A4AL6@;JW!J].%F]
M #04TQ'] #PDJTZ!#>JF>6D5@,S8#QOVWW(KH'NFCT=[::< *=4R$;WBYM$:
M$T*N=T$HBZCE_EC?'ZBFKBACNV)V@UBI6=+_IGD%TY?=%Y=QX\E%>C Z -5P
M?5V23'5M;IH\F K:"S)IW,;1<U:H^1I[ZY.+<2$XF55R07ZT#%]9 9/M!@(>
M-*1))=5V>77%6O!Z0#M&2<1NXN0XO*K&I,'L E1+M[5QKS4&JH(# UHZ3@3@
M^,N% ;/^\8.[.U!=W[7'=BWLA+#@DJ!B2S5!BHV7>G8_X"@6E"5Y3NLW#SYH
M!>-&&/M;@[ UMX&O*<98%>TF3 5_!158/9X>P^C3_$39<B2 '$N%LGGM=N)J
M"[ %NR\?7MO^I&UMRZ[O#AS?\Z5ST>Y[TE(1[J.[!'H9,![@RB_N^T<K756T
MT?F ,)$47!C0T;#(RG$'$2:ZY\[ECKXPZ&V!CU6(1K@*&N 4Q![2V$$:A#Y<
M/>'D/?3Q,@GAJD;WHK0$&#M(EL*,K50N%IB"S-WL&@UO]L67&92N:0P,"&U]
MA,1NPE/0^_*%^'(?8(RR^H\?RP1&*?1SEV">W 7F:>Z"Q]GM=#F[GCQ,'Y>_
M3Y:/T_NGZ=5ROKBG)2Z8",E<4(>W.5E!4T\0F+I9S1UU&5@=\Q- /Y#&W9^;
MOM2SN0;8V%,2Z,C'DH2BU5"8S8TJ%.$I"7+7^47P6[8/1>M%DJM4[("RVBX
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M]C,OH[ VGIZS-_ TPPW&QLXN 'OE".E_P]I.*Y.\AR3T\0-.<@EDW+-J>H!
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MORW!X?WVO=Z\U>'-Y\V;75R)*7SGH60JS7^9]Q.D^IO5SCSA>V>Q),7F%46
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M2 !B8%.6!AY/[!,M>GZ?UI@RV@A:;;+2!XTGNR6>L]$X\%EQX.2)F>NWRE_
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MM+=G+?5O>;AU5BZCWA90'IZPF.?!)_@U!3Z$)_ELLE,^7XKJGM;ZR]EE)JN
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M"(-1(_2'C4%TO3$>]39(-@:@<%R<[K=@YMNMK5VYENNK6/V+Q.JW5K'Z;^G
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MV^/8#VBIXKD88_U-FA3")%R-9S12,<AQ"PP<,SKR+/QEX_"A76>8')?R+>O
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MJ-T)=6^Q #R%@X(>/&80=1C*M.PNL\4KPDD=6RO2RR!- *U93G#/.:-9%S(
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M"4(K74&,$>:%*7F;&#L'EVDG<+MXVR/!:;[,DB&6IV!?1>2[&L1SG\0VY2?
M2;N#J.8<HQL^\DT>KAE) )VO_"XF4Z+&6'-.#VJP>XT# MK%9E;G#><C!LZ
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MJK%F)II]Z5[>W-N7#T1&\C66&9NS& [GG>EG0:%U$W=^,6T'*/U2#-L[")V
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M=)*1IO1.L2YIDL.P3"_@X U2+<%+92-S:7. N PU;D&C]. @L$[?XA^QTJ>
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M7XHOH"QCJ4:B1E-9D,H$*! F*4$,O65Z9!&?-;F%T:W?(P@L8.#4ZKM');M
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MN/#._!;9[S-XJ/C",T9VT4P)*XGYI<I\W-=TW3/O(7:E?\'P!,)X3945VHP
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M.-;V4:47R-3% O+>EY6PHI@="ZVECB44TKOX>=O^MS70=2L_Z:T<=.HR%FA
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M. )7S7-!$$E@R@8Q'$=\$-1T2>^.*BY*2+%Q/^Z4,-0\GV+\N>6.WF!"4KF
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M6&_HD_&C!8^M35>,U[$=%!TO3(-8[Z5U?K(6FJ3S_%)';UH<M%:KHXWRNXJ
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M'FL-4\N."+'?HSE''1:<RM8>N]YGJ1*E.W1$QL(+*5%Q8OZQ6. OB7SCSD6
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M>L(!]PNZU\=ZOK5D*R7;/ZXEVU^8#6@<Z:GWPJ#0=,1/(E<- RFF.H?WC=^
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M'&T9&23BK/WLW-/,F@6.DE"6X\G899AMA*3I$G?.?>B,4WA/8IX\!C*2P9M
M\I(I)YJ#I\UX'/I8.83@,0/MKS;786* D';V%8\ Q&$R@1#-&E2R2FE$0V/!
MNC(*ONO3ALYAHEL8%X6&=>A0H32")H'3X99.QZ0FHZ.,-Q/(GTX%$89P/VD*
M>6?FB)Z?^ :R69CH'*^.^NKZ:FS_ 0(,4R0^)[J@,Z!2G4@Q4QDSDRD?G!T:
MT 4+:PQ 9.31\H^O_ 0,[K=77SB2S"0P9@SXUY(W$9B2.KO(Y!\8\:K+E^%
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M+U5-1],MQT=I=FL1346[^2)=;S3T6$?[G)IW4/$.-3F5\7ZBU;=WWJGL;J6
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MNF\FN;W:7&LEG\?N6,%FQ!6?&E4T&V\2U;CQB> <:5W:ORO5=<<4EJ<-:5+
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M5M#%#'OU=S&8J5 49H9V1X!<8A+*6=RRX/GCD;<BI2/R3C=-4V0AC"9-2G?
MB*EK[\"U$]V5W_TH]DHD0 WVC/TT.46^>?(3F8Q,3P^%U$>A^AJ *Z_!9BO=
M=OX?I8_(K^6U08$687,\0K5TQ0<HCR;3>ZU<<1,4>/A$8RE  4KP- Y.0:9[
M!A!:+T3+A'3 N_W !CV#:[DFM>8"CN0%W?<U4UG0$62 G*:9A_*/SV5:&>?(
M68S)1,FT^)U9_<X$U<RQ&.\HY#;G=@9</%J+0(GN_7F E=BW^5 ,%;"AN <(
MS"I9EESY&WSZ!0O3^J=;F8%7[M6+.'@U82;,03JKC#ELL2*./(HA$O,?&VN8
MH6.YC7!!7!V_8\AXXB7Y3_<$BZK<MFIHDBY0 N4W%*;UQO=VP2W)3-C\R1,/
M&RF<\_'2@N289\?(H\H?'9\/]NFB%QD__ZS;-(2&LG38W^*_ XINSATPIEQ&
MKO!WN.Z#^,O\KBG!;""5<@:=[Z E6!LV"$:?GT3<?O%I5I>RNI2+QXR<(OH#
M7'&-;YHV5%-IVUSO4'C3?[IF9LK/_O*7?\4F_>NK-]?7 ;,-1$:!IPE^2YV+
MQ!IR_&LXNAAK"@.H^(+<QQR'8R_N@/]&I;A-M[OU^X^13MBI"-Q,+"6#W[KK
MF9>%4LJ,<G.>OZ2"X,QV]RZ'(+..I>W9_T0Z%R%5Z3++#\1;N@D"NOZ_[VOP
M)&:LNZ%#U,@C"RDW,WI4H\[EFP<1BX^&*T)'ZA 4I9V;?W)7-U>9XI]XTI[@
M3_^<+2_P8>O^_G?5?N]Z_ZLFE.*;V,S?1;Q(L^WZ5I Q>7S7,9?67-\^%:4.
MM<!LE^Z.WH?/+?'^Q8D&(",#'*G(3"QO?L4(G/V!NP04&5J>AWV^2_PV%+?#
M*-K(B3/Q!&$U=A%\Q[7EBJ:03RJ,JJ<%#K7I^^JRV6B58E,V8/.50PZ&O-^Y
M.. 3;WC^\?E3;WBN19V/Z(!.#E5&Q1XD^[248O5&Z1]<'+ ( ?#M;/%7_#KH
MQ3,1& F?VU4N)]=ZVPQ\L,7:M/*A,<'FG3,H?9W"5E M@@ M"Z&G);U?<(WZ
MWR5A^)@F$+:$Q7M+4Q>ECEO3'B+VC?Y/+63*?*(D#W_*)E!I&@R]&?QQ&3A<
MZ$S<4;_8AP^JX*VWA)(PCYT\_L[6$'T-T2\6HG]_]>XJA-&F:1-254R<Y21-
M/A:.H,$?OFL:[G$,#B \R.?/OWPW4!^U1DT.__39ET'J(=" <P'7$$BS+PH3
M5CK@9UDZ$))B(CV30,S_1P1>J.!%H1PA1S#FAX2[=>5A.[0=MAH'RIJ_9R%Y
M#[7<%[=E5?A'#R"7:2(C 3^P-AC,DTS[A6,< = .6B'X/_+#\<M8(W@G41M^
M[\7K=UGBCU3 GO)X?2_Z6O@Q9:VETD$O:B\+=)=7@]-UMQ>0CA(QYL-]-]VQ
M[&79N-(\O4X<U9OW]JD#1R[24A.=7SB"=.%5\ROBB(,0<E/;T[1)2.Z_/-#K
M S<!C-R_38*'K[)HJQN\C!LD;%AS0ZPTW"-AKD;NDG/!4SLD^O>^?/9!Z_SX
M]+1&&N?G<@P0(U2HF'_0=)EM$YE11+@&DTR. JRY;(^]&6LDU."J-=/%T\:Q
M#=UT=JDD9T;[2QX/*!$XS*#OO32(-:4"'W]61D5.P8/ZYQIX1@#?9-4,(_I@
M%#7<G0YJF(_A/Z@J,E0W<(\"0I]6-N45P'/=ET;P.3K1@ G6:=4T:PX^[LL%
MRTB7"3"#]*R*Q\*29[?^?,F1SWCP97^<&AAFYHN2;H?5^Y:>A-=M%,3*W*W$
ML?YV9L)F*F;(.3WB[SI(R8K? U/'<.6'!5OP" 32,V,YE-WR V* 6YFDCT3[
M?)37+8E+?SO(V GXA&3:5$S%46MPE=)<SXQ?*W1^T&LN.8:P>?)J-[!?B+(,
MI6$B-YXM0"!<^#J&L@>ARV[=EE/E)AEEM6(YH7AKTGK9<QW27F5)\ALX'#.X
M3 HMF $4K"JAZ\:[V,8[=Q"SK?]R!UB,E?A7PX6H).M/,!(MWROUG42*!F63
M_(K>4,#@3K$Y  ,>7&MGPOFJOX.3]-,27GW)#\WR&1T/Y F<2."?L3(YP8&F
M$[_ L"Z(+#V S49H*GSS(Z:.C@AR7H$Q[]AT+(QG]H D -;CRWT(\4%XG/ <
M1]%VZ\(P0*(Y) #8. ^DG=8LN6,@*CH\CDEBS"-K^]3_W^W S=!)+$MK82=!
M9LBV&#WA#SS5LJ"I'PO,RJUT+A:W:0VQYA(+4S8>5#1X[61\G% J60IJR0O_
MWS)+[5_8'+IE#G2;;8K\0)3$F2I=E0?O+;I&T";"[Z@\Z#RK7AZ#\S(G_,QA
MG)V']T4)0_^&O0^L-+Y LC28N624=L+Z9SIC9'G49J2!EVAW\'I-2]ND-W,6
MD60W >T#R[R_;0YS)"=%8\CU#;QHBN2.@_ZLG!<L"X(Q:EW&)8ZW,3OIGA11
MIE:C)F+4R$:&TN6UXIOB?8:WWOW,UVY?#+H[D1(IQ]39\KM99;5^LQ;Q9T^]
M17SY\2Y#,28$T78T-(QUHK&7WZCLD\UPEH5U1JKHO+O@RO$%*Y^B_.A-'+_M
M9/Y6D'MGQ%?&$CQ/?DKK'==&9QA@9AC>6#J1"ENI2'BVV39$4MP<7">,<Q)I
MT&!,ID-=X"B$;V8?V0=M)#F,I@0Z.KUUI+;-5M%3;%6.B('0@28R%A:XR33[
M/RE:1[CRA, [@>8$#I>$/"KC4]@6>.=S^2QD\B'MX(*NK2E.*L%685@.%M>-
M0\@D@#QWM1!=LHJXB^$S_1OM.PL P%K[Y\'&T9+CF?U8T=!M)UHO]\)';6G0
M.)PX<P7-?H*\'./]*!@*@G-0XO9WK&2=_*MGI?665< 6Y@'C4'>XV3((:POG
M=;"^T2,<J+QC[X+8WGPPA.%& @9757-OQ\$BEYAU@%140DIKU.\@&H+;SG7X
MA8(,0-6T?:?I!F6?Q)74BQI\ <K27BCNB8WZGG.+>1OQWH_*5F,8Q0,60*_^
M8<_PL4TI/YK9+(K_UDRWB5)?RYL_Y:XR?YN(7W]?&R$1M@+0/IB)R;1H.6:"
M3;(F092JZDN7WI5<OW8WC7?.G+/AI2\FJ,3SWN<?N Y"P3[O,JBG[?LP@[5S
M_E;IOF=D'Q*B_*O->R/E9ZV)BY^[Y*LS*SO*!%.)=.;TR\?\6L+X1^00K@LG
M2^1YJ 54.^L>8J/=R&!"PZH4!>_1<R37Z80P(3JT-FHX^*?;>2. UX,C4>H#
M70AZT0X;>:@[_[XZJE73V/'(#4X)5'=CK4$I2%@,[,>V,\\&F.K"9UDRH_+/
MU#X)L"O4JZR]+?0*@OXE;=-HV*"!/J(4F4(ELJ ZD<UYV7!,APEK1</0 47B
M2:>4E\WR2<B!]N3#S9G:TDR@*=*M^I9RDSU@5Z#.%-[2-%((4;RM'.GO!''-
M?%:,=$?.B,;(2^1@/(9^SD:6G$HW2P(R876S1I!3?&2C[ ;RDX&ED5V#O?#O
M<7"\<OM^!1C_QCW2GHI?-W.)G3G)>5YB0FNZ-N_7'N+E#),$S-7X4B;=-(@.
M-"CF0S1>)**EJY&N1GHQ(W64:H<V=KYW,DT0F6)&@I9%V9E_D3RDX.J M_A:
MA"Y4DB^)#9379O:#JYFO9GXQ,R=28A]SJN )J80J7H.\,Q4#1'1M*L?X<!B_
MFNYJNA<SW:AF:6G%DJH,JLR::FE\(=68/22J1N#@6&9"YQF C2*0\XM]5SG1
M@=8WJW6OUGV9J0B&"\BT/^88MP1<67"X0&;L\[N&R[;C;TV%@%;#70WW8F[9
M"D&+:(^:Z8(^.3@REVQ[M=755B]BJV<@(* ^3",),EV(->91OP9(0\P)K$:Z
M&NG%'.JNJ>]<788<C:G']@F4L:D?47%8*6A^4WSAYT\=7[BVASXFMT)-1K^J
MM:$:ZTGQJ _R9,?F*-A\P(3:$VXRH")DPL7BQQF61)"6K1-@2OCX>D:N9^3%
MC%G $[,HUD#@X7PHIQ-A,BZYVN1JDQ>S21]YU3?][9Q1FI8[MXYZ[S(A@0OB
MG*;MUTG>U3PO6Z=AL&)0T;)XM@0.'(!7"0+RTQI*?;4$.8P"+0:!W@%EV%F8
MX00T!D BXS>9P3]2FO*B<PF8>V^$ EL"@69&'SE0!V3"G8\3,8P.BDI+ ^CW
M1P?9?I3TJQ46(IV$D:=E'J!]T^[<LMY9!.]'C;@9 B%2Q<3V$5(')'K$M.7?
M.F$%%\>2:7J!2+O"U1Y4,)J9?PBW1K(=C[M:,C_E/QXPDF-<Y)/'H"Y:"[_F
M5-.[K/=MKA.Y0=H4\^C$/<S\=CR1.[_R&]:6(E G#;,J:MWHV0$OKZYBB@EF
M<'T 2[DY[=6IL!*+6'>SST3C'P3U5_LUI@;AR*&LF# 07\[B-W76BAQ59N:2
MB  +HM0,=QYMC0/-%CPTK4_)HVNI&RNIHW)M76V^H>WU8T[DA?%.Z95ASZ%#
M.[/KE%I"V2I"F-6TRI]EIH;FU7-Y:IP;P"D_JO_AEC3,,1_PU^;>84K$[MC"
M$=*-$+\Z\M]BYB@/VBU89Y4P:^YKZY_F1;JTA2*(H?A&%_5__5&0R^@8A1+.
MB;X!*'1VS;-X"7H1M>KE5"=<M69"FIX8"MS(?[[' X':L>P^*'.:HD-$O2=1
M1$\?,S7)67?*^X_>[2]D/".A=_]<K/.>ITO?,7M7!_EY^EQY4)(0_>K.J'O;
MV(!U(7&Z</5V3C'RD1L8]]J-;BZ5O>^6EI#FQ:+*9) -:G;>Z06'0M.P%"T$
MJ;P8D!Q;YR.2H17-U*'6R862Q:+)=19A^BCN)(XT>/EH^=_3<)K,\=! #LV*
M!CK2R%!YKZ,L54,B(_%H]BM$]\W>C&WSV'1,D!0\U,B66#6I=M7'%N,\6G&8
MQP BBUY9L]K".$I,QD$?'I+4V4/:I )_6><+U@+R@\U3GX'$]JGXK6SC/31<
M+D__@Y&6VB'E'<9=-:WDX19D*N-X>V%7KV6[M2YR05BA*8JP&0;#,\06.4?F
M*3TH3;?ZSP[$9SIGWVFK9.BTP,*-7#<=M$YEK-=Z]6KXES-\=+6;/;,M(=*F
M*=6 @&%,+* Q3(DQVAN6=_D8P8H;UGHTD!D[*"&B.7=.^8R9W!@!_L&G;4P8
MTC'21N)KJGJMU?%U,UQL,PP$"?=IC:N%+P49ER0TDRF(),%E;5I,[E)2,Q?%
M6*:93ZZ(/A&"C[76!VL"EO$EB .;?(4U>".CG!'X,I6"D2R\5%7CM85O+A&8
M7RJL**TA%_X2L*O-J82:&-P$<]09<AF0!4XS:=$;=RTCP)#3=X%@@@&T*VW<
M;P?K^N*IP[I^M>;-E-^$:%'O>/=/V1VATBREW1=-VP[>Q-X$)E72L;2T7U".
MV!(PJ15F,OJ''7]/Z7XC9GUF"%G]!K?3N$@)'R+_H 5;CMD_F1X*E>&%DT>&
MK.A?_(,WS-X\%+**T*"IX;"H&-H$\#]<_BE=/O^_RAY*-*H[#H71<#'#M!2+
MVY-R^=4F\C<]NFWPC[4+B PW;TN2-#$=@DTS])BE%*3=Z"ZO.[!_4<?V#-O/
M/[8;<%Q]\^+-=;:\+YIV=EM,>(;;02@#'[U9F$2%?E[:CA7TH%DCMN.T NTE
M5EW%?]Z4=R()*EQ5.(R%8(<HL;@Z?X+0=%#L"*%!4?HSM^?J-0V;\/^"NG2.
M?A4Z();:'ZQL3$B%4XP^6M9[?U%F>9$_LR1V(,N%P$FDNY1R5V3;#0\.*MB@
ML"52KHFB"_?)2#75N>-FVS0?E)C:OY%"M;2H@N_75!@6]WE)]&.MVU<P!<)Q
MDHR)"'>KQ?D+'!L# X"@[ETI)8C(T6F(=KI3U[L#2^9AZ]*CXUTS3SDXR'[C
MV..W<'G3G5F2KE9^5^(]W(B4A,R;^A?3P)^A.=8EA$18U]QHT:J^KYA:0A(0
M_I'>R(S]DA\)OI(,G>7;3N--RBQTLPS/][<6P+LMFS$G'7W<'8Y5<PKR/V6;
M"+3KE.UQ:'?>U4KA:^%29O,IL_27<<VFKK!@E>#0 72=B_<K!%SFA]%WCRXR
M.C&CTTP[\VKSUNT8!T#_].[E"USI:T<Y@]*]_6\R@YWCYIA_*R"25>$T[&]7
MHT''E)'15X_Y%OU:H%-._)G"*;$@\J0MUA+8!&EG4XW=0 XF#1]^.U#WO'$B
M2J(=7#K)Y*PFBXHG"UA:9_CR25HN)=L>$^6/6!#))_-!#(K,P-7%1:4? ]9,
MJ>&O-G]3ZO@N_<N$D9\;KGQ*DFT+8WO4'U<N;__@!'P():AL(T>,?WU"8QX7
M";ZQ:KH%JJ2]3V,4(F$E&$TEV"=G)";C%TFTQ-$F53+\N=.;* 'E9EUA-V:0
M9PQ?-]3G"EI6%!>.3A6*E4$AI)XSCQ%/HVO--._BNO/*2K]O<NF?,BBWC#>B
MP[$&"2+J>C%DB+UTH]O-M/RX<NN.@[+UT__>MM!+I/\,H:(-+(T %_<^^;/F
MKO,>FT$,C-^A&D1H34=X70#,98JD8P -X'4X@:?XNX^M[WPV/?NKD8=P-V4G
M%5LXZ</FX/T@29PA)IU &1\-8Y2W,04M/GTTVLL??:9A!%F)^O/8T R_K*H_
MS^H Q@W9D#D\Q\(E6Y*68L2.L*+2_CH"W^?/:&9-)U0(T"OF9^WP]B-(?\<@
M#>4D1CNA_."J\K9I_&:M 22!YV4"<'_YV=N/@ :?0W6.]1=DFP?;X]A[I.3
M450(_F?!4_0MG'1C[&='],T N2B\,B_R(VM(8.WALUU\3^8@$$!67C1'==HP
MB-%G](4J^:OY=1!=RN^&0-R\E'@&I/BRJD'T/D?@Q^LHE*?8E$J:)@XN0$H5
M=4CSS=XBF:::J2_A,#^A\/[5C,UD MO#&FZI)<#GE;"M<U/,$G1:#RDU#%#2
MGN-C#T8?@QL<DDHA'.#X '+=U_=YB]W<01ZI";);.Y?8AY7?Y.(SP;Z6V-$3
MF)R_@]>YCZ,WGS__[+FW.N]]6R@5Y9T$O9LW,B7X)BIFT=)<TZ%;P)Q?T!.B
M\D"Z=@?JB03-4%%S?J&B."_#;)8/Q9N:@B[^GUJYH+J^ IXY:IO]):X^^) L
MQZ\E2RV+V-^VX&T/6M#X=!<28\( 3.(P)1QBX7C*JP)HSU+_(U!+IB>$E4BI
MA-2=/,R[+EK;L0'[H/@?EQJN7URKI76)92+-8UD;3B#X3'[$+5B^?Y(J-Y(:
M?X#[BT>,LN,A$_:?4H+E@\C&C7.=<"V52I+,BIP9?EOU%/GI6:TMO+D0$M.5
M$1CZH^80<D)VR%&S (=/P:H'#;9%T&H,E[12$GSB>HOO.L:([AVVVR'1DX1#
M/5 .H,GNV1LQNA+\3 I3-@=BE!(R_,%S&E+^E><_:B1F#\A[5#DY!!"Y,<?C
MNGY'_XE?F:N0.7&+BJ9_?Q3AK)/!EQ8F5R;3VDLUC3<"EPR$K#F<7;([BC-;
M8^OOM:X9WDNW]!=PV>?>ZYSH?_Y9)#IYIZO[X;CGJZ&@*>7OD,_1G9:'7".=
M+*%!H OQ%>(N&&K6Z)!L5Q-Y\DM?; XT$\T:3W1/6.I_3?_U\S_#.U+2:T<!
M="W/NHNX0:D(C7(@CA13H_C!OVQ.)6[])G+>5V!AOO8.'$_ CY0'-\!%:FSC
M@9:K!&!;O^M-D5Q=3T]G78$H.?8^O*C=J=.2;*:R;G*70TV0Y[[L!PDY2^ZV
MTA9OB1!SZW;YT)&B![W<<$KX=^=?O)P3,UXS>"(]7>]Y^J+R%R &_LW6.P 1
M:J7Z;3VR &^IV(^B8, *WSPVR4:OWHMA+?=7FS>R[WU\Y%!6LQ)=4#Z  @'%
M$5EX? H,^]C@"4M 51&IYWB?^WN!QS[U/NL?US[K!4O9*A8?0EML/W_(.<-X
M:W(A["QW(].*)EFI_/_N=ODQQ*7BJ52?E6' 22<0*A>V>)T$T=K'D "Z;2H>
M73$!4) MY'":QQ<0J;+'E1/CA7Q]%)+JK&0D>J33O L2S)__+PYE^#8H,M:3
M^)^V0X^33X_C?S;Z]HVIJ_-Y\@4'A"7<!QV62"HY"M.@U!\P?_)^MT)%)"Y(
MZO^D8T NTKNN6LO$Z:%B BE)6:*RB[09Z-]-U('7XKI^/GD>E['I/TH$"Q*F
MLIA)T#*UL8M?";^B;DYYUP8MA:/FB(Q&8?8':1#:672HUSNX>OM[F0TSZ?5/
M9'4XZN(@1M\<?>NN9#(3@2#ZY;DMCW[I^GM:O2!2@^98#/<B.4H(T0CL2!%!
M19L%*9L4-?,CZJ>3B)=7APH$M-@:A$()0D+!A2 YD\V&:&\:+HZB]X/SQV.!
MJ%TNCZ7@0*N(<\(W;%1F/XVEQ\P1[N/F8]EK_R;:F#^F!]C:MBSTE>_\FVG9
MD<11."A43=I!J4P?'\YTHE>E:Z,$W(B0M6RG;]J,),YF2*]JJ9:<;\EG8P6P
M.LDE99=+A[2CCO]I),&Z/4F-6\:=T(F+5>__G[TO[VH;S?+^*CH]U>\DYPB7
M;?;*3)]#@%3H2H#!I'MJ_I.MQU@567)K@7)_^O=NSR)9)I"PV* ZW4G EI[M
M/G>_ORM1)%:NJ* 3E5FPTCF^A3@0>+_@==6M<7H250SVQ693FOU@ZUX+DHO$
M.655,B^T\4,-9[7?CNKLJ,\)7A:*K%10\$SC/MA^P\,7%'V],S*)ANW4S-SX
M+O);!IV4L'^8,/^*W%$+C77)S%YH!NV099-'ON92RJ*K-$NIY[A88G!]R%DO
M-]V5.M_P-6D?HVF[M*Q,>6D;G(C:VBUIAJ-S9"ED922PM]!2C'S$1B8;7:#!
MG*YM2&"28"IO-R*<F_]*@T?=NO&RT3U$DD>\+L)\Y0R:6BKS.?%TQ"EO''<T
MZ%"1[!&?<+TCJ8^6VX*CUJMMWM(^B*_G!GURU<BJFLH:"<DQU)BL>W>*M3N(
MKT N1&RH!N_57O6*4U\"5LPY;?8R)C"EA574).9+'JI*Y%\SN(4H"B5VH54\
M4=R1KEDQUMJXEH[B[B%OJ7[TP]%!-5A_50(54#93QOK>#".@5CXTN?GT #R@
M'D"\2G 7 HXY<_ZR3$H814-KH5N[91',BB\QK)JF8G,N0.2#VI#,M3.9[ 'C
M?1!Y#DNW(6M]@ $W 2;GP\8T^&HT%73RT;!5*<X!,FI:R->TJ;,<J-TWB, 1
MV(:-3BM08KM()<F5<GJ0:1!YSU"9?76A<E.ASLS#);P7%5O6*8M.&A,<8('V
M"QIAO'.C0NM'DG/FUAI]L[>ZK:&K1+5>=DS9A!>Q27(HF#/JJQ,@-'VR\3+&
M*@BE&C^ZTDJ=D=YNKFO"C9X7[4-Q\--I_E%F48Z18(K?N\%6#D/FE>:?;EY(
MXQMJ-1O5Q%?.1:TG"Y&%@/13>9'8>GC%4KLJXC/D_].C+^OQ*H9QO:OKHA7B
MMO9<MQZNM ##E9&Q+@T0:5::ZV-L.CY.[F8Q47V@FI?X%$UCJRUC1:<.U13=
MW*1BN7T^+#8'(EA0-:*I3Z=\<ZV,6XAEL=%L(]I;^M!:3?C^O6<=+?H)&L_J
M'772(YXN:Z#UBM_F%=]NO>(_JH(XTLG ]KE)L"JYCN"+S')][>IPVL(UI\5:
M9$ &MJ&NLHXPH/151@S F*N@'A&PCIL6HB$"P:YWTQ)?CP)3D:!)"?8MNB^^
M\U"L'X*U Y:F^+,4C8IMJ%V7.B$$N'T8D[N9PITY? _ND6\YO\9Q):,2.?0D
M^'>0A3A5G0PIOLT@1VU)V_2ACJEJP\OQ-E-G0,X_GB\8B29XSW(=6UF1'P+V
MPP:BD9Y %,_9J\!:AIF.UCP\MFQN>9I=)C0=? ].M^0>! VK=#<Y"\(H#5AB
MVFTH<[MLK+.F1".[_XM7!XX7_HXCXO06NDI/BI.%<UM[P-+.!( C[2'A]ZD_
M1PB_)J.G939R,QG)'6 2HN$NNO4:4@Y>JP ?@8U/5;PF%9WO-EEVYG*/J4E3
M%*,M4N,P9#DW$>R+,O4JU?KTS1#+FFBEOU!\!J$=_O*W"P*3NU!<10-;=0+"
MCI*_, !QCJIW5LQ-4?]ZLL$[@9DVP'XZBI>MV:IVI)'0I8O.:+Q.=>#)NDM4
M'#.@("I"_[ /PEI(AN&%*Q/,T8-_C[AZ/1V"SJ**UU/S&CE@AW0 P+TI<D%W
M'YD5^\8E[LBEL*C/AU)[:5E*]6C8?<9>YEG K>4E^[L2F$?TH9@$"'_7P2]P
M3E>R_NIX!%H8$-E@PD_.:5-".,:-R5XQW\2F#:_F@@=.YC0U-LB6;1DK#9WF
M><3&C(66YC(9,N46(!UK,4$GK"\%4;Y)EZ9P1-BI6"C(76ES9LA9*=DP*-BC
ME$B&7G7'1?]:W"$Z4R09?$^03^@ZX0*I[&K=N/)=J?LSARAU/2I:KS=I]E5P
M0#F.[H;H1Y+33TH0;M](91WOLT!B&&1(>1VYV$VIC&^IB7VRAFAUN-2!JF49
MK7N!(^PI"LPK'%:7?B\4*6'F)F;](H)(K$S^*ZDE[OW#G+,-#$Y;)HKPE5Q%
M,)S7\$N3C4E:4N:H3/X*KL:,R&A()#?ETEB#00)K1NV*E$FB<:9H7>U8<W'G
M4TS<R]Q#P$S2--E@Z]I$C/F:9IP=0Y%D.R77Q\6'(J$]\C^@K@9Z*CK2)9I5
M@9+U\@E%T5P7@U0X+,,W6<#+91<=YV40^*C154/\JN8\N-=8D"AGS^)*P-5<
MCY1%H**L9?2F!V.&J6URRE0I8="8ZVY1 <C?0US"L_R/D-J:2S)I?"QMQ(2'
M1.=K\/Z20-"5CDYV%&GS\&_*]ZBWJS5LB;\/DA?NQRR6D=@5KO#-.B @J4-E
M@A<#)5 -/@!7!%L'E"X=RZ4LU4&UTVS1QIND<,=HM+K4M$:?"_ ]7Y/T1@>;
M6J#0%BAT&5 H9?A2-F"4Y86!.N#\8&204H=ZK<'E5,!(R802#,(>DPF$:L6L
MXBPCOKI2HTQO:3$26UBXIR7E<12K)DK48.VY2^0M>;;D^2CD*;@X4M5B, @I
MB8$5+)WMA(:,VR"T9@^%)9.PTN!V==W:?: EYY:<'X6<K15YF[#7V?3&?U51
M%5KB;(GST8E3M%)M]I+IQ?U+Q.R*U>.'2OE/KPV(;^V\](!X:_NN$Y?0[$$$
M$U@+)A..BS&J>,72@DG8B2Z>L-EO%..>5^(]!DO= I)RKBZ7  OB@H. W$K%
M5BH^KH$L-*ACEL;!:_/8E\88C8^7+TY=>K;TVM+K@S:]J&/ $NVJ/[&()C<&
M,+49*X*BI/2@#+<S=UBY4T3M)"K,)%&!21J=1G(/M)/=&75<DH7S#CAX2^PM
ML3\&L;O)@P*W/:::E(H58T+N+H,6@M=PS_F=NE;\T&X_-JC&,N!YO0U37+''
MB':$;D4LP*G=HA0*)XCI6^3K$:+)U#-X&!<QF5MMS</;7XF#8KXVL ^.\\UK
M8<]J7U'B(Z\EV\:<3D-C7&+7[.LTJ#S2$L2%*96HLJ-_N+$DYX@-Q%\M)EPI
M\JJ]W>9A:>#L9CDPLT!INHNKJ_KXC:%U[E0PKS<":X9HL E?3E%%4]<5/=-X
MOH3 FR;#L>SJ//P*!4N9@-;[*$<T,X@0..$I1Z3A:?HH45?:S]QHTE3('N]0
M%;B'LJ)O!12M([]*]ERU5H&R('3[A^8Z( UQI7=+RD3J+%+ H'*$_M)(EP:+
MDGX+MP%;[ (5D>;!Z/HX4W>E*J&!537Y%,:#C9W2V6M:DIR 4(W%1UI/X).)
M10LU1IV%FBI];"Y%-+R*6%^9:$A^! AC^*QJ0]XTB><&'(NW0NK%EV<8+J6Z
MIAM@,/W8Q&6_6R7?(:[(M<!-%8GGYMHB0%J.&",A-@T>9>I!*RQ7O43Z4&>P
M,)S5M\(]]5TG(G8K_V3#E^2-$$*-@T.&LV_RZHO'OXI_3CE_5+NLVVG70@$F
M/4P'#$R6C3 F#-0:D!^AIUH @3(28""ND1Y[C@^GXWTH,^2N4\*F+QJG%A@F
M@"[%L-#I;=AC1)+0+%KFO)[:P'I'0,"6>M,ZWE&4S\I"ZI,9%U?#U)BL=<WY
M<V<&7/V%'YE\().79Q4]O3A$62 ^DJNZ;UO#!Z?7NH4SI]HO-L7F3<%21-CN
MQ3.KLQS*L[0R5ONO0J6PR@#E0)3C/?8YERW+" R.H2+U9&'F\!OXMDWX-+HM
M&5=UW'@'&(GR^7VN\A:"F0125.!F)*(['W'MD;'@ATYY=S"$=5.;] 7>U?'.
M1)=F" GN3B!=/S!WK%J14B815C(+V+P![F6BK><5.%]@M"<B))_SPN??T'B6
MJOA(. Y @0/F"3P>DXM)9G,;\+EC 5MA(OFY4AF)A'(C^82FQ9G,Q/<0/6LY
MG5:_JY$!=(D' 6Z0:.#21]NQ%1^3Y1!$T=2F(:<ZSVW=,GAO-6(^EYPJ=3=O
M1)1K'M0@^*17Q#@*!?$-\_LV)NF-+UG72.9T)*_%^##5U#6MI;)K@H-;V3FD
MS3+AS8*=UALIB-%.-GI:K>OS]'%R;ERC(<$RN]$%5:T>JT" ^09>S!'V5CX:
MY)&H,'56PD['@DI%B=FP0YPQNI2(FK9#KQ]%.N+6S6>*&PMASK0T.EQX<PCC
M7BD-I^4P75=%#:,<^W<X957&)L^QW[A)K-6"-Y=Z>.=!T0\04'[*A0>8<TW&
M(-*Z=S#"_DL$<^9S\KD<$'6<XA^B6VZ<[0A:S@09Q6%9SL*H[Q.98O4=M13D
M[NLKTE0O4\?Z6D)"NO&+<[2H^<_XZO)WAO,JD2SX@!"HGTZM,-VZV#=@F\:0
MTA/C_>4?3',=;M$ 6HOTC*.P-+>9<X^-4K-K;>>,*/V8WBC*37>QOF")*KO?
M%)18Y(AX7'#V(8ERT;*HCZK>*8U3X-Q8=U_K%TOPVY:M1[,3';]TFXHAB$UH
MD#1,Z6G%H'2/;[QT5AWO.-$*68#I!]%4PD>.*3JWC0]@S<@)8M$BL#B+^\S=
MG7OA0]P(.$)?1(,"#"R?50SDH>Q96,R__\;6$9H@F=D5& U"A[8_MQ +3Y11
MLOO2,TJ>NLF&"^DE("X!==:V &U&[>)2_8JE[Q8%.1@MIF:(*UJ9;U/S@0HW
MH?$H S8V9JZCV%7XRXFQ-7&"#AP*:BH(91-:D#:,<[N\U&6?S,#555J!KPD<
M;"&-%5IO3&,15QRPIN:"Q:_*P1==%&LIP:.7B45U9=V%,,]*[./UBG2)#[8.
MWS;N-'[\>\@#_JKCU&%GPS<PR0:-!=MN65K=J[XDH;L<YJ@!L(F.) ]G*B!S
M310ME95S=F;4RV3=97 ](4$]RR5![S519[55.F\?%55:>]UY4W4IO#O<?@I?
M*B@2].@];(@U,SGO7.M?!38CC28WF5R:$W(I">PFPE6C&^\&$\;H!P%67/#T
M--HEK\:")Z\IPZ(W;"]IC$WJ=6P029RP>#7&(5%=YPA<"'7W+,P+FH^B#K3E
M3-.^.]1NX*H#&QW"I,:.73QH"5 GXSCB,%$ZC 79+Q<55)L/9G+<S"6PS6K)
M5R[,1I-?4SGMITBC!NH%5)R$')TRQAD[H)U8Y2*=+Z7QBGQDM"::H@Y_&2<C
MO]1W 8W)<<!^WFF:,',TT#$+?=50.I+L;3;JV</HF[9%ZL]17*)54+F/Y(^E
MKTH\U/_&>SO>@%Z8(#KY2/#M*-+YK;Z*52?2,3+X:I>Y*M]VMDR.I;)ML3W1
MNOO<$3H:#R<)N0L:-:,)C+72X)L*KBP N+EM+XJ??S?*35.V P8[BG3T]26#
MW7Q@-H;:"UG'W C>89GRB8[*U2%K0E#E-,69] U",9BD<<CI2NNY;3\$%.]F
M#CAAH%% [1M,!"Y1*ER(B4JK%>IP2%(LQJR%T.W)BEB=64 YD@LOKW+3ZJNY
M8[#S#)V4 85VB=Y2 "B%I48Y31-*;Q,.FG)/48;(,6[K^IMHMDXB@IX>+2!O
MVIXATQMU$6;RLW-8M*UH$*$VUJ_A)$#_ID8(#KLTI$JH'G#JC+AK->,KPC[E
MX%5>XCO2K$K7SD@OBFV2HTRGW6*F85G@MI&$NB&D(*W1SIS"/^H^9K;U95ST
M;F<[2I8,?$ 79:!F!;?PV.SZV#%HT_11PS\:MTZ2(V)L=$N AD*MJ!.5&=P?
MV,>>W]WO^UN[7>=2NM?(EP(4& 9)%$,_@@QL3HYANN&YGS8[O1V,5/&[!(S,
MF9DYQSM,K)SAC[TM?W=[U]_>WGN(^>UV=O?L_,13ZQ"@I$E\!QGB7/4JB)*S
M*C-Z$N)LO;?BO=UKO;<_RIL'%$9=2")E:'FQJCSJ$$50\V*,5&\FY5&91G*9
M F6 +HJ5@&XB%B4/D@E+25+2^,%8ON86+PCZ)1)@17;YK@K=@4XP!1:4%-*5
ML@'1'[F.A?[&(I)<D(4IY0IWQU79*E%LX+NQ;62%G7[- :(#@X.2LM_HV(8C
MDUXW9&FFV!:(GLK4B(."25I5W^P+;9H2V$(Q=6<EKV/D(@A6LF GW!#4!"X9
MM6JN3?PEXVA5,\6-$W60U$ZWN2#'_TP^::B&A8:EJX(2DB:G>W8C0AQYWB?1
M,"HD5XP<F29"84!G[81,8^^A6EQZNHA:5U5:N>^1OBD+2J=CXO#E(1T %X_#
M:11XQD/,L%>?]NS>>H7<UAH)QJ&]= 2:K^MXJ>J]\BJ'+?!MK:O)@^J,T<U4
M)G'T57&>L&Y1'MA%I[K+&S,)#I!&W]BU-5/]OJD4FX.Z;=5T7^B"7:<(_A<K
M'>*V&USK6:^_6,VH;W;SQ"FUQT'3ZC8J?!GZ]ST*4ESZUR?@?VOG?;/U%> ^
MDT0DGX+-V6!HNC>H 1T8ZX?DSHB*'%#Z2#!,KY5S[^%?<V9"4HEB'F!%6(*-
M_.6F8Z\0GS"X*!G'I=*XL-3OD/M)N%FN+4A@"Y2P")3 3G "=H=/HQGY1(&:
M\/>FG\]"7R>-)4O=72+C6!&5AZ%CX6:U@ =M3>U3TJW3);M.LE=9>H-=E#D1
M3OKX59/K6F)MB?51B-6%MR;3VM:ZZI(ZJNZXJ?S<D&MDC!JPDK*K%IZC)=C'
M(=A:(P,<>Q$J!NF0H(275BUB-S.L!BXX-'W=$FQ+L(_$8:W@GTWF.2@$ 9B#
MDS3GF&):;TF/7B);'O\M@F[@Q$387)G7$G5+U(\$8I>DV.B O6]NPQ?.;Q.\
MNK2*98))G6X"PNA?923=%;![&BK V.M,/SZ)9O#[/]((OJO;9;@Y>)RUEIGP
M/+H?(G8(MH3?$OYCJQ\,BZW3+Z5V>PDBL5^OZ;\%4JFEW99V'PW9+E.CK&0F
M2>2KD-E*$0S6BLR [Z9)HEK5H:7"QZ%"I]OE5*E"4O6P]Z9UW6)'I*G!^0$6
M^8<NTC8E\#KV1U(?"YCF+<6V%/L\#EV'7)U4"TYIH5B#7^F_B$N(=9_G3!&
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M@]O* ?+RE5DS>V]PC2\^&49X?,#6YW++R*R2S"1,K@ZNTXQW&HM&60,M$.+
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MCY.LAHPZ7W/>*0B@( MU;>^R,X(UF9>*&I W2D(MGUQ.[[UA<3@B.(,"@;-
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M]AL+@EMR#VUU>[VPO0!Y=4-&*OZ$ '!7#J3&#..=N-D@$;O;W!B.$)!O0?T
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MN_$L%\$TB#@88SP]?RD"X1Q+3]!:_AVF>;6ZA_X,]L#>ZN[&XUO)+X&[O\]
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MR=>WO123 (@0J.IZ[KQZV3L[B\!<2W*6(]X.XRJ:!HTPG8M;V5)6E;(F$E'
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M0-#"Z&R8,QOE83L>0%N$,A)UW[$F4]>W8HRNE6];$RLP([BN?0/7<2?(ZVS
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M8X1G^^[<;.>]<H;4!%@N\BQ9;,LUI]WQLX^I+OP]/AG^-K1\,_*3I+?!@("
M$IR!-#]W*#XE&'B"H2J+83Y\"IG+I@^,<J-$E8FQA,]B5V:*> 7%!"+L/E5F
MY,.S/N/9W12SR"2"Q<IW#,:>&SZ,%U)E\4LSXF2O'%$*O!OOC/FBGQ.GT#&U
MF;05U C(IRSR>281><5L1G],+6Z;LQ=(RN1XYV3&/DJ3<3BNS?@-&;Q=8,)/
MCQ/3'Y%D8@9FC)V(IV=S,%MJS1X?QP@;'[IQ.;<!COA+F!KPUCY&9.!D%;9<
M&K"&="//#&&V'B!:]X/Y*@;11# %-!AO9/%%=2A(,GQX#$.KG%@>."H:_[PI
MC3+K=O_Y)&YX3T[)BG[D,L&R=8)EQ9R^3+.LO0_W&MB!1XZOIES\Q/-?3[G,
M/[U%RF5QW"]S+IFD7.9OM#KEHM?J2DNMK<JXI$N!1(3[6A)D,4DA<R#R0K9/
MC;K<[Q"7:5_XJ77I[+N!A:0(2_5M\]GG^ G^Y%>I=?;9#(@UDV3V[(56\ZJA
M&DJM;DA>K4YN&;.)"7<+R)ACY"VI1?(N7;8P3B/OFBHDR[G"N6(3#WTM>;A]
M[G#EX],F#^.$Y>X)Q'6O,<\@8B[+6Y-(1%-@UP2\GB93UEJ*_R+H9&^<H!J$
MQO+O3Q>0]NYE3N ]SS_B1$3)WY<C(8GF[2@S=;I2:ZU*5];TFM)LJ^R1?ZW#
M/VKHCJ(V[/!\^_D]]D@G&+?P"=T^HQFG%Y**XZO6W;.<F%.1>4Z9YQ3<U:R+
MJUXED.WRH$F+4E83X\8\J))[#BOY3EED79>&C.0XYTA!DJ]% W/VC<[A'^"R
M QI=: #ARW>^[]US,+GCD9O9_4"6ZPAP-<0^N&#QVHB%NUD&L_G"'WN6SZY3
M8EG>%YU2%,82O L::X$VV]5<.).MQ*[B:0Q1 *\A'=(I91=9E)]X$_4C?-V\
MLL,^KK]@=N/96(@,4$O(OX#^ES?*L#@G&34H,\<W7/N-^-&LMASUQJX/2<AF
M 4<4A2#_X>\G_'TCFEV#FL7O%DVGF? /[Q_.6THKL%1W0LXX"[PDRDTTF5F
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M,',*\'A<>-I<\>SK6$%C!0&E)R\^\-DUO2'J?-:>#ZO\(@RX4\NQ6*&I&20
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MC5U#M?.9RE")Z%JOG?G/KNA2UXT_J><.37^\,7]R+-PN;44E[P%XS5V#NI3
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M$@M5$04;"#/]>>U7]WG [(%1W0F]!-O/Q6%+$$L0)T&<?G,]U1Z0!+0$= Z
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M[7M3\(H^L5^]9?4'T8EF*+HA=P,%D;P'G.YY-_ M,.6',6N*)N#EO165O >
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MN_I L*:+)!3[O] /K-'SQP7Q3%8LJ.]Z0^JQX5K.PP>5C8>-[(64:(94]6^
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MD3$X]9 RN.I/AT/NRU^J"_XL<P[5-=2!.%*WU4$U0T\6[SB8U)=)9*J_D7$
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M!(LJ#E\E6%076R58E"/!XOJZ7/I_^4R\(MQZFXQ9N[[>2X)%OM#)22'$JXF
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M#;W7Z^MU8_6$C3)@XK[:&L?_J1EMVRU-^K5J#$25OEB8L$;U,*\3QA8$.2M
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ME_1AXY=WZ[&:I>/)5JD[<@CGP 5D H3VJ,D<Q[0B*&US.DOD\&836>X^5-M
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M)T9UL[+A'S'*^ 6D0C<;T6HC/(D3MU6]<>?4!#VY20;;(=RS1%&+J7U!= )
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MU>WNPMX_)VE)#Q>HBS7:>K?7U8TMS4[R0FG8+WJ%.@$T>"-?^S)%)@!0)FE
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MH]*4CX-S@Z:</GCS4"BZX\%M]:JI8DE6WKVF7&#L:'>#V]JU3KW2>%\=WS1
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M]$+32<,_7;/'@MYTO!Y!@#^0QV!_D2<A3GP&.EP UZ@%S']"S)^2'X>W'F%
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M0[!)@\7@'3"$^ !,&0L@U=4<!EZ(-@2A?@ T%36"M?S9 S99)P;Q%"_]Z6*
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M7A639!5#"A@)5J+ 9[#J%XIX-O0$@F8RZ&81N!=;$L'(M\G+?#/^C(5(I!3
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MUXVE4/J&@[3E[_3,;A, JLTKE]&5\1%]$XB*H'V05!S@]O@\\8\O\2,B86@
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M/6K$H3&YDW=#;=>2ZQOR)O!.2GUNRJL61N"-XZ27+8C 3],(_%0RL.77+X+
M%V 7VL<)9R'H>[]U$M6$,=/7LA57Z&4W.%[9%!Z9>&;+19LW_RK;B=E0NTN%
M^2^*#&@X (,F G&BD@PJS; ELTYYX.E[Y0+8V6 =S3X.'BX^L6!SUQG;&+N>
M38>J8ENI#237PN#,+Y:&R5$Q]<T;ZI.T8ZXJ"3LJ+$!N,,2>@T # 9KP.>$K
M1K4?=RK%NZ:I%![,M@C5R^5L$ $)6-.;V+!YO@:<N#_$SWW/]336YVO15F?4
MI)9%=J)[#/!GQ.C^=!IM&,V?I[D*(WB$$(=(X[%F6I^GMLMB_J[_[!K??8:G
M N7H&IXK\J;4OA:3%GR3&F7Z@+!^8IYSXMC^>!*\+Z8 Q*$QA<3>EN<HPQ0&
M7%OT3>5_]QP=LDKT]*I[>S2XNE%T4V?P,R10Z:C?4FCT6 FQ@QB?0Y7!_I T
M"%EYV4,GL"J0FTS"?-&)]@HT8!B(XJ2UM906BF&;7L%$(9)T^?QPIY9JA@;Y
M/WY&\6S?@V-@VV%6@-0;]6G#J^;^$LR1]^*]"\'E&]QZ(QD0@_%9P?,,!8KW
M#!_.V,,E%G[_EN=B;64$2)[45@TJ7VNF\Q5%;YCC<S,D^89Z1Z_7MI3D:R:
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M+@#FCJ(- 3Q;T12<'$4CHM XMQV<I*<I,Y"]P!_V:&10TP+6! 1^OV \WCS
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M$ PL;&Q<'%Q"7%Q"!E)B4H;_]87Z"1#A8LABQ&!B, *WB# PB3!0OP!Z ,#
MPOAS 7]=&+<P;V-AX^#BX=]!"U3=!VYA8&+>0J\?K0"ZU0O=#MPFPB)^R"V%
M_4#5&(?1GH3'-S(=E^EY62OIF^$C9MYW#GYX^&3D%)14CQZSL#YAX^,7$!02
M%I%^(2,K)Z_P4DU=0U-+6T?7Y+VIF;F%I96CD[.+JYN[A_^G@,"@S\$A4='?
M8F+CXA,2,S*SLG-R\_(+RBLJJZIK:NOJV]I_=4 [N[I[1D;'QB<FIZ9GEE=6
MU]8W-K>V=XY/3L_.+RZOKF]^ZX4!8&+\_?JW>A&A];J%WI;;.+_UPKCE^EN
MZ#;60VYL8BE5'&/[!XP\OK@DSR/3RUKQF'C?')&^<QC&)V/F6WYT_%NU/YK]
MSQ3S^W_2[!^*_5.O&8  $P.]>9A$  B <86PIMWZ4]@[(!;@_G>#/^L9+1(#
MQK/'%S]S%"M/EQH.9VMQ$)BI7\<H4S()[8:S8L[DE6+8[:?>O1I=+@EPS&R_
M5YBO6!B_UC!QR"]MO6M%B1LY?:?P/D]1%NO W(/$GA$48$%XW]#-47LBJ;WZ
M!-+&F]$$K;,-V1G>,;*P>(,E+*J&.\(M^EE?!6?$2>O3U8.5N(BJKBK^";$'
MB'0QER-#[9S$H]FF7[93=E$Z4\9N#R_OMHMAZM"3G3_]K$N7N7Q(XF:U<BB3
MU+'33%D[XGSGQW;N7)]RM(,OY5?Y-(&7R1^:W-,(,RU*$^%*Q]100XQCC"OG
M97'FW>)E!-?"QL:I1F1V(@IP412.S%;F^."  B0(*0"-"")/EXG*%MJ9Z6V!
M6/(;K=D]:SMCL Z9GF:MAI @G1G4OG:)P_J9L!5PPQ-R L&XZH6F/#T."F5J
MK!XV/MH(*#*TQ'U'C"B1^YP#%7X$S'2RY(L#G1+F*TH.I^KCWL^LJ"XCG)7O
M[1B2" US%#MC5X4SWS\,D;[/H+31C--'78+-PXJY\Y)]HQO)[[8K5SE\9J H
M]P-"[!8A-U+BQ!=%26I:ES A^BT>>]5,<<GFY])XSM7TJFA$B.",0.JR]J-A
MOB9[/KUN9FIFH#P]67[$IXXS)J+7IIU>P )S*Y%]L]:;ZVK<DWR%D,RJ_,KU
M]:A-E8*3%\BFN/_7J#[G8*R@;!%&#Z8/A>=<% YIO[ZG_#'Y%S'QY< )SLE7
M8WPMP53>T8)3T^EZGUKM$@2KYPY:#?J$T@@++$KIK@2]/MPH_Q(-+=RT8^JX
M*>"(KK/'9^?"80F@\VOL_-G,<$P6N;IX;_:J766<_[NB5M1Z457_TU]MIZ_'
MCL*7Q+^NL+;MMVI0,-#K C?-(=<M4E>(@EU-"2(!%##EN&"5R)6;;_5,KX)7
MM]\V(%.IH5MR:DV0)9E(BQ/)Y;;YXLC<'\EPM3(I&=IVLYHQ3RO,PC.3%;N^
MZJ#S R_R@RPNX)M\*DG_7-5(9,IM%*I;^EE,V$O /[MSI5^Y];*^N-RV%H_Z
MVC?M4VY"I5]10S!U^6M<&C6GEHC)F<U _A82W9+O.=LBIN&I>(DK(^Z]5M%?
M33^Q/>/(NS=G?WI?$2/QMRU<*ZM?Q:PHDU^)3(B_FW=JDI,['DC([;KXF/8
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MXE*%C_R9G-C3RR@9@MR=N\K_VKN3Y .T#.K+)$FJ(7O+=PA#ODR.MKVKS.<
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MF7FN*M,"9I/NRN^/>S_0%&+Z7JO/& 4E7,Q9X6MX%(D/3L+9<S4T5 K2U0D
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M,N917V+ >J-'Q]CSGALP3Y0B==6TGG/""S=#/.;P+\GV@Z0]8!#A.2>.HDC
MZ)0BB0U^S]=7.LL\7%N7MW!4MQ,WOGRO8[HT"=E-?UZTZN'\=,-$Y&M8,2LM
M3C!?KSB386U91:P[9XSJU[F<;G('_ZJ@O $1PK3BQ7L15]$LL'[X;K ^ZT\*
MTEDW1Z1D/O(4(G(]P/I:2#VIH1X>4;YLEO*P:AII494'/;%TA/K?SB>=GG'+
M&-2M.(H9D^"@8KZ1E#^_0_G^_>GX<_^ K>L9^\G BY*WJQ$O@_:JD6;'^(>[
M(RV/<L-B25_V;,\>@>0[WF8&V]M,%R)%#YP%FEF.]B=_*1-9O7F=J#$_7M":
ML\,K=P*=Q:^ $;M$IK1E3O+?,5#[B9>QJ[N>4E?"/!U^,NP6S#M?VPV5.N\Z
MZW=TT&M_>C,UWERY%BXT:6UU_^,;]R]R"ITQAEIP ^3I%]/*3%V>#1=-.+EW
MQ_>GAN-/JRC0,>0^N,MI78JSBSNCVZ'L))(,TW%MU<_#+&>D\<5,0&#NQNZ0
MQ<WL3K[3^Q39+X;3DK<>&4]:4,PN'A>(DC1OJ%!/)*RU,UU_H8H][W!\TZD1
M\ VQ?PF9Z$P7J_ZB.><U7_UR<73'<C=NXB:G">)E)16B2:U-@-WFHW?,D'B\
M<\Y[20'3BM74UJF/87EB.X\\K2%24LO%E;,H])I H[,/Z$2E!++;B@+.WCNO
M.>^F J"UM#ET=NN/)JE=NXL_(8UR8]=[G5?$9Q+9&2'L!X-^#/^6H^9SH8#5
M <C-QF)/9AD:<$U+$0[*:T_.6/()0"?4S>C<V1ZR=YZN@W;*+EL8LJX#!51,
M!"BKIEMDA)C@_WY/^I]+S[B9G@'CQG*259;Y!D<[;7T>AT3: ]VJE]LF8"V=
M->X7ZH'V#Y_CP'[Z251BK%.]G)(KFM5IM^?<SS1R+\L>/S^>>]70SF=V/\"?
MYL0^);?)(S ]=VI'4W;B9MSVW1P%.^3./>E;PK<]PL&?8=:<)=_EN79!^P]M
MROB[^V8;YWWA7V<%#EJG$:.I5F?UP,;&4760L[F=N4 ,D=\<#]2?#;#5IJ&3
M$I<:^#B1'"L0_:B>CU5SNKVM]J<L)N"[1TB:*0.\F[:HMTWR<G0V-R%YH)_<
MM25LJP#'5A"B[>:ODB$!WA #S$<XCJH*C% ,VUP?'&8$&W]PUL/-[1GN(2\O
M)>"A)1=H?)T1B0)<;CR\K-H8H;ZJS_/VGIRI8"BY$_//[?NJ= NT$6EY!F5$
M;'AA\3]\]"E:X')_JT7Y. T[^@,*X GX\A'G=NK0L2$()NG>WGIC%-\E-QLT
M_P:TGO1QLDKPY7'JS /DBWY!9$L0,O3OU)%.\(I8PCHC*9'7*"^5P<*B?J)X
M&07LV^TE!5;'J00\%.1N8/X1\.'Z.>'M59RI\7D6J.Y$=/H.E4%Q,B'GSLOH
M!26Q@9'KA+E!2@CG[.WED,UL8[.PR3BQY@#9N=B-X=(WHKQ9$V(VQ6ZAK[T$
M-6MJ/KZW,!QC%[#!EV42%5Y[1LFP&27?X5@Y-YRXE?F<A*E;28=(N,<N4;JP
MYF@1[LN$ MQ;OG^8+EEL-T<R!R-A$!%TF Z#S$\6P".:EPE76^1N:+'CW&U,
M5N[RER;RE1- 35BO@:FIP=60$0.]UAN_:=EF@V\VKD_C:UA,N+9"G[P3QF5^
M*&?-6O388 3;%(<$&G@WJ_*M[^!+N 1%E=)'09+Q&WC$^#$EI#JN4LUR-KT,
MG&=QXWGG@:',0[,?8!^:^@ILB%"$BA#S/1'UBQMHT-V1XOGQK ])H4V]X,='
M3!8_G]<QFX;;'W:2:BY*5]<?E5Y<SD915"L]IF,J\\STHSSU438.MSIU>TTZ
M7@GCSI=C6RA3M:?!2D<!FH,Q'Z;L&L)HJ,[5\GOIM-DM;>H;,C<W\AWYV<)O
M%N6&=0*:-@,GMF;ZG<$7TGD',CKA!/3FHCH1*JY+]!>UVSH>-IT!!YSOHFQ2
MK1(7R*/HA6,863YX\M)1W,^E9$G!R%FPG'"YB*V9< UV!SN5&,?+FECGMS]1
M2[YOE1J-W[SD0Z^[7/Q9?;U7B+U4KF[;^&AA1&PLEQVD4;UVLD_W5OH;Y8R7
MG-5)P?EC$)/777=#<"K.1;-<;O ,Z%FI[A5F(URR<4H2-'UX&0A9SW)>>[_1
MY'KAB0*B IQ1P-M+='2.G!Q: BTP[7A.F,#Q/.A5;!I10,I7-&/%@5O,NJ,
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MR9C+4M4_'V)/#6,Q/(V8^ON,VD\1F/R[BQ6'\&]Z+3"</\F@/_]N2\66V56
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M3G8-HU[FB=-!+/-H<P"36'H.<B$6;[J%!6W0A+P?'FFK&@VF7Y+=]UJ=N$X
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M3BU9OI1=N75+:FOQ>ZL #LA-GL4!Q#C@HBIQ9Y$>'PJGOX>"!YH1Q+EKC:E
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M9R/?BZ/7.2P8B-P]C9UYJHMNXQY3H#V_AQ[OAEZ5%+Y\?G]4=UJG6=.7@Z2
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MNYWDD+;6H53#<[N*'RTH5YP*%RZV?[',X(4*29.0US\/(>GO4>I;EHDY/*<
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MRO4%" U&H\OJ,>\@)!P+6CS<6FX&K92)]IDPMU1?GCF[Q-WR*;6:MS0'K]_
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M5^'7>1^INPVOR*C=F0NR[8<;F]T]7]7#9KA.JF&._1+=_E<[WQG55+>U&RR
M5)4J""B@(%6EUP@*"(BA(QWI$" @O4910.E%NO0.AH 0>I'>!*1+J &D@PE2
M @G)C>\YWSWGOG?<,6[Y?MP?WX_]8^^QUYISC6>NN>:SUER3- '$2;-/17&'
MH,RR='3J08J0L_,(;.@2C-CO(+N 163 $32]J'!+*J 7QIEJ0R/JS5W#W<;(
M4<"7M*?[8S,@)0]29F8ZFZNE*'9GS)UEZ"9FWT\^T"#NRK;DF64D3UM#"TZ
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M7MZ?IC3E,=\CCR'W'(\9<13'*O0_\<:_Z1#HDIXSSK>E.T8/'0^47KK>F?S
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MLLBQ0P']E/#QZVX#<O?^7#AK-)<EO/6.U\2[ HS&AH))0E:CC<UXR$4B8"
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MYOHS\L7GC^)M?FQWJ\4 6:L'XMEN-?]5P7&++CG943K;4^)4GRW# !N-J#C
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M' )A80%M+O7XXQU:'<),/QK#21_^P;=K4VX^9KKV[N+)VD2Q'=ZSK=_4Z/R
MF[,#CU?E87ECJL =5I'>K]N*S[?[DIR<_E"++S^-Y>G!JJ6H]EY\S)ZV$]"@
M:C"$ 5"'H>@+=WB>% 8X'*:\V&WO#!'4-?""8 #Y)0P G47Q_K-1#NDC@\>+
M&&!$6FF_'@L]8G]JA3M%9_3//F+_U JH^__=BP[;X[(/-/>PEE5K>4X'+K74
M0SE(6<++]E ]D<+9#//6V@OG1H,&IYD** :L6W.!ZQU1[DDDO!^@Q0>_&=XG
ML.II.33NDC\ 6YO^Y05-'I:==K7!XE9&@7 OM*94.&1G!P/82G08^<(A$)20
M,-G9$_H+(X3W12'4LQU>L(D!.*>*$'U3(/#?*5<9KO@Z!IO!OR;' )>! Q@@
M)[V!\OP-!O VM*MPAWS:/^5BO)!_SXB]<&'P-@X#)&6W-%SD(3-0?,TTDVU_
M,YCY'_Z_G( D83G"80/V#&)Q' E:767\ORML^$:IC\)\[WUC4Q@XHJ/2$(K?
MJDY\'M.$ 0)1O#@/DAZS?4)5G:;!+A<1)=?#I?5=;-@&]K1+2CY__KRD-_KW
M0?^O"^%;E MV>&Q],( Y-C2-EOXP/:_\A8^D(W_@X\*S4[AE*2KQX'LV GH/
MFVB<)W_Y;<^E \%@YIX'N;]0!KH:M/.K]J,'0IRABQP+,]_H6#P36&#"1KW*
MRS<P0O/]CI$_R<,P-%D;:"U@$BU]GK?OA+4>QG-.I7^=T";*\U?8^3-0L$$K
M8\?[>)\'_=)I36F;YG),RT5;[S[OAT25?ZN<G65?D&!LU5:#R*RY)*XF5[!U
MD?S[)J95A7,8J?O*D%IO5S=,STG'>=I4-2?%G5KDJA1(TNK:0XI;19R%/[V4
MV3-4_7^:-D1Y*YC.]!FUQA@%W?X2&)G*[T$<[9!BW'OKX:/P57G$ODF 4FR=
M7?7[]MKRNJ8] =?"T/XX'14?,=&8YQWR9&XR9R&&-T(43*.[1H^#Y!Y5D=J4
MF6TGF87%KY@]UY-:35+>RM)RT\$QX&X\6!Q4/>16ZI0+3/ZFSZQQP_K3,YRN
M>^J;"MI;^JHDMUMT?-:2!VRVM0!)7I+V##'_I( 3RR=\4__9=/]CVM/!OZ;=
MTA<[[1]^FW:^\P;LM"==_!X6>1OFI5>@JQQHTF-(DJ*E.%KT2/)HD1B985IS
M89>0.[]@NE:900NYR5E\Y1C%IZ#4I<@Q);SG?:FDWM38BDU1+'$+V84\#O%B
M#3=".&%EQ_/4J[KPX;IR1\_A(JU LRC.E_.M76W]CTLV9,CC4\;,MYLK(]"<
MJ-L^H_OR9NX^M(8-Y$4@WL]LP3NN9)]?I/03IFS0O7\\7,LCK<KC"KWP%0NG
MIA!)=A_9:[=YU09OCZR=W=%DN:38)BWMY7<G%3*U%GF=8Z^@>B<P=\?4+<^U
M<-'1E_XTC8N(P_NL8.#S[,X(W=SVXC<,0 XV6%JD-_V^?;4GT)TKS51K;<&V
MI_CI;"/]AI+(TJGEE]V(J%I#^'!&N7'=_G=Q&9#6A+N$\@>3?;=,-S"NVK?7
MR;#V.MO+4G/>P=2MXUGSEK1C::=*^W,'?]NINI[W:].^NHQN'%ZLB0V/GCQ3
MJ7#_G1FT9?2QDX\=O><T;*V>J"P3$A]$[@:/!=[TF;Q3;'-]C8PU:\X')6_?
M;>[Z"TIGBJ+C>2A^7'H?RZ3<U/N8QTG2,A+:?F "%L,.M.7%S0J*EL4_RY62
MO\,H-+L/I/^;?W&<BX;_*Y%P AW?Q!*)YC\3B6+(9-$O(I%=JZE*J\?[[Q8;
M!B;S)F>^J!0,N+-]X\AM,G08D0^M#>U?56C;24ONE)J9&J[S7R$N=UV?/$(4
M$95)B7YX^97+[@EIO38K /3)5)Q' ZOB0Y3=-'ZAVE.MJA(QDN_<N:BX4U>X
M[6>8#><(%JB /.F!M:FX.UU*,\S)_>/J[@[U!V4:),O0,;XWCAGUMY\I+;@[
M;6_F4'!V0D%3XAD;T*G\VD/ZWL6'<0(-^$]CGK,UX(3+-5, ;%K/C_X,LKVV
M=X5^TJES94T9B3V^G!_KV!G+1A'N*#,X?,0 -A'3VA?(Q57U;\O'R6BT%'(4
M/YJO_0]A[$0ZZ"D&:(]#B^-81U?^4PJ*!YDH[:]"X@#C#Z67?PB@/WI3IN?]
M/[-O]D!$#5K#=N/R>0P&N%WYAM%-#Z<G2!/1++V$- B\OL^EQ6#$@X36_9@A
M02FA>^#2,$$K<[T5$8XXFRN6-?UC+F].9E,@&9^N0],$>M0IU1_-S\Z.GJ%\
M& SK3ZHMWZT;RA9%B6\RP[01] 6V3MWK+(%%<10!< H^%KDA9^W6P')AT[9/
M[Y#^KA7,DNXEA.E'[4B5HR"S1TG;!"F"D%H)7J&>UOX2EVMD5CHBO3\#UP(,
MBFK&W(]DK-&=6FHH/XO.=<;RM7L%]@*^*6?:(['4 4LV;6X(VN;;IXO[]46B
M85JSLS9?]BJ$?(@75G7:TD]^H(\F^I\^/T\>4KG5E*T=HYUT8%3WXMUJ2---
M%BD]AAR>Z;:(AW!T:/&,DZQ;28DZK9>IHU #Q75J@F=KW;&T^'//FCC;9<HB
MP5*%<PX!UMO93@W&@CZ:134F'ZCOPN_A]K7;/0QZZ#6+6V\<+:Q.WO[EG&I9
MURD+ ZP_\W1B;OM1)MF<6AX82(9'U><A=Z\J/IN7)WK]=R+5EJT%%PYS%Q9J
ML%ALO3T\O,?"RV7"8_!>P^9UN[2>R&<V_QY_ACC!#]73!37A:JF,-U+%?0$Q
M7A=<Y56)S2X:M0*9V^EUY1--\LFO)HLFU_E;D7(8@#N[2^GX& -4IR_5F"]V
M'%,BDKOXOO?-M+!"B"MD,4!G6AXJOAG"&J0-_4OW@'6#U%3^-9F-N;R/ 9KY
MI8QJ7SGXHK#!G/T ,JB&WCHM%9FY;?7PZ44>VE2J:+HT5\FA1=7H@E6Q&K+8
MBP&8%?LHR[)/$>V]^1]ZZ"Q_/CO'/@IA03G\LP50]9?M0P1T#=!_" E573L\
MERAW1 XIK0'D#Z&HC[F78GX. _A'H;UQ!/\= 5,1WR)BJ?XZQU?)_?$FCYT7
M>7.$Q^G;R\GSBPO]#V'6@V(,KR\W%+21)(!UY[ATT@XA:YG-7B4RO>4_7A:A
MQ5E78J65ZASL43J<$;XD@6I<L"K-5Y9#I2 #0BT8H&(4 VP:'*0$9:G3\0E=
M+JXE9'PU,X"J*GVZTR)=%!0M<%3ZR&@LR((M@>==BF('A5=]VD_= (./?)>O
M NF&KG_\UEG!2*%JYQ=:_NG$?<NL+G2%LLWUR'W+!/;RT7S<S98A1I\%%!N6
M!PPM)YR?8X#O6L\,_ML%/P,,$":L?L:>(AP7D W65:5#$([12B2< 5AJ"VO-
M/B<NU<$ )=JGJ@;32FMX6"9L<0#9O%%^!UV@-$\[W7WYP?3_AJA=T;N7J#9^
M[TMQGL#79\#'Z=-IW^?AV],'+#$>F8.T+]+B6^/YR!^22P9)^DRMOM2D:EEG
M8#PXJ91Q0;R(/7QL%Y-?42(<Y>/,8C!>&Z<WYK)+I?XCZF5IJ*=^+%XK_IZ!
MRAXO7EW#M'?,%GK$_N/WN:&7X$9[(Y<@G)+R?9>]5,.ZYF@/&MK7O<OUM[8I
M9)D/+_F&#^^TU\ +?L0GI3$$N PX%V^-OEV[P_SQ_=+:82-KZ*0-7;AXVQW5
MD&_FQK-;EHX3>L/++D\7;%\"(PH#G;'T>E>]AI^N(939NUC'AJ@':2+B/MO:
MRI!1WB8WKI#JA'(T3G*CAUK'K2=,!)ZT-6CZMTX><,W1:7^YU65'Q,0>WL('
MV(A^3+7#4=<+("E9U_!"E[W-19^J08IR3HO\R;E:UI]\H1QDO,B;.T]O4B:+
M%X_"5<M]])SV_.^3_G]7*&\AL1/)U;N/;E'% +E&7R2.(["^=79#"G+\FTD^
MK&SJ5WIY:;F6\.YK>]P!??1]_FU*7M.;O(6XTZ!(Q>.&L?8"UVD&;*T=6_.T
MAH0/%:,<>BKVE_91J1 R" R&_N(<6G'X2W0GP]K,(E9>QR: )!:QQS=1SI,7
MV]&\E;&*KT;^;#\5=]"Y2O-TVG^9$NB;T4PF1?/FZ_RM9YG,A!U7I!4^=F(8
M]S<\V7R:B,C$^2E[R4\]TFOH.WZ'QO'T1$_3S^7V_%W:?*C.&P(@TU:;'<6J
M0U!?E;=U?I(BE%9J=OEAV,4_D=YV_B71CWL*RA^?0VG&7*T:P^4"HZR;8KL$
M?!F2'Y9%%'<UX<$KHJ.!C=IVTLUTP8DYQVE;(:8KP2Y)K154K+MD/^\]/F&D
M<ZV]H&]OA ;Z^!>\,FMID(FE?KZ$B$W.MKCD-XT&.L;!<GG((%OT0-6%S!N^
MJH7AYQ7/BP4>TCY=5L>3)UGX$^WBD^&.IQ7F=#4--^F42HV!ZO>KH$9R\N-!
M"U$WW$4?+L0<@:9#V$[Z@[BQ\5T+31M4#=* [$] PDP^A/#_0P"Y1(Q;7APM
M+ALZY) L_B&HSUX[2D-?2B$-TGEQ&_X0=/_1&9U=-%#^?V37!^UQR>H\G1<]
M.F>'R]NO( SCT$=#03:(+K2&^>+E\XA?U";9>=^3\M0(S7/&N5XCO H.&V+*
M_P!]=?#;.81!(@P+GNY8\#1+^:/V&)F]+.:DQ"R"C:3*'<&B?E89TA>65MG+
M$ATP?[C[KZ4.I9W]7TL=ARF_4%0MP!LML1VT\9=Z0F^=TW :M;[:]%VEAO2U
M9A\,M3<'?9PS>GUVLSO;&S(HB?48NW]E\&Z@8PTL@]_4UA.NO[,E?'GN#L_;
M?7VNB0&",U!\0W3<=-#OE/GMIUOMG0E_-"@5U\%W_ZO6M#AF_Y!X+YXJ)F&
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M1EM(34-J3ZO@,T+CT,UOT=P_/]<,%98J&"-:TZQZ>$-2.-CC4L:002B\3'1
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M_G:Q+*8_B%G!=AQ[W#;L2=OK)%+B[2D&XO"#)LF[$.!ZUHD/IB]>7M-#\_S
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MZ8;%&Z/]\U_$$F5C:'O+0XD\N&8FX3/I($26>B=RM]C/W[FXL&2E)BG!**]
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MZO&&GK*#GQ >ICR*BD\9G17513S\N'*52FQ0'UJWF5DG8;!9W2-16L $C1'
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MT\"_)ZV,F^>IJ?/D/R,^_V?$B\(BWA86\>]W8-I1^L<96-;X8_C?X;B+51B
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MZ[5 7'E\Z@@'J'QC"9\6+6R9*U8,W[?E:1FT?;>*M_1Z.]R!'6 9-6Y&>%/
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M;E.7R[:DRD%.HWI:,+N5D/Q9EG,_T0U$3,(P -]>X+F(C>BZ@U'LMI2*VE?
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MOWIOD(8P['N-H;/\_'5?VLVRM?4'9AQFWX@)#-'J=#/7$OF*M\)?W*YFDRK
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MCE*,1JH-"W5/V"I28E0S)=,Z%.DIL-Q^DFV:W 2E>%B\=!.8[1#NM_>@I71
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MB30AN;4G7<BJBU6/*J-YL[THNN%9&S>;)U%EGAB.EI^)6_:G5]R-V.MLW 0
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MQ,*M'$N3!" Z((K5Z$]1W*;PU7@!.)>I7SIVE<L^A>$8W,:H4N3\Q;N;*<&
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M%,N)B:380[&7N"R?3)"Y9)$Q8:]GF?28'*8AMOMXYY6^W+:F=WD?89EH,'U
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M1Z\$9Q\.C')$!^"X4AL:4]'R?IH1&G"-DCW8*?]VC.L\XI"Q;!2.SC?&L$H
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M$8#[Q7_Y#&96.56]QN8 >U@#'.RF?G"_BV1FBBA.YI_TU+JU2G1_9]\?NV(
M/X9Q+@GTWE$>EP4__B$!CY =I;7Q))UO-92!=#.9,\%:W<1VQ ;+4NY7I_:U
M8<SO%$\@SA^5-($5 2?'81=M.+N@@EVG@P]'"8J;6R[32TV5Y2;W:_8I7D5+
MZLS=P? M><%V\B1GYQY3<4#FG/!T6)+8@,J?ECA.6I46 UL-N$DC92O]3<;7
M6@V#_1^#U8HBO[6V5W9_.+K$0=W_>@YUU>G$.>'E- IQT/Q:_+;H*-A'VFNW
M@BWT/?2(RRUJB"%7TN*-Q4,L_KZ13/Z?96-]?1MOKC&N3Q_.I0;3?&<9J6O/
M _F#G@&S4"=U_/X]S391\RP<+DO.WAKM/\G[[G>,2X=N+3)W3X:<^M\3WN?,
MQ?YBI0T8TS!8>@1MASX#0C/6?,F"O=Z8(MF\Z#^7)W8^ XAA(_*&-1/V-5W;
MBS+M!P+DT0E.8ZC--K-J9P-"HX.>-1NY;/5U2W23"BX_;H+G8_I2M?O0PX@Y
M,DJ.)(J68K.T#"O':"J9("N<N-&S\@F&U7"6/Q".=K8_$,#_KG^/A*,,P?:3
M2@E*($31LN7[=PC&#Y:+%Y\'T%B+Q4A0&DS<RGW?A\N?9FR'']7,\/=9TR3/
MXO"*BFJ2SW\CIQ%$%Q/?SE(Y(KH:?9^L?/35->K1G#.8./I\M\?B,:YKOT2U
MW&KIB)>(^=S@[2!28%E?(]V"W%Y):AR#)>Z46+7YY.\,C-.+RPK2N?QTM,QG
M21#Y.^FM&<;3YR;M3P]O&R0N6Y,7F&99MK5;_NK"S'QA@:B4(82S4NL%'"UM
MX;YH)4(2W*E+6,^ :G!DJ'4J:29BV 7+]X=>&'Z@UW;F*_M%3U 7NY"+4-CH
MFD->,S"WD0UIZ_D#+3-FO$(%T/.OQ^.M\:HM7TUIY(E&>K[6BY*:''G5'FH>
MPX<CZ*S<1[$?E#IN2J??%\ =72LJ:$R]^\TL>$:0L7^BLZKV8)6]RSN^SP#<
M%_+PR@UUQ F$!FW+C!^VQS/S8C[/8[L=E#G](8=N'OT2W)(2<O"@C\[Y^FF"
M&J:\M/6529 ML!;I7FGVJV]].9!:MOL8LX.$'.-VF9)[O2F^T[P?\NY==;#<
M'CZ B,^S_((F4$D%2=S12EC7 *$&OLKOR<,A+B-7L+#YD?SI82.H?O62<M]0
M1(9E_-+06 8LJAE[QBVG:M@L;K;*LYZ .=17SH;F#^EHG+UHDBQELVA>Y.61
M&4Q@'8WB$2#\Y9BWCB:M3JL,W0-L-2NL&;-V7XT7Y-.4<N&:+".Q#=C-S!^4
M!SV%Z1)MO=:@+[?O'8RS="$(UU(G+@:52I0,:/5Q?,BH@!]GX=VDGH6V<[F]
M90.9[I:J%K723,VACUJ4)MR!L0GVTY(IIDHF?/PNI!_:UEE?[RJ-WYF:68R,
M*(_-<'"BN^_W;:^]#]K2K%]K(I*8U<6M7'R?^&YMW0VW3!P7GP'R9@G*W8,M
MFE?'/:% :A6D0/()Y?]&T6RVBE=,YVUKH2Y^'J0UG#- (S;ZR K>V581FT8O
M3R%#W:D"&B_HF<(3ZQGIB"'AQ]3F_*_,8GU(:ZA]B4=J9E:ATI8=^=75P.-N
M'I:LEJG /CVIE&6I(,>>K-GW[6OWTLUGP/J*SV6Y#"@-L1\G@/0JMW*)&>WY
M]<32/+"EL9#NL.<R1-0Z*)/;>I.SFD;@ 0)*>K^-80D@X+^;E?4Z[>HB:$7X
M4-]G.9:$7-J=QLBV9_),$QI,RC5:V,>\\3)[X@XR5DCID"4W(A45T#=@WV_5
M[/9_B7]>?#?#4MB%W_4P< 6SK)+8E9&V+9%UR5[D?P;8F[6-3XO<7,W?^@K4
M7S?)/BC(X;>#_L@&()5_WC$W.#S^^KQQ@^/P#.!N?K_]B'!X&BR_*7Q\_?3/
MD2N'T<?)Y3U>A_W-+'5+? 9DZV2T]8&QT\@EU [DIRE-;^/U)WW1HI\!Q:>$
M],<+V\\ ZS*?L:!6A@ABRQ)]HWN9G8%'_//\$4C8WC/ L4*?+L;ZU*?#XQOI
M)388>"CTZF'V3:.Q; \=_;3GY&6I:M@3<A#-7RGUMNO3C>XZ6-J#EFFQH@RO
MROP$4S;?.<7 /[=P8'-9?\SN]KZJ]].38N[^KPA?QX?QQYKU4\9#H].9N,Y6
M:?C#%R28)N[@T6Z/E);Q'(?U\<Q95N6"FW@]N1A%^7))1++_?@BS_QF0(G^G
M,U7-X0P'5G37(]]<C]]AI,"<6^E/9\,>E$F%EN2DSI\!/&</"?Y*%6NI>^%+
M%9K$T;-"QA/CJ=XY-G\@4U_^\0G=P@ER'J67&[=^E,O='6&=HA1A4"'Y_:M\
M&^+X:PO]3(.:0V>EW?+KB<L=!XNJEDEF+CKA5UO=7?C$:'-W5V5V"DW"$XN=
M998\AISS!6XU>T.UTS7W34.EDJ!^J_H:LQ1"QN )(@$TO$6=3$^H5FOO0.'?
M 4:@N<W&I_XN=+KOGR6E1;K4\;B@FL2O%P]RDV6VH38:'\Q5-EQ&K-1R=\\6
MN6?GS0V_@X<XV/#P9V!L^0T\[$?.%6N&IM7<91Y$7&^LTM MJU9\LKK@=8RP
M>REV$GDL" G*W,L6I34CF(TBM"%M?$*2Y%JY\ %2Z.3'Q4VD-)5>N]G?5_@M
MX++4E++$@TQC[#JJD&)0G,9/0D?H[WF^T"TB[DN#43ZHS'!QTP*#?/&S1T@8
MY>HVQ3:\UJ7'*N#K'/BE>7P8GPLCS:-7T3.@:OO[ULR=WC-@WKQ>MVB*OO-P
MSYE=VY2H+:=Z(1&F$7X8^=)KS?('6GU.K__O9\"^]J$3C>>YA])15]Q8OOSX
MDIU>.;[)!$Q?2J%H6=_@L61%:R)O<CZ$#>2EZ\/BK#2(Z%_/09.BB5W3-T;+
MQ= 4P-I1 +X=HZZY,2]9O'&?,S8RV"77T-=K_W8@=U; )W*^3>/;G942Z(AY
MZ@J-H5^#S^V3+?P<<;C_==3^/?D74Z*0A009@$>JNEUCX&Y[DBT;G[/^QJ?(
MP-/$T[S^'GQ 10J-*0K\YN1F?\SD'-R'MFTIE=DWDYNV9ML(3Z4>B@*E-5P8
MEK)OI;[JJ>"A 3*W7]R>MV_@FIV:5/[+K<GR5VG?4=\#:]*D9<Z68)*2*; D
MWWIS0D,@=1.>LZI )H:W=?ZKDW(@-PS+JKXZ017*XR,667<+9D[P2../?BAJ
M:O\D?NNC6S[QELYL&6V:Z116VR!]61;UXGK!M[V\"H@=FGNF$DQP-K_H0=8G
M5@1]HEI6RMXUD$5 N;34:YNJR<F<2!,^)].S6S)&B^UYR1I<JK"AC?!(B98%
M?-7S=)?F_1 L[L"=Z@.5]LV#L%$:-:$-N+.1OAT5'$"V\$#8 '\@;&C4QI.S
M.B=/N?E5.>0Z9_+G%T/L-$]NNIV-ELM1:Z]X@:V_K>MK:I69XK$Y>A3%QH1#
M*U@CA;,HYG8:04:VJ0I-S--;?V)@A1W]P;(5I_3JLTW;I#_![.*&8%QS6^ @
MPG9/58%$IZ#C_V*%1]74,.J+?-#/O=%I7[+3I7#&3WGIPE0XCK_G6;8IULFC
MZ?X.S.SN,"+D?BJ4J%S9F\LU[ BX9&F.ZVFCY/IFH"K[JK?N//95US.@1.M
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M/1-;F5DP(X]PBH;^8UC3].ZY+N&J;/@":]>2A*$TK672MMGYXL?V@==H:&(
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MA:7WYK_?%WF7E=#0CU9:G;A%5D%&J97?U,:N&F.M8LAFG9370G1T&[*X'$;
M'SED7\):<Y@W1*]UX,J;?S&46%FW2-W5#]DR#+#,&SX)P!U0PM>[=#4T!M %
M>9ACC'P@R%+Y!=7?P +[?'.6J64NR8(&<T;?'F7<$FG,@.$I<&G$E?VGP5%B
M[PW"S!OI<*TQE;5FA=/<=AG*V16YYL;?1XR25C:OEW]D*<KDCJ,9Q\2T9I7M
MUBXD9Q5+724JTE&^F0_7%!-'C%!8\GA0);8T4>MVS>1_%&8F)^5.T_FP E'>
MBO.U+V\M<>;L>V+PQ8$_." %*Y1*50M,^DFM$!3Q%@M\> )\CH#]A19^H>+7
M7Z^NX7GAE%PHF'L8''K/ !C99V"R^!_6%U.'#-ZS8(-/Q70Z1]%_ZP?G##+A
M:4[)LP;ISX!@7_K"&_HN0AMO$/"-8J]2@ORY\G8I?;_3S@MWSO.ON;'?G@%E
M,>/WT7'#3NKZC#]H8RF\0U(U(!"-V,Y2\>GT$FV/1(]O9V,15'UA_N3YL]$Y
M<!VP@P:. XT=XGVHDJD"P)P)-_.%E2_W3?\* 6]Y3=H2C?Z*/'TF%"<E9IP
M7^.''..^<7BL%#%Y#./$ZP:" 5M+WSIR?K6FZTKPZY^$_5)Q'Y-,U<=]T4[:
MU.L;)P_6)Y/7-ZUPX6K\--]?1++NPAL.M1:,A?ZT$2O/=,%SV*;B6GP*?3C=
M&JJ1QWB(F]+.Z\97T],]>;HJI/EU?N5\<@]*-+'(!C]&[9-GP']6/(2GJ6IS
MTZP]6/Y52:<B>GK&R+4V[L6!I*XHTH'*9$\A]<[+%8'Q#-#]@O;5-OQ1Z,NX
MC^O=93G&L6EC,C'((NJ+[;]$?FVU;NI26/.G5T/"+"B+&S(")O\8!;^>!5TK
MY>YG2DTS\:2DUGA;6.=#(\Y9^IHRPW<A:T?-:M\F*;],QDRMG"\_:0FF;OEL
MG-F4(1Q<MCF0'-,>/]-$F$]%JAD64MXL^;U^FS58-%!L1QQ0UIKQ5&X')8G]
M:EJS^ P8Z\ZZGB]\;#RWGW0\D*;8^M]8>\N@-K@H;# M+;10H+A#6ZQ%"P6*
MTY;BI;A;<0G! \$I%)<4*%"D!'<I$CRXNTN"!G="D6!AW^_;V=EO=F9W9V?V
MQ_/SW'OFSCWG/N?,O<\MG?A T>?*]IX;#&1+]E*ZM*US9R#MULN"Z*WS;J6#
MJ6'K/&H.!V1@-I-R&L?!W& 9)"-4UM15??%33?O$WU$Y;2NTCZBQM:$@XNS
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MQ7O)/B+E&_;U/FE;!J]>;&\C\>((6&<1R?]G?WOMEBC+@9EA"LXK\F_P[3W
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MV!^T>$;%(U.U[>ZW5#Z]U-(R7IM.!O2^@'QCC?#[^W'[)LOG1MO0J7SM[L,
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M@CGQ!B:R;P8S/U+"+\)':$WYK,V>[#U;$@DTO&8U5+H'K"54:GXS-<-^'OU
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MVV".<F^_U@J8 6\.T" +3C<E\M3>KHV5/CL-@%-1DJ9]1I]B0*HYR\9$EO<
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M.SP0%-HSDGRGJ+ZU=!-9%^2!@.3?R A+\G-"10* SU3KHXJ:PELW;$BAJ5W
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M*3RX@O%;ULVVO"_8_VYX)%A=U-D?_HP@7WO2CR'?WHO;H]7JW\M!H3RFPFG
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M0YU&V//X5KQ_4ERI/SK[O_ED3R_5))>;,4Q$BA;@>C7'6VI_G>'P3ZHC\^6
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M^6-=N2 ^TYR_).QYZ.0HS^_K9^87O8DN2BU[D-)CH-#D>-9I/G])=*V>K'W
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M#MC2]\RZ\MHKTPDI.MVGMMDZ/JG^["K"N)G Z@ULF/W_30!02P,$%     @
M\H&55XR&Z-#6,P  4#T  !    !C=FU?,3!K:6UG,3<N:G!GO7H'7%/+MO=&
M!)0. DH-2E4$E(Z4B BAB!1!FA0%I,10I->(2"^A" @(2*\!D=ZE@X#T(KWW
MWDM(ON#SG'O.N??<=]_W?M^WDY5?9LWLV;-FK?FOM68V9A@S!9 KR,K+ C@X
M.( A]@-@1@%I .\B]L(]_\7'P\._1'+I$@'!)7(BXLLD5\BIKE"24U)2766D
MI:)AH*&DI&.A8V "7;]^G8J6E8.5F9V1^3KS>2<X>/CXEP@ND5VZ1,9,34G-
M_#^^,%\!BDLXRCCSN#@W@ L4.+@4.)A&  0 .'@X/R_@UX5S ?<B'C[!I<N$
M1-@&Q>3 !1Q<W O8\6,%P-:Z8^N!BQ1XE-?O2N%?47U.<,.&BL\S+.D2RX."
M.FJUGBU6_A>OWUXFI+EZC9:.C9V#\^8M 4$A81'1>](/960A<O(*3]0UGFIJ
M:>L8&9N\-#4SM["ULW=P=')V\7KG[>/KYQ\0'O$^,BKZ0TQL<DIJ6GI&9E;V
ME\*BXI+2LO**^H;&IN:6UK9OO7W] X-#PS]&IF=FY^87%I>65[9W=O?V#PZ/
MCD_.Y<(!<'%^N_ZE7!18N2Y@U7*1X%PNG N.YPTH+N)=OXM/*:5*\-SFR@T^
MSTM4#\*2"NHNL_"K;5&_>-U#2,,J,,VV?2[:3\G^,\'>_E])]KM@_Y!K!"#&
MQ<$J#Y<"  .G/ &<GR[\3EP=B]L#8_>B_?)20V;HH2(;R+VEV,E#8?[[WJE&
M''H_(#A.]"H)\E.X?9SY-\MJMMV_3 Q+SU"7G[(5UZ1PS^4PO$J6":6>OL3)
MB MKGLDP$QQR,M"B:Q2^2FD $1R*B>&.2,M<RMIP$A4/'GTCKD*@*D.E@O/_
MFYZM'!D]T+-04BW:/WW4U&[I<'?#?F2-/#[I@[4<+0O23EV%@-]HFI=LN21]
M\'MCJJS6PO4TQ]L]L^T7"UBSIYZ[$)/>&HQ+6G9Y=$AI?K! DTA?Z]3YYO)U
M3=9U%>V0'L\H<5O=]__S4:DJBM]Y\S+2B"!]-B J:TRR[5T WU/::_#9(J!V
MA :\>TQV=L")[B[  (FM\,V"9R!OE$W62JS;$%UB>*5DDS_-=RWKOL]X0OR4
M7XU?2.U\/*7KP0#O)EK<WW5OGE*WQ@-.77&W,WNR6:$)\CRR9.*V073 "@8H
MN@U?W &=KJF>)1EA ' H!IA\46A/XM*GX#03Q16S8&\N'N<4%%*0)RR*^[GU
M4'2*+BGYZ*V2 LQR1U;+KI*6^D58!$[?-VWBRE*&MZ!T?("I"K #_ZL!6SB=
M--.W#];Z0*%2<V=AQ@CC0BO(:VO=:R/EM'7K05,:IP@&LX/NCNT6^]=M%S7O
MIJH&==%_R31N8S 9RKNW'0LL_>O1EG<*-Y'8YXZ;ET852G&,C! YW"6O>A#^
MZF4;_9;6B8U\+E0G/6ZFFF=HOK0G3RBW5,EL%Y=+1".HXC/%(C,^<U H)V[J
M/X:I4'KPZ@%R[&'$&^$0J+=O8P*[X\#ZQ+6HDQ%8F\4!C#9DM,.>TL?\0L<E
MC25-AL7/8O<>EXQ,1+#UM5E^N<S26<5;GG0Q?_*0@]5NEG'W/J,>E>I]O/^0
M+JL<]S@GL]SP9;GN2)Q8GY[N;*8EV5-F)S*GYKAT$6Q1LH/J*I(I%7.TNM:5
M;K8[3=IJ?/^;,-\&+6Y_'^J#P_I.GZ5M$/'+Z':$#2PP_,[C>P$(UU;D)70?
M/OEQFZ_(DS*WEM'!Z'7RYQC ';2!Q@ =D@;Y:?+S$.^S$52M8\A[9U74Y W4
MI&M(D>N$5!)YF>]KYA@BD;$4ZW8RU57("+*JEG^= O9]?+29?SDVHAUA#4MA
M-@1)*>T\'RUM5ZJV\0SJV73&]Q(_DO[BG,THNZ#7P.P2JUS4\,Y*4ERT/GYV
M07*BF#?J4]1(I5^=R%S [CA9 QW)0=C%(3JEPE;9F>:[_0FU.KT4[_.S[V8]
M"6_C2O ZR)2$3V;\/E;A=?*-AY1)IK2J92:^F?MY3]#DDR2[&( R4-\%O6:[
MOY]#9^F=:JXSGQM%YT8NUR.7-GN?5%)?,M(R3N_167&LDJ4=W*)DV'AW=IAT
M?-2'?UEQL9XQ])OGFS%-ZU:FHDUVQDJWHM&/L[BT*>>3F%,6="5$+E=BDR5'
M*M&\="1X$?*':73# +6(0SA\ <0[U)NZD_*5_BI1WU\G\>H(\U@ >U!A4.88
M7\/H(*)8U]D$W</TU2%J[ Y9FN)\2ZA#4+YTR/O)/SQZ8H<$_WAK\^YQ5A5)
MDR.QYZK\09Q[YH2;DZVWF,^U$\*?"O9B-?SX6H8C@@;8&<+]--J+5;4.R>E#
M$'AS]FQR\MBW?7\O]?0A?=C#5NUF=4O:Y^NK:LXVOT96JR->MI-A^&U/9!E2
M/4='X9X]VLY[X'> 6U0R_<;]ID</Z4[""RM<FW/]]1[?6>>:3^_]W;)21)IM
MOG,>5ODF@4:0!SG.R\7?J3:N&2W=G#3S73Q#P2M/,<"=8X^:]YOLXCCS>012
MGDU,ZG#AC:&%TS'[E,,$J4]=10\4.&,NVT32^W9(5)M[#%A]KAUA&28ELKQ&
MT)LXWQ(IAJ^Y\=$N_=>37\OB\Y\/DTEI-K!3$N3WW)XH1ZM[6;7HQ8(,H7(\
MN\+&K 0_PL+*MTI^&L:K%@X-5GXLET 37!63?'$.\4""JRA"N:#Z"&''^PJY
M\<#<&G;E87[I8>]>ZTPI?!K4#5^ZC%T0;]K0U _*%]=GR'QR2^#+6V1?I!B+
MG"I43\O&]:AKX'%09A9)=/J'D9;Z0\KCZ)Y'.X65\FQ3IF.C^%--.]><S=^*
MTCOE2V,!%RZ% 3ZQ^:)Q.8Y4,< EM!<&N*](AL)7WLJP89!-FMGTK?B$6'>I
MW_0F?B&W^="R=7@L+;*.><H8I! UU PG78=M(*=KB^1X'B_?V W-<0OXT+R&
M4ZQNE$'] UX/_H0!NBD;, !.!(KS+P^S%I\61/@4E)L,7HIXS:=TEA1S8R1-
MG<6JE5[;1X($NG3@<7F;NFEW66S#.)ROL$*/'R<\OH%!R$B-[%G0T/,_#S5[
M\*YYA5-9F<_$1*^HP8M<U7=C5T/>O+:-O:\))S9'XD+HGS7==/SP.*(V]HN
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MS97:TFWUBO>Q8%\>9FAS6<CZ^K#^PW=S)'76VJX,>RW/7E9>QP#7*WD/V3#
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M^2<D<W:%EI(#%B6 Y #.OR/<\/+9&;8?ZV>1E[#W]VJ<#<0[V6Q?6$7766.
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MNOAE*NH:$"ZF:?$[<#E;EQ5:,9T%F_BM0C0H>7(.%KI^')JNH34-RD^K/_Q
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MXUD#A.W[YBT!_WG3$;X6BPO6?'PNKR5DI+&B17EA (E\\):!#09HU"3*-,
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MNGQO6ZY-E16[2PU,Q>"FX$+%#+WJYG"/U*HJ>:MT'$44KR%SGQ<7!SQJLJ3
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M[V>+<>)#G]Q$L8N,ANP$58UUA>70[Y['WBZ\#;;8R(PZO[KS!VHC[=.C56R
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MYEN^5$,G9 G7%"K(T"Z*/]H\C0[%-.;A2;X*U^7GY;F&2*<.B;/F[&W8CIV
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MF^P^-?)D;K8CTIMF[1/5];B[KC2> 4YYE!QX62->[*?G&+ MJ'\Z=U;A8.J
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M:[DJH5&ML(6*)WI9?S28.3R226LZ' BS6,:5)M?+#UQ;KI_YH3HHD,>MM65
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M!K7>EWTY@9-Y^^2:WLGA(.&'FZYYY%>GS$D5JS=*5?[*YF8!;&S&TER/52[
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M\VJO"9O9I[!H@OFMD98F9C"[9<USW3-"76:U4F'T$G;J1T@G)V0%,T!)3QO
M.C_HF)0:*KI>3^1.<=^N&Q^D8;( AV"::C*"22T6(-Y;NL,.@DB#D758,FG_
M^<QJR=DH 0-+UP'Y#] @2=.<QW@X^>^>RH&R5<<E#^L0 "?C[1CVOFS$X<*A
M$#QY9=PJ:SYY)HB!.<.ARR5^I+)2\'=E&(O9_O1QH,O(F?+N-> [<0TL,SJ=
MT0K&7MQAN5 'G-U\)5$M"/>>1*4RG.<^))'V\LX/9A/NQY$0.D/6SJ8&I?$@
M0M.JH7!ULD.;55CRG!$#!V40VX$9H1&A8U;2^ S6'UV6)XS 5, 8]V^M^[T2
MXRU\LGC!=A,CY?&KKX&@FTP]/(=,];P+6:0?[U<)"=5OSS1OHC%]J?JS*D0S
M75%65.3GH^U(/FR 7-R[.6.;:4_ZS,RZY.03]/;5RZK>&8!CJC,),,%<J-N_
MP_JC\I&>E;9+X1E*D2'K H=_]!JO <+5@-$?90%+RG]ET+@1U:CHBJ_"LW7S
M&N]J)Z\LSU^*>3^A[0>^?[EGS:X=CLL>ZE>R$;E\SD*N3N5MN=],&I@ZKV+E
M\//>2_^C6N1\J#2?P1)L7;\:ZW]PKKAL,0UU 5X<QB+N)V]ZWL!+,UCZ;^IS
M 2\0H(XW*GF*(DMGYR1GFL!J DVWAS=B^,&<9>>I9\E2,ZV5$$\U-#X4<WX-
M(-_<T0;#:*QS1NYPS*,_9J=R 8OAY3]]I;TN\^S9IJ%N]MH7$YB0)30,ZP]U
MNJ+HO09R/^I> QTWCM(]2L!R,]EN=7=+/Y<R;+#/)9]$J]#R7J\#5=2SCI>B
MECBZ]2JXU1L5.U(L8\?E0GT:T^WUQYP.+RL6[%T?I"GAT9@%?B#IP G$P93[
M9)/-WRGW'ZFT77_9WC8T@$K7.)=JMMW\3^MV2SH,\=3EU&K5()[1_QKX!24Y
MK.+1@MD/K'H-$\XO2JPU8-V6?2)GQ2NYP!JUJA8S]?F/;\=7X<^1ISUS%5V;
MMBZ">!_;LPO18RJF)>SQU_T4O2L+_TT_.N>=1DP-K^N%SMK2-[[2;/X,53I_
MX6K^*^J M$YH;& IRD6E&&NL,G5,M^\$@K\4IK7A'A\MH:.F%UD;G@LNFNEU
M=KY#/0D+8["9K=REZV/9_DML2;T4<XN#V-RB':)I+K4O[7;GY9[;V'M<_FD5
M:"B#J8M0M9L;]1RLQD P5R<-')T'"FP N)P!IMO"\F-FXXZFH5-0XI2L8T>.
M!!\M(D[=")+;VEH==*N@(T/R?TR@Q..F)SN#A9N.AEJQ][E./)E:[Y\WY) 5
M1G3>A$&7]BT3N#0*%( 6?$U.OL PF"O46OH9ES?!?[0E^H8<DI<#[E0Z]_\I
M-'IYMQ)).^6.--YK>^,H;6-PT-^'VBS< 78XRWBQ2@Q7H:0W'/J6T@W;U"Y$
M7<XT0^_N(AH_U7KU(8D[$"X74C<#2/OG '2.NJ;-%H6\,166"QD,2>?-H?NE
MVVG ]M9_$NGD*^U1?Y_%?!KJT3CC6^4(/C"/*?WKHFAP&Z-#GMA5=?;9Z8T/
M\/YS,4D17%^J49>KNB^<H$A#QV>>0:YM;8/;X/:_>8[27[M^/D;_<]>/#W[I
M@O&G:XC9N%)Q+W\M+>0W,.C<Z$Z8<^_P>"DVA[K05VSQSS,[%BRE-#9-[<7;
M]2&NBO[%;XV0%FF(.W$\1VMII'/Q.DM=Y:/,Q:X_I0&H&.%+$OJ^*[S8*XZO
M'$CJ@9_+YR-(+O=8HZFA1J4C#00X=-4)M7D^Y?E/)\._>7D!Z_$']-?$75_V
M@X8ZT<S^CJ7;X("_C=]QS* B=WEWJBIN9A?1;.#;+-MHK)5UH\KF?R*21T2'
M$UE;[XUAWJ[N._OKF2TT.ZPB70,FG(:IX)& 'LDTLO@P_C'6^W<+RRTA#7EQ
M#=A,0TU\-P[1KBW?;V"(]-_:RRC6?V]^_@X4:2!'YYN("5ESH+MB,1@E4%<P
M#>@4^5_Z*_,5][S,+Q%$ZN^U:?T\5QZ^B H@+WR/6_BMZF]KI-V .IY)F-T[
MPU2\'3R?FZN\4W<-U.Y&_%MCD9#TJ-_%J/N ;22ZAQW!^_L,394G;G^92\C?
M%6)+'$LV1ZP2W=9>^M5#J,-1::&/I6M7AHG][X'[K<.%N+.#J8#=64.*R8+4
MN!1&](I%;VJBS&RBC*TV9"W^S2/?\L;4!!70B2A'(._8_Y4?_>L(R/<HB\D5
MU+:8OB'KT>I]<JOT365A?W0>K:B]#_/QU)@,K3>N[6N(IX:#J8<MJ6/HD@F)
MU%@6@7P:M%2]6'_K!$ROD&9LG&_QP_&0$*ZT1\P<7%>40P;^(6 W 7GR\T*+
M:FSG&FC1#WJFV1U.B_MIZ19?H+A94PEG#AGN,O(@@B< %K#\,.:/&0H*0RQ3
M(.6SXR%TO00O*]E(O/I\W6+$QL=DF WM7%8*IO[H2ZII3EV-7>:Z;:@^#:Q/
MN/TU^#3][5*- W$_8!E^?$S/F4/.@998O%M^S%4PL=&6-7*NI2?@!)"8'5*5
MJ<IEI_R:(Z[J]8[C@N.[C.CI<>(.^JJ[KVA@U7C-Q@\$)VO"S>_+,;PL"H]8
MFV4*XVE)<%69DV'A9=H//ON2Q321#[_+\0V^Y4A%8J:>Y[FK5Z=)@+.R6^ZZ
MV.UM_CX \7H.:4.S(%)MPR.67^,@PMU!Q\K+?3R.8KQB:T!]HH24+.@*FCX?
M?#) 18E77A?8@@.CQ?2XWPBA6+6+5A57PYMPA(K[A'\GK#1WVBC):B[HK*:(
M@;! EBS<2Q;)#WRU(.Z56.6\UM>\Q/J7)13,D](=(G2]XI9>R[&"6U2:!'PK
M&TT:)(;IXI'G7M@[[)^,+'(V8VY5SV98!"K3E?'>68 $'W6#28L-;.._O7O!
M4=\&/5P5B,M/3>6D-9(]C5G14(=N?='$=_RF?\Z#S+.9ZG[U=K;(!N?'>0Y*
M?Y3Y>$.*H14]E_5T;+7U:BI%V9@/5X.LZXECXDE"PL><PT!2:/A/X,CHAP+P
M8)@,7Z, LN:=TKWM],A!3;VURJWHGAW5+5$SUL\>BK\:+T>-19)%!KU-B#"J
MG$ E"UJQ&&TI:'R/)S)GF#OY-WXVB+_SAXSU_,/0\W$A@@'_+;;* 'FXA/JW
MK7OZ\J5&?FEJ>?44Z^('4A_?2YSKY//GH_+'$K0F^1,(E\[I 6Z$4GWX1E0?
M&^?33VO%?0];#OKH4V++6Y2<R,/^-">/P8=7_7HJ4]B>]W+,O--@?8P+X#9D
MV[.H6A$5I 82@+*FZ)43%6L4?XP%6EJ*XGE' !L7]X3*I3]^V)B6./*G3E9J
M4(_!FE%_9F56)&=ET21]C:X[.V[M_?P!W (RH$DFAM E+SD+-<>P 32.$'$7
MPQZY_>K><6&BG.J.$2J<?BR-G^JJ6DO#) _T\=A^;%Q:4F,$9!I@O"AY]DH7
MD-)T28Q(Z7MC&X\UJ8AU<7?X8*61-CY?Z*'I!B,>".TPG*\U-+"O4:3STJ%C
M:BC;@-<U_.DJD;R0^R4:.SPRV"#4*=4<1(73AZ59[;U/#X<^BF!M#'M*XB)]
M5B1EU?D (>R;KF()NC>-WR1-+57-\NE8"84=+N*>W<,:=@N)!<V=D>LE3'<C
M2/\@##R:REM&2N6F:609.%8$@5K>JCEIL>GX<4Z$"NU#3O;4#$!2'?"*_51Q
M\7[AP<3J5$#=4&'O:T>S688.ZFHVRIQPDG3@32C"BTG=V^%'JKZJ*?#K[A[I
M:+W(I2V7SZQ^EP@TD^.9LFFBS7 ?0/E]$<__@X*/G>1\3X9 WIR^PU$>P89Z
M%U=V40XY"'55@%:I>"[N,R1U9F<UB3-9L3;S_3:A!>&/=V8Z/^<$$H W$9B(
M&]<GFX+RAGN<T,,2F4N,SY5IAUK;ML;9K7_31X>)?U$Z(JEX15O)T=JH[XK_
MY&U\YO>B[S?(XK72 S=%DZ3 P7I[WKXTO.S='H0U=S*J7L2P/_$/:.G&+$W+
M+[NW&Q/;+"(\$PSG3^5_)>M&.<ZAXV1$<8$,DE41NHJ("&!%PI+\,WOCA$:8
M(V]NDV*"(L6S0SHMXMMQ=]T:ZXNV)\_>M+'\K!A:MI1Z*.SDS6ZZ8<C3YQ+H
M2E42QZ]K$K.06@&/ );\'QI!$B84JVZ2$P=>7TS+&RZ$P@93X+VZJ'M'C&2I
M(WA%HL6^+"XK[RH%Y<NY9SY3/>')NU-C-M+*UG&:1[R^=/13(LNN\5N@* NC
MP2[-%<DDB_RY3+MS),-LX4G4?9QTVD<X;AF/V:HXJGP9BB [1SWJU\ =H10W
MZX( BZZUNBSCD6?V FT+VK,@Y!(G;J/@]@T<6!6 QK93WNCU'KZ*%U?\C&-E
M\AW [77;-=):-E1;84Q;#'LPE:)CYW=8/C'H +5ZK8^7\!$'<CZK<2)O+8A\
MJXECQ,6<NPIO;ZEO:8+G1.UP)L/X?B>KSX:[K@[V?^+4I+(0X#M%9_AHWU#.
M"&SA^8H<)%LW3-'N8*]*L^4GKAGG8?,+U@?LL4.-7V $(!XN1%$.22MW)8MR
MK<_,@GAA$$GI@]M)F.B.U:C-B8CE%G7A*.2Q.G@/+/9QYBOK>ZD^QX*5R\GV
MARA/7,Y(+TE<#\;IPC$91H+@?8EW@O/7P 4HTCF*^F7D4U/S&+^11E.1T[P9
M-M'-!*]=M95"]%NQ+J$4R=\36=VGX0ZW:E]TON]J8J0<]U)4+T6.IAW<&*<
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M[FJ2Y5?BSW/KLVO@D=?AQ0@&LRIYZ561\/_F;YO_/QKN]>__ 5!+ P04
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M>6D;E:?_KNKD_;JJ*JC _-OMUY*?7&>+WYL*R&[RJK17XM+K37VXL"!,M?I
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MV2][Y_6/>868^>8G!GA>Y"+T'A^[@^_QDI&\3GWQ-C7 HY4-$MTY6T#2)?D
MTI/HWL@O%NOUZE&I([%+P+587>]5K%N>Q77T!!"'.L=B59?,[?,OL,"G/F<\
MP<:CE&B?1<A(4Y9Q+^\E3X"]6\!A A1^?!TQJEF*XE668D.1K<:%8B3KH9IQ
MJ;R#.W9%, O2[P@.R)H'#C2C(BN2(5@IFJ?PI(.,,A-/%8("VO%6<E9J(&6?
M!#J05K.MPZV6" M_Y_.VF=U#K1F$!$0B.FPD[!6"):^S--%&<I:NJ"3PT[-/
M1,+/<?MW7OO9?<D.X+W_W=6F688P]/ZX_=KDT\!2BZ87W]Z3T%9B;FG8;C+#
MGD"F?/#L)1VQM@GL[)GB9/",'Q@D0=NL]V[=D%YI*F+%C$$!0:"E-C[Y..3M
M%(S[08&?I6*%# ->7Z//?&%%9D08+$5H7Y-2:D2(M36Z,)<;,\0V_?F%(88^
ME@7#0R8&375OL*,\\!I) ]%XA[C'HH$/<^]5IL#R^CQ%% 3]3C(1^,.5;$)+
M'B#]3YJ.(Y-SP LW:5"SLQI<MPV!D$<!?F% <EC(OAX*.(927)VQ_G_IK\JI
MJ(HZ\]FROZ?:%*2;_%*:7KIAAO)4N+_'V[+TJF@1Z7\/!;1V,]BBF4U&:-MA
MA32)EN:_[2<M*RDYV*A-7IEZL%83-Q28*]W#TFXZF!Z"%1'5-94F=U8,NH"%
M(^&D?G\^#:C)___1;0#VOA52P+RS:"/H<>]"R^'=%W:O91'I"P;!A>EM(]"?
M2U2<*44!FRO<\#W-ZVI2:A5CKEO55X(]>.Q*P8QO%GBH6?R!)1<C <(_AVG]
M^3J,Y!G)V!G7&9MQ>Z..YT.<%4&^#7@\EASU[8/$ZMZQ+D9+3Y\ZL7'7&*.
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M.,_YZS:0'H:MH?+OOED%*R>(XY.[G&NZ\6,PHI.9)8:BMFWY81FA:\B1%0K
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MF'O'W(_&W-7"0O,^&%!+ LT(3J)A)%I7)\F"HA>67]DC1XES/1#8L>#"*/G
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ML E@9GVK_13UG7'D*G^8Y3%;1Z'HJ^%6Z1N*_O(Y1:5$79+/XFOUEO:"FL1
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M,C,P.3,P+GAS9%!+ 0(4 Q0    ( /*!E5?OH2>N7Q   .[!   4
M      "  ?X4  !C=FTM,C R,S Y,S!?8V%L+GAM;%!+ 0(4 Q0    ( /*!
ME5=!XFTI=B,  *%& @ 4              "  8\E  !C=FTM,C R,S Y,S!?
M9&5F+GAM;%!+ 0(4 Q0    ( /*!E5=NZ@]USVD   FC!0 4
M  "  3=)  !C=FTM,C R,S Y,S!?;&%B+GAM;%!+ 0(4 Q0    ( /*!E5?3
M<Y=9\%(   "=!  4              "  3BS  !C=FTM,C R,S Y,S!?<')E
M+GAM;%!+ 0(4 Q0    ( /*!E5?->6!^GDL" .-7&  +              "
M 5H& 0!C=FU?,3!K+FAT;5!+ 0(4 Q0    ( /*!E5='3@)7ATX  &!6   0
M              "  2%2 P!C=FU?,3!K:6UG,3 N:G!G4$L! A0#%     @
M\H&55Q\MV"478@  X'0  !               ( !UJ # &-V;5\Q,&MI;6<Q
M,2YJ<&=02P$"% ,4    " #R@9573"6O,*ML   .?0  $
M@ $; P0 8W9M7S$P:VEM9S$T+FIP9U!+ 0(4 Q0    ( /*!E5<D4W95B7X
M $>.   0              "  ?1O! !C=FU?,3!K:6UG,34N:G!G4$L! A0#
M%     @ \H&55X#9]<@,A@  ((D  !               ( !J^X$ &-V;5\Q
M,&MI;6<Q-BYJ<&=02P$"% ,4    " #R@957C(;HT-8S  !0/0  $
M        @ 'E= 4 8W9M7S$P:VEM9S$W+FIP9U!+ 0(4 Q0    ( /*!E5?,
M@&1_VF8  !!T   0              "  >FH!0!C=FU?,3!K:6UG,3@N:G!G
M4$L! A0#%     @ \H&55\'-$B_O2P  >E8   \              ( !\0\&
M &-V;5\Q,&MI;6<Y+FIP9U!+ 0(4 Q0    ( /*!E5?!$#23QP(  ,L(   -
M              "  0U<!@!C=FU?97@R,S$N:'1M4$L! A0#%     @ \H&5
M5^X2L 8="   4V$   P              ( !_UX& &-V;5]E>#,Q+FAT;5!+
M 0(4 Q0    ( /*!E5??5&6)G ,  )P,   ,              "  49G!@!C
M=FU?97@S,BYH=&U02P$"% ,4    " #R@957@1G?^T<9  #KHP  #
M        @ $,:P8 8W9M7V5X.3<N:'1M4$L%!@     2 !( 5P0  'V$!@
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
